Torsade	Torsade	PROPN	NNP	2	B-Disease
de	de	PROPN	NNP	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
intermittent	intermittent	NOUN	NN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
dilated	dilated	ADJ	JJ	5	B-Disease
cardiomyopathy	cardiomyopathy	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
56	56	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
dilated	dilate	VERB	VBN	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
one	one	NUM	CD	5	O
cycle	cycle	NOUN	NN	9	O
of	of	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mcg	mcg	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
supports	support	VERB	VBZ	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
unpredictable	unpredictable	ADJ	JJ	5	O
fatal	fatal	ADJ	JJ	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
even	even	ADV	RB	5	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
rhythm	rhythm	NOUN	NN	5	O
disturbances	disturbance	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
proarrhythmic	proarrhythmic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Dubutamine	Dubutamine	PROPN	NNP	_	B-Chemical
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Positive	positive	ADJ	JJ	7	O
skin	skin	NOUN	NN	5	O
tests	test	NOUN	NNS	5	O
in	in	ADP	IN	5	O
late	late	ADJ	JJ	9	O
reactions	reaction	NOUN	NNS	9	O
to	to	ADP	IN	5	O
radiographic	radiographic	ADJ	JJ	5	O
contrast	contrast	NOUN	NN	9	B-Chemical
media	medium	NOUN	NNS	9	I-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
few	few	ADJ	JJ	5	O
years	year	NOUN	NNS	5	O
delayed	delay	VERB	VBD	9	O
reactions	reaction	NOUN	NNS	9	O
several	several	ADJ	JJ	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
radiographic	radiographic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
contrast	contrast	NOUN	NN	9	B-Chemical
materials	material	NOUN	NNS	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
PRC	PRC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
with	with	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
frequency	frequency	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
report	report	VERB	VBP	5	O
two	two	NUM	CD	5	O
observations	observation	NOUN	NNS	9	O
on	on	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
delayed	delay	VERB	VBN	9	O
reactions	reaction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
intradermoreactions	intradermoreaction	NOUN	NNS	_	O
(	(	PUNCT	-LRB-	9	O
IDR	IDR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
patch	patch	NOUN	NN	5	O
tests	test	NOUN	NNS	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
ionic	ionic	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
ionic	ionic	ADJ	JJ	0	O
PRC	PRC	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
angiography	angiography	NOUN	NN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
venous	venous	ADJ	JJ	5	O
route	route	NOUN	NN	5	O
in	in	ADP	IN	5	O
patient	patient	NOUN	NN	5	O
n	n	CCONJ	CC	9	O
degree	degree	NOUN	NN	5	O
1	1	NUM	CD	9	O
a	a	DET	DT	5	O
biphasic	biphasic	ADJ	JJ	9	O
reaction	reaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
immediate	immediate	ADJ	JJ	5	O
reaction	reaction	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
dyspnea	dyspnea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
consciousness	consciousness	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
delayed	delay	VERB	VBN	9	O
macro	macro	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
papular	papular	ADJ	JJ	5	I-Disease
rash	rash	NOUN	NN	5	I-Disease
appeared	appear	VERB	VBD	9	O
,	,	PUNCT	,	9	O
whilst	whilst	ADP	IN	9	O
patient	patient	ADJ	JJ	5	O
n	n	CCONJ	CC	9	O
degree	degree	NOUN	NN	5	O
2	2	NUM	CD	9	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
generalised	generalised	ADJ	JJ	5	O
sensation	sensation	NOUN	NN	5	O
of	of	ADP	IN	5	O
heat	heat	NOUN	NN	9	O
,	,	PUNCT	,	9	O
persistent	persistent	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
immediately	immediately	ADV	RB	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
generalised	generalised	ADJ	JJ	5	O
macro	macro	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
papular	papular	ADJ	JJ	5	O
reaction	reaction	NOUN	NN	9	O
after	after	ADP	IN	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
skin	skin	NOUN	NN	5	O
tests	test	VERB	VBZ	5	O
revealed	reveal	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
delayed	delay	VERB	VBN	9	O
reactions	reaction	NOUN	NNS	9	O
of	of	ADP	IN	5	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
48	48	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
by	by	ADP	IN	9	O
IDR	IDR	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
patch	patch	NOUN	NN	5	O
tests	test	NOUN	NNS	5	O
to	to	ADP	IN	5	O
only	only	ADV	RB	9	O
some	some	DET	DT	5	O
PRC	PRC	PROPN	NNP	9	B-Chemical
with	with	ADP	IN	5	O
common	common	ADJ	JJ	5	O
chains	chain	NOUN	NNS	9	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
structures	structure	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
skin	skin	NOUN	NN	5	O
tests	test	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
in	in	ADP	IN	5	O
favour	favour	NOUN	NN	5	O
of	of	ADP	IN	5	O
immunological	immunological	ADJ	JJ	9	O
reactions	reaction	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
help	help	VERB	VB	5	O
in	in	ADP	IN	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
allergy	allergy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
hyperammonemic	hyperammonemic	ADJ	JJ	5	B-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
dehydration	dehydration	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
infection	infection	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
1986	1986	NUM	CD	2	O
to	to	ADP	IN	5	O
1998	1998	NUM	CD	2	O
,	,	PUNCT	,	9	O
29	29	NUM	CD	7	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
32	32	NUM	CD	7	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
hyperammonemic	hyperammonemic	ADJ	JJ	5	B-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
decompensated	decompensate	VERB	VBN	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Onset	onset	NOUN	NN	9	O
of	of	ADP	IN	5	O
hyperammonemic	hyperammonemic	ADJ	JJ	5	B-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
varied	vary	VERB	VBN	9	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
:	:	PUNCT	:	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
ammonium	ammonium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
ranged	range	VERB	VBD	9	O
from	from	ADP	IN	9	O
248	248	NUM	CD	7	O
to	to	PART	TO	5	O
2387	2387	NUM	CD	7	O
microg	microg	NOUN	NN	0	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
:	:	PUNCT	:	9	O
626	626	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
431	431	NUM	CD	7	O
microg	microg	NOUN	NN	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
the	the	DET	DT	5	O
32	32	NUM	CD	7	O
episodes	episode	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
26	26	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
81	81	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
various	various	ADJ	JJ	9	O
degrees	degree	NOUN	NNS	5	O
of	of	ADP	IN	5	O
azotemia	azotemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
18	18	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
56	56	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
occurred	occur	VERB	VBD	9	O
during	during	ADP	IN	5	O
bacterial	bacterial	ADJ	JJ	9	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
infection	infection	NOUN	NN	9	B-Disease
occurred	occur	VERB	VBD	9	O
during	during	ADP	IN	5	O
periods	period	NOUN	NNS	5	O
of	of	ADP	IN	5	O
dehydration	dehydration	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Higher	high	ADJ	JJR	9	O
plasma	plasma	NOUN	NN	9	O
ammonium	ammonium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
rapid	rapid	ADJ	JJ	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
hyperammonemia	hyperammonemia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
18	18	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
bacterial	bacterial	ADJ	JJ	9	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
003	003	NUM	CD	2	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0006	0006	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
high	high	ADJ	JJ	9	O
daily	daily	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
2600	2600	NUM	CD	2	O
or	or	CCONJ	CC	5	O
1800	1800	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
and	and	CCONJ	CC	5	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
25	25	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
32	32	NUM	CD	7	O
episodes	episode	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
78	78	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
ammonium	ammonium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
within	within	ADP	IN	9	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
adequate	adequate	ADJ	JJ	5	O
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
hyperammonemic	hyperammonemic	ADJ	JJ	5	B-Disease
encephalopathy	encephalopathy	NOUN	NN	5	I-Disease
can	can	VERB	MD	5	O
occur	occur	VERB	VB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

Azotemia	Azotemia	PROPN	NNP	7	B-Disease
,	,	PUNCT	,	9	O
body	body	NOUN	NN	5	O
fluid	fluid	ADJ	JJ	5	O
insufficiency	insufficiency	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
bacterial	bacterial	ADJ	JJ	9	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
frequently	frequently	ADV	RB	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
therefore	therefore	ADV	RB	5	O
important	important	ADJ	JJ	9	O
to	to	PART	TO	5	O
recognize	recognize	VERB	VB	9	O
this	this	DET	DT	5	O
condition	condition	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
conditioned	conditioned	ADJ	JJ	9	O
place	place	NOUN	NN	5	O
preference	preference	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

1	1	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
unselective	unselective	ADJ	JJ	0	O
potassium	potassium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
)	)	PUNCT	-RRB-	9	O
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
quinine	quinine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
25	25	NUM	CD	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
conditioned	conditioned	ADJ	JJ	9	O
place	place	NOUN	NN	5	O
preference	preference	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
biphasic	biphasic	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Quinine	Quinine	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
block	block	VERB	VB	9	O
voltage	voltage	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
ATP	ATP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
channels	channel	NOUN	NNS	9	O
while	while	ADP	IN	9	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
block	block	VERB	VB	9	O
voltage	voltage	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
channels	channel	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

2	2	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
counterbalanced	counterbalanced	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
,	,	PUNCT	,	9	O
quinine	quinine	NOUN	NN	0	B-Chemical
attenuated	attenuate	VERB	VBD	3	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
place	place	NOUN	NN	5	O
preference	preference	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
ineffective	ineffective	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
motor	motor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
test	test	NOUN	NN	5	O
measured	measure	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
Animex	Animex	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
activity	activity	NOUN	NN	9	O
meter	meter	NOUN	NN	0	O
neither	neither	CCONJ	CC	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
affected	affect	VERB	VBD	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypoactivity	hypoactivity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
both	both	CCONJ	CC	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
prevented	prevent	VERB	VBD	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
secondary	secondary	ADJ	JJ	9	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
channels	channel	NOUN	NNS	9	O
in	in	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
reward	reward	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
also	also	ADV	RB	9	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
channels	channel	NOUN	NNS	9	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
these	these	DET	DT	5	O
blockers	blocker	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypoactivity	hypoactivity	NOUN	NN	5	B-Disease
whereas	whereas	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
connected	connect	VERB	VBN	5	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
quinine	quinine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
channels	channel	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Nociceptin	Nociceptin	PROPN	NNP	7	B-Chemical
/	/	SYM	SYM	9	O
orphanin	orphanin	ADJ	JJ	3	B-Chemical
FQ	FQ	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
nocistatin	nocistatin	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
learning	learning	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
impairment	impairment	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

1	1	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Nociceptin	nociceptin	ADV	RB	7	B-Chemical
,	,	PUNCT	,	9	O
also	also	ADV	RB	9	O
known	know	VERB	VBN	9	O
as	as	ADP	IN	5	O
orphanin	orphanin	ADJ	JJ	3	B-Chemical
FQ	FQ	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
endogenous	endogenous	ADJ	JJ	3	O
ligand	ligand	NOUN	NN	3	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
orphan	orphan	NOUN	NN	9	O
opioid	opioid	NOUN	NN	5	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
receptor	receptor	NOUN	NN	3	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
ORL1	ORL1	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
involves	involve	VERB	VBZ	5	O
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
functions	function	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CNS	CNS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
nocistatin	nocistatin	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
recently	recently	ADV	RB	9	O
isolated	isolate	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
precursor	precursor	NOUN	NN	9	O
as	as	ADP	IN	5	O
nociceptin	nociceptin	ADV	RB	3	B-Chemical
and	and	CCONJ	CC	5	O
blocks	block	VERB	VBZ	9	O
nociceptin	nociceptin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
allodynia	allodynia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

2	2	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
ORL1	ORL1	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
which	which	DET	WDT	5	O
display	display	VERB	VBP	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
sequence	sequence	NOUN	NN	1	O
homology	homology	NOUN	NN	1	O
with	with	ADP	IN	5	O
classical	classical	ADJ	JJ	9	O
opioid	opioid	NOUN	NN	5	O
receptors	receptor	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
abundant	abundant	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
little	little	ADJ	JJ	9	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
regarding	regard	VERB	VBG	5	O
their	-PRON-	DET	PRP$	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
learning	learning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
.	.	PUNCT	.	9	O

3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
nociceptin	nociceptin	ADJ	JJ	3	B-Chemical
/	/	SYM	SYM	9	O
orphanin	orphanin	ADJ	JJ	3	B-Chemical
FQ	FQ	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
nocistatin	nocistatin	NOUN	NN	9	B-Chemical
could	could	VERB	MD	9	O
modulate	modulate	VERB	VB	9	O
impairment	impairment	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
cholinergic	cholinergic	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
alternation	alternation	NOUN	NN	5	O
of	of	ADP	IN	5	O
Y	Y	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
maze	maze	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
step	step	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
down	down	PART	RP	9	O
type	type	NOUN	NN	9	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
tasks	task	NOUN	NNS	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

4	4	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
nocistatin	nocistatin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
nmol	nmol	NOUN	NN	0	O
mouse	mouse	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBD	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
alternation	alternation	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
training	training	NOUN	NN	5	O
session	session	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
alternation	alternation	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
behaviours	behaviour	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
alternation	alternation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
shorter	short	ADJ	JJR	9	O
median	median	ADJ	JJ	9	O
step	step	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
down	down	PART	RP	9	O
latency	latency	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
retention	retention	NOUN	NN	9	O
test	test	NOUN	NN	5	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
nociceptin	nociceptin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
nmol	nmol	NOUN	NN	0	O
mouse	mouse	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
normal	normal	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

5	5	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
nocistatin	nocistatin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
nmol	nmol	NOUN	NN	0	O
mouse	mouse	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
alternation	alternation	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
training	training	NOUN	NN	5	O
session	session	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
,	,	PUNCT	,	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
alternation	alternation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
behaviours	behaviour	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

6	6	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
nocistatin	nocistatin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
biologically	biologically	ADV	RB	9	O
active	active	ADJ	JJ	9	O
peptide	peptide	NOUN	NN	9	O
,	,	PUNCT	,	9	O
ameliorates	ameliorate	VERB	VBZ	3	O
impairments	impairment	NOUN	NNS	5	O
of	of	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
alternation	alternation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
peptides	peptide	NOUN	NNS	9	O
play	play	VERB	VBP	9	O
opposite	opposite	ADJ	JJ	9	O
roles	role	NOUN	NNS	9	O
in	in	ADP	IN	5	O
learning	learning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Meloxicam	Meloxicam	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
liver	liver	NOUN	NN	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
female	female	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	O
cytolytic	cytolytic	ADJ	JJ	3	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
meloxicam	meloxicam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
introduced	introduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
Belgium	Belgium	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
meloxicam	meloxicam	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
antiinflammatory	antiinflammatory	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
with	with	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
inducible	inducible	ADJ	JJ	3	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
cytolytic	cytolytic	ADJ	JJ	3	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
occurred	occur	VERB	VBD	9	O
rapidly	rapidly	ADV	RB	9	O
after	after	ADP	IN	9	O
meloxicam	meloxicam	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
antinuclear	antinuclear	ADJ	JJ	3	O
antibodies	antibody	NOUN	NNS	3	O
suggesting	suggest	VERB	VBG	9	O
a	a	DET	DT	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
mechanism	mechanism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
meloxicam	meloxicam	ADJ	JJ	0	B-Chemical
related	related	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
demonstrates	demonstrate	VERB	VBZ	9	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
apoptosis	apoptosis	NOUN	NN	3	O
by	by	ADP	IN	9	O
remoxipride	remoxipride	NOUN	NN	5	B-Chemical
metabolites	metabolite	NOUN	NNS	0	O
in	in	ADP	IN	5	O
HL60	HL60	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
CD34	CD34	PROPN	NNP	3	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
CD19	CD19	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
human	human	ADJ	JJ	3	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
progenitor	progenitor	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
:	:	PUNCT	:	9	O
potential	potential	ADJ	JJ	9	O
relevance	relevance	NOUN	NN	9	O
to	to	PART	TO	5	O
remoxipride	remoxipride	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
remoxipride	remoxipride	NOUN	NN	5	B-Chemical
[	[	PUNCT	-LRB-	9	O
(	(	PUNCT	-LRB-	9	B-Chemical
S	S	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
bromo	bromo	NOUN	NNS	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ethyl	ethyl	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pyrrolidinyl	pyrrolidinyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
6	6	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dimethoxybenz	dimethoxybenz	NOUN	NN	_	I-Chemical
amide	amide	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
acquired	acquire	VERB	VBN	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
examined	examine	VERB	VBN	9	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
remoxipride	remoxipride	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
pyrrolidine	pyrrolidine	NOUN	NN	0	B-Chemical
ring	ring	NOUN	NN	0	O
metabolites	metabolite	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
aromatic	aromatic	ADJ	JJ	0	O
ring	ring	NOUN	NN	0	O
metabolites	metabolite	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
parent	parent	NOUN	NN	9	O
compound	compound	NOUN	NN	0	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
apoptosis	apoptosis	NOUN	NN	3	O
in	in	ADP	IN	5	O
HL60	HL60	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
human	human	ADJ	JJ	3	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
progenitor	progenitor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
HBMP	HBMP	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
with	with	ADP	IN	5	O
each	each	DET	DT	5	O
compound	compound	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
200	200	NUM	CD	0	O
microM	microM	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Apoptosis	apoptosis	NOUN	NN	3	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
fluorescence	fluorescence	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
in	in	ADP	IN	5	O
Hoechst	Hoechst	PROPN	NNP	3	B-Chemical
33342	33342	NUM	CD	3	I-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
propidium	propidium	NOUN	NN	0	B-Chemical
iodide	iodide	ADV	RB	0	I-Chemical
stained	stain	VERB	VBD	3	O
cell	cell	NOUN	NN	3	O
samples	sample	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
internucleosomal	internucleosomal	ADJ	JJ	3	O
DNA	dna	NOUN	NN	9	O
fragmentation	fragmentation	NOUN	NN	9	O
using	use	VERB	VBG	9	O
gel	gel	NOUN	NN	0	O
electrophoresis	electrophoresis	NOUN	NN	0	O
for	for	ADP	IN	5	O
HL60	HL60	PROPN	NNP	3	O
cell	cell	NOUN	NN	3	O
samples	sample	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
terminal	terminal	ADJ	JJ	9	O
deoxynucleotidyl	deoxynucleotidyl	NOUN	NN	3	O
transferase	transferase	NOUN	NN	1	O
assay	assay	NOUN	NN	3	O
in	in	ADP	IN	5	O
HBMP	HBMP	PROPN	NNP	_	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
catechol	catechol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
hydroquinone	hydroquinone	NOUN	NN	0	B-Chemical
metabolites	metabolite	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
NCQ436	NCQ436	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
NCQ344	NCQ344	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
induced	induce	VERB	VBN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
in	in	ADP	IN	5	O
HL60	HL60	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
HBMP	HBMP	PROPN	NNP	_	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
concentration	concentration	NOUN	NN	0	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
phenols	phenol	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
NCR181	NCR181	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
FLA873	FLA873	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
FLA797	FLA797	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
derivatives	derivative	NOUN	NNS	0	O
formed	form	VERB	VBN	9	O
by	by	ADP	IN	9	O
oxidation	oxidation	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pyrrolidine	pyrrolidine	NOUN	NN	0	B-Chemical
ring	ring	NOUN	NN	0	O
,	,	PUNCT	,	9	O
FLA838	FLA838	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
NCM001	NCM001	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
NCL118	NCL118	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
necrosis	necrosis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
cells	cell	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
NCQ436	NCQ436	PROPN	NNP	_	B-Chemical
but	but	CCONJ	CC	9	O
NCQ344	NCQ344	PROPN	NNP	_	B-Chemical
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
biphasic	biphasic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
cell	cell	NOUN	NN	3	O
types	type	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
inducing	induce	VERB	VBG	3	O
apoptosis	apoptosis	NOUN	NN	3	O
at	at	ADP	IN	9	O
lower	low	ADJ	JJR	9	O
concentrations	concentration	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
at	at	ADP	IN	9	O
higher	high	ADJ	JJR	9	O
concentrations	concentration	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
catechol	catechol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
hydroquinone	hydroquinone	NOUN	NN	0	B-Chemical
metabolites	metabolite	NOUN	NNS	0	O
of	of	ADP	IN	5	O
remoxipride	remoxipride	NOUN	NN	5	B-Chemical
have	have	VERB	VBP	5	O
direct	direct	ADJ	JJ	9	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
HL60	HL60	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
HBMP	HBMP	PROPN	NNP	_	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
apoptosis	apoptosis	NOUN	NN	3	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
phenol	phenol	NOUN	NN	0	B-Chemical
metabolites	metabolite	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
inactive	inactive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
benzene	benzene	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
catechol	catechol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
hydroquinone	hydroquinone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
phenol	phenol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
induce	induce	VERB	VB	3	O
apoptosis	apoptosis	NOUN	NN	3	O
in	in	ADP	IN	5	O
HBMP	HBMP	PROPN	NNP	_	O
cells	cell	NOUN	NNS	3	O
[	[	PUNCT	-LRB-	9	O
Moran	Moran	PROPN	NNP	6	O
et	et	PROPN	NNP	6	O
al	al	PROPN	NNP	6	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
Mol	Mol	PROPN	NNP	2	O
.	.	PUNCT	.	9	O
Pharmacol	Pharmacol	PROPN	NNP	2	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
(	(	PUNCT	-LRB-	9	O
1996	1996	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
610	610	NUM	CD	7	O
-	-	SYM	SYM	7	O
615	615	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
propose	propose	VERB	VBP	9	O
that	that	DET	DT	5	O
remoxipride	remoxipride	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
benzene	benzene	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
induce	induce	VERB	VB	3	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
via	via	ADP	IN	9	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
reactive	reactive	ADJ	JJ	9	O
metabolites	metabolite	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
NCQ436	NCQ436	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
NCQ344	NCQ344	PROPN	NNP	_	B-Chemical
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
apoptosis	apoptosis	NOUN	NN	3	O
in	in	ADP	IN	5	O
HBMP	HBMP	PROPN	NNP	_	O
cells	cell	NOUN	NNS	3	O
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
underlying	underlie	VERB	VBG	5	O
acquired	acquire	VERB	VBD	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
remoxipride	remoxipride	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Synthesis	synthesis	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
preliminary	preliminary	ADJ	JJ	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
investigations	investigation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydro	dihydro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acenaphthylenyl	acenaphthylenyl	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
piperazine	piperazine	NOUN	NN	0	I-Chemical
derivatives	derivative	NOUN	NNS	0	O
as	as	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
atypical	atypical	ADJ	JJ	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
research	research	NOUN	NN	5	O
towards	towards	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
new	new	ADJ	JJ	5	O
atypical	atypical	ADJ	JJ	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
strategy	strategy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
modulated	modulate	VERB	VBN	9	O
through	through	ADP	IN	9	O
manipulation	manipulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
serotonergic	serotonergic	NOUN	NN	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
synthesis	synthesis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
preliminary	preliminary	ADJ	JJ	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
atypical	atypical	ADJ	JJ	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
structure	structure	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydro	dihydro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acenaphthylenyl	acenaphthylenyl	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
piperazine	piperazine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Compound	Compound	PROPN	NNP	0	O
7e	7e	NUM	CD	7	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
{	{	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydro	dihydro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acenaphthylenyl	acenaphthylenyl	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
piperazinyl	piperazinyl	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
ethyl	ethyl	ADV	RB	0	I-Chemical
}	}	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihy	dihy	ADJ	JJ	9	I-Chemical
dro	dro	NOUN	NN	2	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1H	1h	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
indol	indol	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
one	one	NUM	CD	5	I-Chemical
,	,	PUNCT	,	9	O
from	from	ADP	IN	9	O
this	this	DET	DT	5	O
series	series	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
affinities	affinity	NOUN	NNS	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
HT1A	ht1a	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT2A	ht2a	ADJ	JJ	1	O
receptors	receptor	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
moderate	moderate	ADJ	JJ	9	O
affinity	affinity	NOUN	NN	0	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

7e	7e	PUNCT	LS	7	O
exhibits	exhibit	NOUN	NNS	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
indicating	indicate	VERB	VBG	9	O
its	-PRON-	DET	PRP$	9	O
atypical	atypical	ADJ	JJ	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
nature	nature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
chronic	chronic	ADJ	JJ	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
synthesis	synthesis	NOUN	NN	9	O
modifies	modifie	NOUN	NNS	9	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
NADPH	NADPH	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
diaphorase	diaphorase	NOUN	NN	0	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

RATIONALE	rationale	VERB	VB	2	O
:	:	PUNCT	:	9	O
NG	ng	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitro	nitro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
L	L	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NOARG	NOARG	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
NOS	NOS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
induces	induce	NOUN	NNS	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
undergoes	undergoe	NOUN	NNS	9	O
rapid	rapid	ADJ	JJ	5	O
tolerance	tolerance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
showing	show	VERB	VBG	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
after	after	ADP	IN	9	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
chronic	chronic	NOUN	NN	5	O
L	L	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NOARG	NOARG	PROPN	NNP	9	I-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	no	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
influence	influence	VERB	VB	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurotransmission	neurotransmission	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Neuroleptic	neuroleptic	ADJ	JJ	2	O
drugs	drug	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
block	block	VERB	VBP	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptors	receptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
also	also	ADV	RB	9	O
cause	cause	VERB	VB	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
subchronic	subchronic	ADJ	JJ	0	O
L	L	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NOARG	NOARG	PROPN	NNP	9	I-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
NOS	NOS	PROPN	NNP	9	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
areas	area	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Male	male	ADJ	JJ	7	O
albino	albino	ADJ	JJ	3	O
Swiss	swiss	ADJ	JJ	2	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
chronically	chronically	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
twice	twice	ADV	RB	9	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
L	L	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NOARG	NOARG	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Catalepsy	Catalepsy	PROPN	NNP	0	B-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
beginning	beginning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatments	treatment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Reduced	reduce	VERB	VBN	9	O
nicotinamide	nicotinamide	NOUN	NN	0	B-Chemical
adenine	adenine	NOUN	NN	0	I-Chemical
dinucleotide	dinucleotide	VERB	VBP	1	I-Chemical
phosphate	phosphate	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
diaphorase	diaphorase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
NADPH	NADPH	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
d	d	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
histochemistry	histochemistry	NOUN	NN	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
employed	employ	VERB	VBN	5	O
to	to	PART	TO	5	O
visualize	visualize	VERB	VB	9	O
NOS	NOS	PROPN	NNP	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
index	index	NOUN	NN	5	O
of	of	ADP	IN	5	O
enzyme	enzyme	ADJ	JJ	0	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
brain	brain	NOUN	NN	5	O
regions	region	NOUN	NNS	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
L	L	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NOARG	noarg	NOUN	NN	9	I-Chemical
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
chronic	chronic	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
produced	produce	VERB	VBD	9	O
tolerance	tolerance	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	L	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NOARG	NOARG	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
induced	induce	VERB	VBD	3	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
NADPH	NADPH	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
d	d	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dorsal	dorsal	ADJ	JJ	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
caudate	caudate	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
accumbens	accumben	NOUN	NNS	5	O
nuclei	nucleus	NOUN	NNS	3	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pedunculopontine	pedunculopontine	NOUN	NN	5	O
tegmental	tegmental	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
NADPH	NADPH	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
d	d	PROPN	NNP	9	O
neuron	neuron	NOUN	NN	5	O
number	number	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
substantia	substantia	ADJ	JJ	9	O
nigra	nigra	NOUN	NN	4	O
,	,	PUNCT	,	9	O
pars	par	NOUN	NNS	4	O
compacta	compacta	NOUN	NNS	4	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
L	L	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NOARG	NOARG	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
give	give	VERB	VBP	5	O
further	further	ADJ	JJ	9	O
support	support	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
NO	no	NOUN	NN	9	B-Chemical
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
behavior	behavior	NOUN	NN	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
take	take	VERB	VB	5	O
part	part	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
synaptic	synaptic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Prolonged	prolong	VERB	VBN	9	O
left	leave	VERB	VBD	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
both	both	DET	DT	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
exercise	exercise	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischaemia	ischaemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
leads	lead	VERB	VBZ	9	O
to	to	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
reversible	reversible	ADJ	JJ	9	O
left	leave	VERB	VBN	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
seen	see	VERB	VBN	9	O
after	after	ADP	IN	9	O
exercise	exercise	NOUN	NN	5	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
randomised	randomise	VERB	VBN	5	O
crossover	crossover	NOUN	NN	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
recovery	recovery	NOUN	NN	9	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
systolic	systolic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	NOUN	NN	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
after	after	ADP	IN	9	O
exercise	exercise	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
dobutamine	dobutamine	VERB	VB	5	B-Chemical
induced	induce	VERB	VBN	3	O
ischaemia	ischaemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

SUBJECTS	subject	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
stable	stable	ADJ	JJ	9	B-Disease
angina	angina	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
angiographically	angiographically	ADV	RB	5	O
proven	prove	VERB	VBN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

INTERVENTIONS	intervention	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Treadmill	treadmill	NOUN	NN	5	O
exercise	exercise	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
dobutamine	dobutamine	VERB	VB	5	B-Chemical
stress	stress	NOUN	NN	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
different	different	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Quantitative	quantitative	ADJ	JJ	9	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
systolic	systolic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	NOUN	NN	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
using	use	VERB	VBG	9	O
transthoracic	transthoracic	NOUN	NNS	5	O
echocardiography	echocardiography	NOUN	NN	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
regular	regular	ADJ	JJ	5	O
intervals	interval	NOUN	NNS	5	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Both	both	DET	DT	9	O
forms	form	NOUN	NNS	9	O
of	of	ADP	IN	5	O
stress	stress	NOUN	NN	9	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
reversible	reversible	ADJ	JJ	9	O
systolic	systolic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
dysfunction	dysfunction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
double	double	ADJ	JJ	9	O
product	product	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
53	53	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
ST	ST	PROPN	NNP	9	O
depression	depression	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
63	63	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
exercise	exercise	NOUN	NN	5	O
,	,	PUNCT	,	9	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
at	at	ADP	IN	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
SEM	SEM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
30	30	NUM	CD	9	O
and	and	CCONJ	CC	5	O
45	45	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Regional	regional	ADJ	JJ	2	O
analysis	analysis	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
worst	bad	ADJ	JJS	5	O
affected	affected	ADJ	JJ	9	O
segment	segment	NOUN	NN	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
exercise	exercise	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
32	32	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
isovolumic	isovolumic	ADJ	JJ	5	O
relaxation	relaxation	NOUN	NN	5	O
period	period	NOUN	NN	5	O
was	be	VERB	VBD	9	O
prolonged	prolong	VERB	VBN	9	O
45	45	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
stress	stress	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
induced	induce	VERB	VBN	3	O
ischaemia	ischaemia	NOUN	NN	9	B-Disease
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
reversible	reversible	ADJ	JJ	9	O
left	leave	VERB	VBN	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
presumed	presume	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
stunning	stunning	ADJ	JJ	5	I-Disease
,	,	PUNCT	,	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
seen	see	VERB	VBN	9	O
after	after	ADP	IN	9	O
exercise	exercise	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dobutamine	Dobutamine	PROPN	NNP	0	B-Chemical
induced	induce	VERB	VBD	3	O
ischaemia	ischaemia	NOUN	NN	9	B-Disease
could	could	VERB	MD	9	O
therefore	therefore	ADV	RB	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
phenomenon	phenomenon	NOUN	NN	5	O
further	further	ADV	RB	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Anorexigens	anorexigen	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
results	result	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
surveillance	surveillance	NOUN	NN	5	O
of	of	ADP	IN	5	O
North	north	ADJ	JJ	4	O
American	american	ADJ	JJ	9	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
appetite	appetite	ADJ	JJ	5	O
suppressants	suppressant	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Europe	Europe	PROPN	NNP	4	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
primary	primary	ADJ	JJ	9	B-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PPH	PPH	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
fenfluramine	fenfluramine	ADJ	JJ	5	B-Chemical
appetite	appetite	NOUN	NN	5	O
suppressants	suppressant	NOUN	NNS	5	O
became	become	VERB	VBD	9	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
but	but	CCONJ	CC	9	O
were	be	VERB	VBD	9	O
withdrawn	withdraw	VERB	VBN	9	O
in	in	ADP	IN	5	O
September	September	PROPN	NNP	2	O
1997	1997	NUM	CD	2	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
concerns	concern	NOUN	NNS	5	O
over	over	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
surveillance	surveillance	NOUN	NN	5	O
study	study	NOUN	NN	9	O
on	on	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
at	at	ADP	IN	9	O
12	12	NUM	CD	9	O
large	large	ADJ	JJ	5	O
referral	referral	ADJ	JJ	5	O
centers	center	NOUN	NNS	5	O
in	in	ADP	IN	5	O
North	North	PROPN	NNP	4	O
America	America	PROPN	NNP	4	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
collected	collect	VERB	VBD	9	O
on	on	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
seen	see	VERB	VBN	9	O
from	from	ADP	IN	9	O
September	September	PROPN	NNP	2	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
1996	1996	NUM	CD	2	O
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
December	December	PROPN	NNP	2	O
31	31	NUM	CD	7	O
,	,	PUNCT	,	9	O
1997	1997	NUM	CD	2	O
,	,	PUNCT	,	9	O
included	include	VERB	VBD	5	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
severity	severity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
identifiable	identifiable	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
classed	class	VERB	VBN	5	O
as	as	ADP	IN	5	O
PPH	PPH	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
also	also	ADV	RB	9	O
was	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
with	with	ADP	IN	5	O
special	special	ADJ	JJ	5	O
attention	attention	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
antidepressants	antidepressant	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
anorexigens	anorexigen	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
amphetamines	amphetamine	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Five	five	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
seventy	seventy	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
,	,	PUNCT	,	9	O
205	205	NUM	CD	7	O
with	with	ADP	IN	5	O
PPH	PPH	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
374	374	NUM	CD	7	O
with	with	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
from	from	ADP	IN	9	O
other	other	ADJ	JJ	5	O
causes	cause	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
secondary	secondary	ADJ	JJ	9	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
[	[	PUNCT	-LRB-	9	O
SPH	SPH	PROPN	NNP	0	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
anorexigens	anorexigen	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
medications	medication	NOUN	NNS	5	O
surveyed	survey	VERB	VBN	5	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
the	the	DET	DT	5	O
fenfluramines	fenfluramine	NOUN	NNS	5	B-Chemical
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
preferential	preferential	ADJ	JJ	9	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
PPH	PPH	PROPN	NNP	5	B-Disease
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
SPH	SPH	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
adjusted	adjust	VERB	VBN	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
for	for	ADP	IN	5	O
use	use	NOUN	NN	5	O
>	>	X	XX	0	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
association	association	NOUN	NN	9	O
was	be	VERB	VBD	9	O
stronger	strong	ADJ	JJR	9	O
with	with	ADP	IN	5	O
longer	long	ADJ	JJR	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
use	use	NOUN	NN	5	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
shorter	short	ADJ	JJR	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
pronounced	pronounced	ADJ	JJ	9	O
in	in	ADP	IN	5	O
recent	recent	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
remote	remote	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
unexpectedly	unexpectedly	ADV	RB	9	O
high	high	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
SPH	SPH	PROPN	NNP	0	O
had	have	VERB	VBD	9	O
used	use	VERB	VBN	5	O
anorexigens	anorexigen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
PPH	PPH	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
specificity	specificity	NOUN	NN	9	O
for	for	ADP	IN	5	O
fenfluramines	fenfluramine	NOUN	NNS	5	B-Chemical
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
fenfluramines	fenfluramine	NOUN	NNS	5	B-Chemical
are	be	VERB	VBP	5	O
causally	causally	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
PPH	PPH	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
anorexigen	anorexigen	NOUN	NN	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
SPH	SPH	PROPN	NNP	0	O
also	also	ADV	RB	9	O
raises	raise	VERB	VBZ	9	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
precipitate	precipitate	VERB	VBP	0	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
underlying	underlie	VERB	VBG	5	O
conditions	condition	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
SPH	SPH	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
aspects	aspect	NOUN	NNS	5	O
of	of	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Heparin	Heparin	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
first	first	ADV	RB	9	O
used	use	VERB	VBD	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
clotting	clotting	NOUN	NN	5	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
clinically	clinically	ADV	RB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
for	for	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
several	several	ADJ	JJ	9	O
new	new	ADJ	JJ	5	O
anticoagulant	anticoagulant	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
in	in	ADP	IN	5	O
development	development	NOUN	NN	9	O
,	,	PUNCT	,	9	O
heparin	heparin	NOUN	NN	0	B-Chemical
remains	remain	VERB	VBZ	9	O
the	the	DET	DT	5	O
anticoagulant	anticoagulant	NOUN	NN	9	O
of	of	ADP	IN	5	O
choice	choice	NOUN	NN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
acute	acute	ADJ	JJ	9	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
meritorious	meritorious	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
do	do	VERB	VBP	5	O
exist	exist	VERB	VB	9	O
.	.	PUNCT	.	9	O

Bleeding	bleeding	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
untoward	untoward	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Major	major	ADJ	JJ	9	O
bleeding	bleeding	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
of	of	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
concern	concern	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
heparin	heparin	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
additional	additional	ADJ	JJ	9	O
important	important	ADJ	JJ	9	O
untoward	untoward	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
include	include	VERB	VBP	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
eosinophilia	eosinophilia	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
skin	skin	NOUN	NN	5	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
allergic	allergic	ADJ	JJ	9	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
other	other	ADJ	JJ	5	O
than	than	ADP	IN	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
alopecia	alopecia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
transaminasemia	transaminasemia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hypoaldosteronism	hypoaldosteronism	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
priapism	priapism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
relatively	relatively	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
given	give	VERB	VBN	5	O
individual	individual	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
given	give	VERB	VBN	5	O
the	the	DET	DT	5	O
extremely	extremely	ADV	RB	5	O
widespread	widespread	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
some	some	DET	DT	5	O
are	be	VERB	VBP	5	O
quite	quite	ADV	RB	5	O
common	common	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
HITT	HITT	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
reasonable	reasonable	ADJ	JJ	5	O
incidences	incidence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
many	many	ADJ	JJ	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
"	"	PUNCT	``	5	O
softly	softly	ADV	RB	5	O
"	"	PUNCT	''	5	O
deduced	deduce	VERB	VBN	9	O
from	from	ADP	IN	9	O
current	current	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
dealing	deal	VERB	VBG	5	O
with	with	ADP	IN	5	O
unfractionated	unfractionated	ADJ	JJ	9	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
present	present	ADJ	JJ	9	O
the	the	DET	DT	5	O
incidences	incidence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
with	with	ADP	IN	5	O
newer	new	ADJ	JJR	5	O
low	low	ADJ	JJ	9	O
molecular	molecular	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
heparins	heparin	NOUN	NNS	0	B-Chemical
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
much	much	ADV	RB	5	O
less	less	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
longer	long	ADJ	JJR	5	O
experience	experience	NOUN	NN	5	O
will	will	VERB	MD	5	O
more	more	ADV	RBR	5	O
clearly	clearly	ADV	RB	9	O
define	define	VERB	VB	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
molecular	molecular	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
preparations	preparation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
on	on	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
FK506	FK506	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
receiving	receiving	NOUN	NN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
Prograf	Prograf	PROPN	NNP	0	O
;	;	PUNCT	:	9	O
Fujisawa	Fujisawa	PROPN	NNP	6	O
USA	USA	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
Inc	Inc	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Deerfield	Deerfield	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
Illinois	Illinois	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
immunosuppression	immunosuppression	NOUN	NN	5	O
after	after	ADP	IN	9	O
orthotropic	orthotropic	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
58	58	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
receiving	receive	VERB	VBG	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
orthotropic	orthotropic	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
serial	serial	ADJ	JJ	9	O
neuro	neuro	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ophthalmologic	ophthalmologic	ADJ	JJ	5	O
examinations	examination	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
episodic	episodic	ADJ	JJ	5	O
deterioration	deterioration	NOUN	NN	5	O
of	of	ADP	IN	5	O
vision	vision	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
eyes	eye	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
resembling	resemble	VERB	VBG	9	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
optic	optic	ADJ	JJ	5	I-Disease
neuropathies	neuropathy	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Deterioration	deterioration	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
vision	vision	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
despite	despite	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
optic	optic	ADJ	JJ	5	B-Disease
nerve	nerve	NOUN	NN	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Hypercalcemia	Hypercalcemia	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
mood	mood	NOUN	NN	5	O
stabilizers	stabilizer	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
patient	patient	NOUN	NN	5	O
receiving	receive	VERB	VBG	9	O
maintenance	maintenance	NOUN	NN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
bradyarrhythmia	bradyarrhythmia	NOUN	NN	5	B-Disease
prompted	prompt	VERB	VBD	9	O
the	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
to	to	PART	TO	5	O
conduct	conduct	VERB	VB	5	O
a	a	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
printout	printout	NOUN	NN	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
presented	present	VERB	VBD	5	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
was	be	VERB	VBD	9	O
generated	generate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
eliminating	eliminate	VERB	VBG	5	O
spurious	spurious	ADJ	JJ	5	O
hypercalcemias	hypercalcemia	NOUN	NNS	_	B-Disease
or	or	CCONJ	CC	5	O
those	those	DET	DT	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
fluids	fluid	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
identified	identify	VERB	VBD	9	O
18	18	NUM	CD	7	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hypercalcemias	hypercalcemia	NOUN	NNS	_	B-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
malignancies	malignancy	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
comparable	comparable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
were	be	VERB	VBD	9	O
medically	medically	ADV	RB	5	O
compromised	compromise	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
multiple	multiple	ADJ	JJ	5	O
pharmacotherapies	pharmacotherapie	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
generated	generate	VERB	VBN	9	O
:	:	PUNCT	:	9	O
group	group	NOUN	NN	9	O
C1	C1	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
included	include	VERB	VBD	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
sex	sex	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
comparable	comparable	ADJ	JJ	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
normocalcemic	normocalcemic	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
group	group	NOUN	NN	9	O
C2	C2	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
included	include	VERB	VBD	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
normocalcemic	normocalcemic	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
mood	mood	NOUN	NN	5	O
stabilizers	stabilizer	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
electrocardiographic	electrocardiographic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ECG	ECG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
findings	finding	NOUN	NNS	9	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
C1	C1	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
C2	c2	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
groups	group	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
overall	overall	ADJ	JJ	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
ECG	ECG	PROPN	NNP	5	O
abnormalities	abnormality	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
conduction	conduction	NOUN	NN	5	O
defects	defect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
resulting	result	VERB	VBG	9	O
from	from	ADP	IN	9	O
medical	medical	ADJ	JJ	5	O
diseases	disease	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
had	have	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
frequencies	frequency	NOUN	NNS	9	O
of	of	ADP	IN	5	O
conduction	conduction	NOUN	NN	5	O
defects	defect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
had	have	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
mortality	mortality	NOUN	NN	5	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
28	28	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
zero	zero	NUM	CD	5	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
implications	implication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Attenuation	attenuation	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
lipid	lipid	NOUN	NN	0	O
nanosphere	nanosphere	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
718	718	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
incorporating	incorporate	VERB	VBG	5	O
amphotericin	amphotericin	NOUN	NN	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
.	.	PUNCT	.	9	O

NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
718	718	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
lipid	lipid	NOUN	NN	0	O
nanosphere	nanosphere	ADV	RB	0	O
incorporating	incorporate	VERB	VBG	5	O
amphotericin	amphotericin	NOUN	NN	0	B-Chemical
B	b	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
effective	effective	ADJ	JJ	5	O
against	against	ADP	IN	9	O
pathogenic	pathogenic	ADJ	JJ	9	O
fungi	fungus	NOUN	NNS	4	O
and	and	CCONJ	CC	5	O
has	have	VERB	VBZ	9	O
low	low	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
718	718	PROPN	NNP	7	O
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
Fungizone	Fungizone	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
amphotericin	amphotericin	PROPN	NNP	0	B-Chemical
B	b	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
deoxycholate	deoxycholate	NOUN	NN	0	I-Chemical
;	;	PUNCT	:	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
AmB	AmB	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
using	use	VERB	VBG	9	O
renal	renal	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
cultures	culture	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
by	by	ADP	IN	9	O
biochemical	biochemical	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
histopathological	histopathological	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphotericin	amphotericin	NOUN	NN	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
following	follow	VERB	VBG	9	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
formulation	formulation	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Incubation	incubation	NOUN	NN	0	O
with	with	ADP	IN	5	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
718	718	PROPN	NNP	7	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
damage	damage	NOUN	NN	9	O
of	of	ADP	IN	5	O
cultured	cultured	ADJ	JJ	3	O
human	human	ADJ	JJ	3	O
renal	renal	ADJ	JJ	9	O
proximal	proximal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
epithelial	epithelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
AmB	AmB	PROPN	NNP	0	I-Chemical
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
urea	urea	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
an	an	DET	DT	5	O
iv	iv	NUM	CD	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
AmB	AmB	PROPN	NNP	0	I-Chemical
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
given	give	VERB	VBN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
718	718	NUM	CD	7	O
.	.	PUNCT	.	9	O

Histopathological	histopathological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
tubular	tubular	ADJ	JJ	9	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
AmB	AmB	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
718	718	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Amphotericin	Amphotericin	PROPN	NNP	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
in	in	ADP	IN	5	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
718	718	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
AmB	AmB	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
incorporation	incorporation	NOUN	NN	0	O
of	of	ADP	IN	5	O
amphotericin	amphotericin	PROPN	NNP	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
into	into	ADP	IN	9	O
lipid	lipid	NOUN	NN	0	O
nanospheres	nanosphere	NOUN	NNS	0	O
of	of	ADP	IN	5	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
718	718	PROPN	NNP	7	O
attenuates	attenuate	VERB	VBZ	3	O
the	the	DET	DT	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
amphotericin	amphotericin	PROPN	NNP	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
.	.	PUNCT	.	9	O

Patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
sulfadiazine	sulfadiazine	NOUN	NN	0	B-Chemical
acute	acute	ADJ	JJ	9	B-Disease
nephrotoxicity	nephrotoxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Sulfadiazine	sulfadiazine	ADJ	JJ	7	B-Chemical
acute	acute	ADJ	JJ	9	B-Disease
nephrotoxicity	nephrotoxicity	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
reviving	revive	VERB	VBG	5	O
specially	specially	ADV	RB	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
toxoplasmosis	toxoplasmosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
4	4	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
previously	previously	ADV	RB	9	O
healthy	healthy	ADJ	JJ	5	O
person	person	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Under	under	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
sulfadiazine	sulfadiazine	NOUN	NN	0	B-Chemical
they	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
oliguria	oliguria	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
showed	show	VERB	VBD	9	O
multiple	multiple	ADJ	JJ	5	O
radiolucent	radiolucent	NOUN	NN	5	O
renal	renal	ADJ	JJ	9	B-Disease
calculi	calculi	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
echography	echography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
recovered	recover	VERB	VBD	9	O
their	-PRON-	DET	PRP$	5	O
previous	previous	ADJ	JJ	9	O
normal	normal	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
after	after	ADP	IN	9	O
adequate	adequate	ADJ	JJ	5	O
hydration	hydration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
alcalinization	alcalinization	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
nephrostomy	nephrostomy	ADJ	JJ	5	O
tube	tube	NOUN	NN	9	O
had	have	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
placed	place	VERB	VBN	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
for	for	ADP	IN	5	O
ureteral	ureteral	ADJ	JJ	5	B-Disease
lithiasis	lithiasis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
functional	functional	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
needed	need	VERB	VBD	5	O
dialysis	dialysis	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
biopsy	biopsy	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
typical	typical	ADJ	JJ	9	O
benign	benign	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
sulfadiazine	sulfadiazine	NOUN	NN	0	B-Chemical
requires	require	VERB	VBZ	5	O
exquisite	exquisite	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
water	water	NOUN	NN	0	O
ingestion	ingestion	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
possibly	possibly	ADV	RB	9	O
the	the	DET	DT	5	O
alcalinization	alcalinization	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
urine	urine	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
communicate	communicate	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
previously	previously	ADV	RB	9	O
healthy	healthy	ADJ	JJ	5	O
person	person	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
fact	fact	NOUN	NN	9	O
not	not	ADV	RB	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
recent	recent	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Probably	probably	ADV	RB	9	O
many	many	ADJ	JJ	5	O
more	more	ADJ	JJR	5	O
cases	case	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
detected	detect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
think	think	VERB	VBP	5	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Downbeat	Downbeat	VERB	VBN	5	B-Disease
nystagmus	nystagmus	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
patient	patient	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

IMPLICATIONS	implications	NOUN	NN	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
documents	document	VERB	VBZ	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
dizziness	dizziness	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
downbeating	downbeate	VERB	VBG	5	B-Disease
nystagmus	nystagmus	NOUN	NN	5	I-Disease
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
large	large	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
IV	IV	PROPN	NNP	9	O
patient	patient	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
analgesia	analgesia	NOUN	NN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
there	there	ADV	EX	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
epidural	epidural	ADJ	JJ	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
these	these	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
signs	sign	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
documented	document	VERB	VBN	9	O
with	with	ADP	IN	5	O
IV	IV	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
patient	patient	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
analgesia	analgesia	NOUN	NN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Hemodynamic	hemodynamic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
antiadrenergic	antiadrenergic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dronedarone	dronedarone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
healed	heal	VERB	VBN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hemodynamic	hemodynamic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
antiadrenergic	antiadrenergic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dronedarone	dronedarone	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
noniodinated	noniodinate	VERB	VBN	0	O
compound	compound	NOUN	NN	0	O
structurally	structurally	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
at	at	ADP	IN	9	O
rest	rest	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
healed	heal	VERB	VBN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
dogs	dog	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
randomly	randomly	ADV	RB	5	O
received	receive	VERB	VBD	9	O
orally	orally	ADV	RB	0	O
dronedarone	dronedarone	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
placebo	placebo	VERB	VB	9	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
washout	washout	NOUN	NN	0	O
between	between	ADP	IN	5	O
consecutive	consecutive	ADJ	JJ	5	O
treatments	treatment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Heart	heart	NOUN	NN	2	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HR	HR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MBP	MBP	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
positive	positive	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
LVdP	LVdP	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
dt	dt	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
echocardiographically	echocardiographically	ADV	RB	5	O
assessed	assess	VERB	VBN	9	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
LVEF	LVEF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
fractional	fractional	ADJ	JJ	5	O
shortening	shortening	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
FS	FS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
chronotropic	chronotropic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
exercise	exercise	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
sympathetic	sympathetic	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
under	under	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
posttreatment	posttreatment	ADJ	JJ	9	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Resting	rest	VERB	VBG	9	O
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
LVEF	LVEF	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
FS	FS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
+	+	CCONJ	CC	9	O
LVdP	LVdP	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
dt	dt	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
MBP	MBP	PROPN	NNP	3	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
whatever	whatever	DET	WDT	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
dosing	dosing	ADJ	JJ	9	O
regimen	regiman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
resting	rest	VERB	VBG	5	O
HR	hr	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	:	7	O
dependently	dependently	ADV	RB	3	O
lowered	lower	VERB	VBN	9	O
after	after	ADP	IN	9	O
dronedarone	dronedarone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
lesser	less	ADJ	JJR	9	O
extent	extent	NOUN	NN	9	O
after	after	ADP	IN	9	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
dronedarone	dronedarone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
exercise	exercise	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
dronedarone	dronedarone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
displayed	display	VERB	VBD	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
antiadrenergic	antiadrenergic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
impair	impair	VERB	VB	9	O
the	the	DET	DT	5	O
resting	rest	VERB	VBG	5	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Consequently	consequently	ADV	RB	9	O
,	,	PUNCT	,	9	O
dronedarone	dronedarone	NOUN	NN	5	B-Chemical
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
particularly	particularly	ADV	RB	5	O
suitable	suitable	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
various	various	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
compromising	compromise	VERB	VBG	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Phase	Phase	PROPN	NNP	9	O
2	2	NUM	CD	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
platinum	platinum	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
refractory	refractory	NOUN	NN	9	O
ovarian	ovarian	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
fallopian	fallopian	ADJ	JJ	5	I-Disease
tube	tube	NOUN	NN	9	I-Disease
cancers	cancer	NOUN	NNS	9	I-Disease
and	and	CCONJ	CC	5	O
primary	primary	ADJ	JJ	9	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
peritoneum	peritoneum	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Several	several	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
demonstrated	demonstrate	VERB	VBN	9	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Doxil	Doxil	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
active	active	ADJ	JJ	9	O
antineoplastic	antineoplastic	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
in	in	ADP	IN	5	O
platinum	platinum	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
limiting	limit	VERB	VBG	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
dosing	dosing	NOUN	NN	9	O
regimen	regimen	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
q	q	NOUN	NN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
being	be	VERB	VBG	5	O
severe	severe	ADJ	JJ	5	O
erythrodysesthesia	erythrodysesthesia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
"	"	PUNCT	``	5	O
hand	hand	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
foot	foot	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
"	"	PUNCT	''	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
stomatitis	stomatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
wished	wish	VERB	VBD	9	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
tolerable	tolerable	ADJ	JJ	5	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
regimen	regiman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
document	document	VERB	VB	5	O
its	-PRON-	DET	PRP$	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
defined	define	VERB	VBN	5	O
patient	patient	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
with	with	ADP	IN	5	O
platinum	platinum	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
refractory	refractory	NOUN	NN	9	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
MATERIALS	material	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
or	or	CCONJ	CC	5	I-Disease
fallopian	fallopian	ADJ	JJ	5	I-Disease
tube	tube	NOUN	NN	9	I-Disease
cancers	cancer	NOUN	NNS	9	I-Disease
or	or	CCONJ	CC	5	O
primary	primary	ADJ	JJ	9	O
peritoneal	peritoneal	ADJ	JJ	3	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
with	with	ADP	IN	5	O
platinum	platinum	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
refractory	refractory	NOUN	NN	9	O
disease	disease	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
stable	stable	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
progressive	progressive	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
previous	previous	ADJ	JJ	9	O
objective	objective	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
<	<	X	XX	0	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
in	in	ADP	IN	5	O
duration	duration	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
q	q	NOUN	NN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
49	49	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
:	:	PUNCT	:	9	O
60	60	NUM	CD	9	O
;	;	PUNCT	:	9	O
range	range	VERB	VBP	9	O
41	41	NUM	CD	7	O
-	-	SYM	SYM	7	O
81	81	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
entered	enter	VERB	VBD	5	O
this	this	DET	DT	5	O
phase	phase	NOUN	NN	5	O
2	2	NUM	CD	9	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
regimens	regimen	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
grade	grade	NOUN	NN	9	O
2	2	NUM	CD	9	O
hand	hand	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
foot	foot	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
stomatitis	stomatitis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
no	no	DET	DT	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBN	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
diarrhea	diarrhea	NOUN	NN	5	B-Disease
requiring	require	VERB	VBG	5	O
hospitalization	hospitalization	NOUN	NN	5	O
for	for	ADP	IN	5	O
hydration	hydration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
individuals	individual	NOUN	NNS	5	O
required	require	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
reductions	reduction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
administered	administer	VERB	VBN	9	O
on	on	ADP	IN	5	O
this	this	DET	DT	5	O
protocol	protocol	NOUN	NN	9	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
of	of	ADP	IN	5	O
44	44	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
evaluable	evaluable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
response	response	NOUN	NN	9	O
exhibited	exhibit	VERB	VBD	9	O
objective	objective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
subjective	subjective	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
antineoplastic	antineoplastic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
modified	modify	VERB	VBN	9	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
regimen	regimen	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
less	less	ADJ	JJR	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
stomatitis	stomatitis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
hand	hand	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
foot	foot	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
FDA	FDA	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
approved	approve	VERB	VBN	2	O
dose	dose	NOUN	NN	9	O
schedule	schedule	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Definite	definite	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
limited	limited	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
antineoplastic	antineoplastic	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
defined	define	VERB	VBN	5	O
platinum	platinum	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
refractory	refractory	NOUN	NN	9	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Efficacy	efficacy	NOUN	NN	5	O
of	of	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
mania	mania	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Olanzipine	Olanzipine	PROPN	NNP	_	B-Chemical
HGGW	HGGW	PROPN	NNP	_	O
Study	Study	PROPN	NNP	5	O
Group	Group	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
vs	vs	ADP	IN	7	O
placebo	placebo	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
mania	mania	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Four	four	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
parallel	parallel	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
115	115	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
DSM	DSM	PROPN	NNP	4	O
-	-	PUNCT	HYPH	7	O
IV	IV	PROPN	NNP	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
manic	manic	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	O
mixed	mixed	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	ADP	IN	5	O
olanzapine	olanzapine	VERB	VB	5	B-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
55	55	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
60	60	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
measure	measure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
Young	Young	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Mania	Mania	PROPN	NNP	5	B-Disease
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
Y	Y	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MRS	MRS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
total	total	ADJ	JJ	9	O
score	score	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Response	response	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
euthymia	euthymia	NOUN	NN	5	O
were	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
priori	priori	X	FW	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
a	a	DET	DT	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
improvement	improvement	NOUN	NN	5	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
to	to	ADP	IN	5	O
end	end	NOUN	NN	9	O
point	point	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
score	score	NOUN	NN	5	O
of	of	ADP	IN	5	O
no	no	DET	DT	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
12	12	NUM	CD	9	O
at	at	ADP	IN	9	O
end	end	NOUN	NN	9	O
point	point	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Y	Y	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MRS	MRS	PROPN	NNP	9	O
total	total	ADJ	JJ	9	O
score	score	NOUN	NN	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
using	use	VERB	VBG	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
Extrapyramidal	Extrapyramidal	PROPN	NNP	5	B-Disease
Symptom	Symptom	PROPN	NNP	5	I-Disease
(	(	PUNCT	-LRB-	9	O
EPS	EPS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
rating	rating	NOUN	NN	5	O
scales	scale	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
laboratory	laboratory	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
electrocardiograms	electrocardiogram	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
vital	vital	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
weight	weight	NOUN	NN	9	O
change	change	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Olanzapine	olanzapine	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
greater	great	ADJ	JJR	5	O
mean	mean	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
Y	Y	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MRS	MRS	PROPN	NNP	9	O
total	total	ADJ	JJ	9	O
score	score	NOUN	NN	5	O
than	than	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
evident	evident	ADJ	JJ	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
postbaseline	postbaseline	ADJ	JJ	5	O
observation	observation	NOUN	NN	9	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
after	after	ADP	IN	9	O
randomization	randomization	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
last	last	ADJ	JJ	5	O
observation	observation	NOUN	NN	9	O
carried	carry	VERB	VBN	9	O
forward	forward	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Olanzapine	Olanzapine	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
65	65	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
euthymia	euthymia	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
61	61	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
36	36	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
EPSs	eps	NOUN	NNS	0	B-Disease
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
greater	great	ADJ	JJR	5	O
mean	mean	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
than	than	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
vs	vs	ADP	IN	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
45	45	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
experienced	experience	VERB	VBD	5	O
more	more	ADJ	JJR	5	O
treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
emergent	emergent	NOUN	NN	5	O
somnolence	somnolence	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
21	21	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
[	[	PUNCT	-LRB-	9	O
38	38	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
vs	vs	ADP	IN	7	O
5	5	NUM	CD	9	O
[	[	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Olanzapine	Olanzapine	PROPN	NNP	7	B-Chemical
demonstrated	demonstrate	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
efficacy	efficacy	NOUN	NN	9	O
than	than	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
mania	mania	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
generally	generally	ADV	RB	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
pupil	pupil	NOUN	NN	5	B-Disease
dilation	dilation	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
tropicamide	tropicamide	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
vision	vision	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
driving	drive	VERB	VBG	5	O
simulator	simulator	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
pupil	pupil	NOUN	NN	5	B-Disease
dilation	dilation	NOUN	NN	5	I-Disease
on	on	ADP	IN	5	O
vision	vision	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
driving	drive	VERB	VBG	5	O
ability	ability	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
tests	test	NOUN	NNS	5	O
on	on	ADP	IN	5	O
various	various	ADJ	JJ	9	O
parameters	parameter	NOUN	NNS	5	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
driving	drive	VERB	VBG	5	O
simulator	simulator	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
12	12	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
drivers	driver	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
pupil	pupil	NOUN	NN	5	B-Disease
dilation	dilation	NOUN	NN	5	I-Disease
using	use	VERB	VBG	9	O
guttae	guttae	NOUN	NN	5	O
tropicamide	tropicamide	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
driving	drive	VERB	VBG	5	O
simulator	simulator	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
Transport	Transport	PROPN	NNP	9	O
Research	Research	PROPN	NNP	2	O
Laboratory	Laboratory	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
reaction	reaction	NOUN	NN	9	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
RT	RT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
speed	speed	NOUN	NN	5	O
maintenance	maintenance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
steering	steering	NOUN	NN	5	O
accuracy	accuracy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Tests	test	NOUN	NNS	5	O
of	of	ADP	IN	5	O
basic	basic	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
included	include	VERB	VBD	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
contrast	contrast	NOUN	NN	9	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
HCVA	HCVA	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
LCVA	LCVA	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Pelli	Pelli	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Robson	Robson	PROPN	NNP	6	O
contrast	contrast	NOUN	NN	9	O
threshold	threshold	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CT	CT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Goldmann	Goldmann	PROPN	NNP	6	O
perimetry	perimetry	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
FIELDS	FIELDS	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Useful	useful	ADJ	JJ	5	O
Field	Field	PROPN	NNP	9	O
of	of	ADP	IN	5	O
View	View	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
UFOV	UFOV	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	:	7	O
a	a	DET	DT	5	O
test	test	NOUN	NN	5	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	O
attention	attention	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
undertaken	undertake	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
dilatation	dilatation	ADJ	JJ	5	O
measurements	measurement	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
level	level	NOUN	NN	9	O
using	use	VERB	VBG	9	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
tail	tail	NOUN	NN	9	O
paired	pair	VERB	VBN	9	O
t	t	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Pupillary	pupillary	ADJ	JJ	5	B-Disease
dilation	dilation	NOUN	NN	5	I-Disease
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
deterioration	deterioration	NOUN	NN	5	O
in	in	ADP	IN	5	O
CT	CT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
HCVA	HCVA	PROPN	NNP	7	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
drivers	driver	NOUN	NNS	5	O
also	also	ADV	RB	9	O
exhibited	exhibit	VERB	VBD	9	O
deterioration	deterioration	NOUN	NN	5	O
in	in	ADP	IN	5	O
LCVA	LCVA	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
CT	CT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
RT	RT	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Little	little	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
emerged	emerge	VERB	VBD	9	O
for	for	ADP	IN	5	O
deterioration	deterioration	NOUN	NN	5	O
in	in	ADP	IN	5	O
FIELDS	FIELDS	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
UFOV	UFOV	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
drivers	driver	NOUN	NNS	5	O
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
adjust	adjust	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
driving	drive	VERB	VBG	5	O
behaviour	behaviour	NOUN	NN	5	O
by	by	ADP	IN	9	O
reducing	reduce	VERB	VBG	9	O
their	-PRON-	DET	PRP$	5	O
speed	speed	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
driving	driving	NOUN	NN	5	O
simulator	simulator	NOUN	NN	5	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
improved	improve	VERB	VBN	5	O
steering	steering	NOUN	NN	5	O
accuracy	accuracy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Pupillary	pupillary	ADJ	JJ	5	B-Disease
dilation	dilation	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
vision	vision	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
daylight	daylight	NOUN	NN	5	O
driving	drive	VERB	VBG	5	O
performance	performance	NOUN	NN	5	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
people	people	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
larger	large	ADJ	JJR	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
a	a	DET	DT	5	O
broader	broad	ADJ	JJR	5	O
spectrum	spectrum	NOUN	NN	9	O
of	of	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
before	before	ADP	IN	9	O
guidelines	guideline	NOUN	NNS	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
recommended	recommend	VERB	VBN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
isotretinoin	isotretinoin	NOUN	NN	5	B-Disease
embryopathy	embryopathy	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
anotia	anotia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
Taussig	Taussig	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Bing	Bing	PROPN	NNP	6	I-Disease
malformation	malformation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
newborn	newborn	ADJ	JJ	9	O
infant	infant	NOUN	NN	5	O
with	with	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
congenital	congenital	ADJ	JJ	5	O
anomalies	anomaly	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
anotia	anotia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
Taussig	Taussig	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Bing	Bing	PROPN	NNP	6	I-Disease
malformation	malformation	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
exposure	exposure	NOUN	NN	9	O
to	to	PART	TO	5	O
isotretinoin	isotretinoin	VERB	VB	5	B-Chemical
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
trimester	trimester	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
aim	aim	VERB	VBP	5	O
to	to	PART	TO	5	O
draw	draw	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
fact	fact	NOUN	NN	9	O
that	that	ADP	IN	5	O
caution	caution	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
needed	need	VERB	VBN	5	O
when	when	ADV	WRB	5	O
prescribing	prescribe	VERB	VBG	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
A	a	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
drugs	drug	NOUN	NNS	5	O
to	to	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
of	of	ADP	IN	5	O
childbearing	childbeare	VERB	VBG	5	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
methoxamine	methoxamine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
maximum	maximum	ADJ	JJ	5	O
urethral	urethral	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
genuine	genuine	ADJ	JJ	5	O
stress	stress	NOUN	NN	9	B-Disease
incontinence	incontinence	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
crossover	crossover	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
alpha1	alpha1	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
agonist	agonist	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	B-Disease
stress	stress	NOUN	NN	9	I-Disease
incontinence	incontinence	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
randomised	randomise	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
crossover	crossover	NOUN	NN	5	O
study	study	NOUN	NN	9	O
design	design	NOUN	NN	5	O
was	be	VERB	VBD	9	O
employed	employ	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Half	half	NOUN	NN	9	O
log	log	VERB	VBP	9	O
incremental	incremental	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
methoxamine	methoxamine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
saline	saline	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
genuine	genuine	ADJ	JJ	5	O
stress	stress	NOUN	NN	9	B-Disease
incontinence	incontinence	NOUN	NN	5	I-Disease
while	while	ADP	IN	9	O
measuring	measure	VERB	VBG	9	O
maximum	maximum	ADJ	JJ	5	O
urethral	urethral	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MUP	MUP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Methoxamine	Methoxamine	PROPN	NNP	0	B-Chemical
evoked	evoke	VERB	VBD	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
significant	significant	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
MUP	MUP	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	B-Disease
significant	significant	ADJ	JJ	9	I-Disease
rise	rise	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	I-Disease
systolic	systolic	ADJ	JJ	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
significant	significant	ADJ	JJ	9	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
at	at	ADP	IN	9	O
maximum	maximum	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
including	include	VERB	VBG	9	O
piloerection	piloerection	NOUN	NN	5	O
,	,	PUNCT	,	9	O
headache	headache	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cold	cold	ADJ	JJ	9	O
extremities	extremity	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
experienced	experience	VERB	VBN	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
usefulness	usefulness	NOUN	NN	5	O
of	of	ADP	IN	5	O
direct	direct	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
peripherally	peripherally	ADV	RB	9	O
acting	act	VERB	VBG	9	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
selective	selective	ADJ	JJ	9	O
alpha1	alpha1	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
agonists	agonist	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
stress	stress	NOUN	NN	9	B-Disease
incontinence	incontinence	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
limited	limit	VERB	VBN	5	O
by	by	ADP	IN	9	O
associated	associated	ADJ	JJ	9	O
piloerection	piloerection	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Hyperglycemic	Hyperglycemic	PROPN	NNP	3	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
amino	amino	ADJ	JJ	1	B-Chemical
compounds	compound	NOUN	NNS	0	O
structurally	structurally	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	PART	TO	5	O
caproate	caproate	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
feeding	feeding	NOUN	NN	5	O
of	of	ADP	IN	5	O
small	small	ADJ	JJ	9	O
amounts	amount	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
diet	diet	NOUN	NN	9	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
amino	amino	ADJ	JJ	1	B-Chemical
derivatives	derivative	NOUN	NNS	0	O
of	of	ADP	IN	5	O
caproate	caproate	NOUN	NN	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
hyperglycemia	hyperglycemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
tolerance	tolerance	NOUN	NN	9	O
curve	curve	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
occasionally	occasionally	ADV	RB	5	O
,	,	PUNCT	,	9	O
glucosuria	glucosuria	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Effective	effective	ADJ	JJ	5	O
compounds	compound	NOUN	NNS	0	O
included	include	VERB	VBD	5	O
norleucine	norleucine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
norvaline	norvaline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
epsilon	epsilon	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminocaproate	aminocaproate	ADJ	JJ	0	I-Chemical
,	,	PUNCT	,	9	O
methionine	methionine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
leucine	leucine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Toleration	toleration	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
converting	convert	VERB	VBG	9	I-Chemical
enzyme	enzyme	ADJ	JJ	0	I-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
results	result	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
ATLAS	ATLAS	PROPN	NNP	2	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Assessment	Assessment	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Treatment	Treatment	PROPN	NNP	9	O
with	with	ADP	IN	5	O
Lisinopril	Lisinopril	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
Survival	Survival	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
converting	convert	VERB	VBG	9	I-Chemical
enzyme	enzyme	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
ACE	ACE	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
reduces	reduce	VERB	VBZ	9	O
mortality	mortality	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
morbidity	morbidity	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CHF	CHF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
most	most	ADJ	JJS	9	O
affected	affected	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
receiving	receive	VERB	VBG	9	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
are	be	VERB	VBP	5	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
efficacious	efficacious	ADJ	JJ	5	O
in	in	ADP	IN	5	O
trials	trial	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
primarily	primarily	ADV	RB	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
concerns	concern	NOUN	NNS	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
recommended	recommend	VERB	VBN	5	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
examines	examine	VERB	VBZ	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
high	high	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
lisinopril	lisinopril	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
Assessment	Assessment	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Lisinopril	Lisinopril	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
Survival	Survival	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
previous	previous	ADJ	JJ	9	O
ACE	ACE	PROPN	NNP	9	B-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
treatment	treatment	NOUN	NN	9	O
were	be	VERB	VBD	9	O
stabilized	stabilize	VERB	VBN	9	O
receiving	receive	VERB	VBG	9	O
medium	medium	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
lisinopril	lisinopril	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
or	or	CCONJ	CC	5	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
[	[	PUNCT	-LRB-	9	O
OD	OD	PROPN	NNP	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
randomized	randomize	VERB	VBN	5	O
to	to	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
(	(	PUNCT	-LRB-	9	O
35	35	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
or	or	CCONJ	CC	5	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
OD	OD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	NUM	CD	7	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
OD	OD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
New	New	PROPN	NNP	2	O
York	York	PROPN	NNP	2	O
Heart	Heart	PROPN	NNP	2	O
Association	Association	PROPN	NNP	2	O
classes	class	VERB	VBZ	5	O
II	II	PROPN	NNP	9	O
to	to	ADP	IN	5	O
IV	IV	PROPN	NNP	9	O
CHF	CHF	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fractions	fraction	NOUN	NNS	0	O
of	of	ADP	IN	5	O
no	no	DET	DT	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
30	30	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
3164	3164	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
followed	follow	VERB	VBD	9	O
up	up	PART	RP	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
median	median	NOUN	NN	9	O
of	of	ADP	IN	5	O
46	46	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
discontinuation	discontinuation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
focus	focus	NOUN	NN	5	O
on	on	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Of	of	ADP	IN	9	O
405	405	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
receiving	receive	VERB	VBG	9	O
an	an	DET	DT	5	O
ACE	ACE	PROPN	NNP	9	B-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
,	,	PUNCT	,	9	O
doses	dose	VERB	VBZ	0	O
in	in	ADP	IN	5	O
only	only	ADV	RB	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
could	could	VERB	MD	9	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
titrated	titrate	VERB	VBN	0	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
medium	medium	ADJ	JJ	0	O
doses	dose	NOUN	NNS	0	O
required	require	VERB	VBN	9	O
for	for	ADP	IN	5	O
randomization	randomization	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
possibly	possibly	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Doses	dose	NOUN	NNS	0	O
in	in	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
randomized	randomize	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
titrated	titrate	VERB	VBN	0	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
assigned	assign	VERB	VBN	5	O
target	target	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
blinded	blinded	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
remained	remain	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Withdrawals	withdrawal	NOUN	NNS	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Subgroups	subgroup	NOUN	NNS	5	O
presumed	presume	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
at	at	ADP	IN	9	O
higher	high	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
ACE	ACE	PROPN	NNP	9	B-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
intolerance	intolerance	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
<	<	X	XX	0	O
120	120	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
;	;	PUNCT	:	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
132	132	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
[	[	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
]	]	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
70	70	NUM	CD	9	O
years	year	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
)	)	PUNCT	-RRB-	9	O
generally	generally	ADV	RB	5	O
tolerated	tolerate	VERB	VBD	9	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
strategy	strategy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
ACE	ACE	PROPN	NNP	9	B-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
successfully	successfully	ADV	RB	5	O
titrated	titrate	VERB	VBN	0	O
to	to	ADP	IN	5	O
and	and	CCONJ	CC	5	O
maintained	maintain	VERB	VBD	9	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
more	more	ADV	RBR	5	O
aggressive	aggressive	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Cocaine	Cocaine	PROPN	NNP	5	B-Chemical
,	,	PUNCT	,	9	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cocaethylene	cocaethylene	VERB	VB	0	B-Chemical
cardiotoxity	cardiotoxity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
ethanol	ethanol	NOUN	NN	0	I-Disease
abuse	abuse	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Simultaneous	simultaneous	ADJ	JJ	9	O
abuse	abuse	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
cocaine	cocaine	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
ethanol	ethanol	NOUN	NN	0	I-Disease
affects	affect	VERB	VBZ	9	O
12	12	NUM	CD	9	O
million	million	NUM	CD	5	O
Americans	Americans	PROPN	NNPS	5	O
annually	annually	ADV	RB	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
combination	combination	NOUN	NN	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
substances	substance	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
substantially	substantially	ADV	RB	9	O
more	more	ADV	RBR	5	O
toxic	toxic	ADJ	JJ	0	O
than	than	ADP	IN	5	O
either	either	DET	DT	9	O
drug	drug	NOUN	NN	5	O
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

Their	-PRON-	DET	PRP$	5	O
combined	combine	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
independent	independent	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
drug	drug	NOUN	NN	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
cocaethylene	cocaethylene	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CE	CE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
metabolite	metabolite	NOUN	NN	0	O
formed	form	VERB	VBN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
delineate	delineate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
CE	CE	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
simulating	simulate	VERB	VBG	5	O
their	-PRON-	DET	PRP$	5	O
abuse	abuse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
either	either	CCONJ	CC	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
three	three	NUM	CD	9	O
intravenous	intravenous	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
IV	IV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
boluses	bolus	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
with	with	ADP	IN	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
IV	IV	PROPN	NNP	9	O
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
C	c	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
E	e	NOUN	NN	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
three	three	NUM	CD	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
boluses	boluse	VERB	VBZ	5	O
only	only	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
C	c	NOUN	NN	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
only	only	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
E	e	NOUN	NN	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
placebo	placebo	NOUN	NN	9	O
boluses	bolus	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Hemodynamic	hemodynamic	ADJ	JJ	5	O
measurements	measurement	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
electrocardiograms	electrocardiogram	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
serum	serum	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
at	at	ADP	IN	9	O
fixed	fix	VERB	VBN	9	O
time	time	NOUN	NN	5	O
intervals	interval	NOUN	NNS	5	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
of	of	ADP	IN	5	O
eight	eight	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
C	c	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
E	e	NOUN	NN	9	O
group	group	NOUN	NN	9	O
experienced	experience	VERB	VBD	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
collapse	collapse	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
dramatic	dramatic	ADJ	JJ	9	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
bolus	bolus	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
C	c	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
E	E	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
C	C	PROPN	NNP	9	O
only	only	ADV	RB	9	O
groups	group	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
persistent	persistent	ADJ	JJ	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
C	c	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
E	e	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Peak	Peak	PROPN	NNP	9	O
CE	CE	PROPN	NNP	9	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
45	45	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SD	sd	NOUN	NN	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
69	69	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
decrease	decrease	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
cardiac	cardiac	ADJ	JJ	5	I-Disease
output	output	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
56	56	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SD	sd	NOUN	NN	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
23	23	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
32	32	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
dP	dP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dt	dt	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
max	max	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
006	006	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
23	23	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SD	sd	NOUN	NN	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
49	49	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
SVO	SVO	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
025	025	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
primarily	primarily	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
C	c	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
E	e	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
four	four	NUM	CD	9	O
of	of	ADP	IN	5	O
eight	eight	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
toxic	toxic	ADJ	JJ	0	O
than	than	ADP	IN	5	O
either	either	DET	DT	9	O
substance	substance	NOUN	NN	5	O
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

Co	co	NOUN	NN	0	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
dysrhythmogenic	dysrhythmogenic	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Peak	peak	NOUN	NN	9	O
serum	serum	NOUN	NN	9	O
cocaethylene	cocaethylene	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
depression	depression	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Worsening	worsen	VERB	VBG	5	O
of	of	ADP	IN	5	O
Parkinsonism	Parkinsonism	PROPN	NNP	5	B-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
veralipride	veralipride	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
menopause	menopause	NOUN	NN	5	O
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
female	female	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
stable	stable	ADJ	JJ	9	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
has	have	VERB	VBZ	9	O
shown	show	VERB	VBN	9	O
a	a	DET	DT	5	O
marked	mark	VERB	VBN	9	O
worsening	worsening	NOUN	NN	5	O
of	of	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
motor	motor	NOUN	NN	5	O
functions	function	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
menopause	menopause	NOUN	NN	5	O
related	relate	VERB	VBN	9	O
symptoms	symptom	NOUN	NNS	5	O
with	with	ADP	IN	5	O
veralipride	veralipride	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
symptoms	symptom	NOUN	NNS	5	O
back	back	ADV	RB	5	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
emphasize	emphasize	VERB	VBP	5	O
the	the	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
veralipride	veralipride	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Viracept	viracept	ADJ	JJ	7	B-Chemical
and	and	CCONJ	CC	5	O
irregular	irregular	ADJ	JJ	5	B-Disease
heartbeat	heartbeat	ADJ	JJ	5	I-Disease
warning	warning	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
doctors	doctor	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Boston	Boston	PROPN	NNP	2	O
warn	warn	VERB	VBP	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
protease	protease	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
Viracept	Viracept	PROPN	NNP	7	B-Chemical
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
an	an	DET	DT	5	O
irregular	irregular	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
beat	beat	VERB	VBD	5	I-Disease
,	,	PUNCT	,	9	O
known	know	VERB	VBN	9	O
as	as	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
people	people	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Bradycardia	Bradycardia	PROPN	NNP	7	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
45	45	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
Viracept	Viracept	PROPN	NNP	7	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
HIV	hiv	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
ceased	cease	VERB	VBD	5	O
after	after	ADP	IN	9	O
switching	switch	VERB	VBG	5	O
to	to	ADP	IN	5	O
another	another	DET	DT	9	O
drug	drug	NOUN	NN	5	O
combination	combination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
myeloperoxidase	myeloperoxidase	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
antineutrophil	antineutrophil	NOUN	NN	3	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
antibody	antibody	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
Graves	Graves	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Myeloperoxidase	myeloperoxidase	NOUN	NN	0	O
antineutrophil	antineutrophil	NOUN	NN	3	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
antibody	antibody	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Graves	Graves	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PTU	PTU	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
of	of	ADP	IN	5	O
being	be	VERB	VBG	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
PTU	PTU	PROPN	NNP	0	B-Chemical
because	because	ADP	IN	5	O
the	the	DET	DT	5	O
titres	titre	NOUN	NNS	9	O
of	of	ADP	IN	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
decreased	decrease	VERB	VBD	9	O
when	when	ADV	WRB	5	O
PTU	PTU	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Nevertheless	nevertheless	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
no	no	DET	DT	9	O
studies	study	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
PTU	PTU	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
in	in	ADP	IN	5	O
untreated	untreated	ADJ	JJ	3	O
Graves	Graves	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
sought	seek	VERB	VBD	9	O
to	to	PART	TO	5	O
address	address	VERB	VB	5	O
these	these	DET	DT	5	O
parameters	parameter	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Graves	Graves	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
102	102	NUM	CD	7	O
untreated	untreated	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hyperthyroidism	hyperthyroidism	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
Graves	Graves	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
PTU	ptu	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
later	later	ADV	RB	9	O
excluded	exclude	VERB	VBN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
PTU	PTU	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
because	because	ADP	IN	5	O
the	the	DET	DT	5	O
observation	observation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
was	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
73	73	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
55	55	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
men	man	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
adopted	adopt	VERB	VBN	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
observation	observation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
was	be	VERB	VBD	9	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
:	:	PUNCT	:	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
37	37	NUM	CD	9	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

MEASUREMENTS	measurement	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
at	at	ADP	IN	9	O
intervals	interval	NOUN	NNS	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Before	before	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
titres	titre	NOUN	NNS	9	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
102	102	NUM	CD	7	O
untreated	untreated	ADJ	JJ	3	O
Graves	Graves	PROPN	NNPS	5	B-Disease
'	'	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
reference	reference	NOUN	NN	9	O
range	range	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
below	below	ADP	IN	9	O
10	10	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
73	73	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
for	for	ADP	IN	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
at	at	ADP	IN	9	O
13	13	NUM	CD	7	O
,	,	PUNCT	,	9	O
16	16	NUM	CD	9	O
and	and	CCONJ	CC	5	O
17	17	NUM	CD	7	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
PTU	PTU	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
titres	titre	NOUN	NNS	9	O
transiently	transiently	ADV	RB	3	O
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
continued	continue	VERB	VBN	9	O
PTU	PTU	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
vasculitic	vasculitic	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
developed	develop	VERB	VBD	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
titre	titre	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
204	204	NUM	CD	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
she	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
fever	fever	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
oral	oral	ADJ	JJ	9	B-Disease
ulcers	ulcer	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
polyarthralgia	polyarthralgia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
resolved	resolve	VERB	VBD	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
stopping	stop	VERB	VBG	5	O
PTU	PTU	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
titre	titre	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
to	to	ADP	IN	5	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
by	by	ADP	IN	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
discontinuing	discontinue	VERB	VBG	5	O
PTU	PTU	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
PTU	ptu	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
MPO	MPO	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
closely	closely	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Prevalence	prevalence	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
chronic	chronic	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
outpatient	outpatient	NOUN	NN	5	O
young	young	ADJ	JJ	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
chronic	chronic	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
35	35	NUM	CD	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
32	32	NUM	CD	7	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
controls	control	NOUN	NNS	9	O
underwent	undergo	VERB	VBD	5	O
resting	rest	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
exercise	exercise	NOUN	NN	5	O
electrocardiography	electrocardiography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ECG	ECG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Doppler	Doppler	PROPN	NNP	5	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Findings	finding	NOUN	NNS	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
34	34	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Decreased	Decreased	PROPN	NNP	9	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
systolic	systolic	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
055	055	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
resting	rest	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
peak	peak	NOUN	NN	9	O
exercise	exercise	NOUN	NN	5	O
abnormal	abnormal	ADJ	JJ	9	B-Disease
left	leave	VERB	VBN	5	I-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
filling	filling	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
38	38	NUM	CD	7	O
and	and	CCONJ	CC	5	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
19	19	NUM	CD	7	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
11	11	NUM	CD	7	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	I-Disease
myocardial	myocardial	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
common	common	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
38	38	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
chronic	chronic	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
screening	screen	VERB	VBG	5	O
ECG	ECG	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
echocardiography	echocardiography	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
warranted	warrant	VERB	VBN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cardioprotective	cardioprotective	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Picrorrhiza	Picrorrhiza	PROPN	NNP	4	O
kurroa	kurroa	VERB	VBP	4	O
against	against	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
extract	extract	NOUN	NN	0	O
of	of	ADP	IN	5	O
Picrorrhiza	Picrorrhiza	PROPN	NNP	4	O
kurroa	kurroa	VERB	VBP	4	O
rhizomes	rhizome	NOUN	NNS	4	O
and	and	CCONJ	CC	5	O
roots	root	NOUN	NNS	4	O
(	(	PUNCT	-LRB-	9	O
PK	PK	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
metabolism	metabolism	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
tissue	tissue	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
PK	PK	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
15	15	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
significantly	significantly	ADV	RB	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
maintained	maintain	VERB	VBD	9	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
at	at	ADP	IN	9	O
near	near	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
status	status	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Phase	phase	NOUN	NN	9	O
2	2	NUM	CD	9	O
early	early	ADJ	JJ	9	O
afterdepolarization	afterdepolarization	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
trigger	trigger	NOUN	NN	9	O
of	of	ADP	IN	5	O
polymorphic	polymorphic	ADJ	JJ	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
acquired	acquire	VERB	VBN	5	O
long	long	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
QT	QT	PROPN	NNP	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
direct	direct	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
from	from	ADP	IN	9	O
intracellular	intracellular	ADJ	JJ	3	O
recordings	recording	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intact	intact	ADJ	JJ	9	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
phase	phase	NOUN	NN	5	O
2	2	NUM	CD	9	O
early	early	ADJ	JJ	9	O
afterdepolarization	afterdepolarization	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EAD	EAD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
producing	produce	VERB	VBG	9	O
a	a	DET	DT	5	O
trigger	trigger	NOUN	NN	9	O
to	to	PART	TO	5	O
initiate	initiate	VERB	VB	9	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TdP	tdp	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
dl	dl	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
sotalol	sotalol	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
azimilide	azimilide	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
contribution	contribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
transmural	transmural	ADJ	JJ	5	O
dispersion	dispersion	NOUN	NN	5	O
of	of	ADP	IN	5	O
repolarization	repolarization	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
TDR	TDR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
transmural	transmural	ADJ	JJ	5	O
propagation	propagation	NOUN	NN	5	O
of	of	ADP	IN	5	O
EAD	EAD	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
TdP	tdp	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Transmembrane	Transmembrane	PROPN	NNP	7	O
action	action	NOUN	NN	5	O
potentials	potential	NOUN	NNS	5	O
from	from	ADP	IN	9	O
epicardium	epicardium	NOUN	NN	5	O
,	,	PUNCT	,	9	O
midmyocardium	midmyocardium	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
endocardium	endocardium	NOUN	NN	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
simultaneously	simultaneously	ADV	RB	5	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
transmural	transmural	ADJ	JJ	5	O
ECG	ECG	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
arterially	arterially	ADV	RB	0	O
perfused	perfuse	VERB	VBN	0	O
canine	canine	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
rabbit	rabbit	NOUN	NN	3	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
preparations	preparation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

dl	dl	NOUN	NN	7	O
-	-	PUNCT	:	7	O
Sotalol	Sotalol	PROPN	NNP	7	B-Chemical
preferentially	preferentially	ADV	RB	9	O
prolonged	prolong	VERB	VBD	9	O
action	action	NOUN	NN	5	O
potential	potential	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
APD	APD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
M	M	PROPN	NNP	9	O
cells	cell	NOUN	NNS	3	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependently	dependently	ADV	RB	3	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
100	100	NUM	CD	0	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
TDR	TDR	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Azimilide	azimilide	ADV	RB	9	B-Chemical
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
significantly	significantly	ADV	RB	9	O
prolonged	prolong	VERB	VBD	9	O
APD	APD	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
at	at	ADP	IN	9	O
concentrations	concentration	NOUN	NNS	0	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
to	to	PART	TO	5	O
10	10	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
but	but	CCONJ	CC	9	O
shortened	shorten	VERB	VBD	9	O
them	-PRON-	PRON	PRP	5	O
at	at	ADP	IN	9	O
30	30	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Unlike	unlike	ADP	IN	9	O
dl	dl	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
sotalol	sotalol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
azimilide	azimilide	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
3	3	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBN	9	O
epicardial	epicardial	ADJ	JJ	5	O
APD	APD	PROPN	NNP	5	O
markedly	markedly	ADV	RB	9	O
,	,	PUNCT	,	9	O
causing	cause	VERB	VBG	9	O
a	a	DET	DT	5	O
diminished	diminished	ADJ	JJ	9	O
TDR	TDR	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
both	both	DET	DT	9	O
dl	dl	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
sotalol	sotalol	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
azimilide	azimilide	ADP	IN	9	B-Chemical
rarely	rarely	ADV	RB	5	O
induced	induce	VERB	VBN	3	O
EADs	ead	NOUN	NNS	3	O
in	in	ADP	IN	5	O
canine	canine	NOUN	NN	9	O
left	leave	VERB	VBN	5	O
ventricles	ventricle	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
produced	produce	VERB	VBD	9	O
frequent	frequent	ADJ	JJ	5	O
EADs	ead	NOUN	NNS	3	O
in	in	ADP	IN	5	O
rabbits	rabbit	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
more	more	ADV	RBR	5	O
pronounced	pronounced	ADJ	JJ	9	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
TDR	TDR	PROPN	NNP	5	O
by	by	ADP	IN	9	O
dl	dl	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
sotalol	sotalol	NOUN	NN	5	B-Chemical
facilitated	facilitate	VERB	VBN	5	O
transmural	transmural	ADJ	JJ	5	O
propagation	propagation	NOUN	NN	5	O
of	of	ADP	IN	5	O
EADs	ead	NOUN	NNS	3	O
that	that	DET	WDT	5	O
initiated	initiate	VERB	VBD	9	O
multiple	multiple	ADJ	JJ	5	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
TdP	tdp	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
rabbit	rabbit	NOUN	NN	3	O
left	leave	VERB	VBN	5	O
ventricles	ventricle	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
note	note	VERB	VB	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
azimilide	azimilide	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
to	to	PART	TO	5	O
10	10	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBD	9	O
APD	APD	PROPN	NNP	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
dl	dl	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
sotalol	sotalol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
EADs	ead	NOUN	NNS	3	O
often	often	ADV	RB	5	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
propagate	propagate	VERB	VB	5	O
transmurally	transmurally	ADV	RB	5	O
,	,	PUNCT	,	9	O
probably	probably	ADV	RB	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
diminished	diminished	ADJ	JJ	9	O
TDR	TDR	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
provides	provide	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
direct	direct	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
from	from	ADP	IN	9	O
intracellular	intracellular	ADJ	JJ	3	O
action	action	NOUN	NN	5	O
potential	potential	ADJ	JJ	9	O
recordings	recording	NOUN	NNS	5	O
that	that	DET	WDT	5	O
phase	phase	NOUN	NN	5	O
2	2	NUM	CD	9	O
EAD	EAD	PROPN	NNP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
generated	generate	VERB	VBN	9	O
from	from	ADP	IN	9	O
intact	intact	ADJ	JJ	9	O
ventricular	ventricular	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
produce	produce	VERB	VB	9	O
a	a	DET	DT	5	O
trigger	trigger	NOUN	NN	9	O
to	to	PART	TO	5	O
initiate	initiate	VERB	VB	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
TdP	tdp	NOUN	NN	5	B-Disease
under	under	ADP	IN	9	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
pilot	pilot	NOUN	NN	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
stress	stress	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

STUDY	study	NOUN	NN	2	O
OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
setting	setting	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
poses	pose	VERB	VBZ	5	O
a	a	DET	DT	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
dilemma	dilemma	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dobutamine	dobutamine	NOUN	NN	0	B-Chemical
stress	stress	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DSE	DSE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
available	available	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
sensitive	sensitive	ADJ	JJ	9	O
test	test	NOUN	NN	5	O
for	for	ADP	IN	5	O
evaluating	evaluate	VERB	VBG	5	O
cardiac	cardiac	ADJ	JJ	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
theoretical	theoretical	ADJ	JJ	5	O
concern	concern	NOUN	NN	5	O
regarding	regard	VERB	VBG	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
setting	setting	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
pilot	pilot	NOUN	NN	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
DSE	DSE	PROPN	NNP	9	O
in	in	ADP	IN	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
series	series	NOUN	NN	5	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intensive	intensive	ADJ	JJ	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
unit	unit	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ED	ED	PROPN	NNP	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
urban	urban	ADJ	JJ	5	O
tertiary	tertiary	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
care	care	NOUN	NN	5	O
teaching	teaching	NOUN	NN	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
eligible	eligible	ADJ	JJ	5	O
for	for	ADP	IN	5	O
DSE	DSE	PROPN	NNP	9	O
if	if	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
used	use	VERB	VBN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
within	within	ADP	IN	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
preceding	precede	VERB	VBG	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
ECG	ECG	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
tropinin	tropinin	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
level	level	VERB	VBP	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
exhibiting	exhibit	VERB	VBG	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
continuing	continue	VERB	VBG	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
for	for	ADP	IN	5	O
serial	serial	ADJ	JJ	9	O
testing	testing	NOUN	NN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
DSE	DSE	PROPN	NNP	9	O
testing	testing	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intensive	intensive	ADJ	JJ	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
unit	unit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
inadequate	inadequate	ADJ	JJ	5	O
resting	rest	VERB	VBG	5	O
images	image	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
DSE	DSE	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
terminated	terminate	VERB	VBN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
inferior	inferior	ADJ	JJ	5	O
hypokinesis	hypokinesis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
another	another	DET	DT	9	O
DSE	DSE	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
terminated	terminate	VERB	VBN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
rate	rate	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
atrial	atrial	ADJ	JJ	5	O
conduction	conduction	NOUN	NN	5	O
deficit	deficit	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reach	reach	VERB	VB	5	O
the	the	DET	DT	5	O
target	target	NOUN	NN	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
19	19	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
completed	complete	VERB	VBD	5	O
a	a	DET	DT	5	O
DSE	DSE	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
reached	reach	VERB	VBD	9	O
their	-PRON-	DET	PRP$	5	O
target	target	NOUN	NN	9	O
heart	heart	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
exaggerated	exaggerated	ADJ	JJ	5	O
adrenergic	adrenergic	NOUN	NN	9	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
of	of	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
200	200	NUM	CD	0	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
tachydysrhythmias	tachydysrhythmia	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
excluding	exclude	VERB	VBG	9	O
sinus	sinus	NOUN	NN	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Further	further	ADV	RB	9	O
suggesting	suggest	VERB	VBG	9	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
exaggerated	exaggerated	ADJ	JJ	5	O
adrenergic	adrenergic	NOUN	NN	9	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
65	65	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
required	require	VERB	VBD	9	O
supplemental	supplemental	ADJ	JJ	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
reach	reach	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
target	target	NOUN	NN	9	O
heart	heart	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
No	no	DET	DT	9	O
exaggerated	exaggerated	ADJ	JJ	5	O
adrenergic	adrenergic	NOUN	NN	9	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
when	when	ADV	WRB	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Prenatal	prenatal	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cranial	cranial	ADJ	JJ	5	O
sonographic	sonographic	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
preterm	preterm	ADJ	JJ	5	B-Disease
infants	infant	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Prenatal	prenatal	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
linked	link	VERB	VBN	9	O
with	with	ADP	IN	5	O
subependymal	subependymal	ADJ	JJ	3	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
cysts	cyst	NOUN	NNS	5	B-Disease
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
detectable	detectable	ADJ	JJ	9	O
on	on	ADP	IN	5	O
cranial	cranial	ADJ	JJ	5	O
sonography	sonography	NOUN	NN	5	O
in	in	ADP	IN	5	O
neonates	neonate	NOUN	NNS	9	O
born	bear	VERB	VBN	5	O
at	at	ADP	IN	9	O
term	term	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
sought	seek	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
prenatal	prenatal	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
subependymal	subependymal	ADJ	JJ	3	B-Disease
cysts	cyst	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
preterm	preterm	ADJ	JJ	5	B-Disease
infants	infant	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
retrospectively	retrospectively	ADV	RB	5	O
reviewed	review	VERB	VBD	9	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
cranial	cranial	ADJ	JJ	5	O
sonograms	sonogram	NOUN	NNS	5	O
obtained	obtain	VERB	VBN	9	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
on	on	ADP	IN	5	O
122	122	NUM	CD	7	O
premature	premature	ADJ	JJ	9	B-Disease
(	(	PUNCT	-LRB-	9	I-Disease
<	<	X	XX	0	I-Disease
36	36	NUM	CD	9	I-Disease
weeks	week	NOUN	NNS	9	I-Disease
of	of	ADP	IN	5	I-Disease
gestation	gestation	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
infants	infant	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Infants	infant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
categorized	categorize	VERB	VBN	5	O
into	into	ADP	IN	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
those	those	DET	DT	5	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
not	not	ADV	RB	5	O
exposed	expose	VERB	VBN	9	O
to	to	PART	TO	5	O
cocaine	cocaine	VERB	VB	5	B-Chemical
.	.	PUNCT	.	9	O

Infants	infant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
group	group	NOUN	NN	9	O
if	if	ADP	IN	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
maternal	maternal	ADJ	JJ	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
if	if	ADP	IN	5	O
maternal	maternal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
neonatal	neonatal	ADJ	JJ	9	O
urine	urine	NOUN	NN	9	O
toxicology	toxicology	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
delivery	delivery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
122	122	NUM	CD	7	O
infants	infant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
insufficient	insufficient	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	O
histories	history	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
subependymal	subependymal	ADJ	JJ	3	B-Disease
cysts	cyst	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
117	117	NUM	CD	7	O
remaining	remain	VERB	VBG	9	O
infants	infant	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
16	16	NUM	CD	9	O
of	of	ADP	IN	5	O
117	117	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
subependymal	subependymal	ADJ	JJ	3	B-Disease
cysts	cyst	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
infants	infant	NOUN	NNS	5	O
exposed	expose	VERB	VBN	9	O
to	to	PART	TO	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
prenatally	prenatally	ADV	RB	5	O
was	be	VERB	VBD	9	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
of	of	ADP	IN	5	O
18	18	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
of	of	ADP	IN	5	O
99	99	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
unexposed	unexposed	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
subependymal	subependymal	ADJ	JJ	3	B-Disease
cyst	cyst	NOUN	NN	5	I-Disease
formation	formation	NOUN	NN	9	O
in	in	ADP	IN	5	O
preterm	preterm	ADJ	JJ	5	B-Disease
infants	infant	NOUN	NNS	5	I-Disease
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
exposed	expose	VERB	VBN	9	O
to	to	PART	TO	5	O
cocaine	cocaine	VERB	VB	5	B-Chemical
prenatally	prenatally	ADV	RB	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
result	result	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
term	term	NOUN	NN	5	O
infants	infant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thalidomide	thalidomide	VERB	VB	0	B-Chemical
neuropathy	neuropathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
prospectively	prospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBD	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
using	use	VERB	VBG	9	O
electrodiagnostic	electrodiagnostic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
seven	seven	NUM	CD	9	O
men	man	NOUN	NNS	5	O
with	with	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
androgen	androgen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
independent	independent	ADJ	JJ	9	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
underwent	undergo	VERB	VBD	5	O
neurologic	neurologic	ADJ	JJ	5	O
examinations	examination	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
nerve	nerve	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
NCS	NCS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
intervals	interval	NOUN	NNS	5	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

NCS	NCS	PROPN	NNP	9	O
included	include	VERB	VBD	5	O
recording	recording	NOUN	NN	5	O
of	of	ADP	IN	5	O
sensory	sensory	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
action	action	NOUN	NN	5	O
potentials	potential	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
SNAPs	snap	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
median	median	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
radial	radial	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
ulnar	ulnar	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sural	sural	ADJ	JJ	5	O
nerves	nerve	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

SNAP	SNAP	NOUN	NNS	9	O
amplitudes	amplitude	NOUN	NNS	5	O
for	for	ADP	IN	5	O
each	each	DET	DT	5	O
nerve	nerve	NOUN	NN	5	O
were	be	VERB	VBD	9	O
expressed	express	VERB	VBN	3	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mean	mean	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
four	four	NUM	CD	9	O
was	be	VERB	VBD	9	O
termed	term	VERB	VBN	9	O
the	the	DET	DT	5	O
SNAP	SNAP	PROPN	NNP	9	O
index	index	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SNAP	SNAP	PROPN	NNP	9	O
index	index	NOUN	NN	5	O
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Thalidomide	Thalidomide	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
in	in	ADP	IN	5	O
55	55	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
for	for	ADP	IN	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
67	67	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
initially	initially	ADV	RB	9	O
enrolled	enrol	VERB	VBD	5	O
,	,	PUNCT	,	9	O
24	24	NUM	CD	9	O
remained	remain	VERB	VBD	9	O
on	on	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
remained	remain	VERB	VBD	9	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
remained	remain	VERB	VBD	9	O
at	at	ADP	IN	9	O
9	9	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
neuropathy	neuropathy	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SNAP	SNAP	PROPN	NNP	9	O
index	index	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
concurrently	concurrently	ADV	RB	9	O
.	.	PUNCT	.	9	O

Older	old	ADJ	JJR	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
were	be	VERB	VBD	9	O
possible	possible	ADJ	JJ	5	O
contributing	contributing	NOUN	NN	9	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Neuropathy	Neuropathy	PROPN	NNP	7	B-Disease
may	may	VERB	MD	5	O
thus	thus	ADV	RB	9	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
SNAP	SNAP	PROPN	NNP	9	O
index	index	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
monitor	monitor	VERB	VB	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
for	for	ADP	IN	5	O
early	early	ADJ	JJ	9	O
detection	detection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Overexpression	overexpression	NOUN	NN	3	O
of	of	ADP	IN	5	O
copper	copper	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
zinc	zinc	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
protects	protect	NOUN	NNS	3	O
from	from	ADP	IN	9	O
kanamycin	kanamycin	NOUN	NN	1	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hearing	hearing	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
participation	participation	NOUN	NN	5	O
of	of	ADP	IN	5	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
in	in	ADP	IN	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
deduced	deduce	VERB	VBN	9	O
from	from	ADP	IN	9	O
observations	observation	NOUN	NNS	9	O
that	that	ADP	IN	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
iron	iron	NOUN	NN	0	B-Chemical
complexes	complex	NOUN	NNS	9	O
catalyze	catalyze	VERB	VBP	0	O
the	the	DET	DT	5	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
radicals	radical	NOUN	NNS	0	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
antioxidants	antioxidant	NOUN	NNS	0	O
attenuate	attenuate	VERB	VBP	9	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
therefore	therefore	ADV	RB	5	O
hypothesized	hypothesize	VERB	VBD	9	O
that	that	DET	DT	5	O
overexpression	overexpression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Cu	Cu	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
Zn	zn	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
h	h	NOUN	NN	0	O
-	-	PUNCT	:	7	O
SOD1	SOD1	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
should	should	VERB	MD	5	O
protect	protect	VERB	VB	9	O
transgenic	transgenic	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
from	from	ADP	IN	9	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Immunocytochemistry	immunocytochemistry	NOUN	NN	3	O
confirmed	confirm	VERB	VBD	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
h	h	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
SOD1	SOD1	PROPN	NNP	3	O
in	in	ADP	IN	5	O
inner	inner	ADJ	JJ	9	O
ear	ear	NOUN	NN	5	O
tissues	tissue	NOUN	NNS	9	O
of	of	ADP	IN	5	O
transgenic	transgenic	ADJ	JJ	3	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
TgN	tgn	NOUN	NN	3	O
[	[	PUNCT	-LRB-	9	O
SOD1	SOD1	PROPN	NNP	3	O
]	]	PUNCT	-RRB-	9	O
3Cje	3cje	NUM	CD	_	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Transgenic	transgenic	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
nontransgenic	nontransgenic	ADJ	JJ	3	O
littermates	littermate	NOUN	NNS	3	O
received	receive	VERB	VBD	9	O
kanamycin	kanamycin	NOUN	NN	1	B-Chemical
(	(	PUNCT	-LRB-	9	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
beginning	begin	VERB	VBG	5	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
10	10	NUM	CD	9	O
after	after	ADP	IN	9	O
birth	birth	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Auditory	auditory	NOUN	NN	5	O
thresholds	threshold	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
by	by	ADP	IN	9	O
evoked	evoked	ADJ	JJ	5	O
auditory	auditory	NOUN	NN	5	O
brain	brain	NOUN	NN	5	O
stem	stem	NOUN	NN	3	O
responses	response	NOUN	NNS	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
after	after	ADP	IN	9	O
birth	birth	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
nontransgenic	nontransgenic	ADJ	JJ	3	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
threshold	threshold	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kanamycin	kanamycin	NOUN	NN	1	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
45	45	NUM	CD	9	O
-	-	SYM	SYM	7	O
50	50	NUM	CD	0	O
dB	db	NOUN	NN	5	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
injected	inject	VERB	VBN	3	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
transgenic	transgenic	ADJ	JJ	3	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
kanamycin	kanamycin	NOUN	NN	1	B-Chemical
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
threshold	threshold	NOUN	NN	5	O
by	by	ADP	IN	9	O
only	only	ADV	RB	9	O
15	15	NUM	CD	9	O
dB	db	NOUN	NN	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
respective	respective	ADJ	JJ	9	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
at	at	ADP	IN	9	O
12	12	NUM	CD	9	O
and	and	CCONJ	CC	5	O
24	24	NUM	CD	9	O
kHz	khz	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protection	protection	NOUN	NN	9	O
by	by	ADP	IN	9	O
overexpression	overexpression	NOUN	NN	3	O
of	of	ADP	IN	5	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
supports	support	VERB	VBZ	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	DT	5	O
oxidant	oxidant	ADJ	JJ	0	O
stress	stress	NOUN	NN	9	O
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
also	also	ADV	RB	9	O
suggest	suggest	VERB	VBP	9	O
transgenic	transgenic	ADJ	JJ	3	O
animals	animal	NOUN	NNS	9	O
as	as	ADP	IN	5	O
suitable	suitable	ADJ	JJ	5	O
models	model	NOUN	NNS	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
mechanisms	mechanism	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
strategies	strategy	NOUN	NNS	5	O
for	for	ADP	IN	5	O
prevention	prevention	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fatty	Fatty	PROPN	NNP	0	B-Disease
liver	liver	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
tetracycline	tetracycline	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
relationships	relationship	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
sex	sex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
relationships	relationship	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
biochemical	biochemical	NOUN	NN	9	O
mechanisms	mechanism	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sex	sex	NOUN	NN	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
fatty	fatty	ADJ	JJ	0	B-Disease
liver	liver	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
tetracycline	tetracycline	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intact	intact	ADJ	JJ	9	O
rat	rat	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
isolated	isolate	VERB	VBN	9	O
perfused	perfuse	VERB	VBN	0	O
rat	rat	NOUN	NN	3	O
liver	liver	NOUN	NN	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
intact	intact	ADJ	JJ	9	O
male	male	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
female	female	ADJ	JJ	9	O
rat	rat	NOUN	NN	3	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
direct	direct	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
tetracycline	tetracycline	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
hepatic	hepatic	ADJ	JJ	9	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
provision	provision	NOUN	NN	5	O
of	of	ADP	IN	5	O
adequate	adequate	ADJ	JJ	5	O
oleic	oleic	NUM	CD	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
substrate	substrate	NOUN	NN	0	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
isolated	isolate	VERB	VBN	9	O
perfused	perfuse	VERB	VBN	0	O
liver	liver	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
tetracycline	tetracycline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
both	both	DET	DT	9	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
depression	depression	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
output	output	NOUN	NN	5	O
of	of	ADP	IN	5	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
livers	liver	NOUN	NNS	3	O
from	from	ADP	IN	9	O
male	male	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Marked	marked	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
female	female	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	ADP	IN	5	O
base	base	NOUN	NN	5	O
line	line	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
hepatic	hepatic	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
output	output	NOUN	NN	5	O
of	of	ADP	IN	5	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
of	of	ADP	IN	5	O
control	control	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
graded	graded	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
tetracycline	tetracycline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
between	between	ADP	IN	5	O
male	male	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
female	female	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
pregnant	pregnant	ADJ	JJ	5	O
rat	rat	NOUN	NN	3	O
livers	liver	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
livers	liver	NOUN	NNS	3	O
from	from	ADP	IN	9	O
female	female	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
especially	especially	ADV	RB	5	O
pregnant	pregnant	ADJ	JJ	5	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
strikingly	strikingly	ADV	RB	9	O
resistant	resistant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
tetracycline	tetracycline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
depression	depression	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
output	output	NOUN	NN	5	O
of	of	ADP	IN	5	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
under	under	ADP	IN	9	O
these	these	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
sexes	sex	NOUN	NNS	9	O
could	could	VERB	MD	9	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
altered	alter	VERB	VBN	9	O
disposition	disposition	NOUN	NN	5	O
of	of	ADP	IN	5	O
tetracycline	tetracycline	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
altered	altered	ADJ	JJ	9	O
uptake	uptake	NOUN	NN	0	O
of	of	ADP	IN	5	O
oleic	oleic	NUM	CD	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Depressed	depressed	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	O
secretion	secretion	NOUN	NN	3	O
of	of	ADP	IN	5	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
accounted	account	VERB	VBD	5	O
only	only	ADV	RB	9	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
to	to	PART	TO	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
accumulated	accumulate	VERB	VBN	9	O
hepatic	hepatic	ADJ	JJ	9	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
additional	additional	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
rich	rich	ADJ	JJ	9	O
fatty	fatty	ADJ	JJ	0	B-Disease
liver	liver	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
tetracycline	tetracycline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Prednisone	prednisone	NOUN	NN	0	B-Chemical
induces	induce	VERB	VBZ	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
glial	glial	ADJ	JJ	3	O
cerebral	cerebral	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
whether	whether	ADP	IN	9	O
prednisone	prednisone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PDN	PDN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
produces	produce	VERB	VBZ	9	O
anxiety	anxiety	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
cerebral	cerebral	ADJ	JJ	5	O
glial	glial	ADJ	JJ	3	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Male	Male	PROPN	NNP	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
formed	form	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
per	per	ADP	IN	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
moderate	moderate	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
group	group	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
PDN	pdn	NOUN	NN	0	B-Chemical
released	release	VERB	VBN	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
implant	implant	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
implants	implant	NOUN	NNS	5	O
containing	contain	VERB	VBG	0	O
PDN	PDN	PROPN	NNP	0	B-Chemical
equivalent	equivalent	ADJ	JJ	9	O
to	to	ADP	IN	5	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
were	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
implants	implant	NOUN	NNS	5	O
contained	contain	VERB	VBD	9	O
no	no	DET	DT	9	O
PDN	pdn	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Anxiety	anxiety	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
using	use	VERB	VBG	9	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
elevated	elevated	ADJ	JJ	9	O
plus	plus	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
maze	maze	NOUN	NN	5	O
devices	device	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
transformation	transformation	NOUN	NN	9	O
of	of	ADP	IN	5	O
astrocytes	astrocyte	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
microglia	microglia	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
analyses	analysis	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Anxiety	anxiety	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
PDN	PDN	PROPN	NNP	0	B-Chemical
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
transformation	transformation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
microglia	microglia	NOUN	NNS	3	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
intersections	intersection	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PDN	PDN	PROPN	NNP	0	B-Chemical
groups	group	NOUN	NNS	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prefrontal	prefrontal	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
moderate	moderate	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
;	;	PUNCT	:	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
;	;	PUNCT	:	9	O
controls	control	VERB	VBZ	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
striatum	striatum	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
moderate	moderate	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
;	;	PUNCT	:	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
;	;	PUNCT	:	9	O
controls	control	NOUN	NNS	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
hippocampus	hippocampus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
stained	stain	VERB	VBN	3	O
microglia	microglia	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PDN	pdn	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBD	3	O
groups	group	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prefrontal	prefrontal	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
moderate	moderate	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
29	29	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
;	;	PUNCT	:	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
;	;	PUNCT	:	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
cells	cell	NOUN	NNS	3	O
per	per	ADP	IN	9	O
field	field	NOUN	NN	5	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Stained	stained	ADJ	JJ	3	O
microglia	microglia	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
numerous	numerous	ADJ	JJ	9	O
striatum	striatum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hippocampus	hippocampus	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
group	group	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Subacute	subacute	VERB	VB	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
PDN	PDN	PROPN	NNP	0	B-Chemical
induced	induced	ADJ	JJ	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
reactivity	reactivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
microglia	microglia	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
relevance	relevance	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
features	feature	NOUN	NNS	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
PDN	PDN	PROPN	NNP	0	B-Chemical
remains	remain	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
elucidated	elucidate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Phase	phase	VERB	VB	9	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
squamous	squamous	ADJ	JJ	5	B-Disease
cell	cell	NOUN	NN	3	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
cervix	cervix	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
Phase	Phase	PROPN	NNP	9	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
cervical	cervical	ADJ	JJ	5	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
curve	curve	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
AUC	AUC	PROPN	NNP	9	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Doxil	Doxil	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
starting	start	VERB	VBG	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
intravenously	intravenously	ADV	RB	0	O
every	every	DET	DT	5	O
28	28	NUM	CD	7	O
days	day	NOUN	NNS	9	O
to	to	ADP	IN	5	O
37	37	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
squamous	squamous	ADJ	JJ	5	B-Disease
cell	cell	NOUN	NN	3	I-Disease
cervical	cervical	ADJ	JJ	5	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
antitumor	antitumor	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
profile	profile	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessable	assessable	ADJ	JJ	5	O
for	for	ADP	IN	5	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
35	35	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessable	assessable	ADJ	JJ	5	O
for	for	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
38	38	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
10	10	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
26	26	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
was	be	VERB	VBD	9	O
37	37	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
toxic	toxic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
Grade	Grade	PROPN	NNP	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
16	16	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
anemia	anemia	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
neutropenic	neutropenic	ADJ	JJ	5	B-Disease
fever	fever	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
five	five	NUM	CD	9	O
infusion	infusion	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
reactions	reaction	NOUN	NNS	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Grade	Grade	PROPN	NNP	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
2	2	NUM	CD	9	O
nonhematologic	nonhematologic	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
included	include	VERB	VBD	5	O
nausea	nausea	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
17	17	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
emesis	emesis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
fatigue	fatigue	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
9	9	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
mucositis	mucositis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
stomatitis	stomatitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
constipation	constipation	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
weight	weight	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
hand	hand	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
foot	foot	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
skin	skin	NOUN	NN	5	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
liposomal	liposomal	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
modest	modest	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
cervical	cervical	ADJ	JJ	5	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Antimicrobial	Antimicrobial	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mania	mania	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
antibiomania	antibiomania	NOUN	NN	_	B-Disease
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
reviewed	review	VERB	VBD	9	O
reported	report	VERB	VBD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
manic	manic	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
by	by	ADP	IN	9	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
MEDLINE	MEDLINE	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
PsychLit	PsychLit	PROPN	NNP	9	O
search	search	NOUN	NN	5	O
for	for	ADP	IN	5	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mania	mania	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Unpublished	unpublished	ADJ	JJ	2	O
reports	report	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
requested	request	VERB	VBN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
World	World	PROPN	NNP	5	O
Health	Health	PROPN	NNP	2	O
Organization	Organization	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
WHO	who	PRON	WP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Food	Food	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Drug	Drug	PROPN	NNP	5	O
Administration	Administration	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
FDA	FDA	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
antimicrobial	antimicrobial	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mania	mania	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
6	6	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
implicating	implicate	VERB	VBG	9	O
clarithromycin	clarithromycin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
implicating	implicate	VERB	VBG	9	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
case	case	NOUN	NN	5	O
each	each	DET	DT	5	O
implicating	implicate	VERB	VBG	9	O
erythromycin	erythromycin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
amoxicillin	amoxicillin	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
WHO	who	PRON	WP	5	O
reported	report	VERB	VBD	9	O
82	82	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
these	these	DET	DT	5	O
,	,	PUNCT	,	9	O
clarithromycin	clarithromycin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
23	23	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
ciprofloxacin	ciprofloxacin	VERB	VBD	0	B-Chemical
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
ofloxacin	ofloxacin	ADV	RB	0	B-Chemical
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cotrimoxazole	Cotrimoxazole	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
metronidazole	metronidazole	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
erythromycin	erythromycin	ADV	RB	0	B-Chemical
were	be	VERB	VBD	9	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
15	15	NUM	CD	9	O
reported	report	VERB	VBD	9	O
manic	manic	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cases	case	NOUN	NNS	9	O
reported	report	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
FDA	FDA	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
clarithromycin	clarithromycin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
ciprofloxacin	ciprofloxacin	VERB	VBD	0	B-Chemical
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
frequently	frequently	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
mania	mania	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Statistical	statistical	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
would	would	VERB	MD	5	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
demonstrated	demonstrate	VERB	VBN	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
statistical	statistical	ADJ	JJ	5	O
correlative	correlative	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
therefore	therefore	ADV	RB	5	O
not	not	ADV	RB	5	O
undertaken	undertake	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
mania	mania	NOUN	NN	5	B-Disease
while	while	ADP	IN	9	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
antimicrobials	antimicrobial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
,	,	PUNCT	,	9	O
physicians	physician	NOUN	NNS	5	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reversibility	reversibility	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
research	research	NOUN	NN	5	O
clearly	clearly	ADV	RB	9	O
is	be	VERB	VBZ	5	O
required	require	VERB	VBN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
antimicrobial	antimicrobial	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mania	mania	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
an	an	DET	DT	5	O
antimicrobial	antimicrobial	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
manic	manic	ADJ	JJ	5	B-Disease
episode	episode	NOUN	NN	5	O
among	among	ADP	IN	5	O
various	various	ADJ	JJ	9	O
demographic	demographic	ADJ	JJ	5	O
populations	population	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
continue	continue	VERB	VBP	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
persistent	persistent	ADJ	JJ	5	O
affective	affective	ADJ	JJ	5	O
disorders	disorder	NOUN	NNS	5	O
once	once	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
episode	episode	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
occurs	occur	VERB	VBZ	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
taking	take	VERB	VBG	5	O
antibiotics	antibiotic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
subsides	subside	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
elected	elect	VERB	VBD	5	O
to	to	PART	TO	5	O
name	name	VERB	VB	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
"	"	PUNCT	''	5	O
antibiomania	antibiomania	NOUN	NN	_	B-Disease
.	.	PUNCT	.	9	O
"	"	PUNCT	''	5	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ocular	ocular	ADJ	JJ	5	B-Disease
dyskinesias	dyskinesia	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ocular	ocular	ADJ	JJ	5	B-Disease
dyskinesias	dyskinesia	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
very	very	ADV	RB	5	O
uncommon	uncommon	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Usually	usually	ADV	RB	5	O
they	-PRON-	PRON	PRP	5	O
occur	occur	VERB	VBP	5	O
simultaneously	simultaneously	ADV	RB	5	O
with	with	ADP	IN	5	O
limb	limb	NOUN	NN	5	O
peak	peak	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
choreatic	choreatic	ADJ	JJ	5	B-Disease
dyskinesias	dyskinesia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
leftward	leftward	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
upward	upward	ADJ	JJ	5	O
deviations	deviation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
gaze	gaze	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
peak	peak	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hypothesize	hypothesize	VERB	VB	9	O
that	that	DET	WDT	5	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
denervation	denervation	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
caudate	caudate	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
needed	need	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induce	induce	NOUN	NN	3	O
ocular	ocular	ADJ	JJ	5	B-Disease
dyskinesias	dyskinesia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
with	with	ADP	IN	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
dysmenorrhea	dysmenorrhea	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
over	over	PART	RP	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Primary	primary	ADJ	JJ	9	O
dysmenorrhea	dysmenorrhea	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
painful	painful	ADJ	JJ	5	O
uterine	uterine	ADJ	JJ	5	O
contractility	contractility	NOUN	NN	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
hypersecretion	hypersecretion	NOUN	NN	9	O
of	of	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	O
prostaglandins	prostaglandin	NOUN	NNS	0	B-Chemical
;	;	PUNCT	:	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
steroidal	steroidal	ADJ	JJ	0	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
choice	choice	NOUN	NN	5	O
for	for	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
demonstrated	demonstrate	VERB	VBN	9	O
that	that	ADP	IN	5	O
myometrial	myometrial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
targets	target	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
relaxant	relaxant	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	no	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
NO	no	NOUN	NN	9	B-Chemical
donor	donor	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
dysmenorrhea	dysmenorrhea	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DCF	DCF	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
primary	primary	ADJ	JJ	9	O
dysmenorrhea	dysmenorrhea	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
during	during	ADP	IN	5	O
two	two	NUM	CD	5	O
consecutive	consecutive	ADJ	JJ	5	O
menstrual	menstrual	ADJ	JJ	5	O
cycles	cycle	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
over	over	ADV	RB	5	O
,	,	PUNCT	,	9	O
controlled	control	VERB	VBN	5	O
design	design	NOUN	NN	5	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
either	either	CCONJ	CC	9	O
DCF	DCF	NOUN	NNS	0	B-Chemical
per	per	ADP	IN	9	O
os	os	X	FW	9	O
or	or	CCONJ	CC	5	O
GTN	GTN	PROPN	NNP	0	B-Chemical
patches	patch	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
menses	mense	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
menstrual	menstrual	ADJ	JJ	5	O
cramps	cramp	NOUN	NNS	5	O
became	become	VERB	VBD	9	O
unendurable	unendurable	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
subsequent	subsequent	ADJ	JJ	9	O
cycle	cycle	NOUN	NN	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
up	up	PART	RP	5	O
to	to	PART	TO	5	O
3	3	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
DCF	DCF	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
24	24	NUM	CD	9	O
h	h	DET	DT	0	O
transdermal	transdermal	ADJ	JJ	0	O
GTN	GTN	PROPN	NNP	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cycle	cycle	NOUN	NN	9	O
,	,	PUNCT	,	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
needs	need	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
participants	participant	NOUN	NNS	5	O
recorded	record	VERB	VBD	5	O
menstrual	menstrual	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
at	at	ADP	IN	9	O
different	different	ADJ	JJ	9	O
times	time	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
,	,	PUNCT	,	9	O
120	120	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cycle	cycle	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
score	score	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DPI	DPI	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
variable	variable	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
treatments	treatment	NOUN	NNS	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
DPI	DPI	PROPN	NNP	0	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
30th	30th	ADJ	JJ	9	O
minute	minute	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
;	;	PUNCT	:	9	O
DCF	DCF	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
DCF	DCF	PROPN	NNP	0	B-Chemical
continued	continue	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
reducing	reduce	VERB	VBG	9	O
pelvic	pelvic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
for	for	ADP	IN	5	O
two	two	NUM	CD	5	O
hours	hour	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
scores	score	NOUN	NNS	5	O
remained	remain	VERB	VBD	9	O
more	more	ADV	RBR	5	O
or	or	CCONJ	CC	5	O
less	less	ADV	RBR	5	O
stable	stable	ADJ	JJ	9	O
after	after	ADP	IN	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
for	for	ADP	IN	5	O
DFC	DFC	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
hour	hour	NOUN	NN	0	O
:	:	PUNCT	:	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
;	;	PUNCT	:	9	O
DFC	DFC	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
two	two	NUM	CD	5	O
hours	hour	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
-	-	PUNCT	:	7	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
;	;	PUNCT	:	9	O
DFC	DFC	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
59	59	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Low	low	ADJ	JJ	9	B-Disease
back	back	ADJ	JJ	5	I-Disease
pain	pain	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
relieved	relieve	VERB	VBN	5	O
by	by	ADP	IN	9	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Headache	Headache	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
by	by	ADP	IN	9	O
DCF	DCF	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
stopped	stop	VERB	VBD	9	O
using	use	VERB	VBG	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
because	because	ADP	IN	5	O
headache	headache	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
became	become	VERB	VBD	9	O
intolerable	intolerable	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
GTN	GTN	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
reduced	reduce	VERB	VBN	9	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
by	by	ADP	IN	9	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
DCF	DCF	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
dysmenorrhea	dysmenorrhea	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Temocapril	Temocapril	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
SH	SH	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
modulates	modulate	NOUN	NNS	9	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
temocapril	temocapril	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
SH	SH	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
converting	convert	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
ACE	ACE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
inhibited	inhibited	ADJ	JJ	3	O
glomerular	glomerular	ADJ	JJ	5	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
prevented	prevent	VERB	VBN	9	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Nephrosis	nephrosis	NOUN	NN	2	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15mg	15mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
100g	100g	PROPN	NNP	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
SD	SD	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
,	,	PUNCT	,	9	O
i	i	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
ii	ii	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
temocapril	temocapril	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
13	13	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
iii	iii	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
temocapril	temocapril	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
iv	iv	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
untreated	untreated	ADJ	JJ	3	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Temocapril	Temocapril	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
killed	kill	VERB	VBN	9	O
at	at	ADP	IN	9	O
weeks	week	NOUN	NNS	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
or	or	CCONJ	CC	5	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
each	each	DET	DT	5	O
time	time	NOUN	NN	5	O
point	point	NOUN	NN	5	O
,	,	PUNCT	,	9	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BP	BP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
urinary	urinary	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
excretion	excretion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
histopathological	histopathological	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
morphometric	morphometric	ADJ	JJ	5	O
image	image	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Systolic	Systolic	PROPN	NNP	7	O
BP	BP	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
high	high	ADJ	JJ	9	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
temocapril	temocapril	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Urinary	urinary	NOUN	NN	9	O
protein	protein	NOUN	NN	1	O
excretion	excretion	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
peaking	peak	VERB	VBG	9	O
at	at	ADP	IN	9	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
then	then	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
rose	rise	VERB	VBD	9	O
again	again	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
at	at	ADP	IN	9	O
14	14	NUM	CD	7	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Temocapril	Temocapril	PROPN	NNP	9	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
attenuate	attenuate	VERB	VB	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
at	at	ADP	IN	9	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
did	do	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
lower	lower	VERB	VB	9	O
it	-PRON-	PRON	PRP	5	O
from	from	ADP	IN	9	O
weeks	week	NOUN	NNS	9	O
4	4	NUM	CD	9	O
to	to	ADP	IN	5	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
index	index	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
GSI	GSI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
respectively	respectively	ADV	RB	9	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O
49	49	NUM	CD	7	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
14	14	NUM	CD	7	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
excretion	excretion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
GSI	GSI	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
808	808	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
tuft	tuft	NOUN	NN	4	O
area	area	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
Bowman	Bowman	PROPN	NNP	6	O
'	'	PART	POS	9	O
s	s	VERB	VBZ	9	O
capsules	capsule	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
GT	GT	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
BC	BC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
temocapril	temocapril	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
appears	appear	VERB	VBZ	9	O
that	that	ADP	IN	5	O
temocapril	temocapril	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
retarding	retard	VERB	VBG	9	O
renal	renal	ADJ	JJ	9	O
progression	progression	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
protected	protect	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
neprotic	neprotic	ADJ	JJ	_	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pulmonary	pulmonary	ADJ	JJ	9	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
ibuprofen	ibuprofen	ADJ	JJ	0	B-Chemical
prophylaxis	prophylaxis	NOUN	NN	5	O
in	in	ADP	IN	5	O
very	very	ADV	RB	5	O
preterm	preterm	ADJ	JJ	5	O
infants	infant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
three	three	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hypoxaemia	hypoxaemia	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
ibuprofen	ibuprofen	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
randomised	randomise	VERB	VBN	5	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
patent	patent	NOUN	NN	5	B-Disease
ductus	ductus	NOUN	NN	5	I-Disease
arteriosus	arteriosu	VERB	VBN	5	I-Disease
with	with	ADP	IN	5	O
ibuprofen	ibuprofen	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
premature	premature	ADJ	JJ	9	O
infants	infant	NOUN	NNS	5	O
born	bear	VERB	VBN	5	O
at	at	ADP	IN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
28	28	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Echocardiography	echocardiography	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
severely	severely	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
pulmonary	pulmonary	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hypoxaemia	Hypoxaemia	PROPN	NNP	5	B-Disease
resolved	resolve	VERB	VBD	9	O
quickly	quickly	ADV	RB	5	O
on	on	ADP	IN	5	O
inhaled	inhale	VERB	VBN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
investigators	investigator	NOUN	NNS	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
trials	trial	NOUN	NNS	5	O
pay	pay	VERB	VBP	5	O
close	close	ADJ	JJ	5	O
attention	attention	NOUN	NN	5	O
to	to	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
if	if	ADP	IN	5	O
hypoxaemia	hypoxaemia	NOUN	NN	5	B-Disease
occurs	occur	VERB	VBZ	9	O
after	after	ADP	IN	9	O
prophylactic	prophylactic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ibuprofen	ibuprofen	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Hyponatremia	Hyponatremia	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
syndrome	syndrome	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
inappropriate	inappropriate	ADJ	JJ	5	I-Disease
anti	anti	ADJ	JJ	3	I-Disease
-	-	ADJ	JJ	7	I-Disease
diuretic	diuretic	ADJ	JJ	5	I-Disease
hormone	hormone	NOUN	NN	9	I-Disease
reported	report	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
Vincristine	Vincristine	PROPN	NNP	0	B-Chemical
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
over	over	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
representation	representation	NOUN	NN	5	O
of	of	ADP	IN	5	O
Asians	Asians	PROPN	NNPS	5	O
?	?	PUNCT	.	5	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
used	use	VERB	VBD	5	O
a	a	DET	DT	5	O
pharmaceutical	pharmaceutical	ADJ	JJ	5	O
company	company	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
global	global	ADJ	JJ	5	O
safety	safety	NOUN	NN	5	O
database	database	NOUN	NN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
reporting	reporting	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
hyponatremia	hyponatremia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
syndrome	syndrome	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
inappropriate	inappropriate	ADJ	JJ	5	I-Disease
secretion	secretion	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	I-Disease
anti	anti	ADJ	JJ	3	I-Disease
-	-	ADJ	JJ	7	I-Disease
diuretic	diuretic	ADJ	JJ	5	I-Disease
hormone	hormone	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
SIADH	SIADH	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
among	among	ADP	IN	5	O
vincristine	vincristine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
explore	explore	VERB	VB	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
at	at	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
population	population	NOUN	NN	5	O
subgroups	subgroup	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
searched	search	VERB	VBD	9	O
the	the	DET	DT	5	O
Eli	Eli	PROPN	NNP	2	O
Lilly	Lilly	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
Company	Company	PROPN	NNP	2	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
computerized	computerize	VERB	VBN	5	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
database	database	NOUN	NN	5	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hyponatremia	hyponatremia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
SIADH	SIADH	PROPN	NNP	5	B-Disease
as	as	ADP	IN	5	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
November	November	PROPN	NNP	2	O
1999	1999	NUM	CD	2	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
76	76	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hyponatremia	hyponatremia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
SIADH	SIADH	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
use	use	NOUN	NN	5	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
reporting	reporting	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
35	35	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
62	62	NUM	CD	7	O
%	%	NOUN	NN	9	O
were	be	VERB	VBD	9	O
males	male	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Approximately	approximately	ADV	RB	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
leukemia	leukemia	NOUN	NN	3	B-Disease
or	or	CCONJ	CC	5	O
lymphoma	lymphoma	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
the	the	DET	DT	5	O
39	39	NUM	CD	7	O
reports	report	NOUN	NNS	9	O
that	that	DET	WDT	5	O
included	include	VERB	VBD	5	O
information	information	NOUN	NN	5	O
on	on	ADP	IN	5	O
race	race	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
racial	racial	ADJ	JJ	5	O
distribution	distribution	NOUN	NN	9	O
was	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
Black	Black	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
Caucasian	Caucasian	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
35	35	NUM	CD	9	O
Asian	asian	ADJ	JJ	4	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
Asian	asian	ADJ	JJ	4	O
patients	patient	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
at	at	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
hyponatremia	hyponatremia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
SIADH	SIADH	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
reported	report	VERB	VBN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
SIADH	SIADH	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
very	very	ADV	RB	5	O
low	low	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
physicians	physician	NOUN	NNS	5	O
caring	care	VERB	VBG	5	O
for	for	ADP	IN	5	O
Asian	asian	ADJ	JJ	4	O
oncology	oncology	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
serious	serious	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
reversible	reversible	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Delayed	delay	VERB	VBN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
of	of	ADP	IN	5	O
DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
female	female	ADJ	JJ	9	O
mouse	mouse	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
describes	describe	VERB	VBZ	5	O
the	the	DET	DT	5	O
delayed	delay	VERB	VBN	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
bladder	bladder	NOUN	NN	9	O
pathology	pathology	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
susceptible	susceptible	ADJ	JJ	9	O
strain	strain	NOUN	NN	1	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
resistant	resistant	ADJ	JJ	9	O
strain	strain	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
when	when	ADV	WRB	5	O
both	both	DET	DT	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CY	CY	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Inbred	inbreed	VERB	VBN	3	O
DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
female	female	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
CY	CY	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
during	during	ADP	IN	5	O
100	100	NUM	CD	0	O
days	day	NOUN	NNS	9	O
by	by	ADP	IN	9	O
light	light	ADJ	JJ	9	O
microscopy	microscopy	NOUN	NN	9	O
using	use	VERB	VBG	9	O
different	different	ADJ	JJ	9	O
staining	staining	NOUN	NN	3	O
procedures	procedure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
30	30	NUM	CD	9	O
days	day	NOUN	NNS	9	O
by	by	ADP	IN	9	O
conventional	conventional	ADJ	JJ	5	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Early	early	ADJ	JJ	9	O
CY	CY	PROPN	NNP	9	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
typical	typical	ADJ	JJ	9	O
haemorrhagic	haemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
strains	strain	NOUN	NNS	1	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
repaired	repair	VERB	VBN	5	O
in	in	ADP	IN	5	O
about	about	ADV	RB	5	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
30	30	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CY	CY	PROPN	NNP	9	B-Chemical
injection	injection	NOUN	NN	9	O
ulcerous	ulcerous	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
ulcerous	ulcerous	ADJ	JJ	5	O
forms	form	NOUN	NNS	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
cystitis	cystiti	NOUN	NNS	9	B-Disease
appeared	appear	VERB	VBD	9	O
in	in	ADP	IN	5	O
86	86	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Delayed	delay	VERB	VBN	5	O
cystitis	cystitis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
infiltration	infiltration	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
transepithelial	transepithelial	ADJ	JJ	0	O
passage	passage	NOUN	NN	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
lumen	lumen	NOUN	NN	9	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
frequent	frequent	ADJ	JJ	5	O
exfoliation	exfoliation	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
urothelium	urothelium	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Mast	mast	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
appeared	appear	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
connective	connective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
muscular	muscular	ADJ	JJ	5	O
layers	layer	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
much	much	ADV	RB	5	O
higher	high	ADJ	JJR	9	O
number	number	NOUN	NN	9	O
in	in	ADP	IN	5	O
DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
untreated	untreated	ADJ	JJ	3	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Electron	Electron	PROPN	NNP	0	O
microscopy	microscopy	NOUN	NN	9	O
disclosed	disclose	VERB	VBD	9	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
typical	typical	ADJ	JJ	9	O
discoidal	discoidal	NOUN	NN	4	O
vesicles	vesicle	NOUN	NNS	9	O
normally	normally	ADV	RB	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cytoplasm	cytoplasm	NOUN	NN	3	O
of	of	ADP	IN	5	O
surface	surface	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Instead	instead	ADV	RB	5	O
,	,	PUNCT	,	9	O
numerous	numerous	ADJ	JJ	9	O
abnormal	abnormal	ADJ	JJ	9	O
vesicles	vesicle	NOUN	NNS	9	O
containing	contain	VERB	VBG	0	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
several	several	ADJ	JJ	9	O
dark	dark	ADJ	JJ	9	O
granules	granule	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cytoplasm	cytoplasm	NOUN	NN	3	O
of	of	ADP	IN	5	O
cells	cell	NOUN	NNS	3	O
from	from	ADP	IN	9	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
epithelial	epithelial	ADJ	JJ	3	O
layers	layer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Delayed	delay	VERB	VBN	5	O
cystitis	cystitis	NOUN	NN	9	B-Disease
still	still	ADV	RB	5	O
persisted	persist	VERB	VBD	9	O
in	in	ADP	IN	5	O
DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
100	100	NUM	CD	0	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
delayed	delay	VERB	VBN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
CY	CY	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
causes	cause	VERB	VBZ	9	O
a	a	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
pathology	pathology	NOUN	NN	5	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
pathology	pathology	NOUN	NN	5	O
resembles	resemble	VERB	VBZ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
could	could	VERB	MD	9	O
perhaps	perhaps	ADV	RB	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
studies	study	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
/	/	SYM	SYM	9	O
folinic	folinic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
three	three	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
weekly	weekly	NOUN	NN	5	O
mitomycin	mitomycin	NOUN	NN	3	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
gastric	gastric	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
folinic	folinic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
FA	FA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
several	several	ADJ	JJ	9	O
new	new	ADJ	JJ	5	O
multidrug	multidrug	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
regimens	regimen	NOUN	NNS	5	O
in	in	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
gastric	gastric	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
AGC	AGC	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
II	ii	NUM	CD	9	O
study	study	NOUN	NN	9	O
with	with	ADP	IN	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
weekly	weekly	ADJ	JJ	5	O
bolus	bolus	NOUN	NN	0	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	FU	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
FA	FA	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
mitomycin	mitomycin	NOUN	NN	3	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
MMC	MMC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
response	response	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
comparable	comparable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
regimens	regimen	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
ELF	ELF	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
FAM	FAM	PROPN	NNP	0	O
or	or	CCONJ	CC	5	O
FAMTX	FAMTX	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
promising	promising	ADJ	JJ	5	O
median	median	ADJ	JJ	9	O
overall	overall	ADJ	JJ	5	O
survival	survival	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
this	this	DET	DT	5	O
MMC	mmc	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
schedule	schedule	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
initiated	initiate	VERB	VBD	9	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
/	/	SYM	SYM	9	O
FA	FA	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
weekly	weekly	ADJ	JJ	5	O
bolus	bolus	NOUN	NN	0	O
MMC	mmc	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
From	from	ADP	IN	5	O
February	February	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
1998	1998	NUM	CD	2	O
to	to	ADP	IN	5	O
September	September	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
2000	2000	NUM	CD	9	O
we	-PRON-	PRON	PRP	5	O
recruited	recruit	VERB	VBD	9	O
33	33	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
AGC	AGC	PROPN	NNP	9	B-Disease
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
weekly	weekly	ADJ	JJ	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
FA	FA	PROPN	NNP	9	B-Chemical
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
rest	rest	NOUN	NN	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Bolus	Bolus	PROPN	NNP	0	O
MMC	MMC	PROPN	NNP	9	B-Chemical
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
added	add	VERB	VBN	0	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
weekly	weekly	ADJ	JJ	5	O
intervals	interval	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
given	give	VERB	VBN	5	O
on	on	ADP	IN	5	O
an	an	DET	DT	5	O
outpatient	outpatient	NOUN	NN	5	O
basis	basis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
portable	portable	ADJ	JJ	5	O
pump	pump	NOUN	NN	0	O
systems	system	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
repeated	repeat	VERB	VBN	5	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
57	57	NUM	CD	7	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
characteristics	characteristic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
male	male	ADJ	JJ	9	O
/	/	SYM	SYM	9	O
female	female	ADJ	JJ	9	O
ratio	ratio	NOUN	NN	9	O
20	20	NUM	CD	9	O
/	/	SYM	SYM	9	O
13	13	NUM	CD	7	O
;	;	PUNCT	:	9	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
57	57	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
27	27	NUM	CD	7	O
-	-	SYM	SYM	7	O
75	75	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
years	year	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
median	median	NOUN	NN	9	O
WHO	who	PRON	WP	5	O
status	status	NOUN	NN	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

18	18	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
AGC	AGC	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
relapsed	relapsed	ADJ	JJ	5	O
AGC	AGC	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
was	be	VERB	VBD	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
those	those	DET	DT	5	O
surviving	survive	VERB	VBG	9	O
:	:	PUNCT	:	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
32	32	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
evaluable	evaluable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
response	response	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
partial	partial	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
45	45	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
15	15	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
progressive	progressive	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
overall	overall	ADJ	JJ	5	O
survival	survival	NOUN	NN	9	O
time	time	NOUN	NN	5	O
was	be	VERB	VBD	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
[	[	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
median	median	ADJ	JJ	9	O
progression	progression	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
time	time	NOUN	NN	5	O
was	be	VERB	VBD	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
worst	bad	ADJ	JJS	5	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
observed	observe	VERB	VBN	9	O
were	be	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
CTC	CTC	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
NCI	NCI	PROPN	NNP	2	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
leukopenia	leukopenia	PROPN	NNP	9	B-Disease
45	45	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
/	/	SYM	SYM	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
vomitus	vomitus	NOUN	NN	5	B-Disease
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
diarrhea	diarrhea	NOUN	NN	5	B-Disease
36	36	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
,	,	PUNCT	,	9	O
stomatitis	stomatitis	NOUN	NN	9	B-Disease
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
hand	hand	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
foot	foot	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
HUS	HUS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
/	/	SYM	SYM	9	O
FA	FA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
MMC	MMC	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
outpatient	outpatient	NOUN	NN	5	O
regimen	regiman	NOUN	NNS	5	O
for	for	ADP	IN	5	O
AGC	AGC	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
objective	objective	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
54	54	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
serve	serve	VERB	VB	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
alternative	alternative	NOUN	NN	5	O
to	to	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
regimens	regimen	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
that	that	ADP	IN	5	O
possibly	possibly	ADV	RB	9	O
HUS	HUS	PROPN	NNP	9	B-Disease
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
.	.	PUNCT	.	9	O

Persistent	persistent	ADJ	JJ	9	O
sterile	sterile	ADJ	JJ	0	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	B-Disease
immunodeficiency	immunodeficiency	NOUN	NN	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
type	type	NOUN	NN	9	I-Disease
1	1	NUM	CD	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
children	child	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
indinavir	indinavir	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Prolonged	prolonged	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
indinavir	indinavir	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
documented	document	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
restricted	restrict	VERB	VBN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
protease	protease	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
monitor	monitor	VERB	VB	5	O
indinavir	indinavir	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
human	human	ADJ	JJ	3	B-Disease
immunodeficiency	immunodeficiency	NOUN	NN	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
type	type	NOUN	NN	9	I-Disease
1	1	NUM	CD	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
children	child	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
indinavir	indinavir	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Urinary	Urinary	PROPN	NNP	9	O
pH	pH	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
albumin	albumin	NOUN	NN	0	O
,	,	PUNCT	,	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
erythrocytes	erythrocyte	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
leukocytes	leukocyte	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
bacteria	bacteria	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
crystals	crystal	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
culture	culture	NOUN	NN	9	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
for	for	ADP	IN	5	O
96	96	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
routinely	routinely	ADV	RB	9	O
determined	determine	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
points	point	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Steady	steady	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
state	state	NOUN	NN	5	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
of	of	ADP	IN	5	O
indinavir	indinavir	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
4	4	NUM	CD	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
indinavir	indinavir	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
sterile	sterile	ADJ	JJ	0	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
75	75	NUM	CD	9	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
micro	micro	NOUN	NN	0	O
L	l	NOUN	NN	0	O
in	in	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
2	2	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
visits	visit	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
96	96	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
53	53	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Persistent	persistent	ADJ	JJ	9	O
sterile	sterile	ADJ	JJ	0	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
frequently	frequently	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
mild	mild	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urine	urine	NOUN	NN	9	O
albumin	albumin	NOUN	NN	0	O
/	/	SYM	SYM	9	O
creatinine	creatinine	VERB	VB	0	B-Chemical
ratio	ratio	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
microscopic	microscopic	ADJ	JJ	9	O
hematuria	hematuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
>	>	X	XX	0	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
above	above	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
was	be	VERB	VBD	9	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
after	after	ADP	IN	9	O
96	96	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
sterile	sterile	ADJ	JJ	0	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
had	have	VERB	VBD	9	O
serum	serum	ADJ	JJ	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
above	above	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
children	child	NOUN	NNS	5	O
without	without	ADP	IN	9	O
persistent	persistent	ADJ	JJ	5	O
sterile	sterile	ADJ	JJ	0	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
children	child	NOUN	NNS	5	O
younger	young	ADJ	JJR	5	O
than	than	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
persistent	persistent	ADJ	JJ	5	O
sterile	sterile	ADJ	JJ	0	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
higher	high	ADJ	JJR	9	O
cumulative	cumulative	ADJ	JJ	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
curve	curve	NOUN	NN	9	O
>	>	X	XX	0	O
19	19	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
x	x	SYM	SYM	9	O
h	h	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
peak	peak	NOUN	NN	9	O
serum	serum	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
indinavir	indinavir	ADJ	JJ	0	B-Chemical
>	>	X	XX	0	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
4	4	NUM	CD	9	O
children	child	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
indinavir	indinavir	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Subsequently	subsequently	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
decreased	decrease	VERB	VBD	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
urine	urine	NOUN	NN	9	O
albumin	albumin	NOUN	NN	0	O
/	/	SYM	SYM	9	O
creatinine	creatinine	VERB	VB	0	B-Chemical
ratios	ratio	NOUN	NNS	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
zero	zero	NUM	CD	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
disappeared	disappear	VERB	VBD	9	O
within	within	ADP	IN	9	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Children	child	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
indinavir	indinavir	NOUN	NN	0	B-Chemical
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
cumulative	cumulative	ADJ	JJ	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
sterile	sterile	ADJ	JJ	0	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
sterile	sterile	ADJ	JJ	0	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
>	>	X	XX	0	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
above	above	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Younger	young	ADJ	JJR	5	O
children	child	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
impairment	impairment	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
children	child	NOUN	NNS	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
nephrolithiasis	nephrolithiasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Indinavir	Indinavir	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
monitored	monitor	VERB	VBN	9	O
closely	closely	ADV	RB	9	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
sterile	sterile	ADJ	JJ	0	O
leukocyturia	leukocyturia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
<	<	X	XX	0	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
curve	curve	NOUN	NN	9	O
of	of	ADP	IN	5	O
indinavir	indinavir	NOUN	NN	0	B-Chemical
>	>	X	XX	0	O
19	19	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
x	x	SYM	SYM	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
C	c	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
max	max	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
>	>	X	XX	0	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Utility	utility	NOUN	NN	5	O
of	of	ADP	IN	5	O
troponin	troponin	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Baseline	Baseline	PROPN	NNP	9	O
electrocardiogram	electrocardiogram	VERB	VBP	5	O
abnormalities	abnormality	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
market	market	NOUN	NN	5	O
elevations	elevation	NOUN	NNS	9	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
make	make	VERB	VBP	5	O
accurate	accurate	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MI	MI	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
difficult	difficult	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Troponin	troponin	NOUN	NN	7	O
sampling	sampling	NOUN	NN	5	O
may	may	VERB	MD	5	O
offer	offer	VERB	VB	5	O
greater	great	ADJ	JJR	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
utility	utility	NOUN	NN	5	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
outcomes	outcome	NOUN	NNS	5	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
troponin	troponin	ADJ	JJ	9	O
positivity	positivity	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
admitted	admit	VERB	VBN	5	O
for	for	ADP	IN	5	O
exclusion	exclusion	NOUN	NN	5	O
of	of	ADP	IN	5	O
MI	MI	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Outcomes	outcome	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
admitted	admit	VERB	VBN	5	O
for	for	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
MI	MI	PROPN	NNP	9	B-Disease
after	after	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
underwent	undergo	VERB	VBD	5	O
a	a	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
rule	rule	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
in	in	PART	RP	5	O
protocol	protocol	NOUN	NN	9	O
that	that	DET	WDT	5	O
included	include	VERB	VBD	5	O
serial	serial	ADJ	JJ	9	O
sampling	sampling	NOUN	NN	5	O
of	of	ADP	IN	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
CK	CK	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
troponin	troponin	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
(	(	PUNCT	-LRB-	9	O
cTnI	cTnI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
over	over	ADP	IN	5	O
eight	eight	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Outcomes	Outcomes	PROPN	NNP	5	O
included	include	VERB	VBD	5	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
MI	MI	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
8	8	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
index	index	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
(	(	PUNCT	-LRB-	9	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
x	x	SYM	SYM	9	O
100	100	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
total	total	ADJ	JJ	9	O
CK	ck	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
death	death	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
significant	significant	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
246	246	NUM	CD	7	O
admitted	admit	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
34	34	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
met	meet	VERB	VBD	5	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
MI	MI	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
38	38	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
cTnI	ctni	NUM	CD	9	O
elevations	elevation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Angiography	Angiography	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
29	29	NUM	CD	7	O
of	of	ADP	IN	5	O
38	38	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
cTnI	ctni	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
present	present	NOUN	NN	9	O
in	in	ADP	IN	5	O
25	25	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
86	86	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
significant	significant	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
cTnI	cTnI	PROPN	NNP	9	O
elevations	elevation	NOUN	NNS	9	O
met	meet	VERB	VBD	5	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
MI	MI	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
peak	peak	NOUN	NN	9	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
ng	ng	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Sensitivities	sensitivity	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
specificities	specificity	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
positive	positive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
negative	negative	ADJ	JJ	9	O
likelihood	likelihood	NOUN	NN	5	O
ratios	ratio	NOUN	NNS	9	O
for	for	ADP	IN	5	O
predicting	predict	VERB	VBG	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
death	death	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
significant	significant	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
were	be	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
for	for	ADP	IN	5	O
both	both	CCONJ	CC	9	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
MI	MI	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
cTnI	cTnI	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Most	Most	ADJ	JJS	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cTnI	ctni	NOUN	NN	9	O
elevations	elevation	NOUN	NNS	9	O
meet	meet	VERB	VBP	5	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
MI	MI	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
underlying	underlie	VERB	VBG	5	O
significant	significant	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Troponin	Troponin	PROPN	NNP	7	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
an	an	DET	DT	5	O
equivalent	equivalent	ADJ	JJ	9	O
diagnostic	diagnostic	ADJ	JJ	5	O
accuracy	accuracy	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
for	for	ADP	IN	5	O
diagnosing	diagnose	VERB	VBG	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
suspected	suspect	VERB	VBN	5	O
MI	MI	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
nicergoline	nicergoline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Sermion	Sermion	PROPN	NNP	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
AIN	AIN	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
nicergoline	nicergoline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Sermion	Sermion	PROPN	NNP	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
50	50	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
hospital	hospital	NOUN	NN	5	O
for	for	ADP	IN	5	O
fever	fever	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Before	before	ADP	IN	9	O
admission	admission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
taking	take	VERB	VBG	5	O
nicergoline	nicergoline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
bendazac	bendazac	ADJ	JJ	_	B-Chemical
lysine	lysine	NOUN	NN	0	I-Chemical
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
vein	vein	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
at	at	ADP	IN	9	O
ophthalmologic	ophthalmologic	ADJ	JJ	5	O
department	department	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thereafter	thereafter	ADV	RB	9	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
experienced	experience	VERB	VBD	5	O
intermittent	intermittent	ADJ	JJ	5	O
fever	fever	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
skin	skin	NOUN	NN	5	B-Disease
rash	rash	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
clinical	clinical	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
arthralgia	arthralgia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
fever	fever	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
findings	finding	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
eosinophilia	eosinophilia	NOUN	NNS	3	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
suggested	suggest	VERB	VBD	9	O
AIN	AIN	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
pathologic	pathologic	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
biopsy	biopsy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
lymphocyte	lymphocyte	ADJ	JJ	3	O
transformation	transformation	NOUN	NN	9	O
test	test	NOUN	NN	5	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
result	result	NOUN	NN	9	O
against	against	ADP	IN	9	O
nicergoline	nicergoline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
consisted	consist	VERB	VBN	5	O
of	of	ADP	IN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
nicergoline	nicergoline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
intravenous	intravenous	ADJ	JJ	0	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
his	-PRON-	DET	PRP$	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
recovered	recover	VERB	VBN	9	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
nicergoline	nicergoline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
AIN	ain	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Neuroleptic	neuroleptic	ADJ	JJ	2	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
complicated	complicate	VERB	VBN	5	O
by	by	ADP	IN	9	O
massive	massive	ADJ	JJ	9	O
intestinal	intestinal	ADJ	JJ	9	O
bleeding	bleeding	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CRF	CRF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
NMS	NMS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
levomepromazine	levomepromazine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
typical	typical	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
NMS	NMS	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
massive	massive	ADJ	JJ	9	O
intestinal	intestinal	ADJ	JJ	9	O
bleeding	bleeding	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
episode	episode	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
NMS	NMS	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
CRF	CRF	PROPN	NNP	9	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
complicated	complicate	VERB	VBN	5	O
by	by	ADP	IN	9	O
intestinal	intestinal	ADJ	JJ	9	O
bleeding	bleeding	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
needs	need	VERB	VBZ	5	O
special	special	ADJ	JJ	5	O
caution	caution	NOUN	NN	5	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
in	in	ADP	IN	5	O
right	right	NOUN	NN	5	O
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
left	left	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
pawed	pawed	ADJ	JJ	9	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
staining	staining	NOUN	NN	3	O
method	method	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
asymmetrical	asymmetrical	ADJ	JJ	5	O
breakdown	breakdown	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BBB	BBB	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Paw	Paw	PROPN	NNP	5	O
preference	preference	NOUN	NN	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
food	food	NOUN	NN	5	O
reaching	reach	VERB	VBG	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
destroy	destroy	VERB	VB	9	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
using	use	VERB	VBG	9	O
triphenyltetrazolium	triphenyltetrazolium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
TTC	ttc	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
staining	staining	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
slices	slice	NOUN	NNS	9	O
just	just	ADV	RB	5	O
after	after	ADP	IN	9	O
giving	give	VERB	VBG	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
whole	whole	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
sections	section	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
complete	complete	ADJ	JJ	9	O
staining	staining	NOUN	NN	3	O
with	with	ADP	IN	5	O
TTC	TTC	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
s	s	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
large	large	ADJ	JJ	5	O
unstained	unstained	ADJ	JJ	3	O
areas	area	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
in	in	ADP	IN	5	O
right	right	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
pawed	paw	VERB	VBN	9	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
vice	vice	NOUN	NN	9	O
versa	versa	ADV	RB	9	O
in	in	ADP	IN	5	O
left	left	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
pawed	paw	VERB	VBN	9	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
breakdown	breakdown	NOUN	NN	9	O
of	of	ADP	IN	5	O
BBB	BBB	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
explained	explain	VERB	VBN	5	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
asymmetric	asymmetric	ADJ	JJ	9	O
cerebral	cerebral	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
depending	depend	VERB	VBG	5	O
upon	upon	ADP	IN	9	O
the	the	DET	DT	5	O
paw	paw	DET	PRP$	5	O
preference	preference	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
new	new	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
contralateral	contralateral	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
control	control	NOUN	NN	9	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
important	important	ADJ	JJ	9	O
in	in	ADP	IN	5	O
determining	determine	VERB	VBG	9	O
the	the	DET	DT	5	O
dominant	dominant	ADJ	JJ	9	O
cerebral	cerebral	NOUN	NN	5	O
hemisphere	hemisphere	NOUN	NN	5	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Carvedilol	Carvedilol	PROPN	NNP	0	B-Chemical
protects	protect	VERB	VBZ	3	O
against	against	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
cytopathic	cytopathic	ADJ	JJ	3	O
mechanisms	mechanism	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
to	to	PART	TO	5	O
mediate	mediate	VERB	VB	3	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
cumulative	cumulative	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
irreversible	irreversible	ADJ	JJ	9	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
are	be	VERB	VBP	5	O
key	key	ADJ	JJ	9	O
factors	factor	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenic	pathogenic	ADJ	JJ	9	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
test	test	VERB	VB	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	DT	5	O
carvedilol	carvedilol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
nonselective	nonselective	ADJ	JJ	0	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
with	with	ADP	IN	5	O
potent	potent	ADJ	JJ	3	O
antioxidant	antioxidant	ADJ	JJ	0	O
properties	property	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
protects	protect	VERB	VBZ	3	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
hepatic	hepatic	ADJ	JJ	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
bioenergetic	bioenergetic	ADJ	JJ	9	O
dysfunction	dysfunction	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
subchronic	subchronic	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Heart	heart	NOUN	NN	2	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
mitochondria	mitochondria	NOUN	NN	3	O
were	be	VERB	VBD	9	O
isolated	isolate	VERB	VBN	9	O
from	from	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
with	with	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
sc	sc	NOUN	NN	9	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
carvedilol	carvedilol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
ip	ip	NOUN	NN	0	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Heart	heart	NOUN	NN	2	O
mitochondria	mitochondria	NOUN	NN	3	O
isolated	isolate	VERB	VBD	9	O
from	from	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
depressed	depressed	ADJ	JJ	5	O
rates	rate	NOUN	NNS	5	O
for	for	ADP	IN	5	O
state	state	NOUN	NN	5	O
3	3	NUM	CD	9	O
respiration	respiration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
336	336	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
26	26	NUM	CD	7	O
versus	versus	ADP	IN	9	O
425	425	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
53	53	NUM	CD	7	O
natom	natom	NOUN	NN	9	O
O	o	INTJ	UH	9	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
protein	protein	NOUN	NN	1	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
lower	lower	ADV	RBR	9	O
respiratory	respiratory	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
RCR	RCR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
versus	versus	ADP	IN	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
mitochondria	mitochondria	NOUN	NN	3	O
isolated	isolate	VERB	VBN	9	O
from	from	ADP	IN	9	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Mitochondrial	mitochondrial	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
loading	load	VERB	VBG	9	O
capacity	capacity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
NADH	NADH	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
dehydrogenase	dehydrogenase	PROPN	NNP	1	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
suppressed	suppress	VERB	VBN	3	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
mitochondria	mitochondria	NOUN	NN	3	O
from	from	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
also	also	ADV	RB	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
RCR	RCR	PROPN	NNP	5	O
for	for	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
mitochondria	mitochondria	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
versus	versus	ADP	IN	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
for	for	ADP	IN	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
cytochrome	cytochrome	ADJ	JJ	0	O
oxidase	oxidase	NOUN	NN	0	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Coadministration	coadministration	NOUN	NN	0	O
of	of	ADP	IN	5	O
carvedilol	carvedilol	NOUN	NN	0	B-Chemical
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
cellular	cellular	ADJ	JJ	3	O
vacuolization	vacuolization	NOUN	NN	3	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
myocytes	myocyte	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
respiration	respiration	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
heart	heart	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Carvedilol	Carvedilol	PROPN	NNP	0	B-Chemical
also	also	ADV	RB	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
loading	loading	NOUN	NN	9	O
capacity	capacity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
respiratory	respiratory	ADJ	JJ	5	O
complexes	complex	NOUN	NNS	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
mitochondria	mitochondria	NOUN	NN	3	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Carvedilol	carvedilol	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
itself	-PRON-	PRON	PRP	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
parameters	parameter	NOUN	NNS	5	O
measured	measure	VERB	VBN	9	O
for	for	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
mitochondria	mitochondria	NOUN	NN	3	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
protection	protection	NOUN	NN	9	O
by	by	ADP	IN	9	O
carvedilol	carvedilol	NOUN	NN	0	B-Chemical
against	against	ADP	IN	9	O
both	both	DET	DT	9	O
the	the	DET	DT	5	O
structural	structural	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
damage	damage	NOUN	NN	9	O
may	may	VERB	MD	5	O
afford	afford	VERB	VB	5	O
significant	significant	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
advantage	advantage	NOUN	NN	5	O
in	in	ADP	IN	5	O
minimizing	minimize	VERB	VBG	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
accompanies	accompany	VERB	VBZ	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
more	more	ADV	RBR	5	O
influenced	influence	VERB	VBN	5	O
by	by	ADP	IN	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
agonists	agonist	VERB	VBZ	3	O
than	than	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
agonists	agonist	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
antagonists	antagonist	NOUN	NNS	3	O
on	on	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
agonists	agonist	VERB	VBZ	3	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	B-Disease
the	the	DET	DT	5	I-Disease
locomotor	locomotor	NOUN	NN	5	I-Disease
activity	activity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
seems	seem	VERB	VBZ	5	O
that	that	DET	DT	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
A1	A1	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
A2	a2	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
agonists	agonist	VERB	VBZ	3	O
:	:	PUNCT	:	9	O
2	2	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboxyethyl	carboxyethyl	ADV	RB	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
phenethylamino	phenethylamino	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
'	'	PROPN	NNPS	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ethylcarboxamidoadenosine	ethylcarboxamidoadenosine	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
CGS	CGS	PROPN	NNP	9	B-Chemical
21680	21680	NUM	CD	3	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
A2A	A2A	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
N6	n6	NOUN	NN	8	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
cyclopentyladenosine	cyclopentyladenosine	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CPA	CPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
A1	A1	PROPN	NNP	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	B-Chemical
'	'	PROPN	NNPS	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ethylcarboxamidoadenosine	ethylcarboxamidoadenosine	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
NECA	NECA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
A2	a2	NOUN	NN	9	O
/	/	SYM	SYM	9	O
A1	A1	PROPN	NNP	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
significantly	significantly	ADV	RB	9	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	,	7	O
dependently	dependently	ADV	RB	3	O
decreased	decrease	VERB	VBN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CPA	cpa	NOUN	NN	9	B-Chemical
reduced	reduce	VERB	VBN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
action	action	NOUN	NN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
which	which	DET	WDT	5	O
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
influence	influence	VERB	VB	5	O
motility	motility	NOUN	NN	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
CGS	CGS	PROPN	NNP	9	B-Chemical
21680	21680	NUM	CD	3	I-Chemical
and	and	CCONJ	CC	5	O
NECA	NECA	PROPN	NNP	0	B-Chemical
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
which	which	DET	WDT	5	O
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
although	although	ADP	IN	9	O
agonists	agonist	NOUN	NNS	3	O
of	of	ADP	IN	5	O
A1	A1	PROPN	NNP	9	O
receptors	receptor	NOUN	NNS	3	O
seem	seem	VERB	VBP	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
stronger	strong	ADJ	JJR	9	O
influence	influence	NOUN	NN	5	O
on	on	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
A2	a2	NOUN	NN	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
by	by	ADP	IN	9	O
DMPX	DMPX	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dimethyl	dimethyl	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
propargylxanthine	propargylxanthine	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
significantly	significantly	ADV	RB	9	O
enhanced	enhance	VERB	VBD	3	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Caffeine	caffeine	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

CPT	CPT	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
cyclopentyltheophylline	cyclopentyltheophylline	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
-	-	PUNCT	HYPH	7	O
A1	A1	PROPN	NNP	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
show	show	VERB	VB	9	O
any	any	DET	DT	5	O
influence	influence	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
agonists	agonist	VERB	VBZ	3	O
decreased	decrease	VERB	VBD	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
active	active	ADJ	JJ	9	O
in	in	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
A2	a2	NOUN	NN	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
DMPX	DMPX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
all	all	DET	DT	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
agonists	agonist	VERB	VBZ	3	O
(	(	PUNCT	-LRB-	9	O
A1	A1	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
A2	a2	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
reduce	reduce	VERB	VB	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
more	more	ADV	RBR	5	O
influenced	influence	VERB	VBN	5	O
by	by	ADP	IN	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
agonists	agonist	VERB	VBZ	3	O
(	(	PUNCT	-LRB-	9	O
particularly	particularly	ADV	RB	5	O
A1	A1	PROPN	NNP	9	O
receptors	receptor	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Amiodarone	Amiodarone	PROPN	NNP	7	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
bradyarrhythmia	bradyarrhythmia	NOUN	NN	5	B-Disease
requiring	require	VERB	VBG	5	O
permanent	permanent	ADJ	JJ	5	O
pacemaker	pacemaker	NOUN	NN	5	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
prior	prior	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AF	AF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
bradyarrhythmia	bradyarrhythmia	NOUN	NN	5	B-Disease
requiring	require	VERB	VBG	5	O
a	a	DET	DT	5	O
permanent	permanent	ADJ	JJ	5	O
pacemaker	pacemaker	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Reports	report	NOUN	NNS	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
bradyarrhythmia	bradyarrhythmia	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
are	be	VERB	VBP	5	O
infrequent	infrequent	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
limited	limit	VERB	VBN	5	O
to	to	ADP	IN	5	O
studies	study	NOUN	NNS	9	O
assessing	assess	VERB	VBG	5	O
the	the	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
study	study	NOUN	NN	9	O
cohort	cohort	NOUN	NN	9	O
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
770	770	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
age	age	NOUN	NN	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
65	65	NUM	CD	7	O
years	year	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
AF	AF	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
provincewide	provincewide	NOUN	NN	5	O
database	database	NOUN	NN	5	O
of	of	ADP	IN	5	O
Quebec	Quebec	PROPN	NNP	2	O
residents	resident	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MI	MI	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
between	between	ADP	IN	5	O
1991	1991	NUM	CD	2	O
and	and	CCONJ	CC	5	O
1999	1999	NUM	CD	2	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
nested	nested	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
design	design	NOUN	NN	5	O
,	,	PUNCT	,	9	O
477	477	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bradyarrhythmia	bradyarrhythmia	NOUN	NN	5	B-Disease
requiring	require	VERB	VBG	5	O
a	a	DET	DT	5	O
permanent	permanent	ADJ	JJ	5	O
pacemaker	pacemaker	NOUN	NN	5	O
were	be	VERB	VBD	9	O
matched	match	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
:	:	SYM	SYM	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
908	908	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Multivariable	multivariable	ADJ	JJ	5	O
logistic	logistic	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
estimate	estimate	VERB	VB	5	O
the	the	DET	DT	5	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
pacemaker	pacemaker	NOUN	NN	5	O
insertion	insertion	NOUN	NN	1	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
controlling	control	VERB	VBG	9	O
for	for	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
sotalol	sotalol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
Class	Class	PROPN	NNP	9	O
I	-PRON-	PRON	PRP	9	O
antiarrhythmic	antiarrhythmic	VERB	VBP	5	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
use	use	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
pacemaker	pacemaker	NOUN	NN	5	O
insertion	insertion	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
:	:	PUNCT	:	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
14	14	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
]	]	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
30	30	NUM	CD	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
54	54	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
modified	modify	VERB	VBN	9	O
by	by	ADP	IN	9	O
gender	gender	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
risk	risk	NOUN	NN	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
versus	versus	ADP	IN	9	O
men	man	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
:	:	SYM	SYM	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
86	86	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
70	70	NUM	CD	9	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
OR	or	CCONJ	CC	9	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
52	52	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
80	80	NUM	CD	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
89	89	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Digoxin	Digoxin	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
other	other	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
pacemaker	pacemaker	NOUN	NN	5	O
insertion	insertion	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
78	78	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
37	37	NUM	CD	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
31	31	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
AF	AF	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
MI	MI	PROPN	NNP	9	B-Disease
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
bradyarrhythmia	bradyarrhythmia	NOUN	NN	5	B-Disease
requiring	require	VERB	VBG	5	O
a	a	DET	DT	5	O
permanent	permanent	ADJ	JJ	5	O
pacemaker	pacemaker	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
finding	finding	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
augmented	augmented	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
pacemaker	pacemaker	NOUN	NN	5	O
insertion	insertion	NOUN	NN	1	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
requires	require	VERB	VBZ	5	O
further	further	ADJ	JJ	9	O
investigation	investigation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Indomethacin	indomethacin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
morphologic	morphologic	NOUN	NN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
urinary	urinary	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
epithelium	epithelium	NOUN	NN	3	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
morphologic	morphologic	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
urothelium	urothelium	NOUN	NN	3	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
indomethacin	indomethacin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Nonsteroidal	Nonsteroidal	PROPN	NNP	2	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
poorly	poorly	ADV	RB	9	O
recognized	recognize	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
under	under	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
reported	report	VERB	VBN	9	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
tiaprofenic	tiaprofenic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
established	establish	VERB	VBN	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
one	one	NUM	CD	5	O
intraperitoneal	intraperitoneal	ADJ	JJ	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
indomethacin	indomethacin	ADJ	JJ	0	B-Chemical
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
oral	oral	ADJ	JJ	9	O
indomethacin	indomethacin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
killed	kill	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
bladders	bladder	NOUN	NNS	9	O
removed	remove	VERB	VBD	9	O
for	for	ADP	IN	5	O
light	light	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
electron	electron	VERB	VB	0	O
microscopic	microscopic	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
light	light	ADJ	JJ	9	O
microscopic	microscopic	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
some	some	DET	DT	5	O
focal	focal	ADJ	JJ	5	O
epithelial	epithelial	ADJ	JJ	3	O
degeneration	degeneration	NOUN	NN	9	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
prominent	prominent	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
indomethacin	indomethacin	ADJ	JJ	0	B-Chemical
groups	group	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
increased	increased	ADJ	JJ	9	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mast	mast	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mucosa	mucosa	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
penetration	penetration	NOUN	NN	5	O
of	of	ADP	IN	5	O
lanthanum	lanthanum	NOUN	NN	0	B-Chemical
nitrate	nitrate	NOUN	NN	0	I-Chemical
through	through	ADP	IN	9	O
intercellular	intercellular	ADJ	JJ	3	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
epithelium	epithelium	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
mast	mast	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
counts	count	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Indomethacin	Indomethacin	PROPN	NNP	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
histopathologic	histopathologic	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
typical	typical	ADJ	JJ	9	O
of	of	ADP	IN	5	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
leaky	leaky	ADJ	JJ	5	O
bladder	bladder	NOUN	NN	9	O
epithelium	epithelium	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
mucosal	mucosal	NOUN	NN	9	O
mastocytosis	mastocytosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
true	true	ADJ	JJ	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
clarified	clarify	VERB	VBN	9	O
by	by	ADP	IN	9	O
prospective	prospective	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
androgen	androgen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
independent	independent	ADJ	JJ	9	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antiangiogenic	antiangiogenic	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
various	various	ADJ	JJ	9	O
solid	solid	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
haematological	haematological	ADJ	JJ	5	B-Disease
malignancies	malignancy	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Thalidomide	Thalidomide	PROPN	NNP	0	B-Chemical
blocks	block	VERB	VBZ	9	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
angiogenic	angiogenic	ADJ	JJ	3	O
agents	agent	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
bFGF	bFGF	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
VEGF	VEGF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
undertook	undertake	VERB	VBD	9	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
study	study	NOUN	NN	9	O
using	use	VERB	VBG	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
in	in	ADP	IN	5	O
20	20	NUM	CD	9	O
men	man	NOUN	NNS	5	O
with	with	ADP	IN	5	O
androgen	androgen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
independent	independent	ADJ	JJ	9	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
109	109	NUM	CD	7	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
median	median	ADJ	JJ	9	O
107	107	NUM	CD	9	O
,	,	PUNCT	,	9	O
range	range	VERB	VBP	9	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
184	184	NUM	CD	7	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
underwent	undergo	VERB	VBD	5	O
regular	regular	ADJ	JJ	5	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
prostate	prostate	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
antigen	antigen	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
PSA	PSA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
urea	urea	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
electrolytes	electrolyte	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
bFGF	bFGF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
VEGF	VEGF	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
men	man	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
PSA	PSA	PROPN	NNP	9	O
of	of	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
sustained	sustain	VERB	VBN	5	O
throughout	throughout	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
16	16	NUM	CD	9	O
men	man	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
six	six	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
37	37	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
absolute	absolute	ADJ	JJ	5	O
PSA	PSA	PROPN	NNP	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
median	median	NOUN	NN	9	O
of	of	ADP	IN	5	O
48	48	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Increasing	increase	VERB	VBG	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
bFGF	bFGF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
VEGF	VEGF	PROPN	NNP	3	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
;	;	PUNCT	:	9	O
five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
men	man	NOUN	NNS	5	O
who	who	PRON	WP	5	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
PSA	PSA	PROPN	NNP	9	O
also	also	ADV	RB	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
bFGF	bFGF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
VEGF	VEGF	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
men	man	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
rising	rise	VERB	VBG	5	O
PSA	PSA	PROPN	NNP	9	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
growth	growth	NOUN	NN	3	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Adverse	Adverse	PROPN	NNP	5	O
effects	effect	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
constipation	constipation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
morning	morning	NOUN	NN	5	O
drowsiness	drowsiness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
dizziness	dizziness	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
rash	rash	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
by	by	ADP	IN	9	O
three	three	NUM	CD	9	O
men	man	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
sensory	sensory	ADJ	JJ	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
nine	nine	NUM	CD	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
men	man	NOUN	NNS	5	O
before	before	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
seven	seven	NUM	CD	9	O
men	man	NOUN	NNS	5	O
who	who	PRON	WP	5	O
completed	complete	VERB	VBD	5	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
on	on	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
subclinical	subclinical	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
before	before	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
seven	seven	NUM	CD	9	O
at	at	ADP	IN	9	O
repeat	repeat	NOUN	NN	9	O
testing	testing	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
option	option	NOUN	NN	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
failed	fail	VERB	VBN	9	O
other	other	ADJ	JJ	5	O
forms	form	NOUN	NNS	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
provided	provide	VERB	VBD	9	O
close	close	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
maintained	maintain	VERB	VBN	9	O
for	for	ADP	IN	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Central	central	ADJ	JJ	4	B-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
lumbar	lumbar	ADJ	JJ	5	O
plexus	plexus	NOUN	NN	9	O
block	block	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
OBJECTIVES	objective	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Central	central	ADJ	JJ	4	B-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
cardiac	cardiac	ADJ	JJ	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
recognized	recognize	VERB	VBN	9	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
regional	regional	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Levobupivacaine	Levobupivacaine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
pure	pure	ADJ	JJ	9	O
S	S	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
enantiomer	enantiomer	NOUN	NN	0	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
safety	safety	NOUN	NN	5	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
2	2	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
grand	grand	ADJ	JJ	5	B-Disease
mal	mal	NOUN	NN	2	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
following	follow	VERB	VBG	9	O
accidental	accidental	ADJ	JJ	5	O
intravascular	intravascular	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
REPORT	REPORT	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
presenting	present	VERB	VBG	5	O
for	for	ADP	IN	5	O
elective	elective	ADJ	JJ	5	O
orthopedic	orthopedic	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
limb	limb	NOUN	NN	5	O
underwent	underwent	NOUN	NN	5	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lumbar	lumbar	ADJ	JJ	5	O
plexus	plexus	NOUN	NN	9	O
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
posterior	posterior	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
with	with	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microgram	microgram	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	mL	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
grand	grand	ADJ	JJ	5	B-Disease
mal	mal	NOUN	NN	2	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
negative	negative	ADJ	JJ	9	O
aspiration	aspiration	NOUN	NN	5	O
for	for	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
clinical	clinical	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
successfully	successfully	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
thiopental	thiopental	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neither	neither	DET	DT	9	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBN	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
preoperatively	preoperatively	ADV	RB	5	O
with	with	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
medications	medication	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
masked	mask	VERB	VBN	5	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
unintentional	unintentional	ADJ	JJ	5	O
intravascular	intravascular	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
safer	safe	ADJ	JJR	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
profile	profile	NOUN	NN	9	O
than	than	ADP	IN	5	O
racemic	racemic	NOUN	NN	0	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
if	if	ADP	IN	5	O
adequate	adequate	ADJ	JJ	5	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
reach	reach	VERB	VBP	5	O
the	the	DET	DT	5	O
circulation	circulation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
will	will	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
concentrations	concentration	NOUN	NNS	0	O
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
central	central	ADJ	JJ	5	B-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
manifestations	manifestation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Amiodarone	amiodarone	ADV	RB	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
during	during	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
irrigation	irrigation	NOUN	NN	5	O
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
presentation	presentation	NOUN	NN	5	O
-	-	PUNCT	:	7	O
-	-	PUNCT	:	7	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
early	early	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
within	within	ADP	IN	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TdP	tdp	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
TdP	tdp	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
context	context	NOUN	NN	5	O
of	of	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
exacerbating	exacerbating	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
including	include	VERB	VBG	9	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
excess	excess	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Transient	transient	ADJ	JJ	9	O
prolongation	prolongation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
QT	QT	PROPN	NNP	5	O
during	during	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
irrigation	irrigation	NOUN	NN	5	O
prompted	prompt	VERB	VBD	9	O
the	the	DET	DT	5	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
TdP	tdp	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
known	know	VERB	VBN	9	O
that	that	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
exacerbates	exacerbate	NOUN	NNS	9	O
acquired	acquire	VERB	VBD	5	O
TdP	tdp	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
speculate	speculate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
vagal	vagal	ADJ	JJ	5	O
tone	tone	NOUN	NN	5	O
during	during	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
irrigation	irrigation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
vagal	vagal	ADJ	JJ	5	O
maneuver	maneuver	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
context	context	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
proarrhythmia	proarrhythmia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
irrigation	irrigation	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
induce	induce	VERB	VB	3	O
TdP	tdp	NOUN	NN	5	B-Disease
despite	despite	ADP	IN	9	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hypomagnesemia	hypomagnesemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Anaesthetic	anaesthetic	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
myotonia	myotonia	NOUN	NN	5	B-Disease
congenita	congenita	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
study	study	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
myotonic	myotonic	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Myotonia	Myotonia	PROPN	NNP	2	B-Disease
congenita	congenita	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MC	MC	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
defect	defect	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
skeletal	skeletal	ADJ	JJ	9	O
muscle	muscle	NOUN	NN	9	O
chloride	chloride	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
sustained	sustained	ADJ	JJ	5	B-Disease
membrane	membrane	ADJ	JJ	9	I-Disease
depolarisation	depolarisation	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
previously	previously	ADV	RB	9	O
healthy	healthy	ADJ	JJ	5	O
32	32	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
muscle	muscle	NOUN	NN	9	B-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
secondary	secondary	ADJ	JJ	9	O
ventilation	ventilation	NOUN	NN	5	O
difficulties	difficulty	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
preoperative	preoperative	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
muscle	muscle	NOUN	NN	9	B-Disease
spasms	spasm	NOUN	NNS	5	I-Disease
disappeared	disappear	VERB	VBD	9	O
spontaneously	spontaneously	ADV	RB	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
surgery	surgery	NOUN	NN	5	O
proceeded	proceed	VERB	VBD	9	O
without	without	ADP	IN	9	O
further	further	ADJ	JJ	9	O
problems	problem	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
subsequently	subsequently	ADV	RB	9	O
questioned	question	VERB	VBN	5	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
reported	report	VERB	VBD	9	O
minor	minor	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
suggesting	suggest	VERB	VBG	9	O
a	a	DET	DT	5	O
myotonic	myotonic	ADJ	JJ	5	B-Disease
condition	condition	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Myotonia	Myotonia	PROPN	NNP	2	B-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
on	on	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
EMG	EMG	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
MC	MC	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
genetically	genetically	ADV	RB	9	O
.	.	PUNCT	.	9	O

Neither	neither	CCONJ	CC	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
nor	nor	CCONJ	CC	9	O
the	the	DET	DT	5	O
anaesthetist	anaesthetist	NOUN	NN	5	O
were	be	VERB	VBD	9	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
before	before	ADP	IN	9	O
this	this	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
lethal	lethal	ADJ	JJ	9	O
complication	complication	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
give	give	VERB	VBP	5	O
a	a	DET	DT	5	O
brief	brief	ADJ	JJ	5	O
overview	overview	NOUN	NN	5	O
of	of	ADP	IN	5	O
ion	ion	NOUN	NN	0	B-Disease
channel	channel	NOUN	NN	9	I-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
including	include	VERB	VBG	9	O
malignant	malignant	ADJ	JJ	3	B-Disease
hyperthermia	hyperthermia	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
anaesthetic	anaesthetic	ADJ	JJ	5	O
considerations	consideration	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Respiratory	respiratory	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Apnea	Apnea	PROPN	NNP	5	B-Disease
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
occur	occur	VERB	VB	5	O
during	during	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
systematic	systematic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ictal	ictal	ADJ	JJ	5	O
respiratory	respiratory	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
few	few	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
regarding	regard	VERB	VBG	5	O
respiratory	respiratory	ADJ	JJ	5	O
pattern	pattern	NOUN	NN	9	O
defects	defect	NOUN	NNS	9	O
during	during	ADP	IN	5	O
interictal	interictal	ADJ	JJ	5	O
periods	period	NOUN	NNS	5	O
also	also	ADV	RB	9	O
are	be	VERB	VBP	5	O
scarce	scarce	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
sought	seek	VERB	VBD	9	O
to	to	PART	TO	5	O
generate	generate	VERB	VB	9	O
information	information	NOUN	NN	5	O
with	with	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
interictal	interictal	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
with	with	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Twelve	twelve	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
six	six	NUM	CD	9	O
chronically	chronically	ADV	RB	9	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
animals	animal	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
six	six	NUM	CD	9	O
controls	control	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
anesthetized	anesthetize	VERB	VBN	0	O
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
tracheotomies	tracheotomy	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
hyperventilation	hyperventilation	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
hypoventilation	hypoventilation	NOUN	NN	5	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Breathing	breathing	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
caused	cause	VERB	VBD	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
thoracic	thoracic	NOUN	NN	5	O
volume	volume	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
forced	force	VERB	VBN	5	O
air	air	NOUN	NN	5	O
to	to	PART	TO	5	O
flow	flow	VERB	VB	5	O
tidally	tidally	ADV	RB	5	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
pneumotachograph	pneumotachograph	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
flow	flow	NOUN	NN	5	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
pressure	pressure	NOUN	NN	5	O
transducer	transducer	NOUN	NN	5	O
,	,	PUNCT	,	9	O
passed	pass	VERB	VBD	5	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
polygraph	polygraph	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
from	from	ADP	IN	9	O
this	this	DET	DT	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
computer	computer	NOUN	NN	5	O
with	with	ADP	IN	5	O
custom	custom	NOUN	NN	5	O
software	software	NOUN	NN	5	O
that	that	DET	WDT	5	O
derived	derive	VERB	VBD	9	O
ventilation	ventilation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
VE	VE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
tidal	tidal	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
VT	VT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
inspiratory	inspiratory	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
TI	TI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
expiratory	expiratory	NOUN	NN	5	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
TE	TE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
breathing	breathing	NOUN	NN	5	O
frequency	frequency	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
f	f	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
mean	mean	VERB	VB	5	O
inspiratory	inspiratory	ADJ	JJ	5	O
flow	flow	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
VT	VT	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
TI	TI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
breath	breath	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
by	by	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
breath	breath	NOUN	NN	5	O
basis	basis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
hyperventilation	hyperventilation	NOUN	NN	5	B-Disease
maneuver	maneuver	NOUN	NN	5	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
ventilation	ventilation	NOUN	NN	5	O
in	in	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
VE	VE	PROPN	NNP	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
VE	VE	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
TE	TE	PROPN	NNP	9	O
peak	peak	NOUN	NN	9	O
in	in	ADP	IN	5	O
relation	relation	NOUN	NN	5	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hypoventilation	hypoventilation	NOUN	NN	5	O
maneuver	maneuver	NOUN	NN	5	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
arterial	arterial	NOUN	NN	5	O
Paco2	Paco2	PUNCT	,	0	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
VE	VE	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
VE	VE	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
TE	TE	PROPN	NNP	9	O
peak	peak	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
KCN	KCN	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	O
chemoreception	chemoreception	NOUN	NN	5	O
activation	activation	NOUN	NN	3	O
on	on	ADP	IN	5	O
ventilation	ventilation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
VE	VE	PROPN	NNP	9	O
for	for	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
an	an	DET	DT	5	O
altered	altered	ADJ	JJ	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
react	react	VERB	VB	9	O
to	to	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
or	or	CCONJ	CC	5	O
compensate	compensate	VERB	VB	5	O
for	for	ADP	IN	5	O
)	)	PUNCT	-RRB-	9	O
blood	blood	NOUN	NN	9	O
gas	gas	NOUN	NN	0	O
changes	change	NOUN	NNS	9	O
with	with	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
ventilation	ventilation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
centrally	centrally	ADV	RB	5	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
speculate	speculate	VERB	VBP	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
relation	relation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
on	on	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
different	different	ADJ	JJ	9	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Fatal	fatal	ADJ	JJ	5	O
myeloencephalopathy	myeloencephalopathy	NOUN	NN	9	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Vincristine	Vincristine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
accidentally	accidentally	ADV	RB	5	O
given	give	VERB	VBN	5	O
intrathecally	intrathecally	ADV	RB	3	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
child	child	NOUN	NN	5	O
with	with	ADP	IN	5	O
leukaemia	leukaemia	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
producing	produce	VERB	VBG	9	O
sensory	sensory	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
motor	motor	NOUN	NN	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Separate	separate	ADJ	JJ	5	O
times	time	NOUN	NNS	5	O
for	for	ADP	IN	5	O
administering	administer	VERB	VBG	9	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Progesterone	progesterone	NOUN	NN	9	B-Chemical
potentiation	potentiation	NOUN	NN	3	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
arrhythmogenicity	arrhythmogenicity	NOUN	NN	5	O
in	in	ADP	IN	5	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
anesthetized	anesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
beating	beat	VERB	VBG	5	O
rat	rat	NOUN	NN	3	O
heart	heart	NOUN	NN	5	O
cell	cell	NOUN	NN	3	O
cultures	culture	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
arrhythmogenicity	arrhythmogenicity	NOUN	NN	5	O
in	in	ADP	IN	5	O
beating	beat	VERB	VBG	5	O
rat	rat	NOUN	NN	3	O
heart	heart	NOUN	NN	5	O
myocyte	myocyte	NOUN	NN	3	O
cultures	culture	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
determining	determine	VERB	VBG	9	O
the	the	DET	DT	5	O
bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
AD50	AD50	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
the	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
that	that	DET	WDT	5	O
caused	cause	VERB	VBD	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
beating	beat	VERB	VBG	5	O
rat	rat	NOUN	NN	3	O
heart	heart	NOUN	NN	5	O
myocyte	myocyte	NOUN	NN	3	O
cultures	culture	NOUN	NNS	3	O
to	to	PART	TO	5	O
become	become	VERB	VB	5	O
arrhythmic	arrhythmic	ADJ	JJ	5	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
determined	determine	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
HCl	HCl	NOUN	NNS	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
on	on	ADP	IN	5	O
myocyte	myocyte	NOUN	NN	3	O
contractile	contractile	NOUN	NN	9	O
rhythm	rhythm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Each	each	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
25	25	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
concentration	concentration	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
AD50	AD50	PROPN	NNP	0	O
for	for	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Estradiol	Estradiol	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
also	also	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
arrhythmogenicity	arrhythmogenicity	NOUN	NN	5	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
myocyte	myocyte	NOUN	NN	3	O
cultures	culture	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
fourth	fourth	ADJ	JJ	9	O
as	as	ADV	RB	5	O
potent	potent	ADJ	JJ	3	O
as	as	ADP	IN	5	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Neither	neither	CCONJ	CC	9	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
nor	nor	CCONJ	CC	9	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
arrhythmogenicity	arrhythmogenicity	NOUN	NN	5	O
were	be	VERB	VBD	9	O
potentiated	potentiate	VERB	VBN	3	O
by	by	ADP	IN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
21	21	NUM	CD	7	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
arrhythmogenicity	arrhythmogenicity	NOUN	NN	5	O
in	in	ADP	IN	5	O
intact	intact	ADJ	JJ	9	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
anesthetized	anesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
to	to	PART	TO	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
nonprogesterone	nonprogesterone	NOUN	NN	_	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
can	can	VERB	MD	5	O
potentiate	potentiate	VERB	VB	3	O
bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
arrhythmogenicity	arrhythmogenicity	NOUN	NN	5	O
both	both	CCONJ	CC	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
.	.	PUNCT	.	9	O

Potentiation	potentiation	NOUN	NN	3	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
myocyte	myocyte	NOUN	NN	3	O
cultures	culture	NOUN	NNS	3	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
partly	partly	ADV	RB	9	O
mediated	mediate	VERB	VBN	3	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
myocyte	myocyte	NOUN	NN	3	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
serum	serum	ADV	RB	9	O
soluble	soluble	ADJ	JJ	0	O
Fas	Fas	PROPN	NNP	3	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
paracetamol	paracetamol	ADJ	JJ	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	PROPN	NNP	2	O
/	/	SYM	SYM	9	O
AIMS	AIMS	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Experimental	experimental	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
apoptosis	apoptosis	NOUN	NN	3	O
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
Fas	Fas	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
Fas	Fas	PROPN	NNP	3	O
Ligand	Ligand	PROPN	NNP	9	O
signaling	signal	VERB	VBG	3	O
system	system	NOUN	NN	5	O
may	may	VERB	MD	5	O
play	play	VERB	VB	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
soluble	soluble	ADJ	JJ	0	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
Fas	Fas	PROPN	NNP	3	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODOLOGY	methodology	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
sFas	sFas	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
soluble	soluble	ADJ	JJ	0	O
Fas	Fas	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
ELISA	ELISA	PROPN	NNP	3	O
in	in	ADP	IN	5	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
normal	normal	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
necrosis	necrosis	NOUN	NN	9	B-Disease
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
interferon	interferon	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
gamma	gamma	NOUN	NN	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
ELISA	ELISA	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Serum	Serum	PROPN	NNP	9	O
sFas	sFas	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
median	median	NOUN	NN	9	O
,	,	PUNCT	,	9	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
;	;	PUNCT	:	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
-	-	SYM	SYM	7	O
52	52	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
median	median	NOUN	NN	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
;	;	PUNCT	:	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Levels	level	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
(	(	PUNCT	-LRB-	9	O
median	median	NOUN	NN	9	O
,	,	PUNCT	,	9	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
;	;	PUNCT	:	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
52	52	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
17	17	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
A	a	NOUN	NN	9	O
to	to	ADP	IN	5	O
E	e	NOUN	NN	9	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
median	median	NOUN	NN	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
;	;	PUNCT	:	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
-	-	SYM	SYM	7	O
46	46	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
relationship	relationship	NOUN	NN	5	O
of	of	ADP	IN	5	O
sFas	sFas	PROPN	NNP	3	O
to	to	ADP	IN	5	O
eventual	eventual	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
sFas	sFas	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
aspartate	aspartate	VERB	VB	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
613	613	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
sFas	sFas	PROPN	NNP	3	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
reflect	reflect	VERB	VB	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
Fas	Fas	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
tumor	tumor	NOUN	NN	3	B-Disease
necrosis	necrosis	NOUN	NN	9	B-Disease
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
cell	cell	NOUN	NN	3	O
loss	loss	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Bilateral	bilateral	ADJ	JJ	5	O
subthalamic	subthalamic	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
stimulation	stimulation	NOUN	NN	3	O
for	for	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
subthalamic	subthalamic	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
STN	STN	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
ameliorate	ameliorate	VERB	VB	9	O
the	the	DET	DT	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
STN	STN	PROPN	NNP	5	O
stimulation	stimulation	NOUN	NN	3	O
in	in	ADP	IN	5	O
23	23	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
severe	severe	ADJ	JJ	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
Stages	Stages	PROPN	NNP	5	O
III	III	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
V	v	NOUN	NN	9	O
on	on	ADP	IN	5	O
Hoehn	Hoehn	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Yahr	Yahr	PROPN	NNP	5	O
scale	scale	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
bradykinesia	bradykinesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
rigidity	rigidity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
underwent	undergo	VERB	VBD	5	O
bilateral	bilateral	ADJ	JJ	5	O
implantation	implantation	NOUN	NN	5	O
of	of	ADP	IN	5	O
electrodes	electrode	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
STN	STN	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Preoperative	preoperative	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
postoperative	postoperative	ADJ	JJ	5	O
assessments	assessment	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
"	"	PUNCT	``	5	O
on	on	ADP	IN	5	O
"	"	PUNCT	''	5	O
and	and	CCONJ	CC	5	O
"	"	PUNCT	``	5	O
off	off	ADP	IN	5	O
"	"	PUNCT	``	5	O
drug	drug	NOUN	NN	5	O
conditions	condition	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
using	use	VERB	VBG	9	O
Unified	Unified	PROPN	NNP	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
Disease	Disease	PROPN	NNP	2	I-Disease
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
Hoehn	Hoehn	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Yahr	Yahr	PROPN	NNP	5	O
staging	staging	NOUN	NN	5	O
,	,	PUNCT	,	9	O
England	England	PROPN	NNP	2	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
living	living	NOUN	NN	5	O
score	score	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
video	video	NOUN	NN	5	O
recordings	recording	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
After	after	ADP	IN	9	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
of	of	ADP	IN	5	O
electrical	electrical	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
STN	STN	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
scores	score	NOUN	NNS	5	O
for	for	ADP	IN	5	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
living	living	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
motor	motor	NOUN	NN	5	O
examination	examination	NOUN	NN	5	O
scores	score	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
Unified	Unified	PROPN	NNP	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
Disease	Disease	PROPN	NNP	2	I-Disease
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
parts	part	NOUN	NNS	5	O
II	II	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
III	III	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
off	off	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
improved	improve	VERB	VBN	5	O
by	by	ADP	IN	9	O
62	62	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
61	61	NUM	CD	7	O
%	%	NOUN	NN	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0005	0005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
subscores	subscore	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
akinesia	akinesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
rigidity	rigidity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
tremor	tremor	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
gait	gait	NOUN	NN	5	O
also	also	ADV	RB	9	O
improved	improve	VERB	VBD	5	O
.	.	PUNCT	.	9	O

(	(	PUNCT	-LRB-	9	O
p	p	X	FW	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0005	0005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
dose	dose	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
813	813	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
to	to	ADP	IN	5	O
359	359	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cognitive	cognitive	ADJ	JJ	5	O
functions	function	NOUN	NNS	9	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
device	device	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
complications	complication	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
abnormal	abnormal	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
gain	gain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Bilateral	bilateral	ADJ	JJ	5	O
subthalamic	subthalamic	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
stimulation	stimulation	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
"	"	PUNCT	``	5	O
off	off	ADP	IN	5	O
"	"	PUNCT	``	5	O
phase	phase	NOUN	NN	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
improves	improve	VERB	VBZ	5	O
the	the	DET	DT	5	O
axial	axial	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
reduces	reduce	VERB	VBZ	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
requirements	requirement	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
dose	dose	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
controlling	control	VERB	VBG	9	O
drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
dyskinesias	dyskinesia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
occurring	occur	VERB	VBG	9	O
during	during	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
desferrioxamine	desferrioxamine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
recovery	recovery	NOUN	NN	9	O
after	after	ADP	IN	9	O
haemodialysis	haemodialysis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
transfusion	transfusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
thalassemia	thalassemia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
undergoing	undergo	VERB	VBG	9	O
home	home	ADV	RB	5	O
intravenous	intravenous	ADJ	JJ	0	O
desferrioxamine	desferrioxamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DFX	DFX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
by	by	ADP	IN	9	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
totally	totally	ADV	RB	9	O
implanted	implanted	ADJ	JJ	9	O
system	system	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
poor	poor	ADJ	JJ	5	O
compliance	compliance	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
nightly	nightly	ADV	RB	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
accidental	accidental	ADJ	JJ	5	O
malfunctioning	malfunctioning	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
pump	pump	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
inadvertently	inadvertently	ADV	RB	5	O
administered	administer	VERB	VBN	9	O
a	a	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
which	which	DET	WDT	5	O
caused	cause	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
the	the	DET	DT	5	O
progressive	progressive	ADJ	JJ	5	O
deterioration	deterioration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
laboratory	laboratory	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
adequate	adequate	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
decision	decision	NOUN	NN	5	O
was	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
to	to	PART	TO	5	O
introduce	introduce	VERB	VB	5	O
haemodialytical	haemodialytical	ADJ	JJ	_	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
remove	remove	VERB	VB	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
therapy	therapy	NOUN	NN	5	O
reduce	reduce	VERB	VB	5	O
the	the	DET	DT	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
obtained	obtain	VERB	VBN	9	O
,	,	PUNCT	,	9	O
haemodialysis	haemodialysis	NOUN	NN	5	O
can	can	VERB	MD	5	O
therefore	therefore	ADV	RB	5	O
be	be	VERB	VB	5	O
suggested	suggest	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
rare	rare	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
desferrioxamine	desferrioxamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Ocular	ocular	ADJ	JJ	5	O
motility	motility	NOUN	NN	9	O
changes	change	NOUN	NNS	9	O
after	after	ADP	IN	9	O
subtenon	subtenon	NOUN	NN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
retinoblastoma	retinoblastoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Focal	focal	ADJ	JJ	9	O
subtenon	subtenon	NOUN	NN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
injections	injection	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
recently	recently	ADV	RB	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
presumably	presumably	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
adjunct	adjunct	NOUN	NN	5	O
to	to	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
intraocular	intraocular	ADJ	JJ	5	O
retinoblastoma	retinoblastoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
our	-PRON-	DET	PRP$	5	O
clinical	clinical	ADJ	JJ	5	O
experience	experience	NOUN	NN	5	O
with	with	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	B-Disease
ocular	ocular	ADJ	JJ	5	I-Disease
motility	motility	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
subtenon	subtenon	NOUN	NN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
noted	note	VERB	VBD	9	O
abnormal	abnormal	ADJ	JJ	9	B-Disease
ocular	ocular	ADJ	JJ	5	I-Disease
motility	motility	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
retinoblastoma	retinoblastoma	NOUN	NN	3	B-Disease
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
subtenon	subtenon	NOUN	NN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
ocular	ocular	ADJ	JJ	5	O
manipulation	manipulation	NOUN	NN	5	O
under	under	ADP	IN	9	O
general	general	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
assessed	assess	VERB	VBD	9	O
their	-PRON-	DET	PRP$	5	O
eyes	eye	NOUN	NNS	5	O
by	by	ADP	IN	9	O
forced	force	VERB	VBN	5	O
duction	duction	NOUN	NN	0	O
testing	testing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
comparing	compare	VERB	VBG	9	O
ocular	ocular	ADJ	JJ	5	O
motility	motility	NOUN	NN	9	O
after	after	ADP	IN	9	O
tumor	tumor	NOUN	NN	3	B-Disease
control	control	NOUN	NN	9	O
with	with	ADP	IN	5	O
ocular	ocular	ADJ	JJ	5	O
motility	motility	NOUN	NN	9	O
at	at	ADP	IN	9	O
diagnosis	diagnosis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Eyes	eye	NOUN	NNS	5	O
subsequently	subsequently	ADV	RB	9	O
enucleated	enucleate	VERB	VBD	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
failure	failure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
histologically	histologically	ADV	RB	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Limitation	limitation	NOUN	NN	5	O
of	of	ADP	IN	5	O
ocular	ocular	ADJ	JJ	5	O
motility	motility	NOUN	NN	9	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
12	12	NUM	CD	9	O
eyes	eye	NOUN	NNS	5	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
intraocular	intraocular	ADJ	JJ	5	O
retinoblastoma	retinoblastoma	NOUN	NN	3	B-Disease
with	with	ADP	IN	5	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
subtenon	subtenon	NOUN	NN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
multimodality	multimodality	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Histopathological	histopathological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
many	many	ADJ	JJ	5	O
lipophages	lipophage	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
periorbital	periorbital	ADJ	JJ	5	O
fat	fat	NOUN	NN	9	O
surrounding	surround	VERB	VBG	9	O
the	the	DET	DT	5	O
optic	optic	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
eye	eye	NOUN	NN	5	O
,	,	PUNCT	,	9	O
indicative	indicative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
phagocytosis	phagocytosis	NOUN	NN	3	O
of	of	ADP	IN	5	O
previously	previously	ADV	RB	9	O
existing	exist	VERB	VBG	5	O
fat	fat	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
suggesting	suggest	VERB	VBG	9	O
prior	prior	ADJ	JJ	9	O
fat	fat	ADJ	JJ	9	O
necrosis	necrosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
enucleations	enucleation	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
technically	technically	ADV	RB	5	O
difficult	difficult	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
hazardous	hazardous	ADJ	JJ	5	O
for	for	ADP	IN	5	O
globe	globe	NOUN	NN	5	O
rupture	rupture	NOUN	NN	5	B-Disease
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
extensive	extensive	ADJ	JJ	5	O
orbital	orbital	ADJ	JJ	5	O
soft	soft	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
adhesions	adhesion	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Subtenon	subtenon	NOUN	NN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
orbital	orbital	ADJ	JJ	5	O
soft	soft	ADJ	JJ	5	O
tissues	tissue	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
mechanical	mechanical	ADJ	JJ	5	O
restriction	restriction	NOUN	NN	9	O
of	of	ADP	IN	5	O
eye	eye	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
making	make	VERB	VBG	5	O
subsequent	subsequent	ADJ	JJ	9	O
enucleation	enucleation	NOUN	NN	5	O
difficult	difficult	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Subtenon	Subtenon	PROPN	NNP	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
free	free	ADJ	JJ	9	O
of	of	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
best	best	ADV	RBS	5	O
restricted	restrict	VERB	VBN	9	O
to	to	ADP	IN	5	O
specific	specific	ADJ	JJ	9	O
indications	indication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ethambutol	Ethambutol	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
demonstrate	demonstrate	VERB	VB	9	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Thirteen	thirteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
tuberculosis	tuberculosis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
lung	lung	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	I-Disease
lymph	lymph	NOUN	NN	9	I-Disease
node	node	NOUN	NN	5	I-Disease
at	at	ADP	IN	9	O
Siriraj	Siriraj	PROPN	NNP	2	O
Hospital	Hospital	PROPN	NNP	2	O
between	between	ADP	IN	5	O
1997	1997	NUM	CD	2	O
and	and	CCONJ	CC	5	O
2001	2001	NUM	CD	2	O
were	be	VERB	VBD	9	O
retrospectively	retrospectively	ADV	RB	5	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
characteristics	characteristic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
initial	initial	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
final	final	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
visual	visual	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
between	between	ADP	IN	5	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dosage	dosage	NOUN	NN	9	O
ranging	range	VERB	VBG	9	O
from	from	ADP	IN	9	O
13	13	NUM	CD	7	O
to	to	PART	TO	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
=	=	SYM	SYM	7	O
17	17	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
54	54	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
visual	visual	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
after	after	ADP	IN	9	O
stopping	stop	VERB	VBG	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
irreversible	irreversible	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
heavy	heavy	ADJ	JJ	9	O
smoking	smoking	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Early	early	ADJ	JJ	9	O
recognition	recognition	NOUN	NN	5	O
of	of	ADP	IN	5	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prompt	prompt	ADJ	JJ	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
individuals	individual	NOUN	NNS	5	O
with	with	ADP	IN	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
heavy	heavy	ADJ	JJ	9	O
smokers	smoker	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
compensatory	compensatory	ADJ	JJ	5	O
gustatory	gustatory	ADJ	JJ	5	B-Disease
hyperhidrosis	hyperhidrosis	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Gustatory	gustatory	NOUN	NN	5	B-Disease
hyperhidrosis	hyperhidrosis	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
facial	facial	ADJ	JJ	5	O
sweating	sweating	NOUN	NN	5	B-Disease
usually	usually	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
eating	eating	NOUN	NN	5	O
of	of	ADP	IN	5	O
hot	hot	ADJ	JJ	5	O
spicy	spicy	ADJ	JJ	5	O
food	food	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
even	even	ADV	RB	5	O
smelling	smell	VERB	VBG	5	O
this	this	DET	DT	5	O
food	food	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Current	current	ADJ	JJ	9	O
options	option	NOUN	NNS	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
include	include	VERB	VBP	5	O
oral	oral	ADJ	JJ	9	O
anticholinergic	anticholinergic	NOUN	NN	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
topical	topical	ADJ	JJ	0	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
anticholinergics	anticholinergic	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
aluminum	aluminum	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
botulinum	botulinum	ADJ	JJ	9	O
toxin	toxin	NOUN	NN	1	O
.	.	PUNCT	.	9	O

Thirteen	thirteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
to	to	ADP	IN	5	O
date	date	NOUN	NN	5	O
with	with	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
topical	topical	ADJ	JJ	0	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
gustatory	gustatory	ADJ	JJ	5	B-Disease
hyperhidrosis	hyperhidrosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
interfered	interfere	VERB	VBD	9	O
with	with	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
social	social	ADJ	JJ	5	O
activities	activity	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
transthroacic	transthroacic	NOUN	NNS	_	O
endoscopic	endoscopic	VERB	VBP	5	O
sympathectomy	sympathectomy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
compensatory	compensatory	ADJ	JJ	5	O
focal	focal	ADJ	JJ	5	O
hyperhidrosis	hyperhidrosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
applying	apply	VERB	VBG	5	O
topical	topical	ADJ	JJ	0	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
subjective	subjective	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
excellent	excellent	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
no	no	DET	DT	9	O
sweating	sweating	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
eating	eat	VERB	VBG	5	O
hot	hot	ADJ	JJ	5	O
spicy	spicy	ADJ	JJ	5	O
food	food	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
77	77	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
fair	fair	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
clearly	clearly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
sweating	sweating	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
23	23	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
had	have	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
incidents	incident	NOUN	NNS	5	O
of	of	ADP	IN	5	O
being	be	VERB	VBG	5	O
very	very	ADV	RB	5	O
embarrassed	embarrassed	ADJ	JJ	5	O
whilst	whilst	ADP	IN	9	O
eating	eat	VERB	VBG	5	O
hot	hot	ADJ	JJ	5	O
spicy	spicy	ADJ	JJ	5	O
foods	food	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Adverse	Adverse	PROPN	NNP	5	O
effects	effect	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
a	a	DET	DT	5	O
mildly	mildly	ADV	RB	9	O
dry	dry	ADJ	JJ	0	B-Disease
mouth	mouth	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
sore	sore	ADJ	JJ	5	B-Disease
throat	throat	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
light	light	ADJ	JJ	9	O
headache	headache	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
topical	topical	ADJ	JJ	0	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
pad	pad	NOUN	NN	5	O
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
safe	safe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
efficacious	efficacious	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
well	well	INTJ	UH	9	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
convenient	convenient	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
gustatory	gustatory	ADJ	JJ	5	B-Disease
hyperhidrosis	hyperhidrosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
post	post	ADJ	JJ	9	O
transthoracic	transthoracic	NOUN	NN	5	O
endoscopic	endoscopic	ADJ	JJ	5	O
sympathectomy	sympathectomy	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
sympathicotomy	sympathicotomy	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
few	few	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Neuroleptic	Neuroleptic	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Can	Can	VERB	MD	5	O
it	-PRON-	PRON	PRP	5	O
be	be	VERB	VB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
?	?	PUNCT	.	5	O

Six	six	NUM	CD	9	O
stable	stable	ADJ	JJ	9	O
psychiatric	psychiatric	ADJ	JJ	5	O
outpatients	outpatient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
amenorrhea	amenorrhea	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	O
oligomenorrhea	oligomenorrhea	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Chemical
medications	medication	NOUN	NNS	5	I-Chemical
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Daily	daily	ADJ	JJ	5	O
dosages	dosage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
corrected	correct	VERB	VBD	5	O
the	the	DET	DT	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
restored	restore	VERB	VBD	3	O
menstruation	menstruation	NOUN	NN	5	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
woman	woman	NOUN	NN	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
developed	develop	VERB	VBD	5	O
worsened	worsen	VERB	VBN	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
while	while	ADP	IN	9	O
taking	take	VERB	VBG	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
their	-PRON-	DET	PRP$	5	O
menstrual	menstrual	ADJ	JJ	5	O
irregularity	irregularity	NOUN	NN	5	O
successfully	successfully	ADV	RB	5	O
corrected	correct	VERB	VBN	5	O
with	with	ADP	IN	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
further	further	ADV	RB	9	O
evaluated	evaluate	VERB	VBN	9	O
as	as	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
amenorrhea	amenorrhea	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	O
galactorrhea	galactorrhea	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Ethacrynic	ethacrynic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
neurotransmitters	neurotransmitter	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Intracerebroventricular	intracerebroventricular	ADJ	JJ	3	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
ethacrynic	ethacrynic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
dose	dose	NOUN	NN	9	O
;	;	PUNCT	:	9	O
50	50	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mouse	mouse	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
accelerated	accelerate	VERB	VBD	9	O
the	the	DET	DT	5	O
synthesis	synthesis	NOUN	NN	9	O
/	/	SYM	SYM	9	O
turnover	turnover	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptamine	hydroxytryptamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	SYM	SYM	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
suppressed	suppress	VERB	VBD	3	O
the	the	DET	DT	5	O
synthesis	synthesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
mouse	mouse	NOUN	NN	3	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
antagonized	antagonize	VERB	VBN	3	O
by	by	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
aminophosphonovaleric	aminophosphonovaleric	ADJ	JJ	9	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
ethacrynic	ethacrynic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
neurotransmitter	neurotransmitter	NOUN	NN	9	O
systems	system	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
differentially	differentially	ADV	RB	9	O
modulated	modulate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
probably	probably	ADV	RB	9	O
through	through	ADP	IN	9	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
glutaminergic	glutaminergic	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pharmacology	pharmacology	NOUN	NN	2	O
of	of	ADP	IN	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acidA	acidA	PROPN	NNP	7	I-Chemical
receptor	receptor	NOUN	NN	3	O
complex	complex	NOUN	NN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anxioselective	anxioselective	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboline	carboline	NOUN	NN	0	I-Chemical
derivative	derivative	ADJ	JJ	0	O
abecarnil	abecarnil	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rodents	rodent	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboline	carboline	NOUN	NN	0	I-Chemical
derivative	derivative	ADJ	JJ	0	O
isopropyl	isopropyl	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
6	6	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
benzyloxy	benzyloxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methoxymethyl	methoxymethyl	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
beta	beta	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboline	carboline	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboxylate	carboxylate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
abecarrnil	abecarrnil	NOUN	NN	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
ligand	ligand	NOUN	NN	3	O
for	for	ADP	IN	5	O
benzodiazepine	benzodiazepine	ADJ	JJ	5	B-Chemical
receptors	receptor	NOUN	NNS	3	O
possessing	possess	VERB	VBG	9	O
anxiolytic	anxiolytic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
A	a	DET	DT	9	O
receptor	receptor	NOUN	NN	3	O
complex	complex	NOUN	NN	9	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Added	add	VERB	VBN	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
to	to	PART	TO	5	O
rat	rat	VERB	VB	3	O
cortical	cortical	ADJ	JJ	5	O
membrane	membrane	NOUN	NN	9	O
preparation	preparation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
abecarnil	abecarnil	NOUN	NN	9	B-Chemical
increased	increase	VERB	VBN	9	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
binding	binding	NOUN	NN	1	O
,	,	PUNCT	,	9	O
enhanced	enhance	VERB	VBD	3	O
muscimol	muscimol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
stimulated	stimulate	VERB	VBN	3	O
36Cl	36cl	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
uptake	uptake	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
binding	binding	NOUN	NN	1	O
of	of	ADP	IN	5	O
t	t	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
35S	35s	NUM	CD	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
butylbicyclophosphorothionate	butylbicyclophosphorothionate	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
[	[	PUNCT	-LRB-	9	B-Chemical
35S	35s	NUM	CD	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
TBPS	tbps	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
agonist	agonist	NOUN	NN	3	O
Ro	Ro	PROPN	NNP	0	B-Chemical
16	16	NUM	CD	9	I-Chemical
-	-	SYM	SYM	7	I-Chemical
6028	6028	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
tert	tert	NOUN	NN	1	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
butyl	butyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
S	S	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
bromo	bromo	NOUN	NNS	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
11	11	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	I-Chemical
12	12	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
13	13	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	I-Chemical
13a	13a	NOUN	NNS	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrahydro	tetrahydro	NUM	CD	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
oxo	oxo	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9H	9h	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
imidazo	imidazo	NOUN	NN	0	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
a	a	DET	DT	5	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pyrrolo	pyrrolo	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
c	c	NOUN	NN	9	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
benzodiazepine	benzodiazepine	NOUN	NN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboxylate	carboxylate	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
very	very	ADV	RB	5	O
weak	weak	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
biochemical	biochemical	ADJ	JJ	9	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
injection	injection	NOUN	NN	9	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
abecarnil	abecarnil	VERB	VB	9	B-Chemical
and	and	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
decreased	decrease	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
manner	manner	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	B-Chemical
35S	35s	NUM	CD	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
TBPS	tbps	NOUN	NN	0	I-Chemical
binding	bind	VERB	VBG	1	O
measured	measure	VERB	VBN	9	O
ex	ex	NOUN	NN	9	O
vivo	vivo	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cerebral	cerebral	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
antagonized	antagonize	VERB	VBN	3	O
completely	completely	ADV	RB	9	O
the	the	DET	DT	5	O
convulsant	convulsant	ADJ	JJ	0	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
35S	35s	NUM	CD	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
TBPS	tbps	NOUN	NN	0	I-Chemical
binding	bind	VERB	VBG	1	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
isoniazide	isoniazide	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
350	350	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
35S	35s	NUM	CD	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
TBPS	tbps	NOUN	NN	0	I-Chemical
binding	bind	VERB	VBG	1	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
foot	foot	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
shock	shock	NOUN	NN	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
better	better	ADV	RB	5	O
correlate	correlate	VERB	VB	9	O
the	the	DET	DT	5	O
biochemical	biochemical	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
abecarnil	abecarnil	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
35S	35s	NUM	CD	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
TBPS	tbps	NOUN	NN	0	I-Chemical
binding	binding	NOUN	NN	1	O
,	,	PUNCT	,	9	O
exploratory	exploratory	ADJ	JJ	5	O
motility	motility	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
biochemical	biochemical	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
these	these	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
abecarnil	abecarnil	NOUN	NN	9	B-Chemical
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
paralleled	parallel	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
motor	motor	NOUN	NN	5	O
behavior	behavior	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cortical	cortical	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
35S	35s	NUM	CD	1	O
]	]	PUNCT	-RRB-	9	O
TBPS	tbps	NOUN	NN	0	O
binding	bind	VERB	VBG	1	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboline	carboline	NOUN	NN	0	I-Chemical
reduced	reduce	VERB	VBN	9	O
markedly	markedly	ADV	RB	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
35S	35s	NUM	CD	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
TBPS	tbps	NOUN	NN	0	I-Chemical
binding	binding	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Recurrent	recurrent	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
postpartum	postpartum	NOUN	NN	5	O
patient	patient	NOUN	NN	5	O
receiving	receive	VERB	VBG	9	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
puerperium	puerperium	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
infrequently	infrequently	ADV	RB	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Spasm	Spasm	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
coronary	coronary	ADJ	JJ	5	O
dissection	dissection	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
atheromatous	atheromatous	ADJ	JJ	5	O
etiology	etiology	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Bromocriptine	Bromocriptine	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
several	several	ADJ	JJ	9	O
previous	previous	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
puerperium	puerperium	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
case	case	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
including	include	VERB	VBG	9	O
an	an	DET	DT	5	O
inadvertent	inadvertent	ADJ	JJ	5	O
rechallenge	rechallenge	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
suggests	suggest	VERB	VBZ	9	O
such	such	DET	PDT	5	O
a	a	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
generally	generally	ADV	RB	5	O
regarded	regard	VERB	VBN	5	O
as	as	ADP	IN	5	O
"	"	PUNCT	``	5	O
safe	safe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
"	"	PUNCT	''	5	O
possible	possible	ADJ	JJ	5	O
serious	serious	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
acknowledged	acknowledge	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Asterixis	Asterixis	PROPN	NNP	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
very	very	ADV	RB	5	O
few	few	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
about	about	ADP	IN	5	O
asterixis	asterixis	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
psychopharmacologic	psychopharmacologic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
report	report	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
present	present	VERB	VBP	9	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
different	different	ADJ	JJ	9	O
psychotropic	psychotropic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
asterixis	asterixis	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
triggered	trigger	VERB	VBN	9	O
either	either	CCONJ	CC	9	O
by	by	ADP	IN	9	O
adding	add	VERB	VBG	0	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
regimen	regimen	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
by	by	ADP	IN	9	O
increasing	increase	VERB	VBG	9	O
its	-PRON-	DET	PRP$	9	O
dosage	dosage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Neither	neither	DET	DT	9	O
dosage	dosage	NOUN	NN	9	O
nor	nor	CCONJ	CC	9	O
serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
range	range	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
consider	consider	VERB	VBP	5	O
asterixis	asterixis	NOUN	NN	5	B-Disease
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
easily	easily	ADV	RB	5	O
overlooked	overlooked	ADJ	JJ	5	O
sign	sign	NOUN	NN	5	O
of	of	ADP	IN	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
even	even	ADV	RB	5	O
at	at	ADP	IN	9	O
low	low	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
moderate	moderate	ADJ	JJ	9	O
dosage	dosage	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
if	if	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
as	as	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
are	be	VERB	VBP	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Pharmacodynamics	pharmacodynamic	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
in	in	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
stable	stable	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
fluctuating	fluctuating	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
was	be	VERB	VBD	9	O
concentration	concentration	NOUN	NN	0	O
dependent	dependent	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
fit	fit	ADJ	JJ	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
Emax	Emax	PROPN	NNP	0	O
model	model	NOUN	NN	5	O
in	in	ADP	IN	5	O
fluctuating	fluctuating	NOUN	NN	5	O
responders	responder	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Stable	stable	ADJ	JJ	9	O
responders	responder	NOUN	NNS	5	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
small	small	ADJ	JJ	9	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Baseline	baseline	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
pressures	pressure	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
fluctuating	fluctuate	VERB	VBG	5	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
baseline	baseline	NOUN	NN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Antiparkinsonian	antiparkinsonian	ADJ	JJ	7	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
temporally	temporally	ADV	RB	5	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Phenylalanine	Phenylalanine	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
large	large	ADJ	JJ	5	O
neutral	neutral	ADJ	JJ	5	O
amino	amino	NOUN	NN	1	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
LNAA	LNAA	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
competing	compete	VERB	VBG	5	O
with	with	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
for	for	ADP	IN	5	O
transport	transport	NOUN	NN	9	O
across	across	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
central	central	ADJ	JJ	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
action	action	NOUN	NN	5	O
that	that	DET	WDT	5	O
parallels	parallel	VERB	VBZ	9	O
the	the	DET	DT	5	O
motor	motor	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
fluctuating	fluctuate	VERB	VBG	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
baseline	baseline	NOUN	NN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
observed	observe	VERB	VBD	9	O
in	in	ADP	IN	5	O
fluctuating	fluctuate	VERB	VBG	5	O
patients	patient	NOUN	NNS	5	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
stable	stable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Syndrome	syndrome	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
inappropriate	inappropriate	ADJ	JJ	5	I-Disease
secretion	secretion	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	I-Disease
antidiuretic	antidiuretic	ADJ	JJ	5	I-Disease
hormone	hormone	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
infusional	infusional	ADJ	JJ	5	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
77	77	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
refractory	refractory	ADJ	JJ	9	O
multiple	multiple	ADJ	JJ	5	B-Disease
myeloma	myeloma	NOUN	NN	3	I-Disease
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
continuous	continuous	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Nine	nine	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
her	-PRON-	DET	PRP$	5	O
second	second	ADJ	JJ	9	O
cycle	cycle	NOUN	NN	9	O
she	-PRON-	PRON	PRP	5	O
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
lethargy	lethargy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
weakness	weakness	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hyponatremia	hyponatremia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Evaluation	evaluation	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
inappropriate	inappropriate	ADJ	JJ	5	I-Disease
secretion	secretion	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	I-Disease
antidiuretic	antidiuretic	ADJ	JJ	5	I-Disease
hormone	hormone	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
returned	return	VERB	VBD	5	O
,	,	PUNCT	,	9	O
further	further	ADJ	JJ	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
without	without	ADP	IN	9	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Heart	heart	NOUN	NN	2	B-Disease
failure	failure	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
to	to	PART	TO	5	O
digitalise	digitalise	VERB	VB	9	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
?	?	PUNCT	.	5	O

The	the	DET	DT	5	O
view	view	NOUN	NN	5	O
against	against	ADP	IN	9	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
extensive	extensive	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
experience	experience	NOUN	NN	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
not	not	ADV	RB	5	O
well	well	ADV	RB	9	O
defined	define	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
digoxin	digoxin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
beneficial	beneficial	ADJ	JJ	9	O
for	for	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
sinus	sinus	NOUN	NN	5	O
rhythm	rhythm	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
the	the	DET	DT	5	O
situation	situation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
less	less	ADV	RBR	5	O
clear	clear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Digoxin	Digoxin	PROPN	NNP	7	B-Chemical
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
narrow	narrow	ADJ	JJ	5	O
therapeutic	therapeutic	NOUN	NN	5	O
:	:	PUNCT	:	9	O
toxic	toxic	ADJ	JJ	0	O
ratio	ratio	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
concentrations	concentration	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
,	,	PUNCT	,	9	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
undesirable	undesirable	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
peripheral	peripheral	ADJ	JJ	9	O
resistance	resistance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
myocardial	myocardial	ADJ	JJ	9	O
demands	demand	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
causing	cause	VERB	VBG	9	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
paucity	paucity	NOUN	NN	9	O
of	of	ADP	IN	5	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
designed	design	VERB	VBN	9	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
trials	trial	NOUN	NNS	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
available	available	ADJ	JJ	5	O
are	be	VERB	VBP	5	O
generally	generally	ADV	RB	5	O
small	small	ADJ	JJ	9	O
with	with	ADP	IN	5	O
limitations	limitation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
design	design	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
these	these	DET	DT	5	O
show	show	VERB	VBP	9	O
variation	variation	NOUN	NN	5	O
in	in	ADP	IN	5	O
patient	patient	ADJ	JJ	5	O
benefit	benefit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

More	more	ADV	RBR	5	O
convincing	convincing	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
required	require	VERB	VBN	9	O
showing	show	VERB	VBG	9	O
that	that	DET	DT	5	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
improves	improve	VERB	VBZ	5	O
symptoms	symptom	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
exercise	exercise	NOUN	NN	5	O
capacity	capacity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
trial	trial	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
had	have	VERB	VBN	9	O
sufficient	sufficient	ADJ	JJ	9	O
power	power	NOUN	NN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pooled	pooled	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
inotropic	inotropic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
shows	show	VERB	VBZ	9	O
an	an	DET	DT	5	O
excess	excess	ADJ	JJ	9	O
mortality	mortality	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
increase	increase	VERB	VB	9	O
mortality	mortality	NOUN	NN	5	O
after	after	ADP	IN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MI	MI	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Angiotensin	angiotensin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
ACE	ACE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
first	first	ADV	RB	9	O
as	as	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
safer	safe	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
do	do	VERB	VB	5	O
not	not	ADV	RB	5	O
require	require	VERB	VB	5	O
blood	blood	NOUN	NN	9	O
level	level	NOUN	NN	9	O
monitoring	monitoring	NOUN	NN	5	O
,	,	PUNCT	,	9	O
modify	modify	VERB	VB	9	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
disease	disease	NOUN	NN	5	O
,	,	PUNCT	,	9	O
relieve	relieve	VERB	VB	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
improve	improve	VERB	VB	5	O
exercise	exercise	NOUN	NN	5	O
tolerance	tolerance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reduce	reduce	VERB	VB	5	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Caution	caution	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
exercised	exercise	VERB	VBN	5	O
in	in	ADP	IN	5	O
using	use	VERB	VBG	9	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
until	until	ADP	IN	5	O
large	large	ADJ	JJ	5	O
mortality	mortality	NOUN	NN	5	O
trials	trial	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
completed	complete	VERB	VBN	5	O
showing	show	VERB	VBG	9	O
either	either	DET	DT	9	O
benefit	benefit	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
harm	harm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Until	until	ADP	IN	5	O
then	then	ADV	RB	9	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
a	a	DET	DT	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Isradipine	isradipine	ADJ	JJ	7	B-Chemical
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
general	general	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
in	in	ADP	IN	5	O
Hong	Hong	PROPN	NNP	2	O
Kong	Kong	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
open	open	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
introduction	introduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
isradipine	isradipine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
general	general	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
in	in	ADP	IN	5	O
Hong	Hong	PROPN	NNP	2	O
Kong	Kong	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

303	303	NUM	CD	7	O
Chinese	chinese	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
to	to	PART	TO	5	O
moderate	moderate	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
entered	enter	VERB	VBD	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
caused	cause	VERB	VBD	9	O
withdrawal	withdrawal	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
headache	headache	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
dizziness	dizziness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
palpitation	palpitation	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
flushing	flushing	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
these	these	DET	DT	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
than	than	ADP	IN	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
other	other	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
with	with	ADP	IN	5	O
isradipine	isradipine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Supine	supine	ADJ	JJ	7	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
170	170	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
20	20	NUM	CD	9	O
/	/	SYM	SYM	9	O
102	102	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
mmHg	mmHg	PROPN	NNP	7	O
to	to	ADP	IN	5	O
153	153	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
19	19	NUM	CD	7	O
/	/	SYM	SYM	9	O
92	92	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
147	147	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
18	18	NUM	CD	7	O
/	/	SYM	SYM	9	O
88	88	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
and	and	CCONJ	CC	5	O
144	144	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
14	14	NUM	CD	7	O
/	/	SYM	SYM	9	O
87	87	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
mmHg	mmhg	NOUN	NN	7	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
respectively	respectively	ADV	RB	9	O
in	in	ADP	IN	5	O
evaluable	evaluable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
reductions	reduction	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
standing	stand	VERB	VBG	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
postural	postural	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Normalization	normalization	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
responder	responder	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
86	86	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
69	69	NUM	CD	7	O
%	%	NOUN	NN	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Dosage	Dosage	PROPN	NNP	0	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
from	from	ADP	IN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
diastolic	diastolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
90	90	NUM	CD	9	O
mmHg	mmHg	NOUN	NNS	7	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
further	further	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
on	on	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O

Pharmacological	pharmacological	ADJ	JJ	9	O
characteristics	characteristic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
galenic	galenic	ADJ	JJ	5	O
formulation	formulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
without	without	ADP	IN	9	O
soyabean	soyabean	ADJ	JJ	0	O
oil	oil	NOUN	NN	0	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
pharmacodynamics	pharmacodynamic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
galenic	galenic	ADJ	JJ	5	O
formulation	formulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
propofol	propofol	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AM149	am149	NUM	CD	_	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
contain	contain	VERB	VB	9	O
soyabean	soyabean	ADJ	JJ	0	O
oil	oil	NOUN	NN	0	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
formulation	formulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
propofol	propofol	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Disoprivan	Disoprivan	PROPN	NNP	9	B-Chemical
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
randomised	randomise	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
over	over	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
intravenous	intravenous	ADJ	JJ	0	O
bolus	bolus	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
propofol	propofol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
propofol	propofol	ADJ	JJ	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
for	for	ADP	IN	5	O
48	48	NUM	CD	9	O
h	h	DET	DT	0	O
following	follow	VERB	VBG	9	O
drug	drug	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
evaluated	evaluate	VERB	VBD	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
three	three	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
compartment	compartment	NOUN	NN	9	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pharmacodynamic	pharmacodynamic	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
assessed	assess	VERB	VBD	9	O
included	include	VERB	VBN	5	O
induction	induction	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
emergence	emergence	NOUN	NN	9	O
times	time	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respiratory	respiratory	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
for	for	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
over	over	ADP	IN	5	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Owing	owe	VERB	VBG	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
thrombophlebitis	thrombophlebitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
terminated	terminate	VERB	VBN	9	O
prematurely	prematurely	ADV	RB	5	O
and	and	CCONJ	CC	5	O
only	only	ADV	RB	9	O
the	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
parallel	parallel	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
analysed	analyse	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
concentrations	concentration	NOUN	NNS	0	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
formulations	formulation	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Anaesthesia	Anaesthesia	PROPN	NNP	2	O
induction	induction	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
emergence	emergence	NOUN	NN	9	O
times	time	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respiratory	respiratory	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
variables	variable	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pain	pain	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
thrombophlebitis	thrombophlebitis	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
93	93	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
occurred	occur	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
with	with	ADP	IN	5	O
AM149	am149	NUM	CD	_	O
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
Disoprivan	Disoprivan	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
both	both	DET	DT	9	O
formulations	formulation	NOUN	NNS	0	O
had	have	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
pharmacodynamic	pharmacodynamic	ADJ	JJ	5	O
profiles	profile	NOUN	NNS	9	O
the	the	DET	DT	5	O
new	new	ADJ	JJ	5	O
formulation	formulation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
suitable	suitable	ADJ	JJ	5	O
for	for	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
thrombophlebitis	thrombophlebitis	NOUN	NN	5	B-Disease
produced	produce	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Pure	pure	ADJ	JJ	0	B-Disease
red	red	ADJ	JJ	9	I-Disease
cell	cell	NOUN	NN	3	I-Disease
aplasia	aplasia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
toxic	toxic	ADJ	JJ	0	B-Disease
dermatitis	dermatitis	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
lymphadenopathy	lymphadenopathy	ADJ	JJ	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	ADJ	JJ	5	O
taking	take	VERB	VBG	5	O
diphenylhydantoin	diphenylhydantoin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	ADJ	JJ	5	O
taking	take	VERB	VBG	5	O
diphenylhydantoin	diphenylhydantoin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
generalized	generalized	ADJ	JJ	5	O
skin	skin	NOUN	NN	5	B-Disease
rash	rash	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
lymphadenopathy	lymphadenopathy	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
pure	pure	ADJ	JJ	9	B-Disease
red	red	ADJ	JJ	9	I-Disease
cell	cell	NOUN	NN	3	I-Disease
aplasia	aplasia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pharmacon	pharmacon	NOUN	NN	0	O
all	all	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
disappeared	disappear	VERB	VBD	9	O
spontaneously	spontaneously	ADV	RB	5	O
.	.	PUNCT	.	9	O

Skin	skin	NOUN	NN	9	B-Disease
rash	rash	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
known	know	VERB	VBN	9	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
diphenylhydantoin	diphenylhydantoin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
as	as	ADP	IN	5	O
is	be	VERB	VBZ	5	O
benign	benign	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
malignant	malignant	ADJ	JJ	3	O
lymphadenopathy	lymphadenopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Pure	pure	ADJ	JJ	0	B-Disease
red	red	ADJ	JJ	9	I-Disease
cell	cell	NOUN	NN	3	I-Disease
aplasia	aplasia	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
diphenylhydantoin	diphenylhydantoin	NOUN	NN	0	B-Chemical
medication	medication	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
exact	exact	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
diphenylhydantoin	diphenylhydantoin	NOUN	NN	0	B-Chemical
exerts	exert	VERB	VBZ	9	O
its	-PRON-	DET	PRP$	9	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
known	know	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
relation	relation	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
ingestion	ingestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
diphenylhydantoin	diphenylhydantoin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
skin	skin	NOUN	NN	5	B-Disease
rash	rash	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
lymphadenopathy	lymphadenopathy	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
pure	pure	ADJ	JJ	9	B-Disease
red	red	ADJ	JJ	9	I-Disease
cell	cell	NOUN	NN	3	I-Disease
aplasia	aplasia	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
very	very	ADV	RB	5	O
suggestive	suggestive	ADJ	JJ	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
connection	connection	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Vinorelbine	vinorelbine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
meta	meta	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
randomized	randomize	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
vinorelbine	vinorelbine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
VNR	VNR	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
quantify	quantify	VERB	VB	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
meta	meta	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
comparing	compare	VERB	VBG	9	O
VNR	VNR	PROPN	NNP	3	B-Chemical
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agents	agent	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
various	various	ADJ	JJ	9	O
malignancies	malignancy	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Randomized	randomize	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
comparing	compare	VERB	VBG	9	O
VNR	VNR	PROPN	NNP	3	B-Chemical
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
were	be	VERB	VBD	9	O
searched	search	VERB	VBN	9	O
in	in	ADP	IN	5	O
Medline	Medline	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
Embase	Embase	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
Evidence	evidence	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
Medicine	Medicine	PROPN	NNP	2	O
Reviews	Reviews	PROPN	NNP	5	O
databases	database	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Cochrane	Cochrane	PROPN	NNP	5	O
library	library	NOUN	NN	9	O
from	from	ADP	IN	9	O
1987	1987	NUM	CD	2	O
to	to	ADP	IN	5	O
2002	2002	NUM	CD	2	O
.	.	PUNCT	.	9	O

Outcomes	outcome	NOUN	NNS	5	O
of	of	ADP	IN	5	O
interest	interest	NOUN	NN	5	O
were	be	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
toxic	toxic	ADJ	JJ	0	O
deaths	death	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
deaths	death	NOUN	NNS	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
publication	publication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
19	19	NUM	CD	7	O
trials	trial	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
involving	involve	VERB	VBG	5	O
2441	2441	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
VNR	VNR	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
2050	2050	NUM	CD	5	O
control	control	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
with	with	ADP	IN	5	O
VNR	VNR	PROPN	NNP	3	B-Chemical
was	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
19	19	NUM	CD	7	O
%	%	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
;	;	SYM	SYM	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
67	67	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
between	between	ADP	IN	5	O
VNR	VNR	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
[	[	PUNCT	-LRB-	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
:	:	PUNCT	:	9	O
0	0	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
92	92	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
54	54	NUM	CD	7	O
;	;	SYM	SYM	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
55	55	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
VNR	VNR	PROPN	NNP	3	B-Chemical
cardiac	cardiac	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
vindesine	vindesine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
VDS	VDS	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
cardiotoxic	cardiotoxic	ADJ	JJ	5	B-Disease
drugs	drug	NOUN	NNS	5	O
[	[	PUNCT	-LRB-	9	O
fluorouracil	fluorouracil	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
anthracyclines	anthracycline	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
gemcitabine	gemcitabine	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
GEM	gem	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
em	em	INTJ	UH	2	O
leader	leader	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Even	even	ADV	RB	5	O
if	if	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reach	reach	VERB	VB	5	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
trials	trial	NOUN	NNS	5	O
excluding	exclude	VERB	VBG	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
seemed	seem	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
trials	trial	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
existing	exist	VERB	VBG	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Vinorelbine	vinorelbine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
concern	concern	NOUN	NN	5	O
about	about	ADV	RB	5	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
treated	treated	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
VNR	VNR	PROPN	NNP	3	B-Chemical
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agents	agent	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
indications	indication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

MRI	MRI	PROPN	NNP	5	O
findings	finding	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hypoxic	hypoxic	ADJ	JJ	3	O
cortical	cortical	ADJ	JJ	5	O
laminar	laminar	NOUN	NN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
child	child	NOUN	NN	5	O
with	with	ADP	IN	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
crisis	crisis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	image	VERB	VBG	5	O
findings	finding	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
rapidly	rapidly	ADV	RB	9	O
installing	instal	VERB	VBG	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
crisis	crisis	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
trimethoprim	trimethoprim	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sulfomethoxazole	sulfomethoxazole	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
anoxia	anoxia	NOUN	NN	9	I-Disease
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
permanent	permanent	ADJ	JJ	5	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Magnetic	Magnetic	PROPN	NNP	5	O
Resonance	Resonance	PROPN	NNP	5	O
imaging	imaging	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
cortical	cortical	ADJ	JJ	5	O
laminar	laminar	NOUN	NN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
border	border	NOUN	NN	9	O
zones	zone	NOUN	NNS	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
cerebral	cerebral	ADJ	JJ	5	O
hemispheres	hemisphere	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
ischemic	ischemic	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
subcortical	subcortical	ADJ	JJ	5	O
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	O
cerebral	cerebral	ADJ	JJ	5	O
hemisphere	hemisphere	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
putamen	putaman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
cortical	cortical	ADJ	JJ	5	O
laminar	laminar	NOUN	NN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
classic	classic	ADJ	JJ	5	O
entity	entity	NOUN	NN	5	O
in	in	ADP	IN	5	O
adulthood	adulthood	NOUN	NN	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
conditions	condition	NOUN	NNS	9	O
of	of	ADP	IN	5	O
energy	energy	NOUN	NN	5	O
depletions	depletion	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
few	few	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
available	available	ADJ	JJ	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
wide	wide	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
also	also	ADV	RB	9	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
natural	natural	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
Vigabatrin	Vigabatrin	PROPN	NNP	0	B-Chemical
associated	associate	VERB	VBN	9	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
electing	elect	VERB	VBG	5	O
to	to	PART	TO	5	O
continue	continue	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
natural	natural	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
Vigabatrin	Vigabatrin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
changes	change	NOUN	NNS	9	O
who	who	PRON	WP	5	O
elected	elect	VERB	VBD	5	O
to	to	PART	TO	5	O
continue	continue	VERB	VB	5	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
good	good	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
Vigabatrin	Vigabatrin	PROPN	NNP	0	B-Chemical
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
entered	enter	VERB	VBN	5	O
into	into	ADP	IN	9	O
a	a	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
surveillance	surveillance	NOUN	NN	5	O
programme	programme	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
up	up	PART	RP	5	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
monthly	monthly	ADJ	JJ	5	O
intervals	interval	NOUN	NNS	5	O
for	for	ADP	IN	5	O
not	not	ADV	RB	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
18	18	NUM	CD	7	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
18	18	NUM	CD	7	O
-	-	SYM	SYM	7	O
43	43	NUM	CD	7	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	DT	5	O
,	,	PUNCT	,	9	O
16	16	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
unequivocal	unequivocal	ADJ	JJ	9	O
defects	defect	NOUN	NNS	9	O
continued	continue	VERB	VBD	9	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
already	already	ADV	RB	5	O
published	publish	VERB	VBN	9	O
methodology	methodology	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
Eye	Eye	PROPN	NNP	2	O
2002	2002	NUM	CD	2	O
;	;	PUNCT	:	9	O
16	16	NUM	CD	9	O
;	;	PUNCT	:	9	O
567	567	NUM	CD	7	O
-	-	SYM	SYM	7	O
571	571	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
monocular	monocular	ADJ	JJ	5	O
mean	mean	ADJ	JJ	5	O
radial	radial	ADJ	JJ	5	O
degrees	degree	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
MRDs	mrd	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
I	i	NOUN	NN	9	O
/	/	SYM	SYM	9	O
4e	4e	NUM	CD	0	O
isopter	isopter	NOUN	NN	5	O
on	on	ADP	IN	5	O
Goldmann	Goldmann	PROPN	NNP	6	O
perimetry	perimetry	NOUN	NN	5	O
was	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
eye	eye	NOUN	NN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
discovery	discovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
defect	defect	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
again	again	ADV	RB	9	O
after	after	ADP	IN	9	O
not	not	ADV	RB	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
18	18	NUM	CD	7	O
months	month	NOUN	NNS	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Mean	mean	VERB	VB	9	O
right	right	ADJ	JJ	5	O
eye	eye	NOUN	NN	5	O
MRD	MRD	PROPN	NNP	9	O
at	at	ADP	IN	9	O
presentation	presentation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
36	36	NUM	CD	9	O
.	.	PUNCT	.	9	O
98	98	NUM	CD	7	O
degrees	degree	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VBP	9	O
22	22	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
51	51	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
38	38	NUM	CD	7	O
.	.	PUNCT	.	9	O
40	40	NUM	CD	9	O
degrees	degree	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VBP	9	O
22	22	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
49	49	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
338	338	NUM	CD	7	O
unpaired	unpaired	ADJ	JJ	9	O
t	t	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
deterioration	deterioration	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	I-Disease
visual	visual	ADJ	JJ	5	I-Disease
field	field	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
period	period	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
discontinued	discontinue	VERB	VBD	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Established	establish	VERB	VBN	9	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
presumed	presume	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
Vigabatrin	Vigabatrin	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
usually	usually	ADV	RB	5	O
progress	progress	VERB	VB	5	O
in	in	ADP	IN	5	O
spite	spite	NOUN	NN	9	O
of	of	ADP	IN	5	O
continuing	continue	VERB	VBG	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
give	give	VERB	VBP	5	O
support	support	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
Vigabatrin	Vigabatrin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
idiosyncratic	idiosyncratic	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
rosaceiform	rosaceiform	NOUN	NN	_	O
dermatitis	dermatitis	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
facial	facial	ADJ	JJ	5	B-Disease
inflammatory	inflammatory	ADJ	JJ	3	I-Disease
dermatoses	dermatosis	NOUN	NNS	5	I-Disease
with	with	ADP	IN	5	O
tacrolimus	tacrolimus	ADJ	JJ	0	B-Chemical
ointment	ointment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Tacrolimus	Tacrolimus	PROPN	NNP	0	B-Chemical
ointment	ointment	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
increasingly	increasingly	ADV	RB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
sensitive	sensitive	ADJ	JJ	9	O
areas	area	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
face	face	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
recent	recent	ADJ	JJ	5	O
observations	observation	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
aggravated	aggravate	VERB	VBN	9	O
rosacea	rosacea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
perioral	perioral	ADJ	JJ	5	B-Disease
dermatitis	dermatitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
on	on	ADP	IN	5	O
rosaceiform	rosaceiform	NOUN	NN	_	O
dermatitis	dermatitis	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
tacrolimus	tacrolimus	ADJ	JJ	0	B-Chemical
ointment	ointment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

OBSERVATIONS	observation	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Six	six	NUM	CD	9	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	B-Disease
facial	facial	ADJ	JJ	5	I-Disease
dermatoses	dermatosis	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
tacrolimus	tacrolimus	ADJ	JJ	0	B-Chemical
ointment	ointment	NOUN	NN	0	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ineffectiveness	ineffectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
treatments	treatment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Within	within	ADP	IN	9	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
initially	initially	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
rosacea	rosacea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
acne	acne	NOUN	NN	5	B-Disease
experienced	experience	VERB	VBD	5	O
sudden	sudden	ADJ	JJ	5	O
worsening	worsen	VERB	VBG	5	O
with	with	ADP	IN	5	O
pustular	pustular	ADJ	JJ	5	O
rosaceiform	rosaceiform	NOUN	NN	_	O
lesions	lesion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Biopsy	Biopsy	PROPN	NNP	9	O
revealed	reveal	VERB	VBD	9	O
an	an	DET	DT	5	O
abundance	abundance	NOUN	NN	9	O
of	of	ADP	IN	5	O
Demodex	Demodex	PROPN	NNP	4	O
mites	mite	VERB	VBZ	4	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
eyelid	eyelid	ADJ	JJ	5	O
eczema	eczema	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
rosaceiform	rosaceiform	VERB	VB	_	O
periocular	periocular	ADJ	JJ	5	B-Disease
dermatitis	dermatitis	NOUN	NN	5	I-Disease
gradually	gradually	ADV	RB	9	O
appeared	appear	VERB	VBD	9	O
after	after	ADP	IN	9	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
atopic	atopic	ADJ	JJ	5	B-Disease
dermatitis	dermatitis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
telangiectatic	telangiectatic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
papular	papular	ADJ	JJ	5	B-Disease
rosacea	rosacea	NOUN	NN	5	I-Disease
insidiously	insidiously	ADV	RB	5	O
appeared	appear	VERB	VBD	9	O
after	after	ADP	IN	9	O
5	5	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
observations	observation	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
spectrum	spectrum	NOUN	NN	9	O
of	of	ADP	IN	5	O
rosaceiform	rosaceiform	NOUN	NN	_	O
dermatitis	dermatitis	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
tacrolimus	tacrolimus	ADJ	JJ	0	B-Chemical
ointment	ointment	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
heterogeneous	heterogeneous	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
factors	factor	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
vasoactive	vasoactive	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
proliferation	proliferation	NOUN	NN	3	O
of	of	ADP	IN	5	O
Demodex	Demodex	PROPN	NNP	4	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
local	local	ADJ	JJ	5	O
immunosuppression	immunosuppression	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
occlusive	occlusive	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ointment	ointment	NOUN	NN	0	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
phenomena	phenomenon	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Future	future	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
individual	individual	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Intravascular	intravascular	ADJ	JJ	5	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
intermittent	intermittent	ADJ	JJ	5	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Intravascular	intravascular	ADJ	JJ	5	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
extremely	extremely	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
leprosy	leprosy	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Structural	structural	ADJ	JJ	9	O
abnormalities	abnormality	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brains	brain	NOUN	NNS	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
use	use	VERB	VBP	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
visualize	visualize	VERB	VBP	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
structural	structural	ADJ	JJ	9	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
human	human	ADJ	JJ	3	I-Disease
brain	brain	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
MA	MA	PROPN	NNP	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
abuse	abuse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
used	use	VERB	VBN	5	O
MA	MA	PROPN	NNP	2	B-Chemical
chronically	chronically	ADV	RB	9	O
have	have	VERB	VBP	5	O
revealed	reveal	VERB	VBN	9	O
deficits	deficit	NOUN	NNS	5	O
in	in	ADP	IN	5	O
dopaminergic	dopaminergic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
serotonergic	serotonergic	NOUN	NN	5	O
systems	system	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
cerebral	cerebral	ADJ	JJ	5	O
metabolic	metabolic	ADJ	JJ	9	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MRI	MRI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
new	new	ADJ	JJ	5	O
computational	computational	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
mapping	mapping	NOUN	NN	5	O
techniques	technique	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
determined	determine	VERB	VBD	9	O
the	the	DET	DT	5	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
structural	structural	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
alterations	alteration	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
MA	MA	PROPN	NNP	2	B-Chemical
abuse	abuse	NOUN	NN	5	O
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	O
subjects	subject	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
related	relate	VERB	VBD	9	O
these	these	DET	DT	5	O
deficits	deficit	NOUN	NNS	5	O
to	to	PART	TO	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
resolution	resolution	NOUN	NN	5	O
MRI	mri	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
surface	surface	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
computational	computational	ADJ	JJ	5	O
image	image	NOUN	NN	5	O
analyses	analyse	VERB	VBZ	9	O
to	to	PART	TO	5	O
map	map	VERB	VB	5	O
regional	regional	ADJ	JJ	5	O
abnormalities	abnormality	NOUN	NNS	9	B-Disease
in	in	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
cortex	cortex	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	I-Disease
hippocampus	hippocampus	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	I-Disease
white	white	ADJ	JJ	9	I-Disease
matter	matter	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
ventricles	ventricle	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
22	22	NUM	CD	7	O
human	human	ADJ	JJ	3	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
used	use	VERB	VBD	5	O
MA	MA	PROPN	NNP	2	B-Chemical
and	and	CCONJ	CC	5	O
21	21	NUM	CD	7	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
,	,	PUNCT	,	9	O
healthy	healthy	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Cortical	cortical	ADJ	JJ	5	O
maps	map	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
gray	gray	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
matter	matter	NOUN	NN	5	O
deficits	deficit	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cingulate	cingulate	NOUN	NN	5	O
,	,	PUNCT	,	9	O
limbic	limbic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
paralimbic	paralimbic	ADJ	JJ	5	O
cortices	cortex	NOUN	NNS	5	O
of	of	ADP	IN	5	O
MA	MA	PROPN	NNP	2	B-Chemical
abusers	abuser	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
averaging	average	VERB	VBG	5	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
below	below	ADP	IN	9	O
control	control	NOUN	NN	9	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
average	average	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
MA	MA	PROPN	NNP	2	B-Chemical
abusers	abuser	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
smaller	small	ADJ	JJR	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
volumes	volume	NOUN	NNS	5	O
than	than	ADP	IN	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
;	;	PUNCT	:	9	O
left	leave	VERB	VBN	5	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
;	;	PUNCT	:	9	O
right	right	INTJ	UH	5	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
significant	significant	ADJ	JJ	9	O
white	white	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
matter	matter	NOUN	NN	5	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Hippocampal	hippocampal	ADJ	JJ	3	O
deficits	deficit	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
mapped	map	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
word	word	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
recall	recall	NOUN	NN	5	O
test	test	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

MRI	MRI	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
maps	map	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
abuse	abuse	NOUN	NN	5	O
causes	cause	VERB	VBZ	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
deterioration	deterioration	NOUN	NN	5	O
that	that	DET	WDT	5	O
contributes	contribute	VERB	VBZ	9	O
to	to	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
memory	memory	NOUN	NN	5	I-Disease
performance	performance	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

MA	MA	PROPN	NNP	2	B-Chemical
may	may	VERB	MD	5	O
selectively	selectively	ADV	RB	3	O
damage	damage	VERB	VB	9	O
the	the	DET	DT	5	O
medial	medial	ADJ	JJ	5	O
temporal	temporal	ADJ	JJ	5	O
lobe	lobe	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
metabolic	metabolic	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
cingulate	cingulate	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
limbic	limbic	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
inducing	induce	VERB	VBG	3	O
neuroadaptation	neuroadaptation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
neuropil	neuropil	ADJ	JJ	5	O
reduction	reduction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Prominent	prominent	ADJ	JJ	5	O
white	white	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
matter	matter	NOUN	NN	5	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
altered	altered	ADJ	JJ	9	O
myelination	myelination	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
adaptive	adaptive	ADJ	JJ	5	O
glial	glial	ADJ	JJ	3	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
gliosis	gliosis	NOUN	NN	3	B-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
brain	brain	NOUN	NN	5	O
substrates	substrate	NOUN	NNS	0	O
may	may	VERB	MD	5	O
help	help	VERB	VB	5	O
account	account	VERB	VB	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
MA	MA	PROPN	NNP	2	B-Chemical
abuse	abuse	NOUN	NN	5	O
,	,	PUNCT	,	9	O
providing	provide	VERB	VBG	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
targets	target	NOUN	NNS	9	O
for	for	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
brain	brain	NOUN	NN	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
lipid	lipid	NOUN	NN	0	O
homeostasis	homeostasis	NOUN	NN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
after	after	ADP	IN	9	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
peroxisome	peroxisome	ADJ	JJ	3	O
proliferator	proliferator	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
activated	activate	VERB	VBN	3	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
target	target	NOUN	NN	9	O
gene	gene	NOUN	NN	1	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Amiodarone	amiodarone	ADV	RB	7	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
efficacious	efficacious	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
gain	gain	VERB	VB	5	O
insight	insight	NOUN	NN	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
unwanted	unwanted	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
various	various	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
histology	histology	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
gene	gene	NOUN	NN	1	O
regulation	regulation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Amiodarone	Amiodarone	PROPN	NNP	7	B-Chemical
induced	induced	ADJ	JJ	3	O
hepatomegaly	hepatomegaly	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hepatocyte	hepatocyte	VERB	VBZ	3	O
microvesicular	microvesicular	ADJ	JJ	3	O
lipid	lipid	NOUN	NN	0	O
accumulation	accumulation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
triglycerides	triglyceride	NOUN	NNS	9	B-Chemical
and	and	CCONJ	CC	5	O
glucose	glucose	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Northern	northern	ADJ	JJ	4	O
blot	blot	NOUN	NN	3	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
RNA	RNA	PROPN	NNP	9	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
genes	gene	NOUN	NNS	1	O
critical	critical	ADJ	JJ	9	O
for	for	ADP	IN	5	O
fatty	fatty	ADJ	JJ	0	B-Chemical
acid	acid	ADJ	JJ	0	I-Chemical
oxidation	oxidation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
lipoprotein	lipoprotein	NOUN	NN	9	O
assembly	assembly	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
lipid	lipid	NOUN	NN	0	O
transport	transport	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Many	many	ADJ	JJ	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
genes	gene	NOUN	NNS	1	O
are	be	VERB	VBP	5	O
regulated	regulate	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
peroxisome	peroxisome	ADJ	JJ	3	O
proliferator	proliferator	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
activated	activate	VERB	VBN	3	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PPARalpha	PPARalpha	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
ligand	ligand	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
activated	activate	VERB	VBN	3	O
nuclear	nuclear	ADJ	JJ	3	O
hormone	hormone	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
transcription	transcription	NOUN	NN	1	O
factor	factor	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
genes	gene	NOUN	NNS	1	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
hepatomegaly	hepatomegaly	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
PPARalpha	PPARalpha	PROPN	NNP	3	O
knockout	knockout	ADJ	JJ	3	O
[	[	PUNCT	-LRB-	9	O
PPARalpha	PPARalpha	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
]	]	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
dependent	dependent	ADJ	JJ	9	O
upon	upon	ADP	IN	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
PPARalpha	PPARalpha	PROPN	NNP	3	O
gene	gene	NOUN	NN	1	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
PPARalpha	PPARalpha	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
resulted	result	VERB	VBN	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
total	total	ADJ	JJ	9	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
inability	inability	NOUN	NN	9	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
directly	directly	ADV	RB	9	O
activate	activate	VERB	VB	3	O
either	either	CCONJ	CC	9	O
human	human	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
mouse	mouse	NOUN	NN	3	O
PPARalpha	PPARalpha	PROPN	NNP	3	O
transiently	transiently	ADV	RB	3	O
expressed	express	VERB	VBD	3	O
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	O
HepG2	HepG2	PROPN	NNP	3	O
hepatoma	hepatoma	ADJ	JJ	3	B-Disease
cells	cell	NOUN	NNS	3	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
receptor	receptor	NOUN	NN	3	O
were	be	VERB	VBD	9	O
indirect	indirect	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
upon	upon	ADP	IN	9	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
amiodarone	amiodarone	DET	DT	0	B-Chemical
disrupts	disrupt	VERB	VBZ	9	O
hepatic	hepatic	ADJ	JJ	9	O
lipid	lipid	NOUN	NN	0	O
homeostasis	homeostasis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
PPARalpha	PPARalpha	PROPN	NNP	3	O
target	target	NOUN	NN	9	O
genes	gene	NOUN	NNS	1	O
is	be	VERB	VBZ	5	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
provide	provide	VERB	VBP	5	O
important	important	ADJ	JJ	9	O
new	new	ADJ	JJ	5	O
mechanistic	mechanistic	ADJ	JJ	9	O
information	information	NOUN	NN	5	O
regarding	regard	VERB	VBG	5	O
the	the	DET	DT	5	O
hepatotoxic	hepatotoxic	ADJ	JJ	0	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
PPARalpha	PPARalpha	PROPN	NNP	3	O
protects	protect	VERB	VBZ	3	O
against	against	ADP	IN	9	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
compliance	compliance	NOUN	NN	5	O
with	with	ADP	IN	5	O
once	once	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
daily	daily	ADV	RB	5	O
niacin	niacin	ADJ	JJ	0	B-Chemical
extended	extend	VERB	VBN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
release	release	NOUN	NN	9	I-Chemical
/	/	SYM	SYM	9	I-Chemical
lovastatin	lovastatin	NOUN	NN	0	I-Chemical
as	as	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Impact	Impact	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Medical	Medical	PROPN	NNP	2	O
Subspecialty	Subspecialty	PROPN	NNP	2	O
on	on	ADP	IN	5	O
Patient	Patient	PROPN	NNP	5	O
Compliance	Compliance	PROPN	NNP	5	O
to	to	ADP	IN	5	O
Treatment	Treatment	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
IMPACT	IMPACT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Niacin	niacin	ADJ	JJ	0	B-Chemical
extended	extend	VERB	VBN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
release	release	NOUN	NN	9	I-Chemical
/	/	SYM	SYM	9	I-Chemical
lovastatin	lovastatin	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
combination	combination	NOUN	NN	9	O
product	product	NOUN	NN	9	O
approved	approve	VERB	VBN	2	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
hypercholesterolemia	hypercholesterolemia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
mixed	mixed	ADJ	JJ	9	O
dyslipidemia	dyslipidemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
open	open	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
labeled	labeled	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
multicenter	multicenter	NOUN	NN	5	O
study	study	NOUN	NN	9	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
bedtime	bedtime	NOUN	NN	5	O
niacin	niacin	ADJ	JJ	0	B-Chemical
extended	extend	VERB	VBN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
release	release	NOUN	NN	9	I-Chemical
/	/	SYM	SYM	9	I-Chemical
lovastatin	lovastatin	NOUN	NN	0	I-Chemical
when	when	ADV	WRB	5	O
dosed	dose	VERB	VBN	0	O
as	as	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
patient	patient	ADJ	JJ	5	O
compliance	compliance	NOUN	NN	5	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
settings	setting	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
499	499	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
dyslipidemia	dyslipidemia	NOUN	NN	5	B-Disease
requiring	require	VERB	VBG	5	O
drug	drug	NOUN	NN	5	O
intervention	intervention	NOUN	NN	5	O
was	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
081	081	NUM	CD	7	O
sites	site	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
1	1	NUM	CD	9	O
tablet	tablet	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
niacin	niacin	ADJ	JJ	0	B-Chemical
extended	extend	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
/	/	SYM	SYM	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
once	once	ADV	RB	5	O
nightly	nightly	ADV	RB	5	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
2	2	NUM	CD	9	O
tablets	tablet	NOUN	NNS	0	O
for	for	ADP	IN	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
also	also	ADV	RB	9	O
received	receive	VERB	VBD	9	O
dietary	dietary	ADJ	JJ	5	O
counseling	counseling	NOUN	NN	5	O
,	,	PUNCT	,	9	O
educational	educational	ADJ	JJ	5	O
materials	material	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
reminders	reminder	NOUN	NNS	5	O
to	to	PART	TO	5	O
call	call	VERB	VB	5	O
a	a	DET	DT	5	O
toll	toll	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
that	that	DET	WDT	5	O
provided	provide	VERB	VBD	9	O
further	further	ADJ	JJ	9	O
education	education	NOUN	NN	5	O
about	about	ADP	IN	5	O
dyslipidemia	dyslipidemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
niacin	niacin	ADV	RB	0	B-Chemical
extended	extend	VERB	VBN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
release	release	NOUN	NN	9	I-Chemical
/	/	SYM	SYM	9	I-Chemical
lovastatin	lovastatin	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Primary	primary	ADJ	JJ	9	O
end	end	NOUN	NN	9	O
points	point	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
study	study	NOUN	NN	9	O
compliance	compliance	NOUN	NN	5	O
,	,	PUNCT	,	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transaminases	transaminase	NOUN	NNS	9	O
to	to	ADP	IN	5	O
>	>	X	XX	0	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
limit	limit	NOUN	NN	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
myopathy	myopathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Final	final	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
status	status	NOUN	NN	9	O
was	be	VERB	VBD	9	O
available	available	ADJ	JJ	5	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
217	217	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
94	94	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Compliance	compliance	NOUN	NN	5	O
to	to	PART	TO	5	O
niacin	niacin	ADV	RB	0	B-Chemical
extended	extend	VERB	VBN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
release	release	NOUN	NN	9	I-Chemical
/	/	SYM	SYM	9	I-Chemical
lovastatin	lovastatin	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
77	77	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
245	245	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
completing	complete	VERB	VBG	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
southeast	southeast	NOUN	NN	4	O
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
enrolled	enrol	VERB	VBN	5	O
by	by	ADP	IN	9	O
endocrinologists	endocrinologist	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
lowest	low	ADJ	JJS	9	O
compliance	compliance	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
highest	high	ADJ	JJS	9	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Flushing	flush	VERB	VBG	5	B-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
,	,	PUNCT	,	9	O
reported	report	VERB	VBN	9	O
by	by	ADP	IN	9	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
discontinuation	discontinuation	NOUN	NN	5	O
by	by	ADP	IN	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Incidence	incidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
aspartate	aspartate	NOUN	NN	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
alanine	alanine	NOUN	NN	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
>	>	X	XX	0	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
limit	limit	NOUN	NN	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
was	be	VERB	VBD	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
phosphokinase	phosphokinase	NOUN	NN	0	O
to	to	ADP	IN	5	O
>	>	X	XX	0	O
5	5	NUM	CD	9	O
times	time	NOUN	NNS	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
limit	limit	NOUN	NN	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myopathy	myopathy	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Niacin	niacin	ADJ	JJ	0	B-Chemical
extended	extend	VERB	VBN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
release	release	NOUN	NN	9	I-Chemical
/	/	SYM	SYM	9	I-Chemical
lovastatin	lovastatin	VERB	VBP	0	I-Chemical
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
/	/	SYM	SYM	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
dosed	dose	VERB	VBN	0	O
as	as	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
good	good	ADJ	JJ	5	O
compliance	compliance	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
very	very	ADV	RB	5	O
low	low	ADJ	JJ	9	O
incidences	incidence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
muscle	muscle	NOUN	NN	9	O
enzymes	enzyme	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
Terminalia	Terminalia	PROPN	NNP	4	B-Chemical
chebula	chebula	ADP	IN	4	I-Chemical
against	against	ADP	IN	9	O
experimental	experimental	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Cardioprotective	cardioprotective	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
ethanolic	ethanolic	ADJ	JJ	0	B-Chemical
extract	extract	NOUN	NN	0	I-Chemical
of	of	ADP	IN	5	I-Chemical
Terminalia	Terminalia	PROPN	NNP	4	I-Chemical
chebula	chebula	ADP	IN	4	I-Chemical
fruits	fruit	NOUN	NNS	4	I-Chemical
(	(	PUNCT	-LRB-	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
wt	wt	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
wt	wt	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
administered	administer	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxides	peroxide	NOUN	NNS	0	B-Chemical
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	O
marker	marker	NOUN	NN	3	O
enzymes	enzyme	VERB	VBZ	1	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Histopathological	histopathological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
to	to	PART	TO	5	O
confirm	confirm	VERB	VB	9	O
the	the	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	O
necrosis	necrosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

T	t	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	I-Chemical
chebula	chebula	ADP	IN	4	I-Chemical
extract	extract	NOUN	NN	0	I-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
ameliorate	ameliorate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
lipid	lipid	ADJ	JJ	0	O
peroxide	peroxide	NOUN	NN	0	B-Chemical
formation	formation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
retained	retain	VERB	VBD	9	O
the	the	DET	DT	5	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
marker	marker	NOUN	NN	3	O
enzymes	enzyme	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
droperidol	droperidol	NOUN	NN	0	B-Chemical
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
patient	patient	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
analgesia	analgesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
multiparous	multiparous	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
in	in	ADP	IN	5	O
good	good	ADJ	JJ	5	O
psychological	psychological	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
underwent	undergo	VERB	VBD	5	O
urgent	urgent	ADJ	JJ	5	O
caesarean	caesarean	ADJ	JJ	5	O
section	section	NOUN	NN	5	O
in	in	ADP	IN	5	O
labour	labour	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Postoperatively	postoperatively	ADV	RB	5	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
analgesia	analgesia	NOUN	NN	5	O
device	device	NOUN	NN	5	O
delivering	deliver	VERB	VBG	5	O
boluses	bolus	NOUN	NNS	5	O
of	of	ADP	IN	5	O
diamorphine	diamorphine	NOUN	NN	5	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
droperidol	droperidol	ADV	RB	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
025	025	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Whilst	whilst	ADP	IN	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
device	device	NOUN	NN	5	O
she	-PRON-	PRON	PRP	5	O
gradually	gradually	ADV	RB	9	O
became	become	VERB	VBD	9	O
anxious	anxious	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
feeling	feeling	NOUN	NN	5	O
worsening	worsen	VERB	VBG	5	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
bolus	bolus	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
droperidol	droperidol	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
psychological	psychological	ADJ	JJ	5	B-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
made	make	VERB	VBN	5	O
straight	straight	ADV	RB	5	O
away	away	ADV	RB	5	O
although	although	ADP	IN	9	O
on	on	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
close	close	ADJ	JJ	5	O
questioning	question	VERB	VBG	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
gave	give	VERB	VBD	9	O
a	a	DET	DT	5	O
very	very	ADV	RB	5	O
clear	clear	ADJ	JJ	9	O
history	history	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
only	only	ADV	RB	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
droperidol	droperidol	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
syringe	syringe	NOUN	NN	0	O
containing	contain	VERB	VBG	0	O
diamorphine	diamorphine	NOUN	NN	5	B-Chemical
only	only	ADV	RB	9	O
was	be	VERB	VBD	9	O
substituted	substitute	VERB	VBN	0	O
and	and	CCONJ	CC	5	O
her	-PRON-	DET	PRP$	5	O
unease	unease	NOUN	NN	5	O
resolved	resolve	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
feel	feel	VERB	VBP	5	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
dramatic	dramatic	ADJ	JJ	9	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
antiemetics	antiemetic	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
well	well	ADV	RB	9	O
known	know	VERB	VBN	9	O
,	,	PUNCT	,	9	O
more	more	ADV	RBR	5	O
subtle	subtle	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
may	may	VERB	MD	5	O
easily	easily	ADV	RB	5	O
be	be	VERB	VB	5	O
overlooked	overlook	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Accurate	accurate	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
history	history	NOUN	NN	5	O
contributes	contribute	VERB	VBZ	9	O
to	to	ADP	IN	5	O
differentiating	differentiate	VERB	VBG	9	O
diabetes	diabetes	NOUN	NN	5	B-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
study	study	NOUN	NN	9	O
highlights	highlight	VERB	VBZ	5	O
the	the	DET	DT	5	O
important	important	ADJ	JJ	9	O
contribution	contribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
nursing	nursing	NOUN	NN	5	O
in	in	ADP	IN	5	O
obtaining	obtain	VERB	VBG	5	O
an	an	DET	DT	5	O
accurate	accurate	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
history	history	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
discussed	discuss	VERB	VBD	5	O
herein	herein	NOUN	NN	9	O
initially	initially	ADV	RB	9	O
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
neurogenic	neurogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
DI	DI	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
traumatic	traumatic	ADJ	JJ	5	B-Disease
brain	brain	NOUN	NN	5	I-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
nursing	nursing	NOUN	NN	5	O
staff	staff	NOUN	NN	5	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
reviewing	review	VERB	VBG	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
health	health	NOUN	NN	5	O
history	history	NOUN	NN	5	O
with	with	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
family	family	NOUN	NN	9	O
,	,	PUNCT	,	9	O
discovered	discover	VERB	VBD	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
polydipsia	polydipsia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
standing	stand	VERB	VBG	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
DI	di	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
because	because	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
not	not	ADV	RB	5	O
received	receive	VERB	VBN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
since	since	ADP	IN	9	O
being	be	VERB	VBG	5	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
,	,	PUNCT	,	9	O
his	-PRON-	DET	PRP$	5	O
treatment	treatment	NOUN	NN	9	O
changed	change	VERB	VBD	9	O
to	to	PART	TO	5	O
focus	focus	VERB	VB	5	O
on	on	ADP	IN	5	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
DI	di	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
combining	combine	VERB	VBG	5	O
information	information	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
radiologic	radiologic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
care	care	NOUN	NN	5	O
team	team	NOUN	NN	5	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
treating	treat	VERB	VBG	5	O
his	-PRON-	DET	PRP$	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
DI	di	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
developed	develop	VERB	VBD	5	O
neurogenic	neurogenic	ADJ	JJ	5	B-Disease
DI	di	NOUN	NN	9	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
brain	brain	NOUN	NN	5	B-Disease
trauma	trauma	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
successful	successful	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
required	require	VERB	VBD	9	O
that	that	ADP	IN	5	O
nephrogenic	nephrogenic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
neurogenic	neurogenic	ADJ	JJ	5	B-Disease
DI	di	NOUN	NN	9	I-Disease
be	be	VERB	VB	5	O
treated	treat	VERB	VBN	3	O
concomitantly	concomitantly	ADV	RB	9	O
.	.	PUNCT	.	9	O

Factors	factor	NOUN	NNS	5	O
contributing	contribute	VERB	VBG	9	O
to	to	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
anemia	anemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Interferon	Interferon	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	ADJ	JJ	9	B-Chemical
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
produces	produce	VERB	VBZ	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
the	the	DET	DT	5	O
factors	factor	NOUN	NNS	9	O
contributing	contribute	VERB	VBG	9	O
to	to	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
anemia	anemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Eighty	eighty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
interferon	interferon	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2b	2b	NUM	CD	9	I-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
MU	MU	PROPN	NNP	9	O
administered	administer	VERB	VBD	9	O
intramuscularly	intramuscularly	ADV	RB	0	O
for	for	ADP	IN	5	O
24	24	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
administered	administer	VERB	VBD	9	O
orally	orally	ADV	RB	0	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
participated	participate	VERB	VBD	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
hemoglobin	hemoglobin	NOUN	NN	0	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
<	<	X	XX	0	O
10	10	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
anemia	anemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Ribavirin	Ribavirin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
18	18	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
anemia	anemia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
2	2	NUM	CD	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
concentration	concentration	NOUN	NN	0	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
decrease	decrease	NOUN	NN	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
2	2	NUM	CD	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
significantly	significantly	ADV	RB	9	O
lower	lower	ADV	RBR	9	O
even	even	ADV	RB	5	O
after	after	ADP	IN	9	O
week	week	NOUN	NN	9	O
2	2	NUM	CD	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
<	<	NUM	CD	0	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
decrease	decrease	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
concentrations	concentration	NOUN	NNS	0	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
anemia	anemia	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
as	as	ADP	IN	5	O
sex	sex	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
female	female	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
60	60	NUM	CD	9	O
years	year	NOUN	NNS	5	O
old	old	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
dose	dose	NOUN	NN	9	O
by	by	ADP	IN	9	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
by	by	ADP	IN	9	O
univariate	univariate	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Careful	careful	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
necessary	necessary	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
60	60	NUM	CD	9	O
years	year	NOUN	NNS	5	O
old	old	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
experience	experience	VERB	VBP	5	O
a	a	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
2	2	NUM	CD	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
monitored	monitor	VERB	VBN	9	O
with	with	ADP	IN	5	O
particular	particular	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Zidovudine	Zidovudine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
38	38	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
whereby	whereby	ADV	WRB	5	O
the	the	DET	DT	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
known	know	VERB	VBN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
tolerated	tolerate	VERB	VBD	9	O
well	well	ADV	RB	9	O
an	an	DET	DT	5	O
alternative	alternative	ADJ	JJ	5	O
reverse	reverse	ADJ	JJ	9	O
transcriptase	transcriptase	NOUN	NN	9	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	B-Chemical
'	'	PART	POS	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
'	'	PART	POS	9	I-Chemical
dideoxyinosine	dideoxyinosine	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Physicians	physician	NOUN	NNS	5	O
caring	care	VERB	VBG	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
hitherto	hitherto	NOUN	NN	9	O
rarely	rarely	ADV	RB	5	O
reported	report	VERB	VBD	9	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Oxidative	oxidative	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
precedes	precede	VERB	VBZ	9	O
nitrative	nitrative	ADJ	JJ	3	O
damage	damage	NOUN	NN	9	O
in	in	ADP	IN	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
elevated	elevate	VERB	VBN	9	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ROS	ROS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
nitrogen	nitrogen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
(	(	PUNCT	-LRB-	9	O
RNS	RNS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
reported	report	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
actually	actually	ADV	RB	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
oxidative	oxidative	ADJ	JJ	9	O
/	/	SYM	SYM	9	O
nitrative	nitrative	ADJ	JJ	3	O
damage	damage	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
quantitatively	quantitatively	ADV	RB	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
subcellular	subcellular	ADJ	JJ	3	O
localization	localization	NOUN	NN	3	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
postulated	postulate	VERB	VBN	9	O
damage	damage	NOUN	NN	9	O
products	product	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
an	an	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
approach	approach	VERB	VBP	5	O
.	.	PUNCT	.	9	O

B6C3	b6c3	NOUN	NN	3	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
ADR	ADR	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Ultrastructural	ultrastructural	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxy	hydroxy	NUM	CD	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nonenal	nonenal	ADJ	JJ	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
4HNE	4hne	NUM	CD	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
protein	protein	NOUN	NN	1	O
adducts	adduct	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitrotyrosine	nitrotyrosine	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
3NT	3nt	NUM	CD	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Quantitative	quantitative	ADJ	JJ	9	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
using	use	VERB	VBG	9	O
computerized	computerized	ADJ	JJ	5	O
image	image	NOUN	NN	5	O
techniques	technique	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
injury	injury	NOUN	NN	9	O
as	as	ADV	RB	5	O
early	early	ADV	RB	9	O
as	as	ADP	IN	5	O
3	3	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
mitochondria	mitochondria	NOUN	NN	3	O
being	be	VERB	VBG	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
extensively	extensively	ADV	RB	9	O
and	and	CCONJ	CC	5	O
progressively	progressively	ADV	RB	9	O
injured	injure	VERB	VBN	5	O
subcellular	subcellular	ADJ	JJ	3	O
organelle	organelle	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
4HNE	4hne	NUM	CD	0	B-Chemical
protein	protein	NOUN	NN	1	O
adducts	adduct	NOUN	NNS	0	O
by	by	ADP	IN	9	O
immunogold	immunogold	NOUN	NN	3	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
4HNE	4hne	NUM	CD	0	B-Chemical
protein	protein	NOUN	NN	1	O
adducts	adduct	NOUN	NNS	0	O
in	in	ADP	IN	5	O
mitochondria	mitochondria	NOUN	NN	3	O
as	as	ADV	RB	5	O
early	early	ADV	RB	9	O
as	as	ADP	IN	5	O
3	3	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
peak	peak	NOUN	NN	9	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
decline	decline	NOUN	NN	9	O
at	at	ADP	IN	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

3NT	3nt	NUM	CD	3	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
subcellular	subcellular	ADJ	JJ	3	O
compartments	compartment	NOUN	NNS	9	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
subsequently	subsequently	ADV	RB	9	O
declined	decline	VERB	VBD	9	O
at	at	ADP	IN	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
induced	induce	VERB	VBD	3	O
4HNE	4hne	NUM	CD	0	B-Chemical
-	-	PUNCT	HYPH	7	O
protein	protein	NOUN	NN	1	O
adducts	adduct	NOUN	NNS	0	O
in	in	ADP	IN	5	O
mitochondria	mitochondria	NOUN	NN	3	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
point	point	NOUN	NN	5	O
as	as	ADP	IN	5	O
when	when	ADV	WRB	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
initially	initially	ADV	RB	9	O
appeared	appear	VERB	VBD	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
document	document	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
that	that	DET	WDT	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
oxidative	oxidative	ADJ	JJ	9	I-Disease
damage	damage	NOUN	NN	9	I-Disease
precedes	precede	VERB	VBZ	9	O
nitrative	nitrative	ADJ	JJ	3	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
progressive	progressive	ADJ	JJ	5	O
nature	nature	NOUN	NN	5	O
of	of	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
mitochondria	mitochondria	NOUN	NN	3	O
,	,	PUNCT	,	9	O
not	not	ADV	RB	5	O
other	other	ADJ	JJ	5	O
subcellular	subcellular	ADJ	JJ	3	O
organelles	organelle	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
intracellular	intracellular	ADJ	JJ	3	O
injury	injury	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Sotalol	Sotalol	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
coronary	coronary	ADJ	JJ	5	B-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
dilated	dilated	ADJ	JJ	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
sustained	sustain	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
54	54	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
dilated	dilated	ADJ	JJ	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
referred	refer	VERB	VBN	5	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
hospital	hospital	NOUN	NN	5	O
for	for	ADP	IN	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
incessant	incessant	NOUN	NN	5	O
sustained	sustain	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
VT	VT	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
nifekalant	nifekalant	ADJ	JJ	5	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
sustained	sustain	VERB	VBD	5	O
VT	VT	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
terminated	terminate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
alternate	alternate	ADJ	JJ	9	O
class	class	NOUN	NN	9	O
III	iii	NUM	CD	9	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
sotalol	sotalol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
VT	VT	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
after	after	ADP	IN	9	O
switching	switch	VERB	VBG	5	O
over	over	PART	RP	5	O
nifekalant	nifekalant	ADJ	JJ	5	B-Chemical
to	to	PART	TO	5	O
sotalol	sotalol	VERB	VB	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
short	short	ADJ	JJ	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
ST	ST	PROPN	NNP	9	O
elevation	elevation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
in	in	ADP	IN	5	O
ECG	ECG	PROPN	NNP	5	O
monitoring	monitor	VERB	VBG	5	O
at	at	ADP	IN	9	O
almost	almost	ADV	RB	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
for	for	ADP	IN	5	O
three	three	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

ST	ST	PROPN	NNP	9	O
elevation	elevation	NOUN	NN	9	O
with	with	ADP	IN	5	O
chest	chest	NOUN	NN	5	O
discomfort	discomfort	NOUN	NN	5	O
disappeared	disappear	VERB	VBD	9	O
since	since	ADP	IN	9	O
he	-PRON-	PRON	PRP	5	O
began	begin	VERB	VBD	5	O
taking	take	VERB	VBG	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
diltiazem	diltiazem	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Coronary	coronary	ADJ	JJ	5	B-Disease
vasospasm	vasospasm	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocking	block	VERB	VBG	3	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sotalol	sotalol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antidepressant	antidepressant	ADJ	JJ	5	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	ht	NOUN	NN	9	I-Chemical
2A	2a	NOUN	NN	9	O
/	/	SYM	SYM	9	O
2C	2c	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
behaviors	behavior	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RATIONALE	RATIONALE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
Hydroxytryptamine	Hydroxytryptamine	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
via	via	ADP	IN	9	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
2C	2c	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
exerts	exert	VERB	VBZ	9	O
a	a	DET	DT	5	O
tonic	tonic	NOUN	NN	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
influence	influence	NOUN	NN	5	O
on	on	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurotransmission	neurotransmission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
2A	2a	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
enhances	enhance	NOUN	NNS	3	O
stimulated	stimulate	VERB	VBD	3	O
DAergic	DAergic	PROPN	NNP	3	O
neurotransmission	neurotransmission	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antidepressant	antidepressant	ADJ	JJ	5	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	ht	NOUN	NN	9	I-Chemical
2A	2a	NOUN	NN	9	O
/	/	SYM	SYM	9	O
2C	2c	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
trazodone	trazodone	NUM	CD	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
behaviors	behavior	NOUN	NNS	5	O
dependent	dependent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
status	status	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nigrostriatal	nigrostriatal	ADJ	JJ	3	O
DAergic	DAergic	PROPN	NNP	3	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
dexamphetamine	dexamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
oral	oral	ADJ	JJ	9	B-Disease
stereotypies	stereotypie	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
ergometrine	ergometrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
wet	wet	ADJ	JJ	5	O
dog	dog	NOUN	NN	5	O
shake	shake	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
WDS	WDS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
behavior	behavior	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
penile	penile	NOUN	NN	5	O
erections	erection	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
also	also	ADV	RB	9	O
investigated	investigate	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
induces	induce	NOUN	NNS	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Trazodone	trazodone	NOUN	NN	7	B-Chemical
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
induce	induce	VERB	VB	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
antagonize	antagonize	VERB	VB	3	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
stereotypy	stereotypy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
pretreatment	pretreatment	ADJ	JJ	0	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
enhanced	enhance	VERB	VBD	3	O
dexamphetamine	dexamphetamine	NOUN	NN	5	B-Chemical
stereotypy	stereotypy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
antagonized	antagonize	VERB	VBN	3	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
ergometrine	ergometrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
WDS	WDS	PROPN	NNP	5	O
behavior	behavior	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
penile	penile	NOUN	NN	5	O
erections	erection	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Trazodone	trazodone	NOUN	NN	7	B-Chemical
at	at	ADP	IN	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
antagonized	antagonized	ADJ	JJ	3	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
dexamphetamine	dexamphetamine	NOUN	NN	5	B-Chemical
stereotypies	stereotypie	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
block	block	VERB	VB	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
and	and	CCONJ	CC	5	O
postsynaptic	postsynaptic	ADJ	JJ	3	O
striatal	striatal	ADJ	JJ	3	O
D2	d2	NOUN	NN	9	O
DA	DA	PROPN	NNP	9	O
receptors	receptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
at	at	ADP	IN	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
it	-PRON-	PRON	PRP	5	O
blocks	block	VERB	VBZ	9	O
postsynaptic	postsynaptic	ADJ	JJ	3	O
striatal	striatal	ADJ	JJ	3	O
D2	d2	NOUN	NN	9	O
DA	DA	PROPN	NNP	9	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
blocks	block	VERB	VBZ	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	ht	NOUN	NN	9	I-Chemical
2A	2a	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	B-Chemical
-	-	SYM	SYM	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
2C	2c	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
blocking	block	VERB	VBG	3	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
2C	2c	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
releases	release	VERB	VBZ	9	O
the	the	DET	DT	5	O
nigrostriatal	nigrostriatal	ADJ	JJ	3	O
DAergic	DAergic	PROPN	NNP	3	O
neurons	neuron	NOUN	NNS	3	O
from	from	ADP	IN	9	O
tonic	tonic	NOUN	NN	5	O
inhibition	inhibition	NOUN	NN	3	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	SYM	SYM	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
thereby	thereby	ADV	RB	9	O
potentiates	potentiate	VERB	VBZ	3	O
dexamphetamine	dexamphetamine	NOUN	NN	5	B-Chemical
stereotypy	stereotypy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
antagonizes	antagonize	NOUN	NNS	3	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Swallowing	swallow	VERB	VBG	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
and	and	CCONJ	CC	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
known	know	VERB	VBN	9	O
for	for	ADP	IN	5	O
almost	almost	ADV	RB	9	O
two	two	NUM	CD	5	O
centuries	century	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
many	many	ADJ	JJ	5	O
aspects	aspect	NOUN	NNS	5	O
concerning	concern	VERB	VBG	5	O
their	-PRON-	DET	PRP$	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
completely	completely	ADV	RB	9	O
clarified	clarify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
characterize	characterize	VERB	VB	9	O
the	the	DET	DT	5	O
oropharyngeal	oropharyngeal	ADJ	JJ	5	O
dynamics	dynamic	NOUN	NNS	5	O
in	in	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Fifteen	fifteen	NUM	CD	9	O
dyskinetic	dyskinetic	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
nondyskinetic	nondyskinetic	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
asked	ask	VERB	VBN	5	O
about	about	ADP	IN	5	O
dysphagia	dysphagia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
evaluated	evaluate	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
Unified	Unified	PROPN	NNP	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
Disease	Disease	PROPN	NNP	2	I-Disease
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
Parts	part	NOUN	NNS	9	O
II	II	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
III	III	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Hoehn	Hoehn	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Yahr	Yahr	PROPN	NNP	5	O
scale	scale	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Deglutition	Deglutition	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
using	use	VERB	VBG	9	O
modified	modify	VERB	VBN	9	O
barium	barium	NOUN	NN	0	B-Chemical
swallow	swallow	ADJ	JJ	5	O
with	with	ADP	IN	5	O
videofluoroscopy	videofluoroscopy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Nondyskinetic	nondyskinetic	ADJ	JJ	_	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
ones	one	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
showed	show	VERB	VBD	9	O
less	less	ADV	RBR	5	O
oropharyngeal	oropharyngeal	ADJ	JJ	5	O
swallowing	swallow	VERB	VBG	5	O
efficiency	efficiency	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OPSE	OPSE	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
liquid	liquid	ADJ	JJ	0	O
food	food	NOUN	NN	5	O
than	than	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
Dunnett	Dunnett	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Dyskinetic	dyskinetic	ADJ	JJ	7	B-Disease
patients	patient	NOUN	NNS	5	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
OPSE	OPSE	PROPN	NNP	5	O
than	than	ADP	IN	5	O
nondyskinetic	nondyskinetic	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
Dunnett	Dunnett	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
06	06	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
OPSE	OPSE	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
trend	trend	NOUN	NN	9	O
toward	toward	ADP	IN	5	O
a	a	DET	DT	5	O
smaller	small	ADJ	JJR	5	O
oral	oral	ADJ	JJ	9	O
transit	transit	NOUN	NN	9	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
Pearson	Pearson	PROPN	NNP	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
correlation	correlation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Neither	neither	CCONJ	CC	9	O
the	the	DET	DT	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
dysphagia	dysphagia	NOUN	NN	5	B-Disease
nor	nor	CCONJ	CC	9	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
PD	pd	NOUN	NN	9	B-Disease
severity	severity	NOUN	NN	5	O
parameters	parameter	NOUN	NNS	5	O
correlated	correlate	VERB	VBD	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
videofluoroscopic	videofluoroscopic	ADJ	JJ	5	O
variables	variable	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
performed	perform	VERB	VBD	9	O
better	better	ADV	RBR	5	O
in	in	ADP	IN	5	O
swallowing	swallow	VERB	VBG	5	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
explained	explain	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
deglutition	deglutition	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
confirm	confirm	VERB	VB	9	O
that	that	DET	DT	5	O
dysphagia	dysphagia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
a	a	DET	DT	5	O
good	good	ADJ	JJ	5	O
predictor	predictor	NOUN	NN	5	O
of	of	ADP	IN	5	O
deglutition	deglutition	NOUN	NN	5	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
nuclear	nuclear	ADJ	JJ	3	O
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
kappaB	kappaB	PROPN	NNP	3	O
activation	activation	NOUN	NN	3	O
attenuates	attenuate	VERB	VBZ	3	O
tubulointerstitial	tubulointerstitial	ADJ	JJ	3	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBD	3	O
with	with	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
show	show	VERB	VB	9	O
residual	residual	ADJ	JJ	9	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
interstitial	interstitial	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
nuclear	nuclear	ADJ	JJ	3	O
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
kappaB	kappaB	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
NF	NF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
kappaB	kappaB	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
mitogen	mitogen	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
activated	activate	VERB	VBN	3	O
protein	protein	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
MAP	MAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
kinases	kinase	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
macrophages	macrophage	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
cortex	cortex	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
structural	structural	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
+	+	SYM	SYM	9	O
pyrrolidine	pyrrolidine	NOUN	NN	0	B-Chemical
dithiocarbamate	dithiocarbamate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PDTC	PDTC	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
NF	NF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
kappaB	kappaB	PROPN	NNP	3	O
inhibitor	inhibitor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
38	38	NUM	CD	7	O
female	female	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADV	RB	0	O
,	,	PUNCT	,	9	O
twice	twice	DET	PDT	9	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
9	9	NUM	CD	7	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
38	38	NUM	CD	7	O
with	with	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
+	+	SYM	SYM	9	O
PDTC	pdtc	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
28	28	NUM	CD	7	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
M	M	PROPN	NNP	9	O
NaCl	NaCl	PROPN	NNP	0	B-Chemical
solution	solution	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
killed	kill	VERB	VBN	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
these	these	DET	DT	5	O
injections	injection	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
removed	remove	VERB	VBN	9	O
for	for	ADP	IN	5	O
histological	histological	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
scored	score	VERB	VBN	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
staining	staining	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
fractional	fractional	ADJ	JJ	5	O
interstitial	interstitial	ADJ	JJ	9	O
area	area	NOUN	NN	5	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
morphometry	morphometry	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
presented	present	VERB	VBD	5	O
a	a	DET	DT	5	O
transitory	transitory	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
ED	ED	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
MAP	MAP	PROPN	NNP	9	O
kinases	kinase	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
NF	NF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
kappaB	kappaB	PROPN	NNP	3	O
staining	staining	NOUN	NN	3	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
cortex	cortex	NOUN	NN	5	O
from	from	ADP	IN	9	O
all	all	DET	DT	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
killed	kill	VERB	VBN	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
30	30	NUM	CD	9	O
also	also	ADV	RB	9	O
presented	present	VERB	VBN	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
cortex	cortex	NOUN	NN	5	O
despite	despite	ADP	IN	9	O
the	the	DET	DT	5	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
PDTC	PDTC	PROPN	NNP	3	B-Chemical
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
structural	structural	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
NF	NF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
kappaB	kappaB	PROPN	NNP	3	O
activation	activation	NOUN	NN	3	O
attenuates	attenuate	VERB	VBZ	3	O
tubulointerstitial	tubulointerstitial	ADJ	JJ	3	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Glucose	glucose	NOUN	NN	0	B-Chemical
metabolism	metabolism	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
atypical	atypical	ADJ	JJ	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
frequently	frequently	ADV	RB	5	O
sampled	sample	VERB	VBN	5	O
intravenous	intravenous	ADJ	JJ	0	O
glucose	glucose	NOUN	NN	0	B-Chemical
tolerance	tolerance	NOUN	NN	9	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
minimal	minimal	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
While	while	ADP	IN	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
new	new	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
increasing	increase	VERB	VBG	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
atypical	atypical	ADJ	JJ	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
remains	remain	VERB	VBZ	9	O
unclear	unclear	ADJ	JJ	9	O
whether	whether	ADP	IN	9	O
atypical	atypical	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
directly	directly	ADV	RB	9	O
affecting	affect	VERB	VBG	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
metabolism	metabolism	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
simply	simply	ADV	RB	5	O
increasing	increase	VERB	VBG	9	O
known	know	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
drugs	drug	NOUN	NNS	5	O
most	most	ADV	RBS	9	O
clearly	clearly	ADV	RB	9	O
implicated	implicate	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
frequently	frequently	ADV	RB	5	O
sampled	sample	VERB	VBN	5	O
intravenous	intravenous	ADJ	JJ	0	O
glucose	glucose	NOUN	NN	0	B-Chemical
tolerance	tolerance	NOUN	NN	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
sectional	sectional	ADJ	JJ	5	O
design	design	NOUN	NN	5	O
in	in	ADP	IN	5	O
stable	stable	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
treated	treat	VERB	VBD	3	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
evaluated	evaluate	VERB	VBD	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
frequently	frequently	ADV	RB	5	O
sampled	sample	VERB	VBN	5	O
intravenous	intravenous	ADJ	JJ	0	O
glucose	glucose	NOUN	NN	0	B-Chemical
tolerance	tolerance	NOUN	NN	9	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Bergman	Bergman	PROPN	NNP	6	O
minimal	minimal	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

SETTING	setting	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
recruited	recruit	VERB	VBN	9	O
from	from	ADP	IN	9	O
an	an	DET	DT	5	O
urban	urban	ADJ	JJ	5	O
community	community	NOUN	NN	5	O
mental	mental	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
clinic	clinic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
general	general	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
research	research	NOUN	NN	5	O
center	center	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	Patients	PROPN	NNP	5	O
Fifty	Fifty	PROPN	NNP	9	O
subjects	subject	NOUN	NNS	5	O
signed	sign	VERB	VBD	5	O
informed	informed	ADJ	JJ	5	O
consent	consent	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
41	41	NUM	CD	7	O
underwent	undergo	VERB	VBD	5	O
the	the	DET	DT	5	O
frequently	frequently	ADV	RB	5	O
sampled	sample	VERB	VBN	5	O
intravenous	intravenous	ADJ	JJ	0	O
glucose	glucose	NOUN	NN	0	B-Chemical
tolerance	tolerance	NOUN	NN	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
nonobese	nonobese	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
schizoaffective	schizoaffective	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
matched	match	VERB	VBN	9	O
by	by	ADP	IN	9	O
body	body	NOUN	NN	5	O
mass	mass	NOUN	NN	9	O
index	index	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

MAIN	MAIN	PROPN	NNP	2	O
OUTCOME	OUTCOME	PROPN	NNP	2	O
MEASURES	MEASURES	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Fasting	fast	VERB	VBG	7	O
plasma	plasma	NOUN	NN	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
fasting	fast	VERB	VBG	9	O
serum	serum	ADJ	JJ	9	O
insulin	insulin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
insulin	insulin	NOUN	NN	3	B-Disease
sensitivity	sensitivity	NOUN	NN	9	I-Disease
index	index	NOUN	NN	5	O
,	,	PUNCT	,	9	O
homeostasis	homeostasis	NOUN	NN	9	O
model	model	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
insulin	insulin	NOUN	NN	3	B-Disease
resistance	resistance	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
glucose	glucose	NOUN	NN	0	B-Chemical
effectiveness	effectiveness	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
identified	identify	VERB	VBN	9	O
atypical	atypical	ADJ	JJ	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
was	be	VERB	VBD	9	O
68	68	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
29	29	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
40	40	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Fasting	fast	VERB	VBG	7	O
serum	serum	ADJ	JJ	9	O
insulin	insulin	NOUN	NN	3	O
concentrations	concentration	NOUN	NNS	0	O
differed	differ	VERB	VBN	9	O
among	among	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
F	F	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
047	047	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
clozapine	clozapine	VERB	VB	5	B-Chemical
>	>	X	XX	0	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
>	>	X	XX	0	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
32	32	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
insulin	insulin	NOUN	NN	3	B-Disease
sensitivity	sensitivity	NOUN	NN	9	I-Disease
index	index	NOUN	NN	5	O
among	among	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
F	F	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
66	66	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
clozapine	clozapine	VERB	VB	5	B-Chemical
<	<	X	XX	0	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
<	<	X	XX	0	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
exhibiting	exhibit	VERB	VBG	9	O
significant	significant	ADJ	JJ	9	O
insulin	insulin	NOUN	NN	3	B-Disease
resistance	resistance	NOUN	NN	9	I-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
vs	vs	ADP	IN	7	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
-	-	PUNCT	:	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
29	29	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
;	;	PUNCT	:	9	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
vs	vs	ADP	IN	7	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
=	=	PROPN	NNP	7	O
-	-	PUNCT	:	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
62	62	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
[	[	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
homeostasis	homeostasis	NOUN	NN	9	O
model	model	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
insulin	insulin	NOUN	NN	3	B-Disease
resistance	resistance	NOUN	NN	9	I-Disease
also	also	ADV	RB	9	O
differed	differ	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
among	among	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
F	F	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
92	92	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
clozapine	clozapine	VERB	VB	5	B-Chemical
>	>	X	XX	0	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
>	>	X	XX	0	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
vs	vs	ADP	IN	7	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
94	94	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	NOUN	NNS	7	O
.	.	NOUN	NN	9	O
006	006	NUM	CD	7	O
;	;	PUNCT	:	9	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
vs	vs	ADP	IN	7	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
42	42	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
among	among	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
in	in	ADP	IN	5	O
glucose	glucose	NOUN	NN	0	B-Chemical
effectiveness	effectiveness	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
F	F	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
18	18	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
clozapine	clozapine	VERB	VB	5	B-Chemical
<	<	X	XX	0	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
<	<	X	XX	0	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
=	=	PROPN	NNP	7	O
-	-	PUNCT	:	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
59	59	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
=	=	PROPN	NNP	7	O
-	-	PUNCT	:	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Both	both	DET	DT	9	O
nonobese	nonobese	ADJ	JJ	9	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
groups	group	NOUN	NNS	9	O
displayed	display	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
insulin	insulin	NOUN	NN	3	B-Disease
resistance	resistance	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
glucose	glucose	NOUN	NN	0	B-Chemical
effectiveness	effectiveness	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
insulin	insulin	NOUN	NN	3	B-Disease
resistance	resistance	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
consequences	consequence	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thoracic	Thoracic	PROPN	NNP	5	B-Disease
hematomyelia	hematomyelia	VERB	VBP	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	PART	TO	5	O
coumadin	coumadin	VERB	VB	5	B-Chemical
anticoagulant	anticoagulant	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
thoracic	thoracic	NOUN	NN	5	B-Disease
hematomyelia	hematomyelia	NOUN	NNS	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	PART	TO	5	O
anticoagulant	anticoagulant	VERB	VB	9	O
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
other	other	ADJ	JJ	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
high	high	ADJ	JJ	9	O
index	index	NOUN	NN	5	O
of	of	ADP	IN	5	O
suspicion	suspicion	NOUN	NN	5	O
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
quick	quick	ADJ	JJ	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
procedure	procedure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
successful	successful	ADJ	JJ	5	O
decompressive	decompressive	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Mania	Mania	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBD	9	O
with	with	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
adolescents	adolescent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fluoxetine	Fluoxetine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
gaining	gain	VERB	VBG	5	O
increased	increase	VERB	VBN	9	O
acceptance	acceptance	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
adolescent	adolescent	ADJ	JJ	5	O
depression	depression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Generally	generally	ADV	RB	5	O
safe	safe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
by	by	ADP	IN	9	O
adults	adult	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
mania	mania	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
five	five	NUM	CD	9	O
depressed	depressed	ADJ	JJ	5	B-Disease
adolescents	adolescent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
-	-	SYM	SYM	7	O
16	16	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
mania	mania	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
pharmacotherapy	pharmacotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
here	here	ADV	RB	5	O
.	.	PUNCT	.	9	O

Apparent	apparent	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
mania	mania	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
hypomania	hypomania	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
pharmacotherapy	pharmacotherapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
population	population	NOUN	NN	5	O
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
attention	attention	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
deficit	deficit	NOUN	NN	5	I-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
affective	affective	ADJ	JJ	5	O
instability	instability	NOUN	NN	5	O
;	;	PUNCT	:	9	O
major	major	ADJ	JJ	9	O
depression	depression	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
features	feature	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
a	a	DET	DT	5	O
family	family	NOUN	NN	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
affective	affective	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
that	that	DET	WDT	5	O
increase	increase	VERB	VBP	9	O
individual	individual	ADJ	JJ	5	O
vulnerability	vulnerability	NOUN	NN	5	O
to	to	PART	TO	5	O
fluoxetine	fluoxetine	VERB	VB	0	B-Chemical
induced	induced	ADJ	JJ	3	O
mania	mania	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
adolescents	adolescent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
melphalan	melphalan	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
primary	primary	ADJ	JJ	9	B-Disease
systemic	systemic	ADJ	JJ	9	I-Disease
amyloidosis	amyloidosis	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
primary	primary	ADJ	JJ	9	B-Disease
systemic	systemic	ADJ	JJ	9	I-Disease
amyloidosis	amyloidosis	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AL	AL	PROPN	NNP	2	B-Disease
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
poor	poor	ADJ	JJ	5	O
prognosis	prognosis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
survival	survival	NOUN	NN	9	O
time	time	NOUN	NN	5	O
from	from	ADP	IN	9	O
standard	standard	ADJ	JJ	5	O
treatments	treatment	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
only	only	ADV	RB	9	O
17	17	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
intravenous	intravenous	ADJ	JJ	0	O
melphalan	melphalan	NOUN	NN	0	B-Chemical
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplant	transplant	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PBSCT	PBSCT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
promising	promising	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
treatment	treatment	NOUN	NN	9	O
mortality	mortality	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
high	high	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
noted	note	VERB	VBN	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
melphalan	melphalan	ADJ	JJ	0	B-Chemical
conditioning	conditioning	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
further	further	ADV	RB	9	O
examine	examine	VERB	VB	9	O
its	-PRON-	DET	PRP$	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
impact	impact	NOUN	NN	5	O
on	on	ADP	IN	5	O
posttransplant	posttransplant	ADJ	JJ	5	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Consecutive	consecutive	ADJ	JJ	5	O
AL	AL	PROPN	NNP	2	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
PBSCT	PBSCT	PROPN	NNP	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
retrospectively	retrospectively	ADV	RB	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
ARI	ARI	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
melphalan	melphalan	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
minimum	minimum	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
44	44	NUM	CD	7	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
conditioning	condition	VERB	VBG	5	O
.	.	PUNCT	.	9	O

Urine	urine	ADJ	JJ	9	O
sediment	sediment	ADJ	JJ	0	O
score	score	NOUN	NN	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
sum	sum	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
individual	individual	ADJ	JJ	5	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sediment	sediment	NOUN	NN	0	O
identified	identify	VERB	VBN	9	O
on	on	ADP	IN	5	O
urine	urine	NOUN	NN	9	O
microscopy	microscopy	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
80	80	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
studied	study	VERB	VBD	9	O
,	,	PUNCT	,	9	O
ARI	ARI	PROPN	NNP	5	B-Disease
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
melphalan	melphalan	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Univariate	univariate	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
identified	identify	VERB	VBD	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hypoalbuminemia	hypoalbuminemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
heavy	heavy	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
diuretic	diuretic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
urine	urine	ADJ	JJ	9	O
sediment	sediment	ADJ	JJ	0	O
score	score	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Age	age	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
sediment	sediment	ADJ	JJ	0	O
score	score	NOUN	NN	5	O
remained	remain	VERB	VBD	9	O
independently	independently	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
multivariate	multivariate	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
ARI	ARI	PROPN	NNP	5	B-Disease
after	after	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
melphalan	melphalan	NOUN	NN	0	B-Chemical
underwent	undergo	VERB	VBD	5	O
dialysis	dialysis	NOUN	NN	5	O
more	more	ADV	RBR	5	O
often	often	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
007	007	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
worse	bad	ADJ	JJR	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
survival	survival	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
timing	timing	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
strongly	strongly	ADV	RB	9	O
suggests	suggest	VERB	VBZ	9	O
melphalan	melphalan	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
causative	causative	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Ongoing	ongoing	ADJ	JJ	5	O
tubular	tubular	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
prerequisite	prerequisite	NOUN	NN	9	O
for	for	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
by	by	ADP	IN	9	O
melphalan	melphalan	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
evidenced	evidence	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
active	active	ADJ	JJ	9	O
urinary	urinary	ADJ	JJ	9	O
sediment	sediment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Development	development	NOUN	NN	2	O
of	of	ADP	IN	5	O
ARI	ARI	PROPN	NNP	5	B-Disease
adversely	adversely	ADV	RB	5	O
affected	affect	VERB	VBD	9	O
the	the	DET	DT	5	O
outcome	outcome	NOUN	NN	5	O
after	after	ADP	IN	9	O
PBSCT	PBSCT	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Effective	effective	ADJ	JJ	5	O
preventive	preventive	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
may	may	VERB	MD	5	O
help	help	VERB	VB	5	O
decrease	decrease	VERB	VB	9	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
mortality	mortality	NOUN	NN	5	O
of	of	ADP	IN	5	O
PBSCT	PBSCT	PROPN	NNP	5	O
in	in	ADP	IN	5	O
AL	AL	PROPN	NNP	2	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Focal	focal	ADJ	JJ	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
reperfusion	reperfusion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
180	180	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
temporary	temporary	ADJ	JJ	5	O
middle	middle	ADJ	JJ	9	B-Disease
cerebral	cerebral	ADJ	JJ	5	I-Disease
artery	artery	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
brain	brain	NOUN	NN	5	I-Disease
injury	injury	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
permeability	permeability	NOUN	NN	0	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
manipulated	manipulate	VERB	VBN	5	O
by	by	ADP	IN	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
schedules	schedule	NOUN	NNS	5	O
during	during	ADP	IN	5	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
reperfusion	reperfusion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
normotensive	normotensive	ADJ	JJ	9	O
reperfusion	reperfusion	NOUN	NN	9	O
;	;	PUNCT	:	9	O
90	90	NUM	CD	9	O
/	/	SYM	SYM	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
90	90	NUM	CD	9	O
/	/	SYM	SYM	9	O
HTN	HTN	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
35	35	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
90	90	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
reperfusion	reperfusion	NOUN	NN	9	O
only	only	ADV	RB	9	O
;	;	PUNCT	:	9	O
15	15	NUM	CD	9	O
/	/	SYM	SYM	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
/	/	SYM	SYM	9	O
HTN	HTN	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
normotensive	normotensive	ADJ	JJ	9	O
reperfusion	reperfusion	NOUN	NN	9	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
75	75	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
normotension	normotension	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Part	Part	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
eight	eight	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
brain	brain	NOUN	NN	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
staining	stain	VERB	VBG	3	O
tissue	tissue	NOUN	NN	9	O
using	use	VERB	VBG	9	O
2	2	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
triphenyltetrazolium	triphenyltetrazolium	NOUN	NN	0	I-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
edema	edema	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
microgravimetry	microgravimetry	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Part	part	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
eight	eight	NUM	CD	9	O
different	different	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
permeability	permeability	NOUN	NN	0	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
measuring	measure	VERB	VBG	9	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
extravasation	extravasation	NOUN	NN	3	O
of	of	ADP	IN	5	O
Evans	Evans	PROPN	NNP	6	O
Blue	Blue	PROPN	NNP	0	O
dye	dye	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Brain	brain	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
hemisphere	hemisphere	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
15	15	NUM	CD	9	O
/	/	SYM	SYM	9	O
HTN	HTN	PROPN	NNP	9	B-Disease
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
16	16	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
mean	mean	ADJ	JJ	5	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
the	the	DET	DT	5	O
90	90	NUM	CD	9	O
/	/	SYM	SYM	9	O
HTN	HTN	PROPN	NNP	9	B-Disease
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
turn	turn	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
42	42	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Specific	specific	ADJ	JJ	9	O
gravity	gravity	NOUN	NN	5	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
15	15	NUM	CD	9	O
/	/	SYM	SYM	9	O
HTN	HTN	PROPN	NNP	9	B-Disease
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
043	043	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
the	the	DET	DT	5	O
90	90	NUM	CD	9	O
/	/	SYM	SYM	9	O
HTN	HTN	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
036	036	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
003	003	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
037	037	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
003	003	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Evans	Evans	PROPN	NNP	6	B-Chemical
Blue	Blue	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
mug	mug	ADV	RB	5	O
g	g	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
tissue	tissue	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
90	90	NUM	CD	9	O
/	/	SYM	SYM	9	O
HTN	HTN	PROPN	NNP	9	B-Disease
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
turn	turn	NOUN	NN	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
15	15	NUM	CD	9	O
/	/	SYM	SYM	9	O
HTN	HTN	PROPN	NNP	9	B-Disease
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
supports	support	VERB	VBZ	9	O
a	a	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
during	during	ADP	IN	5	O
reperfusion	reperfusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
short	short	ADJ	JJ	5	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
decreases	decrease	VERB	VBZ	9	O
brain	brain	NOUN	NN	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
edema	edema	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
that	that	DET	DT	5	O
sustained	sustain	VERB	VBD	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
vasogenic	vasogenic	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

People	People	NOUN	NNS	5	O
aged	aged	ADJ	JJ	9	O
over	over	ADP	IN	5	O
75	75	NUM	CD	9	O
in	in	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
on	on	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
major	major	ADJ	JJ	9	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
stroke	stroke	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
500	500	NUM	CD	0	O
patient	patient	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
major	major	ADJ	JJ	9	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
stroke	stroke	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
people	people	NOUN	NNS	5	O
aged	age	VERB	VBD	9	O
76	76	NUM	CD	7	O
and	and	CCONJ	CC	5	O
older	old	ADJ	JJR	5	O
with	with	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
on	on	ADP	IN	5	O
adjusted	adjust	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
recently	recently	ADV	RB	9	O
been	be	VERB	VBN	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
retrospective	retrospective	ADJ	JJ	5	O
observational	observational	ADJ	JJ	5	O
cohort	cohort	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

SETTING	set	VERB	VBG	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
major	major	ADJ	JJ	9	O
healthcare	healthcare	NOUN	NN	5	O
network	network	NOUN	NN	5	O
involving	involve	VERB	VBG	5	O
four	four	NUM	CD	9	O
tertiary	tertiary	ADJ	JJ	9	O
hospitals	hospital	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

PARTICIPANTS	participant	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
thirty	thirty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
aged	age	VERB	VBD	9	O
76	76	NUM	CD	7	O
and	and	CCONJ	CC	5	O
older	old	ADJ	JJR	5	O
admitted	admit	VERB	VBD	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
healthcare	healthcare	NOUN	NN	5	O
network	network	NOUN	NN	5	O
between	between	ADP	IN	5	O
July	July	PROPN	NNP	2	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2001	2001	NUM	CD	2	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
June	June	PROPN	NNP	2	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
2002	2002	NUM	CD	2	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
on	on	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
.	.	PUNCT	.	9	O

MEASUREMENTS	measurement	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Information	information	NOUN	NN	5	O
regarding	regard	VERB	VBG	5	O
major	major	ADJ	JJ	9	O
bleeding	bleeding	NOUN	NN	5	B-Disease
episodes	episode	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
strokes	stroke	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
relatives	relative	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
primary	primary	ADJ	JJ	9	O
physicians	physician	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
twenty	twenty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
42	42	NUM	CD	7	O
%	%	NOUN	NN	9	O
men	man	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
81	81	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
76	76	NUM	CD	7	O
-	-	SYM	SYM	7	O
94	94	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
on	on	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
530	530	NUM	CD	9	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
28	28	NUM	CD	7	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
53	53	NUM	CD	7	O
major	major	ADJ	JJ	9	O
hemorrhages	hemorrhage	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
annual	annual	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
24	24	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
45	45	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
fatal	fatal	ADJ	JJ	5	O
bleeds	bleed	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
annual	annual	ADJ	JJ	5	O
stroke	stroke	NOUN	NN	5	B-Disease
rate	rate	NOUN	NN	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
major	major	ADJ	JJ	9	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
old	old	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
frail	frail	NOUN	NN	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
excluding	exclude	VERB	VBG	9	O
fatalities	fatality	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
no	no	DET	DT	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
sequelae	sequelae	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
stroke	stroke	NOUN	NN	5	B-Disease
rate	rate	NOUN	NN	9	O
on	on	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
demonstrating	demonstrate	VERB	VBG	9	O
how	how	ADV	WRB	5	O
effective	effective	ADJ	JJ	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
celecoxib	celecoxib	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
skin	skin	NOUN	NN	5	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
to	to	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
nimesulide	nimesulide	NOUN	NN	0	B-Chemical
associated	associate	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
with	with	ADP	IN	5	O
common	common	ADJ	JJ	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
steroidal	steroidal	ADJ	JJ	0	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Acetaminophen	Acetaminophen	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Nimesulide	Nimesulide	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
N	N	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
analgesic	analgesic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
antipyretic	antipyretic	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
reactions	reaction	NOUN	NNS	9	O
to	to	ADP	IN	5	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
generally	generally	ADV	RB	5	O
low	low	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
contrary	contrary	ADJ	JJ	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
steroidal	steroidal	ADJ	JJ	0	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
commonly	commonly	ADV	RB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
such	such	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Celecoxib	Celecoxib	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CE	CE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
selectivity	selectivity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
affinity	affinity	NOUN	NN	0	O
for	for	ADP	IN	5	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
enzyme	enzyme	NOUN	NN	0	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
CE	CE	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
documented	document	VERB	VBN	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
cutaneous	cutaneous	ADJ	JJ	5	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
to	to	ADP	IN	5	O
P	p	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
N	n	CCONJ	CC	9	B-Chemical
associated	associate	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
to	to	PART	TO	5	O
classic	classic	VERB	VB	5	O
NSAIDs	nsaid	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
9	9	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	O
P	p	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
N	N	PROPN	NNP	9	B-Chemical
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
associated	associated	ADJ	JJ	9	O
reactions	reaction	NOUN	NNS	9	O
to	to	ADP	IN	5	O
classic	classic	ADJ	JJ	5	O
NSAIDs	nsaid	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
P	p	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
skin	skin	NOUN	NN	5	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
was	be	VERB	VBD	9	O
based	base	VERB	VBN	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
challenge	challenge	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
was	be	VERB	VBD	9	O
blindly	blindly	ADV	RB	5	O
administered	administer	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
beginning	beginning	NOUN	NN	5	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
challenge	challenge	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
three	three	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
CE	CE	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
refracted	refract	VERB	VBN	5	O
doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
challenge	challenge	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
controlled	control	VERB	VBN	5	O
again	again	ADV	RB	9	O
after	after	ADP	IN	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
to	to	PART	TO	5	O
exclude	exclude	VERB	VB	9	O
delayed	delay	VERB	VBN	9	O
reactions	reaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
challenge	challenge	NOUN	NN	9	O
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
positive	positive	ADJ	JJ	9	O
if	if	ADP	IN	5	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
appeared	appear	VERB	VBD	9	O
:	:	PUNCT	:	9	O
erythema	erythema	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
rush	rush	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
urticaria	urticaria	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
angioedema	angioedema	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
No	no	DET	DT	9	O
reaction	reaction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
88	88	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
tolerated	tolerate	VERB	VBN	9	O
CE	CE	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
moderate	moderate	ADJ	JJ	9	O
angioedema	angioedema	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lips	lip	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
reaction	reaction	NOUN	NN	9	O
to	to	ADP	IN	5	O
CE	CE	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
among	among	ADP	IN	5	O
9	9	NUM	CD	7	O
P	p	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
highly	highly	ADV	RB	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
intolerant	intolerant	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
CE	CE	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
reasonably	reasonably	ADV	RB	5	O
safe	safe	ADJ	JJ	5	O
alternative	alternative	NOUN	NN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
tolerate	tolerate	VERB	VB	5	O
P	p	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
N	n	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
regular	regular	ADJ	JJ	5	O
analgesic	analgesic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Studies	study	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	ADJ	JJ	9	B-Chemical
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
analgesic	analgesic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ESRD	esrd	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
given	give	VERB	VBN	5	O
conflicting	conflicting	ADJ	JJ	5	O
results	result	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
this	this	DET	DT	5	O
association	association	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
with	with	ADP	IN	5	O
incident	incident	NOUN	NN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
entering	enter	VERB	VBG	5	O
the	the	DET	DT	5	O
local	local	ADJ	JJ	5	O
dialysis	dialysis	NOUN	NN	5	O
program	program	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
area	area	NOUN	NN	5	O
between	between	ADP	IN	5	O
June	June	PROPN	NNP	2	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
1995	1995	NUM	CD	2	O
and	and	CCONJ	CC	5	O
November	November	PROPN	NNP	2	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
1997	1997	NUM	CD	2	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
classified	classify	VERB	VBN	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
disease	disease	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
had	have	VERB	VBD	9	O
presumably	presumably	ADV	RB	9	O
led	lead	VERB	VBN	9	O
them	-PRON-	PRON	PRP	5	O
to	to	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Controls	control	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
patients	patient	NOUN	NNS	5	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
hospitals	hospital	NOUN	NNS	5	O
from	from	ADP	IN	9	O
where	where	ADV	WRB	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
arose	arise	VERB	VBD	9	O
,	,	PUNCT	,	9	O
also	also	ADV	RB	9	O
matched	match	VERB	VBN	9	O
by	by	ADP	IN	9	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
sex	sex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Odds	odd	NOUN	NNS	5	O
ratios	ratio	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
conditional	conditional	ADJ	JJ	9	O
logistic	logistic	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
potential	potential	ADJ	JJ	9	O
confounding	confound	VERB	VBG	5	O
factors	factor	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
whole	whole	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
population	population	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
various	various	ADJ	JJ	9	O
underlying	underlying	ADJ	JJ	5	O
diseases	disease	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Five	five	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
and	and	CCONJ	CC	5	O
eighty	eighty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
1190	1190	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
analgesic	analgesic	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
22	22	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
89	89	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
66	66	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
specific	specific	ADJ	JJ	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
risks	risk	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
56	56	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
30	30	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
60	60	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
76	76	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
pyrazolones	pyrazolone	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
80	80	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
39	39	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
63	63	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
94	94	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
57	57	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
56	56	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
nonaspirin	nonaspirin	ADJ	JJ	5	O
NSAIDs	nsaid	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
cumulated	cumulate	VERB	VBN	5	O
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
particularly	particularly	ADV	RB	5	O
high	high	ADJ	JJ	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
subset	subset	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
vascular	vascular	ADJ	JJ	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
as	as	ADP	IN	5	O
underlying	underlie	VERB	VBG	5	O
disease	disease	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
72	72	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
nonaspirin	nonaspirin	ADJ	JJ	5	O
analgesic	analgesic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
NSAIDs	NSAIDs	PROPN	NNPS	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
may	may	VERB	MD	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
for	for	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	B-Disease
QT	QT	PROPN	NNP	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
deliberate	deliberate	ADJ	JJ	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
poisoning	poisoning	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
5	5	NUM	CD	9	O
g	g	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
g	g	NOUN	NN	0	O
of	of	ADP	IN	5	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
both	both	DET	DT	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
hypocalcaemia	hypocalcaemia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
respond	respond	VERB	VB	5	O
to	to	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
gluconate	gluconate	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Growth	growth	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
protein	protein	NOUN	NN	1	O
43	43	NUM	CD	7	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
molecular	molecular	ADJ	JJ	9	O
layer	layer	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
cycloheximide	cycloheximide	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
GAP43	GAP43	PROPN	NNP	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
thought	think	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
linked	link	VERB	VBN	9	O
with	with	ADP	IN	5	O
mossy	mossy	NOUN	NN	5	O
fiber	fiber	NOUN	NN	5	O
sprouting	sprouting	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
MFS	MFS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
investigate	investigate	VERB	VB	9	O
how	how	ADV	WRB	5	O
GAP43	GAP43	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
GAP43	GAP43	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
ir	ir	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
correlates	correlate	VERB	VBZ	9	O
with	with	ADP	IN	5	O
MFS	MFS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
intensity	intensity	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
densitometry	densitometry	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
extension	extension	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
width	width	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
GAP43	GAP43	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
ir	ir	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
inner	inner	ADJ	JJ	9	O
molecular	molecular	ADJ	JJ	9	O
layer	layer	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
IML	IML	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
subject	subject	ADJ	JJ	5	O
to	to	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Pilo	Pilo	PROPN	NNP	6	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
previously	previously	ADV	RB	9	O
injected	inject	VERB	VBD	3	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
with	with	ADP	IN	5	O
cycloheximide	cycloheximide	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
CHX	CHX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
inhibit	inhibit	VERB	VB	3	O
MFS	MFS	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
CHX	CHX	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
Pilo	Pilo	PROPN	NNP	6	B-Chemical
injection	injection	NOUN	NN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
Wistar	wistar	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Pilo	Pilo	PROPN	NNP	6	B-Chemical
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
CHX	CHX	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
killed	kill	VERB	VBN	9	O
between	between	ADP	IN	5	O
30	30	NUM	CD	9	O
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
sections	section	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
processed	process	VERB	VBN	9	O
for	for	ADP	IN	5	O
GAP43	GAP43	PROPN	NNP	3	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Densitometry	Densitometry	PROPN	NNP	3	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
regarding	regard	VERB	VBG	5	O
GAP43	GAP43	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
ir	ir	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
IML	IML	PROPN	NNP	5	O
between	between	ADP	IN	5	O
Pilo	Pilo	PROPN	NNP	6	B-Chemical
,	,	PUNCT	,	9	O
CHX	CHX	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
Pilo	Pilo	PROPN	NNP	6	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
width	width	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
GAP43	GAP43	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
ir	ir	PROPN	NNP	9	O
band	band	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
IML	IML	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
CHX	CHX	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
Pilo	Pilo	PROPN	NNP	6	B-Chemical
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
larger	large	ADJ	JJR	5	O
band	band	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Pilo	Pilo	PROPN	NNP	6	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
current	current	ADJ	JJ	5	O
finding	finding	NOUN	NN	9	O
that	that	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
CHX	CHX	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
Pilo	Pilo	PROPN	NNP	6	B-Chemical
group	group	NOUN	NN	9	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
GAP43	GAP43	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
ir	ir	PROPN	NNP	9	O
band	band	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
IML	IML	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
reinforces	reinforce	NOUN	NNS	9	O
prior	prior	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
MFS	MFS	PROPN	NNP	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
GAP43	GAP43	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
ir	ir	PROPN	NNP	9	O
present	present	NOUN	NN	9	O
in	in	ADP	IN	5	O
Pilo	Pilo	PROPN	NNP	6	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
thinning	thinning	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
band	band	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
very	very	ADV	RB	5	O
narrow	narrow	ADJ	JJ	5	O
layer	layer	NOUN	NN	9	O
just	just	ADV	RB	5	O
above	above	ADP	IN	9	O
the	the	DET	DT	5	O
granule	granule	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
layer	layer	NOUN	NN	9	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
hilar	hilar	ADJ	JJ	5	O
cell	cell	NOUN	NN	3	O
projections	projection	NOUN	NNS	5	O
that	that	DET	WDT	5	O
express	express	VERB	VBP	3	O
GAP	GAP	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
43	43	NUM	CD	7	O
.	.	PUNCT	.	9	O

Nicotine	nicotine	NOUN	NN	0	B-Chemical
antagonizes	antagonize	VERB	VBZ	3	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
-	-	PUNCT	:	7	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
pentylenetetrazole	pentylenetetrazole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

RATIONALE	RATIONALE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Nicotine	nicotine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
widely	widely	ADV	RB	5	O
consumed	consume	VERB	VBN	5	O
licit	licit	ADJ	JJ	5	O
psychoactive	psychoactive	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
worldwide	worldwide	ADV	RB	5	O
.	.	PUNCT	.	9	O

Epidemiological	epidemiological	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
generally	generally	ADV	RB	5	O
used	use	VERB	VBN	5	O
concurrently	concurrently	ADV	RB	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
some	some	DET	DT	5	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
animals	animal	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
clear	clear	ADJ	JJ	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
interactions	interaction	NOUN	NNS	9	O
between	between	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
interaction	interaction	NOUN	NN	9	O
on	on	ADP	IN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
responses	response	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
investigates	investigate	VERB	VBZ	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
another	another	DET	DT	9	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pentylenetetrazole	pentylenetetrazole	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
plus	plus	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
maze	maze	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
EPM	EPM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
test	test	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
on	on	ADP	IN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Adult	adult	ADJ	JJ	9	O
male	male	ADJ	JJ	9	O
Swiss	Swiss	PROPN	NNP	2	O
Webster	Webster	PROPN	NNP	6	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
32	32	NUM	CD	7	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
saline	saline	VERB	VB	0	O
10	10	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
70	70	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
pentylenetetrazole	pentylenetetrazole	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
injections	injection	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
for	for	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
closed	closed	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
arm	arm	NOUN	NN	5	O
time	time	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
entries	entry	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
EPM	EPM	PROPN	NNP	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
min	min	NOUN	NN	0	O
session	session	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
for	for	ADP	IN	5	O
individual	individual	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
protocol	protocol	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
EPM	EPM	PROPN	NNP	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Nicotine	Nicotine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
itself	-PRON-	PRON	PRP	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
any	any	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
EPM	EPM	PROPN	NNP	9	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
70	70	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
pentylenetetrazole	pentylenetetrazole	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
produced	produce	VERB	VBD	9	O
an	an	DET	DT	5	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
apparent	apparent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
arm	arm	NOUN	NN	5	O
time	time	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
entry	entry	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nicotine	Nicotine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
pretreatment	pretreatment	NOUN	NN	0	O
blocked	block	VERB	VBD	3	O
the	the	DET	DT	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
-	-	PUNCT	:	7	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
pentylenetetrazole	pentylenetetrazole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
combinations	combination	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
any	any	DET	DT	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
antagonistic	antagonistic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
specific	specific	ADJ	JJ	9	O
to	to	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
instead	instead	ADV	RB	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
specific	specific	ADJ	JJ	9	O
anxiolytic	anxiolytic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
extend	extend	VERB	VB	9	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
term	term	NOUN	NN	5	O
hormone	hormone	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
perimenopausal	perimenopausal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Hormone	hormone	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
HT	HT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
controlling	control	VERB	VBG	9	O
menopausal	menopausal	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
also	also	ADV	RB	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
dementia	dementia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
women	woman	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
evidence	evidence	NOUN	NN	9	O
supporting	support	VERB	VBG	9	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
for	for	ADP	IN	5	O
these	these	DET	DT	5	O
indications	indication	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
largely	largely	ADV	RB	9	O
observational	observational	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
HT	HT	PROPN	NNP	9	O
on	on	ADP	IN	5	O
mortality	mortality	NOUN	NN	5	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
stroke	stroke	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
transient	transient	ADJ	JJ	9	B-Disease
ischaemic	ischaemic	ADJ	JJ	5	I-Disease
attacks	attack	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
colorectal	colorectal	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
gallbladder	gallbladder	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
dementia	dementia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
fractures	fracture	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

SEARCH	SEARCH	PROPN	NNP	2	O
STRATEGY	strategy	NOUN	NN	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
searched	search	VERB	VBD	9	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
databases	database	NOUN	NNS	5	O
up	up	ADP	IN	5	O
to	to	ADP	IN	5	O
November	November	PROPN	NNP	2	O
2004	2004	NUM	CD	2	O
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
Cochrane	Cochrane	PROPN	NNP	5	O
Menstrual	Menstrual	PROPN	NNP	5	O
Disorders	Disorders	PROPN	NNPS	2	O
and	and	CCONJ	CC	5	O
Subfertility	Subfertility	PROPN	NNP	5	O
Group	Group	PROPN	NNP	9	O
Trials	Trials	PROPN	NNPS	5	O
Register	Register	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
Cochrane	Cochrane	PROPN	NNP	5	O
Central	Central	PROPN	NNP	4	O
Register	Register	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Controlled	Controlled	PROPN	NNP	5	O
Trials	Trials	PROPN	NNPS	5	O
(	(	PUNCT	-LRB-	9	O
CENTRAL	CENTRAL	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
MEDLINE	MEDLINE	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
EMBASE	EMBASE	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Biological	Biological	PROPN	NNP	2	O
Abstracts	Abstracts	PROPN	NNPS	2	O
.	.	PUNCT	.	9	O

Relevant	relevant	ADJ	JJ	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
indexed	indexed	ADJ	JJ	5	O
journals	journal	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
conference	conference	NOUN	NN	5	O
abstracts	abstract	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
searched	search	VERB	VBN	9	O
.	.	PUNCT	.	9	O

SELECTION	selection	NOUN	NN	2	O
CRITERIA	criterion	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Randomised	randomise	VERB	VBN	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
of	of	ADP	IN	5	O
HT	HT	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
oestrogens	oestrogen	VERB	VBZ	5	B-Chemical
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
progestogens	progestogen	NOUN	NNS	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
taken	take	VERB	VBN	5	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
by	by	ADP	IN	9	O
perimenopausal	perimenopausal	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

DATA	data	ADJ	JJ	2	O
COLLECTION	collection	NOUN	NN	2	O
AND	and	CCONJ	CC	2	O
ANALYSIS	analysis	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Fifteen	fifteen	NUM	CD	9	O
RCTs	rct	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Trials	trial	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
for	for	ADP	IN	5	O
quality	quality	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
review	review	NOUN	NN	5	O
authors	author	NOUN	NNS	5	O
extracted	extract	VERB	VBD	9	O
data	datum	NOUN	NNS	5	O
independently	independently	ADV	RB	9	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
calculated	calculate	VERB	VBD	5	O
risk	risk	NOUN	NN	5	O
ratios	ratio	NOUN	NNS	9	O
for	for	ADP	IN	5	O
dichotomous	dichotomous	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
weighted	weight	VERB	VBN	5	O
mean	mean	ADJ	JJ	5	O
differences	difference	NOUN	NNS	9	O
for	for	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
heterogeneity	heterogeneity	NOUN	NN	9	O
precluded	preclude	VERB	VBD	5	O
meta	meta	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
analysis	analysis	NOUN	NN	9	O
for	for	ADP	IN	5	O
most	most	ADJ	JJS	9	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

MAIN	main	ADJ	JJ	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
All	all	DET	PDT	9	O
the	the	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
derived	derive	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
biggest	big	ADJ	JJS	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
relatively	relatively	ADV	RB	5	O
healthy	healthy	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
combined	combine	VERB	VBN	9	O
continuous	continuous	ADJ	JJ	5	O
HT	HT	PROPN	NNP	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
coronary	coronary	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
use	use	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
stroke	stroke	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
after	after	ADP	IN	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
after	after	ADP	IN	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
gallbladder	gallbladder	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
oestrogen	oestrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
only	only	ADV	RB	9	O
HT	HT	PROPN	NNP	9	O
also	also	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
gallbladder	gallbladder	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
benefits	benefit	NOUN	NNS	5	O
of	of	ADP	IN	5	O
HT	HT	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
a	a	DET	DT	5	O
decreased	decrease	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
fractures	fracture	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
colon	colon	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
with	with	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
relatively	relatively	ADV	RB	5	O
healthy	healthy	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
over	over	ADP	IN	5	O
65	65	NUM	CD	7	O
years	year	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
continuous	continuous	ADJ	JJ	5	O
combined	combine	VERB	VBN	9	O
HT	HT	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
dementia	dementia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
combined	combined	ADJ	JJ	9	O
continuous	continuous	ADJ	JJ	5	O
HT	HT	PROPN	NNP	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
trials	trial	NOUN	NNS	5	O
focussed	focusse	VERB	VBD	5	O
specifically	specifically	ADV	RB	9	O
on	on	ADP	IN	5	O
younger	young	ADJ	JJR	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
trial	trial	NOUN	NN	5	O
analysed	analyse	VERB	VBD	9	O
subgroups	subgroup	NOUN	NNS	9	O
of	of	ADP	IN	5	O
2839	2839	NUM	CD	7	O
relatively	relatively	ADV	RB	5	O
healthy	healthy	ADJ	JJ	5	O
50	50	NUM	CD	0	O
to	to	PART	TO	5	O
59	59	NUM	CD	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
combined	combine	VERB	VBN	9	O
continuous	continuous	ADJ	JJ	5	O
HT	HT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
1637	1637	NUM	CD	7	O
taking	take	VERB	VBG	5	O
oestrogen	oestrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
only	only	ADV	RB	9	O
HT	HT	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
versus	versus	ADP	IN	9	O
similar	similar	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sized	sized	ADJ	JJ	5	O
placebo	placebo	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
reported	report	VERB	VBN	9	O
was	be	VERB	VBD	9	O
for	for	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
combined	combine	VERB	VBN	9	O
continuous	continuous	ADJ	JJ	5	O
HT	HT	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
their	-PRON-	DET	PRP$	5	O
absolute	absolute	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
remained	remain	VERB	VBD	9	O
very	very	ADV	RB	5	O
low	low	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

AUTHORS	authors	NOUN	NN	2	O
'	'	PUNCT	''	9	O
CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
HT	HT	PROPN	NNP	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
indicated	indicate	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
routine	routine	ADJ	JJ	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
need	need	VERB	VBP	5	O
more	more	ADJ	JJR	5	O
evidence	evidence	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
HT	HT	PROPN	NNP	9	O
for	for	ADP	IN	5	O
menopausal	menopausal	ADJ	JJ	5	O
symptom	symptom	NOUN	NN	5	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
though	though	ADP	IN	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
relatively	relatively	ADV	RB	5	O
safe	safe	ADJ	JJ	5	O
for	for	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
younger	young	ADJ	JJR	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
liver	liver	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
461	461	NUM	CD	7	O
incidences	incidence	NOUN	NNS	5	O
submitted	submit	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Spanish	spanish	ADJ	JJ	5	O
registry	registry	NOUN	NN	5	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	PROPN	NNP	2	O
&	&	CCONJ	CC	7	O
AIMS	AIMS	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Progress	progress	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
understanding	understanding	NOUN	NN	5	O
of	of	ADP	IN	5	O
susceptibility	susceptibility	NOUN	NN	9	O
factors	factor	NOUN	NNS	9	O
to	to	ADP	IN	5	O
drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
liver	liver	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
DILI	DILI	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
outcome	outcome	NOUN	NN	5	O
predictability	predictability	NOUN	NN	5	O
are	be	VERB	VBP	5	O
hampered	hamper	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
systematic	systematic	ADJ	JJ	5	O
programs	program	NOUN	NNS	5	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
bona	bona	ADJ	JJ	1	O
fide	fide	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
cooperative	cooperative	ADJ	JJ	5	O
network	network	NOUN	NN	5	O
was	be	VERB	VBD	9	O
created	create	VERB	VBN	5	O
in	in	ADP	IN	5	O
1994	1994	NUM	CD	2	O
in	in	ADP	IN	5	O
Spain	Spain	PROPN	NNP	2	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
all	all	DET	DT	5	O
suspicions	suspicion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
DILI	DILI	PROPN	NNP	5	B-Disease
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
structured	structured	ADJ	JJ	5	O
report	report	NOUN	NN	5	O
form	form	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
liver	liver	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
mixed	mixed	ADJ	JJ	9	O
laboratory	laboratory	NOUN	NN	9	O
criteria	criterion	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
to	to	ADP	IN	5	O
histologic	histologic	ADJ	JJ	9	O
criteria	criterion	NOUN	NNS	5	O
when	when	ADV	WRB	5	O
available	available	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
causality	causality	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
was	be	VERB	VBD	9	O
centrally	centrally	ADV	RB	5	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Since	since	ADP	IN	9	O
April	April	PROPN	NNP	2	O
1994	1994	NUM	CD	2	O
to	to	ADP	IN	5	O
August	August	PROPN	NNP	2	O
2004	2004	NUM	CD	2	O
,	,	PUNCT	,	9	O
461	461	NUM	CD	7	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
570	570	NUM	CD	9	O
submitted	submit	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
involving	involve	VERB	VBG	5	O
505	505	NUM	CD	7	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
deemed	deem	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
DILI	DILI	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antiinfective	antiinfective	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
incriminated	incriminate	VERB	VBN	5	O
,	,	PUNCT	,	9	O
amoxicillin	amoxicillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
clavulanate	clavulanate	NOUN	NN	0	I-Chemical
accounting	accounting	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
whole	whole	ADJ	JJ	9	O
series	series	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
damage	damage	NOUN	NN	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
58	58	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
inversely	inversely	ADV	RB	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
age	age	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
worst	bad	ADJ	JJS	5	O
outcome	outcome	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
Cox	Cox	PROPN	NNP	9	O
regression	regression	NOUN	NN	5	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
034	034	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Indeed	indeed	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
if	if	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
jaundice	jaundice	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
presentation	presentation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
corresponding	corresponding	ADJ	JJ	9	O
figure	figure	NOUN	NN	9	O
was	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
nonjaundiced	nonjaundiced	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Factors	factor	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
female	female	ADJ	JJ	9	O
sex	sex	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
25	25	NUM	CD	9	O
;	;	SYM	SYM	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
151	151	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
hepatocellular	hepatocellular	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
;	;	SYM	SYM	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
37	37	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
009	009	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
baseline	baseline	NOUN	NN	5	O
plasma	plasma	NOUN	NN	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
value	value	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
=	=	NOUN	NNS	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
22	22	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatocellular	hepatocellular	ADJ	JJ	9	O
jaundice	jaundice	NOUN	NN	5	B-Disease
have	have	VERB	VBP	5	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
chance	chance	NOUN	NN	5	O
of	of	ADP	IN	5	O
progressing	progress	VERB	VBG	5	O
to	to	ADP	IN	5	O
death	death	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Amoxicillin	amoxicillin	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
clavulanate	clavulanate	NOUN	NN	0	I-Chemical
stands	stand	VERB	VBZ	5	O
out	out	PART	RP	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
DILI	DILI	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Morphological	morphological	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ribose	ribose	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ribose	ribose	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
myocardiopathy	myocardiopathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Adriamycin	Adriamycin	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADV	RB	0	O
evoked	evoke	VERB	VBN	5	O
fully	fully	ADV	RB	9	O
developed	develop	VERB	VBN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ribose	ribose	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
multiple	multiple	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
influence	influence	VERB	VB	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vivo	vivo	NOUN	NNS	3	O
evidences	evidence	NOUN	NNS	9	O
suggesting	suggest	VERB	VBG	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
in	in	ADP	IN	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
protection	protection	NOUN	NN	9	O
by	by	ADP	IN	9	O
erdosteine	erdosteine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aims	aim	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
were	be	VERB	VBD	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
VCM	VCM	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
that	that	DET	WDT	5	O
promotes	promote	VERB	VBZ	3	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
(	(	PUNCT	-LRB-	9	O
ROS	ROS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
erdosteine	erdosteine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
expectorant	expectorant	ADJ	JJ	4	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
also	also	ADV	RB	9	O
antioxidant	antioxidant	ADJ	JJ	0	O
properties	property	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	O
tissue	tissue	NOUN	NN	9	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
VCM	vcm	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
sham	sham	NOUN	NN	9	O
,	,	PUNCT	,	9	O
VCM	VCM	PROPN	NNP	5	B-Chemical
and	and	CCONJ	CC	5	O
VCM	VCM	PROPN	NNP	5	B-Chemical
plus	plus	CCONJ	CC	9	O
erdosteine	erdosteine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

VCM	VCM	PROPN	NNP	5	B-Chemical
was	be	VERB	VBD	9	O
administrated	administrate	VERB	VBN	0	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
200mgkg	200mgkg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
twice	twice	ADV	RB	9	O
daily	daily	ADJ	JJ	5	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Erdosteine	Erdosteine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
orally	orally	ADV	RB	0	O
.	.	PUNCT	.	9	O

VCM	vcm	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
rats	rat	NOUN	NNS	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
urinary	urinary	ADJ	JJ	9	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
acetyl	acetyl	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
d	d	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glucosaminidase	glucosaminidase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
NAG	NAG	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	O
excretion	excretion	NOUN	NN	0	O
but	but	CCONJ	CC	9	O
decreased	decrease	VERB	VBD	9	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
SOD	SOD	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
catalase	catalase	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
CAT	CAT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
activities	activity	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Erdosteine	erdosteine	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
with	with	ADP	IN	5	O
VCM	VCM	PROPN	NNP	5	B-Chemical
injections	injection	NOUN	NNS	9	O
caused	cause	VERB	VBN	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
urinary	urinary	NOUN	NN	9	O
NAG	NAG	PROPN	NNP	0	O
excretion	excretion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
SOD	SOD	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
CAT	cat	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
VCM	VCM	PROPN	NNP	5	B-Chemical
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

Erdosteine	Erdosteine	PROPN	NNP	0	B-Chemical
showed	show	VERB	VBD	9	O
histopathological	histopathological	ADJ	JJ	9	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
VCM	VCM	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
dilatation	dilatation	NOUN	NN	5	O
of	of	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
lumens	lumen	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
extensive	extensive	ADJ	JJ	5	O
epithelial	epithelial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
vacuolization	vacuolization	NOUN	NN	3	O
,	,	PUNCT	,	9	O
atrophy	atrophy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
desquamation	desquamation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
VCM	VCM	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
erdosteine	erdosteine	ADJ	JJ	0	B-Chemical
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Erdosteine	Erdosteine	PROPN	NNP	0	B-Chemical
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
plays	play	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
VCM	VCM	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
with	with	ADP	IN	5	O
erdosteine	erdosteine	NOUN	NN	0	B-Chemical
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
VCM	VCM	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
kidney	kidney	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
both	both	CCONJ	CC	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
biochemical	biochemical	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
histological	histological	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Gemfibrozil	Gemfibrozil	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
hyperlipoproteinemias	hyperlipoproteinemias	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
observational	observational	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
21	21	NUM	CD	7	O
months	month	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
patient	patient	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
,	,	PUNCT	,	9	O
gemfibrozil	gemfibrozil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
80	80	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
mixed	mixed	ADJ	JJ	9	O
hyperlipidemia	hyperlipidemia	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
68	68	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
had	have	VERB	VBD	9	O
atherosclerotic	atherosclerotic	ADJ	JJ	3	B-Disease
vascular	vascular	ADJ	JJ	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
ideal	ideal	ADJ	JJ	5	O
lipid	lipid	NOUN	NN	0	O
targets	target	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
reached	reach	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
density	density	NOUN	NN	9	O
lipoprotein	lipoprotein	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
LDL	LDL	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
130	130	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
density	density	NOUN	NN	9	O
lipoprotein	lipoprotein	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HDL	HDL	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
35	35	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
/	/	PUNCT	,	9	O
HDL	HDL	PROPN	NNP	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
diet	diet	NOUN	NN	9	O
plus	plus	CCONJ	CC	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
gemfibrozil	gemfibrozil	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
primarily	primarily	ADV	RB	9	O
20	20	NUM	CD	9	O
or	or	CCONJ	CC	5	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
visits	visit	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
scheduled	schedule	VERB	VBN	5	O
with	with	ADP	IN	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
every	every	DET	DT	5	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
average	average	NOUN	NN	5	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
visits	visit	NOUN	NNS	5	O
per	per	ADP	IN	9	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
741	741	NUM	CD	7	O
batteries	battery	NOUN	NNS	5	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
714	714	NUM	CD	7	O
creatine	creatine	NOUN	NN	0	B-Chemical
phosphokinase	phosphokinase	NOUN	NN	0	O
levels	level	NOUN	NNS	3	O
measured	measure	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
446	446	NUM	CD	7	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
gamma	gamma	NOUN	NN	9	O
glutamyl	glutamyl	ADJ	JJ	0	O
transferase	transferase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
normal	normal	ADJ	JJ	9	O
limit	limit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
714	714	NUM	CD	7	O
creatine	creatine	NOUN	NN	0	B-Chemical
phosphokinase	phosphokinase	NOUN	NN	0	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
were	be	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
;	;	PUNCT	:	9	O
only	only	ADV	RB	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
normal	normal	ADJ	JJ	9	O
limit	limit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
total	total	ADJ	JJ	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
decreased	decrease	VERB	VBD	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
from	from	ADP	IN	9	O
255	255	NUM	CD	7	O
to	to	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
decreased	decrease	VERB	VBD	9	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
from	from	ADP	IN	9	O
236	236	NUM	CD	7	O
to	to	ADP	IN	5	O
154	154	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
LDL	LDL	PROPN	NNP	0	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
decreased	decrease	VERB	VBD	9	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
from	from	ADP	IN	9	O
176	176	NUM	CD	7	O
to	to	ADP	IN	5	O
131	131	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
/	/	PUNCT	,	9	O
HDL	HDL	PROPN	NNP	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
ratio	ratio	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
from	from	ADP	IN	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
.	.	PUNCT	.	9	O

Myositis	Myositis	PROPN	NNP	2	B-Disease
,	,	PUNCT	,	9	O
attributable	attributable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
combination	combination	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
enough	enough	ADV	RB	5	O
to	to	PART	TO	5	O
discontinue	discontinue	VERB	VB	5	O
it	-PRON-	PRON	PRP	5	O
,	,	PUNCT	,	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
with	with	ADP	IN	5	O
concurrent	concurrent	ADJ	JJ	5	O
high	high	ADJ	JJ	9	O
creatine	creatine	NOUN	NN	0	B-Chemical
phosphokinase	phosphokinase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
769	769	NUM	CD	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
liter	liter	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
no	no	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
myoglobinuria	myoglobinuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Does	do	VERB	VBZ	5	O
domperidone	domperidone	NOUN	NN	0	B-Chemical
potentiate	potentiate	VERB	VB	3	O
mirtazapine	mirtazapine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
restless	restless	NOUN	NN	5	B-Disease
legs	leg	NOUN	NNS	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
?	?	PUNCT	.	5	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
now	now	ADV	RB	5	O
evidence	evidence	NOUN	NN	9	O
to	to	PART	TO	5	O
suggest	suggest	VERB	VB	9	O
a	a	DET	DT	5	O
central	central	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
restless	restless	ADJ	JJ	5	B-Disease
legs	leg	NOUN	NNS	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
RLS	RLS	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
example	example	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
RLS	RLS	PROPN	NNP	5	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
dramatically	dramatically	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
by	by	ADP	IN	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
and	and	CCONJ	CC	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
agonists	agonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
central	central	ADJ	JJ	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
can	can	VERB	MD	5	O
induce	induce	VERB	VB	3	O
or	or	CCONJ	CC	5	O
aggravate	aggravate	VERB	VB	9	O
RLS	RLS	PROPN	NNP	5	B-Disease
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
previous	previous	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
regarding	regard	VERB	VBG	5	O
whether	whether	ADP	IN	9	O
domperidone	domperidone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
can	can	VERB	MD	5	O
also	also	ADV	RB	9	O
induce	induce	VERB	VB	3	O
or	or	CCONJ	CC	5	O
aggravate	aggravate	VERB	VB	9	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
RLS	RLS	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Mirtazapine	Mirtazapine	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
noradrenergic	noradrenergic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
specific	specific	ADJ	JJ	9	O
serotonergic	serotonergic	NOUN	NN	5	O
antidepressant	antidepressant	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
NaSSA	NaSSA	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
RLS	RLS	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
several	several	ADJ	JJ	9	O
recent	recent	ADJ	JJ	5	O
publications	publication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
report	report	VERB	VBP	5	O
here	here	ADV	RB	5	O
a	a	DET	DT	5	O
depressed	depressed	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
comorbid	comorbid	NOUN	NN	5	O
with	with	ADP	IN	5	O
postprandial	postprandial	ADJ	JJ	5	B-Disease
dyspepsia	dyspepsia	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
RLS	rls	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
mirtazapine	mirtazapine	NOUN	NN	5	B-Chemical
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
added	add	VERB	VBN	0	O
to	to	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
domperidone	domperidone	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
patient	patient	NOUN	NN	5	O
started	start	VERB	VBD	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
RLS	RLS	PROPN	NNP	5	B-Disease
only	only	ADV	RB	9	O
after	after	ADP	IN	9	O
he	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
mirtazapine	mirtazapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
his	-PRON-	DET	PRP$	5	O
RLS	RLS	PROPN	NNP	5	B-Disease
symptoms	symptom	NOUN	NNS	5	O
resolved	resolve	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
upon	upon	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
mirtazapine	mirtazapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Such	such	DET	PDT	5	O
a	a	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
mirtazapine	mirtazapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
RLS	RLS	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
support	support	VERB	VB	5	O
a	a	DET	DT	5	O
potentiating	potentiating	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
domperione	domperione	NOUN	NN	_	B-Chemical
on	on	ADP	IN	5	O
mirtazapine	mirtazapine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
RLS	rls	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
physicians	physician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
mirtazapine	mirtazapine	NOUN	NN	5	B-Chemical
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
RLS	RLS	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
individuals	individual	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
those	those	DET	DT	5	O
receiving	receive	VERB	VBG	9	O
concomitant	concomitant	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Antiandrogenic	antiandrogenic	ADJ	JJ	0	O
therapy	therapy	NOUN	NN	5	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
arterial	arterial	ADJ	JJ	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
change	change	NOUN	NN	9	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
metabolism	metabolism	NOUN	NN	9	O
by	by	ADP	IN	9	O
antiandrogen	antiandrogen	NOUN	NN	0	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
follow	follow	VERB	VBP	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
cholesterols	cholesterol	NOUN	NNS	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
C	C	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
triglycerides	triglycerides	X	FW	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
TG	TG	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
lipoproteins	lipoprotein	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
LP	LP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
apolipoproteins	apolipoprotein	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
Apo	apo	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
B	B	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
A	a	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
I	I	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
A	a	DET	DT	9	O
-	-	PUNCT	HYPH	7	O
II	II	PROPN	NNP	9	O
pro	pro	NOUN	NN	9	O
fi	fi	X	FW	9	O
les	les	X	FW	2	O
in	in	ADP	IN	5	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
of	of	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
60	60	NUM	CD	9	O
years	year	NOUN	NNS	5	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
stage	stage	NOUN	NN	9	O
:	:	PUNCT	:	9	O
T1cN0M0	T1cN0M0	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
Gleason	Gleason	PROPN	NNP	9	O
score	score	NOUN	NN	5	O
:	:	PUNCT	:	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyproterone	cyproterone	NOUN	NN	0	B-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CPA	cpa	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
surgical	surgical	ADJ	JJ	5	O
management	management	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
radiation	radiation	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Significant	significant	ADJ	JJ	9	O
decreases	decrease	NOUN	NNS	9	O
of	of	ADP	IN	5	O
HDL	HDL	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
C	C	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
Apo	Apo	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
I	I	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
Apo	Apo	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
II	II	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
VLDL	VLDL	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
CPA	cpa	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
on	on	ADP	IN	5	O
CPA	cpa	NOUN	NN	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
twenty	twenty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Ischaemic	ischaemic	ADJ	JJ	7	O
coronary	coronary	ADJ	JJ	5	B-Disease
arteriosclerosis	arteriosclerosis	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
as	as	ADP	IN	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
CPA	cpa	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
mediated	mediate	VERB	VBN	3	O
through	through	ADP	IN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
HDL	HDL	PROPN	NNP	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
Apo	Apo	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
I	I	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
Apo	Apo	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
II	II	PROPN	NNP	9	O
pro	pro	NOUN	NN	9	O
fi	fi	X	FW	9	O
les	les	X	FW	2	O
,	,	PUNCT	,	9	O
other	other	ADJ	JJ	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
known	know	VERB	VBN	9	O
hyperglyceridemic	hyperglyceridemic	ADJ	JJ	_	B-Disease
effect	effect	NOUN	NN	9	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

5	5	PUNCT	LS	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
Fluorouracil	fluorouracil	ADJ	JJ	0	I-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluoro	fluoro	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
beta	beta	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alanine	alanine	NOUN	NN	1	I-Chemical
.	.	PUNCT	.	9	O

Cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
occurring	occur	VERB	VBG	9	O
during	during	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
malignancies	malignancy	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
herein	herein	ADV	RB	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
70	70	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
serum	serum	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluoro	fluoro	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
beta	beta	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alanine	alanine	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
FBAL	FBAL	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
unresectable	unresectable	ADJ	JJ	5	O
colon	colon	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
metastases	metastasis	NOUN	NNS	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
lung	lung	NOUN	NN	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
referred	refer	VERB	VBN	5	O
to	to	ADP	IN	5	O
us	-PRON-	PRON	PRP	5	O
for	for	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
from	from	ADP	IN	9	O
an	an	DET	DT	5	O
affiliated	affiliated	ADJ	JJ	2	O
hospital	hospital	NOUN	NN	5	O
;	;	PUNCT	:	9	O
he	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
cardiac	cardiac	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
admission	admission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
continuous	continuous	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
1000	1000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
which	which	DET	WDT	5	O
precordial	precordial	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
right	right	ADJ	JJ	5	B-Disease
bundle	bundle	NOUN	NN	5	I-Disease
branch	branch	NOUN	NN	5	I-Disease
block	block	NOUN	NN	9	I-Disease
occurred	occur	VERB	VBD	9	O
concomitantly	concomitantly	ADV	RB	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
FBAL	fbal	ADJ	JJ	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
1955	1955	NUM	CD	2	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
precordial	precordial	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
disappeared	disappear	VERB	VBD	9	O
spontaneously	spontaneously	ADV	RB	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
the	the	DET	DT	5	O
precordial	precordial	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	FU	PROPN	NNP	9	I-Chemical
was	be	VERB	VBD	9	O
abandoned	abandon	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Instead	instead	ADV	RB	5	O
,	,	PUNCT	,	9	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
derivative	derivative	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
twice	twice	DET	PDT	9	O
a	a	DET	DT	5	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
instituted	institute	VERB	VBN	5	O
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
inhibitory	inhibitory	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
dihydropyrimidine	dihydropyrimidine	NOUN	NN	0	B-Chemical
dehydrogenase	dehydrogenase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
catalyzes	catalyze	VERB	VBZ	0	O
the	the	DET	DT	5	O
degradative	degradative	NOUN	NN	3	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
into	into	ADP	IN	9	O
FBAL	FBAL	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
FBAL	fbal	ADJ	JJ	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
subsequently	subsequently	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
to	to	ADP	IN	5	O
352	352	NUM	CD	7	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
value	value	NOUN	NN	9	O
measured	measure	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thereafter	thereafter	ADV	RB	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
achieved	achieve	VERB	VBD	5	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
experience	experience	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
FBAL	FBAL	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
administered	administer	VERB	VBN	9	O
safely	safely	ADV	RB	5	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
Fanconi	Fanconi	PROPN	NNP	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
androgen	androgen	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
corticosteroid	corticosteroid	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
11	11	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
boy	boy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
Fanconi	Fanconi	PROPN	NNP	9	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
androgens	androgen	NOUN	NNS	9	B-Chemical
,	,	PUNCT	,	9	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
and	and	CCONJ	CC	5	O
transfusions	transfusion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
before	before	ADP	IN	9	O
his	-PRON-	DET	PRP$	5	O
death	death	NOUN	NN	9	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
readmitted	readmitte	VERB	VBN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
aplastic	aplastic	ADJ	JJ	5	O
crisis	crisis	NOUN	NN	5	O
with	with	ADP	IN	5	O
septicemia	septicemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
marked	mark	VERB	VBD	9	O
abnormalities	abnormality	NOUN	NNS	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
died	die	VERB	VBD	9	O
of	of	ADP	IN	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
bronchopneumonia	bronchopneumonia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
autopsy	autopsy	ADJ	JJ	5	O
peliosis	peliosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
multiple	multiple	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
which	which	DET	WDT	5	O
histologically	histologically	ADV	RB	9	O
proved	prove	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
differentiated	differentiate	VERB	VBN	3	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
contributes	contribute	VERB	VBZ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
observations	observation	NOUN	NNS	9	O
that	that	DET	WDT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
metastasizing	metastasizing	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
neoplasms	neoplasm	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
peliosis	peliosis	NOUN	NN	5	B-Disease
can	can	VERB	MD	5	O
develop	develop	VERB	VB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
androgen	androgen	NOUN	NN	3	B-Chemical
-	-	PUNCT	,	7	O
and	and	CCONJ	CC	5	O
corticosteroid	corticosteroid	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
Fanconi	Fanconi	PROPN	NNP	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
between	between	ADP	IN	5	O
monoHER	monoHER	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Despite	despite	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
known	know	VERB	VBN	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
anthracyclin	anthracyclin	NOUN	NN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
continues	continue	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

DOX	DOX	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
presumably	presumably	ADV	RB	9	O
results	result	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
free	free	ADJ	JJ	9	O
radicals	radical	NOUN	NNS	0	O
by	by	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Reactive	reactive	ADJ	JJ	0	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
particularly	particularly	ADV	RB	5	O
affect	affect	VERB	VBP	9	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
myocytes	myocyte	NOUN	NNS	3	O
because	because	ADP	IN	5	O
these	these	DET	DT	5	O
cells	cell	NOUN	NNS	3	O
seem	seem	VERB	VBP	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
poor	poor	ADJ	JJ	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
defense	defense	NOUN	NN	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
semisynthetic	semisynthetic	ADJ	JJ	0	O
flavonoid	flavonoid	NOUN	NN	0	B-Chemical
monohydroxyethylrutoside	monohydroxyethylrutoside	NOUN	NN	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
monoHER	monoHER	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
cardioprotection	cardioprotection	NOUN	NN	3	O
against	against	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
through	through	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
radical	radical	ADJ	JJ	0	O
scavenging	scavenging	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
iron	iron	NOUN	NN	0	B-Chemical
chelating	chelate	VERB	VBG	0	O
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
short	short	ADJ	JJ	5	O
final	final	ADJ	JJ	9	O
half	half	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
of	of	ADP	IN	5	O
monoHER	monoHER	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
about	about	ADV	RB	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
expected	expect	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
between	between	ADP	IN	5	O
monoHER	monoHER	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
influence	influence	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
monoHER	monoHER	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
this	this	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Six	six	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
c	c	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
monoHER	monoHER	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
or	or	CCONJ	CC	5	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
a	a	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
period	period	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
additional	additional	ADJ	JJ	9	O
observation	observation	NOUN	NN	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
sacrificed	sacrifice	VERB	VBN	3	O
.	.	PUNCT	.	9	O

Their	-PRON-	DET	PRP$	5	O
cardiac	cardiac	ADJ	JJ	5	O
tissues	tissue	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
processed	process	VERB	VBN	9	O
for	for	ADP	IN	5	O
light	light	ADJ	JJ	9	O
microscopy	microscopy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
which	which	DET	WDT	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
Billingham	Billingham	PROPN	NNP	6	O
(	(	PUNCT	-LRB-	9	O
in	in	ADP	IN	5	O
Cancer	Cancer	PROPN	NNP	2	B-Disease
Treat	Treat	PROPN	NNP	9	O
Rep	Rep	PROPN	NNP	2	O
62	62	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
865	865	NUM	CD	7	O
-	-	SYM	SYM	7	O
872	872	NUM	CD	7	O
,	,	PUNCT	,	9	O
1978	1978	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Microscopic	microscopic	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
that	that	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
alone	alone	ADV	RB	9	O
induced	induce	VERB	VBD	3	O
significant	significant	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
saline	saline	NOUN	NN	0	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
damaged	damage	VERB	VBN	9	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
21	21	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
alone	alone	ADV	RB	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
aberrant	aberrant	ADJ	JJ	3	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
monoHER	monoHER	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
ranged	range	VERB	VBN	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
019	019	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
by	by	ADP	IN	9	O
adding	add	VERB	VBG	0	O
monoHER	monoher	NOUN	NN	0	B-Chemical
before	before	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
reduction	reduction	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
depend	depend	VERB	VB	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
between	between	ADP	IN	5	O
monoHER	monoHER	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
345	345	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
outpatient	outpatient	NOUN	NN	5	O
clinical	clinical	ADJ	JJ	5	O
setting	set	VERB	VBG	5	O
monoHER	monoher	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
administered	administer	VERB	VBN	9	O
shortly	shortly	ADV	RB	9	O
before	before	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
during	during	ADP	IN	5	O
bepridil	bepridil	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
for	for	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
flutter	flutter	ADV	RB	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Bepridil	Bepridil	PROPN	NNP	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
Bpd	Bpd	PROPN	NNP	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
attracted	attract	VERB	VBN	5	O
attention	attention	NOUN	NN	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AF	AF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
atrial	atrial	NOUN	NN	5	B-Disease
flutter	flutter	ADV	RB	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AFL	AFL	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
Tdp	Tdp	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Adverse	Adverse	PROPN	NNP	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Bpd	Bpd	PROPN	NNP	_	B-Chemical
requiring	require	VERB	VBG	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Bpd	Bpd	PROPN	NNP	_	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
459	459	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
361	361	NUM	CD	7	O
males	male	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
63	63	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
years	year	NOUN	NNS	5	O
old	old	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
comprising	comprise	VERB	VBG	9	O
378	378	NUM	CD	7	O
AF	AF	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
81	81	NUM	CD	7	O
AFL	AFL	PROPN	NNP	5	B-Disease
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
atrial	atrial	ADJ	JJ	5	O
dimension	dimension	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
LAD	LAD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
66	66	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
11	11	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
40	40	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
mm	mm	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
19	19	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
marked	mark	VERB	VBN	9	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
55	55	NUM	CD	7	O
s	s	NOUN	NN	9	O
in	in	ADP	IN	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
40	40	NUM	CD	9	O
beats	beat	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
dizziness	dizziness	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
general	general	ADJ	JJ	5	O
fatigue	fatigue	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
each	each	DET	DT	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
4	4	NUM	CD	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
Tdp	Tdp	PROPN	NNP	9	B-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
triggering	triggering	NOUN	NN	9	O
factors	factor	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Tdp	tdp	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
hypokalemia	hypokalemia	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
sudden	sudden	ADJ	JJ	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
backgrounds	background	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
Tdp	tdp	NOUN	NN	9	B-Disease
other	other	ADJ	JJ	5	O
than	than	ADP	IN	5	O
LAD	LAD	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
larger	large	ADJ	JJR	5	O
and	and	CCONJ	CC	5	O
older	old	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Tdp	Tdp	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Careful	careful	ADJ	JJ	5	O
observation	observation	NOUN	NN	9	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
ECG	ECG	PROPN	NNP	5	O
should	should	VERB	MD	5	O
always	always	ADV	RB	5	O
be	be	VERB	VB	5	O
done	do	VERB	VBN	9	O
during	during	ADP	IN	5	O
Bpd	Bpd	PROPN	NNP	_	B-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Enhanced	enhanced	ADJ	JJ	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
transgenic	transgenic	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
previously	previously	ADV	RB	9	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
permanent	permanent	ADJ	JJ	5	O
deficiency	deficiency	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
RAS	RAS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
baroreflex	baroreflex	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
aimed	aim	VERB	VBD	5	O
at	at	ADP	IN	9	O
studying	study	VERB	VBG	5	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
RAS	RAS	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
reactivity	reactivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
AR	ar	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
agonist	agonist	NOUN	NN	3	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Iso	Iso	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Transgenic	transgenic	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
TGR	TGR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
isolated	isolate	VERB	VBN	9	O
hearts	heart	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
Iso	Iso	PROPN	NNP	0	B-Chemical
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
LV	LV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
maximal	maximal	ADJ	JJ	9	O
contraction	contraction	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
dP	dP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dt	dt	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
max	max	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
TGR	TGR	PROPN	NNP	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
SD	SD	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

LV	LV	PROPN	NNP	9	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
Iso	Iso	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
TGR	TGR	PROPN	NNP	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
SD	sd	NOUN	NN	7	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
in	in	ADP	IN	5	O
g	g	NOUN	NN	0	O
LV	LV	PROPN	NNP	9	O
wt	wt	NOUN	NN	3	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
body	body	NOUN	NN	5	O
wt	wt	NOUN	NN	3	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
28	28	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
004	004	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
24	24	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
004	004	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
greater	great	ADJ	JJR	5	O
LV	LV	PROPN	NNP	9	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
TGR	TGR	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
more	more	ADV	RBR	5	O
pronounced	pronounced	ADJ	JJ	9	O
downregulation	downregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
AR	ar	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
LV	LV	PROPN	NNP	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
AR	ar	NOUN	NN	9	O
kinase	kinase	NUM	CD	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
SD	SD	PROPN	NNP	7	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HR	hr	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
AR	ar	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBN	3	O
in	in	ADP	IN	5	O
TGR	TGR	PROPN	NNP	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
SD	sd	NOUN	NN	7	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
-	-	PUNCT	:	7	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
parasympathetic	parasympathetic	ADJ	JJ	5	O
blockade	blockade	NOUN	NN	3	O
by	by	ADP	IN	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
HR	HR	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
strains	strain	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
TGR	TGR	PROPN	NNP	9	O
are	be	VERB	VBP	5	O
more	more	ADV	RBR	5	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
AR	ar	NOUN	NN	9	O
agonist	agonist	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
inotropic	inotropic	ADJ	JJ	5	I-Disease
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	PART	TO	5	O
chronically	chronically	ADV	RB	9	O
low	low	ADJ	JJ	9	O
sympathetic	sympathetic	ADJ	JJ	5	O
outflow	outflow	NOUN	NN	5	O
directed	direct	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
long	long	ADJ	JJ	5	B-Disease
QT	QT	PROPN	NNP	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
methadone	methadone	NOUN	NN	5	B-Chemical
:	:	PUNCT	:	9	O
high	high	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
in	in	ADP	IN	5	O
hospitalized	hospitalize	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
long	long	ADJ	JJ	5	B-Disease
QT	QT	PROPN	NNP	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Methadone	Methadone	PROPN	NNP	7	B-Chemical
prolongs	prolong	VERB	VBZ	9	O
the	the	DET	DT	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
inpatient	inpatient	NOUN	NN	5	O
setting	setting	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
QT	QT	PROPN	NNP	5	B-Disease
interval	interval	ADJ	JJ	5	I-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
dose	dose	NOUN	NN	9	O
dependence	dependence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
cofactors	cofactor	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
remain	remain	VERB	VBP	9	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
systematic	systematic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
retrospective	retrospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
comparing	compare	VERB	VBG	9	O
active	active	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
former	former	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
methadone	methadone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
not	not	ADV	RB	5	O
receiving	receive	VERB	VBG	9	O
methadone	methadone	NOUN	NN	5	B-Chemical
among	among	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
hospitalized	hospitalize	VERB	VBN	5	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
tertiary	tertiary	ADJ	JJ	9	O
care	care	NOUN	NN	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
167	167	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
methadone	methadone	NOUN	NN	5	B-Chemical
fulfilled	fulfil	VERB	VBD	5	O
the	the	DET	DT	5	O
inclusion	inclusion	NOUN	NN	5	O
criteria	criterion	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
80	80	NUM	CD	9	O
injection	injection	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
not	not	ADV	RB	5	O
receiving	receive	VERB	VBG	9	O
methadone	methadone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
demographic	demographic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
biological	biological	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
variables	variable	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Among	among	ADP	IN	9	O
167	167	NUM	CD	7	O
methadone	methadone	NOUN	NN	5	B-Chemical
maintenance	maintenance	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
QTc	qtc	ADJ	JJ	5	O
prolongation	prolongation	NOUN	NN	9	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
50	50	NUM	CD	0	O
second	second	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
longer	longer	ADV	RBR	5	O
was	be	VERB	VBD	9	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
80	80	NUM	CD	9	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
group	group	NOUN	NN	9	O
presented	present	VERB	VBD	5	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

QTc	qtc	ADJ	JJ	5	O
length	length	NOUN	NN	9	O
was	be	VERB	VBD	9	O
weakly	weakly	ADV	RB	9	O
but	but	CCONJ	CC	9	O
significantly	significantly	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Spearman	spearman	NOUN	NN	5	O
rank	rank	NOUN	NN	5	O
correlation	correlation	NOUN	NN	9	O
coefficient	coefficient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
20	20	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Multivariate	multivariate	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
allowed	allow	VERB	VBD	9	O
attribution	attribution	NOUN	NN	5	O
of	of	ADP	IN	5	O
31	31	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
QTc	qtc	ADJ	JJ	5	O
variability	variability	NOUN	NN	5	O
to	to	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
dose	dose	VERB	VB	9	O
,	,	PUNCT	,	9	O
cytochrome	cytochrome	ADJ	JJ	0	O
P	P	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
450	450	NUM	CD	9	O
3A4	3a4	NUM	CD	0	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
altered	altered	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
QT	QT	PROPN	NNP	5	B-Disease
interval	interval	ADJ	JJ	5	I-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
maintenance	maintenance	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
hospitalized	hospitalize	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
tertiary	tertiary	ADJ	JJ	9	O
care	care	NOUN	NN	5	O
center	center	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
frequent	frequent	ADJ	JJ	5	O
finding	finding	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Methadone	Methadone	PROPN	NNP	7	B-Chemical
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
cytochrome	cytochrome	ADJ	JJ	0	O
P	P	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
450	450	NUM	CD	9	O
3A4	3a4	NUM	CD	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
contribute	contribute	VERB	VBP	9	O
to	to	ADP	IN	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	B-Disease
QT	QT	PROPN	NNP	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
can	can	VERB	MD	5	O
occur	occur	VERB	VB	5	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	no	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
deficiency	deficiency	NOUN	NN	9	O
:	:	PUNCT	:	9	O
focus	focus	VERB	VB	5	O
on	on	ADP	IN	5	O
venous	venous	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
endothelial	endothelial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	no	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
hallmark	hallmark	NOUN	NN	9	O
of	of	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Experimental	experimental	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
created	create	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
removal	removal	NOUN	NN	9	O
of	of	ADP	IN	5	O
NO	no	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
involves	involve	VERB	VBZ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	O
arterial	arterial	ADJ	JJ	5	O
vasodilator	vasodilator	NOUN	NN	0	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
include	include	VERB	VBP	5	O
augmented	augmented	ADJ	JJ	9	O
endothelin	endothelin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
ET	ET	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
release	release	NOUN	NN	9	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBD	9	O
sympathetic	sympathetic	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
elevated	elevated	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
hypothesized	hypothesize	VERB	VBD	9	O
that	that	ADP	IN	5	O
increased	increase	VERB	VBD	9	O
venous	venous	ADJ	JJ	5	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
venomotor	venomotor	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
tone	tone	NOUN	NN	5	O
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
Nomega	Nomega	PROPN	NNP	_	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitro	nitro	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
LNNA	LNNA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
through	through	ADP	IN	9	O
these	these	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
NO	no	NOUN	NN	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
inhibitor	inhibitor	NOUN	NN	3	O
LNNA	LNNA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
in	in	ADP	IN	5	O
drinking	drinking	NOUN	NN	5	O
water	water	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
of	of	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
119	119	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
194	194	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
in	in	ADP	IN	5	O
LNNA	LNNA	PROPN	NNP	0	B-Chemical
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Carotid	carotid	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
vena	vena	NOUN	NN	5	O
cava	cava	NOUN	NN	5	O
were	be	VERB	VBD	9	O
removed	remove	VERB	VBN	9	O
for	for	ADP	IN	5	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
isometric	isometric	ADJ	JJ	5	O
contraction	contraction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Maximal	maximal	ADJ	JJ	9	O
contraction	contraction	NOUN	NN	9	O
to	to	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
modestly	modestly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
arteries	artery	NOUN	NNS	5	O
from	from	ADP	IN	9	O
LNNA	LNNA	PROPN	NNP	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
contraction	contraction	NOUN	NN	9	O
to	to	ADP	IN	5	O
ET	ET	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
54	54	NUM	CD	7	O
%	%	NOUN	NN	9	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Maximum	maximum	ADJ	JJ	9	O
contraction	contraction	NOUN	NN	9	O
of	of	ADP	IN	5	O
vena	vena	NOUN	NN	5	O
cava	cava	NOUN	NN	5	O
to	to	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
37	37	NUM	CD	9	O
%	%	NOUN	NN	9	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
also	also	ADV	RB	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
ET	ET	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
circulatory	circulatory	ADJ	JJ	5	O
filling	filling	NOUN	NN	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
measure	measure	NOUN	NN	5	O
of	of	ADP	IN	5	O
venomotor	venomotor	NOUN	NN	9	O
tone	tone	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
elevated	elevate	VERB	VBN	9	O
in	in	ADP	IN	5	O
LNNA	LNNA	PROPN	NNP	0	B-Chemical
hypertension	hypertension	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
LNNA	LNNA	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
scavenger	scavenger	NOUN	NN	0	O
tempol	tempol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
300	300	NUM	CD	0	O
micromol	micromol	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
IV	IV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
but	but	CCONJ	CC	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
LNNA	LNNA	PROPN	NNP	0	B-Chemical
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
18	18	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
26	26	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
54	54	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
ganglionic	ganglionic	ADJ	JJ	3	O
blockade	blockade	NOUN	NN	3	O
with	with	ADP	IN	5	O
hexamethonium	hexamethonium	NOUN	NN	0	B-Chemical
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
LNNA	LNNA	PROPN	NNP	0	B-Chemical
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
76	76	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
35	35	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Carotid	carotid	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
vena	vena	NOUN	NNS	5	O
cava	cava	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
ganglia	ganglion	NOUN	NNS	5	O
from	from	ADP	IN	9	O
LNNA	LNNA	PROPN	NNP	0	B-Chemical
rats	rat	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
basal	basal	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
from	from	ADP	IN	9	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
while	while	ADP	IN	9	O
NO	no	DET	DT	9	B-Chemical
deficiency	deficiency	NOUN	NN	9	O
increases	increase	VERB	VBZ	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
arterial	arterial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
venous	venous	ADJ	JJ	5	O
vessels	vessel	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
impact	impact	NOUN	NN	5	O
on	on	ADP	IN	5	O
veins	vein	NOUN	NNS	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
make	make	VERB	VB	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
contribution	contribution	NOUN	NN	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Association	Association	PROPN	NNP	2	O
of	of	ADP	IN	5	O
DRD2	DRD2	PROPN	NNP	1	O
polymorphisms	polymorphism	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
chlorpromazine	chlorpromazine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
Chinese	chinese	ADJ	JJ	9	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
EPS	EPS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
most	most	ADV	RBS	9	O
commonly	commonly	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
typical	typical	ADJ	JJ	9	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
affinity	affinity	NOUN	NN	0	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
many	many	ADJ	JJ	5	O
research	research	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
genetic	genetic	ADJ	JJ	5	O
variations	variation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
DRD2	DRD2	PROPN	NNP	1	O
gene	gene	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
variations	variation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
receptor	receptor	NOUN	NN	3	O
in	in	ADP	IN	5	O
modulating	modulating	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
evaluate	evaluate	VERB	VBP	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
DRD2	DRD2	PROPN	NNP	1	O
plays	play	VERB	VBZ	9	O
in	in	ADP	IN	5	O
chlorpromazine	chlorpromazine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
EPS	EPS	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
identified	identify	VERB	VBD	9	O
seven	seven	NUM	CD	9	O
SNP	SNP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
single	single	ADJ	JJ	9	O
nucleotide	nucleotide	NOUN	NN	1	O
polymorphism	polymorphism	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
141Cins	141cins	NUM	CD	_	O
>	>	X	XX	0	O
del	del	NOUN	NN	2	O
,	,	PUNCT	,	9	O
TaqIB	TaqIB	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
TaqID	TaqID	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
Ser311Cys	Ser311Cys	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
rs6275	rs6275	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
rs6277	rs6277	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
TaqIA	TaqIA	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
DRD2	DRD2	PROPN	NNP	1	O
gene	gene	NOUN	NN	1	O
in	in	ADP	IN	5	O
146	146	NUM	CD	7	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
inpatients	inpatient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
59	59	NUM	CD	7	O
with	with	ADP	IN	5	O
EPS	EPS	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
87	87	NUM	CD	7	O
without	without	ADP	IN	9	O
EPS	EPS	PROPN	NNP	9	B-Disease
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Simpson	Simpson	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Angus	Angus	PROPN	NNP	6	O
Scale	Scale	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
treated	treat	VERB	VBD	3	O
with	with	ADP	IN	5	O
chlorpromazine	chlorpromazine	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
alleles	allele	NOUN	NNS	1	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
loci	loci	NOUN	NN	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
PCR	PCR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
polymerase	polymerase	NOUN	NN	1	O
chain	chain	NOUN	NN	9	O
reaction	reaction	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Polymorphisms	Polymorphisms	PROPN	NNP	9	O
TaqID	TaqID	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
Ser311Cys	Ser311Cys	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
rs6277	rs6277	PROPN	NNP	7	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
polymorphic	polymorphic	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
population	population	NOUN	NN	5	O
recruited	recruit	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
allele	allele	ADJ	JJ	1	O
distribution	distribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
141Cins	141cins	NUM	CD	_	O
>	>	X	XX	0	O
del	del	NOUN	NN	2	O
,	,	PUNCT	,	9	O
TaqIB	TaqIB	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
rs6275	rs6275	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
TaqIA	TaqIA	PROPN	NNP	1	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
estimated	estimate	VERB	VBN	5	O
haplotypes	haplotype	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
constituted	constitute	VERB	VBN	9	O
by	by	ADP	IN	9	O
TaqIB	TaqIB	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
rs6275	rs6275	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
TaqIA	TaqIA	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
linkage	linkage	NOUN	NN	9	O
disequilibrium	disequilibrium	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
lend	lend	VERB	VB	5	O
strong	strong	ADJ	JJ	9	O
support	support	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
view	view	NOUN	NN	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
genetic	genetic	ADJ	JJ	5	O
variation	variation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
DRD2	DRD2	PROPN	NNP	1	O
gene	gene	NOUN	NN	1	O
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
individually	individually	ADV	RB	9	O
variable	variable	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
chlorpromazine	chlorpromazine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
in	in	ADP	IN	5	O
Chinese	chinese	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
confirmed	confirm	VERB	VBD	9	O
a	a	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
DRD2	DRD2	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
EPS	EPS	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
Caucasians	Caucasians	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O

Physical	physical	ADJ	JJ	5	O
training	training	NOUN	NN	5	O
decreases	decrease	VERB	VBZ	9	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Regular	regular	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
many	many	ADJ	JJ	5	O
benefits	benefit	NOUN	NNS	5	O
for	for	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
physical	physical	ADJ	JJ	5	O
condition	condition	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
its	-PRON-	DET	PRP$	9	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
still	still	ADV	RB	5	O
controversial	controversial	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
elucidate	elucidate	VERB	VB	9	O
this	this	DET	DT	5	O
problem	problem	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
have	have	VERB	VBP	5	O
studied	study	VERB	VBN	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
physical	physical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
on	on	ADP	IN	5	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
repeated	repeat	VERB	VBN	5	O
training	training	NOUN	NN	5	O
sessions	session	NOUN	NNS	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
treadmill	treadmill	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
swimming	swimming	NOUN	NN	5	O
pool	pool	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thereafter	thereafter	ADV	RB	9	O
,	,	PUNCT	,	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
injections	injection	NOUN	NNS	9	O
in	in	ADP	IN	5	O
trained	train	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
trained	trained	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
measured	measure	VERB	VBD	9	O
:	:	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
latency	latency	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
motor	motor	NOUN	NN	5	O
sign	sign	NOUN	NN	5	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
when	when	ADV	WRB	5	O
it	-PRON-	PRON	PRP	5	O
occurred	occur	VERB	VBD	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	NOUN	NN	0	O
observation	observation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
ended	end	VERB	VBD	5	O
.	.	PUNCT	.	9	O

All	all	DET	PDT	9	O
these	these	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
regular	regular	ADJ	JJ	5	O
physical	physical	ADJ	JJ	5	O
exercises	exercise	NOUN	NNS	5	O
decrease	decrease	VERB	VBP	9	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
subsequently	subsequently	ADV	RB	9	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
ameliorate	ameliorate	VERB	VB	9	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
experimentally	experimentally	ADV	RB	9	O
induced	induce	VERB	VBN	3	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Tonic	Tonic	PROPN	NNP	5	O
dopaminergic	dopaminergic	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
impairs	impair	VERB	VBZ	9	B-Disease
associative	associative	ADJ	JJ	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Endogenous	endogenous	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
central	central	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
salience	salience	NOUN	NN	5	O
coding	code	VERB	VBG	1	O
during	during	ADP	IN	5	O
associative	associative	ADJ	JJ	5	O
learning	learning	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
precursor	precursor	NOUN	NN	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
enhances	enhance	NOUN	NNS	3	O
learning	learn	VERB	VBG	5	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
stroke	stroke	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
increases	increase	NOUN	NNS	9	O
both	both	CCONJ	CC	9	O
phasic	phasic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tonic	tonic	NOUN	NN	5	O
dopaminergic	dopaminergic	NOUN	NN	5	O
neurotransmission	neurotransmission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
mediating	mediate	VERB	VBG	9	O
the	the	DET	DT	5	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
learning	learning	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
unresolved	unresolved	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
here	here	ADV	RB	5	O
probed	probe	VERB	VBD	3	O
how	how	ADV	WRB	5	O
selective	selective	ADJ	JJ	9	O
tonic	tonic	NOUN	NN	5	O
dopaminergic	dopaminergic	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
affects	affect	VERB	VBZ	9	O
associative	associative	ADJ	JJ	5	O
learning	learning	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
trained	train	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
vocabulary	vocabulary	NOUN	NN	5	O
of	of	ADP	IN	5	O
45	45	NUM	CD	9	O
concrete	concrete	ADJ	JJ	5	O
nouns	noun	NOUN	NNS	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
training	training	NOUN	NN	5	O
days	day	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
design	design	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
tonically	tonically	ADV	RB	5	O
stimulating	stimulate	VERB	VBG	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
pergolide	pergolide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
vs	vs	ADP	IN	7	O
placebo	placebo	NOUN	NN	9	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
training	training	NOUN	NN	5	O
on	on	ADP	IN	5	O
each	each	DET	DT	5	O
training	training	NOUN	NN	5	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
agonist	agonist	NOUN	NN	3	O
significantly	significantly	ADV	RB	9	O
impaired	impair	VERB	VBD	9	B-Disease
novel	novel	ADJ	JJ	9	I-Disease
word	word	NOUN	NN	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
learning	learn	VERB	VBG	5	O
decrement	decrement	NOUN	NN	5	O
persisted	persist	VERB	VBD	9	O
up	up	PART	RP	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
training	training	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
pergolide	pergolide	NOUN	NN	0	B-Chemical
also	also	ADV	RB	9	O
showed	show	VERB	VBD	9	O
restricted	restrict	VERB	VBN	9	O
emotional	emotional	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
PLACEBO	PLACEBO	PROPN	NNP	2	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
'	'	PUNCT	``	9	O
flattened	flatten	VERB	VBN	5	O
'	'	PUNCT	''	9	O
affect	affect	VERB	VB	9	O
with	with	ADP	IN	5	O
pergolide	pergolide	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
learning	learn	VERB	VBG	5	O
inhibition	inhibition	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
tonic	tonic	NOUN	NN	5	O
occupation	occupation	NOUN	NN	5	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptors	receptor	NOUN	NNS	3	O
impairs	impair	NOUN	NNS	9	O
learning	learn	VERB	VBG	5	O
by	by	ADP	IN	9	O
competition	competition	NOUN	NN	5	O
with	with	ADP	IN	5	O
phasic	phasic	ADJ	JJ	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
signals	signal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
phasic	phasic	NOUN	NN	5	O
signaling	signaling	NOUN	NN	3	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
enhances	enhance	NOUN	NNS	3	O
associative	associative	ADJ	JJ	5	O
learning	learning	NOUN	NN	5	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
stroke	stroke	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Minocycline	Minocycline	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
fulfilling	fulfil	VERB	VBG	5	O
the	the	DET	DT	5	O
criteria	criterion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
polyarteritis	polyarteritis	ADJ	JJ	5	B-Disease
nodosa	nodosa	NOUN	NN	4	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
47	47	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
taking	take	VERB	VBG	5	O
minocycline	minocycline	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
palmoplantar	palmoplantar	NOUN	NN	5	B-Disease
pustulosis	pustulosis	NOUN	NN	5	I-Disease
developed	develop	VERB	VBN	5	O
fever	fever	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
myalgias	myalgias	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
polyneuropathy	polyneuropathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
testicular	testicular	ADJ	JJ	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	O
C	c	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
reactive	reactive	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
CRP	CRP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Neither	neither	DET	DT	9	O
myeloperoxidase	myeloperoxidase	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
nor	nor	CCONJ	CC	9	O
proteinase	proteinase	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
antineutrophil	antineutrophil	NOUN	NN	3	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
antibody	antibody	NOUN	NN	3	O
was	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
manifestations	manifestation	NOUN	NNS	5	O
met	meet	VERB	VBD	5	O
the	the	DET	DT	5	O
American	American	PROPN	NNP	9	O
College	College	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Rheumatology	Rheumatology	PROPN	NNP	2	O
1990	1990	NUM	CD	2	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
classification	classification	NOUN	NN	5	O
of	of	ADP	IN	5	O
polyarteritis	polyarteritis	ADJ	JJ	5	B-Disease
nodosa	nodosa	NOUN	NN	4	I-Disease
.	.	PUNCT	.	9	O

Stopping	stop	VERB	VBG	5	O
minocycline	minocycline	NOUN	NN	0	B-Chemical
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
amelioration	amelioration	NOUN	NN	9	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
normalization	normalization	NOUN	NN	5	O
of	of	ADP	IN	5	O
CRP	CRP	PROPN	NNP	9	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
minocycline	minocycline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
satisfying	satisfy	VERB	VBG	5	O
the	the	DET	DT	5	O
criteria	criterion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Differential	differential	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
for	for	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
disease	disease	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
invaluable	invaluable	ADJ	JJ	6	O
even	even	ADV	RB	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
classical	classical	ADJ	JJ	9	O
polyarteritis	polyarteritis	ADJ	JJ	5	B-Disease
nodosa	nodosa	NOUN	NN	4	I-Disease
.	.	PUNCT	.	9	O

Intramuscular	intramuscular	ADJ	JJ	0	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
immune	immune	ADJ	JJ	3	O
globulin	globulin	NOUN	NN	9	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
recurrence	recurrence	NOUN	NN	5	O
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Combined	combined	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
immune	immune	ADJ	JJ	3	O
globulin	globulin	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HBIg	HBIg	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
lamivudine	lamivudine	VERB	VB	5	B-Chemical
in	in	ADP	IN	5	O
prophylaxis	prophylaxis	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
significantly	significantly	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
the	the	DET	DT	5	O
survival	survival	NOUN	NN	9	O
of	of	ADP	IN	5	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
positive	positive	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
outcomes	outcome	NOUN	NNS	5	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HBV	HBV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
retrospective	retrospective	ADJ	JJ	5	O
chart	chart	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
organ	organ	NOUN	NN	5	O
transplant	transplant	NOUN	NN	9	O
database	database	NOUN	NN	5	O
identified	identify	VERB	VBD	9	O
51	51	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
43	43	NUM	CD	7	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
transplanted	transplant	VERB	VBN	3	O
for	for	ADP	IN	5	O
benign	benign	ADJ	JJ	5	O
HBV	HBV	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cirrhotic	cirrhotic	ADJ	JJ	5	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
between	between	ADP	IN	5	O
June	June	PROPN	NNP	2	O
2002	2002	NUM	CD	2	O
and	and	CCONJ	CC	5	O
December	December	PROPN	NNP	2	O
2004	2004	NUM	CD	2	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
survived	survive	VERB	VBN	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

HBIg	HBIg	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
intravenously	intravenously	ADV	RB	0	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
week	week	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
intramuscularly	intramuscularly	ADV	RB	0	O
thereafter	thereafter	ADV	RB	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
At	at	ADP	IN	9	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
recurrence	recurrence	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
51	51	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
51	51	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
survival	survival	NOUN	NN	9	O
was	be	VERB	VBD	9	O
88	88	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
82	82	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
after	after	ADP	IN	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
daily	daily	ADJ	JJ	5	O
oral	oral	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
before	before	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
enabled	enable	VERB	VBD	5	O
57	57	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
/	/	SYM	SYM	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
62	62	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
DNA	DNA	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
positive	positive	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
respectively	respectively	ADV	RB	9	O
to	to	PART	TO	5	O
convert	convert	VERB	VB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
negative	negative	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Intramuscular	intramuscular	ADJ	JJ	0	O
HBIg	HBIg	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Lamivudine	lamivudine	NOUN	NN	7	B-Chemical
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
intramuscular	intramuscular	ADJ	JJ	9	O
HBIg	HBIg	NOUN	NNS	3	O
can	can	VERB	MD	5	O
effectively	effectively	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
allograft	allograft	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Anticonvulsant	anticonvulsant	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
eslicarbazepine	eslicarbazepine	NOUN	NN	0	B-Chemical
acetate	acetate	ADJ	JJ	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BIA	BIA	PROPN	NNP	5	B-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	SYM	SYM	7	I-Chemical
093	093	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
microperfusion	microperfusion	NOUN	NN	5	O
of	of	ADP	IN	5	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
of	of	ADP	IN	5	O
freely	freely	ADV	RB	5	O
moving	move	VERB	VBG	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Eslicarbazepine	eslicarbazepine	NOUN	NN	0	B-Chemical
acetate	acetate	VERB	VBP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BIA	BIA	PROPN	NNP	5	B-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	SYM	SYM	7	I-Chemical
093	093	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
10	10	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acetoxy	acetoxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
10	10	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
11	11	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydro	dihydro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5H	5h	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dibenzo	dibenzo	NOUN	NN	0	I-Chemical
/	/	SYM	SYM	9	I-Chemical
b	b	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
f	f	X	XX	9	I-Chemical
/	/	SYM	SYM	9	I-Chemical
azepine	azepine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboxamide	carboxamide	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
now	now	ADV	RB	5	O
in	in	ADP	IN	5	O
Phase	Phase	PROPN	NNP	9	O
III	iii	NUM	CD	9	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
designed	design	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
improving	improve	VERB	VBG	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
structurally	structurally	ADV	RB	9	O
related	relate	VERB	VBN	9	O
drugs	drug	NOUN	NNS	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
oxcarbazepine	oxcarbazepine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
OXC	OXC	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
studied	study	VERB	VBN	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
eslicarbazepine	eslicarbazepine	NOUN	NN	0	B-Chemical
acetate	acetate	ADJ	JJ	0	I-Chemical
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
whole	whole	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
partial	partial	ADJ	JJ	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
elicited	elicit	VERB	VBN	9	O
repeatedly	repeatedly	ADV	RB	5	O
on	on	ADP	IN	5	O
different	different	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
without	without	ADP	IN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
threshold	threshold	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
seizure	seizure	NOUN	NN	5	B-Disease
patterns	pattern	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
threshold	threshold	NOUN	NN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
average	average	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
duration	duration	NOUN	NN	5	O
was	be	VERB	VBD	9	O
39	39	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
4s	4s	INTJ	UH	0	O
.	.	PUNCT	.	9	O

Pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
2h	2h	NUM	CD	0	O
before	before	ADP	IN	9	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
microperfusion	microperfusion	NOUN	NN	5	O
prevented	prevent	VERB	VBN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Lower	low	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10mg	10mg	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
suppress	suppress	VERB	VB	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
10mg	10mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
significant	significant	ADJ	JJ	9	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
duration	duration	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
8s	8s	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
seizure	seizure	VERB	VB	5	B-Disease
number	number	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
eslicarbazepine	eslicarbazepine	NOUN	NN	0	B-Chemical
acetate	acetate	ADJ	JJ	0	I-Chemical
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
/	/	SYM	SYM	9	O
EEG	EEG	PROPN	NNP	5	O
patterns	pattern	NOUN	NNS	5	O
studied	study	VERB	VBD	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
sleep	sleep	NOUN	NN	5	O
/	/	SYM	SYM	9	O
wakefulness	wakefulness	ADJ	JJ	5	O
cycle	cycle	NOUN	NN	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
prolonged	prolonged	ADJ	JJ	9	O
intake	intake	NOUN	NN	5	O
of	of	ADP	IN	5	O
slimming	slimme	VERB	VBG	5	O
pills	pill	NOUN	NNS	5	O
containing	contain	VERB	VBG	0	O
anthraquinones	anthraquinone	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

Chinese	chinese	ADJ	JJ	9	B-Chemical
herbal	herbal	ADJ	JJ	5	I-Chemical
medicine	medicine	NOUN	NN	5	O
preparations	preparation	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
widely	widely	ADV	RB	5	O
available	available	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
often	often	ADV	RB	5	O
regarded	regard	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
public	public	NOUN	NN	5	O
as	as	ADP	IN	5	O
natural	natural	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
safe	safe	ADJ	JJ	5	O
remedies	remedy	NOUN	NNS	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
medical	medical	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Nephropathy	Nephropathy	PROPN	NNP	7	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
Chinese	chinese	ADJ	JJ	9	B-Chemical
herbs	herb	NOUN	NNS	5	I-Chemical
has	have	VERB	VBZ	9	O
previously	previously	ADV	RB	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
,	,	PUNCT	,	9	O
usually	usually	ADV	RB	5	O
involving	involve	VERB	VBG	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
aristolochic	aristolochic	ADJ	JJ	0	B-Chemical
acids	acid	NOUN	NNS	0	I-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
23	23	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
prolonged	prolonged	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
proprietary	proprietary	ADJ	JJ	5	O
Chinese	chinese	ADJ	JJ	9	B-Chemical
herbal	herbal	ADJ	JJ	5	I-Chemical
slimming	slimming	NOUN	NN	5	O
pill	pill	NOUN	NN	5	O
that	that	DET	WDT	5	O
contained	contain	VERB	VBD	9	O
anthraquinone	anthraquinone	NOUN	NN	0	B-Chemical
derivatives	derivative	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
extracted	extract	VERB	VBN	9	O
from	from	ADP	IN	9	O
Rhizoma	Rhizoma	PROPN	NNP	4	O
Rhei	Rhei	PROPN	NNP	4	O
(	(	PUNCT	-LRB-	9	O
rhubarb	rhubarb	PROPN	NNP	4	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
probably	probably	ADV	RB	9	O
aggravated	aggravate	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
intake	intake	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
steroidal	steroidal	ADJ	JJ	0	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
pathology	pathology	NOUN	NN	5	O
was	be	VERB	VBD	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
hypocellular	hypocellular	ADJ	JJ	5	O
interstitial	interstitial	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Spontaneous	spontaneous	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
upon	upon	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
slimming	slimme	VERB	VBG	5	O
pills	pill	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
mild	mild	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
tubular	tubular	ADJ	JJ	9	O
atrophy	atrophy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
still	still	ADV	RB	5	O
evident	evident	ADJ	JJ	9	O
histologically	histologically	ADV	RB	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
a	a	DET	DT	5	O
causal	causal	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
anthraquinone	anthraquinone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
herbal	herbal	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
remains	remain	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
proven	prove	VERB	VBN	5	O
,	,	PUNCT	,	9	O
phytotherapy	phytotherapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
interstitial	interstitial	ADJ	JJ	9	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
present	present	VERB	VBP	9	O
with	with	ADP	IN	5	O
unexplained	unexplained	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Chloroacetaldehyde	Chloroacetaldehyde	PROPN	NNP	7	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
sulfhydryl	sulfhydryl	NOUN	NN	0	B-Chemical
reagent	reagent	ADJ	JJ	0	O
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
critical	critical	ADJ	JJ	9	O
thiol	thiol	NOUN	NN	0	B-Chemical
groups	group	NOUN	NNS	9	O
in	in	ADP	IN	5	O
ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Chloroacetaldehyde	Chloroacetaldehyde	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
CAA	CAA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
metabolite	metabolite	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
alkylating	alkylate	VERB	VBG	0	O
agent	agent	NOUN	NN	9	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
IFO	IFO	PROPN	NNP	7	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
putatively	putatively	ADV	RB	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
tumor	tumor	ADJ	JJ	3	B-Disease
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
IFO	IFO	PROPN	NNP	7	B-Chemical
.	.	PUNCT	.	9	O

Depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
sulfhydryl	sulfhydryl	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
SH	SH	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
groups	group	NOUN	NNS	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
from	from	ADP	IN	9	O
cell	cell	NOUN	NN	3	O
culture	culture	NOUN	NN	9	O
,	,	PUNCT	,	9	O
animal	animal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
work	work	NOUN	NN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
CAA	caa	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
human	human	ADJ	JJ	3	O
proximal	proximal	ADJ	JJ	9	O
tubule	tubule	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
culture	culture	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
hRPTEC	hRPTEC	PUNCT	LS	_	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
CAA	CAA	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
protein	protein	NOUN	NN	1	O
content	content	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cell	cell	NOUN	NN	3	O
number	number	NOUN	NN	9	O
,	,	PUNCT	,	9	O
LDH	LDH	PROPN	NNP	0	O
release	release	NOUN	NN	9	O
,	,	PUNCT	,	9	O
trypan	trypan	ADJ	JJ	3	B-Chemical
blue	blue	ADJ	JJ	9	I-Chemical
exclusion	exclusion	NOUN	NN	5	O
assay	assay	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
caspase	caspase	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Free	free	ADJ	JJ	9	O
thiols	thiol	NOUN	NNS	0	B-Chemical
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
method	method	NOUN	NN	5	O
of	of	ADP	IN	5	O
Ellman	Ellman	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

CAA	CAA	PROPN	NNP	9	B-Chemical
reduced	reduce	VERB	VBD	9	O
hRPTEC	hrptec	NUM	CD	_	O
cell	cell	NOUN	NN	3	O
number	number	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
loss	loss	NOUN	NN	9	O
in	in	ADP	IN	5	O
free	free	ADJ	JJ	9	O
intracellular	intracellular	ADJ	JJ	3	O
thiols	thiol	NOUN	NNS	0	B-Chemical
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
markers	marker	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

CAA	caa	NOUN	NN	9	B-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
acrolein	acrolein	VERB	VB	0	B-Chemical
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
cysteine	cysteine	ADJ	JJ	1	B-Chemical
proteases	protease	VERB	VBZ	9	O
caspase	caspase	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
caspase	caspase	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
and	and	CCONJ	CC	5	O
cathepsin	cathepsin	NOUN	NN	3	O
B	B	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Caspase	caspase	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
by	by	ADP	IN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
was	be	VERB	VBD	9	O
inhibited	inhibit	VERB	VBN	3	O
by	by	ADP	IN	9	O
CAA	CAA	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
cells	cell	NOUN	NNS	3	O
stained	stain	VERB	VBN	3	O
with	with	ADP	IN	5	O
fluorescent	fluorescent	ADJ	JJ	3	O
dyes	dye	NOUN	NNS	0	O
targeting	target	VERB	VBG	3	O
lysosomes	lysosome	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
CAA	CAA	PROPN	NNP	9	B-Chemical
induced	induce	VERB	VBD	3	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
lysosomal	lysosomal	ADJ	JJ	3	O
size	size	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
lysosomal	lysosomal	ADJ	JJ	3	O
leakage	leakage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CAA	caa	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
cysteine	cysteine	ADJ	JJ	1	B-Chemical
protease	protease	NOUN	NN	0	O
activities	activity	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
thiols	thiol	NOUN	NNS	0	B-Chemical
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
reproduced	reproduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
cell	cell	NOUN	NN	3	O
lysate	lysate	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Acidification	acidification	NOUN	NN	0	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
slowed	slow	VERB	VBD	9	O
the	the	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
of	of	ADP	IN	5	O
CAA	caa	NOUN	NN	9	B-Chemical
with	with	ADP	IN	5	O
thiol	thiol	NOUN	NN	0	B-Chemical
donors	donor	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
could	could	VERB	MD	9	O
also	also	ADV	RB	9	O
attenuate	attenuate	VERB	VB	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CAA	caa	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
markers	marker	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
thiol	thiol	NOUN	NN	0	B-Chemical
depletion	depletion	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
cysteine	cysteine	ADJ	JJ	1	B-Chemical
protease	protease	NOUN	NN	0	O
inhibition	inhibition	NOUN	NN	3	O
in	in	ADP	IN	5	O
living	live	VERB	VBG	5	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
CAA	CAA	PROPN	NNP	9	B-Chemical
directly	directly	ADV	RB	9	O
reacts	react	VERB	VBZ	0	O
with	with	ADP	IN	5	O
cellular	cellular	ADJ	JJ	3	O
protein	protein	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
protein	protein	ADJ	JJ	1	O
thiols	thiol	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
mediating	mediate	VERB	VBG	9	O
its	-PRON-	DET	PRP$	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
on	on	ADP	IN	5	O
hRPTEC	hrptec	X	ADD	_	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
acidification	acidification	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
urinary	urinary	ADJ	JJ	9	O
acidification	acidification	NOUN	NN	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
option	option	NOUN	NN	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
IFO	IFO	PROPN	NNP	7	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Stereological	stereological	ADJ	JJ	5	O
methods	method	NOUN	NNS	5	O
reveal	reveal	VERB	VBP	9	O
the	the	DET	DT	5	O
robust	robust	ADJ	JJ	5	O
size	size	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
stability	stability	NOUN	NN	9	O
of	of	ADP	IN	5	O
ectopic	ectopic	ADJ	JJ	3	O
hilar	hilar	ADJ	JJ	5	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
after	after	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
adult	adult	NOUN	NN	9	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
,	,	PUNCT	,	9	O
dentate	dentate	ADJ	JJ	3	O
granule	granule	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
neurogenesis	neurogenesis	NOUN	NN	3	O
increases	increase	VERB	VBZ	9	O
greatly	greatly	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
many	many	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
new	new	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
ectopically	ectopically	ADV	RB	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hilar	hilar	ADJ	JJ	5	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
formation	formation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
ectopic	ectopic	ADJ	JJ	3	O
hilar	hilar	ADJ	JJ	5	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
could	could	VERB	MD	9	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
that	that	DET	WDT	5	O
ultimately	ultimately	ADV	RB	5	O
develop	develop	VERB	VBP	5	O
after	after	ADP	IN	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
population	population	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
never	never	ADV	RB	5	O
been	be	VERB	VBN	9	O
quantified	quantify	VERB	VBN	9	O
,	,	PUNCT	,	9	O
so	so	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
unclear	unclear	ADJ	JJ	9	O
whether	whether	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
substantial	substantial	ADJ	JJ	9	O
enough	enough	ADV	RB	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
influence	influence	NOUN	NN	5	O
on	on	ADP	IN	5	O
epileptogenesis	epileptogenesis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
quantify	quantify	VERB	VB	9	O
this	this	DET	DT	5	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
ectopic	ectopic	ADJ	JJ	3	O
hilar	hilar	ADJ	JJ	5	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
using	use	VERB	VBG	9	O
unbiased	unbiased	ADJ	JJ	5	O
stereology	stereology	NOUN	NN	5	O
at	at	ADP	IN	9	O
different	different	ADJ	JJ	9	O
times	time	NOUN	NNS	5	O
after	after	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
hilar	hilar	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
immunoreactive	immunoreactive	ADJ	JJ	3	O
for	for	ADP	IN	5	O
Prox	Prox	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
granule	granule	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
marker	marker	NOUN	NN	3	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
optical	optical	ADJ	JJ	5	O
fractionator	fractionator	NOUN	NN	5	O
method	method	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hilar	hilar	ADJ	JJ	5	O
ectopic	ectopic	NOUN	NN	3	O
granule	granule	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
population	population	NOUN	NN	5	O
after	after	ADP	IN	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
substantial	substantial	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
stable	stable	ADJ	JJ	9	O
over	over	ADP	IN	5	O
time	time	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Interestingly	interestingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
population	population	NOUN	NN	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
behavioral	behavioral	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
with	with	ADP	IN	5	O
more	more	ADJ	JJR	5	O
ectopic	ectopic	ADJ	JJ	3	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hilus	hilus	NOUN	NN	3	O
have	have	VERB	VBP	5	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
behavioral	behavioral	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hilar	hilar	ADJ	JJ	5	O
ectopic	ectopic	NOUN	NN	3	O
granule	granule	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
population	population	NOUN	NN	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
vary	vary	VERB	VB	5	O
systematically	systematically	ADV	RB	5	O
across	across	ADP	IN	5	O
the	the	DET	DT	5	O
septotemporal	septotemporal	ADJ	JJ	5	O
axis	axis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
volume	volume	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hilus	hilus	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
provide	provide	VERB	VBP	5	O
new	new	ADJ	JJ	5	O
insight	insight	NOUN	NN	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
ectopic	ectopic	ADJ	JJ	3	O
hilar	hilar	ADJ	JJ	5	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
temporal	temporal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
galantamine	galantamine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
autistic	autistic	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
mortem	mortem	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
abnormalities	abnormality	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cholinergic	cholinergic	NOUN	NN	3	O
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
autism	autism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
galantamine	galantamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
acetylcholinesterase	acetylcholinesterase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
nicotinic	nicotinic	ADJ	JJ	0	O
receptor	receptor	NOUN	NN	3	O
modulator	modulator	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
interfering	interfere	VERB	VBG	3	O
behaviors	behavior	NOUN	NNS	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
autism	autism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Thirteen	thirteen	NUM	CD	9	O
medication	medication	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
autism	autism	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
participated	participate	VERB	VBD	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
galantamine	galantamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
rated	rate	VERB	VBN	5	O
monthly	monthly	ADV	RB	5	O
by	by	ADP	IN	9	O
parents	parent	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Aberrant	Aberrant	PROPN	NNP	3	O
Behavior	Behavior	PROPN	NNP	5	O
Checklist	Checklist	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
ABC	ABC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Conners	Conners	PROPN	NNPS	5	O
'	'	PART	POS	9	O
Parent	Parent	PROPN	NNP	5	O
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
Revised	revise	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
physician	physician	NOUN	NN	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Children	Children	PROPN	NNPS	5	O
'	'	PART	POS	9	O
s	s	ADJ	JJ	9	O
Psychiatric	Psychiatric	PROPN	NNP	5	O
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Clinical	Clinical	PROPN	NNP	5	O
Global	Global	PROPN	NNP	5	O
Impressions	Impressions	PROPN	NNPS	5	O
scale	scale	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
parent	parent	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
rated	rate	VERB	VBN	5	O
irritability	irritability	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
social	social	ADJ	JJ	5	O
withdrawal	withdrawal	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
ABC	ABC	PROPN	NNP	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
emotional	emotional	ADJ	JJ	5	O
lability	lability	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
inattention	inattention	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Conners	Conners	PROPN	NNPS	5	O
'	'	PART	POS	9	O
Parent	Parent	PROPN	NNP	5	O
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
Revised	revise	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
clinician	clinician	ADJ	JJ	5	O
ratings	rating	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
anger	anger	NOUN	NN	5	O
subscale	subscale	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Children	Children	PROPN	NNPS	5	O
'	'	PART	POS	9	O
s	s	ADJ	JJ	9	O
Psychiatric	Psychiatric	PROPN	NNP	5	O
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
participants	participant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
rated	rate	VERB	VBN	5	O
as	as	ADP	IN	5	O
responders	responder	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
improvement	improvement	NOUN	NN	5	O
scores	score	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Clinical	Clinical	PROPN	NNP	5	O
Global	Global	PROPN	NNP	5	O
Impressions	Impressions	PROPN	NNPS	5	O
scale	scale	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
galantamine	galantamine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
apart	apart	ADV	RB	9	O
from	from	ADP	IN	9	O
headaches	headache	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
open	open	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
galantamine	galantamine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
beneficial	beneficial	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
interfering	interfere	VERB	VBG	3	O
behaviors	behavior	NOUN	NNS	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
autism	autism	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
aggression	aggression	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
dyscontrol	dyscontrol	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
inattention	inattention	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Further	further	ADV	RB	9	O
controlled	control	VERB	VBN	5	O
trials	trial	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Randomized	randomize	VERB	VBN	5	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
versus	versus	ADP	IN	9	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
episode	episode	NOUN	NN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
compared	compare	VERB	VBD	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
outcomes	outcome	NOUN	NNS	5	O
for	for	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
versus	versus	ADP	IN	9	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
episode	episode	NOUN	NN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
spectrum	spectrum	NOUN	NN	9	O
disorders	disorder	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
twelve	twelve	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
male	male	NOUN	NN	9	O
;	;	PUNCT	:	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
=	=	X	XX	7	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
[	[	PUNCT	-LRB-	9	O
SD	sd	NOUN	NN	7	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
episode	episode	NOUN	NN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
schizophreniform	schizophreniform	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
schizoaffective	schizoaffective	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Response	response	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
differ	differ	VERB	VB	9	O
between	between	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
43	43	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	SYM	SYM	7	O
58	58	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
54	54	NUM	CD	7	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	PROPN	NNP	7	O
39	39	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
-	-	SYM	SYM	7	O
68	68	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
those	those	DET	DT	5	O
responding	respond	VERB	VBG	5	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
more	more	ADJ	JJR	5	O
subjects	subject	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
65	65	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
-	-	SYM	SYM	7	O
39	39	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
subsequent	subsequent	ADJ	JJ	9	O
ratings	rating	NOUN	NNS	5	O
not	not	ADV	RB	5	O
meeting	meet	VERB	VBG	5	O
response	response	NOUN	NN	9	O
criteria	criterion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Negative	negative	ADJ	JJ	7	O
symptom	symptom	NOUN	NN	5	O
outcomes	outcome	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
measures	measure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
between	between	ADP	IN	5	O
medications	medication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
symptom	symptom	NOUN	NN	5	I-Disease
severity	severity	NOUN	NN	5	O
scores	score	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Significantly	significantly	ADV	RB	9	O
more	more	ADJ	JJR	5	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
with	with	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
weight	weight	NOUN	NN	9	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
was	be	VERB	VBD	9	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Body	body	NOUN	NN	9	O
mass	mass	NOUN	NN	9	O
index	index	NOUN	NN	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
22	22	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	SYM	SYM	7	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
29	29	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
22	22	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	PROPN	NNP	7	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Clinical	clinical	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
response	response	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
more	more	ADV	RBR	5	O
stable	stable	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Olanzapine	Olanzapine	PROPN	NNP	7	B-Chemical
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
an	an	DET	DT	5	O
advantage	advantage	NOUN	NN	5	O
for	for	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
medications	medication	NOUN	NNS	5	O
caused	cause	VERB	VBD	9	O
substantial	substantial	ADJ	JJ	9	O
rapid	rapid	ADJ	JJ	5	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
with	with	ADP	IN	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Early	early	ADJ	JJ	9	O
paracentral	paracentral	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
hydroxychloroquine	hydroxychloroquine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
review	review	VERB	VB	5	O
the	the	DET	DT	5	O
natural	natural	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
ocular	ocular	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
systemic	systemic	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
hydroxychloroquine	hydroxychloroquine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
who	who	PRON	WP	5	O
attended	attend	VERB	VBD	5	O
an	an	DET	DT	5	O
ophthalmic	ophthalmic	ADJ	JJ	5	O
screening	screening	NOUN	NN	5	O
program	program	NOUN	NN	5	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Retrospective	retrospective	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Records	record	NOUN	NNS	2	O
of	of	ADP	IN	5	O
262	262	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
taking	take	VERB	VBG	5	O
hydroxychloroquine	hydroxychloroquine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
screened	screen	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Department	Department	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Ophthalmology	Ophthalmology	PROPN	NNP	2	O
were	be	VERB	VBD	9	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
262	262	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
76	76	NUM	CD	7	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
treatment	treatment	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
experienced	experience	VERB	VBD	5	O
documented	document	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
ocular	ocular	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
hydroxychloroquine	hydroxychloroquine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
taking	take	VERB	VBG	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
test	test	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
used	use	VERB	VBD	5	O
a	a	DET	DT	5	O
protocol	protocol	NOUN	NN	9	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
color	color	NOUN	NN	5	O
vision	vision	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
,	,	PUNCT	,	9	O
funduscopy	funduscopy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Humphrey	Humphrey	PROPN	NNP	6	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
visual	visual	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
testing	testing	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
appeared	appear	VERB	VBD	9	O
before	before	ADP	IN	9	O
any	any	DET	DT	5	O
corresponding	corresponding	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
other	other	ADJ	JJ	5	O
tested	tested	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
defects	defect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
reproducible	reproducible	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
parameters	parameter	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
reliable	reliable	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
hydroxychloroquine	hydroxychloroquine	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
demonstrate	demonstrate	VERB	VB	9	O
a	a	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
reaction	reaction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
retina	retina	NOUN	NN	9	O
despite	despite	ADP	IN	9	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
known	know	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Screening	screening	NOUN	NN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
Humphrey	Humphrey	PROPN	NNP	6	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
visual	visual	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
yearly	yearly	ADJ	JJ	5	O
thereafter	thereafter	ADV	RB	9	O
.	.	PUNCT	.	9	O

Peri	peri	NOUN	NN	6	O
-	-	PUNCT	HYPH	7	O
operative	operative	ADJ	JJ	5	O
atrioventricular	atrioventricular	ADJ	JJ	5	B-Disease
block	block	NOUN	NN	9	I-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
epirubicin	epirubicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
paclitaxel	paclitaxel	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
47	47	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
for	for	ADP	IN	5	O
mastectomy	mastectomy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
immediate	immediate	ADJ	JJ	5	O
latissimus	latissimus	NOUN	NN	5	O
dorsi	dorsi	ADV	RB	5	O
flap	flap	ADP	IN	5	O
reconstruction	reconstruction	NOUN	NN	5	O
having	have	VERB	VBG	5	O
been	be	VERB	VBN	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
breast	breast	NOUN	NN	3	I-Disease
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
previously	previously	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
preceding	precede	VERB	VBG	5	O
months	month	NOUN	NNS	5	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
neo	neo	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
adjuvant	adjuvant	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
epirubicin	epirubicin	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
paclitaxel	paclitaxel	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Taxol	Taxol	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
apparently	apparently	ADV	RB	9	O
uncomplicated	uncomplicate	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
a	a	DET	DT	5	O
remarkably	remarkably	ADV	RB	9	O
high	high	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
physical	physical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
bradycardic	bradycardic	ADJ	JJ	5	B-Disease
at	at	ADP	IN	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
cardiac	cardiac	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Second	second	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
Mobitz	Mobitz	PROPN	NNP	5	O
type	type	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
atrioventricular	atrioventricular	ADJ	JJ	5	B-Disease
block	block	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
on	on	ADP	IN	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
temporary	temporary	ADJ	JJ	5	O
transvenous	transvenous	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
pacing	pacing	NOUN	NN	5	O
instituted	institute	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
peri	peri	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
operative	operative	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
discuss	discuss	VERB	VBP	5	O
how	how	ADV	WRB	5	O
evidence	evidence	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
guidelines	guideline	NOUN	NNS	5	O
would	would	VERB	MD	5	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
helpful	helpful	ADJ	JJ	6	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
how	how	ADV	WRB	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
can	can	VERB	MD	5	O
exhibit	exhibit	VERB	VB	9	O
substantial	substantial	ADJ	JJ	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
develop	develop	VERB	VB	5	O
over	over	ADP	IN	5	O
many	many	ADJ	JJ	5	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
received	receive	VERB	VBN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
at	at	ADP	IN	9	O
any	any	DET	DT	5	O
time	time	NOUN	NN	5	O
should	should	VERB	MD	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
even	even	ADV	RB	5	O
if	if	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Risks	risk	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
benefits	benefit	NOUN	NNS	5	O
of	of	ADP	IN	5	O
COX	COX	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
vs	vs	ADP	IN	7	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
does	do	VERB	VBZ	9	O
their	-PRON-	DET	PRP$	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
exceed	exceed	VERB	VBP	5	O
their	-PRON-	DET	PRP$	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	O
benefit	benefit	NOUN	NN	5	O
?	?	PUNCT	.	5	O

A	a	DET	DT	9	O
retrospective	retrospective	ADJ	JJ	5	O
cohort	cohort	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
myocardial	myocardial	ADJ	JJ	9	I-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AMI	AMI	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
COX	COX	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
may	may	VERB	MD	5	O
offset	offset	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
GI	GI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
benefit	benefit	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
NS	NS	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
non	non	ADJ	JJ	9	B-Chemical
-	-	ADJ	JJ	7	I-Chemical
steroidal	steroidal	ADJ	JJ	0	I-Chemical
anti	anti	ADJ	JJ	3	I-Chemical
-	-	ADJ	JJ	7	I-Chemical
inflammatory	inflammatory	ADJ	JJ	3	I-Chemical
drugs	drug	NOUN	NNS	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
risks	risk	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hospitalization	hospitalization	NOUN	NN	5	O
for	for	ADP	IN	5	O
AMI	AMI	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
GI	GI	PROPN	NNP	9	B-Disease
bleeding	bleed	VERB	VBG	5	I-Disease
among	among	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
COX	COX	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
,	,	PUNCT	,	9	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
NSAIDs	NSAIDs	PROPN	NNPS	5	O
and	and	CCONJ	CC	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
cohort	cohort	NOUN	NN	9	O
study	study	NOUN	NN	9	O
using	use	VERB	VBG	9	O
administrative	administrative	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
65	65	NUM	CD	7	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
who	who	PRON	WP	5	O
filled	fill	VERB	VBD	9	O
a	a	DET	DT	5	O
prescription	prescription	NOUN	NN	5	O
for	for	ADP	IN	5	O
NSAID	NSAID	PROPN	NNP	5	O
or	or	CCONJ	CC	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
during	during	ADP	IN	5	O
1999	1999	NUM	CD	2	O
-	-	SYM	SYM	7	O
2002	2002	NUM	CD	2	O
.	.	PUNCT	.	9	O

Outcomes	outcome	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
using	use	VERB	VBG	9	O
Cox	Cox	PROPN	NNP	9	O
regression	regression	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
with	with	ADP	IN	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
exposures	exposure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Person	person	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
exposure	exposure	NOUN	NN	9	O
among	among	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
were	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
75	75	NUM	CD	9	O
,	,	PUNCT	,	9	O
761	761	NUM	CD	7	O
to	to	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
42	42	NUM	CD	7	O
,	,	PUNCT	,	9	O
671	671	NUM	CD	7	O
to	to	PART	TO	5	O
rofecoxib	rofecoxib	VERB	VB	5	B-Chemical
65	65	NUM	CD	7	O
,	,	PUNCT	,	9	O
860	860	NUM	CD	9	O
to	to	PART	TO	5	O
celecoxib	celecoxib	VERB	VB	3	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
37	37	NUM	CD	9	O
,	,	PUNCT	,	9	O
495	495	NUM	CD	7	O
to	to	ADP	IN	5	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
NSAIDs	NSAIDs	PROPN	NNPS	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
14	14	NUM	CD	7	O
,	,	PUNCT	,	9	O
671	671	NUM	CD	7	O
to	to	PART	TO	5	O
rofecoxib	rofecoxib	VERB	VB	5	B-Chemical
,	,	PUNCT	,	9	O
22	22	NUM	CD	7	O
,	,	PUNCT	,	9	O
875	875	NUM	CD	7	O
to	to	PART	TO	5	O
celecoxib	celecoxib	VERB	VB	3	B-Chemical
,	,	PUNCT	,	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
832	832	NUM	CD	7	O
to	to	ADP	IN	5	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
NSAIDs	NSAIDs	PROPN	NNPS	5	O
and	and	CCONJ	CC	5	O
38	38	NUM	CD	7	O
,	,	PUNCT	,	9	O
048	048	NUM	CD	7	O
to	to	PART	TO	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
adjusted	adjusted	ADJ	JJ	9	O
hazard	hazard	NOUN	NN	5	O
ratios	ratio	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
hospitalization	hospitalization	NOUN	NN	5	O
for	for	ADP	IN	5	O
AMI	AMI	PROPN	NNP	9	B-Disease
/	/	SYM	SYM	9	O
GI	GI	PROPN	NNP	9	O
vs	vs	ADP	IN	7	O
the	the	DET	DT	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
rofecoxib	rofecoxib	VERB	VB	5	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
27	27	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
42	42	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
celecoxib	celecoxib	VERB	VB	3	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
93	93	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
83	83	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
naproxen	naproxen	ADJ	JJ	0	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
59	59	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
31	31	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
93	93	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
99	99	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
38	38	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
ibuprofen	ibuprofen	VERB	VB	0	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
74	74	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
51	51	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
rofecoxib	rofecoxib	VERB	VB	5	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
73	73	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
52	52	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
98	98	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
celecoxib	celecoxib	VERB	VB	3	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
19	19	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
52	52	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
ibuprofen	ibuprofen	VERB	VB	0	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
51	51	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
95	95	NUM	CD	7	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
41	41	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
69	69	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
naproxen	naproxen	ADJ	JJ	0	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
97	97	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
88	88	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
29	29	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
42	42	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Among	among	ADP	IN	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
naproxen	naproxen	NOUN	NN	0	B-Chemical
seemed	seem	VERB	VBD	9	O
to	to	PART	TO	5	O
carry	carry	VERB	VB	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
AMI	AMI	PROPN	NNP	9	B-Disease
/	/	SYM	SYM	9	O
GI	GI	PROPN	NNP	9	B-Disease
bleeding	bleeding	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
AMI	AMI	PROPN	NNP	9	B-Disease
/	/	SYM	SYM	9	O
GI	GI	PROPN	NNP	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
celecoxib	celecoxib	NOUN	NN	3	B-Chemical
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
seemed	seem	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
better	well	ADJ	JJR	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
rofecoxib	rofecoxib	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
NS	NS	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
NSAIDs	NSAIDs	PROPN	NNPS	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
celecoxib	celecoxib	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
naproxen	naproxen	NOUN	NN	0	B-Chemical
seemed	seem	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
least	least	ADJ	JJS	9	O
toxic	toxic	ADJ	JJ	0	O
.	.	PUNCT	.	9	O

Quinine	Quinine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	B-Disease
malaria	malaria	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
that	that	ADP	IN	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	B-Disease
malaria	malaria	NOUN	NN	5	I-Disease
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
premature	premature	ADJ	JJ	9	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
contraction	contraction	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	O
while	while	ADP	IN	9	O
getting	get	VERB	VBG	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
was	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
man	man	NOUN	NN	5	O
,	,	PUNCT	,	9	O
25	25	NUM	CD	9	O
years	year	NOUN	NNS	5	O
old	old	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
hospital	hospital	NOUN	NN	5	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
fever	fever	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
chill	chill	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
jaundice	jaundice	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
fully	fully	ADV	RB	9	O
conscious	conscious	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
120	120	NUM	CD	9	O
/	/	SYM	SYM	9	O
80	80	NUM	CD	9	O
mmHg	mmHg	PROPN	NNPS	7	O
,	,	PUNCT	,	9	O
pulse	pulse	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
100	100	NUM	CD	0	O
x	x	SYM	SYM	9	O
/	/	SYM	SYM	9	O
minute	minute	NOUN	NN	5	O
,	,	PUNCT	,	9	O
regular	regular	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
laboratory	laboratory	NOUN	NN	9	O
examination	examination	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
Plasmodium	Plasmodium	PROPN	NNP	4	O
falciparum	falciparum	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
+	+	X	XX	9	O
+	+	X	XX	9	O
+	+	X	XX	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
conjugated	conjugate	VERB	VBN	0	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
36	36	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
unconjugated	unconjugate	VERB	VBN	3	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
89	89	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
52	52	NUM	CD	7	O
meq	meq	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
Patient	Patient	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
as	as	ADP	IN	5	O
severe	severe	ADJ	JJ	5	B-Disease
malaria	malaria	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
got	get	VERB	VBD	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
in	in	ADP	IN	5	O
dextrose	dextrose	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
vomitus	vomitus	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
diarrhea	diarrhea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
tinnitus	tinnitus	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
hearing	hearing	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
30	30	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
of	of	ADP	IN	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
felt	feel	VERB	VBD	5	O
palpitation	palpitation	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
electrocardiography	electrocardiography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ECG	ECG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
recording	recording	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
premature	premature	ADJ	JJ	9	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
contraction	contraction	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
PVC	PVC	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
>	>	X	XX	0	O
5	5	NUM	CD	9	O
x	x	SYM	SYM	9	O
/	/	SYM	SYM	9	O
minute	minute	NOUN	NN	5	O
,	,	PUNCT	,	9	O
trigemini	trigemini	NOUN	NNS	4	O
,	,	PUNCT	,	9	O
constant	constant	ADJ	JJ	9	O
type	type	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
sinoatrial	sinoatrial	ADJ	JJ	5	B-Disease
block	block	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
positive	positive	ADJ	JJ	9	O
U	u	NOUN	NN	9	O
wave	wave	NOUN	NN	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
lidocaine	lidocaine	ADJ	JJR	0	B-Chemical
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
intravenously	intravenously	ADV	RB	0	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
infusion	infusion	NOUN	NN	0	O
1500	1500	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
in	in	ADP	IN	5	O
dextrose	dextrose	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
/	/	SYM	SYM	9	O
24	24	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
tablet	tablet	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Quinine	quinine	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
changed	change	VERB	VBN	9	O
with	with	ADP	IN	5	O
sulfate	sulfate	NOUN	NN	0	O
quinine	quinine	NOUN	NN	0	B-Chemical
tablets	tablet	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
later	later	ADV	RB	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
felt	feel	VERB	VBD	5	O
better	better	ADV	RBR	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
PVC	PVC	PROPN	NNP	5	B-Disease
reduced	reduce	VERB	VBD	9	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
x	x	SYM	SYM	9	O
/	/	SYM	SYM	9	O
minute	minute	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
ECG	ECG	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
meq	meq	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
discharged	discharge	VERB	VBN	5	O
on	on	ADP	IN	5	O
7th	7th	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
in	in	ADP	IN	5	O
good	good	ADJ	JJ	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Quinine	Quinine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
like	like	ADP	IN	9	O
quinidine	quinidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
chincona	chincona	NOUN	NN	_	O
alkaloid	alkaloid	NOUN	NN	0	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
arrhythmic	arrhythmic	ADJ	JJ	5	B-Disease
property	property	NOUN	NN	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
pro	pro	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
arrhythmic	arrhythmic	ADJ	JJ	5	B-Disease
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
various	various	ADJ	JJ	9	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
severe	severe	ADJ	JJ	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
PVC	PVC	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
parenteral	parenteral	ADJ	JJ	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
done	do	VERB	VBN	9	O
carefully	carefully	ADV	RB	5	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
good	good	ADJ	JJ	5	O
observation	observation	NOUN	NN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
pro	pro	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
arrhythmic	arrhythmic	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
heart	heart	NOUN	NN	5	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
or	or	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
electrolyte	electrolyte	NOUN	NN	0	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
which	which	DET	WDT	5	O
frequently	frequently	ADV	RB	5	O
occurs	occur	VERB	VBZ	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
or	or	CCONJ	CC	5	O
diarrhea	diarrhea	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
malaria	malaria	NOUN	NN	5	B-Disease
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Penicillamine	penicillamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
lichenoid	lichenoid	ADJ	JJ	5	B-Disease
dermatitis	dermatitis	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
utility	utility	NOUN	NN	5	O
of	of	ADP	IN	5	O
zinc	zinc	NOUN	NN	9	B-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
Wilson	Wilson	PROPN	NNP	6	B-Disease
disease	disease	NOUN	NN	5	I-Disease
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
presentation	presentation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
anxiety	anxiety	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
SPECT	SPECT	PROPN	NNP	5	O
abnormalities	abnormality	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Wilson	Wilson	PROPN	NNP	6	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
autosomal	autosomal	ADJ	JJ	9	O
recessive	recessive	ADJ	JJ	9	O
disorder	disorder	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
copper	copper	NOUN	NN	0	B-Chemical
metabolism	metabolism	NOUN	NN	9	O
with	with	ADP	IN	5	O
consequent	consequent	ADJ	JJ	9	O
copper	copper	NOUN	NN	0	B-Chemical
accumulation	accumulation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
many	many	ADJ	JJ	5	O
tissues	tissue	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
consequent	consequent	NOUN	NN	9	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
,	,	PUNCT	,	9	I-Disease
neurologic	neurologic	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
psychiatric	psychiatric	ADJ	JJ	5	I-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
Wilson	Wilson	PROPN	NNP	6	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
liver	liver	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
;	;	PUNCT	:	9	O
moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
presenting	present	VERB	VBG	5	O
also	also	ADV	RB	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
state	state	NOUN	NN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	O
depression	depression	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
99mTc	99mtc	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
ECD	ecd	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
SPECT	SPECT	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
cortical	cortical	ADJ	JJ	5	O
hypoperfusion	hypoperfusion	NOUN	NN	5	O
in	in	ADP	IN	5	O
frontal	frontal	ADJ	JJ	5	O
lobes	lobes	NOUN	NN	5	O
,	,	PUNCT	,	9	O
more	more	ADV	RBR	5	O
marked	marked	ADJ	JJ	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
frontal	frontal	ADJ	JJ	5	O
lobe	lobe	NOUN	NN	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
penicillamine	penicillamine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
interrupted	interrupt	VERB	VBN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
lichenoid	lichenoid	ADJ	JJ	5	B-Disease
dermatitis	dermatitis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
zinc	zinc	NOUN	NN	9	B-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
permitted	permit	VERB	VBD	5	O
to	to	PART	TO	5	O
continue	continue	VERB	VB	5	O
the	the	DET	DT	5	O
successful	successful	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
without	without	ADP	IN	9	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
case	case	NOUN	NN	5	O
the	the	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
zinc	zinc	NOUN	NN	9	B-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
represented	represent	VERB	VBD	9	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
Wilson	Wilson	PROPN	NNP	6	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patient	patient	NOUN	NN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
penicillamine	penicillamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
appeared	appear	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
zinc	zinc	NOUN	NN	9	B-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
allowed	allow	VERB	VBD	9	O
us	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
other	other	ADJ	JJ	5	O
potentially	potentially	ADV	RB	5	O
toxic	toxic	ADJ	JJ	0	O
chelating	chelate	VERB	VBG	0	O
drugs	drug	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
observation	observation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
in	in	ADP	IN	5	O
line	line	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
growing	grow	VERB	VBG	9	O
evidence	evidence	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Wilson	Wilson	PROPN	NNP	6	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
Wilson	Wilson	PROPN	NNP	6	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
penicillamine	penicillamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
seem	seem	VERB	VB	5	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
this	this	DET	DT	5	O
skin	skin	NOUN	NN	5	B-Disease
lesion	lesion	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
conceivable	conceivable	ADJ	JJ	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
genetic	genetic	ADJ	JJ	5	O
factor	factor	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
better	well	ADJ	JJR	5	O
clarification	clarification	NOUN	NN	5	O
of	of	ADP	IN	5	O
Wilson	Wilson	PROPN	NNP	6	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
particular	particular	ADJ	JJ	5	O
to	to	PART	TO	5	O
differentiate	differentiate	VERB	VB	9	O
specific	specific	ADJ	JJ	9	O
therapies	therapy	NOUN	NNS	5	O
for	for	ADP	IN	5	O
different	different	ADJ	JJ	9	O
Wilson	Wilson	PROPN	NNP	6	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
phenotypes	phenotype	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
dramatic	dramatic	ADJ	JJ	9	O
drop	drop	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
prehospital	prehospital	ADJ	JJ	5	O
GTN	GTN	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
male	male	NOUN	NN	9	O
in	in	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
sixties	sixty	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
awoke	awake	VERB	VBD	5	O
with	with	ADP	IN	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
an	an	DET	DT	5	O
afternoon	afternoon	NOUN	NN	5	O
sleep	sleep	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
self	self	NOUN	NN	5	O
medicate	medicate	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
observations	observation	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
within	within	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
limits	limit	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
via	via	ADP	IN	9	O
a	a	DET	DT	5	O
face	face	NOUN	NN	5	O
mask	mask	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
GTN	GTN	PROPN	NNP	0	B-Chemical
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
experienced	experience	VERB	VBD	5	O
a	a	DET	DT	5	O
sudden	sudden	ADJ	JJ	5	O
drop	drop	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
rectified	rectify	VERB	VBN	5	O
by	by	ADP	IN	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
fluid	fluid	ADJ	JJ	5	O
challenge	challenge	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
further	further	ADJ	JJ	9	O
deterioration	deterioration	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
condition	condition	NOUN	NN	5	O
during	during	ADP	IN	5	O
transport	transport	NOUN	NN	9	O
to	to	ADP	IN	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
very	very	ADV	RB	5	O
few	few	ADJ	JJ	5	O
documented	document	VERB	VBN	9	O
case	case	NOUN	NN	5	O
like	like	ADP	IN	9	O
this	this	DET	DT	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prehospital	prehospital	ADJ	JJ	5	O
scientific	scientific	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
Bezold	Bezold	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Jarish	Jarish	PROPN	NNP	2	O
reflex	reflex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	O
walls	wall	NOUN	NNS	5	O
which	which	DET	WDT	5	O
in	in	ADP	IN	5	O
turn	turn	NOUN	NN	9	O
decreases	decrease	VERB	VBZ	9	O
sympathetic	sympathetic	ADJ	JJ	5	O
outflow	outflow	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
vasomotor	vasomotor	NOUN	NN	5	O
centre	centre	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Prehospital	prehospital	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
providers	provider	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
managing	manage	VERB	VBG	5	O
any	any	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
syncopal	syncopal	NOUN	NN	5	B-Disease
episode	episode	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
fails	fail	VERB	VBZ	9	O
to	to	PART	TO	5	O
recover	recover	VERB	VB	9	O
within	within	ADP	IN	9	O
a	a	DET	DT	5	O
reasonable	reasonable	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
frame	frame	NOUN	NN	5	O
should	should	VERB	MD	5	O
consider	consider	VERB	VB	5	O
the	the	DET	DT	5	O
Bezold	Bezold	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Jarisch	Jarisch	PROPN	NNP	6	O
reflex	reflex	VERB	VBP	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
manage	manage	VERB	VB	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
accordingly	accordingly	ADV	RB	9	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
lesion	lesion	NOUN	NN	5	O
of	of	ADP	IN	5	O
rostral	rostral	ADJ	JJ	5	O
ventrolateral	ventrolateral	ADJ	JJ	5	O
medulla	medulla	NOUN	NN	9	O
in	in	ADP	IN	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
selective	selective	ADJ	JJ	9	O
neuronal	neuronal	ADJ	JJ	3	O
lesion	lesion	NOUN	NN	5	O
of	of	ADP	IN	5	O
rostral	rostral	ADJ	JJ	5	O
ventrolateral	ventrolateral	ADJ	JJ	5	O
medulla	medulla	NOUN	NN	9	O
on	on	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
neurogenic	neurogenic	ADJ	JJ	5	O
tone	tone	NOUN	NN	5	O
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
unrestrained	unrestrained	ADJ	JJ	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
lesions	lesion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
placed	place	VERB	VBN	5	O
via	via	ADP	IN	9	O
bilateral	bilateral	ADJ	JJ	5	O
microinjections	microinjection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
nmol	nmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
200	200	NUM	CD	0	O
nl	nl	NOUN	NN	0	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartic	aspartic	ADJ	JJ	1	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
restimulation	restimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
area	area	NOUN	NN	5	O
with	with	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartic	aspartic	ADJ	JJ	1	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
15	15	NUM	CD	9	O
days	day	NOUN	NNS	9	O
postlesion	postlesion	NOUN	NN	5	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
a	a	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
day	day	NOUN	NN	9	O
postlesion	postlesion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
resting	rest	VERB	VBG	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
lesioned	lesione	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
sham	sham	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
versus	versus	ADP	IN	9	O
173	173	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Fifteen	fifteen	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RBR	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
lesioned	lesione	VERB	VBN	3	O
group	group	NOUN	NN	9	O
still	still	ADV	RB	5	O
showed	show	VERB	VBD	9	O
values	value	NOUN	NNS	5	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
sham	sham	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
150	150	NUM	CD	0	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
versus	versus	ADP	IN	9	O
167	167	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
sham	sham	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
lesioned	lesione	VERB	VBN	3	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ganglionic	ganglionic	ADJ	JJ	3	O
blocker	blocker	NOUN	NN	0	O
trimethaphan	trimethaphan	ADP	IN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
caused	cause	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
lesioned	lesione	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
sham	sham	ADJ	JJ	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
trimethaphan	trimethaphan	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
lesioned	lesione	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
32	32	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
beats	beat	NOUN	NNS	5	O
per	per	ADP	IN	9	O
minute	minute	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
a	a	DET	DT	5	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
sham	sham	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
33	33	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
beats	beat	NOUN	NNS	5	O
per	per	ADP	IN	9	O
minute	minute	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
day	day	NOUN	NN	9	O
postlesion	postlesion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
rostral	rostral	ADJ	JJ	5	O
ventrolateral	ventrolateral	ADJ	JJ	5	O
medulla	medulla	NOUN	NN	9	O
neurons	neuron	NOUN	NNS	3	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
play	play	VERB	VB	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
maintaining	maintain	VERB	VBG	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Spinal	spinal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
suprabulbar	suprabulbar	NOUN	NN	5	O
structures	structure	NOUN	NNS	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
gradual	gradual	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lesioned	lesione	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
vasospasm	vasospasm	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
multiagent	multiagent	NOUN	NN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
including	include	VERB	VBG	9	O
PEG	PEG	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
asparaginase	asparaginase	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
cytarabine	cytarabine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
reaction	reaction	NOUN	NN	9	O
to	to	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
chemotherapy	chemotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
precursor	precursor	NOUN	NN	9	O
B	b	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
ALL	ALL	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
evidenced	evidence	VERB	VBN	9	O
by	by	ADP	IN	9	O
behavioral	behavioral	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
aphasia	aphasia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
incontinence	incontinence	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
right	right	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
sided	sided	ADJ	JJ	5	O
weakness	weakness	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
diffuse	diffuse	NOUN	NN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
vasospasm	vasospasm	NOUN	NN	5	I-Disease
on	on	ADP	IN	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
angiography	angiography	NOUN	NN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
cytarabine	cytarabine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Vincristine	vincristine	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
dexamethasone	dexamethasone	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
polyethylene	polyethylene	VERB	VB	0	B-Chemical
glycol	glycol	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
asparaginase	asparaginase	NOUN	NN	0	I-Chemical
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
administered	administer	VERB	VBN	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
episode	episode	NOUN	NN	5	O
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neurologic	neurologic	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
within	within	ADP	IN	9	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
event	event	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
angiography	angiography	NOUN	NN	5	O
findings	finding	NOUN	NNS	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

Comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
valsartan	valsartan	ADJ	JJ	0	B-Chemical
/	/	SYM	SYM	9	O
hydrochlorothiazide	hydrochlorothiazide	NOUN	NN	0	B-Chemical
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
up	up	ADV	RB	5	O
to	to	ADP	IN	5	O
320	320	NUM	CD	9	O
/	/	SYM	SYM	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
versus	versus	ADP	IN	9	O
monotherapy	monotherapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
study	study	NOUN	NN	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
adults	adult	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
One	one	NUM	CD	5	O
third	third	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
attain	attain	VERB	VB	5	O
adequate	adequate	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BP	BP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
multidrug	multidrug	NOUN	NN	9	O
regimens	regimen	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
often	often	ADV	RB	5	O
required	require	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
the	the	DET	DT	5	O
lifelong	lifelong	ADJ	JJ	5	O
nature	nature	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
need	need	NOUN	NN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
therapies	therapy	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
valsartan	valsartan	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
VAL	VAL	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
hydrochlorothiazide	hydrochlorothiazide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
monotherapy	monotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
combinations	combination	NOUN	NNS	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
essential	essential	ADJ	JJ	9	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
an	an	DET	DT	5	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
parallel	parallel	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
group	group	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
essential	essential	ADJ	JJ	9	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
sitting	sit	VERB	VBG	5	O
diastolic	diastolic	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
[	[	PUNCT	-LRB-	9	O
MSDBP	MSDBP	PROPN	NNP	7	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
95	95	NUM	CD	7	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
<	<	X	XX	0	O
110	110	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
VAL	VAL	PROPN	NNP	9	B-Chemical
160	160	NUM	CD	9	O
or	or	CCONJ	CC	5	O
320	320	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
or	or	CCONJ	CC	5	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
VAL	VAL	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
160	160	NUM	CD	9	O
/	/	SYM	SYM	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
320	320	NUM	CD	9	O
/	/	SYM	SYM	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
320	320	NUM	CD	9	O
/	/	SYM	SYM	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Mean	mean	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
MSDBP	MSDBP	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
mean	mean	VERB	VB	5	O
sitting	sit	VERB	VBG	5	O
systolic	systolic	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
MSSBP	MSSBP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
core	core	NOUN	NN	9	O
study	study	NOUN	NN	9	O
end	end	NOUN	NN	9	O
point	point	NOUN	NN	5	O
.	.	PUNCT	.	9	O

VAL	VAL	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
320	320	NUM	CD	9	O
/	/	SYM	SYM	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
320	320	NUM	CD	9	O
/	/	SYM	SYM	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
were	be	VERB	VBD	9	O
further	further	ADV	RB	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
54	54	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
extension	extension	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Response	Response	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
MSDBP	MSDBP	PROPN	NNP	7	O
<	<	X	XX	0	O
90	90	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
10	10	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
decrease	decrease	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
baseline	baseline	VERB	VB	5	O
.	.	PUNCT	.	9	O

Control	Control	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
MSDBP	MSDBP	PROPN	NNP	7	O
<	<	X	XX	0	O
90	90	NUM	CD	9	O
mm	mm	NOUN	NNS	9	O
Hg	Hg	PROPN	NNP	0	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Tolerability	tolerability	NOUN	NN	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
monitoring	monitor	VERB	VBG	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
at	at	ADP	IN	9	O
randomization	randomization	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
subsequent	subsequent	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
visits	visit	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
regular	regular	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
hematology	hematology	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
chemistry	chemistry	NOUN	NN	0	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
1346	1346	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
core	core	NOUN	NN	9	O
study	study	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
734	734	NUM	CD	7	O
men	man	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
612	612	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
924	924	NUM	CD	7	O
white	white	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
291	291	NUM	CD	7	O
black	black	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
23	23	NUM	CD	7	O
Asian	asian	ADJ	JJ	4	O
,	,	PUNCT	,	9	O
108	108	NUM	CD	9	O
other	other	ADJ	JJ	5	O
;	;	PUNCT	:	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
52	52	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
years	year	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
mean	mean	VERB	VB	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
92	92	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
active	active	ADJ	JJ	9	O
treatments	treatment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
MSSBP	MSSBP	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
MSDBP	MSDBP	PROPN	NNP	7	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
core	core	ADJ	JJ	9	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
each	each	DET	DT	5	O
monotherapy	monotherapy	NOUN	NN	5	O
significantly	significantly	ADV	RB	9	O
contributing	contribute	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
VAL	VAL	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Each	each	DET	DT	5	O
combination	combination	NOUN	NN	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
MSSBP	MSSBP	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
MSDBP	MSDBP	PROPN	NNP	7	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
monotherapies	monotherapie	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
all	all	DET	DT	5	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
MSSBP	MSSBP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
MSDBP	MSDBP	PROPN	NNP	7	O
with	with	ADP	IN	5	O
VAL	VAL	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
320	320	NUM	CD	9	O
/	/	SYM	SYM	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
was	be	VERB	VBD	9	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
/	/	SYM	SYM	9	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
/	/	SYM	SYM	9	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
MSSBP	MSSBP	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
with	with	ADP	IN	5	O
VAL	VAL	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
320	320	NUM	CD	9	O
/	/	SYM	SYM	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
VAL	VAL	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
160	160	NUM	CD	9	O
/	/	SYM	SYM	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
BP	BP	PROPN	NNP	9	O
control	control	NOUN	NN	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
combination	combination	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
monotherapy	monotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
with	with	ADP	IN	5	O
VAL	VAL	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
combinations	combination	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
monotherapies	monotherapie	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
core	core	NOUN	NN	9	O
study	study	NOUN	NN	9	O
were	be	VERB	VBD	9	O
of	of	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
to	to	PART	TO	5	O
moderate	moderate	ADJ	JJ	9	O
severity	severity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
VAL	VAL	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
combinations	combination	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
extension	extension	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
797	797	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
combination	combination	NOUN	NN	9	O
therapies	therapy	NOUN	NNS	5	O
with	with	ADP	IN	5	O
VAL	VAL	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
BP	BP	PROPN	NNP	9	O
reductions	reduction	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
monotherapy	monotherapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
less	less	ADJ	JJR	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
alone	alone	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Succimer	succimer	ADJ	JJ	0	B-Chemical
chelation	chelation	NOUN	NN	0	O
improves	improve	VERB	VBZ	5	O
learning	learning	NOUN	NN	5	O
,	,	PUNCT	,	9	O
attention	attention	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
arousal	arousal	NOUN	NN	5	O
regulation	regulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
lead	lead	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
but	but	CCONJ	CC	9	O
produces	produce	VERB	VBZ	9	O
lasting	last	VERB	VBG	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
lead	lead	ADJ	JJ	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
growing	grow	VERB	VBG	9	O
pressure	pressure	NOUN	NN	5	O
for	for	ADP	IN	5	O
clinicians	clinician	NOUN	NNS	5	O
to	to	PART	TO	5	O
prescribe	prescribe	VERB	VB	5	O
chelation	chelation	NOUN	NN	0	O
therapy	therapy	NOUN	NN	5	O
at	at	ADP	IN	9	O
only	only	ADV	RB	9	O
slightly	slightly	ADV	RB	9	O
elevated	elevated	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
lead	lead	NOUN	NN	5	B-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
very	very	ADV	RB	5	O
few	few	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
evaluated	evaluate	VERB	VBN	9	O
whether	whether	ADP	IN	9	O
chelation	chelation	NOUN	NN	0	O
improves	improve	VERB	VBZ	5	O
cognitive	cognitive	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Pb	Pb	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
children	child	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
whether	whether	ADP	IN	9	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
affect	affect	VERB	VB	9	O
brain	brain	NOUN	NN	5	O
development	development	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
Pb	Pb	PROPN	NNP	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
answer	answer	VERB	VB	5	O
these	these	DET	DT	5	O
questions	question	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
rodent	rodent	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
early	early	ADJ	JJ	9	O
childhood	childhood	NOUN	NN	5	O
Pb	Pb	PROPN	NNP	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
succimer	succimer	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
chelating	chelate	VERB	VBG	0	O
agent	agent	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Pb	Pb	PROPN	NNP	0	B-Disease
poisoning	poisoning	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Pb	Pb	PROPN	NNP	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
produced	produce	VERB	VBD	9	O
lasting	lasting	ADJ	JJ	5	O
impairments	impairment	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	I-Disease
attention	attention	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	I-Disease
inhibitory	inhibitory	ADJ	JJ	3	I-Disease
control	control	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
arousal	arousal	NOUN	NN	5	I-Disease
regulation	regulation	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
paralleling	parallel	VERB	VBG	9	O
the	the	DET	DT	5	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
dysfunction	dysfunction	NOUN	NN	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
Pb	Pb	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Succimer	succimer	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Pb	Pb	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
significantly	significantly	ADV	RB	9	O
improved	improve	VERB	VBD	5	O
learning	learning	NOUN	NN	5	O
,	,	PUNCT	,	9	O
attention	attention	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
arousal	arousal	NOUN	NN	5	O
regulation	regulation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
varied	vary	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Pb	Pb	PROPN	NNP	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
level	level	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
functional	functional	ADJ	JJ	9	O
deficit	deficit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
succimer	succimer	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
Pb	Pb	PROPN	NNP	0	B-Chemical
produced	produce	VERB	VBD	9	O
lasting	lasting	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
pervasive	pervasive	ADJ	JJ	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
affective	affective	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
comparable	comparable	ADJ	JJ	9	O
in	in	ADP	IN	5	O
magnitude	magnitude	NOUN	NN	5	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
Pb	Pb	PROPN	NNP	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
show	show	VERB	VB	9	O
that	that	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
any	any	DET	DT	5	O
chelating	chelate	VERB	VBG	0	O
agent	agent	NOUN	NN	9	O
can	can	VERB	MD	5	O
alleviate	alleviate	VERB	VB	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
Pb	Pb	PROPN	NNP	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
possible	possible	ADJ	JJ	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
a	a	DET	DT	5	O
succimer	succim	ADJ	JJR	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
protocol	protocol	NOUN	NN	9	O
that	that	DET	WDT	5	O
improves	improve	VERB	VBZ	5	O
cognitive	cognitive	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Pb	Pb	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
succimer	succimer	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
strongly	strongly	ADV	RB	9	O
discouraged	discourage	VERB	VBN	5	O
for	for	ADP	IN	5	O
children	child	NOUN	NNS	5	O
who	who	PRON	WP	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
elevated	elevate	VERB	VBN	9	O
tissue	tissue	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
Pb	Pb	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
heavy	heavy	ADJ	JJ	9	O
metals	metal	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Caffeine	caffeine	NOUN	NN	0	B-Chemical
challenge	challenge	NOUN	NN	9	O
test	test	NOUN	NN	5	O
in	in	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
depression	depression	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
aim	aim	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
observe	observe	VERB	VB	9	O
if	if	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
major	major	ADJ	JJ	9	B-Disease
depression	depression	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MDP	MDP	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
Diagnostic	diagnostic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
Statistical	Statistical	PROPN	NNP	5	O
Manual	Manual	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Mental	Mental	PROPN	NNP	5	B-Disease
Disorders	Disorders	PROPN	NNPS	2	I-Disease
,	,	PUNCT	,	9	O
Fourth	Fourth	PROPN	NNP	9	O
Edition	Edition	PROPN	NNP	2	O
criteria	criterion	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
respond	respond	VERB	VBP	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
way	way	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
challenge	challenge	NOUN	NN	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
randomly	randomly	ADV	RB	5	O
selected	select	VERB	VBD	9	O
29	29	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
27	27	NUM	CD	7	O
with	with	ADP	IN	5	O
MDP	MDP	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
25	25	NUM	CD	9	O
with	with	ADP	IN	5	O
major	major	ADJ	JJ	9	B-Disease
depression	depression	NOUN	NN	5	I-Disease
without	without	ADP	IN	9	O
panic	panic	NOUN	NN	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MD	MD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
28	28	NUM	CD	7	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
psychotropic	psychotropic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADJ	JJS	9	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
experiment	experiment	NOUN	NN	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
occasions	occasion	NOUN	NNS	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
apart	apart	ADV	RB	9	O
,	,	PUNCT	,	9	O
480	480	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
placebo	placebo	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
solution	solution	NOUN	NN	0	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
coffee	coffee	NOUN	NN	5	O
form	form	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
scales	scale	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
58	58	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
17	17	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
44	44	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
MDP	MDP	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
MD	MD	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
panic	panic	NOUN	NN	5	B-Disease
attack	attack	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
480	480	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
challenge	challenge	NOUN	NN	9	O
test	test	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
chi	chi	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
=	=	X	XX	7	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
22	22	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
MDP	MDP	PROPN	NNP	9	B-Disease
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
were	be	VERB	VBD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
MD	MD	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
panic	panic	NOUN	NN	5	B-Disease
attack	attack	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
solution	solution	NOUN	NN	0	O
intake	intake	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
MD	MD	PROPN	NNP	9	B-Disease
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
than	than	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
way	way	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
variance	variance	NOUN	NN	5	O
,	,	PUNCT	,	9	O
group	group	NOUN	NN	9	O
by	by	ADP	IN	9	O
time	time	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
Greenhouse	Greenhouse	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Geisser	Geisser	PROPN	NNP	5	O
correction	correction	NOUN	NN	5	O
:	:	PUNCT	:	9	O
F	F	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
762	762	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
=	=	VERB	VBZ	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
85	85	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
026	026	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
no	no	ADV	RB	9	O
matter	matter	ADV	RB	5	O
if	if	ADP	IN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
or	or	CCONJ	CC	5	O
MDP	MDP	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hyperreactivity	hyperreactivity	NOUN	NN	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
challenge	challenge	NOUN	NN	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Mitral	mitral	ADJ	JJ	7	O
annuloplasty	annuloplasty	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	O
restoration	restoration	NOUN	NN	5	O
method	method	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
failing	fail	VERB	VBG	5	B-Disease
left	left	ADJ	JJ	5	I-Disease
ventricle	ventricle	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
pilot	pilot	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
AIM	AIM	PROPN	NNP	9	O
OF	of	ADP	IN	2	O
THE	the	DET	DT	2	O
STUDY	STUDY	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Undersized	undersized	ADJ	JJ	5	O
mitral	mitral	ADJ	JJ	5	O
annuloplasty	annuloplasty	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MAP	MAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
dilated	dilated	ADJ	JJ	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
mitral	mitral	ADJ	JJ	5	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MR	MR	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
since	since	ADV	RB	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
addressing	address	VERB	VBG	5	O
the	the	DET	DT	5	O
MR	MR	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
MAP	MAP	PROPN	NNP	9	O
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
reshape	reshape	VERB	VB	5	O
the	the	DET	DT	5	O
dilated	dilate	VERB	VBN	5	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
LV	LV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
base	base	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
benefits	benefit	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
reshaping	reshaping	NOUN	NN	5	O
on	on	ADP	IN	5	O
LV	LV	PROPN	NNP	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
underlying	underlie	VERB	VBG	5	O
MR	MR	PROPN	NNP	9	B-Disease
remain	remain	VERB	VBP	9	O
incompletely	incompletely	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
aim	aim	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
these	these	DET	DT	5	O
benefits	benefit	NOUN	NNS	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
canine	canine	NOUN	NN	9	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Six	six	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
underwent	undergo	VERB	VBD	5	O
MAP	MAP	PROPN	NNP	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
prosthetic	prosthetic	ADJ	JJ	5	O
band	band	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
posterior	posterior	ADJ	JJ	5	O
mitral	mitral	ADJ	JJ	5	O
annulus	annulus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
four	four	NUM	CD	9	O
mattress	mattress	NOUN	NN	5	O
sutures	suture	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
sutures	suture	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
passed	pass	VERB	VBN	5	O
individually	individually	ADV	RB	9	O
through	through	ADP	IN	9	O
four	four	NUM	CD	9	O
tourniquets	tourniquet	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
exteriorized	exteriorize	VERB	VBD	5	O
untied	untied	ADJ	JJ	5	O
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
atriotomy	atriotomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sonomicrometry	sonomicrometry	NOUN	NN	9	O
crystals	crystal	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
implanted	implant	VERB	VBN	9	O
around	around	ADP	IN	5	O
the	the	DET	DT	5	O
mitral	mitral	ADJ	JJ	5	O
annulus	annulus	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
left	left	ADJ	JJ	5	O
ventricle	ventricle	NOUN	NN	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
geometry	geometry	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
regional	regional	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
volume	volume	NOUN	NN	9	O
loading	loading	NOUN	NN	9	O
after	after	ADP	IN	9	O
weaning	wean	VERB	VBG	5	O
from	from	ADP	IN	9	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
bypass	bypass	NOUN	NN	5	O
;	;	PUNCT	:	9	O
an	an	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
MR	MR	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

MAP	MAP	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
accomplished	accomplish	VERB	VBN	5	O
by	by	ADP	IN	9	O
cinching	cinch	VERB	VBG	5	O
the	the	DET	DT	5	O
tourniquets	tourniquet	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
acquired	acquire	VERB	VBN	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
MAP	MAP	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
MAP	MAP	PROPN	NNP	9	O
decreased	decrease	VERB	VBD	9	O
mitral	mitral	ADJ	JJ	5	O
annular	annular	ADJ	JJ	5	O
dimensions	dimension	NOUN	NNS	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
commissure	commissure	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
commissure	commissure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
septal	septal	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
lateral	lateral	ADJ	JJ	5	O
directions	direction	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Concomitantly	concomitantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
diastolic	diastolic	ADJ	JJ	5	O
diameter	diameter	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
LV	LV	PROPN	NNP	9	O
base	base	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
LV	LV	PROPN	NNP	9	O
sphericity	sphericity	NOUN	NN	5	O
decreased	decrease	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
improved	improve	VERB	VBD	5	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
37	37	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
to	to	ADP	IN	5	O
35	35	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
063	063	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
from	from	ADP	IN	9	O
67	67	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
65	65	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
016	016	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Decreases	decrease	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
evident	evident	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
LV	LV	PROPN	NNP	9	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	NOUN	NN	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
17	17	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
15	15	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
mmHg	mmHg	PROPN	NNPS	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0480	0480	NUM	CD	7	O
and	and	CCONJ	CC	5	O
Tau	Tau	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
48	48	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
to	to	ADP	IN	5	O
45	45	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
ms	ms	NOUN	NN	5	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
fractional	fractional	ADJ	JJ	5	O
shortening	shortening	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
LV	LV	PROPN	NNP	9	O
base	base	NOUN	NN	5	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
045	045	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
MAP	MAP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
increases	increase	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
54	54	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
57	57	NUM	CD	7	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
65	65	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
57	57	NUM	CD	7	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Emax	Emax	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
86	86	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
41	41	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
31	31	NUM	CD	7	O
mmHg	mmHg	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
acquired	acquire	VERB	VBD	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
isolated	isolate	VERB	VBN	9	O
MAP	MAP	PROPN	NNP	9	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
certain	certain	ADJ	JJ	5	O
benefits	benefit	NOUN	NNS	5	O
on	on	ADP	IN	5	O
LV	LV	PROPN	NNP	9	O
dimension	dimension	NOUN	NN	5	O
/	/	SYM	SYM	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
MR	MR	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
further	further	ADJ	JJ	9	O
investigations	investigation	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
warranted	warrant	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Piperacillin	Piperacillin	PROPN	NNP	7	B-Chemical
/	/	SYM	SYM	9	I-Chemical
tazobactam	tazobactam	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizure	seizure	NOUN	NN	5	B-Disease
rapidly	rapidly	ADV	RB	9	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
high	high	ADJ	JJ	9	O
flux	flux	NOUN	NN	9	O
hemodialysis	hemodialysis	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
on	on	ADP	IN	5	O
peritoneal	peritoneal	ADJ	JJ	3	O
dialysis	dialysis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
popular	popular	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
piperacillin	piperacillin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dire	dire	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
piperacillin	piperacillin	NOUN	NN	0	B-Chemical
still	still	ADV	RB	5	O
goes	go	VERB	VBZ	5	O
unrecognized	unrecognized	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
delay	delay	NOUN	NN	5	O
in	in	ADP	IN	5	O
appropriate	appropriate	ADJ	JJ	5	O
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
57	57	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
receiving	receive	VERB	VBG	9	O
continuous	continuous	ADJ	JJ	5	O
ambulatory	ambulatory	ADJ	JJ	5	O
peritoneal	peritoneal	ADJ	JJ	3	O
dialysis	dialysis	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CAPD	CAPD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
slurred	slur	VERB	VBN	5	O
speech	speech	NOUN	NN	5	O
,	,	PUNCT	,	9	O
tremor	tremor	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
bizarre	bizarre	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
progressive	progressive	ADJ	JJ	5	O
mental	mental	ADJ	JJ	5	O
confusion	confusion	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
generalized	generalized	ADJ	JJ	5	O
tonic	tonic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
clonic	clonic	NOUN	NN	5	I-Disease
seizure	seizure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
GTCS	GTCS	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
5	5	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
piperacillin	piperacillin	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	I-Chemical
tazobactam	tazobactam	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
for	for	ADP	IN	5	O
bronchiectasis	bronchiectasis	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
secondary	secondary	ADJ	JJ	9	B-Disease
infection	infection	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
laboratory	laboratory	NOUN	NN	9	O
data	datum	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
electrolyte	electrolyte	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
ammonia	ammonia	ADJ	JJ	0	B-Chemical
levels	level	NOUN	NNS	3	O
but	but	CCONJ	CC	9	O
leukocytosis	leukocytosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Neurologic	neurologic	ADJ	JJ	5	O
examinations	examination	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
dysarthria	dysarthria	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
bilateral	bilateral	ADJ	JJ	5	O
Babinski	Babinski	PROPN	NNP	5	O
sign	sign	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Computed	compute	VERB	VBN	5	O
tomography	tomography	NOUN	NN	5	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
electroencephalogram	electroencephalogram	NOUN	NN	5	O
were	be	VERB	VBD	9	O
unremarkable	unremarkable	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
another	another	DET	DT	9	O
GTCS	GTCS	PROPN	NNP	5	B-Disease
episode	episode	NOUN	NN	5	O
recurred	recur	VERB	VBN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
sixth	sixth	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
piperacillin	piperacillin	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	I-Chemical
tazobactam	tazobactam	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Brain	brain	NOUN	NN	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
demonstrate	demonstrate	VERB	VB	9	O
acute	acute	ADJ	JJ	9	O
infarction	infarction	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
organic	organic	ADJ	JJ	0	B-Disease
brain	brain	NOUN	NN	5	I-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
flux	flux	NOUN	NN	9	O
hemodialysis	hemodialysis	NOUN	NN	5	O
rapidly	rapidly	ADV	RB	9	O
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
neurologic	neurologic	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
within	within	ADP	IN	9	O
4	4	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Piperacillin	Piperacillin	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
uremic	uremic	ADJ	JJ	9	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
unexplained	unexplained	ADJ	JJ	5	O
neurological	neurological	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CAPD	CAPD	PROPN	NNP	5	O
is	be	VERB	VBZ	5	O
inefficient	inefficient	ADJ	JJ	9	O
in	in	ADP	IN	5	O
removing	remove	VERB	VBG	5	O
piperacillin	piperacillin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
hemodialysis	hemodialysis	NOUN	NN	5	O
can	can	VERB	MD	5	O
rapidly	rapidly	ADV	RB	9	O
terminate	terminate	VERB	VB	9	O
the	the	DET	DT	5	O
piperacillin	piperacillin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

Frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
ipsilateral	ipsilateral	ADJ	JJ	5	O
vocal	vocal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
carotid	carotid	ADJ	JJ	5	O
endarterectomy	endarterectomy	NOUN	NN	5	O
under	under	ADP	IN	9	O
local	local	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Especially	especially	ADV	RB	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
neurologic	neurologic	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
,	,	PUNCT	,	9	O
carotid	carotid	ADJ	JJ	5	O
endarterectomy	endarterectomy	NOUN	NN	5	O
done	do	VERB	VBN	9	O
under	under	ADP	IN	9	O
local	local	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
become	become	VERB	VBN	5	O
the	the	DET	DT	5	O
technique	technique	NOUN	NN	5	O
of	of	ADP	IN	5	O
choice	choice	NOUN	NN	5	O
in	in	ADP	IN	5	O
several	several	ADJ	JJ	9	O
centers	center	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Temporary	temporary	ADJ	JJ	5	O
ipsilateral	ipsilateral	ADJ	JJ	5	O
vocal	vocal	ADJ	JJ	5	B-Disease
nerve	nerve	NOUN	NN	5	I-Disease
palsies	palsy	NOUN	NNS	5	I-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
most	most	ADV	RBS	9	O
important	important	ADJ	JJ	9	O
in	in	ADP	IN	5	O
situations	situation	NOUN	NNS	5	O
where	where	ADV	WRB	5	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
existing	existing	ADJ	JJ	5	O
contralateral	contralateral	ADJ	JJ	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
therefore	therefore	ADV	RB	5	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
on	on	ADP	IN	5	O
vocal	vocal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
function	function	NOUN	NN	9	O
to	to	PART	TO	5	O
better	better	ADV	RB	5	O
understand	understand	VERB	VB	5	O
its	-PRON-	DET	PRP$	9	O
possible	possible	ADJ	JJ	5	O
consequences	consequence	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
included	include	VERB	VBD	5	O
28	28	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
carotid	carotid	ADJ	JJ	5	O
endarterectomy	endarterectomy	NOUN	NN	5	O
under	under	ADP	IN	9	O
local	local	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Vocal	vocal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
before	before	ADV	RB	9	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
postoperative	postoperative	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
using	use	VERB	VBG	9	O
flexible	flexible	ADJ	JJ	5	O
laryngoscopy	laryngoscopy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Anesthesia	Anesthesia	PROPN	NNP	2	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
by	by	ADP	IN	9	O
injecting	inject	VERB	VBG	9	O
20	20	NUM	CD	9	O
to	to	PART	TO	5	O
40	40	NUM	CD	9	O
mL	mL	NOUN	NNS	0	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
mixture	mixture	NOUN	NN	0	O
of	of	ADP	IN	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
(	(	PUNCT	-LRB-	9	O
ropivacaine	ropivacaine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
short	short	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
(	(	PUNCT	-LRB-	9	O
prilocaine	prilocaine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
anesthetic	anesthetic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
vocal	vocal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
function	function	NOUN	NN	9	O
preoperatively	preoperatively	ADV	RB	5	O
.	.	PUNCT	.	9	O

Twelve	twelve	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
intraoperative	intraoperative	ADJ	JJ	5	O
ipsilateral	ipsilateral	ADJ	JJ	5	O
vocal	vocal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
resolved	resolve	VERB	VBD	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
cases	case	NOUN	NNS	5	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
operating	operate	VERB	VBG	5	O
time	time	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
volume	volume	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
temporary	temporary	ADJ	JJ	5	O
vocal	vocal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
without	without	ADP	IN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Local	local	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
temporary	temporary	ADJ	JJ	5	O
ipsilateral	ipsilateral	ADJ	JJ	5	O
vocal	vocal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
almost	almost	ADV	RB	9	O
half	half	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
existing	existing	ADJ	JJ	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
relevant	relevant	ADJ	JJ	5	O
frequency	frequency	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
preoperative	preoperative	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
vocal	vocal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
function	function	NOUN	NN	9	O
before	before	ADP	IN	9	O
carotid	carotid	ADJ	JJ	5	O
endarterectomy	endarterectomy	NOUN	NN	5	O
under	under	ADP	IN	9	O
local	local	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
intraoperative	intraoperative	ADJ	JJ	5	O
bilateral	bilateral	ADJ	JJ	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
preoperative	preoperative	ADJ	JJ	5	O
contralateral	contralateral	ADJ	JJ	5	O
vocal	vocal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
surgery	surgery	NOUN	NN	5	O
under	under	ADP	IN	9	O
general	general	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Impaired	impaired	ADJ	JJ	9	B-Disease
fear	fear	VERB	VBP	5	I-Disease
recognition	recognition	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
regular	regular	ADJ	JJ	5	O
recreational	recreational	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

INTRODUCTION	introduction	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
read	read	VERB	VB	5	O
facial	facial	ADJ	JJ	5	O
expressions	expression	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
essential	essential	ADJ	JJ	9	O
for	for	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
human	human	ADJ	JJ	3	O
social	social	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
conduct	conduct	VERB	VB	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
investigation	investigation	NOUN	NN	9	O
of	of	ADP	IN	5	O
facial	facial	ADJ	JJ	5	O
expression	expression	NOUN	NN	3	O
recognition	recognition	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
in	in	ADP	IN	5	O
recreational	recreational	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
comprised	comprise	VERB	VBN	9	O
of	of	ADP	IN	5	O
21	21	NUM	CD	7	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
naive	naive	ADJ	JJ	3	O
participants	participant	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
CN	CN	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
occasional	occasional	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
OC	OC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
48	48	NUM	CD	9	O
regular	regular	ADJ	JJ	5	O
recreational	recreational	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
RC	RC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
users	user	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
emotional	emotional	ADJ	JJ	5	O
facial	facial	ADJ	JJ	5	O
expression	expression	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
EFE	EFE	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
task	task	NOUN	NN	5	O
consisting	consist	VERB	VBG	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
male	male	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
female	female	ADJ	JJ	9	O
face	face	NOUN	NN	5	O
expressing	express	VERB	VBG	3	O
six	six	NUM	CD	9	O
basic	basic	ADJ	JJ	5	O
emotions	emotion	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
happiness	happiness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
surprise	surprise	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sadness	sadness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
anger	anger	NOUN	NN	5	O
,	,	PUNCT	,	9	O
fear	fear	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
disgust	disgust	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Mean	mean	ADJ	JJ	9	O
percent	percent	NOUN	NN	5	O
accuracy	accuracy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
latencies	latency	NOUN	NNS	5	O
for	for	ADP	IN	5	O
correct	correct	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
across	across	ADP	IN	5	O
eight	eight	NUM	CD	9	O
presentations	presentation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
basic	basic	ADJ	JJ	5	O
emotion	emotion	NOUN	NN	5	O
were	be	VERB	VBD	9	O
derived	derive	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Participants	participant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
assessed	assess	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
"	"	PUNCT	``	5	O
Eyes	eye	NOUN	NNS	5	O
task	task	NOUN	NN	5	O
"	"	PUNCT	''	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
their	-PRON-	DET	PRP$	5	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
recognize	recognize	VERB	VB	9	O
more	more	ADV	RBR	5	O
complex	complex	ADJ	JJ	9	O
emotional	emotional	ADJ	JJ	5	O
states	state	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Symptom	Symptom	PROPN	NNP	5	O
CheckList	CheckList	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
90	90	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
Revised	revise	VERB	VBN	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
psychopathology	psychopathology	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
group	group	NOUN	NN	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
psychopathology	psychopathology	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
"	"	PUNCT	``	5	O
eyes	eye	NOUN	NNS	5	O
task	task	NOUN	NN	5	O
"	"	PUNCT	''	5	O
performance	performance	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
RC	rc	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
otherwise	otherwise	ADV	RB	9	O
had	have	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
illicit	illicit	ADJ	JJ	5	O
substance	substance	NOUN	NN	5	O
use	use	NOUN	NN	5	O
histories	history	NOUN	NNS	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
OC	OC	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
exhibited	exhibit	VERB	VBD	9	O
impaired	impaired	ADJ	JJ	9	B-Disease
fear	fear	NOUN	NN	5	I-Disease
recognition	recognition	NOUN	NN	5	I-Disease
accuracy	accuracy	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
OC	OC	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
CN	CN	PROPN	NNP	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
RC	rc	NOUN	NN	9	O
group	group	NOUN	NN	9	O
also	also	ADV	RB	9	O
correctly	correctly	ADV	RB	5	O
identified	identify	VERB	VBD	9	O
anger	anger	NOUN	NN	5	O
,	,	PUNCT	,	9	O
fear	fear	NOUN	NN	5	O
,	,	PUNCT	,	9	O
happiness	happiness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
surprise	surprise	NOUN	NN	5	O
,	,	PUNCT	,	9	O
more	more	ADV	RBR	5	O
slowly	slowly	ADV	RB	5	O
than	than	ADP	IN	5	O
CN	CN	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
OC	OC	PROPN	NNP	9	O
participants	participant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
OC	OC	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
slower	slow	ADJ	JJR	9	O
than	than	ADP	IN	5	O
CN	CN	PROPN	NNP	9	O
when	when	ADV	WRB	5	O
correctly	correctly	ADV	RB	5	O
identifying	identify	VERB	VBG	5	O
disgust	disgust	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
deficit	deficit	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	I-Disease
fear	fear	NOUN	NN	5	I-Disease
recognition	recognition	NOUN	NN	5	I-Disease
accuracy	accuracy	NOUN	NN	5	O
manifested	manifest	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
RC	rc	NOUN	NN	9	O
group	group	NOUN	NN	9	O
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
explained	explain	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
subacute	subacute	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
recent	recent	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
less	less	ADV	RBR	5	O
recent	recent	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
within	within	ADP	IN	9	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
similarly	similarly	ADV	RB	9	O
impaired	impair	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
parallels	parallel	NOUN	NNS	9	O
between	between	ADP	IN	5	O
RC	rc	ADJ	JJ	9	O
users	user	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
psychopaths	psychopath	NOUN	NNS	5	B-Disease
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
fear	fear	NOUN	NN	5	I-Disease
recognition	recognition	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
amygdala	amygdala	NOUN	NN	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
etiology	etiology	NOUN	NN	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Damage	damage	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
substantia	substantia	NOUN	NN	9	I-Disease
nigra	nigra	NOUN	NN	4	I-Disease
pars	par	NOUN	NNS	4	I-Disease
reticulata	reticulata	VERB	VBP	4	I-Disease
during	during	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
:	:	PUNCT	:	9	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
astrocytes	astrocyte	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
serum	serum	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
protein	protein	NOUN	NN	1	O
extravasation	extravasation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
substantia	substantia	ADJ	JJ	9	O
nigra	nigra	NOUN	NN	4	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
gating	gating	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
controlling	control	VERB	VBG	9	O
the	the	DET	DT	5	O
spread	spread	NOUN	NN	5	O
of	of	ADP	IN	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
seizure	seizure	NOUN	NN	5	I-Disease
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	B-Disease
status	status	NOUN	NN	9	I-Disease
epilepticus	epilepticus	VERB	VBP	5	I-Disease
the	the	DET	DT	5	O
pars	par	NOUN	NNS	4	O
reticulata	reticulata	NOUN	NN	4	O
of	of	ADP	IN	5	O
substantia	substantia	NOUN	NN	9	O
nigra	nigra	NOUN	NN	4	O
(	(	PUNCT	-LRB-	9	O
SNR	SNR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
suffers	suffer	VERB	VBZ	5	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
massive	massive	ADJ	JJ	9	O
lesion	lesion	NOUN	NN	5	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
arise	arise	VERB	VB	5	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
massive	massive	ADJ	JJ	9	O
metabolic	metabolic	NOUN	NN	9	B-Disease
derangement	derangement	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
hyperexcitation	hyperexcitation	NOUN	NN	5	O
developing	develop	VERB	VBG	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
activated	activate	VERB	VBN	3	O
SNR	SNR	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
systemic	systemic	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
neuropathology	neuropathology	NOUN	NN	5	O
of	of	ADP	IN	5	O
SNR	SNR	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
using	use	VERB	VBG	9	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
techniques	technique	NOUN	NNS	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
emphasis	emphasis	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
astrocytes	astrocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
surviving	survive	VERB	VBG	9	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
perfusion	perfusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
fixed	fix	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
brains	brain	NOUN	NNS	9	O
processed	process	VERB	VBN	9	O
for	for	ADP	IN	5	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
staining	staining	NOUN	NN	3	O
of	of	ADP	IN	5	O
SNR	SNR	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Nissl	nissl	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
staining	staining	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
antibodies	antibody	NOUN	NNS	3	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
neuron	neuron	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
binding	bind	VERB	VBG	1	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
parvalbumin	parvalbumin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
served	serve	VERB	VBD	9	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
SNR	SNR	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Antibodies	antibody	NOUN	NNS	3	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
astroglia	astroglia	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
cytoskeletal	cytoskeletal	ADJ	JJ	3	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
glial	glial	ADJ	JJ	3	O
fibrillary	fibrillary	ADJ	JJ	3	O
acidic	acidic	ADJ	JJ	0	O
protein	protein	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
GFAP	GFAP	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
glial	glial	ADJ	JJ	3	O
calcium	calcium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
binding	bind	VERB	VBG	1	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
100	100	NUM	CD	0	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
status	status	NOUN	NN	9	O
of	of	ADP	IN	5	O
astrocytes	astrocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Immunohistochemical	immunohistochemical	ADJ	JJ	3	O
staining	staining	NOUN	NN	3	O
for	for	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
albumin	albumin	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
immunoglobulins	immunoglobulin	NOUN	NNS	3	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
tissue	tissue	NOUN	NN	9	O
was	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
as	as	ADP	IN	5	O
indicator	indicator	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
disturbances	disturbance	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
vasogenic	vasogenic	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
formation	formation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Immunohistochemical	immunohistochemical	ADJ	JJ	3	O
staining	staining	NOUN	NN	3	O
indicated	indicate	VERB	VBD	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
GFAP	GFAP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
staining	staining	NOUN	NN	3	O
already	already	ADV	RB	5	O
at	at	ADP	IN	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
oval	oval	NOUN	NN	5	O
focus	focus	NOUN	NN	5	O
situated	situate	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
center	center	NOUN	NN	5	O
of	of	ADP	IN	5	O
SNR	SNR	PROPN	NNP	5	O
while	while	ADP	IN	9	O
sparing	spare	VERB	VBG	5	O
medial	medial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
lateral	lateral	ADJ	JJ	5	O
aspects	aspect	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
1	1	NUM	CD	9	O
h	h	DET	DT	0	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
additional	additional	ADJ	JJ	9	O
vacuolation	vacuolation	NOUN	NN	3	O
in	in	ADP	IN	5	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
100	100	NUM	CD	0	O
protein	protein	NOUN	NN	1	O
staining	staining	NOUN	NN	3	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
2	2	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
parvalbumin	parvalbumin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
staining	staining	NOUN	NN	3	O
changed	change	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
SNR	SNR	PROPN	NNP	5	O
indicating	indicate	VERB	VBG	9	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Nissl	Nissl	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
staining	staining	PROPN	NNP	3	O
visualized	visualize	VERB	VBD	9	O
some	some	DET	DT	5	O
neuronal	neuronal	ADJ	JJ	3	O
distortion	distortion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Staining	stain	VERB	VBG	3	O
for	for	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
proteins	protein	NOUN	NNS	1	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patchy	patchy	NOUN	NN	5	O
manner	manner	NOUN	NN	9	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
forebrain	forebrain	NOUN	NN	3	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
6	6	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
vasogenic	vasogenic	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
covered	cover	VERB	VBD	5	O
the	the	DET	DT	5	O
lesioned	lesione	VERB	VBN	3	B-Disease
SNR	SNR	PROPN	NNP	5	I-Disease
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
glial	glial	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
neuronal	neuronal	ADJ	JJ	3	O
markers	marker	NOUN	NNS	3	O
indicated	indicate	VERB	VBD	9	O
a	a	DET	DT	5	O
massive	massive	ADJ	JJ	9	O
lesion	lesion	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
center	center	NOUN	NN	5	O
of	of	ADP	IN	5	O
SNR	SNR	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
48	48	NUM	CD	9	O
-	-	SYM	SYM	7	O
72	72	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
astrocytes	astrocyte	NOUN	NNS	3	O
surrounding	surround	VERB	VBG	9	O
the	the	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
increased	increase	VERB	VBD	9	O
in	in	ADP	IN	5	O
size	size	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
polymorphic	polymorphic	ADJ	JJ	9	O
phagocytotic	phagocytotic	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
invaded	invade	VERB	VBD	4	O
the	the	DET	DT	5	O
damaged	damage	VERB	VBN	9	O
area	area	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
further	further	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
surviving	survive	VERB	VBG	9	O
1	1	NUM	CD	9	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
conventional	conventional	ADJ	JJ	5	O
paraffin	paraffin	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
sections	section	NOUN	NNS	9	O
confirmed	confirm	VERB	VBD	9	O
the	the	DET	DT	5	O
neuronal	neuronal	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
glial	glial	ADJ	JJ	3	O
damage	damage	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
SNR	SNR	PROPN	NNP	5	I-Disease
.	.	PUNCT	.	9	O

Additional	additional	ADJ	JJ	9	O
pathology	pathology	NOUN	NN	5	O
of	of	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
quality	quality	NOUN	NN	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
globus	globus	NOUN	NN	5	O
pallidus	pallidus	NOUN	NN	4	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
astrocytes	astrocyte	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
always	always	ADV	RB	5	O
damaged	damage	VERB	VBN	9	O
in	in	ADP	IN	5	O
parallel	parallel	NOUN	NN	5	O
with	with	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
SNR	SNR	PROPN	NNP	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
proposed	propose	VERB	VBN	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
anatomical	anatomical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
interrelationship	interrelationship	NOUN	NN	9	O
between	between	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
astrocytes	astrocyte	NOUN	NNS	3	O
is	be	VERB	VBZ	5	O
particularly	particularly	ADV	RB	5	O
tight	tight	ADJ	JJ	9	O
in	in	ADP	IN	5	O
SNR	SNR	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
cell	cell	NOUN	NN	3	O
elements	element	NOUN	NNS	5	O
may	may	VERB	MD	5	O
suffer	suffer	VERB	VB	5	O
in	in	ADP	IN	5	O
common	common	ADJ	JJ	5	O
from	from	ADP	IN	9	O
metabolic	metabolic	ADJ	JJ	9	O
disturbance	disturbance	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
neurotransmitter	neurotransmitter	NOUN	NN	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
as	as	ADP	IN	5	O
occur	occur	ADJ	JJ	5	O
during	during	ADP	IN	5	O
massive	massive	ADJ	JJ	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Neuroprotective	neuroprotective	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
upon	upon	ADP	IN	9	O
the	the	DET	DT	5	O
offspring	offspring	NOUN	NN	9	O
cerebellar	cerebellar	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cortical	cortical	ADJ	JJ	5	B-Disease
dysplasia	dysplasia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Cortical	cortical	ADJ	JJ	5	B-Disease
dysplasia	dysplasia	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
malformation	malformation	NOUN	NN	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
defects	defect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
proliferation	proliferation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
migration	migration	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
maturation	maturation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
offspring	offspring	NOUN	NN	9	O
rat	rat	NOUN	NN	3	O
cerebellum	cerebellum	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
maternal	maternal	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
to	to	PART	TO	5	O
carmustine	carmustine	VERB	VB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
[	[	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
bis	bis	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloroethyl	chloroethyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitrosoure	nitrosoure	NOUN	NN	_	I-Chemical
]	]	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
exogenous	exogenous	ADJ	JJ	3	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
upon	upon	ADP	IN	9	O
cerebellar	cerebellar	ADJ	JJ	5	O
BCNU	bcnu	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cortical	cortical	ADJ	JJ	5	B-Disease
dysplasia	dysplasia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
histological	histological	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
analyses	analysis	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pregnant	pregnant	ADJ	JJ	5	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
five	five	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
intact	intact	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
,	,	PUNCT	,	9	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
plus	plus	CCONJ	CC	9	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
exposed	expose	VERB	VBN	9	O
to	to	PART	TO	5	O
BCNU	bcnu	VERB	VB	0	B-Chemical
on	on	ADP	IN	5	O
embryonic	embryonic	ADJ	JJ	3	O
day	day	NOUN	NN	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
until	until	ADP	IN	5	O
delivery	delivery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Immuno	Immuno	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
histochemistry	histochemistry	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
were	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
offspring	offspring	NOUN	NN	9	O
cerebellum	cerebellum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Histopathologically	histopathologically	ADV	RB	5	O
,	,	PUNCT	,	9	O
typical	typical	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cerebella	cerebella	NOUN	NN	3	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
early	early	ADJ	JJ	9	O
embryonic	embryonic	ADJ	JJ	3	O
development	development	NOUN	NN	9	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
cortical	cortical	ADJ	JJ	5	B-Disease
dysplasia	dysplasia	ADJ	JJ	5	I-Disease
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
TUNEL	tunel	NOUN	NN	3	O
positive	positive	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
nestin	nestin	ADJ	JJ	3	O
positive	positive	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
a	a	DET	DT	5	O
decreased	decrease	VERB	VBN	9	O
immunoreactivity	immunoreactivity	NOUN	NN	3	O
to	to	PART	TO	5	O
glial	glial	VERB	VB	3	O
fibrillary	fibrillary	ADJ	JJ	3	O
acidic	acidic	ADJ	JJ	0	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
synaptophysin	synaptophysin	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
transforming	transform	VERB	VBG	9	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
beta1	beta1	NOUN	NN	3	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
a	a	DET	DT	5	O
delayed	delay	VERB	VBN	9	O
maturation	maturation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
significantly	significantly	ADV	RB	9	O
reversed	reverse	VERB	VBD	9	O
these	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Malondialdehyde	Malondialdehyde	PROPN	NNP	0	B-Chemical
level	level	NOUN	NN	9	O
in	in	ADP	IN	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
decreased	decrease	VERB	VBD	9	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
levels	level	NOUN	NNS	3	O
between	between	ADP	IN	5	O
these	these	DET	DT	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	DET	DT	5	O
exposure	exposure	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
to	to	PART	TO	5	O
BCNU	bcnu	VERB	VB	0	B-Chemical
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
leads	lead	NOUN	NNS	9	O
to	to	ADP	IN	5	O
delayed	delay	VERB	VBN	9	O
maturation	maturation	NOUN	NN	3	O
of	of	ADP	IN	5	O
offspring	offspre	VERB	VBG	9	O
cerebellum	cerebellum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
protects	protect	VERB	VBZ	3	O
the	the	DET	DT	5	O
cerebellum	cerebellum	NOUN	NN	9	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Reduced	reduce	VERB	VBN	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
given	give	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxypropyl	hydroxypropyl	ADJ	JJ	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
methacrylamide	methacrylamide	ADJ	JJ	0	I-Chemical
conjugates	conjugate	NOUN	NNS	0	O
:	:	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
experimental	experimental	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
general	general	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
late	late	ADJ	JJ	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
given	give	VERB	VBN	5	O
either	either	CCONJ	CC	9	O
as	as	ADP	IN	5	O
free	free	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxypropyl	hydroxypropyl	ADJ	JJ	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
methacrylamide	methacrylamide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
HPMA	HPMA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
copolymer	copolymer	NOUN	NN	0	O
conjugates	conjugate	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
these	these	DET	DT	5	O
HPMA	HPMA	PROPN	NNP	0	B-Chemical
copolymers	copolymer	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
covalently	covalently	ADV	RB	0	O
bound	bind	VERB	VBN	9	O
via	via	ADP	IN	9	O
peptide	peptide	NOUN	NN	9	O
linkages	linkage	NOUN	NNS	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
biodegradable	biodegradable	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
Gly	Gly	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
Gly	Gly	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
degradable	degradable	ADJ	JJ	0	O
by	by	ADP	IN	9	O
lysosomal	lysosomal	ADJ	JJ	3	O
proteinases	proteinase	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
Gly	Gly	PROPN	NNP	1	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Phe	Phe	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Leu	Leu	PROPN	NNP	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Gly	Gly	PROPN	NNP	1	I-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
biodegradable	biodegradable	ADJ	JJ	0	O
conjugate	conjugate	NOUN	NN	0	O
containing	contain	VERB	VBG	0	O
galactosamine	galactosamine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
residue	residue	NOUN	NN	1	O
was	be	VERB	VBD	9	O
targeted	target	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Over	over	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
free	free	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
polymer	polymer	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
bound	bind	VERB	VBN	9	O
DOX	dox	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
transient	transient	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
maximal	maximal	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
polymer	polymer	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
bound	bind	VERB	VBN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
free	free	ADJ	JJ	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
mixture	mixture	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
unmodified	unmodified	ADJ	JJ	9	O
parent	parent	NOUN	NN	9	O
HPMA	HPMA	PROPN	NNP	0	B-Chemical
copolymer	copolymer	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
free	free	ADJ	JJ	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Throughout	throughout	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
deaths	death	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
free	free	ADJ	JJ	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
mixture	mixture	NOUN	NN	0	O
of	of	ADP	IN	5	O
HPMA	HPMA	PROPN	NNP	0	B-Chemical
copolymer	copolymer	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
free	free	ADJ	JJ	9	O
DOX	dox	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
histological	histological	ADJ	JJ	9	O
investigations	investigation	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
marked	marked	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Sequential	sequential	ADJ	JJ	5	O
measurements	measurement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
in	in	ADP	IN	5	O
surviving	survive	VERB	VBG	9	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
free	free	ADJ	JJ	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
mixture	mixture	NOUN	NN	0	O
of	of	ADP	IN	5	O
HPMA	HPMA	PROPN	NNP	0	B-Chemical
copolymer	copolymer	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
free	free	ADJ	JJ	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
function	function	NOUN	NN	9	O
beginning	beginning	NOUN	NN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
4th	4th	ADJ	JJ	9	O
week	week	NOUN	NN	9	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
approximately	approximately	ADV	RB	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
the	the	DET	DT	5	O
HPMA	HPMA	PROPN	NNP	0	B-Chemical
copolymer	copolymer	NOUN	NN	0	O
conjugates	conjugate	NOUN	NNS	0	O
containing	contain	VERB	VBG	0	O
DOX	DOX	PROPN	NNP	0	B-Chemical
exhibited	exhibit	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
histological	histological	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
HPMA	HPMA	PROPN	NNP	0	B-Chemical
copolymer	copolymer	NOUN	NN	0	O
conjugates	conjugate	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
killed	kill	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
beginning	beginning	NOUN	NN	5	O
at	at	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
400	400	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Corneal	Corneal	PROPN	NNP	5	B-Disease
ulcers	ulcer	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
aerosolized	aerosolized	ADJ	JJ	0	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
4	4	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
corneal	corneal	ADJ	JJ	5	B-Disease
ulcers	ulcer	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
drug	drug	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
ulcers	ulcer	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Review	review	VERB	VB	2	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
corneal	corneal	ADJ	JJ	5	B-Disease
ulcers	ulcer	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
drug	drug	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
seen	see	VERB	VBN	9	O
at	at	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
institution	institution	NOUN	NN	5	O
from	from	ADP	IN	9	O
July	July	PROPN	NNP	2	O
2006	2006	NUM	CD	2	O
to	to	ADP	IN	5	O
December	December	PROPN	NNP	2	O
2006	2006	NUM	CD	2	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
corneal	corneal	ADJ	JJ	5	B-Disease
ulcers	ulcer	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
use	use	NOUN	NN	5	O
were	be	VERB	VBD	9	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
corneal	corneal	ADJ	JJ	5	B-Disease
ulcers	ulcer	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
cultured	culture	VERB	VBN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
for	for	ADP	IN	5	O
intensive	intensive	ADJ	JJ	5	O
topical	topical	ADJ	JJ	0	O
antibiotic	antibiotic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
received	receive	VERB	VBD	9	O
comprehensive	comprehensive	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
care	care	NOUN	NN	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
medical	medical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
substance	substance	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
consultations	consultation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Streptococcal	streptococcal	ADJ	JJ	2	O
organisms	organism	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
Capnocytophaga	Capnocytophaga	PROPN	NNP	4	O
and	and	CCONJ	CC	5	O
Brevibacterium	Brevibacterium	PROPN	NNP	4	O
casei	casei	VERB	VBZ	4	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
infections	infection	NOUN	NNS	5	B-Disease
responded	respond	VERB	VBD	9	O
to	to	ADP	IN	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
needed	need	VERB	VBD	5	O
a	a	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
tarsorrhaphy	tarsorrhaphy	NOUN	NN	5	O
for	for	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
epithelial	epithelial	ADJ	JJ	3	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Aerosolized	aerosolized	ADJ	JJ	0	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
use	use	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
corneal	corneal	ADJ	JJ	5	B-Disease
ulcers	ulcer	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
provides	provide	VERB	VBZ	5	O
additional	additional	ADJ	JJ	9	O
challenges	challenge	NOUN	NNS	5	O
for	for	ADP	IN	5	O
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Not	not	ADV	RB	9	O
only	only	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
infections	infection	NOUN	NNS	5	B-Disease
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
poor	poor	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
noncompliance	noncompliance	NOUN	NN	5	O
need	need	VERB	VBP	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
addressed	address	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Comprehensive	comprehensive	ADJ	JJ	2	O
care	care	NOUN	NN	5	O
may	may	VERB	MD	5	O
provide	provide	VERB	VB	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
the	the	DET	DT	5	O
opportunity	opportunity	NOUN	NN	5	O
to	to	PART	TO	5	O
discontinue	discontinue	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
substance	substance	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
improve	improve	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
overall	overall	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
prevent	prevent	VERB	VB	5	O
future	future	ADJ	JJ	5	O
corneal	corneal	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Topical	Topical	PROPN	NNP	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
025	025	NUM	CD	7	O
%	%	NOUN	NN	9	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
post	post	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
herpetic	herpetic	ADJ	JJ	5	I-Disease
neuralgia	neuralgia	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
efficacy	efficacy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
course	course	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
39	39	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
post	post	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
herpetic	herpetic	ADJ	JJ	5	I-Disease
neuralgia	neuralgia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PHN	PHN	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
median	median	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
24	24	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
025	025	NUM	CD	7	O
%	%	NOUN	NN	9	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
cream	cream	NOUN	NN	0	O
for	for	ADP	IN	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
rated	rate	VERB	VBD	5	O
their	-PRON-	DET	PRP$	5	O
pain	pain	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
analogue	analogue	NOUN	NN	0	O
scale	scale	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
VAS	VAS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
verbal	verbal	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
investigation	investigation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
study	study	NOUN	NN	9	O
onset	onset	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
improved	improve	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Nineteen	nineteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
48	48	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
substantially	substantially	ADV	RB	9	O
improved	improve	VERB	VBD	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
;	;	PUNCT	:	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
discontinued	discontinue	VERB	VBN	5	O
therapy	therapy	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
intolerable	intolerable	ADJ	JJ	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
burning	burning	NOUN	NN	5	O
sensations	sensation	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
mastitis	mastitis	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
15	15	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
38	38	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
reported	report	VERB	VBD	9	O
no	no	DET	DT	9	O
benefit	benefit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
VAS	VAS	PROPN	NNP	5	O
ratings	rating	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
after	after	ADP	IN	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
application	application	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
responders	responder	NOUN	NNS	5	O
72	72	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
were	be	VERB	VBD	9	O
still	still	ADV	RB	5	O
improved	improve	VERB	VBN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
;	;	PUNCT	:	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
third	third	NOUN	NN	9	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
continued	continue	VERB	VBN	9	O
application	application	NOUN	NN	5	O
irregularly	irregularly	ADV	RB	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
dependent	dependent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
localization	localization	NOUN	NN	3	O
of	of	ADP	IN	5	O
PHN	PHN	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
trigeminal	trigeminal	ADJ	JJ	5	O
involvement	involvement	NOUN	NN	9	O
was	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
sensory	sensory	ADJ	JJ	5	B-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
character	character	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
course	course	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
burning	burning	NOUN	NN	5	O
.	.	PUNCT	.	9	O

If	if	ADP	IN	5	O
confirmed	confirm	VERB	VBN	9	O
in	in	ADP	IN	5	O
controlled	control	VERB	VBN	5	O
trials	trial	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
open	open	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
randomized	randomized	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
might	may	VERB	MD	9	O
indicate	indicate	VERB	VB	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
analgesic	analgesic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
PHN	PHN	PROPN	NNP	5	B-Disease
is	be	VERB	VBZ	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
both	both	DET	DT	9	O
interference	interference	NOUN	NN	9	O
with	with	ADP	IN	5	O
neuropeptide	neuropeptide	NOUN	NN	9	O
metabolism	metabolism	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
morphological	morphological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
perhaps	perhaps	ADV	RB	5	O
degeneration	degeneration	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
nociceptive	nociceptive	ADJ	JJ	5	O
afferents	afferent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Myo	myo	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
inositol	inositol	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phosphate	phosphate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MIP	MIP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
synthase	synthase	NOUN	NN	1	O
inhibition	inhibition	NOUN	NN	3	O
:	:	PUNCT	:	9	O
in	in	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
vivo	vivo	NOUN	NNS	3	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
prototypic	prototypic	ADJ	JJ	9	O
mood	mood	NOUN	NN	5	O
stabilizers	stabilizer	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
have	have	VERB	VBP	5	O
diverse	diverse	ADJ	JJ	9	O
structures	structure	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
targets	target	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
influence	influence	VERB	VBP	5	O
inositol	inositol	NOUN	NN	0	B-Chemical
metabolism	metabolism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
inhibits	inhibit	VERB	VBZ	3	O
IMPase	IMPase	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
inhibits	inhibit	VERB	VBZ	3	O
MIP	MIP	PROPN	NNP	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
MIP	MIP	PROPN	NNP	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
inhibition	inhibition	NOUN	NN	3	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
replicate	replicate	VERB	VB	9	O
or	or	CCONJ	CC	5	O
augment	augment	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
inositol	inositol	ADJ	JJ	0	B-Chemical
sensitive	sensitive	ADJ	JJ	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
effects	effect	NOUN	NNS	9	O
may	may	VERB	MD	5	O
stem	stem	VERB	VB	3	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
contribution	contribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
de	de	NOUN	NN	2	O
-	-	PUNCT	HYPH	7	O
novo	novo	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
to	to	ADP	IN	5	O
cellular	cellular	ADJ	JJ	3	O
inositol	inositol	NOUN	NN	0	B-Chemical
supply	supply	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
de	de	NOUN	NN	2	O
-	-	PUNCT	HYPH	7	O
novo	novo	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
by	by	ADP	IN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
itself	-PRON-	PRON	PRP	9	O
.	.	PUNCT	.	9	O

Non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
steroidal	steroidal	ADJ	JJ	0	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
granular	granular	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
basement	basement	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
deposits	deposit	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
tubulo	tubulo	NOUN	NN	2	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
interstitial	interstitial	ADJ	JJ	9	I-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
ATIN	ATIN	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
resulting	result	VERB	VBG	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
insults	insult	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
immune	immune	ADJ	JJ	3	O
complex	complex	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
tubulo	tubulo	ADJ	JJ	2	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
interstitial	interstitial	ADJ	JJ	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
drugs	drug	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
steroidal	steroidal	ADJ	JJ	0	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
a	a	DET	DT	5	O
far	far	ADV	RB	5	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
entity	entity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
ATIN	ATIN	PROPN	NNP	5	B-Disease
remains	remain	VERB	VBZ	9	O
under	under	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
diagnosed	diagnose	VERB	VBN	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
resolve	resolve	VERB	VBP	5	O
spontaneously	spontaneously	ADV	RB	5	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
14	14	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
boy	boy	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
aortic	aortic	ADJ	JJ	9	O
valve	valve	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
put	put	VERB	VBN	5	O
on	on	ADP	IN	5	O
aspirin	aspirin	ADJ	JJ	9	B-Chemical
following	follow	VERB	VBG	9	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
took	take	VERB	VBD	5	O
ibuprofen	ibuprofen	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
fever	fever	NOUN	NN	5	B-Disease
for	for	ADP	IN	5	O
nearly	nearly	ADV	RB	9	O
a	a	DET	DT	5	O
week	week	NOUN	NN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
presentation	presentation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
then	then	ADV	RB	9	O
presented	present	VERB	VBD	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
feeling	feel	VERB	VBG	5	O
quite	quite	ADV	RB	5	O
ill	ill	ADV	RB	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
blood	blood	NOUN	NN	9	B-Chemical
urea	urea	ADJ	JJ	0	I-Chemical
nitrogen	nitrogen	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BUN	BUN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
of	of	ADP	IN	5	O
147	147	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
serum	serum	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mEq	meq	NOUN	NN	0	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Dialysis	dialysis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
immediately	immediately	ADV	RB	9	O
initiated	initiate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
kidney	kidney	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
inflammatory	inflammatory	ADJ	JJ	3	O
infiltrate	infiltrate	NOUN	NN	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
ATIN	ATIN	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
tubular	tubular	ADJ	JJ	9	O
basement	basement	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
TBM	TBM	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
very	very	ADV	RB	5	O
intense	intense	ADJ	JJ	9	O
granular	granular	ADJ	JJ	9	O
deposits	deposit	NOUN	NNS	9	O
of	of	ADP	IN	5	O
polyclonal	polyclonal	ADJ	JJ	3	O
IgG	igg	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
C3	c3	PRON	PRP	9	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
needed	need	VERB	VBD	5	O
dialysis	dialysis	NOUN	NN	5	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
successfully	successfully	ADV	RB	5	O
with	with	ADP	IN	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
renal	renal	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
took	take	VERB	VBD	5	O
a	a	DET	DT	5	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
first	first	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
NSAIDs	NSAIDs	PROPN	NNPS	5	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
ATIN	ATIN	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
showing	show	VERB	VBG	9	O
deposits	deposit	NOUN	NNS	9	O
of	of	ADP	IN	5	O
granular	granular	ADJ	JJ	9	O
immune	immune	ADJ	JJ	3	O
complex	complex	ADJ	JJ	9	O
present	present	NOUN	NN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
TBM	TBM	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
glomeruli	glomeruli	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Rifampicin	rifampicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
segmental	segmental	NOUN	NN	5	O
necrotizing	necrotize	VERB	VBG	5	O
glomerulonephritis	glomerulonephritis	ADJ	JJ	3	B-Disease
in	in	ADP	IN	5	O
staphylococcal	staphylococcal	ADJ	JJ	9	B-Disease
endocarditis	endocarditis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Segmental	Segmental	PROPN	NNP	5	O
necrotising	necrotise	VERB	VBG	5	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
as	as	ADP	IN	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
rifampicin	rifampicin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
tuberculosis	tuberculosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Changing	change	VERB	VBG	5	O
epidemiology	epidemiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
infections	infection	NOUN	NNS	5	B-Disease
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
infective	infective	ADJ	JJ	9	B-Disease
endocarditis	endocarditis	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
IE	IE	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
rifampicin	rifampicin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
Staphylococcal	staphylococcal	ADJ	JJ	9	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
Staphylococcal	Staphylococcal	PROPN	NNP	9	B-Disease
IE	IE	PROPN	NNP	9	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
segmental	segmental	ADJ	JJ	5	O
necrotising	necrotise	VERB	VBG	5	O
glomerulonephritis	glomerulonephritis	ADJ	JJ	3	B-Disease
while	while	ADP	IN	9	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
rifampicin	rifampicin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
review	review	VERB	VB	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
regarding	regard	VERB	VBG	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
rifampicin	rifampicin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Rate	rate	NOUN	NN	5	O
of	of	ADP	IN	5	O
YMDD	YMDD	PROPN	NNP	1	O
motif	motif	NOUN	NN	1	O
mutants	mutant	NOUN	NNS	1	O
in	in	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
untreated	untreated	ADJ	JJ	3	O
Iranian	iranian	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Lamivudine	Lamivudine	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
B	B	PROPN	NNP	9	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
YMDD	YMDD	PROPN	NNP	1	O
motif	motif	NOUN	NN	1	O
mutants	mutant	NOUN	NNS	1	O
(	(	PUNCT	-LRB-	9	O
resistant	resistant	ADJ	JJ	9	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
occur	occur	VERB	VBP	5	O
as	as	ADP	IN	5	O
natural	natural	ADJ	JJ	5	O
genome	genome	ADJ	JJ	9	O
variability	variability	NOUN	NN	5	O
in	in	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
untreated	untreated	ADJ	JJ	3	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
B	B	PROPN	NNP	9	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
YMDD	YMDD	PROPN	NNP	1	O
motif	motif	NOUN	NN	1	O
mutants	mutant	NOUN	NNS	1	O
in	in	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
untreated	untreated	ADJ	JJ	3	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
B	B	PROPN	NNP	9	I-Disease
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Iran	Iran	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
77	77	NUM	CD	7	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
B	B	PROPN	NNP	9	I-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
samples	sample	NOUN	NNS	9	O
from	from	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
by	by	ADP	IN	9	O
polymerase	polymerase	NOUN	NN	1	O
chain	chain	NOUN	NN	9	O
reaction	reaction	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
restriction	restriction	NOUN	NN	9	O
fragment	fragment	NOUN	NN	1	O
length	length	NOUN	NN	9	O
polymorphism	polymorphism	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PCR	PCR	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
RFLP	RFLP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
YMDD	YMDD	PROPN	NNP	1	O
motif	motif	NOUN	NN	1	O
mutants	mutant	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
enzymes	enzyme	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
HCV	HCV	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
anti	anti	ADJ	JJ	3	O
-	-	NOUN	NNS	7	O
HBe	HBe	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
77	77	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
enrolled	enrol	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
73	73	NUM	CD	7	O
%	%	NOUN	NN	9	O
were	be	VERB	VBD	9	O
male	male	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
27	27	NUM	CD	7	O
%	%	NOUN	NN	9	O
were	be	VERB	VBD	9	O
female	female	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
ALT	ALT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
AST	AST	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
124	124	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
73	73	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
103	103	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
81	81	NUM	CD	7	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
in	in	ADP	IN	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
anti	anti	ADJ	JJ	3	O
-	-	NOUN	NNS	7	O
HBe	HBe	NOUN	NNS	3	O
in	in	ADP	IN	5	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Anti	Anti	PROPN	NNP	3	O
-	-	PROPN	NNP	7	O
HCV	HCV	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

YMDD	YMDD	PROPN	NNP	1	O
motif	motif	NOUN	NN	1	O
mutants	mutant	NOUN	NNS	1	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
despite	despite	ADP	IN	9	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
enzyme	enzyme	ADJ	JJ	0	O
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
or	or	CCONJ	CC	5	O
anti	anti	ADJ	JJ	3	O
-	-	NOUN	NNS	7	O
HBe	HBe	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
natural	natural	ADJ	JJ	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
YMDD	YMDD	PROPN	NNP	1	O
motif	motif	NOUN	NN	1	O
mutants	mutant	NOUN	NNS	1	O
in	in	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
untreated	untreated	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
B	B	PROPN	NNP	9	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
mutants	mutant	NOUN	NNS	1	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
Iranian	iranian	ADJ	JJ	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
untreated	untreated	ADJ	JJ	3	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
B	B	PROPN	NNP	9	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Branch	branch	NOUN	NN	2	O
retinal	retinal	ADJ	JJ	5	B-Disease
vein	vein	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
branch	branch	NOUN	NN	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
vein	vein	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
secondary	secondary	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
an	an	DET	DT	5	O
infrequent	infrequent	NOUN	NN	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
that	that	ADP	IN	5	O
ophthalmologists	ophthalmologist	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
aware	aware	ADJ	JJ	5	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
because	because	ADP	IN	5	O
this	this	DET	DT	5	O
class	class	NOUN	NN	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
prescribed	prescribe	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E2	e2	NOUN	NN	3	I-Chemical
release	release	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
blocking	block	VERB	VBG	3	O
nociceptive	nociceptive	ADJ	JJ	5	O
input	input	NOUN	NN	5	O
from	from	ADP	IN	9	O
surgical	surgical	ADJ	JJ	5	O
sites	site	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
local	local	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
might	may	VERB	MD	9	O
directly	directly	ADV	RB	9	O
modulate	modulate	VERB	VB	9	O
inflammation	inflammation	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
proinflammatory	proinflammatory	NOUN	NN	3	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
local	local	ADJ	JJ	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E2	E2	PROPN	NNP	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
production	production	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
COX	COX	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
that	that	DET	WDT	5	O
increases	increase	VERB	VBZ	9	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
114	114	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
undergoing	undergo	VERB	VBG	9	O
extraction	extraction	NOUN	NN	9	O
of	of	ADP	IN	5	O
impacted	impact	VERB	VBN	5	O
third	third	ADJ	JJ	9	O
molars	molar	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
either	either	CCONJ	CC	9	O
rofecoxib	rofecoxib	VERB	VBP	5	B-Chemical
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
orally	orally	ADV	RB	0	O
90	90	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
mucosal	mucosal	NOUN	NN	9	O
biopsies	biopsy	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
extraction	extraction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
microdialysis	microdialysis	NOUN	NN	5	O
probe	probe	NOUN	NN	9	O
was	be	VERB	VBD	9	O
placed	place	VERB	VBN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
surgical	surgical	ADJ	JJ	5	O
site	site	NOUN	NN	9	O
for	for	ADP	IN	5	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
thromboxane	thromboxane	NOUN	NN	0	B-Chemical
B2	b2	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
TXB2	txb2	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
measurements	measurement	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
rofecoxib	rofecoxib	NOUN	NN	5	B-Chemical
group	group	NOUN	NN	9	O
reported	report	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
analog	analog	NOUN	NN	0	O
scale	scale	NOUN	NN	5	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
three	three	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
4	4	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
reported	report	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADJ	JJR	5	O
pain	pain	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
levels	level	NOUN	NNS	3	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
4	4	NUM	CD	9	O
h	h	DET	WDT	0	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
three	three	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
at	at	ADP	IN	9	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thromboxane	thromboxane	NOUN	NN	2	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatments	treatment	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
seen	see	VERB	VBN	9	O
were	be	VERB	VBD	9	O
attributable	attributable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
stimulates	stimulate	NOUN	NNS	3	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
after	after	ADP	IN	9	O
tissue	tissue	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
production	production	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
dissipates	dissipate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

p75NTR	p75ntr	ADJ	JJ	3	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
urinary	urinary	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
sensory	sensory	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
nerve	nerve	NOUN	NN	5	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
NGF	NGF	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
contributing	contribute	VERB	VBG	9	O
to	to	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
voiding	void	VERB	VBG	5	O
frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
altered	altered	ADJ	JJ	9	O
sensation	sensation	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
examined	examine	VERB	VBN	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
tyrosine	tyrosine	NOUN	NN	3	B-Chemical
kinase	kinase	NOUN	NN	3	O
receptors	receptor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
Trks	Trks	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
micturition	micturition	NOUN	NN	5	O
reflexes	reflex	NOUN	NNS	5	O
with	with	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	B-Disease
bladder	bladder	NOUN	NN	9	I-Disease
inflammation	inflammation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
examine	examine	VERB	VBP	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
another	another	DET	DT	9	O
receptor	receptor	NOUN	NN	3	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
bind	bind	VERB	VB	1	O
NGF	NGF	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
p75	p75	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
NTR	NTR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
various	various	ADJ	JJ	9	O
durations	duration	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
inflammation	inflammation	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CYP	CYP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CYP	CYP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
increased	increase	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
p75	p75	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
NTR	NTR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
superficial	superficial	ADJ	JJ	5	O
lateral	lateral	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
medial	medial	ADJ	JJ	5	O
dorsal	dorsal	ADJ	JJ	5	O
horn	horn	NOUN	NN	5	O
in	in	ADP	IN	5	O
L1	L1	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
L2	L2	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
L6	L6	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
S1	s1	ADJ	JJ	9	O
spinal	spinal	ADJ	JJ	5	O
segments	segment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
p75	p75	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
NTR	NTR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
immunoreactive	immunoreactive	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
IR	IR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lumbosacral	lumbosacral	ADJ	JJ	5	O
dorsal	dorsal	ADJ	JJ	5	O
root	root	NOUN	NN	5	O
ganglia	ganglia	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DRG	DRG	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
also	also	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
acute	acute	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
intermediate	intermediate	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	VERB	VB	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Quantitative	quantitative	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
real	real	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
polymerase	polymerase	NOUN	NN	1	O
chain	chain	NOUN	NN	9	O
reaction	reaction	NOUN	NN	9	O
also	also	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
p75	p75	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
NTR	NTR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
mRNA	mRNA	NOUN	NNS	3	O
in	in	ADP	IN	5	O
DRG	DRG	PROPN	NNP	3	O
with	with	ADP	IN	5	O
intermediate	intermediate	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Retrograde	retrograde	ADJ	JJ	5	O
dye	dye	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
tracing	trace	VERB	VBG	5	O
techniques	technique	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Fastblue	Fastblue	PROPN	NNP	_	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
presumptive	presumptive	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
afferent	afferent	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lumbosacral	lumbosacral	ADJ	JJ	5	O
DRG	DRG	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
bladder	bladder	NOUN	NN	9	O
afferent	afferent	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
DRG	DRG	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
p75	p75	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
NTR	NTR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
IR	IR	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
cystitis	cystitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
p75	p75	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
NTR	NTR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
IR	IR	PROPN	NNP	9	O
in	in	ADP	IN	5	O
DRG	DRG	PROPN	NNP	3	O
cell	cell	NOUN	NN	3	O
bodies	body	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
increases	increase	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
pericellular	pericellular	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
encircling	encircle	VERB	VBG	5	O
DRG	DRG	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
p75	p75	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
NTR	NTR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
IR	IR	PROPN	NNP	9	O
in	in	ADP	IN	5	O
DRG	DRG	PROPN	NNP	3	O
also	also	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Confocal	confocal	ADJ	JJ	3	O
analyses	analysis	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
pericellular	pericellular	ADJ	JJ	3	O
p75	p75	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
NTR	NTR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
IR	IR	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
colocalized	colocalize	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
glial	glial	ADJ	JJ	3	O
marker	marker	NOUN	NN	3	O
,	,	PUNCT	,	9	O
glial	glial	ADJ	JJ	3	O
fibrillary	fibrillary	ADJ	JJ	3	O
acidic	acidic	ADJ	JJ	0	O
protein	protein	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
GFAP	GFAP	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	DET	DT	5	O
p75	p75	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
NTR	NTR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
micturition	micturition	NOUN	NN	5	O
reflexes	reflex	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
present	present	ADJ	JJ	9	O
constitutively	constitutively	ADV	RB	3	O
and	and	CCONJ	CC	5	O
modified	modify	VERB	VBN	9	O
by	by	ADP	IN	9	O
bladder	bladder	NOUN	NN	9	B-Disease
inflammation	inflammation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
significance	significance	NOUN	NN	9	O
of	of	ADP	IN	5	O
p75	p75	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
NTR	NTR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
micturition	micturition	NOUN	NN	5	O
reflexes	reflex	NOUN	NNS	5	O
remains	remain	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Azathioprine	Azathioprine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
suicidal	suicidal	ADJ	JJ	5	O
erythrocyte	erythrocyte	NOUN	NN	9	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Azathioprine	Azathioprine	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
include	include	VERB	VBP	5	O
anemia	anemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
suppression	suppression	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Alternatively	alternatively	ADV	RB	9	O
,	,	PUNCT	,	9	O
anemia	anemia	NOUN	NN	9	B-Disease
could	could	VERB	MD	9	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
accelerated	accelerated	ADJ	JJ	9	O
suicidal	suicidal	ADJ	JJ	5	O
erythrocyte	erythrocyte	NOUN	NN	9	O
death	death	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
eryptosis	eryptosis	NOUN	NN	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
of	of	ADP	IN	5	O
phosphatidylserine	phosphatidylserine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PS	PS	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
erythrocyte	erythrocyte	NOUN	NN	9	O
surface	surface	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
cell	cell	NOUN	NN	3	O
shrinkage	shrinkage	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
experiments	experiment	NOUN	NNS	9	O
explored	explore	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
influences	influence	NOUN	NNS	5	O
eryptosis	eryptosis	NOUN	NN	3	O
.	.	PUNCT	.	9	O

According	accord	VERB	VBG	5	O
to	to	ADP	IN	5	O
annexin	annexin	NOUN	NN	3	O
V	v	NOUN	NN	9	O
binding	bind	VERB	VBG	1	O
,	,	PUNCT	,	9	O
erythrocytes	erythrocyte	NOUN	NNS	9	O
from	from	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
indeed	indeed	ADV	RB	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
PS	PS	PROPN	NNP	9	B-Chemical
exposure	exposure	NOUN	NN	9	O
within	within	ADP	IN	9	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
series	series	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cytosolic	cytosolic	ADJ	JJ	3	O
Ca2	Ca2	NOUN	NNS	0	B-Chemical
+	+	CCONJ	CC	9	O
activity	activity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Fluo3	fluo3	ADP	IN	0	B-Chemical
fluorescence	fluorescence	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
cell	cell	NOUN	NN	3	O
volume	volume	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
forward	forward	ADV	RB	9	O
scatter	scatter	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
PS	PS	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
exposure	exposure	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
annexin	annexin	NOUN	NN	3	O
V	v	NOUN	NN	9	O
binding	bind	VERB	VBG	1	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
FACS	fac	NOUN	NNS	3	O
analysis	analysis	NOUN	NN	9	O
in	in	ADP	IN	5	O
erythrocytes	erythrocyte	NOUN	NNS	9	O
from	from	ADP	IN	9	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Exposure	exposure	NOUN	NN	9	O
to	to	PART	TO	5	O
azathioprine	azathioprine	VERB	VB	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
2	2	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
48	48	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
increased	increase	VERB	VBD	9	O
cytosolic	cytosolic	ADJ	JJ	3	O
Ca2	Ca2	NOUN	NNS	0	B-Chemical
+	+	CCONJ	CC	9	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
annexin	annexin	NOUN	NN	3	O
V	v	NOUN	NN	9	O
binding	bind	VERB	VBG	1	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
forward	forward	ADV	RB	9	O
scatter	scatter	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
both	both	DET	DT	9	O
annexin	annexin	NOUN	NN	3	O
V	v	NOUN	NN	9	O
binding	bind	VERB	VBG	1	O
and	and	CCONJ	CC	5	O
forward	forward	ADV	RB	9	O
scatter	scatter	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
blunted	blunt	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
nominal	nominal	ADJ	JJ	9	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
extracellular	extracellular	ADJ	JJ	9	O
Ca2	Ca2	NOUN	NNS	0	B-Chemical
+	+	X	XX	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Azathioprine	Azathioprine	PROPN	NNP	0	B-Chemical
triggers	trigger	NOUN	NNS	9	O
suicidal	suicidal	VERB	VBP	5	O
erythrocyte	erythrocyte	NOUN	NN	9	O
death	death	NOUN	NN	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
presumably	presumably	ADV	RB	9	O
contributing	contribute	VERB	VBG	9	O
to	to	ADP	IN	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Levetiracetam	levetiracetam	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
adjunct	adjunct	NOUN	NN	5	O
to	to	ADP	IN	5	O
phenobarbital	phenobarbital	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
cats	cat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
efficacy	efficacy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
administered	administer	VERB	VBD	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
adjunct	adjunct	NOUN	NN	5	O
to	to	ADP	IN	5	O
phenobarbital	phenobarbital	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
cats	cat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
poorly	poorly	ADV	RB	9	O
controlled	control	VERB	VBN	5	O
suspected	suspect	VERB	VBN	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

DESIGN	DESIGN	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Open	Open	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
,	,	PUNCT	,	9	O
noncomparative	noncomparative	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

ANIMALS	ANIMALS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
12	12	NUM	CD	9	O
cats	cat	NOUN	NNS	9	O
suspected	suspect	VERB	VBN	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
poorly	poorly	ADV	RB	9	O
controlled	control	VERB	VBN	5	O
with	with	ADP	IN	5	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
unacceptable	unacceptable	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

PROCEDURES	procedure	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Cats	cat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
[	[	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
lb	lb	PROPN	NNP	9	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
PO	po	NOUN	NN	9	O
,	,	PUNCT	,	9	O
q	q	NOUN	NN	9	O
8	8	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
a	a	DET	DT	5	O
minimum	minimum	NOUN	NN	5	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
maximum	maximum	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
minimum	minimum	ADJ	JJ	5	O
serum	serum	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
elimination	elimination	NOUN	NN	9	O
half	half	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
were	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Seizure	Seizure	PROPN	NNP	5	B-Disease
frequencies	frequency	NOUN	NNS	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Median	median	ADJ	JJ	7	O
maximum	maximum	ADJ	JJ	5	O
serum	serum	NOUN	NN	9	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
median	median	ADJ	JJ	9	O
minimum	minimum	NOUN	NN	5	O
serum	serum	NOUN	NN	9	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
8	8	NUM	CD	9	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
median	median	ADJ	JJ	9	O
elimination	elimination	NOUN	NN	9	O
half	half	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
seizure	seizure	NOUN	NN	5	B-Disease
frequency	frequency	NOUN	NN	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
/	/	SYM	SYM	9	O
mo	mo	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
median	median	ADJ	JJ	9	O
seizure	seizure	NOUN	NN	5	B-Disease
frequency	frequency	NOUN	NN	5	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
42	42	NUM	CD	7	O
seizures	seizure	NOUN	NNS	5	B-Disease
/	/	SYM	SYM	9	O
mo	mo	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
cats	cat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
classified	classify	VERB	VBN	5	O
as	as	ADP	IN	5	O
having	have	VERB	VBG	5	O
responded	respond	VERB	VBN	9	O
to	to	ADP	IN	5	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ie	ie	X	FW	5	O
,	,	PUNCT	,	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cats	cat	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
transient	transient	ADJ	JJ	9	O
lethargy	lethargy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
inappetence	inappetence	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
AND	and	CCONJ	CC	2	O
CLINICAL	CLINICAL	PROPN	NNP	2	O
RELEVANCE	RELEVANCE	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Results	result	NOUN	NNS	9	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
in	in	ADP	IN	5	O
cats	cat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
adjunct	adjunct	NOUN	NN	5	O
to	to	ADP	IN	5	O
phenobarbital	phenobarbital	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
cats	cat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Serotonin	serotonin	ADP	IN	0	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
paranoia	paranoia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
ventral	ventral	ADJ	JJ	5	O
basal	basal	NOUN	NN	3	O
ganglia	ganglion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Antidepressants	antidepressant	NOUN	NNS	7	O
have	have	VERB	VBP	5	O
previously	previously	ADV	RB	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
paranoid	paranoid	ADJ	JJ	5	B-Disease
reactions	reaction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
psychiatric	psychiatric	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
paranoid	paranoid	ADJ	JJ	5	B-Disease
exacerbation	exacerbation	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
fluoxetine	fluoxetine	VERB	VBP	0	B-Chemical
and	and	CCONJ	CC	5	O
amitriptyline	amitriptyline	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
here	here	ADV	RB	5	O
.	.	PUNCT	.	9	O

Elements	element	NOUN	NNS	9	O
common	common	ADJ	JJ	5	O
to	to	ADP	IN	5	O
these	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
paranoid	paranoid	ADJ	JJ	5	B-Disease
symptomatology	symptomatology	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
psychotic	psychotic	ADJ	JJ	5	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Complicated	complicate	VERB	VBN	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
including	include	VERB	VBG	9	O
atypicality	atypicality	NOUN	NN	5	O
of	of	ADP	IN	5	O
course	course	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
symptomatology	symptomatology	NOUN	NN	5	O
,	,	PUNCT	,	9	O
chronicity	chronicity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
psychosis	psychosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
bipolarity	bipolarity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
secondary	secondary	ADJ	JJ	9	O
onset	onset	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
psychosis	psychosis	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
present	present	VERB	VB	9	O
particular	particular	ADJ	JJ	5	O
vulnerability	vulnerability	NOUN	NN	5	O
to	to	PART	TO	5	O
paranoid	paranoid	VERB	VB	5	B-Disease
exacerbations	exacerbation	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
pharmacology	pharmacology	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
neurobiology	neurobiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
paranoia	paranoia	NOUN	NN	5	B-Disease
remain	remain	VERB	VBP	9	O
cryptic	cryptic	ADJ	JJ	4	O
,	,	PUNCT	,	9	O
several	several	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
5HT3	5ht3	NUM	CD	0	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
release	release	NOUN	NN	9	O
,	,	PUNCT	,	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
noradrenergic	noradrenergic	ADJ	JJ	5	O
receptor	receptor	NOUN	NN	3	O
downregulation	downregulation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
GABAB	gabab	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
upregulation	upregulation	NOUN	NN	3	O
acting	act	VERB	VBG	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
vicinity	vicinity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ventral	ventral	ADJ	JJ	5	O
basal	basal	NOUN	NN	3	O
ganglia	ganglion	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
possibly	possibly	ADV	RB	9	O
in	in	ADP	IN	5	O
lateral	lateral	ADJ	JJ	5	O
orbitofrontal	orbitofrontal	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
anterior	anterior	ADJ	JJ	5	O
cingulate	cingulate	NOUN	NN	5	O
circuits	circuit	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
might	may	VERB	MD	9	O
apply	apply	VERB	VB	5	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
phenomenon	phenomenon	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
call	call	VERB	VBP	5	O
attention	attention	NOUN	NN	5	O
to	to	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
paranoid	paranoid	ADJ	JJ	5	B-Disease
exacerbations	exacerbation	NOUN	NNS	5	O
with	with	ADP	IN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
blockers	blocker	NOUN	NNS	9	O
in	in	ADP	IN	5	O
select	select	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
raise	raise	VERB	VB	9	O
neurobiological	neurobiological	ADJ	JJ	5	O
considerations	consideration	NOUN	NNS	5	O
regarding	regard	VERB	VBG	5	O
paranoia	paranoia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiorespiratory	cardiorespiratory	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
during	during	ADP	IN	5	O
unilateral	unilateral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
conventional	conventional	ADJ	JJ	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Spinal	Spinal	PROPN	NNP	9	O
anaesthesia	anaesthesia	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
employed	employ	VERB	VBN	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
has	have	VERB	VBZ	9	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
drawback	drawback	NOUN	NN	5	O
of	of	ADP	IN	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
spinal	spinal	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Efforts	effort	NOUN	NNS	5	O
must	must	VERB	MD	5	O
therefore	therefore	ADV	RB	5	O
continue	continue	VERB	VB	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
made	make	VERB	VBN	5	O
to	to	PART	TO	5	O
obviate	obviate	VERB	VB	5	O
this	this	DET	DT	5	O
setback	setback	NOUN	NN	5	O
OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
respiratory	respiratory	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
during	during	ADP	IN	5	O
unilateral	unilateral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
conventional	conventional	ADJ	JJ	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
With	with	ADP	IN	5	O
ethical	ethical	ADJ	JJ	5	O
approval	approval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
74	74	NUM	CD	7	O
American	American	PROPN	NNP	9	O
Society	Society	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Anesthesiologists	Anesthesiologists	PROPN	NNPS	5	O
(	(	PUNCT	-LRB-	9	O
ASA	ASA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
physical	physical	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
class	class	NOUN	NN	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
scheduled	schedule	VERB	VBN	5	O
for	for	ADP	IN	5	O
elective	elective	ADJ	JJ	5	O
unilateral	unilateral	ADJ	JJ	5	O
lower	low	ADJ	JJR	9	O
limb	limb	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
into	into	ADP	IN	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
lateral	lateral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
conventional	conventional	ADJ	JJ	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
position	position	NOUN	NN	9	O
with	with	ADP	IN	5	O
operative	operative	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
down	down	ADV	RB	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
recived	recive	VERB	VBD	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
2mls	2mls	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
25	25	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
gauge	gauge	NOUN	NN	5	O
spinal	spinal	ADJ	JJ	5	O
needle	needle	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
unilateral	unilateral	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
position	position	NOUN	NN	9	O
for	for	ADP	IN	5	O
15	15	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
following	follow	VERB	VBG	9	O
spinal	spinal	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
while	while	ADP	IN	9	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
conventional	conventional	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
turned	turn	VERB	VBN	5	O
supine	supine	NOUN	NN	5	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respiratory	respiratory	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
saturation	saturation	NOUN	NN	9	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
over	over	ADP	IN	5	O
1	1	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
unilateral	unilateral	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
conventional	conventional	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
developed	develop	VERB	VBD	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
71	71	NUM	CD	7	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
conventional	conventional	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
unilateral	unilateral	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
required	require	VERB	VBN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
conventional	conventional	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
greater	great	ADJ	JJR	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressures	pressure	NOUN	NNS	5	O
at	at	ADP	IN	9	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
and	and	CCONJ	CC	5	O
45	45	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
baseline	baseline	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
003	003	NUM	CD	2	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
004	004	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
respiratory	respiratory	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
saturations	saturation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
unilateral	unilateral	ADJ	JJ	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
fewer	few	ADJ	JJR	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
perturbations	perturbation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
instituted	institute	VERB	VBN	5	O
affected	affect	VERB	VBD	9	O
neither	neither	CCONJ	CC	9	O
the	the	DET	DT	5	O
respiratory	respiratory	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
nor	nor	CCONJ	CC	9	O
the	the	DET	DT	5	O
arterial	arterial	ADJ	JJ	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
saturation	saturation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Spectrum	Spectrum	PROPN	NNP	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
after	after	ADP	IN	9	O
generic	generic	ADJ	JJ	5	O
HAART	HAART	PROPN	NNP	5	O
in	in	ADP	IN	5	O
southern	southern	ADJ	JJ	4	O
Indian	Indian	PROPN	NNP	4	O
HIV	HIV	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
after	after	ADP	IN	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
,	,	PUNCT	,	9	O
fixed	fix	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
generic	generic	ADJ	JJ	5	O
highly	highly	ADV	RB	9	O
active	active	ADJ	JJ	9	O
antiretroviral	antiretroviral	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
HAART	HAART	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
use	use	NOUN	NN	5	O
among	among	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
individuals	individual	NOUN	NNS	5	O
in	in	ADP	IN	5	O
South	South	PROPN	NNP	4	O
India	India	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
experiences	experience	NOUN	NNS	5	O
of	of	ADP	IN	5	O
3154	3154	NUM	CD	7	O
HIV	HIV	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
individuals	individual	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
minimum	minimum	NOUN	NN	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
generic	generic	ADJ	JJ	5	O
HAART	HAART	PROPN	NNP	5	O
between	between	ADP	IN	5	O
February	February	PROPN	NNP	2	O
1996	1996	NUM	CD	2	O
and	and	CCONJ	CC	5	O
December	December	PROPN	NNP	2	O
2006	2006	NUM	CD	2	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
tertiary	tertiary	ADJ	JJ	9	O
HIV	HIV	PROPN	NNP	5	O
care	care	NOUN	NN	5	O
referral	referral	NOUN	NN	5	O
center	center	NOUN	NN	5	O
in	in	ADP	IN	5	O
South	South	PROPN	NNP	4	O
India	India	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
regimens	regimen	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
3TC	3tc	NUM	CD	0	B-Chemical
+	+	SYM	SYM	9	O
d4T	d4t	NOUN	NN	7	B-Chemical
+	+	SYM	SYM	9	O
nevirapine	nevirapine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
NVP	NVP	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
54	54	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
zidovudine	zidovudine	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
+	+	CCONJ	CC	9	O
3TC	3tc	NUM	CD	0	B-Chemical
+	+	SYM	SYM	9	O
NVP	NVP	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
3TC	3tc	NUM	CD	0	B-Chemical
+	+	SYM	SYM	9	O
d4T	d4t	NOUN	NN	7	B-Chemical
+	+	CCONJ	CC	9	O
efavirenz	efavirenz	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
EFV	EFV	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
3TC	3tc	NUM	CD	0	B-Chemical
+	+	SYM	SYM	9	O
EFV	EFV	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
median	median	NOUN	NN	9	O
CD4	CD4	NOUN	NNS	3	O
at	at	ADP	IN	9	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
event	event	NOUN	NN	5	O
were	be	VERB	VBD	9	O
rash	rash	ADJ	JJ	5	B-Disease
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
CD4	cd4	NOUN	NN	3	O
,	,	PUNCT	,	9	O
285	285	NUM	CD	7	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
microL	microL	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	NOUN	NN	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
348	348	NUM	CD	7	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
microL	microL	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
anemia	anemia	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
hemoglobin	hemoglobin	NOUN	NN	0	O
<	<	X	XX	0	O
7	7	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
CD4	cd4	NOUN	NN	3	O
,	,	PUNCT	,	9	O
165	165	NUM	CD	7	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
microL	microL	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
clinical	clinical	ADJ	JJ	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
alanine	alanine	NOUN	NN	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
>	>	X	XX	0	O
5	5	NUM	CD	9	O
times	time	NOUN	NNS	5	O
upper	upper	ADJ	JJ	9	O
limits	limit	NOUN	NNS	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
CD4	cd4	NOUN	NN	3	O
,	,	PUNCT	,	9	O
260	260	NUM	CD	9	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
microL	microL	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Women	woman	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
experience	experience	VERB	VB	5	O
lactic	lactic	ADJ	JJ	0	B-Disease
acidosis	acidosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
men	man	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
experience	experience	VERB	VB	5	O
immune	immune	ADJ	JJ	3	B-Disease
reconstitution	reconstitution	NOUN	NN	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
of	of	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
,	,	PUNCT	,	9	O
NVP	NVP	PROPN	NNP	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
rash	rash	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
d4T	d4t	NOUN	NN	7	B-Chemical
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Anemia	Anemia	PROPN	NNP	7	B-Disease
and	and	CCONJ	CC	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
often	often	ADV	RB	5	O
occur	occur	VERB	VBP	5	O
within	within	ADP	IN	9	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
initiating	initiate	VERB	VBG	9	O
generic	generic	ADJ	JJ	5	O
HAART	HAART	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Frequent	frequent	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
early	early	ADJ	JJ	9	O
monitoring	monitoring	NOUN	NN	5	O
for	for	ADP	IN	5	O
these	these	DET	DT	5	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
in	in	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
countries	country	NOUN	NNS	5	O
where	where	ADV	WRB	5	O
generic	generic	ADJ	JJ	5	O
HAART	HAART	PROPN	NNP	5	O
is	be	VERB	VBZ	5	O
increasingly	increasingly	ADV	RB	5	O
available	available	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Thalidomide	thalidomide	VERB	VB	0	B-Chemical
and	and	CCONJ	CC	5	O
sensory	sensory	ADJ	JJ	5	B-Disease
neurotoxicity	neurotoxicity	NOUN	NN	9	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
neurophysiological	neurophysiological	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Recent	recent	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
confirmed	confirm	VERB	VBD	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
sensory	sensory	ADJ	JJ	5	B-Disease
axonal	axonal	ADJ	JJ	3	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
aims	aim	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
variations	variation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
sural	sural	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
sensory	sensory	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
potential	potential	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SAP	SAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
amplitude	amplitude	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
refractory	refractory	ADJ	JJ	9	O
cutaneous	cutaneous	ADJ	JJ	5	B-Disease
lupus	lupus	NOUN	NN	9	I-Disease
erythematosus	erythematosus	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
CLE	cle	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
use	use	VERB	VB	5	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
the	the	DET	DT	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
recovery	recovery	NOUN	NN	9	O
capacity	capacity	NOUN	NN	9	O
of	of	ADP	IN	5	O
sensory	sensory	ADJ	JJ	5	O
fibres	fibre	NOUN	NNS	9	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
female	female	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CLE	cle	NOUN	NN	9	B-Disease
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
47	47	NUM	CD	7	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
were	be	VERB	VBD	9	O
analysed	analyse	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Sural	sural	ADJ	JJ	7	O
nerve	nerve	NOUN	NN	5	O
SAP	SAP	PROPN	NNP	9	O
amplitude	amplitude	NOUN	NN	5	O
reduction	reduction	NOUN	NN	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
discontinuing	discontinue	VERB	VBG	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
During	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
sural	sural	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
SAP	SAP	PROPN	NNP	9	O
amplitude	amplitude	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
baseline	baseline	VERB	VB	5	O
values	value	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
<	<	X	XX	0	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
SAP	SAP	PROPN	NNP	9	O
amplitude	amplitude	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
paresthesias	paresthesia	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
leg	leg	NOUN	NN	5	O
cramps	cramp	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
sural	sural	ADJ	JJ	5	O
SAP	SAP	PROPN	NNP	9	O
amplitude	amplitude	NOUN	NN	5	O
recovered	recover	VERB	VBD	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
sural	sural	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
SAP	SAP	PROPN	NNP	9	O
amplitude	amplitude	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
21	21	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
threshold	threshold	NOUN	NN	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
dosage	dosage	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Sural	sural	ADJ	JJ	7	O
nerve	nerve	NOUN	NN	5	O
SAP	SAP	PROPN	NNP	9	O
amplitude	amplitude	NOUN	NN	5	O
reduction	reduction	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
reliable	reliable	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
sensitive	sensitive	ADJ	JJ	9	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
degeneration	degeneration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
sensory	sensory	ADJ	JJ	5	O
fibres	fibre	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
parameter	parameter	NOUN	NN	5	O
provides	provide	VERB	VBZ	5	O
information	information	NOUN	NN	5	O
about	about	ADP	IN	5	O
subclinical	subclinical	ADJ	JJ	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
but	but	CCONJ	CC	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
helpful	helpful	ADJ	JJ	6	O
in	in	ADP	IN	5	O
predicting	predict	VERB	VBG	5	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
sensory	sensory	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
encephalitis	encephalitis	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
loiasis	loiasis	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
diethylcarbamazine	diethylcarbamazine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
encephalitis	encephalitis	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
diethylcarbamazine	diethylcarbamazine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DEC	DEC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
Congolese	congolese	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Loa	loa	ADJ	JJ	4	O
loa	loa	NOUN	NN	4	O
filariasis	filariasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
fatal	fatal	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
sequelae	sequelae	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
notable	notable	ADJ	JJ	9	O
fact	fact	NOUN	NN	9	O
was	be	VERB	VBD	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
hospitalized	hospitalize	VERB	VBN	5	O
before	before	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
began	begin	VERB	VBD	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
whom	whom	PRON	WP	5	O
particularly	particularly	ADV	RB	5	O
strict	strict	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
precautions	precaution	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
initial	initial	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
DEC	DEC	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
very	very	ADV	RB	5	O
gradual	gradual	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
increases	increase	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
associated	associate	VERB	VBN	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
allergic	allergic	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
complication	complication	NOUN	NN	5	O
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
that	that	DET	DT	5	O
uncommon	uncommon	ADJ	JJ	5	O
in	in	ADP	IN	5	O
highly	highly	ADV	RB	9	O
endemic	endemic	ADJ	JJ	4	O
regions	region	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
occurs	occur	VERB	VBZ	9	O
primarily	primarily	ADV	RB	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
exclusively	exclusively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
presenting	present	VERB	VBG	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
microfilarial	microfilarial	ADJ	JJ	5	O
load	load	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
encephalitis	encephalitis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
microfilaremia	microfilaremia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
evident	evident	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pathophysiological	pathophysiological	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
light	light	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
few	few	ADJ	JJ	5	O
other	other	ADJ	JJ	5	O
comments	comment	NOUN	NNS	6	O
on	on	ADP	IN	5	O
this	this	DET	DT	5	O
subject	subject	NOUN	NN	5	O
published	publish	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Amiodarone	amiodarone	ADV	RB	7	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
mass	mass	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
unique	unique	ADJ	JJ	9	O
membranous	membranous	ADJ	JJ	9	B-Disease
glomerulonephritis	glomerulonephritis	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
valvular	valvular	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
Diagnostic	diagnostic	ADJ	JJ	5	O
pitfall	pitfall	NOUN	NN	4	O
and	and	CCONJ	CC	5	O
new	new	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Amiodarone	Amiodarone	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
arrhythmic	arrhythmic	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
various	various	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Reported	report	VERB	VBN	5	O
herein	herein	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
autopsy	autopsy	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
valvular	valvular	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
lung	lung	NOUN	NN	9	B-Disease
mass	mass	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
cm	cm	NOUN	NNS	9	O
in	in	ADP	IN	5	O
diameter	diameter	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
proteinuria	proteinuria	VERB	VB	9	B-Disease
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
76	76	NUM	CD	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
long	long	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
lung	lung	NOUN	NN	9	B-Disease
mass	mass	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
highly	highly	ADV	RB	9	O
suspected	suspect	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
lung	lung	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
on	on	ADP	IN	5	O
CT	CT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
positron	positron	NOUN	NN	5	O
emission	emission	NOUN	NN	0	O
tomography	tomography	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
histologically	histologically	ADV	RB	9	O
the	the	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
was	be	VERB	VBD	9	O
composed	compose	VERB	VBN	9	O
of	of	ADP	IN	5	O
lymphoplasmacytic	lymphoplasmacytic	ADJ	JJ	5	O
infiltrates	infiltrate	NOUN	NNS	9	O
in	in	ADP	IN	5	O
alveolar	alveolar	ADJ	JJ	3	O
walls	wall	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
alveolar	alveolar	ADJ	JJ	3	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
foamy	foamy	NOUN	NN	3	O
macrophages	macrophage	NOUN	NNS	3	O
containing	contain	VERB	VBG	0	O
characteristic	characteristic	ADJ	JJ	9	O
myelinoid	myelinoid	NOUN	NN	0	O
bodies	body	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
an	an	DET	DT	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
lesion	lesion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
lung	lung	NOUN	NN	9	O
tissue	tissue	NOUN	NN	9	O
had	have	VERB	VBD	9	O
unevenly	unevenly	ADV	RB	5	O
distributed	distribute	VERB	VBN	5	O
hemosiderin	hemosiderin	NOUN	NN	5	B-Disease
deposition	deposition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
abnormally	abnormally	ADV	RB	9	O
tortuous	tortuous	ADJ	JJ	5	O
capillaries	capillary	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mass	mass	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
heavily	heavily	ADV	RB	5	O
hemosiderotic	hemosiderotic	ADJ	JJ	5	B-Disease
lung	lung	NOUN	NN	9	O
portions	portion	NOUN	NNS	9	O
outside	outside	ADP	IN	5	O
the	the	DET	DT	5	O
mass	mass	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
glomeruli	glomerulus	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
membrane	membrane	NOUN	NN	9	O
spikes	spike	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
prominent	prominent	ADJ	JJ	9	O
swelling	swelling	NOUN	NN	5	O
of	of	ADP	IN	5	O
podocytes	podocyte	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
subepithelial	subepithelial	ADJ	JJ	5	O
deposits	deposit	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
sometimes	sometimes	ADV	RB	5	O
large	large	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
hump	hump	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Autoimmune	Autoimmune	PROPN	NNP	9	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
viral	viral	ADJ	JJ	9	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
malignant	malignant	ADJ	JJ	3	O
neoplasms	neoplasm	NOUN	NNS	5	B-Disease
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
diseases	disease	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
known	know	VERB	VBN	9	O
relationship	relationship	NOUN	NN	5	O
to	to	ADP	IN	5	O
membranous	membranous	ADJ	JJ	9	B-Disease
glomerulonephritis	glomerulonephritis	NOUN	NN	3	I-Disease
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
highlights	highlight	VERB	VBZ	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
differential	differential	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
between	between	ADP	IN	5	O
an	an	DET	DT	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
lesion	lesion	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
neoplasm	neoplasm	NOUN	NN	5	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
very	very	ADV	RB	5	O
difficult	difficult	ADJ	JJ	5	O
radiologically	radiologically	ADV	RB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
membranous	membranous	ADJ	JJ	9	B-Disease
glomerulonephritis	glomerulonephritis	NOUN	NN	3	I-Disease
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
another	another	DET	DT	9	O
possible	possible	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
sulphonylurea	sulphonylurea	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
type	type	NOUN	NN	9	B-Disease
2	2	NUM	CD	9	I-Disease
diabetes	diabete	NOUN	NNS	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
matched	matched	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

AIMS	aims	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
sought	seek	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CAD	CAD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
type	type	NOUN	NN	9	B-Disease
2	2	NUM	CD	9	I-Disease
diabetes	diabete	NOUN	NNS	5	I-Disease
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
sulphonylureas	sulphonylurea	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
type	type	NOUN	NN	9	B-Disease
2	2	NUM	CD	9	I-Disease
diabetic	diabetic	ADJ	JJ	9	I-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
cases	case	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
CAD	CAD	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
retrospectively	retrospectively	ADV	RB	5	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
that	that	DET	WDT	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
CAD	CAD	PROPN	NNP	5	B-Disease
at	at	ADP	IN	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
UKPDS	UKPDS	PROPN	NNP	5	O
risk	risk	NOUN	NN	5	O
engine	engine	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
match	match	VERB	VB	5	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
76	76	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
CAD	CAD	PROPN	NNP	5	B-Disease
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
152	152	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hazard	hazard	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
CAD	CAD	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	PUNCT	LS	9	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
004	004	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
glibenclamide	glibenclamide	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
2	2	PUNCT	LS	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
099	099	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
glipizide	glipizide	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
000	000	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
with	with	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hazard	hazard	NOUN	NN	5	O
decreased	decrease	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	PUNCT	LS	9	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
385	385	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
glimepiride	glimepiride	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
192	192	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
gliclazide	gliclazide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Initiating	initiate	VERB	VBG	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
type	type	NOUN	NN	9	B-Disease
2	2	NUM	CD	9	I-Disease
diabetes	diabete	NOUN	NNS	5	I-Disease
with	with	ADP	IN	5	O
glibenclamide	glibenclamide	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
glipizide	glipizide	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
CAD	CAD	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
to	to	PART	TO	5	O
gliclazide	gliclazide	VERB	VB	0	B-Chemical
or	or	CCONJ	CC	5	O
glimepiride	glimepiride	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

If	if	ADP	IN	5	O
confirmed	confirm	VERB	VBN	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
important	important	ADJ	JJ	9	O
because	because	ADP	IN	5	O
most	most	ADJ	JJS	9	O
Indian	indian	ADJ	JJ	4	O
patients	patient	NOUN	NNS	5	O
receive	receive	VERB	VBP	5	O
the	the	DET	DT	5	O
cheaper	cheap	ADJ	JJR	5	O
older	old	ADJ	JJR	5	O
sulphonylureas	sulphonylurea	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
present	present	ADJ	JJ	9	O
guidelines	guideline	NOUN	NNS	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
distinguish	distinguish	VERB	VB	9	O
between	between	ADP	IN	5	O
individual	individual	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Reduced	reduce	VERB	VBN	9	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
losartan	losartan	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	II	PROPN	NNP	9	I-Chemical
type	type	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
receptor	receptor	NOUN	NN	3	O
blocker	blocker	NOUN	NN	0	O
,	,	PUNCT	,	9	O
losartan	losartan	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
potential	potential	NOUN	NN	9	O
in	in	ADP	IN	5	O
slowing	slow	VERB	VBG	5	O
down	down	PART	RP	9	O
renal	renal	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
progression	progression	NOUN	NN	9	O
in	in	ADP	IN	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
SHR	SHR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
adriamycin	adriamycin	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Six	six	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
female	female	ADJ	JJ	9	O
SHR	SHR	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
selected	select	VERB	VBN	9	O
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
SH	SH	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
SH	SH	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBN	9	O
vehicle	vehicle	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Groups	group	NOUN	NNS	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
+	+	SYM	SYM	9	O
LOS	LOS	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
+	+	SYM	SYM	9	O
LOS	LOS	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
w	w	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
twice	twice	ADV	RB	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
interval	interval	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Group	Group	PROPN	NNP	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
+	+	CCONJ	CC	9	O
LOS	LOS	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
losartan	losartan	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
w	w	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
by	by	ADP	IN	9	O
gavages	gavage	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
group	group	NOUN	NN	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
+	+	SYM	SYM	9	O
LOS	LOS	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
second	second	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
killed	kill	VERB	VBN	9	O
after	after	ADP	IN	9	O
6	6	NUM	CD	9	O
or	or	CCONJ	CC	5	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Haemodynamic	haemodynamic	ADJ	JJ	5	O
measurements	measurement	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
anaesthetized	anaesthetized	ADJ	JJ	0	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
for	for	ADP	IN	5	O
biochemical	biochemical	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
kidney	kidney	NOUN	NN	9	O
was	be	VERB	VBD	9	O
processed	process	VERB	VBN	9	O
for	for	ADP	IN	5	O
morphological	morphological	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
losartan	losartan	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
besides	besides	ADP	IN	9	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
improved	improve	VERB	VBN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ameliorated	ameliorate	VERB	VBN	9	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Prolonged	prolonged	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
losartan	losartan	NOUN	NN	0	B-Chemical
showed	show	VERB	VBD	9	O
further	further	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
reduced	reduced	ADJ	JJ	9	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
atrophy	atrophy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
fibrosis	fibrosis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
preventing	prevent	VERB	VBG	9	O
heavy	heavy	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
chronic	chronic	VERB	VB	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Losartan	Losartan	PROPN	NNP	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
uraemia	uraemia	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
urea	urea	ADJ	JJ	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
in	in	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Histological	histological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
losartan	losartan	ADJ	JJ	0	B-Chemical
could	could	VERB	MD	9	O
prevent	prevent	VERB	VB	5	O
tubular	tubular	ADJ	JJ	9	O
atrophy	atrophy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
interstitial	interstitial	ADJ	JJ	9	O
infiltration	infiltration	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Losartan	Losartan	PROPN	NNP	0	B-Chemical
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
focal	focal	ADJ	JJ	5	B-Disease
segmental	segmental	NOUN	NN	5	I-Disease
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	I-Disease
to	to	ADP	IN	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risks	risk	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aprotinin	aprotinin	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
1188	1188	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
aim	aim	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
postoperative	postoperative	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
aprotinin	aprotinin	NOUN	NN	0	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
tranexamic	tranexamic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
unselected	unselected	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
consecutive	consecutive	ADJ	JJ	5	O
cohort	cohort	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Perioperative	perioperative	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
consecutive	consecutive	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
prospectively	prospectively	ADV	RB	5	O
collected	collect	VERB	VBN	9	O
between	between	ADP	IN	5	O
September	September	PROPN	NNP	2	O
2005	2005	NUM	CD	2	O
and	and	CCONJ	CC	5	O
June	June	PROPN	NNP	2	O
2006	2006	NUM	CD	2	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
university	university	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
affiliated	affiliate	VERB	VBN	2	O
clinic	clinic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
1188	1188	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
5	5	NUM	CD	9	O
mo	mo	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
596	596	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
aprotinin	aprotinin	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
5	5	NUM	CD	9	O
mo	mo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
592	592	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
T	T	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
antifibrinolytic	antifibrinolytic	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
surgical	surgical	ADJ	JJ	5	O
protocols	protocol	NOUN	NNS	5	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
and	and	CCONJ	CC	5	O
intraoperative	intraoperative	ADJ	JJ	5	O
variables	variable	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Postoperatively	postoperatively	ADV	RB	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
T	T	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
valve	valve	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
subgroups	subgroup	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
003	003	NUM	CD	2	O
;	;	SYM	SYM	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
035	035	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Persistent	persistent	ADJ	JJ	9	O
atrial	atrial	ADJ	JJ	5	O
fibrillation	fibrillation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
020	020	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
T	T	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
valve	valve	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
subgroup	subgroup	NOUN	NN	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
contrary	contrary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
among	among	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
bypass	bypass	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarctions	infarction	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
027	027	NUM	CD	9	O
;	;	PUNCT	:	9	O
22	22	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
036	036	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
yr	yr	NOUN	NN	7	O
mortality	mortality	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
after	after	ADP	IN	9	O
aprotinin	aprotinin	ADJ	JJ	0	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
034	034	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Both	both	DET	DT	9	O
antifibrinolytic	antifibrinolytic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
bear	bear	VERB	VBP	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
depending	depend	VERB	VBG	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
aprotinin	aprotinin	NOUN	NN	0	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
avoided	avoid	VERB	VBN	5	O
in	in	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
bypass	bypass	NOUN	NN	5	O
graft	graft	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
recommended	recommend	VERB	VBN	5	O
in	in	ADP	IN	5	O
valve	valve	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Delirium	delirium	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
possibly	possibly	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Misoprostol	Misoprostol	PROPN	NNP	5	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
gynecologic	gynecologic	ADJ	JJ	5	O
problems	problem	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
headache	headache	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
an	an	DET	DT	5	O
89	89	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
care	care	NOUN	NN	5	O
facility	facility	NOUN	NN	5	O
became	become	VERB	VBD	9	O
confused	confused	ADJ	JJ	4	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
was	be	VERB	VBD	9	O
first	first	ADV	RB	9	O
reported	report	VERB	VBN	9	O
nine	nine	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
delirium	delirium	NOUN	NN	5	B-Disease
significantly	significantly	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
after	after	ADP	IN	9	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
her	-PRON-	DET	PRP$	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
within	within	ADP	IN	9	O
a	a	DET	DT	5	O
week	week	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
changed	change	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
delirium	delirium	NOUN	NN	5	B-Disease
experienced	experience	VERB	VBN	5	O
by	by	ADP	IN	9	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
possibly	possibly	ADV	RB	9	O
resulted	result	VERB	VBD	9	O
from	from	ADP	IN	9	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
biological	biological	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
optical	optical	ADJ	JJ	5	O
isomers	isomer	NOUN	NNS	0	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

1	1	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
optical	optical	ADJ	JJ	5	O
isomers	isomer	NOUN	NNS	0	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
compared	compare	VERB	VBN	9	O
for	for	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocking	blocking	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
activities	activity	NOUN	NNS	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
blocking	block	VERB	VBG	3	O
the	the	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
inotropic	inotropic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
chronotropic	chronotropic	VERB	VB	5	O
responses	response	NOUN	NNS	5	O
to	to	PART	TO	5	O
isoprenaline	isoprenaline	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
one	one	NUM	CD	5	O
hundredth	hundredth	VERB	VBZ	5	O
the	the	DET	DT	5	O
potency	potency	NOUN	NN	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
dose	dose	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
which	which	DET	WDT	5	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
responses	response	NOUN	NNS	5	O
to	to	PART	TO	5	O
isoprenaline	isoprenaline	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
prolongation	prolongation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
PR	pr	NOUN	NN	9	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
.	.	PUNCT	.	9	O
3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
metabolic	metabolic	NOUN	NN	9	O
responses	response	NOUN	NNS	5	O
to	to	PART	TO	5	O
isoprenaline	isoprenaline	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
circulating	circulate	VERB	VBG	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
lactate	lactate	VERB	VB	0	B-Chemical
and	and	CCONJ	CC	5	O
free	free	ADJ	JJ	9	O
fatty	fatty	ADJ	JJ	0	B-Chemical
acids	acid	NOUN	NNS	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
all	all	DET	DT	5	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
Propranolol	Propranolol	PROPN	NNP	0	B-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
fatty	fatty	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
mobilization	mobilization	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
increments	increment	NOUN	NNS	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
lactate	lactate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
glucose	glucose	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
isomers	isomer	NOUN	NNS	0	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
possessed	possess	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
depressant	depressant	ADJ	JJ	5	O
potency	potency	NOUN	NN	9	O
on	on	ADP	IN	5	O
isolated	isolated	ADJ	JJ	9	O
atrial	atrial	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
taken	take	VERB	VBN	5	O
from	from	ADP	IN	9	O
guinea	guinea	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
pigs	pig	NOUN	NNS	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
isomers	isomer	NOUN	NNS	0	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
exhibited	exhibit	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
local	local	ADJ	JJ	5	O
anaesthetic	anaesthetic	ADJ	JJ	5	O
potencies	potency	NOUN	NNS	0	O
on	on	ADP	IN	5	O
an	an	DET	DT	5	O
isolated	isolated	ADJ	JJ	9	O
frog	frog	NOUN	NN	9	O
nerve	nerve	NOUN	NN	5	O
preparation	preparation	NOUN	NN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
level	level	NOUN	NN	9	O
approximately	approximately	ADV	RB	9	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
procaine	procaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
racemic	racemic	NOUN	NN	0	O
compound	compound	NOUN	NN	0	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
than	than	ADP	IN	5	O
either	either	CCONJ	CC	9	O
isomer	isomer	NOUN	NN	0	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
isomers	isomer	NOUN	NNS	0	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
capable	capable	ADJ	JJ	9	O
of	of	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
cats	cat	NOUN	NNS	9	O
anaesthetized	anaesthetize	VERB	VBN	0	O
with	with	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
whereas	whereas	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
prolongation	prolongation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
PR	pr	NOUN	NN	9	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
with	with	ADP	IN	5	O
both	both	DET	DT	9	O
isomers	isomer	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
surmountable	surmountable	ADJ	JJ	5	O
by	by	ADP	IN	9	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
isomers	isomer	NOUN	NNS	0	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
capable	capable	ADJ	JJ	9	O
of	of	ADP	IN	5	O
reversing	reverse	VERB	VBG	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
anaesthetized	anaesthetized	ADJ	JJ	0	O
cats	cat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
smaller	small	ADJ	JJR	5	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
species	specie	NOUN	NNS	4	O
but	but	CCONJ	CC	9	O
much	much	ADV	RB	5	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
required	require	VERB	VBN	9	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockade	blockade	NOUN	NN	3	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
implications	implication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Topotecan	Topotecan	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
radiotherapy	radiotherapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
unresectable	unresectable	ADJ	JJ	5	O
glioblastoma	glioblastoma	NOUN	NN	3	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
2	2	NUM	CD	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Improving	improve	VERB	VBG	5	O
glioblastoma	glioblastoma	NOUN	NN	3	B-Disease
multiforme	multiforme	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
GBM	GBM	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
radio	radio	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
chemotherapy	chemotherapy	NOUN	NN	5	O
remains	remain	VERB	VBZ	9	O
a	a	DET	DT	5	O
challenge	challenge	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Topotecan	Topotecan	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
attractive	attractive	ADJ	JJ	5	O
option	option	NOUN	NN	5	O
as	as	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
exhibits	exhibit	VERB	VBZ	9	O
growth	growth	NOUN	NN	3	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
glioma	glioma	NOUN	NN	3	B-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
penetration	penetration	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
radiotherapy	radiotherapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
Gy	Gy	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
30	30	NUM	CD	9	O
fractions	fraction	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
40	40	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
topotecan	topotecan	VERB	VB	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
on	on	ADP	IN	5	O
weeks	week	NOUN	NNS	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
50	50	NUM	CD	0	O
adults	adult	NOUN	NNS	5	O
with	with	ADP	IN	5	O
histologically	histologically	ADV	RB	9	O
proven	prove	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
untreated	untreated	ADJ	JJ	3	O
GBM	GBM	NOUN	NNS	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
hematological	hematological	ADJ	JJ	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
hematological	hematological	ADJ	JJ	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mainly	mainly	ADV	RB	9	O
lymphopenia	lymphopenia	ADJ	JJ	3	B-Disease
and	and	CCONJ	CC	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
stabilization	stabilization	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
32	32	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
overall	overall	ADJ	JJ	5	O
survival	survival	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OS	OS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
42	42	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
OS	os	NOUN	NN	9	O
of	of	ADP	IN	5	O
40	40	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Topotecan	Topotecan	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
radiotherapy	radiotherapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
stabilization	stabilization	NOUN	NN	9	O
concerned	concern	VERB	VBD	5	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
third	third	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
show	show	VERB	VB	9	O
increased	increase	VERB	VBN	9	O
benefits	benefit	NOUN	NNS	5	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
survival	survival	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
unresectable	unresectable	ADJ	JJ	5	O
GBM	GBM	NOUN	NNS	9	B-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
hyperparathyroidism	hyperparathyroidism	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
reviews	review	VERB	VBZ	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
on	on	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
parathyroid	parathyroid	ADJ	JJ	9	O
glands	gland	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
pathogenesis	pathogenesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
options	option	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
recurrent	recurrent	ADJ	JJ	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
to	to	PART	TO	5	O
better	better	ADV	RB	5	O
understand	understand	VERB	VB	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Primary	primary	ADJ	JJ	9	B-Disease
hyperparathyroidism	hyperparathyroidism	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
potentially	potentially	ADV	RB	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Careful	careful	ADJ	JJ	5	O
patient	patient	ADJ	JJ	5	O
selection	selection	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
can	can	VERB	MD	5	O
reduce	reduce	VERB	VB	5	O
morbidity	morbidity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PRACTICAL	practical	ADJ	JJ	2	O
IMPLICATIONS	implications	NOUN	NN	2	O
:	:	PUNCT	:	9	O
As	as	ADV	RB	9	O
much	much	ADJ	JJ	5	O
as	as	ADP	IN	5	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
become	become	VERB	VBP	5	O
hypercalcemic	hypercalcemic	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
routinely	routinely	ADV	RB	9	O
monitoring	monitor	VERB	VBG	5	O
serum	serum	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
healthcare	healthcare	NOUN	NN	5	O
providers	provider	NOUN	NNS	5	O
can	can	VERB	MD	5	O
improve	improve	VERB	VB	5	O
the	the	DET	DT	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
laryngeal	laryngeal	ADJ	JJ	5	O
mask	mask	NOUN	NN	5	O
with	with	ADP	IN	5	O
endotracheal	endotracheal	ADJ	JJ	5	O
tube	tube	NOUN	NN	9	O
for	for	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
in	in	ADP	IN	5	O
endoscopic	endoscopic	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
surgical	surgical	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
intraoperative	intraoperative	ADJ	JJ	5	O
bleeding	bleeding	NOUN	NN	5	B-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
intraoperative	intraoperative	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
functional	functional	ADJ	JJ	9	O
endoscopic	endoscopic	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
FESS	FESS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
using	use	VERB	VBG	9	O
flexible	flexible	ADJ	JJ	5	O
reinforced	reinforce	VERB	VBN	5	O
laryngeal	laryngeal	ADJ	JJ	5	O
mask	mask	NOUN	NN	5	O
airway	airway	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
FRLMA	FRLMA	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
endotracheal	endotracheal	ADJ	JJ	5	O
tube	tube	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ETT	ETT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
maintaining	maintain	VERB	VBG	9	O
controlled	control	VERB	VBN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
anesthesia	anesthesia	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
propofol	propofol	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
total	total	NOUN	NN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
anesthesia	anesthesia	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
TIVA	tiva	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Sixty	sixty	NUM	CD	5	O
normotensive	normotensive	ADJ	JJ	9	O
American	American	PROPN	NNP	9	O
Society	Society	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Anesthesiologists	Anesthesiologists	PROPN	NNPS	5	O
I	I	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
II	II	PROPN	NNP	9	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
FESS	FESS	PROPN	NNP	5	O
under	under	ADP	IN	9	O
controlled	control	VERB	VBN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
anesthesia	anesthesia	NOUN	NN	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
propofol	propofol	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
TIVA	tiva	NOUN	NN	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
into	into	ADP	IN	9	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
group	group	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
,	,	PUNCT	,	9	O
FRLMA	FRLMA	PROPN	NNP	_	O
;	;	PUNCT	:	9	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
ETT	ETT	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Hemorrhage	Hemorrhage	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
visibility	visibility	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
operative	operative	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
six	six	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
point	point	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Controlled	control	VERB	VBN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
within	within	ADP	IN	9	O
a	a	DET	DT	5	O
shorter	short	ADJ	JJR	9	O
period	period	NOUN	NN	5	O
using	use	VERB	VBG	9	O
laryngeal	laryngeal	ADJ	JJ	5	O
mask	mask	NOUN	NN	5	O
using	use	VERB	VBG	9	O
lower	low	ADJ	JJR	9	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
summary	summary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
airway	airway	NOUN	NN	5	O
management	management	NOUN	NN	5	O
using	use	VERB	VBG	9	O
FRLMA	FRLMA	PROPN	NNP	_	O
during	during	ADP	IN	5	O
controlled	control	VERB	VBN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
anesthesia	anesthesia	NOUN	NN	5	O
provided	provide	VERB	VBD	9	O
better	well	ADJ	JJR	5	O
surgical	surgical	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
operative	operative	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
loss	loss	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
allowed	allow	VERB	VBN	9	O
for	for	ADP	IN	5	O
convenient	convenient	ADJ	JJ	5	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
during	during	ADP	IN	5	O
TIVA	TIVA	PROPN	NNP	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
FESS	FESS	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Nonalcoholic	Nonalcoholic	PROPN	NNP	2	B-Disease
fatty	fatty	ADJ	JJ	0	I-Disease
liver	liver	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Valproic	Valproic	PROPN	NNP	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
effective	effective	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
many	many	ADJ	JJ	5	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
nonalcoholic	nonalcoholic	ADJ	JJ	5	B-Disease
fatty	fatty	ADJ	JJ	0	I-Disease
liver	liver	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
NAFLD	NAFLD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
arising	arise	VERB	VBG	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
child	child	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
obesity	obesity	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Laboratory	laboratory	NOUN	NN	2	O
data	datum	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
hyperinsulinemia	hyperinsulinemia	ADV	RB	5	B-Disease
with	with	ADP	IN	5	O
insulin	insulin	NOUN	NN	3	B-Disease
resistance	resistance	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
body	body	NOUN	NN	5	O
mass	mass	NOUN	NN	9	O
index	index	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
normalization	normalization	NOUN	NN	5	O
of	of	ADP	IN	5	O
metabolic	metabolic	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
endocrine	endocrine	NOUN	NN	9	O
parameters	parameter	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
ultrasound	ultrasound	ADJ	JJ	5	O
measurements	measurement	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
normalization	normalization	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
obesity	obesity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hyperinsulinemia	hyperinsulinemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
insulin	insulin	NOUN	NN	3	B-Disease
resistance	resistance	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
all	all	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
NAFLD	NAFLD	PROPN	NNP	9	B-Disease
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
reversible	reversible	ADJ	JJ	9	O
after	after	ADP	IN	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Carbimazole	Carbimazole	PROPN	NNP	0	B-Chemical
induced	induce	VERB	VBD	3	O
ANCA	ANCA	PROPN	NNP	3	B-Disease
positive	positive	ADJ	JJ	9	I-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Anti	anti	ADJ	JJ	3	B-Chemical
-	-	ADJ	JJ	7	I-Chemical
thyroid	thyroid	ADJ	JJ	9	I-Chemical
drugs	drug	NOUN	NNS	5	I-Chemical
,	,	PUNCT	,	9	O
like	like	ADP	IN	9	O
carbimazole	carbimazole	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PTU	PTU	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
commonly	commonly	ADV	RB	5	O
prescribed	prescribe	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
hyperthyroidism	hyperthyroidism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

One	one	PRON	PRP	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
antithyroid	antithyroid	ADJ	JJ	0	B-Chemical
medications	medication	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

Antineutrophil	antineutrophil	NOUN	NN	3	B-Disease
cytoplasmic	cytoplasmic	ADJ	JJ	3	I-Disease
antibody	antibody	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
ANCA	ANCA	PROPN	NNP	3	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
-	-	PUNCT	:	7	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
associated	associate	VERB	VBN	9	I-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
antithyroidmedications	antithyroidmedication	NOUN	NNS	_	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
Graves	Graves	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
ANCA	anca	ADJ	JJ	3	O
positive	positive	ADJ	JJ	9	O
carbimazole	carbimazole	NOUN	NN	5	B-Chemical
induced	induce	VERB	VBN	3	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
episode	episode	NOUN	NN	5	O
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
vasculitic	vasculitic	ADJ	JJ	5	B-Disease
skin	skin	NOUN	NN	5	B-Disease
rash	rash	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
large	large	ADJ	JJ	5	O
joint	joint	ADJ	JJ	5	O
arthritis	arthritis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
pyrexia	pyrexia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
parotiditis	parotiditis	NOUN	NN	5	B-Disease
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
renal	renal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
involvement	involvement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
referred	refer	VERB	VBN	5	O
to	to	ADP	IN	5	O
us	-PRON-	PRON	PRP	5	O
for	for	ADP	IN	5	O
neurological	neurological	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
because	because	ADP	IN	5	O
he	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
difficulty	difficulty	NOUN	NN	5	O
in	in	ADP	IN	5	O
getting	get	VERB	VBG	5	O
up	up	PART	RP	5	O
from	from	ADP	IN	9	O
squatting	squatting	NOUN	NN	5	O
position	position	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
myositis	myositis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Carbimazole	Carbimazole	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
methimazole	methimazole	NOUN	NN	0	B-Chemical
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
reported	reported	ADJ	JJ	9	O
ANCA	anca	ADJ	JJ	3	O
positive	positive	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
than	than	ADP	IN	5	O
PUT	PUT	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
the	the	DET	DT	5	O
best	good	ADJ	JJS	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
ANCA	ANCA	PROPN	NNP	3	O
positive	positive	ADJ	JJ	9	O
carbimazole	carbimazole	NOUN	NN	5	B-Chemical
induced	induce	VERB	VBN	3	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
case	case	NOUN	NN	5	O
reported	report	VERB	VBD	9	O
from	from	ADP	IN	9	O
India	India	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

Aspirin	Aspirin	PROPN	NNP	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
update	update	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
U	u	NOUN	NN	9	O
.	.	PUNCT	.	9	O
S	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Preventive	Preventive	PROPN	NNP	2	O
Services	Services	PROPN	NNPS	2	O
Task	Task	PROPN	NNP	5	O
Force	Force	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Coronary	coronary	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
cerebrovascular	cerebrovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
leading	lead	VERB	VBG	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
2002	2002	NUM	CD	2	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
U	u	NOUN	NN	9	O
.	.	PUNCT	.	9	O
S	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Preventive	Preventive	PROPN	NNP	2	O
Services	Services	PROPN	NNPS	2	O
Task	Task	PROPN	NNP	5	O
Force	Force	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
USPSTF	USPSTF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
strongly	strongly	ADV	RB	9	O
recommended	recommend	VERB	VBD	5	O
that	that	ADP	IN	5	O
clinicians	clinician	NOUN	NNS	5	O
discuss	discuss	VERB	VBP	5	O
aspirin	aspirin	ADV	RB	9	B-Chemical
with	with	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
at	at	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
benefits	benefit	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
harms	harm	NOUN	NNS	5	O
of	of	ADP	IN	5	O
taking	take	VERB	VBG	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarctions	infarction	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
strokes	stroke	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

DATA	DATA	PROPN	NNP	2	O
SOURCES	source	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
MEDLINE	MEDLINE	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Cochrane	Cochrane	PROPN	NNP	5	O
Library	Library	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
search	search	NOUN	NN	5	O
dates	date	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
January	January	PROPN	NNP	2	O
2001	2001	NUM	CD	2	O
to	to	ADP	IN	5	O
28	28	NUM	CD	7	O
August	August	PROPN	NNP	2	O
2008	2008	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
recent	recent	ADJ	JJ	5	O
systematic	systematic	ADJ	JJ	5	O
reviews	review	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
reference	reference	NOUN	NN	9	O
lists	list	NOUN	NNS	5	O
of	of	ADP	IN	5	O
retrieved	retrieve	VERB	VBN	9	O
articles	article	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
suggestions	suggestion	NOUN	NNS	6	O
from	from	ADP	IN	9	O
experts	expert	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

STUDY	study	NOUN	NN	2	O
SELECTION	selection	NOUN	NN	2	O
:	:	PUNCT	:	9	O
English	english	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
language	language	NOUN	NN	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
controlled	control	VERB	VBN	5	O
trials	trial	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
RCTs	RCTs	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
studies	study	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
meta	meta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
analyses	analysis	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
systematic	systematic	ADJ	JJ	5	O
reviews	review	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	ADJ	JJ	9	B-Chemical
versus	versus	ADP	IN	9	O
control	control	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CVD	CVD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
selected	select	VERB	VBN	9	O
to	to	PART	TO	5	O
answer	answer	VERB	VB	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
questions	question	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Does	do	VERB	VBZ	5	O
aspirin	aspirin	ADV	RB	9	B-Chemical
decrease	decrease	VERB	VB	9	O
coronary	coronary	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
strokes	stroke	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
death	death	NOUN	NN	9	O
from	from	ADP	IN	9	O
coronary	coronary	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
events	event	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
stroke	stroke	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
all	all	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
cause	cause	NOUN	NN	5	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
without	without	ADP	IN	9	O
known	know	VERB	VBN	9	O
CVD	CVD	PROPN	NNP	5	B-Disease
?	?	PUNCT	.	5	O

Does	do	VERB	VBZ	5	O
aspirin	aspirin	ADV	RB	9	B-Chemical
increase	increase	VERB	VB	9	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
bleeding	bleeding	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
hemorrhagic	hemorrhagic	NOUN	NN	5	B-Disease
strokes	stroke	NOUN	NNS	5	I-Disease
?	?	PUNCT	.	5	O

DATA	DATA	PROPN	NNP	2	O
EXTRACTION	EXTRACTION	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
reviewed	review	VERB	VBN	9	O
,	,	PUNCT	,	9	O
abstracted	abstract	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
rated	rate	VERB	VBN	5	O
for	for	ADP	IN	5	O
quality	quality	NOUN	NN	5	O
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
predefined	predefine	VERB	VBN	5	O
USPSTF	uspstf	NOUN	NN	5	O
criteria	criterion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

DATA	DATA	PROPN	NNP	2	O
SYNTHESIS	SYNTHESIS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
New	new	ADJ	JJ	2	O
evidence	evidence	NOUN	NN	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
good	good	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
quality	quality	NOUN	NN	5	O
RCT	RCT	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
good	good	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
quality	quality	NOUN	NN	5	O
meta	meta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
fair	fair	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
quality	quality	NOUN	NN	5	O
subanalyses	subanalyse	NOUN	NNS	5	O
of	of	ADP	IN	5	O
RCTs	rct	NOUN	NNS	5	O
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
aspirin	aspirin	ADJ	JJ	9	B-Chemical
use	use	NOUN	NN	5	O
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
CVD	CVD	PROPN	NNP	5	B-Disease
events	event	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
known	know	VERB	VBN	9	O
CVD	CVD	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Men	man	NOUN	NNS	7	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
experienced	experience	VERB	VBD	5	O
fewer	few	ADJ	JJR	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarctions	infarction	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
women	woman	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
fewer	few	ADJ	JJR	5	O
ischemic	ischemic	ADJ	JJ	9	O
strokes	stroke	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Aspirin	Aspirin	PROPN	NNP	0	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
seem	seem	VERB	VB	5	O
to	to	PART	TO	5	O
affect	affect	VERB	VB	9	O
CVD	CVD	PROPN	NNP	5	B-Disease
mortality	mortality	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
all	all	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
cause	cause	NOUN	NN	5	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
men	man	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
prevention	prevention	NOUN	NN	5	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
major	major	ADJ	JJ	9	O
bleeding	bleeding	NOUN	NN	5	B-Disease
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
primarily	primarily	ADV	RB	9	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
bleeding	bleeding	NOUN	NN	5	I-Disease
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Men	man	NOUN	NNS	7	O
have	have	VERB	VBP	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
strokes	stroke	NOUN	NNS	5	I-Disease
with	with	ADP	IN	5	O
aspirin	aspirin	ADJ	JJ	9	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
new	new	ADJ	JJ	5	O
RCT	RCT	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
meta	meta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
analysis	analysis	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
strokes	stroke	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
statistically	statistically	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
.	.	PUNCT	.	9	O

LIMITATIONS	limitation	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
New	new	ADJ	JJ	2	O
evidence	evidence	NOUN	NN	9	O
on	on	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
CVD	CVD	PROPN	NNP	5	B-Disease
is	be	VERB	VBZ	5	O
limited	limit	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
RCTs	rcts	ADJ	JJ	5	O
varied	varied	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
estimation	estimation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
appropriate	appropriate	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
for	for	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
prevention	prevention	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
RCTs	rct	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
within	within	ADP	IN	9	O
populations	population	NOUN	NNS	9	O
of	of	ADP	IN	5	O
health	health	NOUN	NN	5	O
professionals	professional	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
potentially	potentially	ADV	RB	5	O
limits	limit	VERB	VBZ	5	O
generalizability	generalizability	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Aspirin	Aspirin	PROPN	NNP	0	B-Chemical
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
strokes	stroke	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Aspirin	Aspirin	PROPN	NNP	0	B-Chemical
use	use	NOUN	NN	5	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
bleeding	bleeding	NOUN	NN	5	B-Disease
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Reducing	reduce	VERB	VBG	9	O
harm	harm	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
:	:	PUNCT	:	9	O
practical	practical	ADJ	JJ	5	O
considerations	consideration	NOUN	NNS	5	O
of	of	ADP	IN	5	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Argatroban	Argatroban	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
hepatically	hepatically	ADV	RB	0	O
metabolized	metabolize	VERB	VBN	0	O
,	,	PUNCT	,	9	O
direct	direct	ADJ	JJ	9	O
thrombin	thrombin	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
prophylaxis	prophylaxis	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
HIT	HIT	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
undergoing	undergo	VERB	VBG	9	O
percutaneous	percutaneous	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
intervention	intervention	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PCI	PCI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
review	review	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
summarize	summarize	VERB	VB	5	O
practical	practical	ADJ	JJ	5	O
considerations	consideration	NOUN	NNS	5	O
of	of	ADP	IN	5	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
US	US	PROPN	NNP	5	O
FDA	FDA	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
recommended	recommend	VERB	VBN	5	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
dose	dose	NOUN	NN	9	O
in	in	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
is	be	VERB	VBZ	5	O
2	2	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
paediatric	paediatric	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
adjusted	adjust	VERB	VBN	9	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
activated	activate	VERB	VBN	3	O
partial	partial	ADJ	JJ	9	O
thromboplastin	thromboplastin	NOUN	NN	5	O
times	time	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
aPTTs	aPTTs	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
baseline	baseline	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
not	not	ADV	RB	5	O
>	>	X	XX	0	O
100	100	NUM	CD	0	O
seconds	second	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Contemporary	contemporary	ADJ	JJ	5	O
experiences	experience	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
reduced	reduce	VERB	VBN	9	O
doses	dose	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
needed	need	VERB	VBN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
conditions	condition	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
hypoperfusion	hypoperfusion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
e	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
yet	yet	CCONJ	CC	9	O
are	be	VERB	VBP	5	O
unnecessary	unnecessary	ADJ	JJ	5	O
for	for	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
adult	adult	NOUN	NN	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
race	race	NOUN	NN	5	O
/	/	SYM	SYM	9	O
ethnicity	ethnicity	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
obesity	obesity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Argatroban	Argatroban	PROPN	NNP	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
typically	typically	ADV	RB	5	O
supports	support	VERB	VBZ	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
aPTTs	aptts	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
FDA	FDA	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
recommended	recommend	VERB	VBN	5	O
dose	dose	NOUN	NN	9	O
during	during	ADP	IN	5	O
PCI	PCI	PROPN	NNP	5	O
is	be	VERB	VBZ	5	O
25	25	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
350	350	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
initial	initial	ADJ	JJ	9	O
bolus	bolus	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
adjusted	adjust	VERB	VBN	9	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
activated	activate	VERB	VBN	3	O
clotting	clot	VERB	VBG	5	O
times	time	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
ACTs	ACTs	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
300	300	NUM	CD	0	O
-	-	SYM	SYM	7	O
450	450	NUM	CD	9	O
sec	sec	NOUN	NN	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
PCI	PCI	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
argatroban	argatroban	NOUN	NN	5	B-Chemical
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
hepatically	hepatically	ADV	RB	0	O
impaired	impair	VERB	VBN	9	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	,	9	O
dose	dose	NOUN	NN	9	O
adjustment	adjustment	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
unnecessary	unnecessary	ADJ	JJ	5	O
for	for	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
race	race	NOUN	NN	5	O
/	/	SYM	SYM	9	O
ethnicity	ethnicity	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
obesity	obesity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
lesser	less	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
adequate	adequate	ADJ	JJ	5	O
with	with	ADP	IN	5	O
concurrent	concurrent	ADJ	JJ	5	O
glycoprotein	glycoprotein	NOUN	NN	3	O
IIb	IIb	NOUN	NNS	9	O
/	/	SYM	SYM	9	O
IIIa	IIIa	NOUN	NNS	9	O
inhibition	inhibition	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Argatroban	Argatroban	PROPN	NNP	0	B-Chemical
prolongs	prolong	NOUN	NNS	9	O
the	the	DET	DT	5	O
International	International	PROPN	NNP	2	O
Normalized	Normalized	PROPN	NNP	9	O
Ratio	Ratio	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
published	publish	VERB	VBN	9	O
approaches	approach	NOUN	NNS	5	O
for	for	ADP	IN	5	O
monitoring	monitor	VERB	VBG	5	O
the	the	DET	DT	5	O
argatroban	argatroban	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
transition	transition	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
followed	follow	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Major	major	ADJ	JJ	9	O
bleeding	bleeding	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
argatroban	argatroban	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
interventional	interventional	ADJ	JJ	5	O
setting	setting	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
periprocedurally	periprocedurally	ADV	RB	5	O
.	.	PUNCT	.	9	O

Argatroban	Argatroban	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
no	no	DET	DT	9	O
specific	specific	ADJ	JJ	9	O
antidote	antidote	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
if	if	ADP	IN	5	O
excessive	excessive	ADJ	JJ	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
occurs	occur	VERB	VBZ	9	O
,	,	PUNCT	,	9	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
stopped	stop	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Improved	improved	ADJ	JJ	9	O
familiarity	familiarity	NOUN	NN	5	O
of	of	ADP	IN	5	O
healthcare	healthcare	NOUN	NN	5	O
professionals	professional	NOUN	NNS	5	O
with	with	ADP	IN	5	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
in	in	ADP	IN	5	O
special	special	ADJ	JJ	5	O
populations	population	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
PCI	PCI	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
facilitate	facilitate	VERB	VB	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
harm	harm	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
e	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O
fewer	few	ADJ	JJR	5	O
thromboses	thrombose	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
e	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O
fewer	few	ADJ	JJR	5	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
medication	medication	NOUN	NN	5	O
errors	error	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
heroin	heroin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
male	male	NOUN	NN	9	O
under	under	ADP	IN	9	O
methadone	methadone	NOUN	NN	5	B-Chemical
maintenance	maintenance	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
several	several	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
heroin	heroin	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
.	.	PUNCT	.	9	O

Methadone	Methadone	PROPN	NNP	7	B-Chemical
may	may	VERB	MD	5	O
aggravate	aggravate	VERB	VB	9	O
this	this	DET	DT	5	O
problem	problem	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
clinical	clinical	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
description	description	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
33	33	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
cerebral	cerebral	ADJ	JJ	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
heroin	heroin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
used	use	VERB	VBN	5	O
heroin	heroin	NOUN	NN	5	B-Chemical
since	since	ADP	IN	9	O
age	age	NOUN	NN	5	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
used	use	VERB	VBN	5	O
150	150	NUM	CD	0	O
mg	mg	NUM	CD	0	O
methadone	methadone	NOUN	NN	5	B-Chemical
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
unconsciousness	unconsciousness	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
home	home	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
sent	send	VERB	VBN	5	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
ER	ER	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
his	-PRON-	DET	PRP$	5	O
opiate	opiate	ADJ	JJ	5	O
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
4497	4497	NUM	CD	7	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
ICU	ICU	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
transfer	transfer	NOUN	NN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
internal	internal	ADJ	JJ	5	O
ward	ward	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
noted	note	VERB	VBD	9	O
aphasia	aphasia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
weakness	weakness	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
left	left	ADJ	JJ	5	O
limbs	limb	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
MRI	MRI	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
ischemic	ischemic	ADJ	JJ	9	I-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Those	those	DET	DT	5	O
using	use	VERB	VBG	9	O
methadone	methadone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
heroin	heroin	VERB	VB	5	B-Chemical
simultaneously	simultaneously	ADV	RB	5	O
may	may	VERB	MD	5	O
increase	increase	VERB	VB	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
under	under	ADP	IN	9	O
methadone	methadone	NOUN	NN	5	B-Chemical
maintenance	maintenance	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
warned	warn	VERB	VBN	5	O
regarding	regard	VERB	VBG	5	O
these	these	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hypotheses	hypothesis	NOUN	NNS	5	O
of	of	ADP	IN	5	O
heroin	heroin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
stroke	stroke	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
heroin	heroin	NOUN	NN	5	B-Chemical
abusers	abuser	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
vulnerability	vulnerability	NOUN	NN	5	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxydopamine	hydroxydopamine	NOUN	NN	0	I-Chemical
lesion	lesion	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
lacking	lack	VERB	VBG	1	O
CB1	CB1	NOUN	NNS	3	O
cannabinoid	cannabinoid	NOUN	NN	3	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Motor	motor	NOUN	NN	5	O
impairment	impairment	NOUN	NN	5	O
,	,	PUNCT	,	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
DA	DA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
neuronal	neuronal	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
proenkephalin	proenkephalin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
PENK	PENK	PROPN	NNP	7	B-Chemical
)	)	PUNCT	-RRB-	9	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
caudate	caudate	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
putamen	putaman	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
CPu	CPu	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
lesioned	lesione	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
treated	treat	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
+	+	SYM	SYM	9	I-Chemical
benserazide	benserazide	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
CB1	CB1	VERB	VBZ	3	O
KO	KO	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
WT	WT	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
lesion	lesion	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	OHDA	PROPN	NNP	0	I-Chemical
produced	produce	VERB	VBD	9	O
more	more	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
deterioration	deterioration	NOUN	NN	5	O
in	in	ADP	IN	5	O
CB1	CB1	PROPN	NNP	3	O
KO	KO	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
more	more	ADJ	JJR	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
neurons	neuron	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
PENK	PENK	PROPN	NNP	7	B-Chemical
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
CPu	CPu	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Oxidative	oxidative	ADJ	JJ	9	O
/	/	SYM	SYM	9	O
nitrosative	nitrosative	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
neuroinflammatory	neuroinflammatory	ADJ	JJ	3	O
parameters	parameter	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
CPu	CPu	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
cingulate	cingulate	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
Cg	Cg	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CB1	CB1	NOUN	NNS	3	O
KO	KO	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
exhibited	exhibit	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
iNOS	iNOS	PROPN	NNP	3	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
CPu	CPu	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
Cg	Cg	PROPN	NNP	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
WT	WT	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
+	+	CCONJ	CC	9	I-Chemical
benserazide	benserazide	VERB	VB	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
less	less	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
CB1	CB1	PROPN	NNP	3	O
KO	KO	PROPN	NNP	3	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
WT	WT	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
cannabinoid	cannabinoid	NOUN	NN	3	O
CB1	CB1	NOUN	NNS	3	O
receptors	receptor	NOUN	NNS	3	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
impairment	impairment	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
DA	DA	PROPN	NNP	9	B-Chemical
lesion	lesion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
CB1	CB1	NOUN	NNS	3	O
receptors	receptor	NOUN	NNS	3	O
offers	offer	VERB	VBZ	5	O
neuroprotection	neuroprotection	NOUN	NN	3	O
against	against	ADP	IN	9	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
lesion	lesion	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Hepatocellular	hepatocellular	ADJ	JJ	9	O
oxidant	oxidant	ADJ	JJ	0	O
stress	stress	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
intestinal	intestinal	ADJ	JJ	9	O
ischemia	ischemia	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
reperfusion	reperfusion	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Reperfusion	reperfusion	NOUN	NN	9	O
of	of	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
intestine	intestine	NOUN	NN	9	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
hepatocellular	hepatocellular	ADJ	JJ	9	O
enzyme	enzyme	ADJ	JJ	0	O
release	release	NOUN	NN	9	O
into	into	ADP	IN	9	O
plasma	plasma	NOUN	NN	9	O
,	,	PUNCT	,	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
bile	bile	NOUN	NN	0	O
flow	flow	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
neutrophil	neutrophil	NOUN	NN	3	O
sequestration	sequestration	NOUN	NN	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
underlying	underlie	VERB	VBG	5	O
this	this	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
oxidants	oxidant	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
several	several	ADJ	JJ	9	O
indirect	indirect	ADJ	JJ	5	O
methods	method	NOUN	NNS	5	O
of	of	ADP	IN	5	O
assessing	assess	VERB	VBG	5	O
oxidant	oxidant	ADJ	JJ	0	O
exposure	exposure	NOUN	NN	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
standardized	standardized	ADJ	JJ	5	O
intestinal	intestinal	ADJ	JJ	9	O
ischemia	ischemia	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
reperfusion	reperfusion	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Hepatic	hepatic	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assayed	assay	VERB	VBN	3	O
for	for	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
products	product	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
oxidized	oxidize	VERB	VBN	0	B-Chemical
and	and	CCONJ	CC	5	I-Chemical
reduced	reduce	VERB	VBN	9	I-Chemical
glutathione	glutathione	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
total	total	ADJ	JJ	9	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
following	follow	VERB	VBG	9	O
intestinal	intestinal	ADJ	JJ	9	O
ischemia	ischemia	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
reperfusion	reperfusion	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Oxidized	oxidize	VERB	VBN	0	B-Chemical
glutathione	glutathione	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GSSG	GSSG	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
following	follow	VERB	VBG	9	O
30	30	NUM	CD	9	O
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
reperfusion	reperfusion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
products	product	NOUN	NNS	9	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
injury	injury	NOUN	NN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
GSSG	GSSG	PROPN	NNP	0	B-Chemical
within	within	ADP	IN	9	O
hepatic	hepatic	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
during	during	ADP	IN	5	O
intestinal	intestinal	ADJ	JJ	9	O
reperfusion	reperfusion	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
exposure	exposure	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatocytes	hepatocyte	NOUN	NNS	3	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
oxidant	oxidant	ADJ	JJ	0	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
products	product	NOUN	NNS	9	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
oxidant	oxidant	ADJ	JJ	0	O
stress	stress	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
of	of	ADP	IN	5	O
insufficient	insufficient	ADJ	JJ	5	O
magnitude	magnitude	NOUN	NN	5	O
to	to	PART	TO	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
irreversible	irreversible	ADJ	JJ	9	O
injury	injury	NOUN	NN	9	O
to	to	ADP	IN	5	O
hepatocyte	hepatocyte	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
membranes	membrane	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
also	also	ADV	RB	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
tissue	tissue	NOUN	NN	9	O
GSSG	GSSG	PROPN	NNP	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
sensitive	sensitive	ADJ	JJ	9	O
indicator	indicator	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxidant	oxidant	ADJ	JJ	0	O
stress	stress	NOUN	NN	9	O
than	than	ADP	IN	5	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
products	product	NOUN	NNS	9	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Animal	animal	ADJ	JJ	2	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
mania	mania	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
Evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
in	in	ADP	IN	5	O
submitochondrial	submitochondrial	ADJ	JJ	0	O
particles	particle	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
intracerebroventricular	intracerebroventricular	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
ICV	ICV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
Na	Na	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
ATPase	ATPase	PROPN	NNP	1	O
inhibitor	inhibitor	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
to	to	PART	TO	5	O
mimic	mimic	VERB	VB	9	O
some	some	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
mania	mania	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Herein	Herein	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
ICV	ICV	PROPN	NNP	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
achieve	achieve	VERB	VB	5	O
this	this	DET	DT	5	O
aim	aim	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ouabain	ouabain	ADJ	JJ	0	B-Chemical
injection	injection	NOUN	NN	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
ICV	ICV	PROPN	NNP	9	O
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
at	at	ADP	IN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
M	M	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
locomotion	locomotion	NOUN	NN	5	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
field	field	NOUN	NN	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
thiobarbituric	thiobarbituric	ADJ	JJ	0	B-Chemical
acid	acid	ADJ	JJ	0	I-Chemical
reactive	reactive	ADJ	JJ	9	O
substances	substance	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
TBARSs	tbars	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
production	production	NOUN	NN	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
submitochondrial	submitochondrial	ADJ	JJ	0	O
particles	particle	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
prefrontal	prefrontal	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hippocampus	hippocampus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
striatum	striatum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
amygdala	amygdala	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
M	M	PROPN	NNP	9	O
induced	induced	ADJ	JJ	3	O
hyperlocomotion	hyperlocomotion	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
response	response	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
ICV	ICV	PROPN	NNP	9	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
observed	observe	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
persistent	persistent	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
spontaneous	spontaneous	ADJ	JJ	5	O
locomotion	locomotion	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
TBARS	TBARS	PROPN	NNP	0	O
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
generation	generation	NOUN	NN	9	O
in	in	ADP	IN	5	O
submitochondrial	submitochondrial	ADJ	JJ	0	O
particles	particle	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prefrontal	prefrontal	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
striatum	striatum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
amygdala	amygdala	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mania	mania	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behavior	behavior	NOUN	NN	5	O
may	may	VERB	MD	5	O
provide	provide	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
to	to	PART	TO	5	O
test	test	VERB	VB	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
in	in	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Intraoperative	intraoperative	ADJ	JJ	5	O
dialysis	dialysis	NOUN	NN	5	O
during	during	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
with	with	ADP	IN	5	O
citrate	citrate	ADJ	JJ	0	B-Chemical
dialysate	dialysate	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
for	for	ADP	IN	5	O
acutely	acutely	ADV	RB	9	O
ill	ill	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
carries	carry	VERB	VBZ	9	O
high	high	ADJ	JJ	9	O
intraoperative	intraoperative	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
immediate	immediate	ADJ	JJ	5	O
postoperative	postoperative	ADJ	JJ	5	O
risks	risk	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
are	be	VERB	VBP	5	O
increased	increase	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
acute	acute	ADJ	JJ	9	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
AKI	AKI	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
intraoperative	intraoperative	ADJ	JJ	5	O
dialysis	dialysis	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
sometimes	sometimes	ADV	RB	5	O
required	require	VERB	VBN	9	O
to	to	PART	TO	5	O
allow	allow	VERB	VB	5	O
the	the	DET	DT	5	O
transplant	transplant	NOUN	NN	9	O
to	to	PART	TO	5	O
proceed	proceed	VERB	VB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
derangements	derangement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
procoagulant	procoagulant	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
anticoagulant	anticoagulant	ADJ	JJ	9	O
pathways	pathway	NOUN	NNS	9	O
during	during	ADP	IN	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
can	can	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
difficulties	difficulty	NOUN	NNS	5	O
with	with	ADP	IN	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
during	during	ADP	IN	5	O
dialysis	dialysis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
when	when	ADV	WRB	5	O
continued	continue	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
operating	operating	NOUN	NN	5	O
room	room	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
anticoagulation	anticoagulation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
unsafe	unsafe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
regional	regional	ADJ	JJ	5	O
citrate	citrate	ADJ	JJ	0	B-Chemical
anticoagulation	anticoagulation	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	O
carries	carry	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
citrate	citrate	ADJ	JJ	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Citrate	citrate	ADJ	JJ	0	B-Chemical
dialysate	dialysate	NOUN	NN	0	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
dialysate	dialysate	NOUN	NN	0	O
with	with	ADP	IN	5	O
citric	citric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
cannot	cannot	VERB	VBP	5	O
tolerate	tolerate	ADJ	JJ	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
regional	regional	ADJ	JJ	5	O
citrate	citrate	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
40	40	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
female	female	NOUN	NN	9	O
with	with	ADP	IN	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
associated	associate	VERB	VBN	9	O
AKI	AKI	PROPN	NNP	5	B-Disease
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
intraoperative	intraoperative	ADJ	JJ	5	O
dialytic	dialytic	ADJ	JJ	5	O
support	support	NOUN	NN	5	O
during	during	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
anticoagulated	anticoagulate	VERB	VBN	5	O
with	with	ADP	IN	5	O
citrate	citrate	ADJ	JJ	0	B-Chemical
dialysate	dialysate	NOUN	NN	0	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
procedure	procedure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
tolerated	tolerate	VERB	VBD	9	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
well	well	ADV	RB	9	O
without	without	ADP	IN	9	O
any	any	DET	DT	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
citrate	citrate	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
maintained	maintain	VERB	VBD	9	O
adequate	adequate	ADJ	JJ	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
for	for	ADP	IN	5	O
patency	patency	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dialysis	dialysis	NOUN	NN	5	O
circuit	circuit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Citrate	citrate	ADJ	JJ	0	B-Chemical
dialysate	dialysate	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
alternative	alternative	NOUN	NN	5	O
for	for	ADP	IN	5	O
intradialytic	intradialytic	ADJ	JJ	5	O
support	support	NOUN	NN	5	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
in	in	ADP	IN	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Delirium	delirium	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
describe	describe	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
delirium	delirium	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
69	69	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
white	white	ADJ	JJ	9	O
female	female	NOUN	NN	9	O
presented	present	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
confusion	confusion	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
paranoia	paranoia	NOUN	NN	5	B-Disease
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	ADJ	JJ	5	O
several	several	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
taking	take	VERB	VBG	5	O
carvedilol	carvedilol	NOUN	NN	0	B-Chemical
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
levothyroxine	levothyroxine	NOUN	NN	5	B-Chemical
100	100	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
pantoprazole	pantoprazole	VERB	VB	0	B-Chemical
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
paroxetine	paroxetine	VERB	VB	0	B-Chemical
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
flecainide	flecainide	VERB	VB	0	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
.	.	PUNCT	.	9	O

Flecainide	Flecainide	PROPN	NNP	0	B-Chemical
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
started	start	VERB	VBN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
for	for	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Laboratory	laboratory	NOUN	NN	2	O
test	test	NOUN	NN	5	O
findings	finding	NOUN	NNS	9	O
on	on	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
were	be	VERB	VBD	9	O
notable	notable	ADJ	JJ	9	O
only	only	ADV	RB	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
plasma	plasma	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
1360	1360	NUM	CD	7	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
reference	reference	NOUN	NN	9	O
range	range	NOUN	NN	9	O
200	200	NUM	CD	0	O
-	-	SYM	SYM	7	O
1000	1000	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
metabolic	metabolic	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
taking	take	VERB	VBG	5	O
for	for	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Paroxetine	Paroxetine	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
to	to	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
delirium	delirium	NOUN	NN	5	B-Disease
resolved	resolve	VERB	VBD	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Flecainide	flecainide	VERB	VB	0	B-Chemical
and	and	CCONJ	CC	5	O
pharmacologically	pharmacologically	ADV	RB	9	O
similar	similar	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
that	that	DET	WDT	5	O
interact	interact	VERB	VBP	9	O
with	with	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
channels	channel	NOUN	NNS	9	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
delirium	delirium	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
susceptible	susceptible	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
MEDLINE	MEDLINE	PROPN	NNP	5	O
search	search	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1966	1966	NUM	CD	2	O
-	-	SYM	SYM	7	O
January	January	PROPN	NNP	2	O
2009	2009	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
revealed	reveal	VERB	VBD	9	O
one	one	NUM	CD	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
CYP2D6	cyp2d6	NOUN	NN	9	O
substrate	substrate	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
CYP2D6	CYP2D6	PROPN	NNP	9	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
3	3	NUM	CD	9	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
delirium	delirium	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

According	accord	VERB	VBG	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Naranjo	Naranjo	PROPN	NNP	6	O
probability	probability	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
,	,	PUNCT	,	9	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
probable	probable	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
delirium	delirium	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
Horn	Horn	PROPN	NNP	4	O
Drug	Drug	PROPN	NNP	5	O
Interaction	Interaction	PROPN	NNP	9	O
Probability	Probability	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
indicates	indicate	VERB	VBZ	9	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Supratherapeutic	supratherapeutic	ADJ	JJ	9	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
delirium	delirium	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
when	when	ADV	WRB	5	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
prescribed	prescribe	VERB	VBN	5	O
with	with	ADP	IN	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
potent	potent	ADJ	JJ	3	O
CYP2D6	cyp2d6	NOUN	NN	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
flecainide	flecainide	NOUN	NN	0	B-Chemical
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
monitored	monitor	VERB	VBN	9	O
closely	closely	ADV	RB	9	O
with	with	ADP	IN	5	O
commencement	commencement	NOUN	NN	5	O
of	of	ADP	IN	5	O
CYP2D6	CYP2D6	PROPN	NNP	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Efficacy	efficacy	NOUN	NN	5	O
of	of	ADP	IN	5	O
everolimus	everolimus	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
RAD001	RAD001	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
previously	previously	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
with	with	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
EGFR	egfr	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Treatment	treatment	NOUN	NN	9	O
options	option	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
scarce	scarce	ADJ	JJ	5	O
in	in	ADP	IN	5	O
pretreated	pretreate	VERB	VBN	3	O
advanced	advanced	ADJ	JJ	5	O
non	non	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
small	small	ADJ	JJ	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
cell	cell	NOUN	NN	3	I-Disease
lung	lung	NOUN	NN	9	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
NSCLC	nsclc	NOUN	NN	3	B-Disease
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RAD001	RAD001	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mammalian	mammalian	ADJ	JJ	9	O
target	target	NOUN	NN	9	O
of	of	ADP	IN	5	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
mTOR	mTOR	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
shown	show	VERB	VBN	9	O
phase	phase	NOUN	NN	5	O
I	-PRON-	PRON	PRP	9	O
efficacy	efficacy	VERB	VBP	9	O
in	in	ADP	IN	5	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Stage	stage	VERB	VB	9	O
IIIb	IIIb	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
IV	IV	PROPN	NNP	9	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
two	two	NUM	CD	5	O
or	or	CCONJ	CC	5	O
fewer	few	ADJ	JJR	5	O
prior	prior	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
regimens	regimen	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
platinum	platinum	NOUN	NN	0	B-Chemical
based	base	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
stratum	stratum	VERB	VB	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
epidermal	epidermal	ADJ	JJ	3	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
tyrosine	tyrosine	NOUN	NN	3	B-Chemical
kinase	kinase	NUM	CD	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
stratum	stratum	VERB	VB	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
received	receive	VERB	VBD	9	O
RAD001	RAD001	PROPN	NNP	3	B-Chemical
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
until	until	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
unacceptable	unacceptable	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Primary	primary	ADJ	JJ	9	O
objective	objective	NOUN	NN	5	O
was	be	VERB	VBD	9	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ORR	ORR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Analyses	analysis	NOUN	NNS	9	O
of	of	ADP	IN	5	O
markers	marker	NOUN	NNS	3	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
mTOR	mTOR	PROPN	NNP	3	O
pathway	pathway	NOUN	NN	3	O
were	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
on	on	ADP	IN	5	O
archival	archival	ADJ	JJ	5	O
tumor	tumor	NOUN	NN	3	B-Disease
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
subgroup	subgroup	NOUN	NN	9	O
using	use	VERB	VBG	9	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
IHC	IHC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
direct	direct	ADJ	JJ	9	O
mutation	mutation	NOUN	NN	1	O
sequencing	sequencing	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Eighty	eighty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
,	,	PUNCT	,	9	O
42	42	NUM	CD	7	O
in	in	ADP	IN	5	O
stratum	stratum	NOUN	NN	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
43	43	NUM	CD	7	O
in	in	ADP	IN	5	O
stratum	stratum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

ORR	ORR	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
stratum	stratum	NOUN	NN	9	O
1	1	NUM	CD	9	O
;	;	SYM	SYM	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
stratum	stratum	NOUN	NN	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Overall	overall	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
control	control	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
47	47	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
progression	progression	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
survivals	survival	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
PFSs	pfs	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
stratum	stratum	VERB	VB	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
stratum	stratum	VERB	VB	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Common	Common	PROPN	NNP	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
fatigue	fatigue	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
dyspnea	dyspnea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
stomatitis	stomatitis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
anemia	anemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Pneumonitis	Pneumonitis	PROPN	NNP	7	B-Disease
,	,	PUNCT	,	9	O
probably	probably	ADV	RB	9	O
or	or	CCONJ	CC	5	O
possibly	possibly	ADV	RB	9	O
related	relate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
mainly	mainly	ADV	RB	9	O
grade	grade	VERB	VB	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cox	cox	NOUN	NN	9	O
regression	regression	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
IHC	IHC	PROPN	NNP	9	O
scores	score	NOUN	NNS	5	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
only	only	ADV	RB	9	O
phospho	phospho	NOUN	NN	3	O
AKT	AKT	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
pAKT	pAKT	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
independent	independent	ADJ	JJ	9	O
predictor	predictor	NOUN	NN	5	O
of	of	ADP	IN	5	O
worse	bad	ADJ	JJR	5	O
PFS	PFS	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
RAD001	rad001	NOUN	NN	3	B-Chemical
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
showing	show	VERB	VBG	9	O
modest	modest	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
pretreated	pretreate	VERB	VBN	3	O
NSCLC	nsclc	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
RAD001	RAD001	PROPN	NNP	3	B-Chemical
plus	plus	CCONJ	CC	9	O
standard	standard	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
continues	continue	VERB	VBZ	5	O
.	.	PUNCT	.	9	O

Posttransplant	posttransplant	ADJ	JJ	5	O
anemia	anemia	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Posttransplant	posttransplant	ADJ	JJ	5	O
anemia	anemia	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
problem	problem	NOUN	NN	5	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
hinder	hinder	VERB	VB	5	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
to	to	PART	TO	5	O
76	76	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
immediate	immediate	ADJ	JJ	5	O
posttransplant	posttransplant	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
factors	factor	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
identified	identify	VERB	VBN	9	O
that	that	ADP	IN	5	O
increase	increase	NOUN	NN	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
posttransplant	posttransplant	ADJ	JJ	5	O
anemia	anemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
most	most	ADV	RBS	9	O
important	important	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Sirolimus	Sirolimus	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
mammalian	mammalian	ADJ	JJ	9	O
target	target	NOUN	NN	9	O
of	of	ADP	IN	5	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
as	as	ADP	IN	5	O
playing	play	VERB	VBG	5	O
a	a	DET	DT	5	O
special	special	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
posttransplant	posttransplant	ADJ	JJ	5	O
anemia	anemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
review	review	NOUN	NN	5	O
considers	consider	VERB	VBZ	5	O
anemia	anemia	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
its	-PRON-	DET	PRP$	9	O
presentation	presentation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
mechanisms	mechanism	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Coronary	coronary	ADJ	JJ	5	O
computerized	computerized	ADJ	JJ	5	O
tomography	tomography	NOUN	NN	5	O
angiography	angiography	ADV	RB	5	O
for	for	ADP	IN	5	O
rapid	rapid	ADJ	JJ	5	O
discharge	discharge	NOUN	NN	5	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Most	Most	ADJ	JJS	5	O
patients	patient	NOUN	NNS	5	O
presenting	present	VERB	VBG	5	O
to	to	ADP	IN	5	O
emergency	emergency	NOUN	NN	5	O
departments	department	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
EDs	EDs	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
admitted	admit	VERB	VBN	5	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
12	12	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
receive	receive	VERB	VB	5	O
a	a	DET	DT	5	O
"	"	PUNCT	``	5	O
rule	rule	NOUN	NN	5	O
out	out	ADP	IN	9	O
acute	acute	ADJ	JJ	9	B-Disease
coronary	coronary	ADJ	JJ	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
"	"	PUNCT	''	5	O
protocol	protocol	NOUN	NN	9	O
,	,	PUNCT	,	9	O
often	often	ADV	RB	5	O
with	with	ADP	IN	5	O
noninvasive	noninvasive	ADJ	JJ	5	O
testing	testing	NOUN	NN	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
discharge	discharge	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
coronary	coronary	ADJ	JJ	5	O
computerized	computerized	ADJ	JJ	5	O
tomography	tomography	NOUN	NN	5	O
angiography	angiography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CTA	CTA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
for	for	ADP	IN	5	O
identifying	identify	VERB	VBG	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
low	low	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
who	who	PRON	WP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
safely	safely	ADV	RB	5	O
discharged	discharge	VERB	VBN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
unclear	unclear	ADJ	JJ	9	O
whether	whether	ADP	IN	9	O
a	a	DET	DT	5	O
coronary	coronary	ADJ	JJ	5	O
CTA	cta	NOUN	NN	9	O
strategy	strategy	NOUN	NN	5	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
efficacious	efficacious	ADJ	JJ	5	O
in	in	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
vasospasm	vasospasm	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
account	account	VERB	VB	5	O
for	for	ADP	IN	5	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
a	a	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
CTA	CTA	PROPN	NNP	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
could	could	VERB	MD	9	O
identify	identify	VERB	VB	9	O
a	a	DET	DT	5	O
subset	subset	NOUN	NN	9	O
safe	safe	ADJ	JJ	5	O
for	for	ADP	IN	5	O
discharge	discharge	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
prospectively	prospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	O
CTA	CTA	PROPN	NNP	9	O
for	for	ADP	IN	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
presented	present	VERB	VBD	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
ED	ED	PROPN	NNP	5	O
with	with	ADP	IN	5	O
cocaineassociated	cocaineassociated	ADJ	JJ	_	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
reported	report	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
positive	positive	ADJ	JJ	9	O
urine	urine	NOUN	NN	9	O
test	test	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
immediate	immediate	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
CTA	CTA	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ED	ED	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
without	without	ADP	IN	9	O
serial	serial	ADJ	JJ	9	O
markers	marker	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
underwent	undergo	VERB	VBD	5	O
coronary	coronary	ADJ	JJ	5	O
CTA	CTA	PROPN	NNP	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
brief	brief	ADJ	JJ	5	O
observation	observation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
with	with	ADP	IN	5	O
serial	serial	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
marker	marker	NOUN	NN	3	O
measurements	measurement	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
negative	negative	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
CTA	CTA	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
maximal	maximal	NOUN	NN	9	O
stenosis	stenosis	NOUN	NN	5	B-Disease
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
discharged	discharge	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
was	be	VERB	VBD	9	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
death	death	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
59	59	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
45	45	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
yrs	yr	NOUN	NNS	7	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
86	86	NUM	CD	7	O
%	%	NOUN	NN	9	O
black	black	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
66	66	NUM	CD	7	O
%	%	NOUN	NN	9	O
male	male	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Seventy	seventy	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
nonspecific	nonspecific	ADJ	JJ	3	O
ECG	ECG	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
85	85	NUM	CD	9	O
%	%	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
TIMI	TIMI	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
<	<	X	XX	0	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
coronary	coronary	ADJ	JJ	5	O
CTA	CTA	PROPN	NNP	9	O
immediately	immediately	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ED	ED	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
18	18	NUM	CD	7	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
were	be	VERB	VBD	9	O
discharged	discharge	VERB	VBN	5	O
following	follow	VERB	VBG	9	O
CTA	CTA	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
received	receive	VERB	VBD	9	O
coronary	coronary	ADJ	JJ	5	O
CTA	CTA	PROPN	NNP	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
brief	brief	ADJ	JJ	5	O
observation	observation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
37	37	NUM	CD	9	O
discharged	discharge	VERB	VBN	5	O
home	home	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
CTA	CTA	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
patient	patient	NOUN	NN	5	O
sustained	sustain	VERB	VBD	5	O
a	a	DET	DT	5	O
nonfatal	nonfatal	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
can	can	VERB	MD	5	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
coronary	coronary	ADJ	JJ	5	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
associated	associate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
ECG	ECG	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
TIMI	TIMI	PROPN	NNP	5	O
risk	risk	NOUN	NN	5	O
score	score	NOUN	NN	5	O
<	<	X	XX	0	O
2	2	NUM	CD	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
safely	safely	ADV	RB	5	O
discharged	discharge	VERB	VBN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
ED	ED	PROPN	NNP	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
CTA	cta	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Bilateral	bilateral	ADJ	JJ	5	O
haemorrhagic	haemorrhagic	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
globus	globus	ADJ	JJ	5	I-Disease
pallidus	pallidus	NOUN	NN	4	I-Disease
after	after	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
intoxication	intoxication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
both	both	CCONJ	CC	9	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
haemorrhagic	haemorrhagic	ADJ	JJ	5	I-Disease
stroke	stroke	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
31	31	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
globus	globus	ADJ	JJ	5	I-Disease
pallidus	pallidus	NOUN	NN	4	I-Disease
after	after	ADP	IN	9	O
excessive	excessive	ADJ	JJ	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
intranasal	intranasal	NOUN	NN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
globus	globus	NOUN	NN	5	B-Disease
pallidus	pallidus	NOUN	NN	4	I-Disease
infarctions	infarction	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
most	most	ADV	RBS	9	O
often	often	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
heroin	heroin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Bilateral	bilateral	ADJ	JJ	5	O
basal	basal	NOUN	NN	3	B-Disease
ganglia	ganglion	NOUN	NNS	5	I-Disease
infarcts	infarct	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
concurrent	concurrent	ADJ	JJ	5	O
heroin	heroin	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
never	never	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
transient	transient	ADJ	JJ	9	O
cardiac	cardiac	NOUN	NN	5	B-Disease
arrhythmia	arrhythmia	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
likely	likely	ADJ	JJ	5	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
hypoperfusion	hypoperfusion	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Late	late	ADJ	JJ	9	O
fulminant	fulminant	NOUN	NN	5	O
posterior	posterior	VERB	VBD	5	B-Disease
reversible	reversible	ADJ	JJ	9	I-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Posterior	Posterior	PROPN	NNP	5	B-Disease
leukoencephalopathy	leukoencephalopathy	ADV	RB	5	I-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
calcineurin	calcineurin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
inhibitor	inhibitor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
severe	severe	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
that	that	DET	WDT	5	O
results	result	VERB	VBZ	9	O
from	from	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
primarily	primarily	ADV	RB	9	O
those	those	DET	DT	5	O
administered	administer	VERB	VBN	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
liver	liver	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
kidney	kidney	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pathophysiologic	pathophysiologic	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
that	that	DET	DT	5	O
disorder	disorder	NOUN	NN	5	O
remain	remain	VERB	VBP	9	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
46	46	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
center	center	NOUN	NN	5	O
as	as	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
alcoholic	alcoholic	ADJ	JJ	5	B-Disease
cirrhosis	cirrhosis	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
either	either	CCONJ	CC	9	O
a	a	DET	DT	5	O
fulminant	fulminant	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
posterior	posterior	ADJ	JJ	5	B-Disease
leukoencephalopathy	leukoencephalopathy	ADJ	JJ	5	I-Disease
or	or	CCONJ	CC	5	O
posterior	posterior	ADJ	JJ	5	B-Disease
reversible	reversible	ADJ	JJ	9	I-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
110	110	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
transplant	transplant	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
an	an	DET	DT	5	O
initially	initially	ADV	RB	9	O
uneventful	uneventful	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
transplant	transplant	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
rapidly	rapidly	ADV	RB	9	O
fell	fall	VERB	VBD	5	O
into	into	ADP	IN	9	O
deep	deep	ADJ	JJ	5	O
coma	coma	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Cerebral	cerebral	ADJ	JJ	5	O
MRI	MRI	PROPN	NNP	5	O
scan	scan	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
typical	typical	ADJ	JJ	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
enhancement	enhancement	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pontine	pontine	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
posterior	posterior	ADJ	JJ	5	O
regions	region	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Switching	switch	VERB	VBG	5	O
the	the	DET	DT	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
regimen	regimen	NOUN	NN	5	O
from	from	ADP	IN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
improve	improve	VERB	VB	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
situation	situation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
termination	termination	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
any	any	DET	DT	5	O
calcineurin	calcineurin	NOUN	NN	3	O
inhibitor	inhibitor	NOUN	NN	3	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
that	that	DET	DT	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Posterior	posterior	VERB	VB	5	B-Disease
reversible	reversible	ADJ	JJ	9	I-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recommend	recommend	VERB	VBP	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
calcineurin	calcineurin	NOUN	NN	3	O
inhibitor	inhibitor	NOUN	NN	3	O
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Prolonged	prolonged	ADJ	JJ	9	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
bridge	bridge	NOUN	NN	5	O
to	to	ADP	IN	5	O
recovery	recovery	NOUN	NN	9	O
for	for	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
intracranial	intracranial	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
review	review	VERB	VB	5	O
evidence	evidence	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
treatment	treatment	NOUN	NN	9	O
options	option	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
complicating	complicate	VERB	VBG	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
FHF	FHF	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
discuss	discuss	VERB	VB	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
applications	application	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
observations	observation	NOUN	NNS	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MICU	MICU	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
tertiary	tertiary	ADJ	JJ	9	O
care	care	NOUN	NN	5	O
facility	facility	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
27	27	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
female	female	NOUN	NN	9	O
with	with	ADP	IN	5	O
FHF	FHF	PROPN	NNP	5	B-Disease
from	from	ADP	IN	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
resultant	resultant	ADJ	JJ	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
MICU	MICU	PROPN	NNP	5	O
after	after	ADP	IN	9	O
being	be	VERB	VBG	5	O
found	find	VERB	VBN	9	O
unresponsive	unresponsive	ADJ	JJ	9	O
with	with	ADP	IN	5	O
presumed	presume	VERB	VBN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
from	from	ADP	IN	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
ingested	ingest	VERB	VBN	0	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
depressed	depress	VERB	VBN	5	O
of	of	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
lasting	last	VERB	VBG	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Initial	initial	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
confirmed	confirm	VERB	VBD	9	O
FHF	FHF	PROPN	NNP	5	B-Disease
from	from	ADP	IN	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
hyperosmolar	hyperosmolar	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hyperventilation	hyperventilation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
sedation	sedation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
chemical	chemical	NOUN	NN	0	O
paralysis	paralysis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
intracranial	intracranial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
remained	remain	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
despite	despite	ADP	IN	9	O
maximal	maximal	ADJ	JJ	9	O
medical	medical	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
then	then	ADV	RB	9	O
initiated	initiate	VERB	VBD	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
continued	continue	VERB	VBN	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
re	re	NOUN	NN	5	O
-	-	NOUN	NN	7	O
warming	warming	NOUN	NN	5	O
,	,	PUNCT	,	9	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
intracranial	intracranial	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
discharge	discharge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
complete	complete	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
neurological	neurological	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
hepatic	hepatic	ADJ	JJ	9	O
functions	function	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
FHF	FHF	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
from	from	ADP	IN	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
,	,	PUNCT	,	9	O
prolonged	prolong	VERB	VBD	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
could	could	VERB	MD	9	O
potentially	potentially	ADV	RB	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
life	life	NOUN	NN	5	O
saving	save	VERB	VBG	5	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
bridge	bridge	NOUN	NN	5	O
to	to	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
neurological	neurological	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
condition	condition	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Binasal	binasal	ADJ	JJ	_	B-Disease
visual	visual	ADJ	JJ	5	I-Disease
field	field	NOUN	NN	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
specific	specific	ADJ	JJ	9	O
to	to	PART	TO	5	O
vigabatrin	vigabatrin	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
visual	visual	ADJ	JJ	5	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
vigabatrin	vigabatrin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
VGB	VGB	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
four	four	NUM	CD	9	O
people	people	NOUN	NNS	5	O
with	with	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
grouped	group	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
current	current	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
previous	previous	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
no	no	DET	DT	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
VGB	VGB	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
matched	match	VERB	VBN	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
gender	gender	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
seizure	seizure	VERB	VB	5	B-Disease
frequency	frequency	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
underwent	undergo	VERB	VBD	5	O
objective	objective	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
wide	wide	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
field	field	NOUN	NN	5	O
multifocal	multifocal	ADJ	JJ	5	O
electroretinography	electroretinography	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
conventional	conventional	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
testing	testing	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
static	static	ADJ	JJ	5	O
perimetry	perimetry	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Bilateral	bilateral	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
constriction	constriction	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
59	59	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
currently	currently	ADV	RB	5	O
taking	take	VERB	VBG	5	O
VGB	VGB	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
previously	previously	ADV	RB	9	O
took	take	VERB	VBD	5	O
VGB	VGB	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
VGB	VGB	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
retinal	retinal	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
abnormal	abnormal	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
in	in	ADP	IN	5	O
48	48	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
current	current	ADJ	JJ	5	O
VGB	VGB	PROPN	NNP	0	B-Chemical
users	user	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
VGB	VGB	PROPN	NNP	0	B-Chemical
users	user	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
previous	previous	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
VGB	VGB	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Bilateral	bilateral	ADJ	JJ	5	B-Disease
visual	visual	ADJ	JJ	5	I-Disease
field	field	NOUN	NN	5	I-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
are	be	VERB	VBP	5	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treated	treated	ADJ	JJ	3	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
irrespective	irrespective	ADV	RB	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
history	history	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Assessment	assessment	NOUN	NN	5	O
by	by	ADP	IN	9	O
conventional	conventional	ADJ	JJ	5	O
static	static	ADJ	JJ	5	O
perimetry	perimetry	NOUN	NN	5	O
may	may	VERB	MD	5	O
neither	neither	ADV	RB	9	O
be	be	VERB	VB	5	O
sufficiently	sufficiently	ADV	RB	5	O
sensitive	sensitive	ADJ	JJ	9	O
nor	nor	CCONJ	CC	9	O
specific	specific	ADJ	JJ	9	O
to	to	PART	TO	5	O
reliably	reliably	ADV	RB	5	O
identify	identify	VERB	VB	9	O
retinal	retinal	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
VGB	VGB	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Smoking	smoking	NOUN	NN	7	O
of	of	ADP	IN	5	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
infection	infection	NOUN	NN	9	I-Disease
among	among	ADP	IN	5	O
people	people	NOUN	NNS	5	O
who	who	PRON	WP	5	O
use	use	VERB	VBP	5	O
injection	injection	NOUN	NN	9	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Little	little	ADJ	JJ	9	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
that	that	ADP	IN	5	O
smoking	smoking	NOUN	NN	5	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
has	have	VERB	VBZ	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
infection	infection	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
the	the	DET	DT	5	O
increasing	increase	VERB	VBG	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
sought	seek	VERB	VBD	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
illicit	illicit	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
become	become	VERB	VBN	5	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
infection	infection	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
included	include	VERB	VBD	5	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
people	people	NOUN	NNS	5	O
participating	participate	VERB	VBG	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Vancouver	Vancouver	PROPN	NNP	2	O
Injection	Injection	PROPN	NNP	9	O
Drug	Drug	PROPN	NNP	5	O
Users	Users	PROPN	NNP	5	O
Study	Study	PROPN	NNP	5	O
who	who	PRON	WP	5	O
reported	report	VERB	VBD	9	O
injecting	inject	VERB	VBG	9	O
illicit	illicit	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
once	once	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
month	month	NOUN	NN	5	O
before	before	ADP	IN	9	O
enrolment	enrolment	NOUN	NN	5	O
,	,	PUNCT	,	9	O
lived	live	VERB	VBD	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
greater	great	ADJ	JJR	5	O
Vancouver	Vancouver	PROPN	NNP	2	O
area	area	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
HIV	HIV	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
negative	negative	ADJ	JJ	9	O
at	at	ADP	IN	9	O
enrolment	enrolment	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
completed	complete	VERB	VBN	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
1	1	NUM	CD	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
study	study	NOUN	NN	9	O
visit	visit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
seroconversion	seroconversion	NOUN	NN	5	I-Disease
among	among	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
smokers	smoker	NOUN	NNS	5	O
of	of	ADP	IN	5	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
changed	change	VERB	VBD	9	O
over	over	ADP	IN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
used	use	VERB	VBD	5	O
Cox	Cox	PROPN	NNP	9	O
proportional	proportional	ADJ	JJ	5	O
hazards	hazard	NOUN	NNS	5	O
regression	regression	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
divided	divide	VERB	VBD	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
into	into	ADP	IN	9	O
3	3	NUM	CD	9	O
periods	period	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
May	May	PROPN	NNP	2	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
1996	1996	NUM	CD	2	O
-	-	PUNCT	:	7	O
Nov	Nov	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
1999	1999	NUM	CD	2	O
(	(	PUNCT	-LRB-	9	O
period	period	NOUN	NN	5	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Dec	Dec	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
1999	1999	NUM	CD	2	O
-	-	PUNCT	:	7	O
Nov	Nov	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
2002	2002	NUM	CD	2	O
(	(	PUNCT	-LRB-	9	O
period	period	NOUN	NN	5	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Dec	Dec	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2002	2002	NUM	CD	2	O
-	-	PUNCT	HYPH	7	O
Dec	Dec	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
2005	2005	NUM	CD	2	O
(	(	PUNCT	-LRB-	9	O
period	period	NOUN	NN	5	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
1048	1048	NUM	CD	7	O
eligible	eligible	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
these	these	DET	DT	5	O
,	,	PUNCT	,	9	O
137	137	NUM	CD	7	O
acquired	acquire	VERB	VBN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
infection	infection	NOUN	NN	9	I-Disease
during	during	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
participants	participant	NOUN	NNS	5	O
who	who	PRON	WP	5	O
reported	report	VERB	VBD	9	O
daily	daily	ADJ	JJ	5	O
smoking	smoking	NOUN	NN	5	O
of	of	ADP	IN	5	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
period	period	NOUN	NN	5	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
39	39	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
period	period	NOUN	NN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
adjusting	adjust	VERB	VBG	5	O
for	for	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
confounders	confounder	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
seroconversion	seroconversion	NOUN	NN	5	I-Disease
among	among	ADP	IN	5	O
participants	participant	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
daily	daily	ADJ	JJ	5	O
smokers	smoker	NOUN	NNS	5	O
of	of	ADP	IN	5	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
increased	increase	VERB	VBD	9	O
over	over	ADP	IN	5	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
period	period	NOUN	NN	5	O
1	1	NUM	CD	9	O
:	:	PUNCT	:	9	O
hazard	hazard	NOUN	NN	5	O
ratio	ratio	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
HR	hr	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
]	]	PUNCT	-RRB-	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
57	57	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
85	85	NUM	CD	9	O
;	;	PUNCT	:	9	O
period	period	NOUN	NN	5	O
2	2	NUM	CD	9	O
:	:	PUNCT	:	9	O
HR	hr	NOUN	NN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
68	68	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
80	80	NUM	CD	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
period	period	NOUN	NN	5	O
3	3	NUM	CD	9	O
:	:	PUNCT	:	9	O
HR	hr	NOUN	NN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
74	74	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
06	06	NUM	CD	7	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
11	11	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

INTERPRETATION	interpretation	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Smoking	smoking	NOUN	NN	7	O
of	of	ADP	IN	5	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
independent	independent	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
seroconversion	seroconversion	NOUN	NN	5	I-Disease
among	among	ADP	IN	5	O
people	people	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
injection	injection	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
finding	find	VERB	VBG	9	O
points	point	NOUN	NNS	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
urgent	urgent	ADJ	JJ	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
evidence	evidence	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
public	public	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
initiatives	initiative	NOUN	NNS	5	O
targeted	target	VERB	VBN	9	O
at	at	ADP	IN	9	O
people	people	NOUN	NNS	5	O
who	who	PRON	WP	5	O
smoke	smoke	VERB	VBP	5	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
.	.	PUNCT	.	9	O

Fluoxetine	Fluoxetine	PROPN	NNP	0	B-Chemical
improves	improve	VERB	VBZ	5	O
the	the	DET	DT	5	O
memory	memory	NOUN	NN	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
agent	agent	NOUN	NN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Cancer	cancer	NOUN	NN	2	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
adjuvant	adjuvant	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
have	have	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
experiencing	experience	VERB	VBG	5	O
deteriorations	deterioration	NOUN	NNS	5	O
in	in	ADP	IN	5	O
cognition	cognition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
readily	readily	ADV	RB	9	O
crosses	cross	VERB	VBZ	9	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
so	so	ADV	RB	5	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
particular	particular	ADJ	JJ	5	O
this	this	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
mitotic	mitotic	ADJ	JJ	3	O
drug	drug	NOUN	NN	5	O
could	could	VERB	MD	9	O
reduce	reduce	VERB	VB	5	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
neurogenic	neurogenic	ADJ	JJ	5	O
regions	region	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
adult	adult	NOUN	NN	9	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
reports	report	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
dependent	dependent	ADJ	JJ	9	O
neurogenesis	neurogenesis	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
cognition	cognition	NOUN	NN	5	O
are	be	VERB	VBP	5	O
enhanced	enhance	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
SSRI	SSRI	PROPN	NNP	5	B-Chemical
antidepressant	antidepressant	NOUN	NN	5	O
Fluoxetine	Fluoxetine	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
the	the	DET	DT	5	O
behavioural	behavioural	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
chronic	chronic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
two	two	NUM	CD	5	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
three	three	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
Fluoxetine	Fluoxetine	PROPN	NNP	0	B-Chemical
either	either	CCONJ	CC	9	O
separately	separately	ADV	RB	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	FU	PROPN	NNP	9	I-Chemical
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
on	on	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
Lister	lister	ADJ	JJ	6	O
hooded	hood	VERB	VBN	4	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Behavioural	behavioural	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
context	context	NOUN	NN	5	O
dependent	dependent	ADJ	JJ	9	O
conditioned	conditioned	ADJ	JJ	9	O
emotional	emotional	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
test	test	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CER	CER	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
which	which	DET	WDT	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	FU	PROPN	NNP	9	I-Chemical
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
freezing	freezing	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
separate	separate	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
dependent	dependent	ADJ	JJ	9	O
spatial	spatial	ADJ	JJ	5	O
working	work	VERB	VBG	5	O
memory	memory	NOUN	NN	5	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
object	object	NOUN	NN	5	O
location	location	NOUN	NN	5	O
recognition	recognition	NOUN	NN	5	O
test	test	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
OLR	OLR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBD	3	O
only	only	ADV	RB	9	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	FU	PROPN	NNP	9	I-Chemical
showed	show	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
deficits	deficit	NOUN	NNS	5	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
carry	carry	VERB	VB	9	O
out	out	PART	RP	9	O
the	the	DET	DT	5	O
OLR	OLR	PROPN	NNP	5	O
task	task	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
co	co	NOUN	NN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
Fluoxetine	Fluoxetine	PROPN	NNP	0	B-Chemical
improved	improve	VERB	VBD	5	O
their	-PRON-	DET	PRP$	5	O
performance	performance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

5	5	PUNCT	LS	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
proliferating	proliferate	VERB	VBG	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
sub	sub	NOUN	NN	9	O
granular	granular	ADJ	JJ	9	O
zone	zone	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
eliminated	eliminate	VERB	VBN	9	O
when	when	ADV	WRB	5	O
Fluoxetine	Fluoxetine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
co	co	VERB	VBN	9	O
administered	administer	VERB	VBN	9	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

Fluoxetine	fluoxetine	VERB	VB	0	B-Chemical
on	on	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
own	own	ADJ	JJ	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
proliferating	proliferate	VERB	VBG	3	O
cell	cell	NOUN	NN	3	O
number	number	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
behaviour	behaviour	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	FU	PROPN	NNP	9	I-Chemical
can	can	VERB	MD	5	O
negatively	negatively	ADV	RB	9	O
affect	affect	VERB	VB	9	O
both	both	DET	DT	9	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
dependent	dependent	ADJ	JJ	9	O
working	work	VERB	VBG	5	O
memory	memory	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
deficits	deficit	NOUN	NNS	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
simultaneous	simultaneous	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antidepressant	antidepressant	ADJ	JJ	5	O
Fluoxetine	Fluoxetine	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
ablation	ablation	NOUN	NN	9	O
of	of	ADP	IN	5	O
integrin	integrin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
linked	link	VERB	VBN	9	O
kinase	kinase	NOUN	NN	3	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
enhanced	enhance	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
prolonged	prolong	VERB	VBN	9	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
hepatomegaly	hepatomegaly	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
phenobarbital	phenobarbital	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
recently	recently	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBN	9	O
that	that	ADP	IN	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
extracellular	extracellular	ADJ	JJ	9	O
matrix	matrix	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ECM	ECM	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
integrin	integrin	NOUN	NN	3	O
signaling	signal	VERB	VBG	3	O
via	via	ADP	IN	9	O
elimination	elimination	NOUN	NN	9	O
of	of	ADP	IN	5	O
integrin	integrin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
linked	link	VERB	VBN	9	O
kinase	kinase	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
ILK	ILK	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
hepatocytes	hepatocyte	NOUN	NNS	3	O
interferes	interfere	VERB	VBZ	9	O
with	with	ADP	IN	5	O
signals	signal	NOUN	NNS	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
termination	termination	NOUN	NN	9	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
regeneration	regeneration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
investigates	investigate	VERB	VBZ	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
ILK	ILK	PROPN	NNP	3	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
enlargement	enlargement	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
phenobarbital	phenobarbital	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PB	PB	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Wild	wild	ADJ	JJ	4	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
WT	WT	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
ILK	ILK	PROPN	NNP	3	O
:	:	PUNCT	:	9	O
liver	liver	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
PB	PB	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
drinking	drinking	NOUN	NN	5	O
water	water	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Livers	liver	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
harvested	harvest	VERB	VBN	3	O
on	on	ADP	IN	5	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
during	during	ADP	IN	5	O
PB	PB	PROPN	NNP	9	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
hepatocyte	hepatocyte	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
ILK	ILK	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
liver	liver	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
:	:	PUNCT	:	9	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
was	be	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
double	double	ADJ	JJ	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
h	h	NOUN	NN	0	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
times	time	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
at	at	ADP	IN	9	O
days	day	NOUN	NNS	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
enlarged	enlarge	VERB	VBN	9	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
WT	WT	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
was	be	VERB	VBD	9	O
as	as	ADP	IN	5	O
expected	expect	VERB	VBN	9	O
from	from	ADP	IN	9	O
previous	previous	ADJ	JJ	9	O
literature	literature	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
times	time	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
leveled	level	VERB	VBN	5	O
off	off	PART	RP	5	O
after	after	ADP	IN	9	O
day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
slightly	slightly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
proliferating	proliferate	VERB	VBG	3	O
cell	cell	NOUN	NN	3	O
nuclear	nuclear	ADJ	JJ	3	O
antigen	antigen	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ILK	ILK	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
liver	liver	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
animals	animal	NOUN	NNS	9	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
WT	WT	PROPN	NNP	3	O
after	after	ADP	IN	9	O
PB	PB	PROPN	NNP	9	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
WT	WT	PROPN	NNP	3	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
proliferative	proliferative	ADJ	JJ	3	O
response	response	NOUN	NN	9	O
had	have	VERB	VBD	9	O
come	come	VERB	VBN	5	O
back	back	ADV	RB	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
by	by	ADP	IN	9	O
days	day	NOUN	NNS	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O

Hepatocytes	hepatocyte	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ILK	ILK	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
liver	liver	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
continued	continue	VERB	VBD	9	O
to	to	PART	TO	5	O
proliferate	proliferate	VERB	VB	3	O
up	up	PART	RP	5	O
until	until	ADP	IN	5	O
day	day	NOUN	NN	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O

ILK	ILK	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
liver	liver	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
also	also	ADV	RB	9	O
showed	show	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
key	key	ADJ	JJ	9	O
genes	gene	NOUN	NNS	1	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
hepatocyte	hepatocyte	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
at	at	ADP	IN	9	O
different	different	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
points	point	NOUN	NNS	5	O
during	during	ADP	IN	5	O
PB	PB	PROPN	NNP	9	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
summary	summary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
ECM	ECM	PROPN	NNP	3	O
proteins	protein	NOUN	NNS	1	O
communicate	communicate	VERB	VBP	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
signaling	signal	VERB	VBG	3	O
machinery	machinery	NOUN	NN	9	O
of	of	ADP	IN	5	O
dividing	dividing	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
via	via	ADP	IN	9	O
ILK	ILK	PROPN	NNP	3	O
to	to	PART	TO	5	O
regulate	regulate	VERB	VB	3	O
hepatocyte	hepatocyte	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
termination	termination	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
proliferative	proliferative	ADJ	JJ	3	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
ILK	ILK	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hepatocytes	hepatocyte	NOUN	NNS	3	O
imparts	impart	NOUN	NNS	9	O
prolonged	prolong	VERB	VBN	9	O
proliferative	proliferative	ADJ	JJ	3	O
response	response	NOUN	NN	9	O
not	not	ADV	RB	5	O
only	only	ADV	RB	9	O
to	to	ADP	IN	5	O
stimuli	stimulus	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
regeneration	regeneration	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
to	to	ADP	IN	5	O
xenobiotic	xenobiotic	ADJ	JJ	0	O
chemical	chemical	NOUN	NN	0	O
mitogens	mitogen	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
PB	PB	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Decreased	Decreased	PROPN	NNP	9	O
Expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
K	K	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
ATPase	ATPase	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
NHE3	NHE3	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
NBC1	NBC1	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
AQP1	AQP1	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
OAT	OAT	PROPN	NNP	9	O
in	in	ADP	IN	5	O
Gentamicin	Gentamicin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
Nephropathy	Nephropathy	PROPN	NNP	7	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
altered	altered	ADJ	JJ	9	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
transporters	transporter	NOUN	NNS	1	O
in	in	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
~	~	NUM	CD	9	O
250	250	NUM	CD	0	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
subcutaneously	subcutaneously	ADV	RB	3	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
gentamicin	gentamicin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
transporters	transporter	NOUN	NNS	1	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
immunoblotting	immunoblotte	VERB	VBG	3	O
and	and	CCONJ	CC	5	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mRNA	mRNA	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
OAT	OAT	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBN	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
along	along	ADP	IN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
plasma	plasma	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Accordingly	accordingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
fractional	fractional	ADJ	JJ	5	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Urine	urine	ADJ	JJ	9	O
volume	volume	NOUN	NN	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
urine	urine	NOUN	NN	9	O
osmolality	osmolality	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
free	free	ADJ	JJ	9	O
water	water	NOUN	NN	0	O
reabsorption	reabsorption	NOUN	NN	0	O
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Immunoblotting	immunoblotting	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
revealed	reveal	VERB	VBD	9	O
decreased	decrease	VERB	VBD	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
ATPase	ATPase	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
NHE3	NHE3	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
NBC1	NBC1	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
AQP1	AQP1	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
of	of	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
OAT1	OAT1	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
OAT3	OAT3	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
be	be	VERB	VB	5	O
causally	causally	ADV	RB	9	O
related	relate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
decreased	decrease	VERB	VBN	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
ATPase	ATPase	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
NHE3	NHE3	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
NBC1	NBC1	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
AQP1	AQP1	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
OAT	OAT	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
ileostomy	ileostomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
HD	HD	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MTX	MTX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
Burkitt	Burkitt	PROPN	NNP	3	B-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
when	when	ADV	WRB	5	O
its	-PRON-	DET	PRP$	9	O
clearance	clearance	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
delayed	delay	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
HD	HD	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MTX	MTX	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
ileostomy	ileostomy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
boy	boy	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
a	a	DET	DT	5	O
living	living	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
for	for	ADP	IN	5	O
congenital	congenital	ADJ	JJ	5	O
biliary	biliary	ADJ	JJ	5	B-Disease
atresia	atresia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
833	833	NUM	CD	7	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
PTLD	PTLD	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
post	post	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
transplantation	transplantation	NOUN	NN	9	I-Disease
lymphoproliferative	lymphoproliferative	ADJ	JJ	3	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
Burkitt	Burkitt	PROPN	NNP	3	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
type	type	NOUN	NN	9	I-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
suffered	suffer	VERB	VBD	5	O
ileal	ileal	ADJ	JJ	9	O
perforation	perforation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
ileostomy	ileostomy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Subsequent	subsequent	ADJ	JJ	9	O
HD	HD	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MTX	MTX	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
caused	cause	VERB	VBD	9	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
required	require	VERB	VBD	9	O
continuous	continuous	ADJ	JJ	5	O
hemodialysis	hemodialysis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
supposed	suppose	VERB	VBD	5	O
that	that	DET	DT	5	O
intravascular	intravascular	ADJ	JJ	5	O
hypovolemia	hypovolemia	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
substantial	substantial	ADJ	JJ	9	O
drainage	drainage	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
ileostoma	ileostoma	NOUN	NN	5	O
caused	cause	VERB	VBN	9	O
acute	acute	ADJ	JJ	9	B-Disease
prerenal	prerenal	ADJ	JJ	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
could	could	VERB	MD	9	O
safely	safely	ADV	RB	5	O
treat	treat	VERB	VB	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
HD	HD	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MTX	MTX	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
by	by	ADP	IN	9	O
controlling	control	VERB	VBG	9	O
drainage	drainage	NOUN	NN	5	O
from	from	ADP	IN	9	O
ileostoma	ileostoma	NOUN	NN	5	O
with	with	ADP	IN	5	O
total	total	ADJ	JJ	9	O
parenteral	parenteral	ADJ	JJ	5	O
nutrition	nutrition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Longitudinal	longitudinal	ADJ	JJ	5	O
association	association	NOUN	NN	9	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
progression	progression	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
psychological	psychological	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
consumption	consumption	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
depression	depression	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
progression	progression	NOUN	NN	9	O
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
included	include	VERB	VBD	5	O
871	871	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
recruited	recruit	VERB	VBN	9	O
from	from	ADP	IN	9	O
1993	1993	NUM	CD	2	O
-	-	SYM	SYM	7	O
1995	1995	NUM	CD	2	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
US	US	PROPN	NNP	5	O
cities	city	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
participants	participant	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
,	,	PUNCT	,	9	O
medical	medical	ADJ	JJ	5	O
record	record	NOUN	NN	5	O
extraction	extraction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
venipuncture	venipuncture	NOUN	NN	5	O
,	,	PUNCT	,	9	O
CD4	cd4	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
T	t	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
counts	count	VERB	VBZ	9	O
determination	determination	NOUN	NN	9	O
,	,	PUNCT	,	9	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
depression	depression	NOUN	NN	5	B-Disease
symptoms	symptom	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
report	report	VERB	VB	5	O
Center	Center	PROPN	NNP	2	O
for	for	ADP	IN	5	O
Epidemiological	Epidemiological	PROPN	NNP	5	O
Studies	Studies	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Depression	Depression	PROPN	NNP	5	B-Disease
Scale	Scale	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
at	at	ADP	IN	9	O
enrollment	enrollment	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
semiannually	semiannually	ADV	RB	5	O
until	until	ADP	IN	5	O
March	March	PROPN	NNP	2	O
2000	2000	NUM	CD	9	O
.	.	PUNCT	.	9	O

Multilevel	multilevel	ADJ	JJ	5	O
random	random	ADJ	JJ	5	O
coefficient	coefficient	NOUN	NN	5	O
ordinal	ordinal	ADJ	JJ	5	O
models	model	NOUN	NNS	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
multilevel	multilevel	ADJ	JJ	5	O
models	model	NOUN	NNS	5	O
with	with	ADP	IN	5	O
joint	joint	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
CD4	cd4	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
T	t	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
counts	count	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
participants	participant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
stratified	stratify	VERB	VBN	5	O
by	by	ADP	IN	9	O
antiretroviral	antiretroviral	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ART	ART	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
CD4	cd4	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
T	t	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reach	reach	VERB	VB	5	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
consumption	consumption	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
depression	depression	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Depression	depression	NOUN	NN	5	B-Disease
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
negative	negative	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
CD4	CD4	PROPN	NNP	3	O
+	+	CCONJ	CC	9	O
T	t	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
counts	count	VERB	VBZ	9	O
over	over	ADP	IN	5	O
time	time	NOUN	NN	5	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
ART	ART	PROPN	NNP	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
consumption	consumption	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
depression	depression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
depression	depression	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
progression	progression	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
provision	provision	NOUN	NN	5	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
interventions	intervention	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
psychological	psychological	ADJ	JJ	5	O
resources	resource	NOUN	NNS	5	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
the	the	DET	DT	5	O
health	health	NOUN	NN	5	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Chemokine	chemokine	NOUN	NN	3	O
CCL2	CCL2	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
receptor	receptor	NOUN	NN	3	O
CCR2	CCR2	PROPN	NNP	3	O
are	be	VERB	VBP	5	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Neuroinflammation	neuroinflammation	NOUN	NN	3	B-Disease
occurs	occur	VERB	VBZ	9	O
after	after	ADP	IN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
epileptogenesis	epileptogenesis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CCR2	CCR2	PROPN	NNP	3	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
chemokine	chemokine	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
for	for	ADP	IN	5	O
CCL2	CCL2	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
interaction	interaction	NOUN	NN	9	O
mediates	mediate	VERB	VBZ	3	O
monocyte	monocyte	NOUN	NN	3	O
infiltration	infiltration	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
neuroinflammatory	neuroinflammatory	ADJ	JJ	3	B-Disease
cascade	cascade	NOUN	NN	9	O
triggered	trigger	VERB	VBN	9	O
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
pathologies	pathology	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
work	work	NOUN	NN	5	O
CCR2	CCR2	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
CCL2	ccl2	ADJ	JJ	3	O
expression	expression	NOUN	NN	3	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
following	follow	VERB	VBG	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SE	SE	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
SE	SE	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
instead	instead	ADV	RB	5	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
SE	SE	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
CCR2	CCR2	PROPN	NNP	3	O
staining	staining	NOUN	NN	3	O
in	in	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
glial	glial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
using	use	VERB	VBG	9	O
imunohistochemical	imunohistochemical	ADJ	JJ	3	O
analyses	analysis	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
CCR2	CCR2	PROPN	NNP	3	O
positive	positive	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
using	use	VERB	VBG	9	O
stereology	stereology	NOUN	NN	5	O
probes	probe	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CCL2	ccl2	ADJ	JJ	3	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
by	by	ADP	IN	9	O
molecular	molecular	ADJ	JJ	9	O
assay	assay	NOUN	NN	3	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Increased	Increased	PROPN	NNP	9	O
CCR2	CCR2	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
after	after	ADP	IN	9	O
SE	SE	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Seizures	Seizures	PROPN	NNP	5	B-Disease
also	also	ADV	RB	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
alterations	alteration	NOUN	NNS	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
cell	cell	NOUN	NN	3	O
types	type	NOUN	NNS	9	O
expressing	express	VERB	VBG	3	O
CCR2	CCR2	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

Increased	increased	ADJ	JJ	9	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
that	that	DET	WDT	5	O
expressed	express	VERB	VBD	3	O
CCR2	CCR2	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
following	follow	VERB	VBG	9	O
SE	SE	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Microglial	microglial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
closely	closely	ADV	RB	9	O
apposed	apposed	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
CCR2	CCR2	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
labeled	label	VERB	VBN	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
SE	SE	PROPN	NNP	9	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
experienced	experience	VERB	VBD	5	O
SE	SE	PROPN	NNP	9	B-Disease
exhibited	exhibit	VERB	VBD	9	O
CCR2	CCR2	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
labeling	labeling	NOUN	NN	3	O
in	in	ADP	IN	5	O
populations	population	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hypertrophied	hypertrophied	ADJ	JJ	9	B-Disease
astrocytes	astrocyte	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
CA1	CA1	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
CCR2	CCR2	PROPN	NNP	3	O
+	+	SYM	SYM	9	O
astroctytes	astroctyte	NOUN	NNS	_	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Examination	examination	NOUN	NN	9	O
of	of	ADP	IN	5	O
CCL2	ccl2	ADJ	JJ	3	O
expression	expression	NOUN	NN	3	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
SE	SE	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
CCR2	CCR2	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
CCL2	CCL2	PROPN	NNP	3	O
are	be	VERB	VBP	5	O
up	up	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
regulated	regulated	ADJ	JJ	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
after	after	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
SE	SE	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Seizures	seizure	NOUN	NNS	5	B-Disease
also	also	ADV	RB	9	O
result	result	VERB	VBP	9	O
in	in	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
to	to	ADP	IN	5	O
CCR2	CCR2	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
astrocytes	astrocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
detrimental	detrimental	ADJ	JJ	9	O
neuroplasticity	neuroplasticity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
neuroinflammatory	neuroinflammatory	ADJ	JJ	3	B-Disease
changes	change	NOUN	NNS	9	O
that	that	DET	WDT	5	O
occur	occur	VERB	VBP	5	O
following	follow	VERB	VBG	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Metallothionein	Metallothionein	PROPN	NNP	7	B-Chemical
induction	induction	NOUN	NN	3	O
reduces	reduce	VERB	VBZ	9	O
caspase	caspase	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
TNFalpha	tnfalpha	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
with	with	ADP	IN	5	O
preservation	preservation	NOUN	NN	9	O
of	of	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
intact	intact	ADJ	JJ	9	O
hippocampal	hippocampal	ADJ	JJ	3	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
carmustine	carmustine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Hippocampal	hippocampal	ADJ	JJ	3	O
integrity	integrity	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
essential	essential	ADJ	JJ	9	O
for	for	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
functions	function	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
metallothionein	metallothionein	NOUN	NN	1	B-Chemical
(	(	PUNCT	-LRB-	9	O
MT	MT	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
ZnSO	ZnSO	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
neuroprotection	neuroprotection	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
documented	document	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
explore	explore	VERB	VB	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
MT	MT	PROPN	NNP	9	B-Chemical
induction	induction	NOUN	NN	3	O
on	on	ADP	IN	5	O
carmustine	carmustine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hippocampal	hippocampal	ADJ	JJ	3	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
male	male	ADJ	JJ	9	O
Wistar	wistar	NOUN	NN	9	O
albino	albino	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
/	/	SYM	SYM	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
injected	inject	VERB	VBD	3	O
with	with	ADP	IN	5	O
single	single	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
)	)	PUNCT	-RRB-	9	O
followed	follow	VERB	VBD	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
later	later	ADV	RB	9	O
by	by	ADP	IN	9	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
solvent	solvent	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
administered	administer	VERB	VBD	9	O
ZnSO	ZnSO	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
10	10	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
,	,	PUNCT	,	9	O
once	once	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
then	then	ADV	RB	9	O
BCNU	bcnu	VERB	VB	0	B-Chemical
solvent	solvent	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Third	third	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
,	,	PUNCT	,	9	O
once	once	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
with	with	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Fourth	fourth	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
ZnSO	ZnSO	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
10	10	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
)	)	PUNCT	-RRB-	9	O
then	then	ADV	RB	9	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
,	,	PUNCT	,	9	O
once	once	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
obtained	obtained	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
deterioration	deterioration	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
short	short	ADJ	JJ	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
term	term	NOUN	NN	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
STM	STM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
radial	radial	ADJ	JJ	5	O
arm	arm	NOUN	NN	5	O
water	water	NOUN	NN	0	O
maze	maze	NOUN	NN	5	O
,	,	PUNCT	,	9	O
accompanied	accompany	VERB	VBN	9	O
with	with	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	O
hippocampal	hippocampal	ADJ	JJ	3	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
reductase	reductase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
GR	GR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
GSH	GSH	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
content	content	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
,	,	PUNCT	,	9	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
serum	serum	ADJ	JJ	9	O
tumor	tumor	NOUN	NN	3	B-Disease
necrosis	necrosis	NOUN	NN	9	B-Disease
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
TNFalpha	tnfalpha	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
hippocampal	hippocampal	ADJ	JJ	3	O
MT	MT	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
contents	content	VERB	VBZ	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
caspase	caspase	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
histological	histological	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

ZnSO	ZnSO	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	PUNCT	LS	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
counteracted	counteract	VERB	VBN	9	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
GR	GR	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
GSH	GSH	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
MDA	MDA	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
TNFalpha	TNFalpha	PROPN	NNP	3	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
caspase	caspase	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
histological	histological	ADJ	JJ	9	O
features	feature	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
improved	improve	VERB	VBN	5	O
in	in	ADP	IN	5	O
hippocampus	hippocampus	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
ZnSO	ZnSO	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
+	+	CCONJ	CC	9	O
BCNU	bcnu	VERB	VB	0	B-Chemical
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
only	only	ADV	RB	9	O
BCNU	bcnu	VERB	VB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
MT	MT	PROPN	NNP	9	B-Chemical
induction	induction	NOUN	NN	3	O
halts	halt	NOUN	NNS	9	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hippocampal	hippocampal	ADJ	JJ	3	O
toxicity	toxicity	NOUN	NN	9	B-Disease
as	as	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
prevented	prevent	VERB	VBD	9	O
GR	GR	PROPN	NNP	9	O
inhibition	inhibition	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
GSH	GSH	PROPN	NNP	0	B-Chemical
depletion	depletion	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
counteracted	counteract	VERB	VBD	9	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
TNFalpha	TNFalpha	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
caspase	caspase	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
activity	activity	NOUN	NN	9	O
with	with	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
preservation	preservation	NOUN	NN	9	O
of	of	ADP	IN	5	O
cognition	cognition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fatal	fatal	ADJ	JJ	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBD	3	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
eosinophilic	eosinophilic	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
emphasis	emphasis	NOUN	NN	5	O
on	on	ADP	IN	5	O
anatomical	anatomical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
histological	histological	ADJ	JJ	9	O
characteristics	characteristic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
mechanisms	mechanism	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
genetics	genetic	NOUN	NNS	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	B-Disease
hypersensitivity	hypersensitivity	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
differential	differential	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
severe	severe	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
to	to	PART	TO	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
haemopoietic	haemopoietic	ADJ	JJ	3	O
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
frequently	frequently	ADV	RB	5	O
fatal	fatal	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
exceptionally	exceptionally	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
necrotizing	necrotize	VERB	VBG	5	O
eosinophilic	eosinophilic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
myocarditis	myocarditis	NOUN	NN	9	B-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
myocarditis	myocarditis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
suspected	suspect	VERB	VBN	5	O
clinically	clinically	ADV	RB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
was	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
mortem	mortem	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Histology	histology	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
diffuse	diffuse	NOUN	NN	5	O
infiltration	infiltration	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
myocardium	myocardium	NOUN	NN	9	O
by	by	ADP	IN	9	O
eosinophils	eosinophil	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
with	with	ADP	IN	5	O
myocyte	myocyte	NOUN	NN	3	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Clinically	clinically	ADV	RB	5	O
,	,	PUNCT	,	9	O
death	death	NOUN	NN	9	O
was	be	VERB	VBD	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
cardiogenic	cardiogenic	ADJ	JJ	5	B-Disease
shock	shock	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
best	good	ADJ	JJS	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBN	3	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
English	English	PROPN	NNP	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neuropsychiatric	neuropsychiatric	ADJ	JJ	5	O
behaviors	behavior	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
MPTP	MPTP	PROPN	NNP	3	B-Chemical
marmoset	marmoset	NOUN	NN	9	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Neuropsychiatric	neuropsychiatric	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
increasingly	increasingly	ADV	RB	5	O
recognised	recognise	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
problem	problem	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
'	'	PUNCT	``	9	O
sensitisation	sensitisation	NOUN	NN	5	O
'	'	PUNCT	''	9	O
following	follow	VERB	VBG	9	O
repeated	repeat	VERB	VBN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
state	state	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
MPTP	MPTP	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
lesioned	lesione	VERB	VBN	3	O
marmoset	marmoset	NOUN	NN	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuropsychiatric	neuropsychiatric	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
compare	compare	VERB	VBP	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
motor	motor	NOUN	NN	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
neuropsychiatric	neuropsychiatric	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
behaviors	behavior	NOUN	NNS	5	I-Disease
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Marmosets	Marmosets	PROPN	NNPS	3	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phenyl	phenyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
6	6	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrahydropyridine	tetrahydropyridine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
five	five	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
stable	stable	ADJ	JJ	9	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
benserazide	benserazide	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O

b	b	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
for	for	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
disability	disability	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
motor	motor	NOUN	NN	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
neuropsychiatric	neuropsychiatric	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
behaviors	behavior	NOUN	NNS	5	I-Disease
on	on	ADP	IN	5	O
Day	Day	PROPN	NNP	9	O
0	0	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
Days	Days	PROPN	NNP	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
,	,	PUNCT	,	9	O
27	27	NUM	CD	7	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
using	use	VERB	VBG	9	O
post	post	NOUN	NN	9	O
hoc	hoc	X	FW	5	O
DVD	dvd	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
trained	train	VERB	VBN	5	O
rater	rater	NOUN	NN	5	O
,	,	PUNCT	,	9	O
blind	blind	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
neuropsychiatric	neuropsychiatric	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
behavior	behavior	NOUN	NN	5	I-Disease
rating	rating	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
demonstrated	demonstrate	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
interrater	interrater	NOUN	NN	5	O
reliability	reliability	NOUN	NN	5	O
between	between	ADP	IN	5	O
three	three	NUM	CD	9	O
trained	train	VERB	VBN	5	O
raters	rater	NOUN	NNS	5	O
of	of	ADP	IN	5	O
differing	differ	VERB	VBG	9	O
professional	professional	ADJ	JJ	5	O
backgrounds	background	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
anticipated	anticipate	VERB	VBN	5	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
progressive	progressive	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
motor	motor	NOUN	NN	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
wearing	wear	VERB	VBG	5	O
-	-	PUNCT	HYPH	7	O
off	off	PART	RP	5	O
,	,	PUNCT	,	9	O
that	that	DET	WDT	5	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
neuropsychiatric	neuropsychiatric	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
behaviors	behavior	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
on	on	ADP	IN	5	O
Day	Day	PROPN	NNP	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
severity	severity	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
correlate	correlate	VERB	VB	9	O
with	with	ADP	IN	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
neuropsychiatric	neuropsychiatric	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
are	be	VERB	VBP	5	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
an	an	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
state	state	NOUN	NN	5	O
than	than	ADP	IN	5	O
a	a	DET	DT	5	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
sensitisation	sensitisation	NOUN	NN	5	O
to	to	ADP	IN	5	O
repeated	repeat	VERB	VBN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Contrast	contrast	NOUN	NN	5	B-Chemical
medium	medium	NOUN	NN	0	I-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
renal	renal	ADJ	JJ	9	O
artery	artery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
coronary	coronary	ADJ	JJ	5	O
angioplasty	angioplasty	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
iodinated	iodinate	VERB	VBN	0	O
contrast	contrast	NOUN	NN	9	B-Chemical
medium	medium	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CM	CM	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
can	can	VERB	MD	5	O
minimize	minimize	VERB	VB	5	O
the	the	DET	DT	5	O
benefit	benefit	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
interventional	interventional	ADJ	JJ	5	O
procedure	procedure	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
renal	renal	ADJ	JJ	9	O
angioplasty	angioplasty	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PTRA	PTRA	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
CM	CM	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
PTRA	PTRA	PROPN	NNP	5	O
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
submitted	submit	VERB	VBN	9	O
to	to	ADP	IN	5	O
percutaneous	percutaneous	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
intervention	intervention	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PCI	PCI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

MATERIAL	MATERIAL	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
33	33	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
successfully	successfully	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
PTRA	PTRA	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
PTRA	PTRA	PROPN	NNP	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
70	70	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
23	23	NUM	CD	7	O
female	female	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
basal	basal	NOUN	NN	3	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
46	46	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
79	79	NUM	CD	7	O
,	,	PUNCT	,	9	O
range	range	VERB	VBP	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
33	33	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
successful	successful	ADJ	JJ	5	O
PCI	PCI	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
PCI	PCI	PROPN	NNP	5	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
matched	match	VERB	VBN	9	O
for	for	ADP	IN	5	O
basal	basal	NOUN	NN	3	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
44	44	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
range	range	VERB	VBP	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
gender	gender	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
age	age	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
postprocedural	postprocedural	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
48	48	NUM	CD	9	O
h	h	PUNCT	LS	0	O
)	)	PUNCT	-RRB-	9	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Postprocedural	postprocedural	ADJ	JJ	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
nonsignificantly	nonsignificantly	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PTRA	PTRA	PROPN	NNP	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
46	46	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
NS	NS	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PCI	PCI	PROPN	NNP	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
44	44	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
57	57	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
intervention	intervention	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
after	after	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
before	before	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
PTRA	PTRA	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
PCI	PCI	PROPN	NNP	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
12	12	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
014	014	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
either	either	CCONJ	CC	9	O
a	a	DET	DT	5	O
different	different	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
profile	profile	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
volume	volume	NOUN	NN	9	O
of	of	ADP	IN	5	O
CM	CM	PROPN	NNP	9	B-Chemical
administered	administer	VERB	VBD	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
preliminary	preliminary	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
submitted	submit	VERB	VBN	9	O
to	to	ADP	IN	5	O
PTRA	PTRA	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
CM	CM	PROPN	NNP	9	B-Chemical
administration	administration	NOUN	NN	9	O
than	than	ADP	IN	5	O
PCI	pci	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
PTRA	PTRA	PROPN	NNP	5	O
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
barely	barely	ADV	RB	9	O
influenced	influence	VERB	VBN	5	O
by	by	ADP	IN	9	O
CM	CM	PROPN	NNP	9	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Diphenhydramine	Diphenhydramine	PROPN	NNP	0	B-Chemical
prevents	prevent	VERB	VBZ	9	O
the	the	DET	DT	5	O
haemodynamic	haemodynamic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
ICU	ICU	PROPN	NNP	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cimetidine	Cimetidine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
histamine	histamine	NOUN	NN	0	B-Chemical
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
H2	H2	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
produces	produce	VERB	VBZ	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
vasodilatation	vasodilatation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
critically	critically	ADV	RB	9	O
ill	ill	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
because	because	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
acts	act	VERB	VBZ	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
histamine	histamine	ADJ	JJ	0	B-Chemical
agonist	agonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
,	,	PUNCT	,	9	O
therefore	therefore	ADV	RB	5	O
,	,	PUNCT	,	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
histamine	histamine	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
H1	H1	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
diphenhydramine	diphenhydramine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
haemodynamic	haemodynamic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
observed	observe	VERB	VBN	9	O
after	after	ADP	IN	9	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
ICU	ICU	PROPN	NNP	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
on	on	ADP	IN	5	O
two	two	NUM	CD	5	O
separate	separate	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
random	random	ADJ	JJ	5	O
fashion	fashion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
received	receive	VERB	VBD	9	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
iv	iv	NOUN	NN	9	O
on	on	ADP	IN	5	O
one	one	NUM	CD	5	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
pretreatment	pretreatment	NOUN	NN	0	O
of	of	ADP	IN	5	O
diphenhydramine	diphenhydramine	NOUN	NN	0	B-Chemical
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
iv	iv	NOUN	NN	9	O
with	with	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
iv	iv	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
pretreatment	pretreatment	ADJ	JJ	0	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MAP	MAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
107	107	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mmHg	mmhg	NOUN	NN	7	O
to	to	ADP	IN	5	O
86	86	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mmHg	mmHg	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
two	two	NUM	CD	5	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
,	,	PUNCT	,	9	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SVR	SVR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBD	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
eight	eight	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
observation	observation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pretreatment	pretreatment	NOUN	NN	0	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
little	little	ADJ	JJ	9	O
haemodynamic	haemodynamic	ADJ	JJ	5	O
change	change	NOUN	NN	9	O
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
an	an	DET	DT	5	O
H1	H1	PROPN	NNP	9	O
antagonist	antagonist	NOUN	NN	3	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
iv	iv	NUM	CD	9	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
the	the	DET	DT	5	O
vasodilating	vasodilating	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
mediated	mediate	VERB	VBN	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
,	,	PUNCT	,	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
H1	H1	PROPN	NNP	9	O
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Medical	medical	ADJ	JJ	2	O
and	and	CCONJ	CC	5	O
psychiatric	psychiatric	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
transplanted	transplant	VERB	VBN	3	O
for	for	ADP	IN	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Acetaminophen	Acetaminophen	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ALF	ALF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
UK	UK	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
often	often	ADV	RB	5	O
consume	consume	VERB	VBP	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
with	with	ADP	IN	5	O
suicidal	suicidal	ADJ	JJ	5	O
intent	intent	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
background	background	NOUN	NN	9	O
of	of	ADP	IN	5	O
substance	substance	NOUN	NN	5	O
dependence	dependence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

AIMS	AIMS	PROPN	NNP	5	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
pretransplant	pretransplant	ADJ	JJ	5	O
illness	illness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
psychiatric	psychiatric	ADJ	JJ	5	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
morbidity	morbidity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
medical	medical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
psychosocial	psychosocial	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
undergone	undergo	VERB	VBN	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
LT	LT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
emergently	emergently	ADV	RB	5	O
between	between	ADP	IN	5	O
1999	1999	NUM	CD	2	O
-	-	SYM	SYM	7	O
2004	2004	NUM	CD	2	O
for	for	ADP	IN	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
36	36	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
sex	sex	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
emergent	emergent	NOUN	NN	5	O
LT	LT	PROPN	NNP	9	O
for	for	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
35	35	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
elective	elective	VERB	VB	5	O
LT	LT	PROPN	NNP	9	O
for	for	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
liver	liver	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CLD	CLD	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
34	34	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Acetaminophen	Acetaminophen	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
LT	LT	PROPN	NNP	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
LT	lt	ADJ	JJ	9	O
illness	illness	NOUN	NN	5	O
reflected	reflect	VERB	VBN	5	O
by	by	ADP	IN	9	O
higher	high	ADJ	JJR	9	O
Acute	Acute	PROPN	NNP	5	O
Physiology	Physiology	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
Chronic	Chronic	PROPN	NNP	9	O
Health	Health	PROPN	NNP	2	O
Evaluation	Evaluation	PROPN	NNP	5	O
II	II	PROPN	NNP	9	O
scores	score	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
requirement	requirement	NOUN	NN	9	O
for	for	ADP	IN	5	O
organ	organ	NOUN	NN	5	O
support	support	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
56	56	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
formal	formal	ADJ	JJ	5	O
psychiatric	psychiatric	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
before	before	ADP	IN	9	O
LT	LT	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
/	/	SYM	SYM	9	O
35	35	NUM	CD	9	O
,	,	PUNCT	,	9	O
CLD	CLD	PROPN	NNP	9	B-Disease
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
34	34	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
nine	nine	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
suicide	suicide	NOUN	NN	5	O
attempt	attempt	NOUN	NN	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
median	median	ADJ	JJ	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rejection	rejection	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
acute	acute	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
graft	graft	NOUN	NN	5	O
failure	failure	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
survival	survival	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
87	87	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
88	88	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
78	78	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
CLD	CLD	PROPN	NNP	9	B-Disease
93	93	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
82	82	NUM	CD	7	O
%	%	NOUN	NN	9	O
:	:	PUNCT	:	9	O
P	p	NOUN	NN	9	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
log	log	NOUN	NN	9	O
rank	rank	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
reattempted	reattempte	VERB	VBD	5	O
suicide	suicide	NOUN	NN	5	O
post	post	NOUN	NN	9	O
-	-	PROPN	NNP	7	O
LT	LT	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
one	one	NUM	CD	5	O
died	die	VERB	VBD	9	O
8	8	NUM	CD	9	O
years	year	NOUN	NNS	5	O
post	post	ADJ	JJ	9	O
-	-	PROPN	NNP	7	O
LT	LT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Despite	despite	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
psychiatric	psychiatric	ADJ	JJ	5	O
disturbance	disturbance	NOUN	NN	5	O
,	,	PUNCT	,	9	O
outcomes	outcome	NOUN	NNS	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
transplanted	transplant	VERB	VBN	3	O
emergently	emergently	ADV	RB	5	O
for	for	ADP	IN	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
were	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
transplanted	transplant	VERB	VBN	3	O
for	for	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
electively	electively	ADV	RB	5	O
for	for	ADP	IN	5	O
CLD	CLD	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Multidisciplinary	multidisciplinary	NOUN	NN	5	O
approaches	approach	VERB	VBZ	5	O
with	with	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
psychiatric	psychiatric	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
low	low	ADJ	JJ	9	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
transplant	transplant	ADJ	JJ	9	O
suicide	suicide	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
seen	see	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
graft	graft	NOUN	NN	5	O
loss	loss	NOUN	NN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
compliance	compliance	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Antithrombotic	antithrombotic	ADJ	JJ	7	O
drug	drug	NOUN	NN	5	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
microbleeds	microbleed	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
systematic	systematic	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
published	publish	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
unpublished	unpublished	ADJ	JJ	6	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Cerebral	Cerebral	PROPN	NNP	5	B-Disease
microbleeds	microbleed	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MB	MB	PROPN	NNP	0	B-Disease
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
potential	potential	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
unclear	unclear	ADJ	JJ	9	O
if	if	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
a	a	DET	DT	5	O
contraindication	contraindication	NOUN	NN	5	O
to	to	ADP	IN	5	O
using	use	VERB	VBG	9	O
antithrombotic	antithrombotic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Insights	insight	NOUN	NNS	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
gained	gain	VERB	VBN	5	O
by	by	ADP	IN	9	O
pooling	pool	VERB	VBG	5	O
data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
MB	MB	PROPN	NNP	0	B-Disease
frequency	frequency	NOUN	NN	5	O
stratified	stratify	VERB	VBN	5	O
by	by	ADP	IN	9	O
antithrombotic	antithrombotic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
cohorts	cohort	NOUN	NNS	9	O
with	with	ADP	IN	5	O
ICH	ICH	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
IS	be	VERB	VBZ	9	B-Disease
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
transient	transient	ADJ	JJ	9	B-Disease
ischemic	ischemic	ADJ	JJ	9	I-Disease
attack	attack	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TIA	TIA	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
systematic	systematic	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
published	publish	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
unpublished	unpublished	ADJ	JJ	6	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
cohorts	cohort	NOUN	NNS	9	O
with	with	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
TIA	tia	NOUN	NN	5	B-Disease
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
MB	MB	PROPN	NNP	0	B-Disease
in	in	ADV	RB	5	O
:	:	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
antithrombotic	antithrombotic	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
vs	vs	ADP	IN	7	O
nonantithrombotic	nonantithrombotic	ADJ	JJ	_	O
users	user	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ICH	ICH	PROPN	NNP	5	B-Disease
;	;	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
antithrombotic	antithrombotic	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
vs	vs	ADP	IN	7	O
nonusers	nonuser	NOUN	NNS	5	O
with	with	ADP	IN	5	O
IS	IS	PROPN	NNP	9	B-Disease
/	/	SYM	SYM	9	O
TIA	tia	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
vs	vs	ADP	IN	7	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
events	event	NOUN	NNS	5	O
stratified	stratify	VERB	VBN	5	O
by	by	ADP	IN	9	O
antithrombotic	antithrombotic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
also	also	ADV	RB	9	O
analyzed	analyze	VERB	VBD	9	O
published	publish	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
unpublished	unpublished	ADJ	JJ	6	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
data	datum	NOUN	NNS	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
ICH	ICH	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
antithrombotic	antithrombotic	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
with	with	ADP	IN	5	O
MB	MB	PROPN	NNP	0	B-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
a	a	DET	DT	5	O
pooled	pooled	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
1460	1460	NUM	CD	7	O
ICH	ICH	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
3817	3817	NUM	CD	7	O
IS	IS	PROPN	NNP	9	B-Disease
/	/	SYM	SYM	9	O
TIA	TIA	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
MB	MB	PROPN	NNP	0	B-Disease
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
in	in	ADP	IN	5	O
ICH	ICH	PROPN	NNP	5	B-Disease
vs	vs	ADP	IN	7	O
IS	IS	PROPN	NNP	9	B-Disease
/	/	SYM	SYM	9	O
TIA	tia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
excess	excess	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
;	;	PUNCT	:	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
nonantithrombotic	nonantithrombotic	ADJ	JJ	_	O
users	user	NOUN	NNS	5	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
antiplatelet	antiplatelet	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
difference	difference	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
an	an	DET	DT	5	O
excess	excess	NOUN	NN	9	O
of	of	ADP	IN	5	O
MB	MB	PROPN	NNP	0	B-Disease
in	in	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
vs	vs	ADP	IN	7	O
nonusers	nonuser	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ICH	ICH	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
;	;	SYM	SYM	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
none	none	NOUN	NN	9	O
in	in	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
with	with	ADP	IN	5	O
IS	IS	PROPN	NNP	9	B-Disease
/	/	SYM	SYM	9	O
TIA	TIA	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
33	33	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
difference	difference	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
smaller	small	ADJ	JJR	5	O
excess	excess	NOUN	NN	9	O
of	of	ADP	IN	5	O
MB	MB	PROPN	NNP	0	B-Disease
in	in	ADP	IN	5	O
antiplatelet	antiplatelet	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
vs	vs	ADP	IN	7	O
nonusers	nonuser	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ICH	ICH	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
;	;	SYM	SYM	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
findings	finding	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
for	for	ADP	IN	5	O
antiplatelet	antiplatelet	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
with	with	ADP	IN	5	O
IS	IS	PROPN	NNP	9	B-Disease
/	/	SYM	SYM	9	O
TIA	TIA	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
difference	difference	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
pooled	pool	VERB	VBN	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
data	datum	NOUN	NNS	5	O
for	for	ADP	IN	5	O
768	768	NUM	CD	7	O
antithrombotic	antithrombotic	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
MB	MB	PROPN	NNP	0	B-Disease
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
substantially	substantially	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
42	42	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
excess	excess	NOUN	NN	9	O
of	of	ADP	IN	5	O
MB	MB	PROPN	NNP	0	B-Disease
in	in	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ICH	ICH	PROPN	NNP	5	B-Disease
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
other	other	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
MB	MB	PROPN	NNP	0	B-Disease
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Limited	limited	ADJ	JJ	9	O
prospective	prospective	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
corroborate	corroborate	VERB	VBP	9	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
larger	large	ADJ	JJR	5	O
prospective	prospective	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
urgently	urgently	ADV	RB	5	O
required	require	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
synergy	synergy	NOUN	NN	9	O
between	between	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
,	,	PUNCT	,	9	O
CNSB002	CNSB002	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
determined	determine	VERB	VBD	9	O
the	the	DET	DT	5	O
antihyperalgesic	antihyperalgesic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
CNSB002	CNSB002	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
with	with	ADP	IN	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
properties	property	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
alone	alone	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combinations	combination	NOUN	NNS	9	O
with	with	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Dose	dose	NOUN	NN	0	O
response	response	NOUN	NN	9	O
curves	curve	NOUN	NNS	5	O
for	for	ADP	IN	5	O
nonsedating	nonsedate	VERB	VBG	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
CNSB002	CNSB002	PROPN	NNP	_	B-Chemical
given	give	VERB	VBN	5	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
alone	alone	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
together	together	ADV	RB	9	O
in	in	ADP	IN	5	O
combinations	combination	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
constructed	construct	VERB	VBN	9	O
for	for	ADP	IN	5	O
antihyperalgesic	antihyperalgesic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
using	use	VERB	VBG	9	O
paw	paw	PRON	PRP	5	O
withdrawal	withdrawal	NOUN	NN	5	O
from	from	ADP	IN	9	O
noxious	noxious	ADJ	JJ	5	O
heat	heat	NOUN	NN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
rat	rat	NOUN	NN	3	O
pain	pain	NOUN	NN	5	B-Disease
models	model	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
carrageenan	carrageenan	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
paw	paw	DET	PRP$	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
nonsedating	nonsedating	NOUN	NN	5	O
doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
CNSB002	CNSB002	PROPN	NNP	_	B-Chemical
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
5	5	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
CNSB002	CNSB002	PROPN	NNP	_	B-Chemical
with	with	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
calculated	calculate	VERB	VBN	5	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
(	(	PUNCT	-LRB-	9	O
ED50	ED50	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
54	54	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
81	81	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
83	83	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
54	54	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
carrageenan	carrageenan	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
44	44	NUM	CD	7	O
.	.	PUNCT	.	9	O
18	18	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
37	37	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
14	14	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
24	24	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neuropathy	neuropathy	ADJ	JJ	5	B-Disease
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
CNSB002	CNSB002	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
mean	mean	VERB	VB	5	O
,	,	PUNCT	,	9	O
SEM	SEM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
values	value	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
nonsedating	nonsedating	NOUN	NN	5	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ED50	ED50	PROPN	NNP	0	O
values	value	NOUN	NNS	5	O
for	for	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
CNSB002	CNSB002	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
nonsedating	nonsedating	NOUN	NN	5	O
dose	dose	NOUN	NN	9	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
56	56	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
55	55	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
carrageenan	carrageenan	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
37	37	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
23	23	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
neuropathy	neuropathy	ADJ	JJ	5	B-Disease
model	model	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
mean	mean	VERB	VB	5	O
,	,	PUNCT	,	9	O
SEM	SEM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antinociception	antinociception	NOUN	NN	3	O
after	after	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
with	with	ADP	IN	5	O
CNSB002	CNSB002	PROPN	NNP	_	B-Chemical
from	from	ADP	IN	9	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
and	and	CCONJ	CC	5	O
31	31	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
114	114	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
56	56	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
models	model	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
;	;	PUNCT	:	9	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
way	way	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
variance	variance	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
either	either	DET	DT	9	O
drug	drug	NOUN	NN	5	O
given	give	VERB	VBN	5	O
alone	alone	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
antihyperalgesic	antihyperalgesic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
achievable	achievable	ADJ	JJ	5	O
with	with	ADP	IN	5	O
nonsedating	nonsedate	VERB	VBG	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
increased	increase	VERB	VBN	9	O
significantly	significantly	ADV	RB	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
CNSB002	CNSB002	PROPN	NNP	_	B-Chemical
.	.	PUNCT	.	9	O

Heparin	Heparin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
practical	practical	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Heparin	Heparin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
HIT	HIT	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
remains	remain	VERB	VBZ	9	O
under	under	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
recognized	recognize	VERB	VBN	9	O
despite	despite	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
potentially	potentially	ADV	RB	5	O
devastating	devastating	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
begins	begin	VERB	VBZ	5	O
when	when	ADV	WRB	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
stimulates	stimulate	VERB	VBZ	3	O
the	the	DET	DT	5	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
platelet	platelet	NOUN	NN	9	O
factor	factor	NOUN	NN	9	O
4	4	NUM	CD	9	O
antibodies	antibody	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
in	in	ADP	IN	5	O
turn	turn	NOUN	NN	9	O
triggers	trigger	VERB	VBZ	9	O
the	the	DET	DT	5	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
procoagulant	procoagulant	ADJ	JJ	9	O
platelet	platelet	NOUN	NN	9	O
particles	particle	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Thrombosis	thrombosis	NOUN	NN	2	B-Disease
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
that	that	DET	WDT	5	O
follow	follow	VERB	VBP	5	O
comprise	comprise	VERB	VBP	9	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
hallmark	hallmark	NOUN	NN	9	O
traits	trait	NOUN	NNS	5	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
former	former	ADJ	JJ	5	O
largely	largely	ADV	RB	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
varies	vary	VERB	VBZ	9	O
among	among	ADP	IN	5	O
several	several	ADJ	JJ	9	O
subgroups	subgroup	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
incidence	incidence	NOUN	NN	5	O
in	in	ADP	IN	5	O
surgical	surgical	ADJ	JJ	5	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
medical	medical	ADJ	JJ	5	O
populations	population	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

HIT	HIT	PROPN	NNP	5	B-Disease
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
acknowledged	acknowledge	VERB	VBN	5	O
for	for	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
intense	intense	ADJ	JJ	9	O
predilection	predilection	NOUN	NN	5	O
for	for	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
suspected	suspect	VERB	VBN	5	O
whenever	whenever	ADV	WRB	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
occurs	occur	VERB	VBZ	9	O
after	after	ADP	IN	9	O
heparin	heparin	ADJ	JJ	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Early	early	ADJ	JJ	9	O
recognition	recognition	NOUN	NN	5	O
that	that	DET	WDT	5	O
incorporates	incorporate	VERB	VBZ	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
serologic	serologic	ADJ	JJ	9	O
clues	clue	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
paramount	paramount	ADJ	JJ	5	O
to	to	ADP	IN	5	O
timely	timely	ADJ	JJ	5	O
institution	institution	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
delay	delay	NOUN	NN	5	O
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
catastrophic	catastrophic	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
mandates	mandate	VERB	VBZ	5	O
an	an	DET	DT	5	O
immediate	immediate	ADJ	JJ	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
institution	institution	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
antithrombotic	antithrombotic	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
most	most	ADV	RBS	9	O
commonly	commonly	ADV	RB	5	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	B-Chemical
thrombin	thrombin	NOUN	NN	0	I-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
.	.	PUNCT	.	9	O

Current	current	ADJ	JJ	9	O
"	"	PUNCT	``	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
tests	test	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
primarily	primarily	ADV	RB	9	O
include	include	VERB	VBP	5	O
functional	functional	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
antigenic	antigenic	ADJ	JJ	9	O
assays	assay	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
more	more	ADJ	JJR	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
confirmatory	confirmatory	ADJ	JJ	5	O
than	than	ADP	IN	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Special	special	ADJ	JJ	2	O
attention	attention	NOUN	NN	5	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
paid	pay	VERB	VBN	5	O
to	to	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
often	often	ADV	RB	5	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
multiple	multiple	ADJ	JJ	5	O
times	time	NOUN	NNS	5	O
during	during	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Direct	direct	ADJ	JJ	9	B-Chemical
thrombin	thrombin	NOUN	NN	0	I-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
are	be	VERB	VBP	5	O
appropriate	appropriate	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
evidence	evidence	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
alternatives	alternative	NOUN	NNS	5	O
to	to	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
need	need	VERB	VBP	5	O
to	to	PART	TO	5	O
undergo	undergo	VERB	VB	9	O
percutaneous	percutaneous	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
intervention	intervention	NOUN	NN	5	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
heparin	heparin	NOUN	NN	0	B-Chemical
remains	remain	VERB	VBZ	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
frequently	frequently	ADV	RB	5	O
used	use	VERB	VBN	5	O
medications	medication	NOUN	NNS	5	O
today	today	NOUN	NN	5	O
with	with	ADP	IN	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
with	with	ADP	IN	5	O
every	every	DET	DT	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
close	close	ADJ	JJ	5	O
vigilance	vigilance	NOUN	NN	5	O
of	of	ADP	IN	5	O
platelet	platelet	NOUN	NN	9	O
counts	count	NOUN	NNS	9	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
practiced	practice	VERB	VBN	5	O
whenever	whenever	ADV	WRB	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
initiated	initiate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Abductor	abductor	NOUN	NN	7	O
paralysis	paralysis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
botox	botox	NOUN	NN	5	B-Chemical
injection	injection	NOUN	NN	9	O
for	for	ADP	IN	5	O
adductor	adductor	NOUN	NN	5	B-Disease
spasmodic	spasmodic	ADJ	JJ	5	I-Disease
dysphonia	dysphonia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVES	OBJECTIVES	PROPN	NNP	2	O
/	/	SYM	SYM	9	O
HYPOTHESIS	HYPOTHESIS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Botulinum	botulinum	ADJ	JJ	5	O
toxin	toxin	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
Botox	Botox	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
injections	injection	VERB	VBZ	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
thyroarytenoid	thyroarytenoid	NOUN	NN	5	O
muscles	muscle	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
standard	standard	NOUN	NN	5	O
of	of	ADP	IN	5	O
care	care	NOUN	NN	5	O
for	for	ADP	IN	5	O
adductor	adductor	NOUN	NN	5	B-Disease
spasmodic	spasmodic	ADJ	JJ	5	I-Disease
dysphonia	dysphonia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ADSD	ADSD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Reported	report	VERB	VBN	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
include	include	VERB	VBP	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
breathiness	breathiness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
throat	throat	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
difficulty	difficulty	NOUN	NN	5	O
with	with	ADP	IN	5	O
swallowing	swallowing	NOUN	NN	5	O
liquids	liquid	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
report	report	VERB	VBP	5	O
multiple	multiple	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
abductor	abductor	NOUN	NN	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
Botox	Botox	PROPN	NNP	5	B-Chemical
injections	injection	NOUN	NNS	9	O
for	for	ADP	IN	5	O
ADSD	ADSD	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
previously	previously	ADV	RB	9	O
unreported	unreported	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

STUDY	STUDY	PROPN	NNP	2	O
DESIGN	DESIGN	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Retrospective	retrospective	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
series	series	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
Botox	Botox	PROPN	NNP	5	B-Chemical
injections	injection	NOUN	NNS	9	O
for	for	ADP	IN	5	O
spasmodic	spasmodic	ADJ	JJ	5	B-Disease
dysphonia	dysphonia	NOUN	NN	5	I-Disease
between	between	ADP	IN	5	O
January	January	PROPN	NNP	2	O
2000	2000	NUM	CD	9	O
and	and	CCONJ	CC	5	O
October	October	PROPN	NNP	2	O
2009	2009	NUM	CD	2	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ADSD	ADSD	PROPN	NNP	5	B-Disease
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatments	treatment	NOUN	NNS	9	O
received	receive	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
abductor	abductor	NOUN	NN	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
paralytic	paralytic	ADJ	JJ	5	O
Botox	Botox	PROPN	NNP	5	B-Chemical
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
prior	prior	ADJ	JJ	9	O
Botox	Botox	PROPN	NNP	5	B-Chemical
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
course	course	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
paralysis	paralysis	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
From	from	ADP	IN	5	O
a	a	DET	DT	5	O
database	database	NOUN	NN	5	O
of	of	ADP	IN	5	O
452	452	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
Botox	Botox	PROPN	NNP	5	B-Chemical
,	,	PUNCT	,	9	O
352	352	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
ADSD	ADSD	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
these	these	DET	DT	5	O
352	352	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
suffered	suffer	VERB	VBD	5	O
bilateral	bilateral	ADJ	JJ	5	O
abductor	abductor	NOUN	NN	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
suffered	suffer	VERB	VBD	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
twice	twice	ADV	RB	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
affected	affect	VERB	VBN	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
females	female	NOUN	NNS	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Most	Most	ADJ	JJS	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
treatments	treatment	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
abductor	abductor	NOUN	NN	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
continued	continue	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
after	after	ADP	IN	9	O
paralysis	paralysis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
recovered	recover	VERB	VBD	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
brief	brief	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
restrictions	restriction	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
underwent	undergo	VERB	VBD	5	O
a	a	DET	DT	5	O
tracheotomy	tracheotomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
abductor	abductor	NOUN	NN	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
Botox	Botox	PROPN	NNP	5	B-Chemical
injection	injection	NOUN	NN	9	O
for	for	ADP	IN	5	O
ADSD	ADSD	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Bilateral	bilateral	ADJ	JJ	5	O
abductor	abductor	NOUN	NN	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
Botox	Botox	PROPN	NNP	5	B-Chemical
injections	injection	NOUN	NNS	9	O
for	for	ADP	IN	5	O
ADSD	ADSD	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
causing	cause	VERB	VBG	9	O
difficulty	difficulty	NOUN	NN	5	O
with	with	ADP	IN	5	O
breathing	breathing	NOUN	NN	5	O
upon	upon	ADP	IN	9	O
exertion	exertion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
likely	likely	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
diffusion	diffusion	NOUN	NN	5	O
of	of	ADP	IN	5	O
Botox	Botox	PROPN	NNP	5	B-Chemical
around	around	ADP	IN	5	O
the	the	DET	DT	5	O
muscular	muscular	ADJ	JJ	5	O
process	process	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
arytenoid	arytenoid	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
posterior	posterior	ADJ	JJ	5	O
cricoarytenoid	cricoarytenoid	NOUN	NN	5	O
muscles	muscle	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
temporary	temporary	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
watchful	watchful	ADJ	JJ	5	O
waiting	wait	VERB	VBG	5	O
with	with	ADP	IN	5	O
restriction	restriction	NOUN	NN	9	O
of	of	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
recommended	recommend	VERB	VBN	5	O
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
contributes	contribute	NOUN	NNS	9	O
to	to	PART	TO	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
:	:	PUNCT	:	9	O
Prevention	prevention	NOUN	NN	2	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
targeted	target	VERB	VBN	9	O
antioxidant	antioxidant	NOUN	NN	0	O
MitoQ	MitoQ	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
goal	goal	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ROS	ROS	PROPN	NNP	3	O
production	production	NOUN	NN	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
hypothesized	hypothesize	VERB	VBD	9	O
that	that	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
altered	altered	ADJ	JJ	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
turn	turn	NOUN	NN	9	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
left	leave	VERB	VBN	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
fibers	fiber	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
specifically	specifically	ADV	RB	9	O
through	through	ADP	IN	9	O
complex	complex	ADJ	JJ	9	O
I	-PRON-	PRON	PRP	9	O
and	and	CCONJ	CC	5	O
complex	complex	ADJ	JJ	9	O
III	III	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

ROS	ROS	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
,	,	PUNCT	,	9	O
specifically	specifically	ADV	RB	9	O
in	in	ADP	IN	5	O
interfibrillar	interfibrillar	ADJ	JJ	5	O
mitochondria	mitochondria	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
parallel	parallel	NOUN	NN	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
ATP	ATP	PROPN	NNP	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
no	no	DET	DT	9	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
subsarcolemmal	subsarcolemmal	ADJ	JJ	5	O
mitochondria	mitochondria	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
uncoupling	uncoupling	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
phosphorylation	phosphorylation	NOUN	NN	3	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
detectable	detectable	ADJ	JJ	9	O
after	after	ADP	IN	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
were	be	VERB	VBD	9	O
a	a	DET	DT	5	O
late	late	ADJ	JJ	9	O
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
a	a	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
event	event	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathological	pathological	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

MitoQ	MitoQ	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
mitochondrial	mitochondrial	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
targeted	target	VERB	VBN	9	O
antioxidant	antioxidant	NOUN	NN	0	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
completely	completely	ADV	RB	9	O
prevent	prevent	VERB	VB	5	O
these	these	DET	DT	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
characterized	characterize	VERB	VBN	9	O
here	here	ADV	RB	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
diastolic	diastolic	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
studied	study	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
conductance	conductance	NOUN	NN	5	O
catheter	catheter	NOUN	NN	5	O
to	to	PART	TO	5	O
obtain	obtain	VERB	VB	5	O
pressure	pressure	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
volume	volume	NOUN	NN	9	O
data	datum	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Taken	take	VERB	VBN	9	O
together	together	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
extend	extend	VERB	VBP	9	O
previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
demonstrate	demonstrate	VERB	VB	9	O
that	that	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
defect	defect	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Trimethoprim	Trimethoprim	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
immune	immune	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
pediatric	pediatric	ADJ	JJ	5	O
oncology	oncology	NOUN	NN	5	O
patient	patient	NOUN	NN	5	O
presenting	present	VERB	VBG	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
hemolytic	hemolytic	ADJ	JJ	0	O
transfusion	transfusion	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
chemotherapy	chemotherapy	ADJ	JJ	5	O
anemia	anemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
red	red	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
transfusion	transfusion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
hemoglobinuria	hemoglobinuria	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Transfusion	transfusion	NOUN	NN	2	O
reaction	reaction	NOUN	NN	9	O
workup	workup	NOUN	NN	5	O
was	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
immune	immune	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
positive	positive	ADJ	JJ	9	O
direct	direct	ADJ	JJ	9	O
antiglobulin	antiglobulin	NOUN	NN	3	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
negative	negative	ADJ	JJ	9	O
eluate	eluate	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
microspherocytes	microspherocyte	NOUN	NNS	9	O
on	on	ADP	IN	5	O
smear	smear	ADJ	JJ	5	O
pre	pre	VERB	VBN	9	O
-	-	ADJ	JJ	7	O
and	and	CCONJ	CC	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
transfusion	transfusion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
indirect	indirect	ADJ	JJ	5	O
antiglobulin	antiglobulin	ADJ	JJ	3	O
test	test	NOUN	NN	5	O
were	be	VERB	VBD	9	O
strongly	strongly	ADV	RB	9	O
positive	positive	ADJ	JJ	9	O
with	with	ADP	IN	5	O
trimethoprim	trimethoprim	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
trimethoprim	trimethoprim	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sulfamethoxazole	sulfamethoxazole	NOUN	NN	0	I-Chemical
but	but	CCONJ	CC	9	O
negative	negative	ADJ	JJ	9	O
with	with	ADP	IN	5	O
sulfamethoxazole	sulfamethoxazole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
recovered	recover	VERB	VBD	9	O
after	after	ADP	IN	9	O
discontinuing	discontinue	VERB	VBG	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
recurrence	recurrence	NOUN	NN	5	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
anemia	anemia	NOUN	NN	9	B-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
worse	bad	ADJ	JJR	5	O
-	-	PUNCT	HYPH	7	O
than	than	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
expected	expect	VERB	VBN	9	O
anemia	anemia	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
during	during	ADP	IN	5	O
transfusion	transfusion	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
always	always	ADV	RB	5	O
a	a	DET	DT	5	O
transfusion	transfusion	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
stimulation	stimulation	NOUN	NN	3	O
test	test	NOUN	NN	5	O
in	in	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
anatomic	anatomic	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
stalk	stalk	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
stimulation	stimulation	NOUN	NN	3	O
test	test	NOUN	NN	5	O
was	be	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
investigated	investigate	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
tool	tool	NOUN	NN	5	O
for	for	ADP	IN	5	O
differential	differential	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
with	with	ADP	IN	5	O
conflicting	conflicting	ADJ	JJ	5	O
results	result	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Macroprolactinemia	Macroprolactinemia	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
never	never	ADV	RB	5	O
considered	consider	VERB	VBN	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
re	re	VERB	VB	5	O
-	-	VERB	VB	7	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
all	all	DET	DT	5	O
screened	screen	VERB	VBN	9	O
for	for	ADP	IN	5	O
macroprolactinemia	macroprolactinemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Prolactin	prolactin	NOUN	NN	9	O
responses	response	NOUN	NNS	5	O
to	to	PART	TO	5	O
verapamil	verapamil	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
65	65	NUM	CD	7	O
female	female	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
age	age	NOUN	NN	5	O
:	:	PUNCT	:	9	O
29	29	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
descriptive	descriptive	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
matched	matched	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
PRL	PRL	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
at	at	ADP	IN	9	O
8th	8th	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
16th	16th	ADJ	JJ	5	O
hours	hour	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
immunometric	immunometric	ADJ	JJ	0	O
chemiluminescence	chemiluminescence	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
responsiveness	responsiveness	NOUN	NN	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
peak	peak	NOUN	NN	9	O
percent	percent	NOUN	NN	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
basal	basal	NOUN	NN	3	O
prolactin	prolactin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
PRL	PRL	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
PRL	PRL	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
.	.	NOUN	NN	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
PRL	PRL	PROPN	NNP	3	O
:	:	PUNCT	:	9	O
183	183	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
macroprolactinoma	macroprolactinoma	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
.	.	NOUN	NN	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
PRL	PRL	PROPN	NNP	3	O
:	:	PUNCT	:	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
microprolactinoma	microprolactinoma	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
.	.	PUNCT	.	9	O
19	19	NUM	CD	7	O
,	,	PUNCT	,	9	O
PRL	PRL	PROPN	NNP	3	O
:	:	PUNCT	:	9	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
macroprolactinemia	macroprolactinemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
.	.	PUNCT	.	9	O
23	23	NUM	CD	7	O
,	,	PUNCT	,	9	O
PRL	PRL	PROPN	NNP	3	O
:	:	PUNCT	:	9	O
126	126	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
pseudoprolactinoma	pseudoprolactinoma	NOUN	NN	_	B-Disease
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
.	.	NOUN	NN	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
PRL	PRL	PROPN	NNP	3	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
.	.	NOUN	NN	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
PRL	PRL	PROPN	NNP	3	O
:	:	PUNCT	:	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

ROC	ROC	PROPN	NNP	5	O
curve	curve	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
that	that	DET	DT	5	O
unresponsiveness	unresponsiveness	NOUN	NN	3	O
to	to	PART	TO	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
PRL	PRL	PROPN	NNP	3	O
<	<	X	XX	0	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
discriminated	discriminate	VERB	VBN	5	O
anatomical	anatomical	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
stalk	stalk	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
sensitivity	sensitivity	NOUN	NN	9	O
:	:	PUNCT	:	9	O
74	74	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
specificity	specificity	NOUN	NN	9	O
:	:	PUNCT	:	9	O
73	73	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
AUC	AUC	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
855	855	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
,	,	PUNCT	,	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
768	768	NUM	CD	7	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
942	942	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
pseudoprolactinoma	pseudoprolactinoma	NOUN	NN	_	B-Disease
or	or	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
responsiveness	responsiveness	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
a	a	DET	DT	5	O
reliable	reliable	ADJ	JJ	5	O
finding	finding	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
unresponsiveness	unresponsiveness	NOUN	NN	3	O
discriminates	discriminate	VERB	VBZ	9	O
stalk	stalk	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
anatomically	anatomically	ADV	RB	5	O
or	or	CCONJ	CC	5	O
functionally	functionally	ADV	RB	9	O
inhibited	inhibit	VERB	VBN	3	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
tonus	tonus	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
other	other	ADJ	JJ	5	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
varying	vary	VERB	VBG	5	O
degrees	degree	NOUN	NNS	5	O
of	of	ADP	IN	5	O
responsiveness	responsiveness	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Blockade	Blockade	PROPN	NNP	3	O
of	of	ADP	IN	5	O
endothelial	endothelial	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
mesenchymal	mesenchymal	ADJ	JJ	3	O
transition	transition	NOUN	NN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
Smad3	smad3	ADJ	JJ	3	O
inhibitor	inhibitor	NOUN	NN	3	O
delays	delay	NOUN	NNS	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
early	early	ADJ	JJ	9	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
type	type	NOUN	NN	9	B-Disease
1	1	NUM	CD	9	I-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
normoalbuminuria	normoalbuminuria	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
retard	retard	VERB	VB	9	O
the	the	DET	DT	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
other	other	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
early	early	ADJ	JJ	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
previously	previously	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBN	9	O
that	that	ADP	IN	5	O
endothelial	endothelial	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
mesenchymal	mesenchymal	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
transition	transition	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
EndoMT	EndoMT	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
contributes	contribute	VERB	VBZ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
independently	independently	ADV	RB	9	O
of	of	ADP	IN	5	O
microalbuminuria	microalbuminuria	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetes	diabetes	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
hypothesized	hypothesize	VERB	VBD	9	O
that	that	ADP	IN	5	O
blocking	block	VERB	VBG	3	O
EndoMT	EndoMT	PROPN	NNP	3	O
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

RESEARCH	research	NOUN	NN	2	O
DESIGN	DESIGN	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
EndoMT	EndoMT	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
mouse	mouse	NOUN	NN	3	O
pancreatic	pancreatic	ADJ	JJ	3	O
microvascular	microvascular	ADJ	JJ	5	O
endothelial	endothelial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
line	line	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
MMEC	MMEC	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
glycation	glycation	NOUN	NN	0	O
end	end	NOUN	NN	9	O
products	product	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
AGEs	AGEs	PROPN	NNPS	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
endothelial	endothelial	ADJ	JJ	3	O
lineage	lineage	NOUN	NN	4	O
-	-	PUNCT	HYPH	7	O
traceble	traceble	ADJ	JJ	_	O
mouse	mouse	NOUN	NN	3	O
line	line	NOUN	NN	9	O
Tie2	Tie2	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
Cre	Cre	PROPN	NNP	3	O
;	;	PUNCT	:	9	O
Loxp	Loxp	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
EGFP	EGFP	PROPN	NNP	3	O
by	by	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
AGEs	age	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
nonglycated	nonglycated	ADJ	JJ	0	O
mouse	mouse	NOUN	NN	3	O
albumin	albumin	NOUN	NN	0	O
serving	serve	VERB	VBG	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Phosphorylated	Phosphorylated	PROPN	NNP	3	O
Smad3	Smad3	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
by	by	ADP	IN	9	O
immunoprecipitation	immunoprecipitation	NOUN	NN	3	O
/	/	SYM	SYM	9	O
Western	western	ADJ	JJ	3	O
blotting	blotting	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
confocal	confocal	ADJ	JJ	3	O
microscopy	microscopy	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Blocking	block	VERB	VBG	3	O
studies	study	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
receptor	receptor	NOUN	NN	3	O
for	for	ADP	IN	5	O
AGE	AGE	PROPN	NNP	9	O
siRNA	siRNA	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
Smad3	smad3	X	ADD	3	O
(	(	PUNCT	-LRB-	9	O
SIS3	SIS3	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
MMECs	MMECs	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
Tie2	Tie2	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
Cre	Cre	PROPN	NNP	3	O
;	;	PUNCT	:	9	O
Loxp	Loxp	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
EGFP	EGFP	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Confocal	confocal	ADJ	JJ	3	O
microscopy	microscopy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
real	real	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
PCR	PCR	PROPN	NNP	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
AGEs	AGEs	PROPN	NNPS	3	O
induced	induce	VERB	VBD	3	O
EndoMT	EndoMT	PROPN	NNP	3	O
in	in	ADP	IN	5	O
MMECs	mmec	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
Tie2	Tie2	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
Cre	Cre	PROPN	NNP	3	O
;	;	PUNCT	:	9	O
Loxp	Loxp	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
EGFP	EGFP	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Immunoprecipitation	immunoprecipitation	NOUN	NN	3	O
/	/	SYM	SYM	9	O
Western	western	ADJ	JJ	3	O
blotting	blotting	NOUN	NN	3	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
Smad3	smad3	NOUN	NN	3	O
was	be	VERB	VBD	9	O
activated	activate	VERB	VBN	3	O
by	by	ADP	IN	9	O
AGEs	age	NOUN	NNS	3	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
inhibited	inhibit	VERB	VBN	3	O
by	by	ADP	IN	9	O
SIS3	SIS3	PROPN	NNP	3	O
in	in	ADP	IN	5	O
MMECs	MMECs	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Confocal	confocal	ADJ	JJ	3	O
microscopy	microscopy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
real	real	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
PCR	PCR	PROPN	NNP	9	O
further	further	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
SIS3	SIS3	PROPN	NNP	3	O
abrogated	abrogated	ADJ	JJ	3	O
EndoMT	EndoMT	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
retarded	retarded	ADJ	JJ	9	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
EndoMT	EndoMT	PROPN	NNP	3	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
pathway	pathway	NOUN	NN	3	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
early	early	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Blockade	Blockade	PROPN	NNP	3	O
of	of	ADP	IN	5	O
EndoMT	EndoMT	PROPN	NNP	3	O
by	by	ADP	IN	9	O
SIS3	SIS3	PROPN	NNP	3	O
may	may	VERB	MD	5	O
provide	provide	VERB	VB	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
strategy	strategy	NOUN	NN	5	O
to	to	PART	TO	5	O
retard	retard	VERB	VB	9	O
the	the	DET	DT	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Cytostatic	cytostatic	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
angiogenic	angiogenic	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
temsirolimus	temsirolimus	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
refractory	refractory	ADJ	JJ	9	O
mantle	mantle	NOUN	NN	5	B-Disease
cell	cell	NOUN	NN	3	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Mantle	Mantle	PROPN	NNP	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
MCL	MCL	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
aggressive	aggressive	ADJ	JJ	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
B	b	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
cell	cell	NOUN	NN	3	I-Disease
non	non	ADJ	JJ	9	I-Disease
-	-	PROPN	NNP	7	I-Disease
Hodgkin	Hodgkin	PROPN	NNP	5	I-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
become	become	VERB	VBP	5	O
progressively	progressively	ADV	RB	9	O
refractory	refractory	ADJ	JJ	9	O
to	to	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
prognosis	prognosis	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
poor	poor	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
38	38	NUM	CD	7	O
%	%	NOUN	NN	9	O
remission	remission	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
recently	recently	ADV	RB	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
refractory	refractory	NOUN	NN	9	O
MCL	MCL	PROPN	NNP	9	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
temsirolimus	temsirolimus	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
mTOR	mTOR	PROPN	NNP	3	O
inhibitor	inhibitor	NOUN	NN	3	O
.	.	PUNCT	.	9	O
Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
opportunity	opportunity	NOUN	NN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
refractory	refractory	NOUN	NN	9	O
MCL	MCL	PROPN	NNP	9	B-Disease
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
tumor	tumor	NOUN	NN	3	B-Disease
regression	regression	NOUN	NN	5	O
two	two	NUM	CD	5	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
temsirolimus	temsirolimus	NOUN	NN	3	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
progression	progression	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
lymph	lymph	NOUN	NN	9	O
node	node	NOUN	NN	5	O
biopsies	biopsy	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
temsirolimus	temsirolimus	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Comparison	Comparison	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
biopsies	biopsy	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
temsirolimus	temsirolimus	NOUN	NN	3	B-Chemical
inhibited	inhibited	ADJ	JJ	3	O
tumor	tumor	NOUN	NN	3	B-Disease
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
through	through	ADP	IN	9	O
cell	cell	NOUN	NN	3	O
cycle	cycle	NOUN	NN	9	O
arrest	arrest	NOUN	NN	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
induce	induce	VERB	VB	3	O
any	any	DET	DT	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
apoptotic	apoptotic	ADJ	JJ	3	O
tumor	tumor	NOUN	NN	3	B-Disease
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Apart	apart	ADV	RB	9	O
from	from	ADP	IN	9	O
this	this	DET	DT	5	O
cytostatic	cytostatic	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
temsirolimus	temsirolimus	NOUN	NN	3	B-Chemical
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
antiangiogenic	antiangiogenic	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
with	with	ADP	IN	5	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
microvessel	microvessel	NOUN	NN	3	O
density	density	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
VEGF	VEGF	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
numerous	numerous	ADJ	JJ	9	O
patchy	patchy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
limited	limit	VERB	VBN	5	O
fibrotic	fibrotic	ADJ	JJ	5	O
areas	area	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
compatible	compatible	ADJ	JJ	5	O
with	with	ADP	IN	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
necrotic	necrotic	ADJ	JJ	3	B-Disease
tissue	tissue	NOUN	NN	9	O
repair	repair	NOUN	NN	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
after	after	ADP	IN	9	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
temsirolimus	temsirolimus	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
temsirolimus	temsirolimus	NOUN	NN	3	B-Chemical
reduced	reduce	VERB	VBN	9	O
tumor	tumor	NOUN	NN	3	B-Disease
burden	burden	NOUN	NN	5	O
through	through	ADP	IN	9	O
associated	associate	VERB	VBN	9	O
cytostatic	cytostatic	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
angiogenic	angiogenic	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O
This	this	DET	DT	5	O
dual	dual	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
temsirolimus	temsirolimus	NOUN	NN	3	B-Chemical
on	on	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
tissue	tissue	NOUN	NN	9	O
could	could	VERB	MD	9	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
recently	recently	ADV	RB	9	O
reported	report	VERB	VBN	9	O
efficiency	efficiency	NOUN	NN	9	O
in	in	ADP	IN	5	O
refractory	refractory	NOUN	NN	9	O
MCL	MCL	PROPN	NNP	9	B-Disease
resistant	resistant	NOUN	NN	9	O
to	to	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
rifampicin	rifampicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
23	23	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
bacteriologically	bacteriologically	ADV	RB	5	O
proven	prove	VERB	VBN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
tuberculosis	tuberculosis	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
various	various	ADJ	JJ	9	O
regimens	regimen	NOUN	NNS	5	O
of	of	ADP	IN	5	O
antituberculosis	antituberculosis	NOUN	NN	5	O
drugs	drug	NOUN	NNS	5	O
for	for	ADP	IN	5	O
nearly	nearly	ADV	RB	9	O
15	15	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Rifampicin	Rifampicin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
thrice	thrice	NOUN	NN	0	O
as	as	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
drug	drug	NOUN	NN	5	O
regimen	regiman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
each	each	DET	DT	5	O
time	time	NOUN	NN	5	O
he	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
untoward	untoward	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
like	like	ADP	IN	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
fever	fever	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
chills	chill	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
rigors	rigor	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
such	such	ADJ	JJ	5	O
episode	episode	NOUN	NN	5	O
was	be	VERB	VBD	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
failure	failure	NOUN	NN	5	O
at	at	ADP	IN	9	O
which	which	DET	WDT	5	O
stage	stage	NOUN	NN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
made	make	VERB	VBD	5	O
a	a	DET	DT	5	O
full	full	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Syncope	Syncope	PROPN	NNP	7	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
combined	combine	VERB	VBN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitor	inhibitor	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
76	76	NUM	CD	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
bypass	bypass	NOUN	NN	5	O
grafting	grafting	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
prior	prior	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
transferred	transfer	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
room	room	NOUN	NN	9	O
with	with	ADP	IN	5	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
consciousness	consciousness	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
marked	mark	VERB	VBN	9	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
sinus	sinus	NOUN	NN	5	O
rhythm	rhythm	NOUN	NN	5	O
was	be	VERB	VBD	9	O
restored	restore	VERB	VBN	3	O
after	after	ADP	IN	9	O
correction	correction	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
several	several	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
spiranolactone	spiranolactone	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
intake	intake	NOUN	NN	5	O
of	of	ADP	IN	5	O
ramipril	ramipril	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
ACE	ACE	PROPN	NNP	9	O
inhibitor	inhibitor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
good	good	ADJ	JJ	5	O
example	example	NOUN	NN	5	O
of	of	ADP	IN	5	O
electrolyte	electrolyte	NOUN	NN	0	O
imbalance	imbalance	NOUN	NN	9	O
causing	cause	VERB	VBG	9	O
acute	acute	ADJ	JJ	9	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
cardiac	cardiac	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
alert	alert	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
ACE	ACE	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
ARB	ARB	PROPN	NNP	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
sparing	sparing	NOUN	NN	5	O
agents	agent	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
mild	mild	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	B-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Diffuse	diffuse	VERB	VB	9	O
skeletal	skeletal	ADJ	JJ	9	O
pain	pain	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
alendronate	alendronate	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
bone	bone	NOUN	NN	5	O
resorption	resorption	NOUN	NN	5	O
in	in	ADP	IN	5	O
excess	excess	NOUN	NN	9	O
of	of	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
formation	formation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bisphosphonates	bisphosphonate	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
inhibit	inhibit	VERB	VB	3	O
bone	bone	NOUN	NN	5	O
resorption	resorption	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Alendronate	Alendronate	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
biphosphonate	biphosphonate	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
effective	effective	ADJ	JJ	5	O
for	for	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
relatively	relatively	ADV	RB	5	O
few	few	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
prominently	prominently	ADV	RB	9	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Musculoskeletal	musculoskeletal	ADJ	JJ	2	B-Disease
pain	pain	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
presented	present	VERB	VBD	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
out	out	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
patient	patient	NOUN	NN	5	O
clinic	clinic	NOUN	NN	5	O
with	with	ADP	IN	5	O
diffuse	diffuse	NOUN	NN	5	O
skeletal	skeletal	ADJ	JJ	9	O
pain	pain	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
three	three	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
alendronate	alendronate	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
can	can	VERB	MD	5	O
report	report	VERB	VB	5	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bisphosphonate	bisphosphonate	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
pain	pain	NOUN	NN	5	B-Disease
should	should	VERB	MD	5	O
also	also	ADV	RB	9	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
before	before	ADP	IN	9	O
ascribing	ascribe	VERB	VBG	5	O
this	this	DET	DT	5	O
complaint	complaint	NOUN	NN	5	O
to	to	ADP	IN	5	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	ADJ	JJ	5	O
penetration	penetration	NOUN	NN	5	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
daptomycin	daptomycin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
Staphylococcus	Staphylococcus	PROPN	NNP	4	O
aureus	aureus	NOUN	NN	9	O
meningitis	meningitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
methicillin	methicillin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
Staphylococcus	Staphylococcus	PROPN	NNP	4	O
aureus	aureus	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
MSSA	MSSA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
bacteremia	bacteremia	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
MSSA	MSSA	PROPN	NNP	9	O
meningitis	meningitis	NOUN	NN	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
daptomycin	daptomycin	NOUN	NN	0	B-Chemical
assessed	assess	VERB	VBN	9	O
with	with	ADP	IN	5	O
concurrent	concurrent	ADJ	JJ	5	O
serum	serum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CSF	csf	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
concentrations	concentration	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
54	54	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
presented	present	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
with	with	ADP	IN	5	O
generalized	generalized	ADJ	JJ	5	O
weakness	weakness	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
presumed	presume	VERB	VBN	9	O
health	health	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
care	care	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
pneumonia	pneumonia	NOUN	NN	5	B-Disease
shown	show	VERB	VBN	9	O
on	on	ADP	IN	5	O
chest	chest	NOUN	NN	5	O
radiograph	radiograph	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
empirically	empirically	ADV	RB	5	O
initiated	initiate	VERB	VBN	9	O
with	with	ADP	IN	5	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
piperacillin	piperacillin	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
tazobactam	tazobactam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
cultures	culture	NOUN	NNS	3	O
revealed	reveal	VERB	VBD	9	O
S	S	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
aureus	aureus	VERB	VB	9	O
susceptible	susceptible	ADJ	JJ	9	O
to	to	PART	TO	5	O
oxacillin	oxacillin	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

Empiric	empiric	ADJ	JJ	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
narrowed	narrow	VERB	VBN	5	O
to	to	PART	TO	5	O
nafcillin	nafcillin	VERB	VB	0	B-Chemical
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
serum	serum	ADV	RB	9	O
creatinine	creatinine	VERB	VB	0	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	VERB	VB	7	O
the	the	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
on	on	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
Glasgow	Glasgow	PROPN	NNP	5	O
Coma	Coma	PROPN	NNP	5	O
Score	Score	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
shown	show	VERB	VBN	9	O
on	on	ADP	IN	5	O
computed	compute	VERB	VBN	5	O
tomography	tomography	NOUN	NN	5	O
scan	scan	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
head	head	NOUN	NN	5	O
72	72	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
an	an	DET	DT	5	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
experienced	experience	VERB	VBD	5	O
relapsing	relapse	VERB	VBG	5	O
MSSA	MSSA	PROPN	NNP	9	O
bacteremia	bacteremia	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
suspicion	suspicion	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CNS	CNS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
infection	infection	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Nafcillin	Nafcillin	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
daptomycin	daptomycin	VERB	VBD	0	B-Chemical
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
was	be	VERB	VBD	9	O
initiated	initiate	VERB	VBN	9	O
for	for	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
meningitis	meningitis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
continued	continue	VERB	VBN	9	O
until	until	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
death	death	NOUN	NN	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O

Daptomycin	Daptomycin	PROPN	NNP	0	B-Chemical
serum	serum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
CSF	csf	NOUN	NN	9	O
trough	trough	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
21	21	NUM	CD	7	O
ug	ug	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
52	52	NUM	CD	7	O
ug	ug	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lumbar	Lumbar	PROPN	NNP	5	O
puncture	puncture	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
inconclusive	inconclusive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
further	further	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cultures	culture	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
for	for	ADP	IN	5	O
MSSA	MSSA	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Creatine	creatine	NOUN	NN	7	B-Chemical
kinase	kinase	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
prior	prior	ADV	RB	9	O
to	to	PART	TO	5	O
daptomycin	daptomycin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
reassessed	reassess	VERB	VBN	5	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Daptomycin	Daptomycin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
initiated	initiate	VERB	VBN	9	O
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
nafcillin	nafcillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
relapsing	relapse	VERB	VBG	5	O
bacteremia	bacteremia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
resultant	resultant	ADJ	JJ	9	O
penetration	penetration	NOUN	NN	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
previous	previous	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
more	more	ADV	RBR	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
inflamed	inflamed	ADJ	JJ	3	O
meninges	meninge	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
daptomycin	daptomycin	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
alternative	alternative	ADJ	JJ	5	O
option	option	NOUN	NN	5	O
for	for	ADP	IN	5	O
MSSA	MSSA	PROPN	NNP	9	O
bacteremia	bacteremia	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
a	a	DET	DT	5	O
CNS	CNS	PROPN	NNP	9	O
source	source	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
failed	fail	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
cannot	cannot	VERB	VB	5	O
tolerate	tolerate	ADJ	JJ	5	O
standard	standard	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
confirmed	confirm	VERB	VBN	9	O
meningitis	meningitis	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
lindane	lindane	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Lindane	Lindane	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
organochloride	organochloride	ADJ	JJ	0	O
pesticide	pesticide	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
scabicide	scabicide	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
evokes	evoke	VERB	VBZ	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
mainly	mainly	ADV	RB	9	O
trough	trough	ADP	IN	9	O
the	the	DET	DT	5	O
blockage	blockage	NOUN	NN	9	O
of	of	ADP	IN	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	no	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
gaseous	gaseous	ADJ	JJ	0	O
neurotransmitter	neurotransmitter	NOUN	NN	9	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
contradictor	contradictor	NOUN	NN	_	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
epileptogenesis	epileptogenesis	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
opposite	opposite	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
precursor	precursor	NOUN	NN	9	O
of	of	ADP	IN	5	O
NO	no	DET	DT	9	B-Chemical
syntheses	synthesis	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
NOS	NOS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	NAME	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NOS	NOS	PROPN	NNP	9	O
inhibitor	inhibitor	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
observed	observe	VERB	VBD	9	O
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
NO	no	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
EEG	EEG	PROPN	NNP	5	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Wistar	wistar	NOUN	NN	9	O
albino	albino	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
600	600	NUM	CD	0	O
,	,	PUNCT	,	9	O
800	800	NUM	CD	0	O
and	and	CCONJ	CC	5	O
1000	1000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
convulsion	convulsion	NOUN	NN	5	B-Disease
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
shortened	shortened	ADJ	JJ	9	O
latency	latency	NOUN	NN	5	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
first	first	ADJ	JJ	9	O
convulsion	convulsion	NOUN	NN	5	B-Disease
elicited	elicit	VERB	VBN	9	O
by	by	ADP	IN	9	O
lower	low	ADJ	JJR	9	O
lindane	lindane	ADJ	JJ	0	B-Chemical
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
contrary	contrary	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
pretreatment	pretreatment	ADJ	JJ	0	O
with	with	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	name	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
500	500	NUM	CD	0	O
,	,	PUNCT	,	9	O
700	700	NUM	CD	9	O
and	and	CCONJ	CC	5	O
900	900	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBD	9	O
convulsion	convulsion	NOUN	NN	5	B-Disease
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
prolonged	prolonged	ADJ	JJ	9	O
latency	latency	NOUN	NN	5	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
convulsion	convulsion	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
injection	injection	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

EEG	EEG	PROPN	NNP	5	O
analyses	analyse	VERB	VBZ	9	O
showed	show	VERB	VBD	9	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
number	number	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
ictal	ictal	ADJ	JJ	5	O
periods	period	NOUN	NNS	5	O
in	in	ADP	IN	5	O
EEG	EEG	PROPN	NNP	5	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
receiving	receive	VERB	VBG	9	O
l	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
number	number	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	name	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
conclusion	conclusion	NOUN	NN	9	O
that	that	ADP	IN	5	O
NO	no	DET	DT	9	B-Chemical
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
endogenous	endogenous	ADJ	JJ	3	O
convulsant	convulsant	NOUN	NN	0	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
lindane	lindane	ADJ	JJ	0	B-Chemical
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
polyneuropathy	polyneuropathy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
motor	motor	NOUN	NN	5	O
loss	loss	NOUN	NN	9	O
after	after	ADP	IN	9	O
intrathecal	intrathecal	ADJ	JJ	3	O
thiotepa	thiotepa	NOUN	NNS	0	B-Chemical
combination	combination	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
description	description	NOUN	NN	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
delayed	delay	VERB	VBN	9	O
neurologic	neurologic	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
IT	it	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
combination	combination	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
including	include	VERB	VBG	9	O
thiotepa	thiotepa	NOUN	NNS	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
TSPA	TSPA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
cases	case	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
axonal	axonal	ADJ	JJ	3	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
predominance	predominance	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
extremities	extremity	NOUN	NNS	5	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
IT	it	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Neurologic	neurologic	ADJ	JJ	5	B-Disease
toxicities	toxicity	NOUN	NNS	5	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
with	with	ADP	IN	5	O
IT	it	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
IT	it	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
cytosine	cytosine	NOUN	NN	1	B-Chemical
arabinoside	arabinoside	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
IT	IT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
TSPA	tspa	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
axonal	axonal	ADJ	JJ	3	B-Disease
neuropathy	neuropathy	ADJ	JJ	5	I-Disease
following	follow	VERB	VBG	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
three	three	NUM	CD	9	O
agents	agent	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
spite	spite	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
fact	fact	NOUN	NN	9	O
that	that	ADP	IN	5	O
TSPA	TSPA	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
IT	it	NOUN	NN	9	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
MTX	MTX	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
ara	ara	NOUN	NN	1	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
C	c	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
radiotherapy	radiotherapy	NOUN	NN	5	O
could	could	VERB	MD	9	O
cause	cause	VERB	VB	5	O
severe	severe	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
unexpected	unexpected	ADJ	JJ	9	O
complication	complication	NOUN	NN	5	O
indicates	indicate	VERB	VBZ	9	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
further	further	ADJ	JJ	9	O
toxicology	toxicology	NOUN	NN	5	O
research	research	NOUN	NN	5	O
on	on	ADP	IN	5	O
IT	IT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
TSPA	tspa	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cromakalim	cromakalim	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pinacidil	pinacidil	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
large	large	ADJ	JJ	5	O
epicardial	epicardial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
small	small	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
bolus	bolus	NOUN	NN	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
cromakalim	cromakalim	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
pinacidil	pinacidil	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
100	100	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
large	large	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
circumflex	circumflex	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
small	small	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
chronically	chronically	ADV	RB	9	O
instrumented	instrument	VERB	VBD	5	O
conscious	conscious	ADJ	JJ	5	O
dogs	dog	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Nitroglycerin	Nitroglycerin	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
up	up	ADP	IN	5	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
selectively	selectively	ADV	RB	3	O
increased	increase	VERB	VBD	9	O
circumflex	circumflex	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
diameter	diameter	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CxAD	CxAD	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
simultaneously	simultaneously	ADV	RB	5	O
affecting	affect	VERB	VBG	9	O
any	any	DET	DT	5	O
other	other	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
systemic	systemic	ADJ	JJ	9	O
hemodynamic	hemodynamic	NOUN	NN	5	O
parameter	parameter	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cromakalim	cromakalim	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pinacidil	pinacidil	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
all	all	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
nitroglycerin	nitroglycerin	ADV	RB	5	B-Chemical
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADV	RB	0	O
simultaneously	simultaneously	ADV	RB	5	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	,	7	O
dependently	dependently	ADV	RB	3	O
increased	increase	VERB	VBN	9	O
CxAD	CxAD	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
coronary	coronary	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
coronary	coronary	ADJ	JJ	5	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
aortic	aortic	ADJ	JJ	9	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cromakalim	Cromakalim	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
approximately	approximately	ADV	RB	9	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
than	than	ADP	IN	5	O
pinacidil	pinacidil	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
CxAD	CxAD	PROPN	NNP	_	O
.	.	PUNCT	.	9	O

Vasodilation	vasodilation	NOUN	NN	0	O
of	of	ADP	IN	5	O
large	large	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
small	small	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
vessels	vessel	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
cromakalim	cromakalim	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pinacidil	pinacidil	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
prior	prior	ADV	RB	9	O
combined	combine	VERB	VBN	9	O
beta	beta	NOUN	NN	9	B-Chemical
adrenergic	adrenergic	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	I-Chemical
muscarinic	muscarinic	ADJ	JJ	3	I-Chemical
receptors	receptor	NOUN	NNS	3	I-Chemical
blockade	blockade	NOUN	NN	3	I-Chemical
but	but	CCONJ	CC	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
abolished	abolish	VERB	VBN	3	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
circumflex	circumflex	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
was	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
constant	constant	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
CxAD	CxAD	PROPN	NNP	_	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
cromakalim	cromakalim	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
pinacidil	pinacidil	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
nitroglycerin	nitroglycerin	ADJ	JJ	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
68	68	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
54	54	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
nitroglycerin	nitroglycerin	ADV	RB	5	B-Chemical
preferentially	preferentially	ADV	RB	9	O
and	and	CCONJ	CC	5	O
flow	flow	VERB	VB	5	O
-	-	PUNCT	:	7	O
independently	independently	ADV	RB	9	O
dilates	dilate	VERB	VBZ	5	O
large	large	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
cromakalim	cromakalim	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
pinacidil	pinacidil	NOUN	NN	0	B-Chemical
dilate	dilate	VERB	VBP	5	O
both	both	CCONJ	CC	9	O
large	large	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
small	small	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
dependent	dependent	ADJ	JJ	9	O
upon	upon	ADP	IN	9	O
the	the	DET	DT	5	O
simultaneous	simultaneous	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
adrenoceptors	adrenoceptor	NOUN	NNS	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
metabolic	metabolic	ADJ	JJ	9	O
demand	demand	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
mechanisms	mechanism	NOUN	NNS	9	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
,	,	PUNCT	,	9	O
direct	direct	ADJ	JJ	9	O
vasodilation	vasodilation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
flow	flow	NOUN	NN	5	O
dependency	dependency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cromakalim	cromakalim	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
pinacidil	pinacidil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
CxAD	CxAD	PROPN	NNP	_	O
.	.	PUNCT	.	9	O

Mefenamic	mefenamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
females	female	NOUN	NNS	9	O
with	with	ADP	IN	5	O
hypothyroidism	hypothyroidism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
mefenamic	mefenamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
oliguric	oliguric	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
occurring	occur	VERB	VBG	9	O
simultaneously	simultaneously	ADV	RB	5	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
elderly	elderly	ADJ	JJ	5	O
females	female	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
maturation	maturation	NOUN	NN	3	O
arrest	arrest	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
myeloid	myeloid	ADJ	JJ	3	O
series	series	NOUN	NN	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
hypothyroid	hypothyroid	ADJ	JJ	9	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
clear	clear	ADJ	JJ	9	O
whether	whether	ADP	IN	9	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
predisposing	predispose	VERB	VBG	5	O
factor	factor	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
would	would	VERB	MD	5	O
seem	seem	VERB	VB	5	O
prudent	prudent	ADJ	JJ	5	O
not	not	ADV	RB	5	O
to	to	PART	TO	5	O
use	use	VERB	VB	5	O
mefenamic	mefenamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
hypothyroid	hypothyroid	ADJ	JJ	9	B-Disease
patients	patient	NOUN	NNS	5	O
until	until	ADP	IN	5	O
the	the	DET	DT	5	O
hypothyroidism	hypothyroidism	NOUN	NN	5	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
corrected	correct	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Etiology	etiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
hemodialysis	hemodialysis	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
carbonate	carbonate	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fourteen	fourteen	NUM	CD	9	O
of	of	ADP	IN	5	O
39	39	NUM	CD	7	O
dialysis	dialysis	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
36	36	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
became	become	VERB	VBD	9	O
hypercalcemic	hypercalcemic	ADJ	JJ	5	B-Disease
after	after	ADP	IN	9	O
switching	switch	VERB	VBG	5	O
to	to	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
carbonate	carbonate	NOUN	NN	0	I-Chemical
as	as	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
principal	principal	ADJ	JJ	5	O
phosphate	phosphate	NOUN	NN	0	B-Chemical
binder	binder	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
indirect	indirect	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
of	of	ADP	IN	5	O
intestinal	intestinal	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
reabsorption	reabsorption	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
bone	bone	NOUN	NN	5	O
turnover	turnover	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
eucalcemic	eucalcemic	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
matched	match	VERB	VBN	9	O
for	for	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
length	length	NOUN	NN	9	O
of	of	ADP	IN	5	O
time	time	NOUN	NN	5	O
on	on	ADP	IN	5	O
dialysis	dialysis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
etiology	etiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
experiencing	experience	VERB	VBG	5	O
hypercalcemic	hypercalcemic	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
with	with	ADP	IN	5	O
peak	peak	NOUN	NN	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hypercalcemic	hypercalcemic	ADJ	JJ	5	B-Disease
group	group	NOUN	NN	9	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
obtained	obtain	VERB	VBN	9	O
during	during	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
switch	switch	NOUN	NN	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
obtained	obtain	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
7	7	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
observation	observation	NOUN	NN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
switch	switch	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
[	[	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
006	006	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
eucalcemic	eucalcemic	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
exhibited	exhibit	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
values	value	NOUN	NNS	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
period	period	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
[	[	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CaCO3	caco3	NOUN	NN	0	B-Chemical
dosage	dosage	NOUN	NN	9	O
,	,	PUNCT	,	9	O
calculated	calculate	VERB	VBN	5	O
dietary	dietary	ADJ	JJ	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
intake	intake	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
circulating	circulate	VERB	VBG	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
metabolites	metabolite	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Physical	physical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
index	index	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
predialysis	predialysis	NOUN	NN	5	O
serum	serum	NOUN	NN	9	O
bicarbonate	bicarbonate	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
also	also	ADV	RB	9	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
parameters	parameter	NOUN	NNS	5	O
reflecting	reflect	VERB	VBG	5	O
bone	bone	NOUN	NN	5	O
turnover	turnover	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Late	late	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
scleroderma	scleroderma	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
crisis	crisis	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
prednisolone	prednisolone	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Scleroderma	scleroderma	ADJ	JJ	2	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
crisis	crisis	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SRC	SRC	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	B-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SSc	SSc	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
severe	severe	ADJ	JJ	5	O
enough	enough	ADV	RB	5	O
to	to	PART	TO	5	O
require	require	VERB	VB	5	O
temporary	temporary	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
permanent	permanent	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Moderate	moderate	ADJ	JJ	7	O
to	to	ADP	IN	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
corticosteroid	corticosteroid	ADJ	JJ	5	B-Chemical
use	use	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
recognized	recognize	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
SRC	SRC	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
precipitated	precipitate	VERB	VBN	0	O
by	by	ADP	IN	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
SSc	SSc	NOUN	NNS	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
article	article	NOUN	NN	6	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
SRC	SRC	PROPN	NNP	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
work	work	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
call	call	VERB	VB	5	O
attention	attention	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
tacrolimus	tacrolimus	ADJ	JJ	0	B-Chemical
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
SSc	SSc	NOUN	NNS	9	B-Disease
.	.	PUNCT	.	9	O

Methyldopa	Methyldopa	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
presenting	present	VERB	VBG	5	O
as	as	ADP	IN	5	O
near	near	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
syncope	syncope	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Methyldopa	Methyldopa	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
available	available	ADJ	JJ	5	O
generically	generically	ADV	RB	5	O
and	and	CCONJ	CC	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
trade	trade	NOUN	NN	5	O
name	name	NOUN	NN	5	O
Aldomet	Aldomet	PROPN	NNP	0	B-Chemical
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
prescribed	prescribe	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
adult	adult	NOUN	NN	9	O
population	population	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
infrequently	infrequently	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Methyldopa	Methyldopa	PROPN	NNP	7	B-Chemical
causes	cause	VERB	VBZ	9	O
an	an	DET	DT	5	O
autoimmune	autoimmune	ADJ	JJ	3	B-Disease
hemolytic	hemolytic	ADJ	JJ	0	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
small	small	ADJ	JJ	9	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
take	take	VERB	VBP	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
methyldopa	methyldopa	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
boy	boy	NOUN	NN	5	O
who	who	PRON	WP	5	O
presented	present	VERB	VBD	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	B-Disease
department	department	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
near	near	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
syncope	syncope	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
boy	boy	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
methyldopa	methyldopa	NOUN	NN	0	B-Chemical
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
trauma	trauma	NOUN	NN	5	B-Disease
admission	admission	NOUN	NN	5	O
seven	seven	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
presentation	presentation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Evaluation	evaluation	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
grams	gram	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
Coombs	Coombs	PROPN	NNP	6	O
'	'	PART	POS	9	O
test	test	NOUN	NN	5	O
with	with	ADP	IN	5	O
polyspecific	polyspecific	ADJ	JJ	3	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
human	human	ADJ	JJ	3	O
globulin	globulin	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
monospecific	monospecific	ADJ	JJ	9	O
IgG	igg	NOUN	NN	3	O
reagents	reagent	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
warm	warm	ADJ	JJ	5	O
reacting	react	VERB	VBG	0	O
autoantibody	autoantibody	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Transfusion	transfusion	NOUN	NN	2	O
and	and	CCONJ	CC	5	O
corticosteroid	corticosteroid	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Emergency	emergency	NOUN	NN	2	O
physicians	physician	NOUN	NNS	5	O
treating	treat	VERB	VBG	5	O
children	child	NOUN	NNS	5	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
diagnose	diagnose	VERB	VB	5	O
and	and	CCONJ	CC	5	O
treat	treat	VERB	VB	5	O
it	-PRON-	PRON	PRP	5	O
correctly	correctly	ADV	RB	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
brief	brief	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
autoimmune	autoimmune	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemias	anemias	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
provided	provide	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
associated	associate	VERB	VBN	9	O
factors	factor	NOUN	NNS	9	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
psychosis	psychosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Malaysia	Malaysia	PROPN	NNP	4	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
lifetime	lifetime	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
current	current	ADJ	JJ	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
dependence	dependence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
psychiatric	psychiatric	ADJ	JJ	5	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
sectional	sectional	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
conducted	conduct	VERB	VBN	9	O
concurrently	concurrently	ADV	RB	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
teaching	teaching	NOUN	NN	5	O
hospital	hospital	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
rehabilitation	rehabilitation	NOUN	NN	5	O
center	center	NOUN	NN	5	O
in	in	ADP	IN	5	O
Malaysia	Malaysia	PROPN	NNP	4	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
DSM	DSM	PROPN	NNP	4	O
-	-	PUNCT	HYPH	7	O
IV	IV	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
interviewed	interview	VERB	VBN	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Mini	Mini	PROPN	NNP	0	O
International	International	PROPN	NNP	2	O
Neuropsychiatric	neuropsychiatric	ADJ	JJ	5	O
Interview	Interview	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
M	m	NOUN	NN	9	O
.	.	PUNCT	.	9	O
I	-PRON-	PRON	PRP	9	O
.	.	PUNCT	.	9	O
N	N	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
I	-PRON-	PRON	PRP	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
Axis	Axis	PROPN	NNP	5	O
I	-PRON-	PRON	PRP	9	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
information	information	NOUN	NN	5	O
on	on	ADP	IN	5	O
sociodemographic	sociodemographic	ADJ	JJ	5	O
background	background	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	O
use	use	NOUN	NN	5	O
history	history	NOUN	NN	5	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
interview	interview	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Of	of	ADP	IN	9	O
292	292	NUM	CD	7	O
subjects	subject	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
47	47	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
past	past	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
having	have	VERB	VBG	5	O
current	current	ADJ	JJ	5	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Co	co	ADJ	JJ	0	O
-	-	ADJ	JJ	7	O
morbid	morbid	ADJ	JJ	5	O
major	major	ADJ	JJ	9	O
depressive	depressive	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
18	18	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
CI	ci	NOUN	NN	7	O
=	=	NOUN	NNS	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
612	612	NUM	CD	7	O
-	-	SYM	SYM	7	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
708	708	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
807	807	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
CI	ci	NOUN	NN	7	O
=	=	NOUN	NNS	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
194	194	NUM	CD	7	O
-	-	SYM	SYM	7	O
36	36	NUM	CD	9	O
.	.	PUNCT	.	9	O
706	706	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
antisocial	antisocial	ADJ	JJ	5	B-Disease
personality	personality	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
619	619	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
CI	ci	NOUN	NN	7	O
=	=	NOUN	NNS	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
702	702	NUM	CD	7	O
-	-	SYM	SYM	7	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
759	759	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
heavy	heavy	ADJ	JJ	9	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
uses	use	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
lifetime	lifetime	NOUN	NN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
adjusted	adjust	VERB	VBN	9	O
for	for	ADP	IN	5	O
other	other	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Major	major	ADJ	JJ	9	B-Disease
depressive	depressive	ADJ	JJ	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
870	870	NUM	CD	7	O
,	,	PUNCT	,	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
154	154	NUM	CD	7	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
142	142	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
antisocial	antisocial	ADJ	JJ	5	B-Disease
personality	personality	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
299	299	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
CI	ci	NOUN	NN	7	O
=	=	NOUN	NNS	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
375	375	NUM	CD	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
914	914	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
factors	factor	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
current	current	ADJ	JJ	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
dependence	dependence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
co	co	NOUN	NN	9	O
-	-	ADJ	JJ	7	O
morbid	morbid	ADJ	JJ	5	O
affective	affective	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
antisocial	antisocial	ADJ	JJ	5	B-Disease
personality	personality	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
heavy	heavy	ADJ	JJ	9	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
that	that	ADP	IN	5	O
all	all	DET	DT	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
dependence	dependence	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
screened	screen	VERB	VBN	9	O
for	for	ADP	IN	5	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Cerebellar	cerebellar	ADJ	JJ	9	O
sensory	sensory	ADJ	JJ	5	O
processing	processing	NOUN	NN	5	O
alterations	alteration	NOUN	NNS	9	O
impact	impact	VERB	VBP	5	O
motor	motor	NOUN	NN	5	O
cortical	cortical	ADJ	JJ	5	O
plasticity	plasticity	NOUN	NN	5	O
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
clues	clue	NOUN	NNS	5	O
from	from	ADP	IN	9	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
plasticity	plasticity	NOUN	NN	5	O
of	of	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
motor	motor	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
M1	M1	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
LIDs	LIDs	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
severely	severely	ADV	RB	9	O
impaired	impaired	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recently	recently	ADV	RB	9	O
reported	report	VERB	VBD	9	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
that	that	DET	WDT	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
cerebellar	cerebellar	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
enhanced	enhance	VERB	VBD	3	O
the	the	DET	DT	5	O
sensorimotor	sensorimotor	NOUN	NN	5	O
plasticity	plasticity	NOUN	NN	5	O
of	of	ADP	IN	5	O
M1	M1	PROPN	NNP	9	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
paired	pair	VERB	VBN	9	O
associative	associative	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
PAS	PAS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
deficient	deficient	ADJ	JJ	3	O
sensorimotor	sensorimotor	NOUN	NN	5	O
M1	M1	PROPN	NNP	9	O
plasticity	plasticity	NOUN	NN	5	O
in	in	ADP	IN	5	O
16	16	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
LIDs	lid	NOUN	NNS	5	B-Disease
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
reinstated	reinstate	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
session	session	NOUN	NN	5	O
of	of	ADP	IN	5	O
real	real	ADJ	JJ	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
cerebellar	cerebellar	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
sham	sham	ADJ	JJ	9	O
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
evident	evident	ADJ	JJ	9	O
only	only	ADV	RB	9	O
when	when	ADV	WRB	5	O
a	a	DET	DT	5	O
sensory	sensory	ADJ	JJ	5	O
component	component	NOUN	NN	9	O
was	be	VERB	VBD	9	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
plasticity	plasticity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
sensory	sensory	ADJ	JJ	5	O
processing	processing	NOUN	NN	5	O
function	function	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
resurgence	resurgence	NOUN	NN	5	O
of	of	ADP	IN	5	O
M1	M1	PROPN	NNP	9	O
plasticity	plasticity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
benefit	benefit	NOUN	NN	5	O
of	of	ADP	IN	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
cerebellar	cerebellar	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
on	on	ADP	IN	5	O
LIDs	LIDs	PROPN	NNP	5	B-Disease
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
explore	explore	VERB	VB	5	O
whether	whether	ADP	IN	9	O
this	this	DET	DT	5	O
benefit	benefit	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
linked	link	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
restoration	restoration	NOUN	NN	5	O
of	of	ADP	IN	5	O
sensorimotor	sensorimotor	NOUN	NN	5	O
plasticity	plasticity	NOUN	NN	5	O
of	of	ADP	IN	5	O
M1	M1	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conducted	conduct	VERB	VBD	9	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
looking	look	VERB	VBG	5	O
at	at	ADP	IN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
LIDs	LIDs	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
PAS	PAS	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
plasticity	plasticity	NOUN	NN	5	O
after	after	ADP	IN	9	O
10	10	NUM	CD	9	O
sessions	session	NOUN	NNS	5	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
bilateral	bilateral	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
real	real	ADJ	JJ	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
cerebellar	cerebellar	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
sham	sham	ADJ	JJ	9	O
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
real	real	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
not	not	ADV	RB	5	O
sham	sham	ADJ	JJ	9	O
stimulation	stimulation	NOUN	NN	3	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
antidyskinetic	antidyskinetic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
paralleled	parallel	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
resurgence	resurgence	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
sensorimotor	sensorimotor	NOUN	NN	5	O
plasticity	plasticity	NOUN	NN	5	O
of	of	ADP	IN	5	O
M1	M1	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
sensory	sensory	ADJ	JJ	5	O
processing	processing	NOUN	NN	5	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
occurring	occur	VERB	VBG	9	O
secondary	secondary	ADJ	JJ	9	O
to	to	PART	TO	5	O
abnormal	abnormal	ADJ	JJ	9	O
basal	basal	NOUN	NN	3	O
ganglia	ganglion	NOUN	NNS	5	O
signals	signal	NOUN	NNS	9	O
reaching	reach	VERB	VBG	5	O
it	-PRON-	PRON	PRP	5	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
element	element	NOUN	NN	9	O
contributing	contributing	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
maladaptive	maladaptive	ADJ	JJ	5	O
sensorimotor	sensorimotor	NOUN	NN	5	O
plasticity	plasticity	NOUN	NN	5	O
of	of	ADP	IN	5	O
M1	M1	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
emergence	emergence	NOUN	NN	9	O
of	of	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	B-Disease
involuntary	involuntary	ADJ	JJ	5	I-Disease
movements	movement	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
danazol	danazol	NOUN	NNS	0	B-Chemical
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hereditary	hereditary	ADJ	JJ	5	B-Disease
angioedema	angioedema	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
safety	safety	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
danazol	danazol	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
established	establish	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
settings	setting	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
information	information	NOUN	NN	5	O
exists	exist	VERB	VBZ	9	O
as	as	ADP	IN	5	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
safety	safety	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
therefore	therefore	ADV	RB	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
danazol	danazol	NOUN	NNS	0	B-Chemical
by	by	ADP	IN	9	O
performing	perform	VERB	VBG	5	O
a	a	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
chart	chart	NOUN	NN	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
female	female	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hereditary	hereditary	ADJ	JJ	5	B-Disease
angioedema	angioedema	NOUN	NN	5	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
danazol	danazol	NOUN	NNS	0	B-Chemical
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
continuous	continuous	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
longer	long	ADJ	JJR	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
35	35	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
59	59	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Virtually	virtually	ADV	RB	9	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Menstrual	menstrual	ADJ	JJ	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
(	(	PUNCT	-LRB-	9	O
79	79	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
muscle	muscle	NOUN	NN	9	B-Disease
cramps	cramp	NOUN	NNS	5	I-Disease
/	/	SYM	SYM	9	O
myalgias	myalgias	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
transaminase	transaminase	VERB	VB	0	O
elevations	elevation	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
patient	patient	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
died	die	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
suffered	suffer	VERB	VBN	5	O
any	any	DET	DT	5	O
apparent	apparent	ADJ	JJ	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
sequelae	sequelae	NOUN	NN	5	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
directly	directly	ADV	RB	9	O
attributable	attributable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
a	a	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
danazol	danazol	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
proven	prove	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
remarkably	remarkably	ADV	RB	9	O
safe	safe	ADJ	JJ	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
P2X3	p2x3	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
NK1	NK1	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
on	on	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
explore	explore	VERB	VB	5	O
the	the	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
P2X3	p2x3	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
NK1	NK1	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
antagonists	antagonist	NOUN	NNS	3	O
on	on	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CYP	CYP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Sixty	sixty	NUM	CD	5	O
female	female	ADJ	JJ	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
SD	SD	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
injected	inject	VERB	VBD	3	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
model	model	NOUN	NN	5	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intervention	intervention	NOUN	NN	5	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
with	with	ADP	IN	5	O
subsequently	subsequently	ADJ	JJ	9	O
perfusion	perfusion	NOUN	NN	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
with	with	ADP	IN	5	O
P2X3	p2x3	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
NK1	NK1	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
'	'	PART	POS	9	O
antagonists	antagonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
Suramin	Suramin	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
GR	GR	PROPN	NNP	9	B-Chemical
82334	82334	NUM	CD	_	I-Chemical
.	.	PUNCT	.	9	O

Spontaneous	spontaneous	ADJ	JJ	9	O
pain	pain	NOUN	NN	5	B-Disease
behaviors	behavior	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Urodynamic	urodynamic	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
bladder	bladder	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
volume	volume	NOUN	NN	9	O
curve	curve	NOUN	NN	9	O
,	,	PUNCT	,	9	O
maximum	maximum	ADJ	JJ	5	O
voiding	voiding	NOUN	NN	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MVP	MVP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
maximum	maximum	ADJ	JJ	5	O
cystometric	cystometric	NOUN	NN	5	O
capacity	capacity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
MCC	MCC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Pathological	pathological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
tissue	tissue	NOUN	NN	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Immunofluorescence	Immunofluorescence	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
P2X3	p2x3	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
NK1	NK1	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
behaviors	behavior	NOUN	NNS	5	O
scores	score	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
instability	instability	NOUN	NN	5	O
during	during	ADP	IN	5	O
urine	urine	NOUN	NN	9	O
storage	storage	NOUN	NN	9	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
model	model	NOUN	NN	5	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
intervention	intervention	NOUN	NN	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
X	X	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
619	619	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
007	007	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
X	X	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
755	755	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
000	000	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

MCC	MCC	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
model	model	NOUN	NN	5	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
intervention	intervention	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Histological	histological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
evident	evident	ADJ	JJ	9	O
in	in	ADP	IN	5	O
model	model	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intervention	intervention	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
rats	rat	NOUN	NNS	9	O
'	'	PART	POS	9	O
bladder	bladder	NOUN	NN	9	O
included	include	VERB	VBD	5	O
edema	edema	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
vasodilation	vasodilation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
infiltration	infiltration	NOUN	NN	3	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
model	model	NOUN	NN	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
P2X3	p2x3	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
increased	increase	VERB	VBD	9	O
in	in	ADP	IN	5	O
urothelium	urothelium	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
suburothelium	suburothelium	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
NK1	NK1	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
increased	increase	VERB	VBD	9	O
in	in	ADP	IN	5	O
suburothelium	suburothelium	NOUN	NN	3	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
in	in	ADP	IN	5	O
intervention	intervention	NOUN	NN	5	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
CYP	CYP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
P2X3	p2x3	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
NK1	NK1	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
increased	increase	VERB	VBD	9	O
in	in	ADP	IN	5	O
urothelium	urothelium	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
suburothelium	suburothelium	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Perfusion	perfusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
with	with	ADP	IN	5	O
P2X3	p2x3	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
NK1	NK1	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
antagonists	antagonist	NOUN	NNS	3	O
ameliorated	ameliorate	VERB	VBD	9	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Patient	patient	ADJ	JJ	5	O
tolerance	tolerance	NOUN	NN	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
chlorhexidine	chlorhexidine	NOUN	NN	0	B-Chemical
diphosphanilate	diphosphanilate	NOUN	NN	_	I-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
topical	topical	ADJ	JJ	0	O
agent	agent	NOUN	NN	9	O
for	for	ADP	IN	5	O
burns	burn	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Effective	effective	ADJ	JJ	5	O
topical	topical	ADJ	JJ	0	O
antimicrobial	antimicrobial	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
decrease	decrease	VERB	VBP	9	O
infection	infection	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
burn	burn	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Chlorhexidine	chlorhexidine	NOUN	NN	0	B-Chemical
phosphanilate	phosphanilate	VERB	VBP	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
CHP	CHP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
broad	broad	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
spectrum	spectrum	NOUN	NN	9	O
antimicrobial	antimicrobial	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
evaluated	evaluate	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
topical	topical	ADJ	JJ	0	O
burn	burn	NOUN	NN	5	B-Disease
wound	wound	NOUN	NN	5	O
dressing	dress	VERB	VBG	5	O
in	in	ADP	IN	5	O
cream	cream	NOUN	NN	0	O
form	form	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
preliminary	preliminary	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
reported	report	VERB	VBD	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
painful	painful	ADJ	JJ	5	O
upon	upon	ADP	IN	9	O
application	application	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
compared	compare	VERB	VBD	9	O
various	various	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
CHP	CHP	PROPN	NNP	9	B-Chemical
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
a	a	DET	DT	5	O
tolerable	tolerable	ADJ	JJ	5	O
concentration	concentration	NOUN	NN	0	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
identified	identify	VERB	VBN	9	O
with	with	ADP	IN	5	O
retention	retention	NOUN	NN	9	O
of	of	ADP	IN	5	O
antimicrobial	antimicrobial	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
burn	burn	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
each	each	DET	DT	5	O
with	with	ADP	IN	5	O
two	two	NUM	CD	5	O
similar	similar	ADJ	JJ	9	O
burns	burn	NOUN	NNS	5	B-Disease
which	which	DET	WDT	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
separately	separately	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
pairs	pair	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatments	treatment	NOUN	NNS	9	O
at	at	ADP	IN	9	O
successive	successive	ADJ	JJ	5	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	NOUN	NN	0	O
intervals	interval	NOUN	NNS	5	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
burn	burn	NOUN	NN	5	B-Disease
site	site	NOUN	NN	9	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
each	each	DET	DT	5	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
different	different	ADJ	JJ	9	O
CHP	CHP	PROPN	NNP	9	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
,	,	PUNCT	,	9	O
their	-PRON-	DET	PRP$	5	O
vehicle	vehicle	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
silver	silver	NOUN	NN	0	B-Chemical
sulphadiazine	sulphadiazine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
AgSD	AgSD	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
cream	cream	NOUN	NN	0	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
antimicrobial	antimicrobial	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
frequently	frequently	ADV	RB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
burn	burn	NOUN	NN	5	B-Disease
wounds	wound	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
site	site	NOUN	NN	9	O
was	be	VERB	VBD	9	O
always	always	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
AgSD	AgSD	PROPN	NNP	0	B-Chemical
cream	cream	NOUN	NN	0	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
CHP	CHP	PROPN	NNP	9	B-Chemical
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
ratings	rating	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
an	an	DET	DT	5	O
analogue	analogue	NOUN	NN	0	O
scale	scale	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
CHP	CHP	PROPN	NNP	9	B-Chemical
cream	cream	NOUN	NN	0	O
was	be	VERB	VBD	9	O
closest	close	ADJ	JJS	9	O
to	to	ADP	IN	5	O
AgSD	AgSD	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
tolerance	tolerance	NOUN	NN	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatments	treatment	NOUN	NNS	9	O
differed	differ	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
from	from	ADP	IN	9	O
AgSD	AgSD	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
from	from	ADP	IN	9	O
each	each	DET	DT	5	O
other	other	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
ease	ease	NOUN	NN	5	O
of	of	ADP	IN	5	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
CHP	CHP	PROPN	NNP	9	B-Chemical
creams	cream	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
satisfactory	satisfactory	ADJ	JJ	5	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
AgSD	AgSD	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
formulations	formulation	NOUN	NNS	0	O
at	at	ADP	IN	9	O
or	or	CCONJ	CC	5	O
below	below	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
CHP	CHP	PROPN	NNP	9	B-Chemical
may	may	VERB	MD	5	O
prove	prove	VERB	VB	5	O
acceptable	acceptable	ADJ	JJ	5	O
for	for	ADP	IN	5	O
wound	wound	NOUN	NN	5	O
care	care	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
vehicle	vehicle	NOUN	NN	3	O
system	system	NOUN	NN	5	O
needs	need	VERB	VBZ	5	O
pharmaceutical	pharmaceutical	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
to	to	PART	TO	5	O
render	render	VERB	VB	9	O
it	-PRON-	PRON	PRP	5	O
more	more	ADV	RBR	5	O
tolerable	tolerable	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
easier	easy	ADJ	JJR	5	O
to	to	PART	TO	5	O
use	use	VERB	VB	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
associated	associate	VERB	VBD	9	O
with	with	ADP	IN	5	O
clopidogrel	clopidogrel	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
recognition	recognition	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
responsible	responsible	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
difficult	difficult	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
clopidogrel	clopidogrel	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
strongly	strongly	ADV	RB	9	O
suggested	suggest	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
accurate	accurate	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reports	report	NOUN	NNS	5	O
about	about	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
clopidogrel	clopidogrel	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
increasing	increase	VERB	VBG	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
few	few	ADJ	JJ	5	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
believe	believe	VERB	VBP	5	O
that	that	ADP	IN	5	O
physicians	physician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
carefully	carefully	ADV	RB	5	O
consider	consider	VERB	VB	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
when	when	ADV	WRB	5	O
clopidogrel	clopidogrel	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
prescribed	prescribe	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Bortezomib	bortezomib	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
salvage	salvage	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
relapsed	relapsed	ADJ	JJ	5	O
/	/	SYM	SYM	9	O
refractory	refractory	ADJ	JJ	9	O
multiple	multiple	ADJ	JJ	5	B-Disease
myeloma	myeloma	NOUN	NN	3	I-Disease
:	:	PUNCT	:	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
clinical	clinical	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Bortezomib	Bortezomib	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
bort	bort	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
dex	dex	NOUN	NN	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
relapsed	relapsed	ADJ	JJ	5	O
/	/	SYM	SYM	9	O
refractory	refractory	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
R	r	NOUN	NN	9	O
/	/	SYM	SYM	9	O
R	r	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
multiple	multiple	ADJ	JJ	5	B-Disease
myeloma	myeloma	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
MM	MM	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
bort	bort	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
dex	dex	VERB	VB	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
bort	bort	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
salvage	salvage	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
85	85	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
R	r	NOUN	NN	9	O
/	/	SYM	SYM	9	O
R	r	NOUN	NN	9	O
MM	mm	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
autologous	autologous	ADJ	JJ	3	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
conventional	conventional	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
lines	line	NOUN	NNS	3	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O

Eighty	eighty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
seven	seven	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
immunomodulatory	immunomodulatory	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
line	line	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
before	before	ADP	IN	9	O
bort	bort	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
dex	dex	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
bort	bort	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
dex	dex	NOUN	NN	3	B-Chemical
cycles	cycle	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
up	up	ADP	IN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
maximum	maximum	NOUN	NN	5	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
an	an	DET	DT	5	O
intention	intention	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
treat	treat	VERB	VB	5	O
basis	basis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
55	55	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
achieved	achieve	VERB	VBN	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
19	19	NUM	CD	7	O
%	%	NOUN	NN	9	O
CR	CR	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
achieved	achieve	VERB	VBN	5	O
at	at	ADV	RB	9	O
least	least	ADJ	JJS	9	O
very	very	ADV	RB	5	O
good	good	ADJ	JJ	5	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
durations	duration	NOUN	NNS	5	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
next	next	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
interval	interval	NOUN	NN	5	O
were	be	VERB	VBD	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
relevant	relevant	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
was	be	VERB	VBD	9	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
78	78	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
grade	grade	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
38	38	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
grade	grade	NOUN	NN	9	O
III	III	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
a	a	DET	DT	5	O
median	median	NOUN	NN	9	O
follow	follow	NOUN	NN	5	O
up	up	ADP	IN	5	O
of	of	ADP	IN	5	O
22	22	NUM	CD	7	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
median	median	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
,	,	PUNCT	,	9	O
progression	progression	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PFS	PFS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
overall	overall	ADJ	JJ	5	O
survival	survival	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OS	os	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
22	22	NUM	CD	7	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Prolonged	prolonged	ADJ	JJ	9	O
PFS	PFS	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
OS	OS	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
achieving	achieve	VERB	VBG	5	O
CR	CR	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
receiving	receive	VERB	VBG	9	O
bort	bort	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
dex	dex	VERB	VB	3	B-Chemical
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
line	line	NOUN	NN	9	O
of	of	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Bort	bort	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
dex	dex	PROPN	NNP	3	B-Chemical
was	be	VERB	VBD	9	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
salvage	salvage	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
MM	MM	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
for	for	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
first	first	ADJ	JJ	9	O
relapse	relapse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pubertal	pubertal	ADJ	JJ	7	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
Bisphenol	Bisphenol	PROPN	NNP	0	B-Chemical
A	a	DET	DT	9	I-Chemical
increases	increase	VERB	VBZ	9	O
anxiety	anxiety	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behavior	behavior	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
decreases	decrease	VERB	VBZ	9	O
acetylcholinesterase	acetylcholinesterase	VERB	VBP	0	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
hippocampus	hippocampus	NOUN	NN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
male	male	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Bisphenol	Bisphenol	PROPN	NNP	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
BPA	BPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
neurodevelopment	neurodevelopment	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
behaviors	behavior	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
well	well	ADV	RB	9	O
established	establish	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Acetylcholinesterase	Acetylcholinesterase	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
AChE	AChE	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
regulatory	regulatory	ADJ	JJ	1	O
enzyme	enzyme	NOUN	NN	0	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behavior	behavior	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
investigated	investigate	VERB	VBD	9	O
behavioral	behavioral	ADJ	JJ	5	O
phenotypes	phenotype	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
AChE	AChE	PROPN	NNPS	0	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
following	follow	VERB	VBG	9	O
BPA	BPA	PROPN	NNP	9	B-Chemical
exposure	exposure	NOUN	NN	9	O
during	during	ADP	IN	5	O
puberty	puberty	NOUN	NN	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
postnatal	postnatal	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PND	PND	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
35	35	NUM	CD	9	O
,	,	PUNCT	,	9	O
male	male	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
50mg	50mg	ADJ	JJ	0	O
BPA	BPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
diet	diet	NOUN	NN	9	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
35	35	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
PND71	PND71	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
assay	assay	NOUN	NN	3	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
plus	plus	CCONJ	CC	9	O
maze	maze	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EPM	EPM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
light	light	ADJ	JJ	9	O
/	/	SYM	SYM	9	O
dark	dark	ADJ	JJ	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
AChE	AChE	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prefrontal	prefrontal	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hypothalamus	hypothalamus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cerebellum	cerebellum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hippocampus	hippocampus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
from	from	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
behavioral	behavioral	ADJ	JJ	5	O
phenotyping	phenotyping	NOUN	NN	9	O
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behavior	behavior	NOUN	NN	5	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
BPA	BPA	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

AChE	AChE	NOUN	NNS	0	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
BPA	BPA	PROPN	NNP	9	B-Chemical
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
no	no	DET	DT	9	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prefrontal	prefrontal	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hypothalamus	hypothalamus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cerebellum	cerebellum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
pubertal	pubertal	ADJ	JJ	5	O
BPA	BPA	PROPN	NNP	9	B-Chemical
exposure	exposure	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
anxiety	anxiety	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	O
AChE	AChE	PROPN	NNPS	0	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
male	male	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
necessary	necessary	ADJ	JJ	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
cholinergic	cholinergic	NOUN	NN	3	O
signaling	signaling	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
in	in	ADP	IN	5	O
PBE	PBE	PROPN	NNP	0	O
induced	induced	ADJ	JJ	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behaviors	behavior	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Biochemical	biochemical	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Solidago	Solidago	PROPN	NNP	4	O
virgaurea	virgaurea	NOUN	NN	4	O
extract	extract	NOUN	NN	0	O
on	on	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Cardiovascular	cardiovascular	ADJ	JJ	2	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CVDs	CVDs	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
health	health	NOUN	NN	5	O
problem	problem	NOUN	NN	5	O
of	of	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
countries	country	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
world	world	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Solidago	Solidago	PROPN	NNP	4	O
virgaurea	virgaurea	NOUN	NN	4	O
extract	extract	NOUN	NN	0	O
on	on	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
into	into	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
twice	twice	ADV	RB	9	O
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
two	two	NUM	CD	5	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
lactate	lactate	NOUN	NN	0	B-Chemical
dehydrogenase	dehydrogenase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
creatine	creatine	NOUN	NN	0	B-Chemical
phosphokinase	phosphokinase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
alanine	alanine	NOUN	NN	1	B-Chemical
transaminase	transaminase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
aspartate	aspartate	ADJ	JJ	1	B-Chemical
transaminase	transaminase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
activities	activity	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
triglycerides	triglyceride	NOUN	NNS	9	B-Chemical
,	,	PUNCT	,	9	O
free	free	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
fatty	fatty	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
S	S	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
virgaurea	virgaurea	NOUN	NN	4	O
extract	extract	VERB	VBP	0	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	ADP	IN	0	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
significantly	significantly	ADV	RB	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Captopril	Captopril	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
orally	orally	ADV	RB	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
S	S	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
virgaurea	virgaurea	NOUN	NN	4	O
extract	extract	NOUN	NN	0	O
exerts	exert	VERB	VBZ	9	O
its	-PRON-	DET	PRP$	9	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
by	by	ADP	IN	9	O
decreasing	decrease	VERB	VBG	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
level	level	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
status	status	NOUN	NN	9	O
in	in	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
emphasizes	emphasize	VERB	VBZ	5	O
the	the	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
S	S	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
virgaurea	virgaurea	NOUN	NN	4	O
extract	extract	NOUN	NN	0	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

"	"	PUNCT	``	5	O
Real	real	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
world	world	NOUN	NN	5	O
"	"	PUNCT	''	5	O
data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
lenalidomide	lenalidomide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
relapsed	relapsed	ADJ	JJ	5	O
/	/	SYM	SYM	9	O
refractory	refractory	ADJ	JJ	9	O
multiple	multiple	ADJ	JJ	5	B-Disease
myeloma	myeloma	NOUN	NN	3	I-Disease
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Greek	Greek	PROPN	NNP	5	O
Myeloma	Myeloma	PROPN	NNP	2	B-Disease
Study	Study	PROPN	NNP	5	O
Group	Group	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Lenalidomide	lenalidomide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
RD	RD	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
standard	standard	NOUN	NN	5	O
of	of	ADP	IN	5	O
care	care	NOUN	NN	5	O
for	for	ADP	IN	5	O
relapsed	relapsed	ADJ	JJ	5	O
/	/	SYM	SYM	9	O
refractory	refractory	ADJ	JJ	9	O
multiple	multiple	ADJ	JJ	5	B-Disease
myeloma	myeloma	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
RRMM	RRMM	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
limited	limit	VERB	VBN	5	O
published	publish	VERB	VBN	9	O
data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
"	"	PUNCT	``	5	O
real	real	ADJ	JJ	5	O
world	world	NOUN	NN	5	O
"	"	PUNCT	''	5	O
(	(	PUNCT	-LRB-	9	O
RW	RW	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
International	International	PROPN	NNP	2	O
Society	Society	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Pharmacoeconomics	Pharmacoeconomics	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
Outcomes	Outcomes	PROPN	NNP	5	O
Research	Research	PROPN	NNP	2	O
definition	definition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
212	212	NUM	CD	7	O
RRMM	RRMM	PROPN	NNP	5	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
RD	RD	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
RW	RW	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Objective	objective	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
PR	PR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
77	77	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
complete	complete	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CR	CR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
first	first	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
best	good	ADJ	JJS	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
CR	CR	PROPN	NNP	9	O
when	when	ADV	WRB	5	O
RD	RD	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
as	as	ADP	IN	5	O
2nd	2nd	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
>	>	X	XX	0	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
nd	nd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
independent	independent	ADJ	JJ	9	O
of	of	ADP	IN	5	O
previous	previous	ADJ	JJ	9	O
lines	line	NOUN	NNS	3	O
of	of	ADP	IN	5	O
therapies	therapy	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
previous	previous	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
to	to	PART	TO	5	O
thalidomide	thalidomide	VERB	VB	0	B-Chemical
or	or	CCONJ	CC	5	O
bortezomib	bortezomib	VERB	VB	3	B-Chemical
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
34	34	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
RD	RD	PROPN	NNP	9	B-Chemical
until	until	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
not	not	ADV	RB	5	O
reached	reach	VERB	VBN	9	O
versus	versus	ADP	IN	9	O
19	19	NUM	CD	7	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
humoral	humoral	ADJ	JJ	3	O
immunity	immunity	NOUN	NN	3	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
responders	responder	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
achieved	achieve	VERB	VBD	5	O
stable	stable	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
68	68	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
49	49	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
needed	need	VERB	VBN	5	O
hospitalization	hospitalization	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
deep	deep	ADJ	JJ	5	B-Disease
vein	vein	NOUN	NN	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
reductions	reduction	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
needed	need	VERB	VBN	5	O
in	in	ADP	IN	5	O
31	31	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
permanent	permanent	ADJ	JJ	5	O
discontinuation	discontinuation	NOUN	NN	5	O
in	in	ADP	IN	5	O
38	38	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Performance	performance	NOUN	NN	5	O
status	status	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PS	PS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
initial	initial	ADJ	JJ	9	O
lenalidomide	lenalidomide	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
predicted	predict	VERB	VBN	9	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Extra	extra	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
medullary	medullary	ADJ	JJ	5	O
relapses	relapse	NOUN	NNS	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
study	study	NOUN	NN	9	O
confirms	confirm	VERB	VBZ	9	O
that	that	ADP	IN	5	O
RD	RD	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
safe	safe	ADJ	JJ	5	O
in	in	ADP	IN	5	O
RRMM	RRMM	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
RW	rw	NOUN	NN	9	O
;	;	PUNCT	:	9	O
it	-PRON-	PRON	PRP	5	O
produces	produce	VERB	VBZ	9	O
durable	durable	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
continue	continue	VERB	VBP	5	O
on	on	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
till	till	ADP	IN	9	O
progression	progression	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
improves	improve	VERB	VBZ	5	O
humoral	humoral	ADJ	JJ	3	O
immunity	immunity	NOUN	NN	3	O
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
stable	stable	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cytogenetic	cytogenetic	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
mesna	mesna	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
combination	combination	NOUN	NN	9	O
on	on	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	O
rabbit	rabbit	NOUN	NN	3	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
/	/	PUNCT	,	9	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
cytogenetic	cytogenetic	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Ifosfamide	Ifosfamide	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
IFO	IFO	PROPN	NNP	7	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
alkylating	alkylate	VERB	VBG	0	O
nitrogen	nitrogen	NOUN	NN	0	B-Chemical
mustard	mustard	NOUN	NN	0	O
,	,	PUNCT	,	9	O
administrated	administrate	VERB	VBN	0	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
antineoplasmic	antineoplasmic	ADJ	JJ	_	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
intense	intense	ADJ	JJ	9	O
urotoxic	urotoxic	ADJ	JJ	0	O
action	action	NOUN	NN	5	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
IFO	IFO	PROPN	NNP	7	B-Chemical
raises	raise	VERB	VBZ	9	O
the	the	DET	DT	5	O
requirement	requirement	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
with	with	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sulfanylethanesulfonate	sulfanylethanesulfonate	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
Mesna	Mesna	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
aiming	aim	VERB	VBG	5	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
or	or	CCONJ	CC	5	O
minimize	minimize	VERB	VB	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

IFO	IFO	PROPN	NNP	7	B-Chemical
and	and	CCONJ	CC	5	O
Mesna	Mesna	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
administrated	administrate	VERB	VBN	0	O
separately	separately	ADV	RB	9	O
on	on	ADP	IN	5	O
rabbit	rabbit	NOUN	NN	3	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
later	later	ADV	RB	9	O
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Cytogenetic	cytogenetic	ADJ	JJ	9	O
markers	marker	NOUN	NNS	3	O
for	for	ADP	IN	5	O
sister	sister	NOUN	NN	4	O
chromatid	chromatid	NOUN	NN	1	O
exchanges	exchange	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
SCEs	SCEs	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
proliferation	proliferation	NOUN	NN	3	O
rate	rate	NOUN	NN	9	O
index	index	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PRI	PRI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Mitotic	Mitotic	PROPN	NNP	9	O
Index	Index	PROPN	NNP	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Mesna	Mesna	PROPN	NNP	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
action	action	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
IFO	IFO	PROPN	NNP	7	B-Chemical
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
SCEs	sce	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
SCEs	sce	NOUN	NNS	3	O
recordings	recording	NOUN	NNS	5	O
obtained	obtain	VERB	VBN	9	O
when	when	ADV	WRB	5	O
IFO	IFO	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
administered	administer	VERB	VBN	9	O
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
high	high	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
Mesna	Mesna	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
alone	alone	ADJ	JJ	9	O
significant	significant	ADJ	JJ	9	O
reductions	reduction	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
PRI	PRI	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
,	,	PUNCT	,	9	O
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
IFO	IFO	PROPN	NNP	7	B-Chemical
acting	act	VERB	VBG	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Mesna	Mesna	PROPN	NNP	0	B-Chemical
significantly	significantly	ADV	RB	9	O
reduces	reduce	VERB	VBZ	9	O
IFO	IFO	PROPN	NNP	7	B-Chemical
'	'	PART	POS	9	O
s	s	NOUN	NN	9	O
genotoxicity	genotoxicity	NOUN	NN	0	B-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
it	-PRON-	PRON	PRP	5	O
acts	act	VERB	VBZ	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
fashion	fashion	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
cytostatic	cytostatic	ADJ	JJ	3	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
among	among	ADP	IN	5	O
multiethnic	multiethnic	ADJ	JJ	5	O
Malaysians	Malaysians	PROPN	NNPS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
pulsatile	pulsatile	NOUN	NN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	pd	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
leads	lead	VERB	VBZ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
among	among	ADP	IN	5	O
multiethnic	multiethnic	ADJ	JJ	5	O
Malaysian	malaysian	ADJ	JJ	4	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
sectional	sectional	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
involving	involve	VERB	VBG	5	O
95	95	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
on	on	ADP	IN	5	O
uninterrupted	uninterrupted	ADJ	JJ	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
instrument	instrument	NOUN	NN	5	O
used	use	VERB	VBN	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
UPDRS	UPDRS	PROPN	NNP	5	O
questionnaires	questionnaire	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
using	use	VERB	VBG	9	O
multivariate	multivariate	ADJ	JJ	5	O
logistic	logistic	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
was	be	VERB	VBD	9	O
65	65	NUM	CD	7	O
.	.	NOUN	NN	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
onset	onset	NOUN	NN	5	O
age	age	NOUN	NN	5	O
was	be	VERB	VBD	9	O
58	58	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
duration	duration	NOUN	NN	5	O
was	be	VERB	VBD	9	O
6	6	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Dyskinesia	Dyskinesia	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
42	42	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
median	median	ADJ	JJ	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
64	64	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
Chinese	Chinese	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
31	31	NUM	CD	7	O
%	%	NOUN	NN	9	O
Malays	Malays	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
Indians	Indians	PROPN	NNPS	5	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
ethnic	ethnic	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Eighty	eighty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
had	have	VERB	VBD	9	O
clinical	clinical	ADJ	JJ	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
had	have	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
onset	onset	NOUN	NN	5	O
age	age	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
longer	long	ADJ	JJR	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
longer	long	ADJ	JJR	5	O
disease	disease	NOUN	NN	5	O
duration	duration	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
higher	high	ADJ	JJR	9	O
total	total	ADJ	JJ	9	O
daily	daily	ADJ	JJ	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
total	total	ADJ	JJ	9	O
UPDRS	UPDRS	PROPN	NNP	5	O
scores	score	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
three	three	NUM	CD	9	O
significant	significant	ADJ	JJ	9	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
onset	onset	NOUN	NN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
daily	daily	ADJ	JJ	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
significant	significant	ADJ	JJ	9	O
predictors	predictor	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
daily	daily	ADJ	JJ	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
onset	onset	NOUN	NN	5	O
age	age	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
busulfan	busulfan	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Busulfan	Busulfan	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
humans	human	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
its	-PRON-	DET	PRP$	9	O
acute	acute	ADJ	JJ	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
remains	remain	VERB	VBZ	9	O
poorly	poorly	ADV	RB	9	O
characterized	characterize	VERB	VBN	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
here	here	ADV	RB	5	O
a	a	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
123	123	NUM	CD	9	O
children	child	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
receiving	receive	VERB	VBG	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
busulfan	busulfan	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
before	before	ADP	IN	9	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
for	for	ADP	IN	5	O
malignant	malignant	ADJ	JJ	3	O
solid	solid	ADJ	JJ	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
brain	brain	NOUN	NN	5	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
excluded	exclude	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Busulfan	Busulfan	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
every	every	DET	DT	5	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
for	for	ADP	IN	5	O
16	16	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
over	over	ADP	IN	5	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
total	total	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
consecutively	consecutively	ADV	RB	5	O
used	use	VERB	VBN	5	O
:	:	PUNCT	:	9	O
16	16	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
then	then	ADV	RB	9	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
calculation	calculation	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
children	child	NOUN	NNS	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
16	16	NUM	CD	9	O
to	to	PART	TO	5	O
28	28	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Ninety	ninety	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
given	give	VERB	VBN	5	O
anticonvulsive	anticonvulsive	ADJ	JJ	5	O
prophylaxis	prophylaxis	NOUN	NN	5	O
;	;	PUNCT	:	9	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
busulfan	busulfan	ADJ	JJ	0	B-Chemical
course	course	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
within	within	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
dosing	dosing	NOUN	NN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
busulfan	busulfan	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
into	into	ADP	IN	9	O
account	account	NOUN	NN	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
incidence	incidence	NOUN	NN	5	O
among	among	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
under	under	ADP	IN	9	O
16	16	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
57	57	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
under	under	ADP	IN	9	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
of	of	ADP	IN	5	O
39	39	NUM	CD	7	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
a	a	DET	DT	5	O
600	600	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
busulfan	busulfan	ADJ	JJ	0	B-Chemical
total	total	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
with	with	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
clonazepam	clonazepam	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
none	none	NOUN	NN	9	O
had	have	VERB	VBD	9	O
any	any	DET	DT	5	O
neurological	neurological	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Busulfan	Busulfan	PROPN	NNP	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
gas	gas	NOUN	NN	0	O
chromatographic	chromatographic	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
mass	mass	NOUN	NN	9	O
spectrometry	spectrometry	NOUN	NN	0	O
assay	assay	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
of	of	ADP	IN	5	O
9	9	NUM	CD	7	O
children	child	NOUN	NNS	5	O
without	without	ADP	IN	9	O
central	central	ADJ	JJ	5	B-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
under	under	ADP	IN	9	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
busulfan	busulfan	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
clonazepam	clonazepam	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
busulfan	busulfan	ADJ	JJ	0	B-Chemical
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
:	:	PUNCT	:	9	O
plasma	plasma	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
was	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
39	39	NUM	CD	7	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
:	:	PUNCT	:	9	O
plasma	plasma	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
previously	previously	ADV	RB	9	O
defined	define	VERB	VBN	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
16	16	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
busulfan	busulfan	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
busulfan	busulfan	ADJ	JJ	0	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
efficiently	efficiently	ADV	RB	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
clonazepam	clonazepam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
busulfan	busulfan	ADJ	JJ	0	B-Chemical
dose	dose	NOUN	NN	9	O
calculated	calculate	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
children	child	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
close	close	ADJ	JJ	5	O
to	to	ADP	IN	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
incidence	incidence	NOUN	NN	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
plasma	plasma	ADJ	JJ	9	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
faster	fast	ADJ	JJR	5	O
busulfan	busulfan	ADJ	JJ	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
new	new	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
may	may	VERB	MD	5	O
approximate	approximate	VERB	VB	5	O
more	more	ADV	RBR	5	O
closely	closely	ADV	RB	9	O
the	the	DET	DT	5	O
adult	adult	NOUN	NN	9	O
systemic	systemic	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
obtained	obtain	VERB	VBN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
usual	usual	ADJ	JJ	5	O
16	16	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
inferences	inference	NOUN	NNS	5	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
anticancer	anticancer	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
myeloablative	myeloablative	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
busulfan	busulfan	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
infants	infant	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
reconsidered	reconsider	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
unexpected	unexpected	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
transplant	transplant	NOUN	NN	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
everolimus	everolimus	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
AL	al	NOUN	NN	2	B-Disease
amyloidosis	amyloidosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Proteinuria	Proteinuria	PROPN	NNP	7	B-Disease
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
expected	expect	VERB	VBN	9	O
complication	complication	NOUN	NN	5	O
in	in	ADP	IN	5	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
mammalian	mammalian	ADJ	JJ	9	O
target	target	NOUN	NN	9	O
of	of	ADP	IN	5	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
inhibitors	inhibitor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
mTOR	mTOR	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
i	i	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
clinical	clinical	ADJ	JJ	5	O
suspicion	suspicion	NOUN	NN	5	O
should	should	VERB	MD	5	O
always	always	ADV	RB	5	O
be	be	VERB	VB	5	O
supported	support	VERB	VBN	9	O
by	by	ADP	IN	9	O
histological	histological	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
potential	potential	ADJ	JJ	9	O
alternate	alternate	ADJ	JJ	9	O
diagnoses	diagnosis	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
rejection	rejection	NOUN	NN	5	O
,	,	PUNCT	,	9	O
interstitial	interstitial	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
tubular	tubular	ADJ	JJ	9	O
atrophy	atrophy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
recurrent	recurrent	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
de	de	X	FW	2	O
novo	novo	NOUN	NN	9	O
glomerulopathy	glomerulopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
unexpected	unexpected	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
amyloidosis	amyloidosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
transplant	transplant	NOUN	NN	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
transplant	transplant	ADJ	JJ	9	O
monoclonal	monoclonal	ADJ	JJ	3	O
gammapathy	gammapathy	NOUN	NN	3	O
of	of	ADP	IN	5	O
undetermined	undetermined	ADJ	JJ	9	O
significance	significance	NOUN	NN	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
from	from	ADP	IN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
everolimus	everolimus	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
oral	oral	ADJ	JJ	9	O
galactose	galactose	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
prevents	prevent	NOUN	NNS	9	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBD	3	O
intracerebroventricularly	intracerebroventricularly	ADV	RB	3	O
with	with	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Basic	basic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
research	research	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
demonstrated	demonstrate	VERB	VBN	9	O
that	that	ADP	IN	5	O
dementia	dementia	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
sporadic	sporadic	ADJ	JJ	9	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
sAD	sad	NUM	CD	5	O
)	)	PUNCT	-RRB-	9	O
type	type	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
dysfunction	dysfunction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
insulin	insulin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
IR	IR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
system	system	NOUN	NN	5	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
decreased	decrease	VERB	VBN	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
transport	transport	NOUN	NN	9	O
via	via	ADP	IN	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
transporter	transporter	NOUN	NN	1	O
GLUT4	glut4	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
metabolism	metabolism	NOUN	NN	9	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
alternative	alternative	ADJ	JJ	5	O
source	source	NOUN	NN	5	O
of	of	ADP	IN	5	O
energy	energy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
d	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
galactose	galactose	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
the	the	DET	DT	5	O
C	C	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
epimer	epimer	NOUN	NN	0	O
of	of	ADP	IN	5	O
d	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glucose	glucose	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
transported	transport	VERB	VBN	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
by	by	ADP	IN	9	O
insulin	insulin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
independent	independent	ADJ	JJ	9	O
GLUT3	glut3	X	XX	3	O
transporter	transporter	NOUN	NN	1	O
where	where	ADV	WRB	5	O
it	-PRON-	PRON	PRP	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
metabolized	metabolize	VERB	VBN	0	O
to	to	PART	TO	5	O
glucose	glucose	VERB	VB	0	B-Chemical
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
Leloir	Leloir	PROPN	NNP	2	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Exclusively	exclusively	ADV	RB	9	O
parenteral	parenteral	ADJ	JJ	5	O
daily	daily	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
galactose	galactose	ADJ	JJ	0	B-Chemical
induce	induce	NOUN	NN	3	O
memory	memory	NOUN	NN	5	B-Disease
deterioration	deterioration	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
are	be	VERB	VBP	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
generate	generate	VERB	VB	9	O
animal	animal	NOUN	NN	5	O
aging	aging	NOUN	NN	5	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
galactose	galactose	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
functions	function	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
never	never	ADV	RB	5	O
been	be	VERB	VBN	9	O
tested	test	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
investigated	investigate	VERB	VBN	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
daily	daily	ADJ	JJ	5	O
oral	oral	ADJ	JJ	9	O
galactose	galactose	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
icv	icv	VERB	VBN	0	O
)	)	PUNCT	-RRB-	9	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
sAD	sad	NUM	CD	5	O
,	,	PUNCT	,	9	O
tested	test	VERB	VBN	9	O
by	by	ADP	IN	9	O
Morris	Morris	PROPN	NNP	6	O
Water	Water	PROPN	NNP	0	O
Maze	Maze	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Passive	Passive	PROPN	NNP	5	O
Avoidance	Avoidance	PROPN	NNP	5	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
galactose	galactose	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
initiated	initiate	VERB	VBD	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
icv	icv	VERB	VBN	0	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
successfully	successfully	ADV	RB	5	O
prevented	prevent	VERB	VBN	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
icv	icv	VERB	VBN	0	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Beneficial	beneficial	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
galactose	galactose	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
independent	independent	ADJ	JJ	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
galactose	galactose	ADJ	JJ	0	B-Chemical
dose	dose	NOUN	NN	9	O
ranging	range	VERB	VBG	9	O
from	from	ADP	IN	9	O
100	100	NUM	CD	0	O
to	to	PART	TO	5	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
oral	oral	ADJ	JJ	9	O
galactose	galactose	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
galactose	galactose	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
galactose	galactose	ADJ	JJ	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
was	be	VERB	VBD	9	O
several	several	ADJ	JJ	9	O
times	time	NOUN	NNS	5	O
lower	low	ADJ	JJR	9	O
after	after	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
than	than	ADP	IN	5	O
after	after	ADP	IN	9	O
parenteral	parenteral	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
galactose	galactose	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
galactose	galactose	ADJ	JJ	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
might	may	VERB	MD	9	O
have	have	VERB	VB	5	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
learning	learning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
ability	ability	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
worth	worth	ADJ	JJ	5	O
investigating	investigate	VERB	VBG	5	O
for	for	ADP	IN	5	O
improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
glucose	glucose	NOUN	NN	0	B-Disease
hypometabolism	hypometabolism	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
AD	ad	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
persons	person	NOUN	NNS	5	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
tenofovir	tenofovir	ADJ	JJ	0	B-Chemical
disoproxil	disoproxil	NOUN	NN	0	I-Chemical
fumarate	fumarate	VERB	VB	0	I-Chemical
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
large	large	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
database	database	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MHRA	MHRA	PROPN	NNP	5	O
database	database	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
tenofovir	tenofovir	DET	DT	0	B-Chemical
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
a	a	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	O
syndromes	syndrome	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
established	establish	VERB	VBN	9	O
from	from	ADP	IN	9	O
mechanistic	mechanistic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
randomised	randomise	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
exact	exact	ADJ	JJ	5	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	O
involvement	involvement	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
uncertain	uncertain	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
undertook	undertake	VERB	VBD	9	O
a	a	DET	DT	5	O
descriptive	descriptive	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
Yellow	Yellow	PROPN	NNP	9	O
Card	Card	PROPN	NNP	5	O
records	record	NOUN	NNS	5	O
of	of	ADP	IN	5	O
407	407	NUM	CD	7	O
HIV	HIV	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
persons	person	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
tenofovir	tenofovir	ADJ	JJ	0	B-Chemical
disoproxil	disoproxil	NOUN	NN	0	I-Chemical
fumarate	fumarate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
TDF	TDF	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
antiretroviral	antiretroviral	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
regimen	regiman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
submitted	submit	VERB	VBD	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Medicines	Medicines	PROPN	NNPS	5	O
and	and	CCONJ	CC	5	O
Healthcare	Healthcare	PROPN	NNP	0	O
Products	Products	PROPN	NNPS	0	O
Regulatory	Regulatory	PROPN	NNP	9	O
Agency	Agency	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
MHRA	MHRA	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
kidney	kidney	NOUN	NN	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Reports	report	NOUN	NNS	5	O
that	that	DET	DT	5	O
satisfy	satisfy	NOUN	NN	5	O
defined	define	VERB	VBD	5	O
criteria	criterion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
classified	classify	VERB	VBN	5	O
as	as	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
kidney	kidney	NOUN	NN	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
Fanconi	Fanconi	PROPN	NNP	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
407	407	NUM	CD	7	O
Yellow	Yellow	PROPN	NNP	9	O
Card	Card	PROPN	NNP	5	O
records	record	NOUN	NNS	5	O
analysed	analyse	VERB	VBD	9	O
,	,	PUNCT	,	9	O
106	106	NUM	CD	9	O
satisfied	satisfied	ADJ	JJ	5	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
TDF	tdf	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
kidney	kidney	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
53	53	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
35	35	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
Fanconi	Fanconi	PROPN	NNP	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
TDF	tdf	NOUN	NN	9	B-Chemical
exposure	exposure	NOUN	NN	9	O
was	be	VERB	VBD	9	O
316	316	NUM	CD	7	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
interquartile	interquartile	NOUN	NN	9	O
range	range	NOUN	NN	9	O
120	120	NUM	CD	9	O
-	-	SYM	SYM	7	O
740	740	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hospitalisation	hospitalisation	NOUN	NN	5	O
for	for	ADP	IN	5	O
TDF	tdf	NOUN	NN	9	B-Chemical
kidney	kidney	NOUN	NN	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
amongst	amongst	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Fanconi	Fanconi	PROPN	NNP	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	O
syndromes	syndrome	NOUN	NNS	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
population	population	NOUN	NN	5	O
series	series	NOUN	NN	5	O
mirrors	mirror	NOUN	NNS	5	O
that	that	DET	WDT	5	O
reported	report	VERB	VBD	9	O
in	in	ADP	IN	5	O
randomised	randomise	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
TDF	TDF	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
complete	complete	ADJ	JJ	9	O
restoration	restoration	NOUN	NN	5	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
up	up	ADV	RB	5	O
half	half	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Incidence	incidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
high	high	ADJ	JJ	9	O
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
without	without	ADP	IN	9	O
known	know	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
recognized	recognize	VERB	VBN	9	O
complication	complication	NOUN	NN	5	O
in	in	ADP	IN	5	O
populations	population	NOUN	NNS	9	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
early	early	ADJ	JJ	9	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
without	without	ADP	IN	9	O
known	know	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
ICU	ICU	PROPN	NNP	5	O
for	for	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
after	after	ADP	IN	9	O
elective	elective	ADJ	JJ	5	O
major	major	ADJ	JJ	9	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
secondary	secondary	ADJ	JJ	9	O
outcome	outcome	NOUN	NN	5	O
investigated	investigate	VERB	VBN	9	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
eventual	eventual	ADJ	JJ	5	O
independent	independent	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
among	among	ADP	IN	5	O
demographic	demographic	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
An	an	DET	DT	5	O
observational	observational	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
consecutive	consecutive	ADJ	JJ	5	O
cohort	cohort	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
ICU	ICU	PROPN	NNP	5	O
within	within	ADP	IN	9	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
major	major	ADJ	JJ	9	O
surgical	surgical	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Exclusion	exclusion	NOUN	NN	5	O
criteria	criterion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
any	any	DET	DT	5	O
preexisting	preexisting	ADJ	JJ	9	O
predisposing	predispose	VERB	VBG	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
delirium	delirium	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
potentially	potentially	ADV	RB	5	O
confounding	confound	VERB	VBG	5	O
neurological	neurological	ADJ	JJ	5	B-Disease
dysfunctions	dysfunction	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
daily	daily	ADV	RB	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
confusion	confusion	NOUN	NN	5	B-Disease
assessment	assessment	NOUN	NN	5	O
method	method	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
ICU	ICU	PROPN	NNP	5	O
scale	scale	NOUN	NN	5	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
surgical	surgical	ADJ	JJ	5	O
procedure	procedure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Early	early	ADJ	JJ	9	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
incidence	incidence	NOUN	NN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
assessed	assess	VERB	VBN	9	O
through	through	ADP	IN	9	O
three	three	NUM	CD	9	O
different	different	ADJ	JJ	9	O
multiple	multiple	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
According	accord	VERB	VBG	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
confusion	confusion	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
method	method	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
ICU	ICU	PROPN	NNP	5	O
scale	scale	NOUN	NN	5	O
,	,	PUNCT	,	9	O
28	28	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
early	early	ADJ	JJ	9	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
thiopentone	thiopentone	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
eight	eight	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
higher	high	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
delirium	delirium	NOUN	NN	5	B-Disease
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
propofol	propofol	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
57	57	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
RR	RR	PROPN	NNP	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
,	,	PUNCT	,	9	O
X2	X2	PROPN	NNP	9	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
256	256	NUM	CD	9	O
;	;	PUNCT	:	9	O
df	df	ADP	IN	7	O
=	=	NOUN	NNS	7	O
1	1	NUM	CD	9	O
;	;	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
<	<	X	XX	0	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
early	early	ADJ	JJ	9	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
very	very	ADV	RB	5	O
common	common	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
after	after	ADP	IN	9	O
major	major	ADJ	JJ	9	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
without	without	ADP	IN	9	O
known	know	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Thiopentone	thiopentone	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
independently	independently	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
single	single	ADJ	JJ	9	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
induces	induce	VERB	VBZ	3	O
a	a	DET	DT	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
lasting	last	VERB	VBG	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behaviour	behaviour	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Methamphetamine	Methamphetamine	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
METH	METH	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
triggers	trigger	VERB	VBZ	9	O
a	a	DET	DT	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
monoaminergic	monoaminergic	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
METH	METH	PROPN	NNP	9	B-Chemical
abuse	abuse	NOUN	NN	5	O
leads	lead	VERB	VBZ	9	O
to	to	ADP	IN	5	O
negative	negative	ADJ	JJ	9	O
emotional	emotional	ADJ	JJ	5	O
states	state	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
depressive	depressive	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
during	during	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
currently	currently	ADV	RB	5	O
unknown	unknown	ADJ	JJ	9	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
toxic	toxic	ADJ	JJ	0	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
also	also	ADV	RB	9	O
causes	cause	VERB	VBZ	9	O
a	a	DET	DT	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
lasting	last	VERB	VBG	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
phenotype	phenotype	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
persistent	persistent	ADJ	JJ	5	O
monoaminergic	monoaminergic	ADJ	JJ	5	O
deficits	deficit	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
now	now	ADV	RB	5	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behaviour	behaviour	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
at	at	ADP	IN	9	O
early	early	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
periods	period	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
high	high	ADJ	JJ	9	O
METH	METH	PROPN	NNP	9	B-Chemical
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

METH	METH	PROPN	NNP	9	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
alter	alter	VERB	VB	9	O
the	the	DET	DT	5	O
motor	motor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
procedural	procedural	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
as	as	ADP	IN	5	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
swimming	swim	VERB	VBG	5	O
speed	speed	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
escape	escape	VERB	VB	5	O
latency	latency	NOUN	NN	5	O
to	to	PART	TO	5	O
find	find	VERB	VB	5	O
the	the	DET	DT	5	O
platform	platform	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
cued	cue	VERB	VBN	5	O
version	version	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
water	water	NOUN	NN	0	O
maze	maze	NOUN	NN	5	O
task	task	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
METH	METH	PROPN	NNP	9	B-Chemical
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
immobility	immobility	NOUN	NN	5	O
time	time	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
tail	tail	NOUN	NN	9	O
suspension	suspension	NOUN	NN	0	O
test	test	NOUN	NN	5	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
49	49	NUM	CD	7	O
days	day	NOUN	NNS	9	O
post	post	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
depressive	depressive	VERB	VB	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
profile	profile	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
METH	METH	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
frontostriatal	frontostriatal	ADJ	JJ	5	O
dopaminergic	dopaminergic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
serotonergic	serotonergic	NOUN	NN	5	O
neurotransmission	neurotransmission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
indicated	indicate	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
DOPAC	DOPAC	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
HVA	HVA	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
tyrosine	tyrosine	NOUN	NN	3	B-Chemical
hydroxylase	hydroxylase	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
observed	observe	VERB	VBD	9	O
at	at	ADP	IN	9	O
both	both	DET	DT	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
49	49	NUM	CD	7	O
days	day	NOUN	NNS	9	O
post	post	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
parallel	parallel	NOUN	NN	5	O
,	,	PUNCT	,	9	O
another	another	DET	DT	9	O
neurochemical	neurochemical	ADJ	JJ	5	O
feature	feature	NOUN	NN	5	O
of	of	ADP	IN	5	O
depression	depression	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
astroglial	astroglial	ADJ	JJ	3	O
dysfunction	dysfunction	NOUN	NN	9	O
-	-	PUNCT	,	7	O
-	-	PUNCT	,	7	O
was	be	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
striatal	striatal	ADJ	JJ	3	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
astrocytic	astrocytic	ADJ	JJ	3	O
protein	protein	NOUN	NN	1	O
marker	marker	NOUN	NN	3	O
,	,	PUNCT	,	9	O
glial	glial	ADJ	JJ	3	O
fibrillary	fibrillary	ADJ	JJ	3	O
acidic	acidic	ADJ	JJ	0	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
transiently	transiently	ADV	RB	3	O
increased	increase	VERB	VBN	9	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
that	that	DET	WDT	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
induces	induce	VERB	VBZ	3	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
lasting	last	VERB	VBG	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behaviour	behaviour	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
persistent	persistent	ADJ	JJ	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
frontostriatal	frontostriatal	ADJ	JJ	5	O
dopaminergic	dopaminergic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
serotonergic	serotonergic	NOUN	NN	5	O
homoeostasis	homoeostasis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Linezolid	Linezolid	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Many	many	ADJ	JJ	5	O
systemic	systemic	ADJ	JJ	9	O
antimicrobials	antimicrobial	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
ocular	ocular	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
especially	especially	ADV	RB	5	O
relevant	relevant	ADJ	JJ	5	O
in	in	ADP	IN	5	O
multidrug	multidrug	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
where	where	ADV	WRB	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
one	one	NUM	CD	5	O
drug	drug	NOUN	NN	5	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
ocular	ocular	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
vision	vision	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
linezolid	linezolid	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
45	45	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
tuberculous	tuberculous	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
linezolid	linezolid	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
ethambutol	ethambutol	VERB	VB	0	B-Chemical
for	for	ADP	IN	5	O
extensively	extensively	ADJ	JJ	9	B-Disease
drug	drug	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
resistant	resistant	ADJ	JJ	9	I-Disease
tuberculosis	tuberculosis	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
XDR	XDR	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
TB	TB	PROPN	NNP	5	I-Disease
)	)	PUNCT	-RRB-	9	O
presented	present	VERB	VBD	5	O
to	to	ADP	IN	5	O
us	-PRON-	PRON	PRP	5	O
with	with	ADP	IN	5	O
painless	painless	ADJ	JJ	5	O
progressive	progressive	ADJ	JJ	5	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
vision	vision	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
eyes	eye	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Color	color	NOUN	NN	5	O
vision	vision	NOUN	NN	5	O
was	be	VERB	VBD	9	O
defective	defective	ADJ	JJ	1	O
and	and	CCONJ	CC	5	O
fundus	fundus	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
optic	optic	ADJ	JJ	5	B-Disease
disc	disc	NOUN	NN	5	I-Disease
edema	edema	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
eyes	eye	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ethambutol	Ethambutol	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
toxic	toxic	ADJ	JJ	0	B-Disease
optic	optic	ADJ	JJ	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
tablet	tablet	ADJ	JJ	0	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
withdrawn	withdraw	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Deterioration	deterioration	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
vision	vision	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
despite	despite	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
linezolid	linezolid	NOUN	NN	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
marked	marked	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
vision	vision	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
report	report	NOUN	NN	5	O
emphasizes	emphasize	VERB	VBZ	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
monitoring	monitoring	NOUN	NN	5	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
linezolid	linezolid	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Resuscitation	resuscitation	NOUN	NN	5	O
with	with	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
,	,	PUNCT	,	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
in	in	ADP	IN	5	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
newborn	newborn	ADJ	JJ	9	O
piglets	piglet	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
dosing	dosing	NOUN	NN	9	O
regimens	regimen	NOUN	NNS	5	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
emulsion	emulsion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
yet	yet	ADV	RB	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
neonates	neonate	NOUN	NNS	9	O
in	in	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anaesthetic	anaesthetic	ADJ	JJ	5	O
systemic	systemic	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
LAST	LAST	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Newborn	Newborn	PROPN	NNP	9	O
piglets	piglet	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
until	until	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
collapse	collapse	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Standard	standard	ADJ	JJ	9	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
resuscitation	resuscitation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
electrocardiogram	electrocardiogram	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
ECG	ECG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
for	for	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
fibrillation	fibrillation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
QRS	QRS	PROPN	NNP	5	O
prolongation	prolongation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Piglets	piglet	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
to	to	ADP	IN	5	O
four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
control	control	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
saline	saline	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Intralipid	Intralipid	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
)	)	PUNCT	-RRB-	9	O
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
Intralipd	Intralipd	PROPN	NNP	_	O
plus	plus	CCONJ	CC	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Resuscitation	resuscitation	NOUN	NN	5	O
continued	continue	VERB	VBD	9	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
until	until	ADP	IN	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
return	return	NOUN	NN	5	O
of	of	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
circulation	circulation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ROSC	ROSC	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
at	at	ADP	IN	9	O
or	or	CCONJ	CC	5	O
superior	superior	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
baseline	baseline	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
sinus	sinus	NOUN	NN	5	O
rhythm	rhythm	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
ROSC	ROSC	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
in	in	ADP	IN	5	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
piglets	piglet	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treated	treat	VERB	VBN	3	O
piglets	piglet	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Mortality	mortality	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
ECG	ECG	PROPN	NNP	5	O
abnormalities	abnormality	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
zero	zero	NUM	CD	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Intralipid	Intralipid	PROPN	NNP	0	O
only	only	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
14	14	NUM	CD	7	O
and	and	CCONJ	CC	5	O
17	17	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
lipid	lipid	ADJ	JJ	0	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Lipid	Lipid	PROPN	NNP	0	O
emulsion	emulsion	NOUN	NN	0	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
were	be	VERB	VBD	9	O
equally	equally	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
achieving	achieve	VERB	VBG	5	O
a	a	DET	DT	5	O
return	return	NOUN	NN	5	O
to	to	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
circulation	circulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
LAST	LAST	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

Epinephrine	Epinephrine	PROPN	NNP	0	B-Chemical
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
ECG	ECG	PROPN	NNP	5	O
abnormalities	abnormality	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
emulsion	emulsion	NOUN	NN	0	O
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

Incidence	incidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
type	type	NOUN	NN	9	I-Disease
II	ii	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
postoperative	postoperative	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
platelet	platelet	NOUN	NN	9	O
count	count	NOUN	NN	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
graft	graft	NOUN	NN	5	O
recipients	recipient	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
cohort	cohort	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Thrombocytopenia	Thrombocytopenia	PROPN	NNP	7	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
liver	liver	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
disorder	disorder	NOUN	NN	5	O
caused	cause	VERB	VBN	9	O
mainly	mainly	ADV	RB	9	O
by	by	ADP	IN	9	O
portal	portal	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
thrombopoetin	thrombopoetin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
endotoxemia	endotoxemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
immune	immune	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
heparin	heparin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
type	type	NOUN	NN	9	I-Disease
II	II	PROPN	NNP	9	I-Disease
(	(	PUNCT	-LRB-	9	O
HIT	HIT	PROPN	NNP	5	B-Disease
type	type	NOUN	NN	9	I-Disease
II	II	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
yet	yet	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
few	few	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
citations	citation	NOUN	NNS	5	O
reporting	report	VERB	VBG	5	O
contradictory	contradictory	ADJ	JJ	5	O
results	result	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
demonstrate	demonstrate	VERB	VB	9	O
the	the	DET	DT	5	O
perioperative	perioperative	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
type	type	NOUN	NN	9	I-Disease
II	II	PROPN	NNP	9	I-Disease
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
retrospectively	retrospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
of	of	ADP	IN	5	O
205	205	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
full	full	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
size	size	NOUN	NN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
between	between	ADP	IN	5	O
January	January	PROPN	NNP	2	O
2006	2006	NUM	CD	2	O
and	and	CCONJ	CC	5	O
December	December	PROPN	NNP	2	O
2010	2010	NUM	CD	2	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	I-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
liver	liver	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Preoperative	preoperative	ADJ	JJ	5	O
platelet	platelet	NOUN	NN	9	O
count	count	NOUN	NN	9	O
,	,	PUNCT	,	9	O
postoperative	postoperative	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
platelets	platelet	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
type	type	NOUN	NN	9	I-Disease
II	II	PROPN	NNP	9	I-Disease
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
155	155	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
75	75	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
205	205	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
before	before	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
significantly	significantly	ADV	RB	9	O
influenced	influence	VERB	VBN	5	O
by	by	ADP	IN	9	O
Model	Model	PROPN	NNP	5	O
of	of	ADP	IN	5	O
End	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Stage	Stage	PROPN	NNP	9	I-Disease
Liver	Liver	PROPN	NNP	9	I-Disease
Disease	Disease	PROPN	NNP	2	I-Disease
score	score	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	B-Disease
cirrhosis	cirrhosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
platelet	platelet	NOUN	NN	9	O
count	count	NOUN	NN	9	O
exceeded	exceed	VERB	VBD	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
/	/	SYM	SYM	9	O
uL	ul	NOUN	NN	0	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
193	193	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
medium	medium	NOUN	NN	0	O
of	of	ADP	IN	5	O
7	7	NUM	CD	9	O
d	d	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Regarding	regard	VERB	VBG	9	O
HIT	HIT	PROPN	NNP	5	B-Disease
II	II	PROPN	NNP	9	I-Disease
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
four	four	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
background	background	NOUN	NN	9	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
type	type	NOUN	NN	9	I-Disease
II	II	PROPN	NNP	9	I-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
about	about	ADV	RB	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
further	further	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
type	type	NOUN	NN	9	I-Disease
II	II	PROPN	NNP	9	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
heparin	heparin	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
avoided	avoid	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
molecular	molecular	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
weight	weight	NOUN	NN	9	O
heparin	heparin	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
normalization	normalization	NOUN	NN	5	O
of	of	ADP	IN	5	O
platelet	platelet	NOUN	NN	9	O
count	count	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Takotsubo	takotsubo	NOUN	NN	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
or	or	CCONJ	CC	5	O
apical	apical	ADJ	JJ	9	B-Disease
ballooning	ballooning	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
Zolmitriptan	Zolmitriptan	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Takotsubo	takotsubo	NOUN	NN	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TS	TS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
also	also	ADV	RB	9	O
known	know	VERB	VBN	9	O
as	as	ADP	IN	5	O
broken	broken	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
left	left	ADJ	JJ	5	O
ventricle	ventricle	NOUN	NN	5	O
apical	apical	ADJ	JJ	9	O
ballooning	ballooning	NOUN	NN	5	O
with	with	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
biomarkers	biomarker	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
suggestive	suggestive	VERB	VBP	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	B-Disease
coronary	coronary	ADJ	JJ	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ie	ie	X	FW	5	O
,	,	PUNCT	,	9	O
ST	st	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
elevation	elevation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
T	T	PROPN	NNP	3	O
wave	wave	NOUN	NN	5	O
inversions	inversion	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pathologic	pathologic	VERB	VB	5	O
Q	Q	PROPN	NNP	9	O
waves	wave	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
54	54	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
medical	medical	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
mitral	mitral	ADJ	JJ	5	B-Disease
valve	valve	NOUN	NN	5	I-Disease
prolapse	prolapse	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
migraines	migraine	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
for	for	ADP	IN	5	O
substernal	substernal	ADJ	JJ	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
demonstrated	demonstrate	VERB	VBD	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
ST	ST	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
elevation	elevation	NOUN	NN	9	O
in	in	ADP	IN	5	O
leads	lead	NOUN	NNS	9	O
II	II	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
III	iii	NUM	CD	9	O
,	,	PUNCT	,	9	O
aVF	avf	NOUN	NN	5	O
,	,	PUNCT	,	9	O
V5	v5	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
V6	v6	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
positive	positive	ADJ	JJ	9	O
troponin	troponin	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
.	.	PUNCT	.	9	O

Emergent	emergent	NOUN	NN	5	O
coronary	coronary	ADJ	JJ	5	O
angiogram	angiogram	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
with	with	ADP	IN	5	O
moderately	moderately	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
with	with	ADP	IN	5	O
wall	wall	NOUN	NN	5	O
motion	motion	NOUN	NN	5	O
abnormalities	abnormality	NOUN	NNS	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
TS	TS	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Detailed	detailed	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
obtained	obtain	VERB	VBD	9	O
retrospectively	retrospectively	ADV	RB	5	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
took	take	VERB	VBD	5	O
zolmitriptan	zolmitriptan	ADV	RB	0	B-Chemical
sparingly	sparingly	ADV	RB	0	O
only	only	ADV	RB	9	O
when	when	ADV	WRB	5	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
migraines	migraine	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

But	but	CCONJ	CC	5	O
before	before	ADP	IN	9	O
this	this	DET	DT	5	O
event	event	NOUN	NN	5	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
taking	take	VERB	VBG	5	O
zolmitriptan	zolmitriptan	ADJ	JJ	0	B-Chemical
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
several	several	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
persistent	persistent	ADJ	JJ	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
headache	headache	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
otherwise	otherwise	ADV	RB	9	O
reported	report	VERB	VBD	9	O
that	that	ADP	IN	5	O
she	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
quite	quite	ADV	RB	5	O
active	active	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
rides	ride	VERB	VBZ	5	O
horses	horse	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
does	do	VERB	VBZ	9	O
show	show	VERB	VB	9	O
jumping	jump	VERB	VBG	5	O
without	without	ADP	IN	9	O
any	any	DET	DT	5	O
limitations	limitation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
physical	physical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
recent	recent	ADJ	JJ	5	O
stress	stress	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
status	status	NOUN	NN	9	B-Disease
migrainosus	migrainosus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Extensive	extensive	ADJ	JJ	9	O
literature	literature	NOUN	NN	5	O
search	search	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
multiple	multiple	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
vasospasm	vasospasm	NOUN	NN	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
zolmitriptan	zolmitriptan	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
TS	TS	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Depression	depression	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
impulsiveness	impulsiveness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
sleep	sleep	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
in	in	ADP	IN	5	O
past	past	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
present	present	ADJ	JJ	9	O
polydrug	polydrug	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylenedioxymethamphetamine	methylenedioxymethamphetamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
,	,	PUNCT	,	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RATIONALE	RATIONALE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Ecstasy	Ecstasy	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylenedioxymethamphetamine	methylenedioxymethamphetamine	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
worldwide	worldwide	ADJ	JJ	5	O
recreational	recreational	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
of	of	ADP	IN	5	O
abuse	abuse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Unfortunately	unfortunately	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
from	from	ADP	IN	9	O
human	human	ADJ	JJ	3	O
research	research	NOUN	NN	5	O
investigating	investigate	VERB	VBG	5	O
its	-PRON-	DET	PRP$	9	O
psychological	psychological	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
inconsistent	inconsistent	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
largest	large	ADJ	JJS	5	O
to	to	ADP	IN	5	O
date	date	NOUN	NN	5	O
in	in	ADP	IN	5	O
sample	sample	NOUN	NN	9	O
size	size	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
5HT	5ht	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
behaviors	behavior	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
present	present	ADJ	JJ	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
with	with	ADP	IN	5	O
past	past	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
after	after	ADP	IN	9	O
an	an	DET	DT	5	O
abstinence	abstinence	NOUN	NN	5	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
to	to	PART	TO	5	O
include	include	VERB	VB	5	O
robust	robust	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
for	for	ADP	IN	5	O
other	other	ADJ	JJ	5	O
recreational	recreational	ADJ	JJ	5	O
substances	substance	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
sample	sample	NOUN	NN	9	O
of	of	ADP	IN	5	O
997	997	NUM	CD	7	O
participants	participant	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
52	52	NUM	CD	7	O
%	%	NOUN	NN	9	O
male	male	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
recruited	recruit	VERB	VBN	9	O
to	to	ADP	IN	5	O
four	four	NUM	CD	9	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
drug	drug	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
ND	ND	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
/	/	SYM	SYM	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AN	AN	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
cannabis	cannabis	NOUN	NN	5	B-Chemical
/	/	SYM	SYM	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
/	/	SYM	SYM	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CAN	CAN	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
ecstasy	ecstasy	ADJ	JJ	5	B-Chemical
polydrug	polydrug	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
polydrug	polydrug	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
present	present	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
past	past	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
EX	EX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Participants	participant	NOUN	NNS	5	O
completed	complete	VERB	VBD	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
history	history	NOUN	NN	5	O
questionnaire	questionnaire	NOUN	NN	5	O
,	,	PUNCT	,	9	O
Beck	Beck	PROPN	NNP	6	O
Depression	Depression	PROPN	NNP	5	B-Disease
Inventory	Inventory	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
Barratt	Barratt	PROPN	NNP	6	O
Impulsiveness	Impulsiveness	PROPN	NNP	5	B-Disease
Scale	Scale	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
Pittsburgh	Pittsburgh	PROPN	NNP	2	O
Sleep	Sleep	PROPN	NNP	5	O
Quality	Quality	PROPN	NNP	5	O
Index	Index	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Wechsler	Wechsler	PROPN	NNP	5	O
Memory	Memory	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
Revised	revise	VERB	VBN	5	O
which	which	DET	WDT	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
total	total	NOUN	NN	9	O
,	,	PUNCT	,	9	O
provided	provide	VERB	VBD	9	O
13	13	NUM	CD	7	O
psychometric	psychometric	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
While	while	ADP	IN	9	O
the	the	DET	DT	5	O
CAN	CAN	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
PD	pd	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
record	record	VERB	VB	5	O
greater	great	ADJ	JJR	5	O
deficits	deficit	NOUN	NNS	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
drug	drug	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
and	and	CCONJ	CC	5	O
EX	EX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
groups	group	NOUN	NNS	9	O
recorded	record	VERB	VBD	5	O
greater	great	ADJ	JJR	5	O
deficits	deficit	NOUN	NNS	5	O
than	than	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
on	on	ADP	IN	5	O
ten	ten	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
13	13	NUM	CD	7	O
psychometric	psychometric	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Strikingly	strikingly	ADV	RB	3	O
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
abstinence	abstinence	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
98	98	NUM	CD	7	O
;	;	PUNCT	:	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
9	9	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
past	past	ADJ	JJ	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
few	few	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
recovery	recovery	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
present	present	ADJ	JJ	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
past	past	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
for	for	ADP	IN	5	O
ten	ten	NUM	CD	9	O
measures	measure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
impairment	impairment	NOUN	NN	5	O
for	for	ADP	IN	5	O
two	two	NUM	CD	5	O
measures	measure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
improvement	improvement	NOUN	NN	5	O
on	on	ADP	IN	5	O
just	just	ADV	RB	5	O
one	one	NUM	CD	5	O
measure	measure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Given	give	VERB	VBN	9	O
this	this	DET	DT	5	O
record	record	NOUN	NN	5	O
of	of	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
memory	memory	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
depression	depression	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
impulsiveness	impulsiveness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sleep	sleep	NOUN	NN	5	B-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
prognosis	prognosis	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
generation	generation	NOUN	NN	9	O
of	of	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
for	for	ADP	IN	5	O
concern	concern	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Association	association	NOUN	NN	2	O
of	of	ADP	IN	5	O
common	common	ADJ	JJ	5	O
genetic	genetic	ADJ	JJ	5	O
variants	variant	NOUN	NNS	1	O
of	of	ADP	IN	5	O
HOMER1	homer1	ADJ	JJ	7	O
gene	gene	NOUN	NN	1	O
with	with	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
effective	effective	ADJ	JJ	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
its	-PRON-	DET	PRP$	9	O
chronic	chronic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
could	could	VERB	MD	9	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
chronic	chronic	VERB	VB	5	O
adverse	adverse	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

HOMER1	HOMER1	PROPN	NNP	7	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
protein	protein	NOUN	NN	1	O
with	with	ADP	IN	5	O
pivotal	pivotal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
transmission	transmission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
investigates	investigate	VERB	VBZ	5	O
whether	whether	ADP	IN	9	O
polymorphisms	polymorphism	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
HOMER1	HOMER1	PROPN	NNP	7	O
gene	gene	NOUN	NN	1	O
promoter	promoter	NOUN	NN	1	O
region	region	NOUN	NN	9	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
205	205	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
Parkinson	Parkinson	PROPN	NNP	5	I-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
genotyped	genotype	VERB	VBN	9	O
for	for	ADP	IN	5	O
rs4704559	rs4704559	NOUN	NNS	_	O
,	,	PUNCT	,	9	O
rs10942891	rs10942891	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
rs4704560	rs4704560	VERB	VB	_	O
by	by	ADP	IN	9	O
allelic	allelic	ADJ	JJ	9	O
discrimination	discrimination	NOUN	NN	5	O
with	with	ADP	IN	5	O
Taqman	Taqman	PROPN	NNP	9	O
assays	assay	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rs4704559	rs4704559	NOUN	NNS	_	O
G	g	NOUN	NN	9	O
allele	allele	NOUN	NN	1	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
prevalence	prevalence	NOUN	NN	5	O
ratio	ratio	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PR	PR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
=	=	VERB	VBZ	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
615	615	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
426	426	NUM	CD	7	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
887	887	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
009	009	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PR	PR	PROPN	NNP	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
515	515	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
295	295	NUM	CD	7	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
899	899	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
020	020	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
HOMER1	HOMER1	PROPN	NNPS	7	O
rs4704559	rs4704559	NOUN	NNS	_	O
G	g	NOUN	NN	9	O
allele	allele	NOUN	NN	1	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Crocin	Crocin	PROPN	NNP	0	B-Chemical
improves	improve	VERB	VBZ	5	O
lipid	lipid	ADJ	JJ	0	O
dysregulation	dysregulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
subacute	subacute	NOUN	NN	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
through	through	ADP	IN	9	O
ERK1	ERK1	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
pathway	pathway	NOUN	NN	3	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
liver	liver	NOUN	NN	9	O
.	.	PUNCT	.	9	O

INTRODUCTION	introduction	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Diazinon	diazinon	VERB	VB	7	B-Chemical
Yis	Yis	PROPN	NNP	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
broadly	broadly	ADV	RB	5	O
used	use	VERB	VBN	5	O
organophosphorus	organophosphorus	NOUN	NN	0	B-Chemical
insecticides	insecticide	NOUN	NNS	5	O
in	in	ADP	IN	5	O
agriculture	agriculture	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
that	that	DET	DT	5	O
exposure	exposure	NOUN	NN	9	O
to	to	PART	TO	5	O
diazinon	diazinon	VERB	VB	0	B-Chemical
may	may	VERB	MD	5	O
interfere	interfere	VERB	VB	9	O
with	with	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
metabolism	metabolism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
hypolipidemic	hypolipidemic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
crocin	crocin	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
established	establish	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Earlier	early	ADJ	JJR	9	O
studies	study	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
Extracellular	Extracellular	PROPN	NNP	0	O
signal	signal	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
regulated	regulated	ADJ	JJ	3	O
kinase	kinase	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
ERK	ERK	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
pathways	pathway	VERB	VBZ	9	O
in	in	ADP	IN	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
density	density	NOUN	NN	9	O
lipoprotein	lipoprotein	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
LDLr	LDLr	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
metabolism	metabolism	NOUN	NN	9	O
,	,	PUNCT	,	9	O
ERK	ERK	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
LDLr	LDLr	NOUN	NNS	3	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
exposed	expose	VERB	VBN	9	O
to	to	PART	TO	5	O
subacute	subacute	VERB	VB	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
ameliorating	ameliorate	VERB	VBG	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
crocin	crocin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBN	3	O
disturbed	disturb	VERB	VBN	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
homeostasis	homeostasis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
24	24	NUM	CD	9	O
Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
4	4	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
received	receive	VERB	VBD	9	O
following	follow	VERB	VBG	9	O
treatments	treatment	NOUN	NNS	9	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
Corn	corn	NOUN	NN	0	O
oil	oil	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15mg	15mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
orally	orally	ADV	RB	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
crocin	crocin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
25mg	25mg	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
LDL	LDL	PROPN	NNP	0	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
LDLr	LDLr	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
ERK1	ERK1	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
protein	protein	NOUN	NN	1	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
total	total	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
activated	activate	VERB	VBN	3	O
forms	form	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ERK1	ERK1	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
liver	liver	NOUN	NN	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
Western	western	ADJ	JJ	3	O
blotting	blotting	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
quantitative	quantitative	ADJ	JJ	9	O
real	real	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
polymerase	polymerase	NOUN	NN	1	O
chain	chain	NOUN	NN	9	O
reaction	reaction	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
subacute	subacute	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
to	to	PART	TO	5	O
diazinon	diazinon	VERB	VB	0	B-Chemical
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
triglyceride	triglyceride	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
LDL	LDL	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
decreased	decrease	VERB	VBD	9	O
ERK1	ERK1	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
protein	protein	NOUN	NN	1	O
phosphorylation	phosphorylation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
LDLr	LDLr	NOUN	NNS	3	O
transcript	transcript	ADV	RB	1	O
.	.	PUNCT	.	9	O

Crocin	Crocin	PROPN	NNP	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
ERK	ERK	PROPN	NNP	3	O
activation	activation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperlipemia	hyperlipemia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
LDLr	LDLr	NOUN	NNS	3	O
transcript	transcript	ADV	RB	1	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Crocin	Crocin	PROPN	NNP	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
protective	protective	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
in	in	ADP	IN	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperlipemia	hyperlipemia	NOUN	NN	9	B-Disease
through	through	ADP	IN	9	O
modulating	modulating	NOUN	NN	9	O
of	of	ADP	IN	5	O
ERK	ERK	PROPN	NNP	3	O
pathway	pathway	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
LDLr	LDLr	NOUN	NNS	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

GEM	gem	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
active	active	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
relapsed	relapse	VERB	VBN	5	O
Hodgkin	Hodgkin	PROPN	NNP	5	B-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Hodgkin	hodgkin	NOUN	NN	5	B-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
HL	HL	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
chemosensitive	chemosensitive	ADJ	JJ	5	O
malignancy	malignancy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
relapse	relapse	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
autologous	autologous	ADJ	JJ	3	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplant	transplant	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
choice	choice	NOUN	NN	5	O
which	which	DET	WDT	5	O
relies	rely	VERB	VBZ	5	O
on	on	ADP	IN	5	O
adequate	adequate	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
control	control	NOUN	NN	9	O
with	with	ADP	IN	5	O
salvage	salvage	NOUN	NN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Regimens	Regimens	PROPN	NNP	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
often	often	ADV	RB	5	O
require	require	VERB	VB	5	O
inpatient	inpatient	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
difficult	difficult	ADJ	JJ	5	O
to	to	PART	TO	5	O
deliver	deliver	VERB	VB	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Gemcitabine	Gemcitabine	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
have	have	VERB	VBP	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
HL	HL	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
overlapping	overlapping	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
chemotherapeutics	chemotherapeutic	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
delivered	deliver	VERB	VBN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
outpatient	outpatient	NOUN	NN	5	O
setting	setting	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
centre	centre	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
relapsed	relapsed	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
refractory	refractory	ADJ	JJ	9	O
HL	hl	NOUN	NN	9	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
gemcitabine	gemcitabine	NOUN	NN	3	B-Chemical
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
D	D	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
D8	D8	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
D15	D15	PROPN	NNP	7	O
;	;	PUNCT	:	9	O
methylprednisolone	methylprednisolone	ADJ	JJ	0	B-Chemical
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
D1	D1	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
D15	D15	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
every	every	DET	DT	5	O
28	28	NUM	CD	7	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
GEM	gem	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
P	P	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Demographic	Demographic	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
survival	survival	NOUN	NN	9	O
,	,	PUNCT	,	9	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
eligible	eligible	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
:	:	PUNCT	:	9	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
and	and	CCONJ	CC	5	O
twenty	twenty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
cycles	cycle	NOUN	NNS	9	O
of	of	ADP	IN	5	O
GEM	GEM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
P	P	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
total	total	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
median	median	ADJ	JJ	9	O
3	3	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
range	range	VERB	VB	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
of	of	ADP	IN	5	O
41	41	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
48	48	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
GEM	GEM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
as	as	ADP	IN	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
/	/	SYM	SYM	9	O
41	41	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
27	27	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Overall	overall	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ORR	ORR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
GEM	GEM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
cohort	cohort	NOUN	NN	9	O
was	be	VERB	VBD	9	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
complete	complete	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CR	CR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
37	37	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
14	14	NUM	CD	7	O
/	/	SYM	SYM	9	O
15	15	NUM	CD	9	O
CR	CR	PROPN	NNP	9	O
confirmed	confirm	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
metabolic	metabolic	NOUN	NN	9	O
CR	CR	PROPN	NNP	9	O
on	on	ADP	IN	5	O
PET	PET	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
ORR	ORR	PROPN	NNP	9	O
of	of	ADP	IN	5	O
85	85	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
20	20	NUM	CD	9	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
4	4	NUM	CD	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
haematological	haematological	ADJ	JJ	5	O
:	:	PUNCT	:	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
54	54	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
51	51	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
GEM	GEM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
was	be	VERB	VBD	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
GEM	gem	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
was	be	VERB	VBD	9	O
46	46	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
-	-	SYM	SYM	7	O
62	62	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
overall	overall	ADJ	JJ	5	O
survival	survival	NOUN	NN	9	O
was	be	VERB	VBD	9	O
59	59	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
43	43	NUM	CD	7	O
-	-	SYM	SYM	7	O
74	74	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Fourteen	fourteen	NUM	CD	9	O
of	of	ADP	IN	5	O
41	41	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
proceeded	proceed	VERB	VBN	9	O
directly	directly	ADV	RB	9	O
to	to	ADP	IN	5	O
autologous	autologous	ADJ	JJ	3	O
transplant	transplant	NOUN	NN	9	O
.	.	PUNCT	.	9	O

GEM	gem	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
salvage	salvage	NOUN	NN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
relatively	relatively	ADV	RB	5	O
high	high	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
successful	successful	ADJ	JJ	5	O
transplantation	transplantation	NOUN	NN	9	O
in	in	ADP	IN	5	O
appropriate	appropriate	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
relapsed	relapse	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
refractory	refractory	ADJ	JJ	9	O
HL	hl	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Basal	basal	ADJ	JJ	9	O
functioning	functioning	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hypothalamic	hypothalamic	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
pituitary	pituitary	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
adrenal	adrenal	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
HPA	HPA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
axis	axis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
psychological	psychological	ADJ	JJ	5	O
distress	distress	NOUN	NN	5	O
in	in	ADP	IN	5	O
recreational	recreational	ADJ	JJ	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
polydrug	polydrug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RATIONALE	RATIONALE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Ecstasy	Ecstasy	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
psychostimulant	psychostimulant	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
increasingly	increasingly	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
psychobiological	psychobiological	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
some	some	DET	DT	5	O
recent	recent	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
acute	acute	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
neuroendocrine	neuroendocrine	NOUN	NN	5	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
less	less	ADV	RBR	5	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
about	about	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
HPA	HPA	PROPN	NNP	9	O
functionality	functionality	NOUN	NN	9	O
in	in	ADP	IN	5	O
recreational	recreational	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
to	to	PART	TO	5	O
explore	explore	VERB	VB	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
polydrug	polydrug	NOUN	NN	5	O
use	use	NOUN	NN	5	O
on	on	ADP	IN	5	O
psychological	psychological	ADJ	JJ	5	O
distress	distress	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
basal	basal	NOUN	NN	3	O
functioning	functioning	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
HPA	HPA	PROPN	NNP	9	O
axis	axis	NOUN	NN	5	O
through	through	ADP	IN	9	O
assessing	assess	VERB	VBG	5	O
the	the	DET	DT	5	O
secretion	secretion	NOUN	NN	3	O
of	of	ADP	IN	5	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
across	across	ADP	IN	5	O
the	the	DET	DT	5	O
diurnal	diurnal	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Seventy	seventy	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
participants	participant	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
21	21	NUM	CD	7	O
nonusers	nonuser	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
29	29	NUM	CD	7	O
light	light	ADJ	JJ	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
polydrug	polydrug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
26	26	NUM	CD	7	O
heavy	heavy	ADJ	JJ	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
polydrug	polydrug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
completed	complete	VERB	VBD	5	O
a	a	DET	DT	5	O
substance	substance	NOUN	NN	5	O
use	use	NOUN	NN	5	O
inventory	inventory	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
measures	measure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
psychological	psychological	ADJ	JJ	5	O
distress	distress	NOUN	NN	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
then	then	ADV	RB	9	O
two	two	NUM	CD	5	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
sampling	sampling	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
on	on	ADP	IN	5	O
awakening	awakening	NOUN	NN	5	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
post	post	NOUN	NN	9	O
awakening	awakening	NOUN	NN	5	O
,	,	PUNCT	,	9	O
between	between	ADP	IN	5	O
1400	1400	NUM	CD	9	O
and	and	CCONJ	CC	5	O
1600	1600	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
pre	pre	VERB	VBD	9	O
bedtime	bedtime	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
participants	participant	NOUN	NNS	5	O
also	also	ADV	RB	9	O
attended	attend	VERB	VBD	5	O
the	the	DET	DT	5	O
laboratory	laboratory	NOUN	NN	9	O
to	to	PART	TO	5	O
complete	complete	VERB	VB	9	O
a	a	DET	DT	5	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
min	min	NOUN	NN	0	O
multitasking	multitasking	NOUN	NN	5	O
stressor	stressor	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Both	both	DET	DT	9	O
user	user	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
depression	depression	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
nonusers	nonuser	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
participants	participant	NOUN	NNS	5	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
typical	typical	ADJ	JJ	9	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
profile	profile	NOUN	NN	9	O
,	,	PUNCT	,	9	O
though	though	ADP	IN	9	O
light	light	ADJ	JJ	9	O
users	user	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
elevated	elevate	VERB	VBN	9	O
levels	level	NOUN	NNS	3	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
bed	bed	NOUN	NN	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
heavy	heavy	ADJ	JJ	9	O
users	user	NOUN	NNS	5	O
demonstrated	demonstrate	VERB	VBD	9	O
elevated	elevated	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
upon	upon	ADP	IN	9	O
awakening	awakening	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
polydrug	polydrug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
demonstrated	demonstrate	VERB	VBD	9	O
elevated	elevated	ADJ	JJ	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
bed	bed	ADJ	JJ	5	O
levels	level	NOUN	NNS	3	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
between	between	ADP	IN	5	O
group	group	NOUN	NN	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
afternoon	afternoon	NOUN	NN	5	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
overall	overall	ADJ	JJ	5	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
secretion	secretion	NOUN	NN	3	O
across	across	ADP	IN	5	O
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
depression	depression	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
in	in	ADP	IN	5	O
line	line	NOUN	NN	9	O
with	with	ADP	IN	5	O
previous	previous	ADJ	JJ	9	O
observations	observation	NOUN	NNS	9	O
in	in	ADP	IN	5	O
recreational	recreational	ADJ	JJ	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
polydrug	polydrug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Dysregulated	dysregulated	ADJ	JJ	3	O
diurnal	diurnal	ADJ	JJ	9	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
indicative	indicative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
inappropriate	inappropriate	ADJ	JJ	5	O
anticipation	anticipation	NOUN	NN	5	O
of	of	ADP	IN	5	O
forthcoming	forthcoming	ADJ	JJ	5	O
demands	demand	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
hypersecretion	hypersecretion	NOUN	NN	9	O
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
psychological	psychological	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
physical	physical	ADJ	JJ	5	O
morbidity	morbidity	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
heavy	heavy	ADJ	JJ	9	O
recreational	recreational	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Ifosfamide	Ifosfamide	PROPN	NNP	0	B-Chemical
related	relate	VERB	VBN	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
timely	timely	ADJ	JJ	5	O
EEG	EEG	PROPN	NNP	5	O
evaluation	evaluation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Ifosfamide	Ifosfamide	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
alkylating	alkylate	VERB	VBG	0	O
agent	agent	NOUN	NN	9	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
wide	wide	ADJ	JJ	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
cancers	cancer	NOUN	NNS	9	B-Disease
including	include	VERB	VBG	9	O
sarcomas	sarcomas	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
lymphoma	lymphoma	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
gynecologic	gynecologic	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
testicular	testicular	ADJ	JJ	9	I-Disease
cancers	cancer	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Encephalopathy	Encephalopathy	PROPN	NNP	5	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
IV	iv	NOUN	NN	9	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
highlight	highlight	VERB	VB	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
electroencephalogram	electroencephalogram	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EEG	EEG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
detection	detection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
related	relate	VERB	VBN	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Retrospective	retrospective	ADJ	JJ	9	O
chart	chart	NOUN	NN	5	O
review	review	NOUN	NN	5	O
including	include	VERB	VBG	9	O
clinical	clinical	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
EEG	EEG	PROPN	NNP	5	O
recordings	recording	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
on	on	ADP	IN	5	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
MD	MD	PROPN	NNP	9	O
Anderson	Anderson	PROPN	NNP	6	O
Cancer	Cancer	PROPN	NNP	2	B-Disease
Center	Center	PROPN	NNP	2	O
between	between	ADP	IN	5	O
years	year	NOUN	NNS	5	O
2009	2009	NUM	CD	2	O
and	and	CCONJ	CC	5	O
2012	2012	NUM	CD	2	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
related	relate	VERB	VBN	9	O
acute	acute	ADJ	JJ	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
soon	soon	ADV	RB	5	O
after	after	ADP	IN	9	O
(	(	PUNCT	-LRB-	9	O
within	within	ADP	IN	9	O
12	12	NUM	CD	9	O
h	h	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
receiving	receive	VERB	VBG	9	O
ifosfamide	ifosfamide	ADV	RB	0	B-Chemical
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
generalized	generalize	VERB	VBN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
while	while	ADP	IN	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
continuous	continuous	ADJ	JJ	5	O
non	non	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
convulsive	convulsive	ADJ	JJ	5	I-Disease
status	status	NOUN	NN	9	I-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
NCSE	NCSE	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
that	that	DET	WDT	5	O
required	require	VERB	VBD	9	O
ICU	ICU	PROPN	NNP	5	O
admission	admission	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intubation	intubation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Initial	Initial	PROPN	NNP	9	O
EEG	EEG	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
epileptiform	epileptiform	NOUN	NN	5	O
discharges	discharge	NOUN	NNS	5	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
run	run	VERB	VB	5	O
of	of	ADP	IN	5	O
triphasic	triphasic	ADJ	JJ	5	O
waves	wave	NOUN	NNS	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
moderate	moderate	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
diffuse	diffuse	NOUN	NN	5	O
generalized	generalize	VERB	VBN	5	O
slowing	slowing	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Mixed	mixed	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
sharps	sharp	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
triphasic	triphasic	ADJ	JJ	5	O
waves	wave	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Repeat	repeat	VERB	VB	9	O
EEGs	eeg	NOUN	NNS	5	O
within	within	ADP	IN	9	O
24	24	NUM	CD	9	O
_	_	NOUN	NN	7	O
h	h	DET	DT	0	O
of	of	ADP	IN	5	O
symptom	symptom	NOUN	NN	5	O
onset	onset	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
marked	marked	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
related	related	ADJ	JJ	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
correlates	correlate	NOUN	NNS	9	O
with	with	ADP	IN	5	O
EEG	EEG	PROPN	NNP	5	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
timely	timely	ADJ	JJ	5	O
EEG	EEG	PROPN	NNP	5	O
evaluation	evaluation	NOUN	NN	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
who	who	PRON	WP	5	O
develop	develop	VERB	VBP	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

Incidence	incidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
hospitalised	hospitalise	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
CIN	CIN	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
hospitalised	hospitalise	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Ninety	ninety	NUM	CD	5	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
before	before	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
enhanced	enhance	VERB	VBN	3	O
computed	compute	VERB	VBN	5	O
tomography	tomography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CT	CT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
serially	serially	ADV	RB	9	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
thereafter	thereafter	ADV	RB	9	O
.	.	PUNCT	.	9	O

CIN	CIN	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Cr	Cr	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
Cr	Cr	PROPN	NNP	0	B-Chemical
to	to	ADP	IN	5	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
over	over	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Relationships	relationship	NOUN	NNS	5	O
between	between	ADP	IN	5	O
CIN	CIN	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
CIN	CIN	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
18	18	NUM	CD	7	O
/	/	SYM	SYM	9	O
90	90	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CIN	CIN	PROPN	NNP	9	O
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
%	%	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CIN	CIN	PROPN	NNP	9	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
undergone	undergo	VERB	VBN	5	O
CT	CT	PROPN	NNP	9	O
within	within	ADP	IN	9	O
45	45	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
an	an	DET	DT	5	O
independent	independent	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
017	017	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CIN	CIN	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADJ	JJR	5	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
bevacizumab	bevacizumab	NOUN	NN	9	B-Chemical
/	/	SYM	SYM	9	O
irinotecan	irinotecan	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
021	021	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
044	044	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
CIN	CIN	PROPN	NNP	9	O
after	after	ADP	IN	9	O
CT	CT	PROPN	NNP	9	O
in	in	ADP	IN	5	O
hospitalised	hospitalise	VERB	VBN	5	O
oncological	oncological	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CIN	CIN	PROPN	NNP	9	O
developed	develop	VERB	VBD	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
times	time	NOUN	NNS	5	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
undergone	undergo	VERB	VBN	5	O
recent	recent	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hypertension	Hypertension	PROPN	NNP	7	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
bevacizumab	bevacizumab	NOUN	NN	9	B-Chemical
/	/	SYM	SYM	9	O
irinotecan	irinotecan	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
additional	additional	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
CIN	CIN	PROPN	NNP	9	O
development	development	NOUN	NN	9	O
.	.	PUNCT	.	9	O

KEY	key	ADJ	JJ	2	O
POINTS	point	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
.	.	PUNCT	.	9	O

Contrast	contrast	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
CIN	CIN	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
concern	concern	NOUN	NN	5	O
for	for	ADP	IN	5	O
oncological	oncological	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
CT	CT	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

.	.	PUNCT	.	9	O
CIN	CIN	PROPN	NNP	9	O
occurs	occur	VERB	VBZ	9	O
more	more	ADV	RBR	5	O
often	often	ADV	RB	5	O
when	when	ADV	WRB	5	O
CT	CT	PROPN	NNP	9	O
is	be	VERB	VBZ	5	O
performed	perform	VERB	VBN	9	O
<	<	X	XX	0	O
45	45	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

.	.	PUNCT	.	9	O
Hypertension	hypertension	NOUN	NN	7	B-Disease
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
bevacizumab	bevacizumab	NOUN	NN	9	B-Chemical
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
additional	additional	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Syndrome	syndrome	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
inappropriate	inappropriate	ADJ	JJ	5	I-Disease
antidiuretic	antidiuretic	ADJ	JJ	5	I-Disease
hormone	hormone	NOUN	NN	9	I-Disease
secretion	secretion	NOUN	NN	3	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
desvenlafaxine	desvenlafaxine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
syndrome	syndrome	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
inappropriate	inappropriate	ADJ	JJ	5	I-Disease
anti	anti	ADJ	JJ	3	I-Disease
-	-	ADJ	JJ	7	I-Disease
diuretic	diuretic	ADJ	JJ	5	I-Disease
hormone	hormone	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
SIADH	SIADH	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
secretion	secretion	NOUN	NN	3	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
desvenlafaxine	desvenlafaxine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
57	57	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
female	female	NOUN	NN	9	O
with	with	ADP	IN	5	O
hyponatraemia	hyponatraemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
medications	medication	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
desvenlafaxine	desvenlafaxine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
anxiety	anxiety	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
confusion	confusion	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
this	this	DET	DT	5	O
time	time	NOUN	NN	5	O
was	be	VERB	VBD	9	O
120	120	NUM	CD	9	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
osmolality	osmolality	NOUN	NN	0	O
was	be	VERB	VBD	9	O
263	263	NUM	CD	7	O
mosmol	mosmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
urine	urine	NOUN	NN	9	O
osmolality	osmolality	NOUN	NN	0	O
410	410	NUM	CD	9	O
mosmol	mosmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
63	63	NUM	CD	7	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
SIADH	SIADH	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Desvenlafaxine	Desvenlafaxine	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
ceased	cease	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
fluid	fluid	ADJ	JJ	5	O
restriction	restriction	NOUN	NN	9	O
implemented	implement	VERB	VBN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
the	the	DET	DT	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
128	128	NUM	CD	9	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
fluid	fluid	ADJ	JJ	5	O
restriction	restriction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
relaxed	relax	VERB	VBN	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
further	further	ADJ	JJ	9	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
inpatient	inpatient	NOUN	NN	5	O
admission	admission	NOUN	NN	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
ranged	range	VERB	VBD	9	O
from	from	ADP	IN	9	O
134	134	NUM	CD	7	O
to	to	PART	TO	5	O
137	137	NUM	CD	7	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
mirtazapine	mirtazapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
SIADH	SIADH	PROPN	NNP	5	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
widely	widely	ADV	RB	5	O
reported	report	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
antidepressants	antidepressant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
desvenlafaxine	desvenlafaxine	NOUN	NN	5	B-Chemical
might	may	VERB	MD	9	O
cause	cause	VERB	VB	5	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
hyponatremia	hyponatremia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
antidepressants	antidepressant	NOUN	NNS	5	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
hyponatremia	hyponatremia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
take	take	VERB	VB	5	O
appropriate	appropriate	ADJ	JJ	5	O
corrective	corrective	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
where	where	ADV	WRB	5	O
necessary	necessary	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
on	on	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
single	single	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
multiple	multiple	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
remains	remain	VERB	VBZ	9	O
controversial	controversial	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Wistar	wistar	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
66	66	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
injections	injection	NOUN	NNS	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
experimental	experimental	ADJ	JJ	5	O
protocols	protocol	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
killed	kill	VERB	VBN	9	O
before	before	ADP	IN	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
acute	acute	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
58	58	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
4	4	NUM	CD	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
killed	kill	VERB	VBN	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
M0	M0	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
injection	injection	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
M1	M1	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
M2	M2	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
M3	M3	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
M4	M4	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
chronological	chronological	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
used	use	VERB	VBD	5	O
at	at	ADP	IN	9	O
M0	M0	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
used	use	VERB	VBN	5	O
at	at	ADP	IN	9	O
moment	moment	NOUN	NN	5	O
-	-	PUNCT	:	7	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
total	total	ADJ	JJ	9	O
antioxidant	antioxidant	ADJ	JJ	0	O
performance	performance	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
TAP	TAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
DNA	dna	NOUN	NN	9	O
damage	damage	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
morphology	morphology	NOUN	NN	9	O
analyses	analysis	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
at	at	ADP	IN	9	O
each	each	DET	DT	5	O
time	time	NOUN	NN	5	O
point	point	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
disarrangement	disarrangement	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
necrosis	necrosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
DNA	dna	NOUN	NN	9	O
damage	damage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
strand	strand	NOUN	NN	1	O
breaks	break	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
SBs	sb	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
oxidized	oxidize	VERB	VBN	0	O
pyrimidines	pyrimidine	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
TAP	TAP	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
chronological	chronological	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
on	on	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
R	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
-	-	PUNCT	:	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
99	99	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
011	011	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
necrosis	necrosis	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
R	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
00	00	PUNCT	NFP	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
004	004	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
TAP	TAP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
R	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
95	95	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
049	049	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
DNA	dna	NOUN	NN	9	O
SBs	sb	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
R	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
-	-	PUNCT	:	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
95	95	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
049	049	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

DNA	dna	NOUN	NN	9	O
SBs	sb	NOUN	NNS	5	O
damage	damage	NOUN	NN	9	O
was	be	VERB	VBD	9	O
negatively	negatively	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
TAP	TAP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
R	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
-	-	PUNCT	:	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
98	98	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
018	018	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
R	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
-	-	PUNCT	:	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
97	97	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
027	027	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
resistance	resistance	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
plausible	plausible	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
multiple	multiple	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
different	different	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
versus	versus	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Tacrolimus	Tacrolimus	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
seizure	seizure	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
pediatric	pediatric	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
-	-	PUNCT	:	7	O
-	-	PUNCT	:	7	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
center	center	NOUN	NN	5	O
experience	experience	NOUN	NN	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
identify	identify	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
new	new	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
pediatric	pediatric	ADJ	JJ	5	O
LT	LT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
clinical	clinical	ADJ	JJ	5	O
implications	implication	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
prognosis	prognosis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
data	datum	NOUN	NNS	5	O
of	of	ADP	IN	5	O
27	27	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
children	child	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
LT	LT	PROPN	NNP	9	O
from	from	ADP	IN	9	O
January	January	PROPN	NNP	2	O
2007	2007	NUM	CD	2	O
to	to	ADP	IN	5	O
December	December	PROPN	NNP	2	O
2010	2010	NUM	CD	2	O
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
center	center	NOUN	NN	5	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
retrospectively	retrospectively	ADV	RB	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
seizures	seizure	NOUN	NNS	5	B-Disease
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
intra	intra	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
operative	operative	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Seizures	Seizures	PROPN	NNP	5	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
children	child	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
exhibited	exhibit	VERB	VBD	9	O
generalized	generalized	ADJ	JJ	5	O
tonic	tonic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
clonic	clonic	NOUN	NN	5	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
two	two	NUM	CD	5	O
wk	wk	ADP	IN	9	O
after	after	ADP	IN	9	O
LT	LT	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Univariate	univariate	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
pediatric	pediatric	ADJ	JJ	5	O
LT	LT	PROPN	NNP	9	O
included	include	VERB	VBD	5	O
gender	gender	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pediatric	pediatric	ADJ	JJ	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
liver	liver	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
score	score	NOUN	NN	5	O
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
Child	child	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
Pugh	pugh	VERB	VB	6	O
score	score	NOUN	NN	5	O
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
total	total	ADJ	JJ	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
trough	trough	NOUN	NN	9	O
TAC	TAC	PROPN	NNP	9	B-Chemical
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Multivariate	Multivariate	PROPN	NNP	5	O
analysis	analysis	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
trough	trough	NOUN	NN	9	O
TAC	TAC	PROPN	NNP	9	B-Chemical
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
independent	independent	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
children	child	NOUN	NNS	5	O
who	who	PRON	WP	5	O
experienced	experience	VERB	VBD	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
survived	survive	VERB	VBD	9	O
with	with	ADP	IN	5	O
good	good	ADJ	JJ	5	O
graft	graft	NOUN	NN	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
remained	remain	VERB	VBD	9	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
without	without	ADP	IN	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
drugs	drug	NOUN	NNS	5	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
trough	trough	NOUN	NN	9	O
TAC	tac	NOUN	NN	9	B-Chemical
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
predominant	predominant	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
that	that	DET	WDT	5	O
contributed	contribute	VERB	VBD	9	O
to	to	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
after	after	ADP	IN	9	O
pediatric	pediatric	ADJ	JJ	5	O
LT	LT	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
PELD	PELD	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Child	Child	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
Pugh	Pugh	PROPN	NNP	6	O
scores	score	NOUN	NNS	5	O
before	before	ADP	IN	9	O
LT	LT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
serum	serum	NOUN	NN	9	O
Tbil	Tbil	PROPN	NNP	7	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
contributory	contributory	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
TAC	tac	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
flavonoid	flavonoid	NOUN	NN	0	B-Chemical
apigenin	apigenin	NOUN	NN	0	B-Chemical
delays	delay	NOUN	NNS	5	O
forgetting	forgetting	NOUN	NN	5	O
of	of	ADP	IN	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
conditioning	conditioning	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
experiments	experiment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
flavonoid	flavonoid	NOUN	NN	0	B-Chemical
apigenin	apigenin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADV	RB	0	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
h	h	NOUN	NN	0	O
before	before	ADP	IN	9	O
acquisition	acquisition	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
24	24	NUM	CD	9	O
h	h	DET	DT	0	O
retention	retention	NOUN	NN	9	O
performance	performance	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
forgetting	forgetting	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
step	step	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
through	through	PART	RP	9	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
apigenin	apigenin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
groups	group	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
24	24	NUM	CD	9	O
h	h	DET	DT	0	O
retention	retention	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
apigenin	apigenin	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1mg	1mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
acquisition	acquisition	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
apigenin	apigenin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
step	step	VERB	VB	9	O
through	through	PART	RP	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
dark	dark	ADJ	JJ	9	O
compartment	compartment	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
cut	cut	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
off	off	PART	RP	5	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
540	540	NUM	CD	9	O
s	s	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
retested	reteste	VERB	VBN	9	O
weekly	weekly	ADV	RB	5	O
for	for	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
eight	eight	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
saline	saline	NOUN	NN	0	O
treated	treat	VERB	VBD	3	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
significant	significant	ADJ	JJ	9	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
at	at	ADP	IN	9	O
four	four	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
complete	complete	ADJ	JJ	9	O
memory	memory	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
five	five	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
acquisition	acquisition	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
apigenin	apigenin	NOUN	NN	0	B-Chemical
still	still	ADV	RB	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
step	step	VERB	VB	9	O
through	through	ADV	RB	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
apigenin	apigenin	NOUN	NN	0	B-Chemical
delays	delay	NOUN	NNS	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
forgetting	forgetting	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
modulate	modulate	VERB	VB	9	O
the	the	DET	DT	5	O
24	24	NUM	CD	9	O
h	h	DET	DT	0	O
retention	retention	NOUN	NN	9	O
of	of	ADP	IN	5	O
fear	fear	NOUN	NN	5	O
memory	memory	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
obtained	obtained	ADJ	JJ	9	O
beneficial	beneficial	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
apigenin	apigenin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
conditioning	conditioning	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
mechanisms	mechanism	NOUN	NNS	9	O
that	that	DET	WDT	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
implicate	implicate	VERB	VB	9	O
its	-PRON-	DET	PRP$	9	O
action	action	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
cholinergic	cholinergic	NOUN	NN	3	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Histamine	histamine	NOUN	NN	0	B-Chemical
antagonists	antagonist	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
d	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tubocurarine	tubocurarine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
surgical	surgical	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hemodynamic	hemodynamic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
histamine	histamine	NOUN	NN	0	B-Chemical
release	release	NOUN	NN	9	O
by	by	ADP	IN	9	O
bolus	bolus	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tubocurarine	tubocurarine	NOUN	NN	0	I-Chemical
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

H1	H1	PROPN	NNP	9	O
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
H2	H2	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
histamine	histamine	NOUN	NN	0	B-Chemical
antagonists	antagonist	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
before	before	ADP	IN	9	O
dosing	dose	VERB	VBG	9	O
with	with	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tubocurarine	tubocurarine	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
fashion	fashion	NOUN	NN	5	O
to	to	ADP	IN	5	O
four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
group	group	NOUN	NN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
placebo	placebo	NOUN	NN	9	O
;	;	PUNCT	:	9	O
group	group	NOUN	NN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
plus	plus	CCONJ	CC	9	O
placebo	placebo	NOUN	NN	9	O
;	;	PUNCT	,	9	O
group	group	NOUN	NN	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
chlorpheniramine	chlorpheniramine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
plus	plus	CCONJ	CC	9	O
placebo	placebo	NOUN	NN	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
group	group	NOUN	NN	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
chlorpheniramine	chlorpheniramine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Histamine	histamine	ADJ	JJ	0	B-Chemical
release	release	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
level	level	NOUN	NN	9	O
2	2	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
d	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tubocurarine	tubocurarine	NOUN	NN	0	I-Chemical
dosing	dosing	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Group	group	NOUN	NN	9	O
1	1	NUM	CD	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
moderate	moderate	ADJ	JJ	9	O
negative	negative	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
histamine	histamine	NOUN	NN	0	B-Chemical
change	change	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
58	58	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
not	not	ADV	RB	5	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

Prior	prior	ADV	RB	9	O
dosing	dose	VERB	VBG	9	O
with	with	ADP	IN	5	O
antagonists	antagonist	NOUN	NNS	3	O
partially	partially	ADV	RB	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tubocurarine	tubocurarine	NOUN	NN	0	I-Chemical
dosing	dosing	NOUN	NN	9	O
are	be	VERB	VBP	5	O
only	only	ADV	RB	9	O
partially	partially	ADV	RB	9	O
explained	explain	VERB	VBN	5	O
by	by	ADP	IN	9	O
histamine	histamine	ADJ	JJ	0	B-Chemical
release	release	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
prior	prior	ADV	RB	9	O
dosing	dose	VERB	VBG	9	O
with	with	ADP	IN	5	O
H1	H1	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
H2	H2	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
antagonists	antagonist	NOUN	NNS	3	O
provides	provide	VERB	VBZ	5	O
only	only	ADV	RB	9	O
partial	partial	ADJ	JJ	9	O
protection	protection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cholecystokinin	cholecystokinin	ADJ	JJ	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
octapeptide	octapeptide	NOUN	NN	0	I-Chemical
restored	restore	VERB	VBN	3	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hippocampal	hippocampal	ADJ	JJ	3	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
potentiation	potentiation	NOUN	NN	3	O
impairment	impairment	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Cholecystokinin	cholecystokinin	ADJ	JJ	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
octapeptide	octapeptide	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
typical	typical	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
gut	gut	NOUN	NN	9	O
peptide	peptide	NOUN	NN	9	O
,	,	PUNCT	,	9	O
exerts	exert	VERB	VBZ	9	O
a	a	DET	DT	5	O
wide	wide	ADJ	JJ	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
biological	biological	ADJ	JJ	5	O
activities	activity	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
that	that	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
significantly	significantly	ADV	RB	9	O
alleviated	alleviate	VERB	VBD	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
reversed	reverse	VERB	VBD	9	O
spine	spine	NOUN	NN	5	O
density	density	NOUN	NN	9	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
CA1	CA1	PROPN	NNPS	3	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
in	in	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	NUM	CD	9	I-Chemical
on	on	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
potentiation	potentiation	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
LTP	LTP	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
perforant	perforant	NOUN	NN	5	O
path	path	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
LPP	LPP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
granule	granule	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
synapse	synapse	NOUN	NN	5	O
of	of	ADP	IN	5	O
rat	rat	X	FW	3	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DG	DG	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Population	population	NOUN	NN	5	O
spikes	spike	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
PS	PS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
evoked	evoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
LPP	LPP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
DG	DG	PROPN	NNP	9	O
region	region	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30mg	30mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBD	3	O
hippocampal	hippocampal	ADJ	JJ	3	O
LTP	LTP	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
1ug	1ug	NOUN	NN	3	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
restored	restore	VERB	VBD	3	O
the	the	DET	DT	5	O
amplitude	amplitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
PS	PS	PROPN	NNP	9	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
attenuated	attenuate	VERB	VBN	3	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
1ug	1ug	NOUN	NN	3	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
also	also	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
augmented	augment	VERB	VBD	9	O
hippocampal	hippocampal	ADJ	JJ	3	O
LTP	LTP	PROPN	NNP	3	O
in	in	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
1ml	1ml	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
CCK2	CCK2	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
365	365	NUM	CD	9	O
,	,	PUNCT	,	9	O
260	260	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10ug	10ug	NOUN	NN	3	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
)	)	PUNCT	-RRB-	9	O
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
CCK1	CCK1	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
364	364	NUM	CD	7	O
,	,	PUNCT	,	9	O
718	718	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
10ug	10ug	NOUN	NN	3	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
attenuates	attenuate	VERB	VBZ	3	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
LTP	LTP	PROPN	NNP	3	O
through	through	ADP	IN	9	O
CCK2	CCK2	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
suggest	suggest	VERB	VBP	9	O
an	an	DET	DT	5	O
ameliorative	ameliorative	ADJ	JJ	0	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	NUM	CD	9	I-Chemical
on	on	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Glial	glial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
synaptic	synaptic	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
key	key	ADJ	JJ	9	O
events	event	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Streptozotocin	Streptozotocin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ICV	ICV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBN	3	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
glial	glial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
post	post	VERB	VB	9	O
synaptic	synaptic	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
ICV	ICV	PROPN	NNP	9	O
Streptozotocin	Streptozotocin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBD	3	O
memory	memory	NOUN	NN	5	B-Disease
impaired	impaired	ADJ	JJ	9	I-Disease
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
explored	explore	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
experiment	experiment	NOUN	NN	9	O
set	set	VERB	VBN	5	O
up	up	PART	RP	5	O
1	1	NUM	CD	9	O
:	:	PUNCT	:	9	O
Memory	memory	NOUN	NN	5	B-Disease
deficit	deficit	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
Morris	Morris	PROPN	NNP	6	O
water	water	NOUN	NN	0	O
maze	maze	NOUN	NN	5	O
test	test	NOUN	NN	5	O
on	on	ADP	IN	5	O
14	14	NUM	CD	7	O
-	-	SYM	SYM	7	O
16	16	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ICV	ICV	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
3mg	3mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
Kg	Kg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

STZ	STZ	PROPN	NNP	0	B-Chemical
causes	cause	VERB	VBZ	9	O
increased	increase	VERB	VBD	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
GFAP	GFAP	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
CD11b	CD11b	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
TNF	TNF	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
a	a	DET	DT	5	O
indicating	indicate	VERB	VBG	9	O
glial	glial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
neuroinflammation	neuroinflammation	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

STZ	STZ	PROPN	NNP	0	B-Chemical
also	also	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
ROS	ROS	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
nitrite	nitrite	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
synaptosomal	synaptosomal	ADJ	JJ	3	O
preparation	preparation	NOUN	NN	9	O
illustrating	illustrate	VERB	VBG	9	O
free	free	ADJ	JJ	9	O
radical	radical	ADJ	JJ	0	O
generation	generation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
excitotoxicity	excitotoxicity	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
Caspase	Caspase	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
3	3	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
treated	treated	ADJ	JJ	3	O
rat	rat	NOUN	NN	3	O
which	which	DET	WDT	5	O
specify	specify	VERB	VBP	5	O
apoptotic	apoptotic	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
hippocampus	hippocampus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

STZ	STZ	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
decrease	decrease	NOUN	NN	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
post	post	ADJ	JJ	9	O
synaptic	synaptic	ADJ	JJ	5	O
markers	marker	NOUN	NNS	3	O
CaMKIIa	CaMKIIa	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
PSD	PSD	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
95	95	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
,	,	PUNCT	,	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
synaptic	synaptic	ADJ	JJ	5	O
markers	marker	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
synaptophysin	synaptophysin	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
SNAP	SNAP	PROPN	NNPS	9	O
-	-	PUNCT	HYPH	7	O
25	25	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
remains	remain	VERB	VBZ	9	O
unaltered	unaltered	ADJ	JJ	9	O
indicating	indicate	VERB	VBG	9	O
selective	selective	ADJ	JJ	9	O
post	post	NOUN	NN	9	O
synaptic	synaptic	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
Memantine	Memantine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10mg	10mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Ibuprofen	Ibuprofen	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
13	13	NUM	CD	7	O
days	day	NOUN	NNS	9	O
attenuated	attenuate	VERB	VBN	3	O
STZ	STZ	PROPN	NNP	0	B-Chemical
induced	induced	ADJ	JJ	3	O
glial	glial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
apoptotic	apoptotic	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
post	post	VERB	VB	9	O
synaptic	synaptic	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Further	further	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
experiment	experiment	NOUN	NN	9	O
set	set	VERB	VBN	5	O
up	up	PART	RP	5	O
2	2	NUM	CD	9	O
:	:	PUNCT	:	9	O
where	where	ADV	WRB	5	O
memory	memory	NOUN	NN	5	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
9	9	NUM	CD	7	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
GFAP	GFAP	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
CD11b	CD11b	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
TNF	TNF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
a	a	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
ROS	ROS	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
nitrite	nitrite	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
apoptotic	apoptotic	ADJ	JJ	3	O
marker	marker	NOUN	NN	3	O
,	,	PUNCT	,	9	O
synaptic	synaptic	ADJ	JJ	5	O
markers	marker	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
remained	remain	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Collective	collective	ADJ	JJ	5	O
data	data	NOUN	NN	5	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
neuroinflammatory	neuroinflammatory	ADJ	JJ	3	B-Disease
process	process	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
occurs	occur	VERB	VBZ	9	O
earlier	earlier	ADV	RBR	9	O
to	to	ADP	IN	5	O
apoptosis	apoptosis	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
memory	memory	NOUN	NN	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Present	present	ADJ	JJ	7	O
study	study	NOUN	NN	9	O
clearly	clearly	ADV	RB	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
glial	glial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
post	post	VERB	VB	9	O
synaptic	synaptic	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
key	key	ADJ	JJ	9	O
factors	factor	NOUN	NNS	9	O
in	in	ADP	IN	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
induced	induced	ADJ	JJ	3	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
neuronal	neuronal	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
isotonic	isotonic	ADJ	JJ	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
with	with	ADP	IN	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
in	in	ADP	IN	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

INTRODUCTION	INTRODUCTION	PROPN	NNP	5	O
AND	and	CCONJ	CC	2	O
OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Contrast	contrast	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
CIN	CIN	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
significantly	significantly	ADV	RB	9	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
and	and	CCONJ	CC	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
isotonic	isotonic	ADJ	JJ	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
with	with	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
bicarbonate	bicarbonate	NOUN	NN	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
isotonic	isotonic	ADJ	JJ	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
with	with	ADP	IN	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
CIN	CIN	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
study	study	NOUN	NN	9	O
included	include	VERB	VBD	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
30	30	NUM	CD	9	O
-	-	SYM	SYM	7	O
60	60	NUM	CD	9	O
mL	ml	NOUN	NN	0	O
of	of	ADP	IN	5	O
iodinated	iodinate	VERB	VBN	0	O
contrast	contrast	NOUN	NN	9	B-Chemical
agent	agent	NOUN	NN	9	O
for	for	ADP	IN	5	O
percutaneous	percutaneous	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PCAG	PCAG	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
with	with	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
values	value	NOUN	NNS	5	O
between	between	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
isotonic	isotonic	ADJ	JJ	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
a	a	DET	DT	5	O
solution	solution	NOUN	NN	0	O
that	that	ADP	IN	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
dextrose	dextrose	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
bicarbonate	bicarbonate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
isotonic	isotonic	ADJ	JJ	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
contrast	contrast	NOUN	NN	9	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
first	first	ADJ	JJ	9	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
contrast	contrast	NOUN	NN	9	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
plasma	plasma	NOUN	NN	9	O
blood	blood	NOUN	NN	9	B-Chemical
urea	urea	ADJ	JJ	0	I-Chemical
nitrogen	nitrogen	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BUN	BUN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
seventh	seventh	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
contrast	contrast	NOUN	NN	9	B-Chemical
material	material	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
16	16	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ARF	ARF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	B-Chemical
material	material	NOUN	NN	5	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
ARF	ARF	PROPN	NNP	9	B-Disease
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
five	five	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
six	six	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
five	five	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
isotonic	isotonic	ADJ	JJ	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
bicarbonate	bicarbonate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
isotonic	isotonic	ADJ	JJ	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
with	with	ADP	IN	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
application	application	NOUN	NN	5	O
in	in	ADP	IN	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
CIN	CIN	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Neurocognitive	neurocognitive	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
neuroradiologic	neuroradiologic	ADJ	JJ	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
late	late	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
on	on	ADP	IN	5	O
Pediatric	Pediatric	PROPN	NNP	2	O
Oncology	Oncology	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
POG	POG	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
P9605	P9605	PROPN	NNP	4	O
(	(	PUNCT	-LRB-	9	O
standard	standard	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
P9201	p9201	NOUN	NN	_	O
(	(	PUNCT	-LRB-	9	O
lesser	less	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
protocols	protocol	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
ACCL0131	ACCL0131	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
consequence	consequence	NOUN	NN	5	O
?	?	PUNCT	.	5	O

A	a	DET	DT	9	O
report	report	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
Children	Children	PROPN	NNPS	5	O
'	'	PART	POS	9	O
s	s	PROPN	NNP	9	O
Oncology	Oncology	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Concerns	concern	NOUN	NNS	5	O
about	about	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
MTX	MTX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
1990s	1990s	NUM	CD	5	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
modifications	modification	NOUN	NNS	9	O
in	in	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
IT	it	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
leucovorin	leucovorin	ADJ	JJ	0	O
rescue	rescue	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
MTX	MTX	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
neurocognitive	neurocognitive	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
neuroradiologic	neuroradiologic	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
leukoencephalopathy	leukoencephalopathy	ADJ	JJ	5	B-Disease
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intense	intense	ADJ	JJ	9	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CNS	CNS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
directed	direct	VERB	VBN	9	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P9605	P9605	PROPN	NNP	4	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
those	those	DET	DT	5	O
receiving	receive	VERB	VBG	9	O
fewer	few	ADJ	JJR	5	O
CNS	CNS	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
directed	direct	VERB	VBN	9	O
treatment	treatment	NOUN	NN	9	O
days	day	NOUN	NNS	9	O
during	during	ADP	IN	5	O
intensive	intensive	ADJ	JJ	5	O
consolidation	consolidation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P9201	P9201	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
66	66	NUM	CD	7	O
children	child	NOUN	NNS	5	O
from	from	ADP	IN	9	O
16	16	NUM	CD	9	O
Pediatric	Pediatric	PROPN	NNP	2	O
Oncology	Oncology	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
institutions	institution	NOUN	NNS	5	O
with	with	ADP	IN	5	O
"	"	PUNCT	``	5	O
standard	standard	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
"	"	PUNCT	``	5	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
00	00	NUM	CD	7	O
to	to	ADP	IN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
99	99	NUM	CD	7	O
years	year	NOUN	NNS	5	O
at	at	ADP	IN	9	O
diagnosis	diagnosis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
CNS	CNS	PROPN	NNP	9	O
leukemia	leukemia	NOUN	NN	3	B-Disease
at	at	ADP	IN	9	O
diagnosis	diagnosis	NOUN	NN	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
on	on	ADP	IN	5	O
ACCL0131	ACCL0131	PROPN	NNP	_	O
:	:	PUNCT	:	9	O
28	28	NUM	CD	7	O
from	from	ADP	IN	9	O
P9201	p9201	NOUN	NN	_	O
and	and	CCONJ	CC	5	O
38	38	NUM	CD	7	O
from	from	ADP	IN	9	O
P9605	P9605	PROPN	NNP	4	O
.	.	PUNCT	.	9	O

Magnetic	magnetic	ADJ	JJ	5	O
resonance	resonance	NOUN	NN	5	O
imaging	image	VERB	VBG	5	O
scans	scan	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
standard	standard	ADJ	JJ	5	O
neuropsychological	neuropsychological	ADJ	JJ	5	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
>	>	X	XX	0	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Significantly	significantly	ADV	RB	9	O
more	more	ADJ	JJR	5	O
P9605	p9605	NOUN	NN	4	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
leukoencephalopathy	leukoencephalopathy	ADV	RB	5	B-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
P9201	p9201	NOUN	NN	_	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
68	68	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
49	49	NUM	CD	7	O
%	%	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
83	83	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
identified	identify	VERB	VBN	9	O
as	as	ADV	RB	5	O
late	late	ADV	RB	9	O
as	as	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
scored	score	VERB	VBN	5	O
<	<	X	XX	0	O
85	85	NUM	CD	9	O
on	on	ADP	IN	5	O
either	either	CCONJ	CC	9	O
Verbal	Verbal	PROPN	NNP	5	O
or	or	CCONJ	CC	5	O
Performance	Performance	PROPN	NNP	5	O
IQ	IQ	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Children	child	NOUN	NNS	5	O
on	on	ADP	IN	5	O
both	both	DET	DT	9	O
studies	study	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
attention	attention	NOUN	NN	5	B-Disease
problems	problem	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
P9605	p9605	NOUN	NN	4	O
children	child	NOUN	NNS	5	O
scored	score	VERB	VBD	5	O
below	below	ADP	IN	9	O
average	average	NOUN	NN	5	O
on	on	ADP	IN	5	O
more	more	ADV	RBR	5	O
neurocognitive	neurocognitive	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
treated	treat	VERB	VBN	3	O
on	on	ADP	IN	5	O
P9201	P9201	PROPN	NNP	_	O
(	(	PUNCT	-LRB-	9	O
82	82	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
/	/	SYM	SYM	9	O
17	17	NUM	CD	7	O
measures	measure	NOUN	NNS	5	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
/	/	SYM	SYM	9	O
17	17	NUM	CD	7	O
measures	measure	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
supports	support	VERB	VBZ	9	O
ongoing	ongoing	ADJ	JJ	5	O
concerns	concern	NOUN	NNS	5	O
about	about	ADP	IN	5	O
intensive	intensive	ADJ	JJ	5	O
MTX	MTX	PROPN	NNP	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
contributor	contributor	NOUN	NN	9	O
to	to	ADP	IN	5	O
CNS	CNS	PROPN	NNP	9	O
late	late	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
overdosage	overdosage	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
generalized	generalized	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
45	45	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
lady	lady	NOUN	NN	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
stage	stage	NOUN	NN	9	O
4	4	NUM	CD	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
tubulointerstial	tubulointerstial	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
center	center	NOUN	NN	5	O
for	for	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
anemia	anemia	NOUN	NN	9	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
menorrhagia	menorrhagia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
deterioration	deterioration	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
infused	infuse	VERB	VBN	9	O
three	three	NUM	CD	9	O
units	unit	NOUN	NNS	9	O
of	of	ADP	IN	5	O
packed	packed	ADJ	JJ	0	O
cells	cell	NOUN	NNS	3	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
session	session	NOUN	NN	5	O
of	of	ADP	IN	5	O
hemodialysis	hemodialysis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Tranexamic	Tranexamic	PROPN	NNP	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
TNA	TNA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
g	g	NOUN	NN	0	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hourly	hourly	ADJ	JJ	5	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
her	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
bleeding	bleeding	NOUN	NN	5	B-Disease
per	per	ADP	IN	9	O
vaginum	vaginum	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
sixth	sixth	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
TNA	TNA	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
generalized	generalized	ADJ	JJ	5	O
tonic	tonic	NOUN	NN	5	B-Disease
clonic	clonic	NOUN	NN	5	I-Disease
convulsions	convulsion	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

TNA	TNA	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Investigations	investigation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
no	no	DET	DT	9	O
biochemical	biochemical	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
structural	structural	ADJ	JJ	9	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	B-Disease
system	system	NOUN	NN	5	I-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
that	that	DET	WDT	5	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
provoked	provoke	VERB	VBN	9	O
the	the	DET	DT	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
require	require	VERB	VB	5	O
any	any	DET	DT	5	O
further	further	ADJ	JJ	9	O
dialytic	dialytic	ADJ	JJ	5	O
support	support	NOUN	NN	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
further	further	ADJ	JJ	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
convulsion	convulsion	NOUN	NN	5	B-Disease
till	till	ADP	IN	9	O
dis	dis	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
charge	charge	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
precipitating	precipitating	NOUN	NN	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
believed	believe	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
overdose	overdose	NOUN	NN	0	B-Disease
of	of	ADP	IN	5	O
TNA	TNA	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
depression	depression	NOUN	NN	5	I-Disease
using	use	VERB	VBG	9	O
different	different	ADJ	JJ	9	O
lipid	lipid	NOUN	NN	0	O
formulations	formulation	NOUN	NNS	0	O
of	of	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
emulsions	emulsion	NOUN	NNS	0	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
lethal	lethal	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
lipid	lipid	NOUN	NN	0	O
content	content	NOUN	NN	9	O
of	of	ADP	IN	5	O
propofol	propofol	X	FW	0	B-Chemical
may	may	VERB	MD	5	O
alleviate	alleviate	VERB	VB	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
intralipid	intralipid	NOUN	NNS	0	O
or	or	CCONJ	CC	5	O
medialipid	medialipid	ADJ	JJ	_	O
emulsions	emulsion	NOUN	NNS	0	O
on	on	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
anaesthetised	anaesthetise	VERB	VBN	5	O
with	with	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
propofol	propofol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
intralipid	intralipid	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
P	P	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
propofol	propofol	ADJ	JJ	0	B-Chemical
in	in	ADP	IN	5	O
medialipid	medialipid	NOUN	NN	_	O
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
L	L	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
C	C	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
over	over	ADP	IN	5	O
20	20	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Thereafter	thereafter	ADV	RB	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
was	be	VERB	VBD	9	O
infused	infuse	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recorded	record	VERB	VBD	5	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
first	first	ADJ	JJ	9	O
dysrhythmia	dysrhythmia	NOUN	NN	5	B-Disease
occurrence	occurrence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
respective	respective	ADJ	JJ	9	O
times	time	NOUN	NNS	5	O
to	to	ADP	IN	5	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HR	hr	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
mean	mean	VERB	VB	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
time	time	NOUN	NN	5	O
to	to	PART	TO	5	O
asystole	asystole	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tissue	tissue	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
following	follow	VERB	VBG	9	O
asystole	asystole	ADV	RB	5	B-Disease
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
first	first	ADJ	JJ	9	O
dysrhythmia	dysrhythmia	NOUN	NN	5	B-Disease
occurrence	occurrence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
HR	hr	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
asystole	asystole	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
longer	long	ADJ	JJR	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
P	P	PROPN	NNP	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
given	give	VERB	VBN	5	O
at	at	ADP	IN	9	O
those	those	DET	DT	5	O
time	time	NOUN	NN	5	O
points	point	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
P	P	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
Plasma	plasma	ADJ	JJ	0	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
P	P	PROPN	NNP	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
C	C	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
Bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
P	P	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
Group	Group	PROPN	NNP	9	O
L	L	PROPN	NNP	0	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
C	C	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	NOUN	NN	7	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
intralipid	intralipid	NOUN	NN	0	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
medialipid	medialipid	NOUN	NN	_	O
or	or	CCONJ	CC	5	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
delayed	delay	VERB	VBD	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxic	cardiotoxic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
reduced	reduce	VERB	VBN	9	O
plasma	plasma	NOUN	NN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
explore	explore	VERB	VB	5	O
tissue	tissue	NOUN	NN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
medialipid	medialipid	NOUN	NN	_	O
and	and	CCONJ	CC	5	O
adapt	adapt	VERB	VB	5	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
to	to	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Induced	Induced	PROPN	NNP	9	I-Disease
Acute	Acute	PROPN	NNP	5	I-Disease
Liver	Liver	PROPN	NNP	9	I-Disease
Injury	Injury	PROPN	NNP	5	I-Disease
Within	within	ADP	IN	9	O
12	12	NUM	CD	9	O
Hours	hour	NOUN	NNS	7	O
After	after	ADP	IN	9	O
Fluvastatin	Fluvastatin	PROPN	NNP	7	B-Chemical
Therapy	Therapy	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
statins	statin	NOUN	NNS	5	B-Chemical
are	be	VERB	VBP	5	O
generally	generally	ADV	RB	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
recent	recent	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
liver	liver	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
use	use	NOUN	NN	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
52	52	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Chinese	chinese	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
reported	report	VERB	VBD	9	O
with	with	ADP	IN	5	O
liver	liver	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
appeared	appear	VERB	VBD	9	O
12	12	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
beginning	begin	VERB	VBG	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
fluvastatin	fluvastatin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Patient	Patient	PROPN	NNP	5	O
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
complaints	complaint	NOUN	NNS	5	O
of	of	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
anorexia	anorexia	INTJ	UH	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
upper	upper	ADJ	JJ	9	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
laboratory	laboratory	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
elevated	elevated	ADJ	JJ	9	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
transaminases	transaminase	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Testing	test	VERB	VBG	5	O
for	for	ADP	IN	5	O
autoantibodies	autoantibody	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
negative	negative	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
biochemistries	biochemistry	NOUN	NNS	5	O
eventually	eventually	ADV	RB	5	O
normalized	normalize	VERB	VBN	9	O
within	within	ADP	IN	9	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
stopping	stop	VERB	VBG	5	O
the	the	DET	DT	5	O
fluvastatin	fluvastatin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
prescribing	prescribe	VERB	VBG	5	O
statins	statin	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
taken	take	VERB	VBN	5	O
into	into	ADP	IN	9	O
account	account	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fluconazole	fluconazole	NOUN	NN	0	B-Chemical
associated	associate	VERB	VBD	9	O
agranulocytosis	agranulocytosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
associated	associate	VERB	VBN	9	O
agranulocytosis	agranulocytosis	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
recovery	recovery	NOUN	NN	9	O
upon	upon	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
began	begin	VERB	VBD	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
white	white	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
platelets	platelet	NOUN	NNS	3	O
within	within	ADP	IN	9	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
began	begin	VERB	VBD	5	O
to	to	PART	TO	5	O
recover	recover	VERB	VB	9	O
with	with	ADP	IN	5	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
of	of	ADP	IN	5	O
discontinuation	discontinuation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
highlights	highlight	VERB	VBZ	5	O
that	that	DET	WDT	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
blood	blood	NOUN	NN	9	B-Disease
dyscrasias	dyscrasia	NOUN	NNS	5	I-Disease
can	can	VERB	MD	5	O
occur	occur	VERB	VB	5	O
unexpectedly	unexpectedly	ADV	RB	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
drug	drug	NOUN	NN	5	O
thought	think	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
"	"	PUNCT	``	5	O
safe	safe	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
According	accord	VERB	VBG	5	O
to	to	ADP	IN	5	O
Naranjo	Naranjo	PROPN	NNP	6	O
'	'	PUNCT	''	9	O
s	s	PRON	PRP	9	O
algorithm	algorithm	VERB	VB	5	O
the	the	DET	DT	5	O
likelihood	likelihood	NOUN	NN	5	O
that	that	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
agranulocytosis	agranulocytosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
occurred	occur	VERB	VBD	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
probable	probable	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
points	point	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
feel	feel	VERB	VBP	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
weight	weight	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
evidence	evidence	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
strong	strong	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
particular	particular	ADJ	JJ	5	O
the	the	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
of	of	ADP	IN	5	O
bone	bone	NOUN	NN	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
suppression	suppression	NOUN	NN	9	I-Disease
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
abatement	abatement	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
that	that	DET	WDT	5	O
rapidly	rapidly	ADV	RB	9	O
reversed	reverse	VERB	VBD	9	O
immediately	immediately	ADV	RB	9	O
following	follow	VERB	VBG	9	O
discontinuation	discontinuation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
dimensional	dimensional	ADJ	JJ	5	O
speckle	speckle	NOUN	NN	5	O
tracking	track	VERB	VBG	5	O
echocardiography	echocardiography	NOUN	NN	5	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
troponin	troponin	NOUN	NN	9	O
T	t	NOUN	NN	3	O
in	in	ADP	IN	5	O
early	early	ADJ	JJ	9	O
detection	detection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prediction	prediction	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
during	during	ADP	IN	5	O
epirubicine	epirubicine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

AIMS	aims	NOUN	NN	5	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
alterations	alteration	NOUN	NNS	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
strain	strain	NOUN	NN	1	I-Disease
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
troponin	troponin	NOUN	NN	9	O
T	t	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
cTnT	ctnt	NUM	CD	3	O
)	)	PUNCT	-RRB-	9	O
could	could	VERB	MD	9	O
predict	predict	VERB	VB	5	O
future	future	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
epirubicin	epirubicin	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Seventy	seventy	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
non	non	ADJ	JJ	9	B-Disease
-	-	PROPN	NNP	7	I-Disease
Hodgkin	hodgkin	ADJ	JJ	5	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
epirubicin	epirubicin	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
collection	collection	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
echocardiography	echocardiography	NOUN	NN	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
cycle	cycle	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
using	use	VERB	VBG	9	O
echocardiography	echocardiography	NOUN	NN	5	O
during	during	ADP	IN	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Global	global	ADJ	JJ	5	O
longitudinal	longitudinal	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
GLS	GLS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
circumferential	circumferential	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
GCS	GCS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
radial	radial	ADJ	JJ	5	O
strain	strain	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
GRS	GRS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
using	use	VERB	VBG	9	O
speckle	speckle	ADJ	JJ	5	O
tracking	tracking	NOUN	NN	5	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Left	leave	VERB	VBN	9	O
ventricular	ventricular	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
analysed	analyse	VERB	VBN	9	O
by	by	ADP	IN	9	O
real	real	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
3D	3d	NOUN	NN	5	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cardiotoxicity	Cardiotoxicity	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
LVEF	LVEF	PROPN	NNP	5	O
of	of	ADP	IN	5	O
>	>	X	XX	0	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
<	<	X	XX	0	O
55	55	NUM	CD	7	O
%	%	NOUN	NN	9	O
with	with	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
an	an	DET	DT	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
LVEF	LVEF	PROPN	NNP	5	O
of	of	ADP	IN	5	O
>	>	X	XX	0	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
<	<	X	XX	0	O
55	55	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Fourteen	fourteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
67	67	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

GLS	GLS	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
48	48	NUM	CD	9	O
+	+	SYM	SYM	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
72	72	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
-	-	PUNCT	:	7	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
96	96	NUM	CD	9	O
+	+	SYM	SYM	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
GCS	GCS	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
93	93	NUM	CD	7	O
+	+	SYM	SYM	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
86	86	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
-	-	PUNCT	:	7	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
20	20	NUM	CD	9	O
+	+	SYM	SYM	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
GRS	GRS	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
39	39	NUM	CD	7	O
.	.	PUNCT	.	9	O
23	23	NUM	CD	7	O
+	+	SYM	SYM	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
.	.	PUNCT	.	9	O
98	98	NUM	CD	7	O
+	+	SYM	SYM	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
cTnT	ctnt	NUM	CD	3	O
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0010	0010	NUM	CD	7	O
+	+	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0020	0020	NUM	CD	2	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0073	0073	NUM	CD	7	O
+	+	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0038	0038	NUM	CD	7	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
all	all	DET	DT	5	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
baseline	baseline	ADJ	JJ	5	O
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
>	>	X	XX	0	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
GLS	GLS	PROPN	NNP	9	O
[	[	PUNCT	-LRB-	9	O
sensitivity	sensitivity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
86	86	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
specificity	specificity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	,	9	O
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
curve	curve	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
AUC	AUC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
=	=	VERB	VBZ	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
815	815	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
]	]	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
004	004	NUM	CD	7	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
elevation	elevation	NOUN	NN	9	O
in	in	ADP	IN	5	O
cTnT	ctnt	NUM	CD	3	O
(	(	PUNCT	-LRB-	9	O
sensitivity	sensitivity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
79	79	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
specificity	specificity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
64	64	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
AUC	AUC	PROPN	NNP	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
757	757	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
cycle	cycle	NOUN	NN	9	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
predicted	predict	VERB	VBD	9	O
later	later	ADJ	JJ	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
GLS	GLS	PROPN	NNP	9	O
remained	remain	VERB	VBD	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
independent	independent	ADJ	JJ	9	O
predictor	predictor	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
000	000	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
GLS	GLS	PROPN	NNP	9	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
cTnT	ctnt	NUM	CD	3	O
may	may	VERB	MD	5	O
provide	provide	VERB	VB	5	O
a	a	DET	DT	5	O
reliable	reliable	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
invasive	invasive	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
to	to	PART	TO	5	O
predict	predict	VERB	VB	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
anthracycline	anthracycline	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Prevention	prevention	NOUN	NN	2	O
of	of	ADP	IN	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
superior	superior	ADJ	JJ	5	O
:	:	PUNCT	:	9	O
Fentanyl	Fentanyl	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
?	?	PUNCT	.	5	O

A	a	DET	DT	9	O
Retrospective	Retrospective	PROPN	NNP	9	O
comparative	comparative	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
comparative	comparative	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

MATERIAL	MATERIAL	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
records	record	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Depending	depend	VERB	VBG	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
given	give	VERB	VBN	5	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
separated	separate	VERB	VBN	9	O
into	into	ADP	IN	9	O
4	4	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
no	no	DET	DT	9	O
pretreatment	pretreatment	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
NP	NP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
ug	ug	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
F	F	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
M	M	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
015	015	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
ug	ug	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
FM	FM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
anesthetic	anesthetic	ADJ	JJ	5	O
procedure	procedure	NOUN	NN	5	O
were	be	VERB	VBD	9	O
selected	select	VERB	VBN	9	O
:	:	PUNCT	:	9	O
2	2	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pretreatment	pretreatment	ADJ	JJ	0	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
anesthesia	anesthesia	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
induced	induce	VERB	VBN	3	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
injected	inject	VERB	VBN	3	O
intravenously	intravenously	ADV	RB	0	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
seconds	second	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Myoclonic	myoclonic	ADJ	JJ	7	B-Disease
movements	movement	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
evaluated	evaluate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
graded	grade	VERB	VBN	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
severity	severity	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
etomidate	etomidate	VERB	VBP	5	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
due	due	ADJ	JJ	5	O
to	to	PART	TO	5	O
etomidate	etomidate	VERB	VB	5	B-Chemical
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Study	study	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
incidence	incidence	NOUN	NN	5	O
was	be	VERB	VBD	9	O
85	85	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
NP	NP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
Group	Group	PROPN	NNP	9	O
F	F	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
Group	Group	PROPN	NNP	9	O
M	M	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Group	Group	PROPN	NNP	9	O
FM	FM	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
F	F	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
Group	Group	PROPN	NNP	9	O
FM	FM	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	DET	DT	5	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Convulsant	convulsant	ADJ	JJ	2	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
regional	regional	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Lindane	Lindane	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hexachlorocyclohexane	hexachlorocyclohexane	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
organochlorine	organochlorine	NOUN	NN	0	O
insecticide	insecticide	NOUN	NN	5	O
with	with	ADP	IN	5	O
known	know	VERB	VBN	9	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Its	-PRON-	DET	PRP$	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
well	well	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
although	although	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
proposed	propose	VERB	VBN	5	O
that	that	ADP	IN	5	O
lindane	lindane	ADJ	JJ	0	B-Chemical
acts	act	NOUN	NNS	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
competitive	competitive	ADJ	JJ	9	O
antagonist	antagonist	NOUN	NN	3	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	.	7	O
A	a	DET	DT	9	O
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
GABAergic	GABAergic	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
systems	system	NOUN	NNS	5	O
by	by	ADP	IN	9	O
measuring	measure	VERB	VBG	9	O
the	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
metabolites	metabolite	NOUN	NNS	0	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
brain	brain	NOUN	NN	5	O
areas	area	NOUN	NNS	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
animals	animal	NOUN	NNS	9	O
suffered	suffer	VERB	VBD	5	O
tonic	tonic	NOUN	NN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
at	at	ADP	IN	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
lindane	lindane	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
slightly	slightly	ADV	RB	9	O
but	but	CCONJ	CC	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
colliculi	colliculi	NOUN	NNS	5	O
without	without	ADP	IN	9	O
modifications	modification	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
areas	area	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mesencephalon	mesencephalon	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
metabolite	metabolite	ADJ	JJ	0	O
DOPAC	DOPAC	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mesencephalon	mesencephalon	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cholestatic	cholestatic	ADJ	JJ	7	B-Disease
presentation	presentation	NOUN	NN	5	O
of	of	ADP	IN	5	O
yellow	yellow	ADJ	JJ	9	O
phosphorus	phosphorus	NOUN	NN	0	B-Chemical
poisoning	poisoning	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Yellow	yellow	ADJ	JJ	9	O
phosphorus	phosphorus	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
component	component	NOUN	NN	9	O
of	of	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
pesticide	pesticide	NOUN	NN	5	O
pastes	paste	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
fireworks	firework	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
known	known	ADJ	JJ	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Poisoning	poison	VERB	VBG	2	B-Disease
with	with	ADP	IN	5	O
yellow	yellow	ADJ	JJ	9	O
phosphorus	phosphorus	NOUN	NN	0	B-Chemical
classically	classically	ADV	RB	5	O
manifests	manifest	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
need	need	VERB	VB	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
yellow	yellow	ADJ	JJ	9	O
phosphorus	phosphorus	NOUN	NN	0	B-Chemical
poisoning	poisoning	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
florid	florid	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
highlighting	highlight	VERB	VBG	9	O
the	the	DET	DT	5	O
fact	fact	NOUN	NN	9	O
that	that	ADP	IN	5	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
can	can	VERB	MD	5	O
rarely	rarely	ADV	RB	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
presenting	present	VERB	VBG	5	O
feature	feature	NOUN	NN	5	O
of	of	ADP	IN	5	O
yellow	yellow	ADJ	JJ	9	O
phosphorus	phosphorus	NOUN	NN	0	B-Chemical
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Vasovagal	vasovagal	ADJ	JJ	5	B-Disease
syncope	syncope	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
intranasal	intranasal	NOUN	NN	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
pediatric	pediatric	ADJ	JJ	5	O
procedural	procedural	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
syncope	syncope	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
11	11	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
intranasal	intranasal	NOUN	NN	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
sedation	sedation	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
voiding	void	VERB	VBG	5	O
cystourethrogram	cystourethrogram	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
successful	successful	ADJ	JJ	5	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
VCUG	VCUG	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
60	60	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
min	min	NOUN	NN	0	O
recovery	recovery	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
consciousness	consciousness	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
vital	vital	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
presedation	presedation	NOUN	NN	5	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Upon	upon	ADP	IN	9	O
leaving	leave	VERB	VBG	5	O
the	the	DET	DT	5	O
sedation	sedation	NOUN	NN	5	O
area	area	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
collapsed	collapse	VERB	VBD	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
apparent	apparent	ADJ	JJ	9	O
inciting	incite	VERB	VBG	5	O
event	event	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
quickly	quickly	ADV	RB	5	O
regained	regain	VERB	VBD	5	O
consciousness	consciousness	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
injury	injury	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
abnormality	abnormality	NOUN	NN	9	O
found	find	VERB	VBD	9	O
was	be	VERB	VBD	9	O
persistent	persistent	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
she	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
for	for	ADP	IN	5	O
telemetric	telemetric	ADJ	JJ	5	O
observation	observation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
lasted	last	VERB	VBD	5	O
~	~	PUNCT	NFP	9	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
further	further	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
workup	workup	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
no	no	DET	DT	9	O
underlying	underlying	ADJ	JJ	5	O
abnormality	abnormality	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Unanticipated	unanticipated	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
previously	previously	ADV	RB	9	O
unreported	unreported	ADJ	JJ	9	O
outcomes	outcome	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
witnessed	witness	VERB	VBN	5	O
as	as	ADP	IN	5	O
we	-PRON-	PRON	PRP	5	O
expand	expand	VERB	VBP	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
sedatives	sedative	NOUN	NNS	5	O
to	to	ADP	IN	5	O
alternative	alternative	ADJ	JJ	5	O
routes	route	NOUN	NNS	5	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Paradoxical	paradoxical	ADJ	JJ	5	O
severe	severe	ADJ	JJ	5	O
agitation	agitation	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
add	add	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
on	on	PART	RP	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
doses	dose	NOUN	NNS	0	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
schizo	schizo	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
affective	affective	ADJ	JJ	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
35	35	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
suffering	suffering	NOUN	NN	5	O
from	from	ADP	IN	9	O
schizo	schizo	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
affective	affective	ADJ	JJ	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
since	since	ADP	IN	9	O
the	the	DET	DT	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
19	19	NUM	CD	7	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
antipsychotics	antipsychotic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
zuclopenthixol	zuclopenthixol	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1200	1200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
serum	serum	ADJ	JJ	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
=	=	NOUN	NNS	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
85	85	NUM	CD	9	O
mEq	meq	NOUN	NN	0	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
associated	associate	VERB	VBN	9	O
personality	personality	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
particularly	particularly	ADV	RB	5	O
no	no	DET	DT	9	O
antisocial	antisocial	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
substance	substance	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Within	within	ADP	IN	9	O
the	the	DET	DT	5	O
48	48	NUM	CD	9	O
h	h	DET	DT	0	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
gradual	gradual	ADJ	JJ	9	O
introduction	introduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
up	up	ADP	IN	5	O
to	to	ADP	IN	5	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
severe	severe	ADJ	JJ	5	O
agitation	agitation	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	O
an	an	DET	DT	5	O
environmental	environmental	ADJ	JJ	5	O
explanation	explanation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
contrasting	contrast	VERB	VBG	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
aggressiveness	aggressiveness	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
personality	personality	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
diagnoses	diagnosis	NOUN	NNS	5	O
of	of	ADP	IN	5	O
manic	manic	ADJ	JJ	5	B-Disease
shift	shift	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
dismissed	dismiss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
withdrawal	withdrawal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
gradual	gradual	ADJ	JJ	9	O
reintroduction	reintroduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
another	another	DET	DT	9	O
severe	severe	ADJ	JJ	5	O
agitation	agitation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
enabled	enable	VERB	VBD	5	O
us	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
attribute	attribute	VERB	VB	5	O
the	the	DET	DT	5	O
agitation	agitation	NOUN	NN	5	B-Disease
specifically	specifically	ADV	RB	9	O
to	to	ADP	IN	5	O
quetiapine	quetiapine	VERB	VB	5	B-Chemical
.	.	PUNCT	.	9	O

Antioxidant	antioxidant	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
bovine	bovine	ADJ	JJ	9	O
lactoferrin	lactoferrin	NOUN	NN	0	O
on	on	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Dexamethasone	Dexamethasone	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
(	(	PUNCT	-LRB-	9	O
Dex	dex	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
induced	induced	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
enhanced	enhance	VERB	VBN	3	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lactoferrin	Lactoferrin	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
LF	LF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
iron	iron	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
binding	bind	VERB	VBG	1	O
glycoprotein	glycoprotein	NOUN	NN	3	O
with	with	ADP	IN	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
LF	LF	PROPN	NNP	9	O
on	on	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
upon	upon	ADP	IN	9	O
Dex	Dex	PROPN	NNP	3	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
Dex	Dex	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
u	u	NOUN	NN	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
subcutaneously	subcutaneously	ADV	RB	3	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
saline	saline	VERB	VB	0	O
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
bovine	bovine	NOUN	NN	9	O
LF	LF	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
from	from	ADP	IN	9	O
day	day	NOUN	NN	9	O
8	8	NUM	CD	9	O
to	to	ADP	IN	5	O
14	14	NUM	CD	7	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
reversal	reversal	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
LF	LF	PROPN	NNP	9	O
treatment	treatment	NOUN	NN	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
Dex	Dex	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
continued	continue	VERB	VBD	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Systolic	systolic	ADJ	JJ	7	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SBP	SBP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
using	use	VERB	VBG	9	O
tail	tail	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
cuff	cuff	NOUN	NN	5	O
method	method	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thymus	thymus	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
hydrogen	hydrogen	NOUN	NN	0	B-Chemical
peroxide	peroxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
H2O2	h2o2	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
ferric	ferric	ADJ	JJ	0	O
reducing	reduce	VERB	VBG	9	O
antioxidant	antioxidant	ADJ	JJ	0	O
power	power	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
FRAP	FRAP	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
value	value	NOUN	NN	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Dexamethasone	Dexamethasone	PROPN	NNP	0	B-Chemical
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
SBP	SBP	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
plasma	plasma	VERB	VB	9	O
H2O2	h2o2	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
thymus	thymus	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
body	body	NOUN	NN	5	O
weights	weight	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

LF	LF	PROPN	NNP	9	O
lowered	lower	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
dependently	dependently	ADV	RB	3	O
prevented	prevent	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
Dex	dex	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

LF	lf	NOUN	NN	9	O
prevented	prevent	VERB	VBD	9	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
H2O2	h2o2	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
FRAP	frap	ADJ	JJ	0	O
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
LF	LF	PROPN	NNP	9	O
strongly	strongly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
ROS	ROS	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
improved	improve	VERB	VBN	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
capacity	capacity	NOUN	NN	9	O
in	in	ADP	IN	5	O
Dex	Dex	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
as	as	ADP	IN	5	O
another	another	DET	DT	9	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
LF	LF	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
multivariate	multivariate	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
529	529	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
contemporary	contemporary	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
regarding	regard	VERB	VBG	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
undertook	undertake	VERB	VBD	9	O
a	a	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
prospectively	prospectively	ADV	RB	5	O
collected	collect	VERB	VBN	9	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
11	11	NUM	CD	7	O
529	529	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
bypass	bypass	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
from	from	ADP	IN	9	O
January	January	PROPN	NNP	2	O
2004	2004	NUM	CD	2	O
to	to	ADP	IN	5	O
December	December	PROPN	NNP	2	O
2010	2010	NUM	CD	2	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
seizure	seizure	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
transient	transient	ADJ	JJ	9	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
disturbed	disturbed	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
function	function	NOUN	NN	9	O
characterised	characterise	VERB	VBN	9	O
by	by	ADP	IN	9	O
abnormal	abnormal	ADJ	JJ	9	B-Disease
involuntary	involuntary	ADJ	JJ	5	I-Disease
motor	motor	NOUN	NN	5	I-Disease
movements	movement	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Multivariate	multivariate	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
independent	independent	ADJ	JJ	9	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
postoperative	postoperative	ADJ	JJ	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Generalised	generalised	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
focal	focal	ADJ	JJ	5	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
68	68	NUM	CD	7	O
and	and	CCONJ	CC	5	O
32	32	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
IQR	IQR	PROPN	NNP	7	O
[	[	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
time	time	NOUN	NN	5	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
seizure	seizure	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
was	be	VERB	VBD	9	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
[	[	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
216	216	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
h	h	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
18	18	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Epileptiform	epileptiform	VERB	VB	5	O
findings	finding	NOUN	NNS	9	O
on	on	ADP	IN	5	O
electroencephalography	electroencephalography	NOUN	NN	5	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
19	19	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Independent	independent	ADJ	JJ	9	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
included	include	VERB	VBD	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
female	female	ADJ	JJ	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
redo	redo	VERB	VB	5	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
calcification	calcification	NOUN	NN	5	O
of	of	ADP	IN	5	O
ascending	ascend	VERB	VBG	5	O
aorta	aorta	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
deep	deep	ADJ	JJ	5	O
hypothermic	hypothermic	ADJ	JJ	5	B-Disease
circulatory	circulatory	ADJ	JJ	5	O
arrest	arrest	NOUN	NN	3	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
aortic	aortic	ADJ	JJ	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
clamp	clamp	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
multivariate	multivariate	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
independent	independent	ADJ	JJ	9	O
predictor	predictor	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
36	36	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	B-Disease
had	have	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
times	time	NOUN	NNS	5	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
hospital	hospital	NOUN	NN	5	O
mortality	mortality	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
twice	twice	DET	PDT	9	O
the	the	DET	DT	5	O
length	length	NOUN	NN	9	O
of	of	ADP	IN	5	O
hospital	hospital	NOUN	NN	5	O
stay	stay	VERB	VB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Mean	Mean	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
IQR	IQR	PROPN	NNP	7	O
[	[	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
length	length	NOUN	NN	9	O
of	of	ADP	IN	5	O
stay	stay	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
was	be	VERB	VBD	9	O
115	115	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
49	49	NUM	CD	7	O
-	-	SYM	SYM	7	O
228	228	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
32	32	NUM	CD	7	O
-	-	SYM	SYM	7	O
481	481	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
h	h	NOUN	NN	0	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	B-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
26	26	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
-	-	SYM	SYM	7	O
69	69	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
-	-	SYM	SYM	7	O
1080	1080	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
h	h	NOUN	NN	0	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Convulsive	convulsive	ADJ	JJ	2	B-Disease
seizures	seizure	NOUN	NNS	5	B-Disease
are	be	VERB	VBP	5	O
a	a	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
complication	complication	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
modifiable	modifiable	ADJ	JJ	5	O
factor	factor	NOUN	NN	9	O
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
exceeding	exceed	VERB	VBG	9	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
weighed	weigh	VERB	VBN	9	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Dysfunctional	dysfunctional	ADJ	JJ	5	B-Disease
overnight	overnight	ADJ	JJ	0	I-Disease
memory	memory	NOUN	NN	5	I-Disease
consolidation	consolidation	NOUN	NN	5	O
in	in	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Sleep	sleep	NOUN	NN	5	O
plays	play	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
consolidation	consolidation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
integration	integration	NOUN	NN	5	O
of	of	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
process	process	NOUN	NN	5	O
called	call	VERB	VBN	5	O
overnight	overnight	ADJ	JJ	0	O
memory	memory	NOUN	NN	5	O
consolidation	consolidation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
marked	mark	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
persistent	persistent	ADJ	JJ	5	O
neurocognitive	neurocognitive	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
sleep	sleep	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
related	relate	VERB	VBN	9	I-Disease
impairments	impairment	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
extend	extend	VERB	VBP	9	O
past	past	ADP	IN	5	O
research	research	NOUN	NN	5	O
by	by	ADP	IN	9	O
examining	examine	VERB	VBG	5	O
overnight	overnight	ADJ	JJ	0	O
memory	memory	NOUN	NN	5	O
consolidation	consolidation	NOUN	NN	5	O
among	among	ADP	IN	5	O
regular	regular	ADJ	JJ	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	O
naive	naive	ADJ	JJ	3	O
healthy	healthy	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
26	26	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Memory	memory	NOUN	NN	5	O
recall	recall	NOUN	NN	5	O
of	of	ADP	IN	5	O
word	word	NOUN	NN	5	O
pairs	pair	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
sleep	sleep	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
interference	interference	NOUN	NN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
testing	testing	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
assessed	assess	VERB	VBD	9	O
neurocognitive	neurocognitive	ADJ	JJ	5	O
performances	performance	NOUN	NNS	5	O
across	across	ADP	IN	5	O
tasks	task	NOUN	NNS	5	O
of	of	ADP	IN	5	O
learning	learning	NOUN	NN	5	O
,	,	PUNCT	,	9	O
memory	memory	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
executive	executive	ADJ	JJ	5	O
functioning	functioning	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ecstasy	Ecstasy	PROPN	NNP	7	B-Chemical
users	user	NOUN	NNS	5	O
demonstrated	demonstrate	VERB	VBD	9	O
impaired	impair	VERB	VBN	9	B-Disease
overnight	overnight	ADJ	JJ	0	I-Disease
memory	memory	NOUN	NN	5	I-Disease
consolidation	consolidation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
finding	finding	NOUN	NN	9	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
pronounced	pronounced	ADJ	JJ	9	O
following	follow	VERB	VBG	9	O
associative	associative	ADJ	JJ	5	O
interference	interference	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
demonstrated	demonstrate	VERB	VBD	9	O
impairments	impairment	NOUN	NNS	5	O
on	on	ADP	IN	5	O
tasks	task	NOUN	NNS	5	O
recruiting	recruit	VERB	VBG	9	O
frontostriatal	frontostriatal	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
neural	neural	ADJ	JJ	5	O
circuitry	circuitry	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
domains	domain	NOUN	NNS	1	O
of	of	ADP	IN	5	O
proactive	proactive	ADJ	JJ	5	O
interference	interference	ADJ	JJ	9	O
memory	memory	NOUN	NN	5	O
,	,	PUNCT	,	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
memory	memory	NOUN	NN	5	O
,	,	PUNCT	,	9	O
encoding	encode	VERB	VBG	1	O
,	,	PUNCT	,	9	O
working	work	VERB	VBG	5	O
memory	memory	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
complex	complex	ADJ	JJ	9	O
planning	planning	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
dysfunction	dysfunction	NOUN	NN	9	O
in	in	ADP	IN	5	O
fronto	fronto	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
temporal	temporal	ADJ	JJ	5	O
circuitry	circuitry	NOUN	NN	5	O
may	may	VERB	MD	5	O
underlie	underlie	VERB	VB	5	O
overnight	overnight	ADJ	JJ	0	O
consolidation	consolidation	NOUN	NN	5	O
memory	memory	NOUN	NN	5	B-Disease
impairments	impairment	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
regular	regular	ADJ	JJ	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Normoammonemic	normoammonemic	ADJ	JJ	_	O
encephalopathy	encephalopathy	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
solely	solely	ADV	RB	9	O
valproate	valproate	VERB	VB	0	B-Chemical
induced	induced	ADJ	JJ	3	O
or	or	CCONJ	CC	5	O
multiple	multiple	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
?	?	PUNCT	.	5	O

A	a	DET	DT	9	O
77	77	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
subacute	subacute	NOUN	NN	5	O
onset	onset	NOUN	NN	5	O
progressive	progressive	ADJ	JJ	5	O
confusion	confusion	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
aggression	aggression	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
auditory	auditory	NOUN	NN	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
delusions	delusion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
preceding	precede	VERB	VBG	5	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
admissions	admission	NOUN	NNS	5	O
with	with	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
unilateral	unilateral	ADJ	JJ	5	O
hemiparesis	hemiparesis	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
facial	facial	ADJ	JJ	5	O
droop	droop	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
started	start	VERB	VBN	5	O
on	on	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
presumed	presume	VERB	VBN	9	O
hemiplegic	hemiplegic	ADJ	JJ	5	B-Disease
migraine	migraine	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Valproate	Valproate	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
withdrawn	withdraw	VERB	VBN	9	O
soon	soon	ADV	RB	5	O
after	after	ADP	IN	9	O
admission	admission	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
her	-PRON-	DET	PRP$	5	O
cognitive	cognitive	ADJ	JJ	5	O
abilities	ability	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
gradually	gradually	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
over	over	ADP	IN	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Valproate	valproate	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
taken	take	VERB	VBN	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
were	be	VERB	VBD	9	O
subtherapeutic	subtherapeutic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
normoammonaemic	normoammonaemic	ADJ	JJ	_	O
.	.	PUNCT	.	9	O

EEG	EEG	PROPN	NNP	5	O
undertaken	undertake	VERB	VBN	5	O
during	during	ADP	IN	5	O
inpatient	inpatient	NOUN	NN	5	O
stay	stay	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
changes	change	NOUN	NNS	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
titre	titre	NOUN	NN	9	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
antibodies	antibody	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
aetiologies	aetiology	NOUN	NNS	5	O
of	of	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
NMDA	nmda	ADJ	JJ	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
encephalitis	encephalitis	NOUN	NN	5	B-Disease
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
dilemma	dilemma	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
putative	putative	ADJ	JJ	1	O
combinatorial	combinatorial	ADJ	JJ	5	O
hypothesis	hypothesis	NOUN	NN	9	O
to	to	PART	TO	5	O
explain	explain	VERB	VB	9	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cerebellar	cerebellar	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
oculomotor	oculomotor	NOUN	NN	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
rapid	rapid	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
pethidine	pethidine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Pethidine	Pethidine	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
opioid	opioid	NOUN	NN	5	O
that	that	DET	WDT	5	O
gains	gain	VERB	VBZ	5	O
its	-PRON-	DET	PRP$	9	O
popularity	popularity	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
control	control	NOUN	NN	9	O
through	through	ADP	IN	9	O
acting	act	VERB	VBG	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
opioid	opioid	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
rapid	rapid	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
relief	relief	NOUN	NN	5	O
sometimes	sometimes	ADV	RB	5	O
brings	bring	VERB	VBZ	5	O
about	about	PART	RP	5	O
unfavourable	unfavourable	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
that	that	DET	WDT	5	O
largely	largely	ADV	RB	9	O
limit	limit	VERB	VBP	5	O
its	-PRON-	DET	PRP$	9	O
clinical	clinical	ADJ	JJ	5	O
utility	utility	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Common	common	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
include	include	VERB	VBP	5	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
function	function	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
need	need	VERB	VBP	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
pain	pain	NOUN	NN	5	B-Disease
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
pethidine	pethidine	NOUN	NN	5	B-Chemical
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
excitatory	excitatory	ADJ	JJ	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CNS	CNS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
effects	effect	VERB	VBZ	9	O
through	through	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
metabolite	metabolite	NOUN	NN	0	O
,	,	PUNCT	,	9	O
norpethidine	norpethidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
irritability	irritability	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
seizure	seizure	NOUN	NN	5	B-Disease
attack	attack	NOUN	NN	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
contrary	contrary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
though	though	ADP	IN	9	O
not	not	ADV	RB	5	O
clinically	clinically	ADV	RB	5	O
apparent	apparent	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
pethidine	pethidine	VERB	VBP	5	B-Chemical
potentially	potentially	ADV	RB	5	O
causes	cause	VERB	VBZ	9	O
inhibitory	inhibitory	ADJ	JJ	3	O
impacts	impact	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
CNS	CNS	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
impairs	impair	VERB	VBZ	9	O
normal	normal	ADJ	JJ	9	O
cerebellar	cerebellar	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
oculomotor	oculomotor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
short	short	ADJ	JJ	5	O
term	term	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
highlight	highlight	VERB	VBP	5	O
opioid	opioid	VERB	VB	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
inhibitory	inhibitory	ADJ	JJ	3	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
structure	structure	NOUN	NN	9	O
that	that	DET	WDT	5	O
causes	cause	VERB	VBZ	9	O
dysmetria	dysmetria	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
dysarthria	dysarthria	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBD	9	O
smooth	smooth	ADJ	JJ	5	O
pursuit	pursuit	NOUN	NN	5	O
gain	gain	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
saccadic	saccadic	ADJ	JJ	5	O
velocity	velocity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Baboon	baboon	NOUN	NN	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
27	27	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
maculopapular	maculopapular	ADJ	JJ	5	B-Disease
eruption	eruption	NOUN	NN	5	I-Disease
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
flexural	flexural	ADJ	JJ	5	O
areas	area	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
buttocks	buttock	NOUN	NNS	5	O
after	after	ADP	IN	9	O
using	use	VERB	VBG	9	O
oral	oral	ADJ	JJ	9	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
baboon	baboon	NOUN	NN	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
included	include	VERB	VBD	5	O
prior	prior	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
histopathological	histopathological	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Baboon	baboon	NOUN	NN	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
contact	contact	NOUN	NN	5	O
allergen	allergen	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
maculopapular	maculopapular	ADJ	JJ	5	B-Disease
eruption	eruption	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
typically	typically	ADV	RB	5	O
involves	involve	VERB	VBZ	5	O
the	the	DET	DT	5	O
flexural	flexural	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
gluteal	gluteal	ADJ	JJ	5	O
areas	area	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
the	the	DET	DT	5	O
best	good	ADJ	JJS	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
reported	report	VERB	VBN	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
baboon	baboon	NOUN	NN	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
English	English	PROPN	NNP	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
Case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
Sudden	Sudden	PROPN	NNP	5	B-Disease
Cardiac	Cardiac	PROPN	NNP	9	I-Disease
Death	Death	PROPN	NNP	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
Pilsicainide	Pilsicainide	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
Induced	Induced	PROPN	NNP	9	O
Torsades	Torsades	PROPN	NNP	2	B-Disease
de	de	ADP	IN	2	I-Disease
Pointes	Pointes	PROPN	NNPS	2	I-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
84	84	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
oral	oral	ADJ	JJ	9	O
pilsicainide	pilsicainide	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
pure	pure	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
with	with	ADP	IN	5	O
slow	slow	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
kinetics	kinetic	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
convert	convert	VERB	VB	9	O
his	-PRON-	DET	PRP$	5	O
paroxysmal	paroxysmal	ADJ	JJ	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
sinus	sinus	NOUN	NN	5	O
rhythm	rhythm	NOUN	NN	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
sudden	sudden	ADJ	JJ	5	B-Disease
cardiac	cardiac	ADJ	JJ	5	I-Disease
death	death	NOUN	NN	9	I-Disease
two	two	NUM	CD	5	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Holter	holter	NOUN	NN	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
worn	wear	VERB	VBN	5	O
by	by	ADP	IN	9	O
chance	chance	NOUN	NN	5	O
,	,	PUNCT	,	9	O
revealed	reveal	VERB	VBD	9	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
with	with	ADP	IN	5	O
gradually	gradually	ADV	RB	9	O
prolonged	prolong	VERB	VBN	9	O
QT	QT	PROPN	NNP	5	O
intervals	interval	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
rapidly	rapidly	ADV	RB	9	O
absorbed	absorb	VERB	VBN	0	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	O
tract	tract	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
excreted	excrete	VERB	VBN	0	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
highly	highly	ADV	RB	9	O
impaired	impaired	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
pilsicainide	pilsicainide	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
pilsicainide	pilsicainide	NOUN	NN	5	B-Chemical
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
high	high	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
can	can	VERB	MD	5	O
produce	produce	VERB	VB	9	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
octogenarian	octogenarian	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
class	class	NOUN	NN	9	O
IC	ic	NOUN	NN	9	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
pilsicainide	pilsicainide	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
effective	effective	ADJ	JJ	5	O
to	to	PART	TO	5	O
terminate	terminate	VERB	VB	9	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
careful	careful	ADJ	JJ	5	O
consideration	consideration	NOUN	NN	5	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
taken	take	VERB	VBN	5	O
before	before	ADP	IN	9	O
giving	give	VERB	VBG	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
to	to	ADP	IN	5	O
octogenarians	octogenarian	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
trans	tran	NOUN	NNS	9	I-Chemical
retinoic	retinoic	ADJ	JJ	3	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
inflammatory	inflammatory	ADJ	JJ	3	O
myositis	myositis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
promyelocytic	promyelocytic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
trans	tran	NOUN	NNS	9	I-Chemical
retinoic	retinoic	ADJ	JJ	3	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
component	component	NOUN	NN	9	O
of	of	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
promyelocytic	promyelocytic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
APL	APL	PROPN	NNP	3	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
potentially	potentially	ADV	RB	5	O
serious	serious	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
treatable	treatable	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
involving	involve	VERB	VBG	5	O
numerous	numerous	ADJ	JJ	9	O
organ	organ	NOUN	NN	5	O
systems	system	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
rare	rare	ADJ	JJ	5	O
skeletal	skeletal	ADJ	JJ	9	O
muscle	muscle	NOUN	NN	9	O
involvement	involvement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
a	a	DET	DT	5	O
handful	handful	NOUN	NN	5	O
of	of	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myositis	myositis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
none	none	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
radiology	radiology	NOUN	NN	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
such	such	DET	PDT	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
boy	boy	NOUN	NN	5	O
with	with	ADP	IN	5	O
APL	APL	PROPN	NNP	3	B-Disease
,	,	PUNCT	,	9	O
where	where	ADV	WRB	5	O
recognition	recognition	NOUN	NN	5	O
of	of	ADP	IN	5	O
imaging	image	VERB	VBG	5	O
findings	finding	NOUN	NNS	9	O
played	play	VERB	VBD	9	O
a	a	DET	DT	5	O
crucial	crucial	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
making	make	VERB	VBG	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
facilitated	facilitate	VERB	VBN	5	O
prompt	prompt	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
effective	effective	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
lomustine	lomustine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
lymphoma	lymphoma	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
describes	describe	VERB	VBZ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
protocol	protocol	NOUN	NN	9	O
of	of	ADP	IN	5	O
lomustine	lomustine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CCNU	CCNU	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CTX	CTX	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
lymphoma	lymphoma	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

CCNU	CCNU	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
per	per	ADP	IN	9	O
os	os	X	FW	9	O
(	(	PUNCT	-LRB-	9	O
PO	PO	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
targeted	target	VERB	VBN	9	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
CTX	CTX	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
PO	PO	PROPN	NNP	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
targeted	target	VERB	VBN	9	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
divided	divide	VERB	VBN	5	O
over	over	ADP	IN	5	O
days	day	NOUN	NNS	9	O
0	0	NUM	CD	7	O
through	through	ADP	IN	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
dogs	dog	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
prophylactic	prophylactic	ADJ	JJ	5	O
antibiotics	antibiotic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ninety	ninety	NUM	CD	5	O
treatments	treatment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
57	57	NUM	CD	7	O
dogs	dog	NOUN	NNS	5	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Neutropenia	Neutropenia	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
principal	principal	ADJ	JJ	5	O
toxic	toxic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
grade	grade	NOUN	NN	9	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
CCNU	CCNU	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
CTX	CTX	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
19	19	NUM	CD	7	O
-	-	SYM	SYM	7	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
of	of	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
grade	grade	NOUN	NN	9	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
kg	kg	NOUN	NN	0	O
+	+	CCONJ	CC	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
of	of	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
that	that	DET	WDT	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
develop	develop	VERB	VB	5	O
grade	grade	NOUN	NN	9	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
31	31	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
kg	kg	NOUN	NN	0	O
+	+	CCONJ	CC	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
kg	kg	X	XX	0	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
dog	dog	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
hematologic	hematologic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
suggestive	suggestive	ADJ	JJ	9	O
of	of	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
dogs	dog	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
either	either	CCONJ	CC	9	O
renal	renal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
hemorrhagic	hemorrhagic	NOUN	NN	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
uncommon	uncommon	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
reported	report	VERB	VBD	9	O
herein	herein	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
CCNU	CCNU	PROPN	NNP	0	B-Chemical
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
CTX	CTX	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
divided	divide	VERB	VBN	5	O
over	over	ADP	IN	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
q	q	NOUN	NN	9	O
4	4	NUM	CD	9	O
wk	wk	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
tolerable	tolerable	ADJ	JJ	5	O
in	in	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
bearing	bear	VERB	VBG	3	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Nelarabine	nelarabine	ADJ	JJ	0	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
concurrent	concurrent	ADJ	JJ	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
chemotherapy	chemotherapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
nelarabine	nelarabine	ADJ	JJ	5	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
concurrent	concurrent	ADJ	JJ	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
IT	it	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
37	37	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Caucasian	caucasian	ADJ	JJ	9	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
T	t	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
cell	cell	NOUN	NN	3	I-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
for	for	ADP	IN	5	O
relapsed	relapse	VERB	VBN	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
originally	originally	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
chemotherapy	chemotherapy	NOUN	NN	5	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
autologous	autologous	ADJ	JJ	3	O
transplant	transplant	NOUN	NN	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
relapsed	relapse	VERB	VBN	5	O
disease	disease	NOUN	NN	5	O
10	10	NUM	CD	9	O
months	month	NOUN	NNS	5	O
later	later	ADV	RB	9	O
with	with	ADP	IN	5	O
leukemic	leukemic	ADJ	JJ	3	B-Disease
involvement	involvement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
re	re	VERB	VBN	5	O
-	-	VERB	VBN	7	O
induced	induced	ADJ	JJ	3	O
with	with	ADP	IN	5	O
nelarabine	nelarabine	ADJ	JJ	5	B-Chemical
1500	1500	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
with	with	ADP	IN	5	O
1	1	NUM	CD	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
IT	it	NOUN	NN	9	O
cytarabine	cytarabine	NOUN	NN	0	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
as	as	ADP	IN	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CNS	CNS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
prophylaxis	prophylaxis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
sequelae	sequelae	NOUN	NN	5	O
of	of	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
lysis	lysis	NOUN	NN	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TLS	tls	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
tolerated	tolerate	VERB	VBD	9	O
therapy	therapy	NOUN	NN	5	O
well	well	ADV	RB	9	O
,	,	PUNCT	,	9	O
entered	enter	VERB	VBD	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
recovered	recover	VERB	VBD	9	O
her	-PRON-	DET	PRP$	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
cycle	cycle	NOUN	NN	9	O
of	of	ADP	IN	5	O
nelarabine	nelarabine	NOUN	NN	5	B-Chemical
without	without	ADP	IN	9	O
additional	additional	ADJ	JJ	9	O
IT	IT	PROPN	NNP	9	O
prophylaxis	prophylaxis	NOUN	NN	5	O
one	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
week	week	NOUN	NN	9	O
after	after	ADP	IN	9	O
this	this	DET	DT	5	O
second	second	ADJ	JJ	9	O
cycle	cycle	NOUN	NN	9	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
noted	note	VERB	VBD	9	O
numbness	numbness	NOUN	NN	5	O
in	in	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
lower	low	ADJ	JJR	9	O
extremities	extremity	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Predominantly	predominantly	ADV	RB	9	O
sensory	sensory	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
though	though	ADP	IN	9	O
also	also	ADV	RB	9	O
motor	motor	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
autonomic	autonomic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
started	start	VERB	VBD	5	O
in	in	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
feet	foot	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
ascended	ascend	VERB	VBN	5	O
proximally	proximally	ADV	RB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
mid	mid	ADJ	JJ	9	O
-	-	NOUN	NN	7	O
thoracic	thoracic	NOUN	NN	5	O
region	region	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
eventually	eventually	ADV	RB	5	O
included	include	VERB	VBD	5	O
her	-PRON-	DET	PRP$	5	O
distal	distal	ADJ	JJ	9	O
upper	upper	ADJ	JJ	9	O
extremities	extremity	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MRI	MRI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
spine	spine	NOUN	NN	5	O
demonstrated	demonstrate	VERB	VBD	9	O
changes	change	NOUN	NNS	9	O
from	from	ADP	IN	9	O
C2	C2	PROPN	NNP	9	O
to	to	ADP	IN	5	O
C6	c6	VERB	VB	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
subacute	subacute	ADJ	JJ	5	O
combined	combine	VERB	VBN	9	O
degeneration	degeneration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nelarabine	Nelarabine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
felt	feel	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
stabilized	stabilize	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
showed	show	VERB	VBD	9	O
slight	slight	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
ultimately	ultimately	ADV	RB	5	O
received	receive	VERB	VBD	9	O
an	an	DET	DT	5	O
unrelated	unrelated	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
intensity	intensity	NOUN	NN	5	O
allogeneic	allogeneic	NOUN	NN	3	O
transplant	transplant	NOUN	NN	9	O
while	while	ADP	IN	9	O
in	in	ADP	IN	5	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
relapsed	relapse	VERB	VBN	5	O
disease	disease	NOUN	NN	5	O
10	10	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
currently	currently	ADV	RB	5	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
best	good	ADJ	JJS	5	O
supportive	supportive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
published	publish	VERB	VBN	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
nelarabine	nelarabine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
concurrent	concurrent	ADJ	JJ	5	O
IT	it	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Valproate	valproate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperammonemic	hyperammonemic	ADJ	JJ	5	B-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
transplanted	transplant	VERB	VBN	3	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neurological	neurological	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
renal	renal	ADJ	JJ	9	O
transplantation	transplantation	NOUN	NN	9	O
constitute	constitute	VERB	VBP	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Their	-PRON-	DET	PRP$	5	O
differential	differential	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
difficult	difficult	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
essential	essential	ADJ	JJ	9	O
for	for	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Valproate	valproate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperammonemic	hyperammonemic	ADJ	JJ	5	B-Disease
encephalopathy	encephalopathy	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
uncommon	uncommon	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
serious	serious	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
epilepsy	epilepsy	VERB	VB	5	B-Disease
and	and	CCONJ	CC	5	O
revealed	reveal	VERB	VBD	9	O
impaired	impaired	ADJ	JJ	9	B-Disease
consciousness	consciousness	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
hyperammonemia	hyperammonemia	ADJ	JJ	5	B-Disease
12	12	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
renal	renal	ADJ	JJ	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
withdraw	withdraw	NOUN	NN	5	O
of	of	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
symptoms	symptom	NOUN	NNS	5	O
resolved	resolve	VERB	VBD	9	O
within	within	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
increase	increase	VERB	VB	9	O
their	-PRON-	DET	PRP$	5	O
awareness	awareness	NOUN	NN	5	O
for	for	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
transplanted	transplant	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Necrotising	necrotise	VERB	VBG	5	B-Disease
fasciitis	fasciitis	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
bortezomib	bortezomib	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
regimen	regiman	NOUN	NNS	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
of	of	ADP	IN	5	O
Waldenstrom	Waldenstrom	PROPN	NNP	2	B-Disease
macroglobulinaemia	macroglobulinaemia	NOUN	NN	2	I-Disease
.	.	PUNCT	.	9	O

Bortezomib	Bortezomib	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
regimens	regimen	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
generally	generally	ADV	RB	5	O
tolerable	tolerable	ADJ	JJ	5	O
with	with	ADP	IN	5	O
few	few	ADJ	JJ	5	O
severe	severe	ADJ	JJ	5	O
bacterial	bacterial	ADJ	JJ	9	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
B	b	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
malignancies	malignancy	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
information	information	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
limited	limit	VERB	VBN	5	O
concerning	concern	VERB	VBG	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
regimen	regiman	NOUN	NNS	5	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
76	76	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
Waldenstrom	Waldenstrom	PROPN	NNP	2	B-Disease
macroglobulinaemia	macroglobulinaemia	NOUN	NN	2	I-Disease
who	who	PRON	WP	5	O
suffered	suffer	VERB	VBD	5	O
necrotising	necrotise	VERB	VBG	5	B-Disease
fasciitis	fasciitis	NOUN	NN	5	I-Disease
without	without	ADP	IN	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
bortezomib	bortezomib	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
rituximab	rituximab	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
immediate	immediate	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
antimicrobial	antimicrobial	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
succumbed	succumb	VERB	VBD	3	O
23	23	NUM	CD	7	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Physicians	physician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
recognise	recognise	VERB	VB	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
bacterial	bacterial	ADJ	JJ	9	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	PART	TO	5	O
bortezomib	bortezomib	VERB	VB	3	B-Chemical
plus	plus	CCONJ	CC	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
we	-PRON-	PRON	PRP	5	O
believe	believe	VERB	VBP	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
warrants	warrant	VERB	VBZ	9	O
further	further	ADJ	JJ	9	O
investigation	investigation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
integrated	integrated	ADJ	JJ	5	O
characterization	characterization	NOUN	NN	9	O
of	of	ADP	IN	5	O
serological	serological	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
pathological	pathological	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
events	event	NOUN	NNS	5	O
in	in	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Many	many	ADJ	JJ	5	O
efficacious	efficacious	ADJ	JJ	5	O
cancer	cancer	NOUN	NN	3	B-Disease
treatments	treatment	NOUN	NNS	9	O
cause	cause	VERB	VBP	5	O
significant	significant	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
morbidity	morbidity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
yet	yet	CCONJ	CC	9	O
biomarkers	biomarker	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
indices	index	NOUN	NNS	5	O
of	of	ADP	IN	5	O
early	early	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
would	would	VERB	MD	5	O
allow	allow	VERB	VB	5	O
monitoring	monitoring	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intervention	intervention	NOUN	NN	5	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
lacking	lack	VERB	VBG	1	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
have	have	VERB	VBP	5	O
utilized	utilize	VERB	VBN	9	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
applying	apply	VERB	VBG	5	O
multiple	multiple	ADJ	JJ	5	O
approaches	approach	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
cardiac	cardiac	ADJ	JJ	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MRI	MRI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
provide	provide	VERB	VB	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
comprehensive	comprehensive	ADJ	JJ	5	O
characterization	characterization	NOUN	NN	9	O
to	to	ADP	IN	5	O
date	date	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
timecourse	timecourse	NOUN	NN	5	O
of	of	ADP	IN	5	O
serological	serological	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
pathological	pathological	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
events	event	NOUN	NNS	5	O
underlying	underlie	VERB	VBG	5	O
this	this	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Hannover	Hannover	PROPN	NNP	2	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
dosed	dose	VERB	VBN	0	O
with	with	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
DOX	DOX	PROPN	NNP	0	B-Chemical
weekly	weekly	ADV	RB	5	O
for	for	ADP	IN	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
week	week	NOUN	NN	9	O
off	off	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
dosing	dose	VERB	VBG	9	O
"	"	PUNCT	``	5	O
recovery	recovery	NOUN	NN	9	O
"	"	PUNCT	''	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Electron	Electron	PROPN	NNP	0	O
microscopy	microscopy	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
myocardium	myocardium	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
subcellular	subcellular	ADJ	JJ	3	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
marked	mark	VERB	VBD	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Histopathological	histopathological	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
progressive	progressive	ADJ	JJ	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
/	/	SYM	SYM	9	O
cytomegaly	cytomegaly	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
extensive	extensive	ADJ	JJ	5	O
vacuolation	vacuolation	NOUN	NN	3	O
after	after	ADP	IN	9	O
two	two	NUM	CD	5	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Extensive	extensive	ADJ	JJ	9	O
replacement	replacement	NOUN	NN	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
quantified	quantify	VERB	VBN	9	O
by	by	ADP	IN	9	O
Sirius	Sirius	PROPN	NNP	0	O
red	red	ADJ	JJ	9	O
staining	staining	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
off	off	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
dosing	dose	VERB	VBG	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Functional	functional	ADJ	JJ	9	O
indices	index	NOUN	NNS	5	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
MRI	MRI	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
including	include	VERB	VBG	9	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
LVEF	LVEF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
E	e	NOUN	NN	9	O
/	/	SYM	SYM	9	O
A	a	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
declined	decline	VERB	VBD	9	O
progressively	progressively	ADV	RB	9	O
,	,	PUNCT	,	9	O
reaching	reach	VERB	VBG	5	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
after	after	ADP	IN	9	O
two	two	NUM	CD	5	O
doses	dose	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
culminating	culminate	VERB	VBG	9	O
in	in	ADP	IN	5	O
"	"	PUNCT	``	5	O
clinical	clinical	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
LV	LV	PROPN	NNP	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
by	by	ADP	IN	9	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
peak	peak	NOUN	NN	9	O
myocardial	myocardial	ADJ	JJ	9	O
contrast	contrast	NOUN	NN	9	O
enhancement	enhancement	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
serological	serological	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
troponin	troponin	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
(	(	PUNCT	-LRB-	9	O
cTnI	cTnI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
emerged	emerge	VERB	VBD	9	O
after	after	ADP	IN	9	O
eight	eight	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
importantly	importantly	ADV	RB	9	O
preceding	precede	VERB	VBG	5	O
the	the	DET	DT	5	O
LVEF	LVEF	PROPN	NNP	5	O
decline	decline	NOUN	NN	9	O
to	to	ADP	IN	5	O
<	<	X	XX	0	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Troponin	Troponin	PROPN	NNP	7	O
I	-PRON-	PRON	PRP	9	O
levels	level	VERB	VBZ	3	O
positively	positively	ADV	RB	9	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
delayed	delayed	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
peak	peak	NOUN	NN	9	O
gadolinium	gadolinium	NOUN	NN	0	B-Chemical
contrast	contrast	NOUN	NN	9	O
enhancement	enhancement	NOUN	NN	9	O
,	,	PUNCT	,	9	O
histopathological	histopathological	ADJ	JJ	9	O
grading	grading	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
summary	summary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
subcellular	subcellular	ADJ	JJ	3	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
earliest	early	ADJ	JJS	9	O
marker	marker	NOUN	NN	3	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
progressive	progressive	ADJ	JJ	5	O
functional	functional	ADJ	JJ	9	O
decline	decline	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
histopathological	histopathological	ADJ	JJ	9	O
manifestations	manifestation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	O
contrast	contrast	NOUN	NN	9	O
enhancement	enhancement	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
elevations	elevation	NOUN	NNS	9	O
in	in	ADP	IN	5	O
cTnI	ctni	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
indices	index	NOUN	NNS	5	O
predated	predate	VERB	VBD	4	O
"	"	PUNCT	``	5	O
clinical	clinical	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
LV	LV	PROPN	NNP	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
thus	thus	ADV	RB	9	O
warrant	warrant	VERB	VBP	9	O
further	further	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
as	as	ADP	IN	5	O
predictive	predictive	ADJ	JJ	5	O
biomarkers	biomarker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Intradermal	intradermal	ADJ	JJ	3	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
capsaicin	capsaicin	ADJ	JJ	0	B-Chemical
injections	injection	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
intra	intra	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
interindividual	interindividual	ADJ	JJ	5	O
variability	variability	NOUN	NN	5	O
of	of	ADP	IN	5	O
provoked	provoke	VERB	VBN	9	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
allodynia	allodynia	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

Intradermal	intradermal	ADJ	JJ	3	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
attractive	attractive	ADJ	JJ	5	O
to	to	PART	TO	5	O
use	use	VERB	VB	5	O
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	O
experimental	experimental	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
models	model	NOUN	NNS	5	O
because	because	ADP	IN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
allodynia	allodynia	ADJ	JJ	5	B-Disease
mimic	mimic	NOUN	NN	9	O
isolated	isolate	VERB	VBN	9	O
aspects	aspect	NOUN	NNS	5	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
reproducibility	reproducibility	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
volunteers	volunteer	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
24	24	NUM	CD	9	O
years	year	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
range	range	VERB	VBP	9	O
18	18	NUM	CD	7	O
-	-	SYM	SYM	7	O
38	38	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
intradermal	intradermal	ADJ	JJ	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
volar	volar	ADJ	JJ	5	O
forearm	forearm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Magnitudes	magnitude	NOUN	NNS	5	O
of	of	ADP	IN	5	O
secondary	secondary	ADJ	JJ	9	O
pinprick	pinprick	NOUN	NN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
brush	brush	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
evoked	evoked	ADJ	JJ	5	O
allodynia	allodynia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
using	use	VERB	VBG	9	O
von	von	PROPN	NNP	6	O
Frey	Frey	PROPN	NNP	6	O
filaments	filament	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
gauges	gauge	NOUN	NNS	5	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
and	and	CCONJ	CC	5	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
brush	brush	NOUN	NN	9	O
strokes	stroke	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
secondary	secondary	ADJ	JJ	9	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
allodynia	allodynia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
quantified	quantify	VERB	VBN	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
identical	identical	ADJ	JJ	9	O
experiments	experiment	NOUN	NNS	9	O
separated	separate	VERB	VBN	9	O
by	by	ADP	IN	9	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Reproducibility	reproducibility	NOUN	NN	5	O
across	across	ADP	IN	5	O
and	and	CCONJ	CC	5	O
within	within	ADP	IN	9	O
volunteers	volunteer	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
inter	inter	NOUN	NN	5	O
-	-	ADJ	JJ	7	O
and	and	CCONJ	CC	5	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
individual	individual	ADJ	JJ	5	O
variation	variation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
using	use	VERB	VBG	9	O
intraclass	intraclass	NOUN	NN	5	O
correlation	correlation	NOUN	NN	9	O
coefficient	coefficient	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ICC	ICC	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
coefficient	coefficient	NOUN	NN	5	O
of	of	ADP	IN	5	O
variation	variation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CV	CV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Secondary	secondary	ADJ	JJ	9	O
pinprick	pinprick	NOUN	NN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
analogue	analogue	NOUN	NN	0	O
scale	scale	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
VAS	VAS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
von	von	PROPN	NNP	6	O
Frey	Frey	PROPN	NNP	6	O
gauges	gauge	NOUN	NNS	5	O
60	60	NUM	CD	9	O
and	and	CCONJ	CC	5	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
secondary	secondary	ADJ	JJ	9	O
pinprick	pinprick	NOUN	NN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
with	with	ADP	IN	5	O
all	all	DET	DT	5	O
von	von	DET	DT	6	O
Frey	Frey	PROPN	NNP	6	O
gauges	gauge	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Glutamate	Glutamate	PROPN	NNP	0	B-Chemical
evoked	evoke	VERB	VBD	5	O
reproducible	reproducible	ADJ	JJ	5	O
VAS	VAS	PROPN	NNP	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
all	all	DET	DT	5	O
von	von	DET	DT	6	O
Frey	Frey	PROPN	NNP	6	O
gauges	gauge	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
ICC	ICC	PROPN	NNP	5	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
60	60	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
brush	brush	NOUN	NN	9	O
strokes	stroke	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
ICC	ICC	PROPN	NNP	5	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
83	83	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Capsaicin	capsaicin	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reproducible	reproducible	ADJ	JJ	5	O
for	for	ADP	IN	5	O
secondary	secondary	ADJ	JJ	9	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
ICC	ICC	PROPN	NNP	5	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
70	70	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
allodynia	allodynia	ADJ	JJ	5	B-Disease
(	(	PUNCT	-LRB-	9	O
ICC	ICC	PROPN	NNP	5	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
71	71	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
individual	individual	ADJ	JJ	5	O
variability	variability	NOUN	NN	5	O
was	be	VERB	VBD	9	O
generally	generally	ADV	RB	5	O
lower	low	ADJ	JJR	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
VAS	VAS	PROPN	NNP	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
von	von	PROPN	NNP	6	O
Frey	Frey	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
brush	brush	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
secondary	secondary	ADJ	JJ	9	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
allodynia	allodynia	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
capsaicin	capsaicin	ADJ	JJ	0	B-Chemical
yield	yield	NOUN	NN	9	O
reproducible	reproducible	ADJ	JJ	5	O
hyperalgesic	hyperalgesic	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
allodynic	allodynic	ADJ	JJ	5	B-Disease
responses	response	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
suited	suited	ADJ	JJ	5	O
for	for	ADP	IN	5	O
basic	basic	ADJ	JJ	5	O
research	research	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
for	for	ADP	IN	5	O
assessing	assess	VERB	VBG	5	O
the	the	DET	DT	5	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
phenomena	phenomenon	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ocular	ocular	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
ER	ER	PROPN	NNP	3	O
stress	stress	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
rescues	rescue	NOUN	NNS	3	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
murine	murine	ADJ	JJ	3	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
glucocorticoids	glucocorticoid	NOUN	NNS	9	O
induces	induce	VERB	VBZ	3	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

If	if	ADP	IN	5	O
untreated	untreated	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
can	can	VERB	MD	5	O
develop	develop	VERB	VB	5	O
a	a	DET	DT	5	O
secondary	secondary	ADJ	JJ	9	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
resembles	resemble	VERB	VBZ	9	O
primary	primary	ADJ	JJ	9	B-Disease
open	open	ADJ	JJ	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
angle	angle	NOUN	NN	5	I-Disease
glaucoma	glaucoma	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
POAG	POAG	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
pathology	pathology	NOUN	NN	5	O
of	of	ADP	IN	5	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
fully	fully	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
,	,	PUNCT	,	9	O
due	due	ADJ	JJ	5	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
to	to	ADP	IN	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
appropriate	appropriate	ADJ	JJ	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
murine	murine	ADJ	JJ	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
exhibits	exhibit	VERB	VBZ	9	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
features	feature	NOUN	NNS	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
WT	WT	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
ocular	ocular	ADJ	JJ	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
intraocular	intraocular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
IOP	IOP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
functional	functional	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
structural	structural	ADJ	JJ	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
ganglion	ganglion	NOUN	NN	5	I-Disease
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
axonal	axonal	ADJ	JJ	3	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
resembling	resemble	VERB	VBG	9	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
ER	ER	PROPN	NNP	3	O
stress	stress	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
trabecular	trabecular	ADJ	JJ	5	O
meshwork	meshwork	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
TM	TM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
dexamethasone	dexamethasone	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
reduced	reduce	VERB	VBN	9	O
elevated	elevate	VERB	VBN	9	O
IOP	IOP	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
ER	ER	PROPN	NNP	3	O
stress	stress	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dexamethasone	Dexamethasone	PROPN	NNP	0	B-Chemical
induced	induce	VERB	VBD	3	O
the	the	DET	DT	5	O
transcriptional	transcriptional	ADJ	JJ	1	O
factor	factor	NOUN	NN	9	O
CHOP	CHOP	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
for	for	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
ER	ER	PROPN	NNP	3	O
stress	stress	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
anterior	anterior	ADJ	JJ	5	O
segment	segment	NOUN	NN	9	O
tissues	tissue	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Chop	Chop	PROPN	NNP	3	O
deletion	deletion	NOUN	NN	1	O
reduced	reduce	VERB	VBD	9	O
ER	ER	PROPN	NNP	3	O
stress	stress	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
tissues	tissue	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
prevented	prevent	VERB	VBD	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
ER	ER	PROPN	NNP	3	O
stress	stress	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
TM	TM	PROPN	NNP	9	O
with	with	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phenylbutyrate	phenylbutyrate	NOUN	NN	0	I-Chemical
prevented	prevent	VERB	VBN	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
WT	WT	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
ER	ER	PROPN	NNP	3	O
stress	stress	NOUN	NN	9	O
contributes	contribute	VERB	VBZ	9	O
to	to	PART	TO	5	O
glucocorticoid	glucocorticoid	VERB	VB	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
reducing	reduce	VERB	VBG	9	O
ER	ER	PROPN	NNP	3	O
stress	stress	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
potential	potential	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
strategy	strategy	NOUN	NN	5	O
for	for	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ginsenosides	ginsenoside	NOUN	NNS	0	B-Chemical
on	on	ADP	IN	5	O
opioid	opioid	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Opioid	Opioid	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
(	(	PUNCT	-LRB-	9	O
OIH	OIH	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
nociceptive	nociceptive	ADJ	JJ	5	O
sensitization	sensitization	NOUN	NN	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
opioid	opioid	NOUN	NN	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OIH	OIH	PROPN	NNP	5	B-Disease
can	can	VERB	MD	5	O
limit	limit	VERB	VB	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
opioid	opioid	NOUN	NN	5	O
analgesics	analgesic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
complicate	complicate	VERB	VB	5	O
withdrawal	withdrawal	NOUN	NN	5	O
from	from	ADP	IN	9	O
opioid	opioid	ADJ	JJ	5	B-Disease
addiction	addiction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Re	Re	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
Rg1	rg1	INTJ	UH	0	I-Chemical
,	,	PUNCT	,	9	I-Chemical
and	and	CCONJ	CC	5	I-Chemical
Rb1	rb1	NOUN	NN	3	I-Chemical
ginsenosides	ginsenoside	NOUN	NNS	0	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
bioactive	bioactive	ADJ	JJ	0	O
components	component	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ginseng	ginseng	NOUN	NN	4	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
OIH	OIH	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

OIH	OIH	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
after	after	ADP	IN	9	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
days	day	NOUN	NNS	9	O
8	8	NUM	CD	9	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
Re	Re	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
Rg1	rg1	INTJ	UH	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
Rb1	Rb1	VERB	VBZ	3	B-Chemical
intragastrically	intragastrically	ADV	RB	0	O
two	two	NUM	CD	5	O
times	time	NOUN	NNS	5	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
day	day	NOUN	NN	9	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
thermal	thermal	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
acetic	acetic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
writhing	writhing	NOUN	NN	0	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Re	re	ADP	IN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
inhibited	inhibit	VERB	VBD	3	O
OIH	OIH	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
thermal	thermal	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
acetic	acetic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
writhing	writhing	NOUN	NN	0	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
Rg1	rg1	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	I-Chemical
Rb1	rb1	NOUN	NN	3	I-Chemical
ginsenosides	ginsenoside	NOUN	NNS	0	I-Chemical
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
OIH	OIH	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
Rg1	Rg1	NOUN	NNS	0	B-Chemical
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
tendency	tendency	NOUN	NN	5	O
to	to	PART	TO	5	O
aggravate	aggravate	VERB	VB	9	O
OIH	OIH	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acetic	acetic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
writhing	writhing	NOUN	NN	0	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
ginsenoside	ginsenoside	NOUN	NN	0	B-Chemical
Re	Re	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
Rg1	Rg1	NOUN	NNS	0	B-Chemical
or	or	CCONJ	CC	5	O
Rb1	rb1	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
toward	toward	ADP	IN	5	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
OIH	OIH	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
disturbances	disturbance	NOUN	NNS	5	O
between	between	ADP	IN	5	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
sedation	sedation	NOUN	NN	5	O
in	in	ADP	IN	5	O
neurocritical	neurocritical	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Dexmedetomidine	dexmedetomidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
sedatives	sedative	NOUN	NNS	5	O
in	in	ADP	IN	5	O
neurocritical	neurocritical	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
as	as	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
allow	allow	VERB	VBP	5	O
for	for	ADP	IN	5	O
frequent	frequent	ADJ	JJ	5	O
neurologic	neurologic	ADJ	JJ	5	O
examinations	examination	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
agents	agent	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
neurocritical	neurocritical	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Multicenter	Multicenter	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
retrospective	retrospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
propensity	propensity	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
cohort	cohort	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

SETTING	set	VERB	VBG	2	O
:	:	PUNCT	:	9	O
Neurocritical	neurocritical	ADJ	JJ	2	O
care	care	NOUN	NN	5	O
units	unit	NOUN	NNS	9	O
at	at	ADP	IN	9	O
two	two	NUM	CD	5	O
academic	academic	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
centers	center	NOUN	NNS	5	O
with	with	ADP	IN	5	O
dedicated	dedicated	ADJ	JJ	5	O
neurocritical	neurocritical	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
teams	team	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
board	board	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
certified	certify	VERB	VBN	5	O
neurointensivists	neurointensivist	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Neurocritical	neurocritical	ADJ	JJ	2	O
care	care	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
admitted	admit	VERB	VBN	5	O
between	between	ADP	IN	5	O
July	July	PROPN	NNP	2	O
2009	2009	NUM	CD	2	O
and	and	CCONJ	CC	5	O
September	September	PROPN	NNP	2	O
2012	2012	NUM	CD	2	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
matched	match	VERB	VBD	9	O
1	1	NUM	CD	9	O
:	:	SYM	SYM	9	O
1	1	NUM	CD	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
propensity	propensity	NOUN	NN	5	O
scoring	scoring	NOUN	NN	5	O
of	of	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
characteristics	characteristic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

INTERVENTIONS	intervention	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Continuous	continuous	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
with	with	ADP	IN	5	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

MEASUREMENTS	measurement	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
MAIN	main	ADJ	JJ	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
342	342	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
105	105	NUM	CD	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
237	237	NUM	CD	7	O
propofol	propofol	ADJ	JJ	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
190	190	NUM	CD	9	O
matched	match	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
propensity	propensity	NOUN	NN	5	O
score	score	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
outcome	outcome	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
composite	composite	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
<	<	X	XX	0	O
60	60	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
<	<	X	XX	0	O
50	50	NUM	CD	0	O
beats	beat	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
sedative	sedative	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
composite	composite	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
unmatched	unmatched	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
94	94	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
matched	match	VERB	VBN	9	O
cohorts	cohort	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
28	28	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
34	34	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
analyzed	analyze	VERB	VBN	9	O
separately	separately	ADV	RB	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
either	either	CCONJ	CC	9	O
the	the	DET	DT	5	O
unmatched	unmatched	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
matched	match	VERB	VBN	9	O
cohorts	cohort	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Severe	severe	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
occur	occur	VERB	VBP	5	O
at	at	ADP	IN	9	O
similar	similar	ADJ	JJ	9	O
prevalence	prevalence	NOUN	NN	5	O
in	in	ADP	IN	5	O
neurocritical	neurocritical	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
receive	receive	VERB	VBP	5	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Providers	provider	NOUN	NNS	5	O
should	should	VERB	MD	5	O
similarly	similarly	ADV	RB	9	O
consider	consider	VERB	VB	5	O
the	the	DET	DT	5	O
likelihood	likelihood	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
before	before	ADP	IN	9	O
starting	start	VERB	VBG	9	O
either	either	CCONJ	CC	9	O
sedative	sedative	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hydroxytyrosol	hydroxytyrosol	NOUN	NN	0	B-Chemical
ameliorates	ameliorate	NOUN	NNS	3	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
several	several	ADJ	JJ	9	O
processes	process	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
cancer	cancer	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
aging	aging	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
potentiate	potentiate	VERB	VB	3	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
causes	cause	VERB	VBZ	9	O
significant	significant	ADJ	JJ	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
marked	marked	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Herein	Herein	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigate	investigate	VERB	VBP	9	O
whether	whether	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
chronic	chronic	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
ameliorated	ameliorate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
hydroxytyrosol	hydroxytyrosol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
bearing	bear	VERB	VBG	3	O
breast	breast	NOUN	NN	3	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
induced	induce	VERB	VBD	3	O
chemically	chemically	ADV	RB	0	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
4	4	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
hydroxytyrosol	hydroxytyrosol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5mg	5mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
5days	5days	NUM	CD	0	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1mg	1mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
hydroxytyrosol	hydroxytyrosol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
cellular	cellular	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
electron	electron	NOUN	NN	0	O
transport	transport	NOUN	NN	9	O
chain	chain	NOUN	NN	9	O
complexes	complex	NOUN	NNS	9	O
I	I	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
IV	IV	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
apoptosis	apoptosis	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
inducing	induce	VERB	VBG	3	O
factor	factor	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
markers	marker	NOUN	NNS	3	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
analyzed	analyze	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Hydroxytyrosol	Hydroxytyrosol	PROPN	NNP	0	B-Chemical
improved	improve	VERB	VBD	5	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
enhanced	enhance	VERB	VBN	3	O
by	by	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
significantly	significantly	ADV	RB	9	O
reducing	reduce	VERB	VBG	9	O
the	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
altered	altered	ADJ	JJ	9	O
mitochondria	mitochondria	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
hydroxytyrosol	hydroxytyrosol	NOUN	NN	0	B-Chemical
improve	improve	VERB	VB	5	O
the	the	DET	DT	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
electron	electron	NOUN	NN	0	O
transport	transport	NOUN	NN	9	O
chain	chain	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
hydroxytyrosol	hydroxytyrosol	NOUN	NN	0	B-Chemical
protect	protect	VERB	VB	9	O
rat	rat	NOUN	NN	3	O
heart	heart	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
provoked	provoke	VERB	VBN	9	O
by	by	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
decreasing	decrease	VERB	VBG	9	O
oxidative	oxidative	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Amiodarone	amiodarone	ADV	RB	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myxoedema	myxoedema	NOUN	NN	5	B-Disease
coma	coma	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
62	62	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Thyroid	Thyroid	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
stimulating	stimulate	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
168	168	NUM	CD	7	O
uIU	uiu	NUM	CD	7	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
nl	nl	NOUN	NN	0	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
uIU	uiu	NOUN	NN	7	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
free	free	ADJ	JJ	9	O
thyroxine	thyroxine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
FT4	FT4	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
nl	nl	NOUN	NN	0	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
received	receive	VERB	VBD	9	O
intravenous	intravenous	ADJ	JJ	0	O
fluids	fluid	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
vasopressor	vasopressor	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
stress	stress	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
steroids	steroid	NOUN	NNS	9	B-Chemical
;	;	PUNCT	:	9	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
intubated	intubate	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
received	receive	VERB	VBD	9	O
500	500	NUM	CD	0	O
ug	ug	NOUN	NN	0	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
levothyroxine	levothyroxine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
18	18	NUM	CD	7	O
h	h	NOUN	NN	0	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
150	150	NUM	CD	0	O
ug	ug	NOUN	NN	0	O
intravenous	intravenous	ADJ	JJ	0	O
daily	daily	ADV	RB	5	O
thereafter	thereafter	ADV	RB	9	O
.	.	PUNCT	.	9	O

Haemodynamic	haemodynamic	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
,	,	PUNCT	,	9	O
along	along	ADP	IN	9	O
with	with	ADP	IN	5	O
complete	complete	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
,	,	PUNCT	,	9	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Twelve	twelve	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
FT4	FT4	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
96	96	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
on	on	ADP	IN	5	O
levothyroxine	levothyroxine	NOUN	NN	5	B-Chemical
175	175	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
g	g	NOUN	NN	0	O
POorally	poorally	ADV	RB	_	O
daily	daily	ADV	RB	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
thyroid	thyroid	NOUN	NN	9	O
ultrasound	ultrasound	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
diffuse	diffuse	NOUN	NN	5	O
heterogeneity	heterogeneity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
24	24	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
iodine	iodine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
3657	3657	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
mcg	mcg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
756	756	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
mcg	mcg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myxoedema	myxoedema	NOUN	NN	5	B-Disease
coma	coma	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
report	report	NOUN	NN	5	O
patient	patient	ADJ	JJ	5	O
death	death	NOUN	NN	9	O
despite	despite	ADP	IN	9	O
supportive	supportive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
thyroid	thyroid	NOUN	NN	9	O
hormone	hormone	NOUN	NN	9	O
replacement	replacement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
represents	represent	VERB	VBZ	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
thoroughly	thoroughly	ADV	RB	9	O
investigated	investigate	VERB	VBN	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myxoedema	myxoedema	NOUN	NN	5	B-Disease
coma	coma	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
significant	significant	ADJ	JJ	9	O
for	for	ADP	IN	5	O
subclinical	subclinical	ADJ	JJ	5	O
thyroid	thyroid	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
and	and	CCONJ	CC	5	O
catheter	catheter	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
directed	direct	VERB	VBN	9	O
thrombolysis	thrombolysis	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
alteplase	alteplase	NOUN	NN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
oncology	oncology	NOUN	NN	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
oncology	oncology	NOUN	NN	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
HITT	HITT	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
plus	plus	CCONJ	CC	9	O
catheter	catheter	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
directed	direct	VERB	VBN	9	O
thrombolysis	thrombolysis	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
CDT	CDT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
alteplase	alteplase	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
63	63	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Caucasian	caucasian	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
amyloidosis	amyloidosis	NOUN	NN	5	B-Disease
undergoing	undergo	VERB	VBG	9	O
peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
collection	collection	NOUN	NN	5	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
autologous	autologous	ADJ	JJ	3	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplant	transplant	NOUN	NN	9	O
developed	develop	VERB	VBD	5	O
extensive	extensive	ADJ	JJ	5	O
bilateral	bilateral	ADJ	JJ	5	O
upper	upper	ADJ	JJ	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
extremity	extremity	NOUN	NN	5	I-Disease
deep	deep	ADJ	JJ	5	I-Disease
venous	venous	ADJ	JJ	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
DVT	DVT	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
embolism	embolism	NOUN	NN	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
continuous	continuous	ADJ	JJ	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
argatroban	argatroban	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
initiated	initiate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
managed	manage	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
general	general	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
floor	floor	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
one	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
transferred	transfer	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
with	with	ADP	IN	5	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
compromise	compromise	NOUN	NN	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
superior	superior	ADJ	JJ	5	B-Disease
vena	vena	NOUN	NN	5	I-Disease
cava	cava	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
SVC	SVC	PROPN	NNP	5	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
percutaneous	percutaneous	ADJ	JJ	5	O
mechanical	mechanical	ADJ	JJ	5	O
thrombectomy	thrombectomy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
CDT	CDT	PROPN	NNP	5	O
with	with	ADP	IN	5	O
alteplase	alteplase	NOUN	NN	5	O
were	be	VERB	VBD	9	O
attempted	attempt	VERB	VBN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
aborted	abort	VERB	VBN	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
epistaxis	epistaxis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
epistaxis	epistaxis	NOUN	NN	5	B-Disease
resolved	resolve	VERB	VBD	9	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
restarted	restart	VERB	VBN	5	O
on	on	ADP	IN	5	O
argatroban	argatroban	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
second	second	ADJ	JJ	9	O
percutaneous	percutaneous	ADJ	JJ	5	O
mechanical	mechanical	ADJ	JJ	5	O
thrombectomy	thrombectomy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
six	six	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
and	and	CCONJ	CC	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
partial	partial	ADJ	JJ	9	O
revascularization	revascularization	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
SVC	SVC	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
central	central	ADJ	JJ	5	O
veins	vein	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Postthrombectomy	Postthrombectomy	PROPN	NNP	_	O
continuous	continuous	ADJ	JJ	5	O
CDT	CDT	PROPN	NNP	5	O
with	with	ADP	IN	5	O
alteplase	alteplase	NOUN	NN	5	O
was	be	VERB	VBD	9	O
commenced	commence	VERB	VBN	5	O
while	while	ADP	IN	9	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
was	be	VERB	VBD	9	O
withheld	withhold	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
complete	complete	ADJ	JJ	9	O
patency	patency	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
SVC	SVC	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
central	central	ADJ	JJ	5	O
veins	vein	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
after	after	ADP	IN	9	O
three	three	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Alteplase	Alteplase	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
reinitiated	reinitiate	VERB	VBN	5	O
on	on	ADP	IN	5	O
argatroban	argatroban	NOUN	NN	5	B-Chemical
;	;	PUNCT	:	9	O
ultimately	ultimately	ADV	RB	5	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
transitioned	transition	VERB	VBN	5	O
to	to	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
recovered	recover	VERB	VBD	9	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
experienced	experience	VERB	VBD	5	O
permanent	permanent	ADJ	JJ	5	O
vision	vision	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
hearing	hearing	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
63	63	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
amyloidosis	amyloidosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
SVC	svc	NOUN	NN	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
HITT	HITT	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
successfully	successfully	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
argatroban	argatroban	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
CDT	CDT	PROPN	NNP	5	O
with	with	ADP	IN	5	O
alteplase	alteplase	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dehydroepiandrosterone	dehydroepiandrosterone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
models	model	NOUN	NNS	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dehydroepiandrosterone	dehydroepiandrosterone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DHEA	DHEA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Seventy	seventy	NUM	CD	5	O
Swiss	swiss	ADJ	JJ	2	O
albino	albino	ADJ	JJ	3	O
female	female	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
35	35	NUM	CD	9	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
4	4	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
DHEA	DHEA	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
DHEA	DHEA	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
ip	ip	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Amphetamine	Amphetamine	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBD	3	O
hyper	hyper	NOUN	NN	5	B-Disease
locomotion	locomotion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
subcutaneously	subcutaneously	ADV	RB	3	O
[	[	PUNCT	-LRB-	9	O
sc	sc	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBN	3	O
climbing	climbing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
sc	sc	X	FW	9	O
)	)	PUNCT	-RRB-	9	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
Animal	Animal	PROPN	NNP	2	O
Experiment	Experiment	PROPN	NNP	5	O
Laboratories	Laboratories	PROPN	NNPS	0	O
,	,	PUNCT	,	9	O
Department	Department	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Pharmacology	Pharmacology	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Medical	Medical	PROPN	NNP	2	O
School	School	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Eskisehir	Eskisehir	PROPN	NNP	2	O
Osmangazi	Osmangazi	PROPN	NNP	2	O
University	University	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Eskisehir	Eskisehir	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Turkey	Turkey	PROPN	NNP	4	O
between	between	ADP	IN	5	O
March	March	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
May	May	PROPN	NNP	2	O
2012	2012	NUM	CD	2	O
.	.	PUNCT	.	9	O

Statistical	statistical	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
using	use	VERB	VBG	9	O
Kruskal	Kruskal	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
Wallis	Wallis	PROPN	NNP	9	O
test	test	NOUN	NN	5	O
for	for	ADP	IN	5	O
hyper	hyper	NOUN	NN	5	B-Disease
locomotion	locomotion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
way	way	NOUN	NN	5	O
ANOVA	ANOVA	PROPN	NNP	5	O
for	for	ADP	IN	5	O
climbing	climbing	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
the	the	DET	DT	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotion	locomotion	NOUN	NN	5	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
movements	movement	NOUN	NNS	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
DHEA	DHEA	NOUN	NNS	0	B-Chemical
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
all	all	DET	DT	5	O
movements	movement	NOUN	NNS	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotion	locomotion	NOUN	NN	5	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
test	test	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
total	total	ADJ	JJ	9	O
climbing	climb	VERB	VBG	5	O
time	time	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
climbing	climbing	NOUN	NN	5	O
test	test	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
observed	observe	VERB	VBD	9	O
that	that	ADP	IN	5	O
DHEA	DHEA	PROPN	NNP	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
both	both	DET	DT	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
climbing	climb	VERB	VBG	5	O
behavior	behavior	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
DHEA	DHEA	PROPN	NNP	0	B-Chemical
displays	display	VERB	VBZ	9	O
typical	typical	ADJ	JJ	9	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Availability	availability	NOUN	NN	5	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
induced	induced	ADJ	JJ	3	O
pluripotent	pluripotent	NOUN	NN	3	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
in	in	ADP	IN	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Field	field	NOUN	NN	9	O
potential	potential	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
FPD	FPD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
human	human	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
pluripotent	pluripotent	NOUN	NN	3	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
hiPS	hiPS	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
CMs	CMs	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
can	can	VERB	MD	5	O
express	express	VERB	VB	3	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
tool	tool	NOUN	NN	5	O
to	to	PART	TO	5	O
predict	predict	VERB	VB	5	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
channel	channel	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
report	report	NOUN	NN	5	O
showing	show	VERB	VBG	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
technique	technique	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
predict	predict	VERB	VB	5	O
multichannel	multichannel	NOUN	NN	5	O
blocker	blocker	NOUN	NN	0	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
show	show	VERB	VB	9	O
that	that	ADP	IN	5	O
FPD	FPD	PROPN	NNP	5	O
from	from	ADP	IN	9	O
MEA	MEA	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
Multielectrode	Multielectrode	PROPN	NNP	5	O
array	array	VERB	VB	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
hiPS	hiPS	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
CMs	cm	NOUN	NNS	5	O
can	can	VERB	MD	5	O
detect	detect	VERB	VB	9	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
multichannel	multichannel	NOUN	NN	5	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

hiPS	hips	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
CMs	cm	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
seeded	seed	VERB	VBN	3	O
onto	onto	ADP	IN	0	O
MEA	MEA	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
FPD	FPD	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
for	for	ADP	IN	5	O
2min	2min	NUM	CD	0	O
every	every	DET	DT	5	O
10min	10min	NOUN	NN	0	O
for	for	ADP	IN	5	O
30min	30min	NOUN	NN	0	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
vehicle	vehicle	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
each	each	DET	DT	5	O
drug	drug	NOUN	NN	5	O
concentration	concentration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

IKr	IKr	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
IKs	ik	NOUN	NNS	0	O
blockers	blocker	NOUN	NNS	9	O
concentration	concentration	NOUN	NN	0	O
-	-	PUNCT	:	7	O
dependently	dependently	ADV	RB	3	O
prolonged	prolong	VERB	VBN	9	O
corrected	correct	VERB	VBN	5	O
FPD	FPD	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
FPDc	FPDc	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
concentration	concentration	NOUN	NN	0	O
-	-	PUNCT	:	7	O
dependently	dependently	ADV	RB	3	O
shortened	shorten	VERB	VBN	9	O
FPDc	FPDc	NOUN	NNS	_	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
multichannel	multichannel	NOUN	NN	5	O
blockers	blocker	VERB	VBZ	9	O
Amiodarone	Amiodarone	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
Paroxetine	Paroxetine	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
Terfenadine	Terfenadine	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
Citalopram	Citalopram	PROPN	NNP	7	B-Chemical
prolonged	prolong	VERB	VBD	9	O
FPDc	FPDc	PROPN	NNP	_	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
IKr	IKr	PROPN	NNP	5	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
Terfenadine	Terfenadine	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
Citalopram	Citalopram	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
Torsade	Torsade	PROPN	NNP	2	B-Disease
de	de	ADP	IN	2	I-Disease
Pointes	Pointes	PROPN	NNP	2	I-Disease
(	(	PUNCT	-LRB-	9	O
TdP	TdP	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
,	,	PUNCT	,	9	O
produced	produce	VERB	VBD	9	O
early	early	ADJ	JJ	9	O
afterdepolarization	afterdepolarization	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EAD	EAD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

hiPS	hips	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
CMs	cm	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
MEA	MEA	PROPN	NNP	0	O
system	system	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
FPDc	FPDc	NOUN	NNS	_	O
can	can	VERB	MD	5	O
predict	predict	VERB	VB	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
candidates	candidate	NOUN	NNS	9	O
on	on	ADP	IN	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
also	also	ADV	RB	9	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
assay	assay	NOUN	NN	3	O
can	can	VERB	MD	5	O
help	help	VERB	VB	5	O
detect	detect	VERB	VB	9	O
EAD	EAD	PROPN	NNP	5	O
for	for	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
with	with	ADP	IN	5	O
TdP	tdp	NOUN	NN	5	B-Disease
potential	potential	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dermal	dermal	ADJ	JJ	3	O
developmental	developmental	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
phenylimide	phenylimide	NOUN	NN	_	O
herbicides	herbicide	NOUN	NNS	0	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
53482	53482	NUM	CD	_	I-Chemical
and	and	CCONJ	CC	5	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
23121	23121	NUM	CD	7	I-Chemical
are	be	VERB	VBP	5	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
phenylimide	phenylimide	NOUN	NN	_	O
herbicides	herbicide	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
produced	produce	VERB	VBN	9	O
embryolethality	embryolethality	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
teratogenicity	teratogenicity	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
mainly	mainly	ADV	RB	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
septal	septal	ADJ	JJ	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
and	and	CCONJ	CC	5	O
wavy	wavy	NOUN	NN	5	O
ribs	rib	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
growth	growth	NOUN	NN	3	B-Disease
retardation	retardation	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
oral	oral	ADJ	JJ	9	O
developmental	developmental	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
objective	objective	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
compounds	compound	NOUN	NNS	0	O
induce	induce	VERB	VBP	3	O
developmental	developmental	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
dermal	dermal	ADJ	JJ	3	O
route	route	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
more	more	ADV	RBR	5	O
relevant	relevant	ADJ	JJ	5	O
to	to	ADP	IN	5	O
occupational	occupational	ADJ	JJ	5	O
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
hence	hence	ADV	RB	5	O
better	well	ADJ	JJR	5	O
addressing	address	VERB	VBG	5	O
human	human	ADJ	JJ	3	O
health	health	NOUN	NN	5	O
risks	risk	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
53482	53482	PROPN	NNP	_	I-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
dermally	dermally	ADV	RB	0	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
at	at	ADP	IN	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
during	during	ADP	IN	5	O
organogenesis	organogenesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
23121	23121	NUM	CD	7	I-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
at	at	ADP	IN	9	O
200	200	NUM	CD	0	O
,	,	PUNCT	,	9	O
400	400	NUM	CD	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
the	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
applicable	applicable	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
level	level	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Fetuses	fetus	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
Cesarean	cesarean	ADJ	JJ	5	O
section	section	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
external	external	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
visceral	visceral	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
skeletal	skeletal	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Dermal	dermal	ADJ	JJ	3	O
exposure	exposure	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
to	to	ADP	IN	5	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
53482	53482	NUM	CD	_	I-Chemical
at	at	ADP	IN	9	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	ADP	IN	0	O
produced	produce	VERB	VBN	9	O
patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
developmental	developmental	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
resulting	result	VERB	VBG	9	O
from	from	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Toxicity	toxicity	NOUN	NN	9	B-Disease
included	include	VERB	VBD	5	O
embryolethality	embryolethality	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
teratogenicity	teratogenicity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
growth	growth	NOUN	NN	3	B-Disease
retardation	retardation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Dermal	dermal	ADJ	JJ	3	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
23121	23121	NUM	CD	7	I-Chemical
at	at	ADP	IN	9	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	ADP	IN	0	O
resulted	result	VERB	VBN	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
embryonic	embryonic	ADJ	JJ	3	B-Disease
death	death	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
septal	septal	ADJ	JJ	5	I-Disease
defect	defect	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
retarded	retard	VERB	VBN	9	O
fetal	fetal	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
as	as	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
following	follow	VERB	VBG	9	O
oral	oral	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
23121	23121	NUM	CD	7	I-Chemical
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
53482	53482	PROPN	NNP	_	I-Chemical
and	and	CCONJ	CC	5	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
23121	23121	NUM	CD	7	I-Chemical
were	be	VERB	VBD	9	O
teratogenic	teratogenic	ADJ	JJ	5	B-Disease
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
dermally	dermally	ADV	RB	0	O
to	to	ADP	IN	5	O
pregnant	pregnant	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
as	as	ADP	IN	5	O
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
compounds	compound	NOUN	NNS	0	O
administered	administer	VERB	VBD	9	O
orally	orally	ADV	RB	0	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
investigation	investigation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
human	human	ADJ	JJ	3	O
relevancy	relevancy	NOUN	NN	5	O
become	become	VERB	VBP	5	O
more	more	ADV	RBR	5	O
important	important	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Rates	Rates	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Renal	Renal	PROPN	NNP	9	B-Disease
Toxicity	Toxicity	PROPN	NNP	9	I-Disease
in	in	ADP	IN	5	O
Cancer	Cancer	PROPN	NNP	2	B-Disease
Patients	Patients	PROPN	NNP	5	O
Receiving	receive	VERB	VBG	5	O
Cisplatin	Cisplatin	PROPN	NNP	0	B-Chemical
With	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
Without	without	ADP	IN	9	O
Mannitol	Mannitol	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Cisplatin	Cisplatin	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
antineoplastic	antineoplastic	NOUN	NN	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
use	use	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
many	many	ADJ	JJ	5	O
strategies	strategy	NOUN	NNS	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
this	this	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
nephroprotectant	nephroprotectant	NOUN	NN	0	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
hydration	hydration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
agent	agent	NOUN	NN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
center	center	NOUN	NN	5	O
retrospective	retrospective	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
quasi	quasi	ADJ	JJ	5	O
experiment	experiment	NOUN	NN	9	O
created	create	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
national	national	ADJ	JJ	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
shortage	shortage	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
on	on	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
agent	agent	NOUN	NN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
outpatient	outpatient	NOUN	NN	5	O
from	from	ADP	IN	9	O
January	January	PROPN	NNP	2	O
2011	2011	NUM	CD	2	O
to	to	ADP	IN	5	O
September	September	PROPN	NNP	2	O
2012	2012	NUM	CD	2	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
outcome	outcome	NOUN	NN	5	O
was	be	VERB	VBD	9	O
acute	acute	ADJ	JJ	9	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
AKI	AKI	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
evaluated	evaluate	VERB	VBD	9	O
143	143	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
agent	agent	NOUN	NN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
;	;	PUNCT	:	9	O
97	97	NUM	CD	7	O
.	.	NOUN	NN	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
head	head	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
neck	neck	NOUN	NN	5	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
as	as	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
primary	primary	ADJ	JJ	9	O
malignancy	malignancy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
receive	receive	VERB	VB	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
]	]	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
646	646	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
008	008	NUM	CD	7	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
944	944	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
048	048	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
dosing	dosing	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
also	also	ADV	RB	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
likelihood	likelihood	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
494	494	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
149	149	NUM	CD	7	O
,	,	PUNCT	,	9	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
258	258	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
219	219	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
228	228	NUM	CD	7	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
439	439	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
017	017	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
When	when	ADV	WRB	9	O
limited	limited	ADJ	JJ	5	O
quantities	quantity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
available	available	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
should	should	VERB	MD	5	O
preferentially	preferentially	ADV	RB	9	O
be	be	VERB	VB	5	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
particularly	particularly	ADV	RB	5	O
high	high	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
analysis	analysis	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
those	those	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
the	the	DET	DT	5	O
dosing	dosing	ADJ	JJ	9	O
schedule	schedule	NOUN	NN	5	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
greatest	great	ADJ	JJS	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
would	would	VERB	MD	5	O
benefit	benefit	VERB	VB	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Metformin	Metformin	PROPN	NNP	0	B-Chemical
protects	protect	VERB	VBZ	3	O
against	against	ADP	IN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
learning	learning	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
impairments	impairment	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pentylenetetrazole	pentylenetetrazole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
kindling	kindling	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
comorbidity	comorbidity	NOUN	NN	5	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
greatly	greatly	ADV	RB	9	O
diminishes	diminish	VERB	VBZ	9	O
the	the	DET	DT	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
current	current	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
interventions	intervention	NOUN	NNS	5	O
for	for	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
can	can	VERB	MD	5	O
also	also	ADV	RB	9	O
cause	cause	VERB	VB	5	O
untoward	untoward	ADJ	JJ	5	O
cognitive	cognitive	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
urgent	urgent	ADJ	JJ	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
new	new	ADJ	JJ	5	O
kinds	kind	NOUN	NNS	5	O
of	of	ADP	IN	5	O
agents	agent	NOUN	NNS	5	O
targeting	target	VERB	VBG	3	O
both	both	DET	DT	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
cognition	cognition	NOUN	NN	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
play	play	VERB	VB	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
epileptogenesis	epileptogenesis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
antioxidants	antioxidant	NOUN	NNS	0	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
putative	putative	ADJ	JJ	1	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
potential	potential	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Metformin	Metformin	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
commonly	commonly	ADV	RB	5	O
prescribed	prescribe	VERB	VBN	5	O
antidiabetic	antidiabetic	ADJ	JJ	0	O
oral	oral	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
antioxidant	antioxidant	ADJ	JJ	0	O
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
ameliorative	ameliorative	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
on	on	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
markers	marker	NOUN	NNS	3	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
pentylenetetrazole	pentylenetetrazole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
kindling	kindle	VERB	VBG	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
with	with	ADP	IN	5	O
subconvulsive	subconvulsive	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
pentylenetetrazole	pentylenetetrazole	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
37	37	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
every	every	DET	DT	5	O
other	other	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
injections	injection	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Metformin	Metformin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
in	in	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
200mg	200mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	VERB	VB	0	O
along	along	ADV	RB	9	O
with	with	ADP	IN	5	O
alternate	alternate	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
PTZ	ptz	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
that	that	DET	DT	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
suppressed	suppress	VERB	VBD	3	O
the	the	DET	DT	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
kindling	kindling	NOUN	NN	5	O
,	,	PUNCT	,	9	O
ameliorated	ameliorate	VERB	VBD	9	O
the	the	DET	DT	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
brain	brain	NOUN	NN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
concluded	conclude	VERB	VBD	9	O
that	that	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
medicine	medicine	NOUN	NN	5	O
against	against	ADP	IN	9	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

P53	p53	NOUN	NN	3	O
inhibition	inhibition	NOUN	NN	3	O
exacerbates	exacerbate	VERB	VBZ	9	O
late	late	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
stage	stage	NOUN	NN	9	O
anthracycline	anthracycline	ADJ	JJ	9	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

AIMS	aims	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
cancer	cancer	ADJ	JJ	3	B-Disease
therapeutic	therapeutic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
both	both	CCONJ	CC	9	O
acute	acute	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
late	late	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
stage	stage	NOUN	NN	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Children	child	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
particularly	particularly	ADV	RB	5	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
p53	p53	NOUN	NN	3	O
inhibition	inhibition	NOUN	NN	3	O
on	on	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
late	late	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
stage	stage	NOUN	NN	9	O
DOX	dox	NOUN	NN	0	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
juvenile	juvenile	ADJ	JJ	4	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
MHC	MHC	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
CB7	CB7	PROPN	NNP	0	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
which	which	DET	WDT	5	O
express	express	VERB	VBP	3	O
dominant	dominant	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
interfering	interfere	VERB	VBG	3	O
p53	p53	NOUN	NN	3	O
in	in	ADP	IN	5	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
transgenic	transgenic	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
NON	NON	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
TXG	TXG	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
littermates	littermate	VERB	VBZ	3	O
received	receive	VERB	VBD	9	O
weekly	weekly	ADJ	JJ	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
injections	injection	NOUN	NNS	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
acute	acute	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
MHC	MHC	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
CB7	CB7	PROPN	NNP	0	O
mice	mouse	NOUN	NNS	3	O
exhibited	exhibit	VERB	VBD	9	O
improved	improve	VERB	VBN	5	O
cardiac	cardiac	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
NON	NON	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
TXG	TXG	PROPN	NNP	1	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Surprisingly	surprisingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
13	13	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
late	late	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
MHC	MHC	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
CB7	CB7	PROPN	NNP	0	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
progressive	progressive	ADJ	JJ	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
NON	NON	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
TXG	TXG	PROPN	NNP	1	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

p53	p53	NOUN	NN	3	O
inhibition	inhibition	NOUN	NN	3	O
blocked	block	VERB	VBD	3	O
transient	transient	ADJ	JJ	9	O
DOX	dox	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
STAT3	STAT3	PROPN	NNP	3	O
activation	activation	NOUN	NN	3	O
in	in	ADP	IN	5	O
MHC	MHC	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
CB7	CB7	PROPN	NNP	0	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
enhanced	enhanced	ADJ	JJ	3	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
DNA	dna	NOUN	NN	9	O
repair	repair	NOUN	NN	9	O
proteins	protein	NOUN	NNS	1	O
Ku70	Ku70	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
Ku80	Ku80	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

Mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
restricted	restrict	VERB	VBN	9	O
deletion	deletion	NOUN	NN	1	O
of	of	ADP	IN	5	O
STAT3	STAT3	PROPN	NNP	3	O
exhibited	exhibit	VERB	VBD	9	O
worse	bad	ADJ	JJR	5	O
cardiac	cardiac	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
higher	high	ADJ	JJR	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
Ku70	Ku70	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
Ku80	Ku80	PROPN	NNP	3	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
support	support	VERB	VBP	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
wherein	wherein	ADV	WRB	9	O
a	a	DET	DT	5	O
p53	p53	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
pathway	pathway	NOUN	NN	3	O
,	,	PUNCT	,	9	O
mediated	mediate	VERB	VBN	3	O
via	via	ADP	IN	9	O
STAT3	STAT3	PROPN	NNP	3	O
activation	activation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
mitigates	mitigate	NOUN	NNS	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
during	during	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
delivery	delivery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
an	an	DET	DT	5	O
explanation	explanation	NOUN	NN	5	O
as	as	ADP	IN	5	O
to	to	ADP	IN	5	O
how	how	ADV	WRB	5	O
p53	p53	NOUN	NN	3	O
inhibition	inhibition	NOUN	NN	3	O
can	can	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
cardioprotection	cardioprotection	NOUN	NN	3	O
during	during	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
paradoxically	paradoxically	ADV	RB	9	O
,	,	PUNCT	,	9	O
enhanced	enhance	VERB	VBD	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
long	long	ADV	RB	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Metronidazole	Metronidazole	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
uncommon	uncommon	ADJ	JJ	5	O
scenario	scenario	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Metronidazole	Metronidazole	PROPN	NNP	0	B-Chemical
can	can	VERB	MD	5	O
produce	produce	VERB	VB	9	O
neurological	neurological	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
although	although	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
scenario	scenario	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
where	where	ADV	WRB	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
following	follow	VERB	VBG	9	O
prolonged	prolong	VERB	VBN	9	O
metronidazole	metronidazole	NOUN	NN	0	B-Chemical
intake	intake	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Magnetic	magnetic	ADJ	JJ	5	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MRI	MRI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
brain	brain	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
abnormal	abnormal	ADJ	JJ	9	O
signal	signal	NOUN	NN	9	O
intensity	intensity	NOUN	NN	5	O
involving	involve	VERB	VBG	5	O
both	both	DET	DT	9	O
dentate	dentate	ADJ	JJ	3	O
nuclei	nucleus	NOUN	NNS	3	O
of	of	ADP	IN	5	O
cerebellum	cerebellum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
splenium	splenium	NOUN	NN	5	O
of	of	ADP	IN	5	O
corpus	corpus	NOUN	NN	5	O
callosum	callosum	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
metronidazole	metronidazole	ADJ	JJ	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
MRI	MRI	PROPN	NNP	5	O
findings	finding	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
supported	support	VERB	VBD	9	O
clinically	clinically	ADV	RB	5	O
.	.	PUNCT	.	9	O

Aconitine	Aconitine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
Ca2	Ca2	NOUN	NNS	0	B-Chemical
+	+	PART	POS	9	O
overload	overload	NOUN	NN	9	O
causes	cause	VERB	VBZ	9	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
triggers	trigger	VERB	VBZ	9	O
apoptosis	apoptosis	NOUN	NN	3	O
through	through	ADP	IN	9	O
p38	p38	NOUN	NN	3	O
MAPK	MAPK	PROPN	NNP	3	O
signaling	signal	VERB	VBG	3	O
pathway	pathway	NOUN	NN	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Aconitine	Aconitine	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
bioactive	bioactive	ADJ	JJ	0	O
diterpenoid	diterpenoid	NOUN	NN	0	O
alkaloid	alkaloid	NOUN	NN	0	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
content	content	NOUN	NN	9	O
derived	derive	VERB	VBN	9	O
from	from	ADP	IN	9	O
herbal	herbal	ADJ	JJ	5	O
aconitum	aconitum	NOUN	NN	0	O
plants	plant	NOUN	NNS	4	O
.	.	PUNCT	.	9	O

Emerging	emerge	VERB	VBG	2	O
evidence	evidence	NOUN	NN	9	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
voltage	voltage	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
Na	Na	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
channels	channel	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
pivotal	pivotal	ADJ	JJ	9	O
roles	role	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
reports	report	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
available	available	ADJ	JJ	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
poisoning	poisoning	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
explored	explore	VERB	VBD	9	O
the	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
pathological	pathological	ADJ	JJ	5	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
signaling	signal	VERB	VBG	3	O
in	in	ADP	IN	5	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
poisoning	poisoning	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
overload	overload	NOUN	NN	9	O
lead	lead	NOUN	NN	5	O
to	to	ADP	IN	5	O
accelerated	accelerated	ADJ	JJ	9	O
beating	beat	VERB	VBG	5	O
rhythm	rhythm	NOUN	NN	5	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
rat	rat	NOUN	NN	3	O
ventricular	ventricular	ADJ	JJ	5	O
myocytes	myocyte	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
caused	cause	VERB	VBD	9	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
freely	freely	ADV	RB	5	O
moving	move	VERB	VBG	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
investigate	investigate	VERB	VB	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
performed	perform	VERB	VBD	9	O
cytotoxicity	cytotoxicity	NOUN	NN	3	B-Disease
assay	assay	ADJ	JJ	3	O
in	in	ADP	IN	5	O
neonatal	neonatal	ADJ	JJ	9	O
rat	rat	NOUN	NN	3	O
ventricular	ventricular	ADJ	JJ	5	O
myocytes	myocyte	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
NRVMs	NRVMs	PROPN	NNPS	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
lactate	lactate	NOUN	NN	0	B-Chemical
dehydrogenase	dehydrogenase	NOUN	NN	1	O
level	level	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
culture	culture	NOUN	NN	9	O
medium	medium	NOUN	NN	0	O
of	of	ADP	IN	5	O
NRVMs	nrvm	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
enzymes	enzyme	NOUN	NNS	1	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
NRVMs	nrvm	NOUN	NNS	3	O
viability	viability	NOUN	NN	3	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	:	7	O
dependently	dependently	ADV	RB	3	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
confirm	confirm	VERB	VB	9	O
the	the	DET	DT	5	O
pro	pro	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
apoptotic	apoptotic	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
performed	perform	VERB	VBD	9	O
flow	flow	VERB	VBP	5	O
cytometric	cytometric	ADJ	JJ	3	O
detection	detection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
histology	histology	NOUN	NN	9	O
,	,	PUNCT	,	9	O
transmission	transmission	NOUN	NN	5	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
terminal	terminal	ADJ	JJ	9	O
deoxynucleotidyl	deoxynucleotidyl	NOUN	NN	3	O
transferase	transferase	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
dUTP	dUTP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
biotin	biotin	ADJ	JJ	0	B-Chemical
nick	nick	ADJ	JJ	0	O
end	end	NOUN	NN	9	O
labeling	labeling	NOUN	NN	3	O
assay	assay	ADJ	JJ	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
stimulated	stimulate	VERB	VBD	3	O
apoptosis	apoptosis	NOUN	NN	3	O
time	time	NOUN	NN	5	O
-	-	PUNCT	:	7	O
dependently	dependently	ADV	RB	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
handling	handle	VERB	VBG	5	O
proteins	protein	NOUN	NNS	1	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
promoted	promote	VERB	VBN	3	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
overload	overload	NOUN	NN	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
handling	handle	VERB	VBG	5	O
proteins	protein	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
apoptosis	apoptosis	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
proteins	protein	NOUN	NNS	1	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
pro	pro	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
apoptotic	apoptotic	ADJ	JJ	3	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
was	be	VERB	VBD	9	O
upregulated	upregulate	VERB	VBN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
apoptotic	apoptotic	ADJ	JJ	3	O
protein	protein	NOUN	NN	1	O
BCL	BCL	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
expression	expression	NOUN	NN	3	O
was	be	VERB	VBD	9	O
downregulated	downregulate	VERB	VBN	3	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
phosphorylation	phosphorylation	NOUN	NN	3	O
of	of	ADP	IN	5	O
MAPK	MAPK	PROPN	NNP	3	O
family	family	NOUN	NN	9	O
members	member	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
the	the	DET	DT	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P38	P38	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
P38	P38	PROPN	NNP	3	O
ratio	ratio	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
tissues	tissue	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Hence	hence	ADV	RB	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
significantly	significantly	ADV	RB	9	O
aggravates	aggravate	VERB	VBZ	9	O
Ca	ca	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
overload	overload	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
causes	cause	VERB	VBZ	9	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
finally	finally	ADV	RB	9	O
promotes	promote	VERB	VBZ	3	O
apoptotic	apoptotic	ADJ	JJ	3	O
development	development	NOUN	NN	9	O
via	via	ADP	IN	9	O
phosphorylation	phosphorylation	NOUN	NN	3	O
of	of	ADP	IN	5	O
P38	P38	PROPN	NNP	3	O
mitogen	mitogen	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
activated	activate	VERB	VBN	3	O
protein	protein	NOUN	NN	1	O
kinase	kinase	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
suppresses	suppress	VERB	VBZ	3	O
toll	toll	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
receptor	receptor	NOUN	NN	3	O
4	4	NUM	CD	9	O
signaling	signaling	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
attenuates	attenuate	VERB	VBZ	3	O
left	leave	VERB	VBD	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
responses	response	NOUN	NNS	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
AMP	AMP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
activated	activate	VERB	VBN	3	O
protein	protein	NOUN	NN	1	O
kinase	kinase	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
AMPK	AMPK	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
on	on	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
toll	toll	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
receptor	receptor	NOUN	NN	3	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
TLR4	TLR4	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
activities	activity	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
relation	relation	NOUN	NN	5	O
with	with	ADP	IN	5	O
AMPK	AMPK	PROPN	NNP	3	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
normal	normal	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
25	25	NUM	CD	9	O
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
100mg	100mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Isoproterenol	Isoproterenol	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
100mg	100mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
subcutaneously	subcutaneously	ADV	RB	3	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
13th	13th	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
14th	14th	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
acute	acute	ADJ	JJ	9	B-Disease
myocardial	myocardial	ADJ	JJ	9	I-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
systolic	systolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
myocardial	myocardial	ADJ	JJ	9	O
contractility	contractility	NOUN	NN	9	O
indexed	index	VERB	VBN	5	O
as	as	ADP	IN	5	O
LVdp	LVdp	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
dtmax	dtmax	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
LVdp	LVdp	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
dtmin	dtmin	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
left	left	ADJ	JJ	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
25	25	NUM	CD	9	O
and	and	CCONJ	CC	5	O
50mg	50mg	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Metfromin	Metfromin	PROPN	NNP	_	O
markedly	markedly	ADV	RB	9	O
lowered	lower	VERB	VBD	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
elevation	elevation	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
TLR4	TLR4	PROPN	NNP	3	O
mRNA	mRNA	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
myeloid	myeloid	ADJ	JJ	3	O
differentiation	differentiation	NOUN	NN	3	O
protein	protein	NOUN	NN	1	O
88	88	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
MyD88	MyD88	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
tumor	tumor	NOUN	NN	3	B-Disease
necrosis	necrosis	NOUN	NN	9	B-Disease
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
TNF	TNF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
a	a	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
interleukin	interleukin	NOUN	NN	3	O
6	6	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
tissues	tissue	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
TNF	TNF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
a	a	DET	DT	5	O
and	and	CCONJ	CC	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
25	25	NUM	CD	9	O
and	and	CCONJ	CC	5	O
50mg	50mg	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
effective	effective	ADJ	JJ	5	O
than	than	ADP	IN	5	O
100mg	100mg	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Phosphorylated	phosphorylate	VERB	VBN	3	O
AMPKa	AMPKa	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
p	p	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
AMPK	ampk	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
myocardium	myocardium	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
elevated	elevate	VERB	VBN	9	O
by	by	ADP	IN	9	O
25mg	25mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
slightly	slightly	ADV	RB	9	O
by	by	ADP	IN	9	O
50mg	50mg	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
by	by	ADP	IN	9	O
100mg	100mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
reduces	reduce	VERB	VBZ	9	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
cardiac	cardiac	ADJ	JJ	5	O
dysfunction	dysfunction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
suppresses	suppress	VERB	VBZ	3	O
inflammatory	inflammatory	ADJ	JJ	3	O
responses	response	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
through	through	ADP	IN	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
TLR4	TLR4	PROPN	NNP	3	O
activities	activity	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
target	target	NOUN	NN	9	O
to	to	PART	TO	5	O
protect	protect	VERB	VB	9	O
infarcted	infarcte	VERB	VBN	3	O
myocardium	myocardium	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Unusual	unusual	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
antithyroid	antithyroid	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
four	four	NUM	CD	9	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
methimazole	methimazole	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
lupus	lupus	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
antithyroid	antithyroid	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
for	for	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
occurrence	occurrence	NOUN	NN	5	O
are	be	VERB	VBP	5	O
reviewed	review	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
thyroidectomy	thyroidectomy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
radioiodine	radioiodine	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
antithyroid	antithyroid	ADJ	JJ	0	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
circumstances	circumstance	NOUN	NNS	5	O
131I	131i	NUM	CD	0	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
choice	choice	NOUN	NN	5	O
for	for	ADP	IN	5	O
hyperthyroidism	hyperthyroidism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Neuroleptic	neuroleptic	ADJ	JJ	2	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
tetrabenazine	tetrabenazine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
tiapride	tiapride	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
Japanese	japanese	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
Huntington	Huntington	PROPN	NNP	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
terminal	terminal	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
of	of	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
herein	herein	VERB	VBP	9	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
81	81	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Japanese	japanese	ADJ	JJ	9	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
occurred	occur	VERB	VBD	9	O
36	36	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
tiapride	tiapride	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
tetrabenazine	tetrabenazine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
Huntington	Huntington	PROPN	NNP	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
tiapride	tiapride	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
tetrabenazine	tetrabenazine	NOUN	NN	5	B-Chemical
alone	alone	ADV	RB	9	O
without	without	ADP	IN	9	O
any	any	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
had	have	VERB	VBD	9	O
advanced	advance	VERB	VBN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
initiated	initiate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
the	the	DET	DT	5	O
best	good	ADJ	JJS	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
tetrabenazine	tetrabenazine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
tiapride	tiapride	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Tetrabenazine	tetrabenazine	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
administered	administer	VERB	VBN	9	O
very	very	ADV	RB	5	O
carefully	carefully	ADV	RB	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Chemical
drugs	drug	NOUN	NNS	5	I-Chemical
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
worsening	worsen	VERB	VBG	5	O
general	general	ADJ	JJ	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
terbinafine	terbinafine	NOUN	NN	0	B-Chemical
combination	combination	NOUN	NN	9	O
induced	induce	VERB	VBD	3	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
sinus	sinus	NOUN	NN	5	B-Disease
bradycardia	bradycardia	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
terbinafine	terbinafine	NOUN	NN	0	B-Chemical
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
63	63	NUM	CD	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Caucasian	caucasian	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
on	on	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
stable	stable	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
prescribed	prescribe	VERB	VBN	5	O
a	a	DET	DT	5	O
90	90	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
terbinafine	terbinafine	NOUN	NN	0	B-Chemical
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
onychomycosis	onychomycosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
49th	49th	ADJ	JJ	2	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
terbinafine	terbinafine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
brought	bring	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
room	room	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
global	global	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
status	status	NOUN	NN	9	O
,	,	PUNCT	,	9	O
confusion	confusion	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
falls	fall	VERB	VBZ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
37	37	NUM	CD	9	O
beats	beat	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
sinus	sinus	NOUN	NN	5	B-Disease
bradycardia	bradycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
score	score	NOUN	NN	5	O
of	of	ADP	IN	5	O
7	7	NUM	CD	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Naranjo	Naranjo	PROPN	NNP	6	O
adverse	adverse	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	I-Disease
reaction	reaction	NOUN	NN	9	I-Disease
probability	probability	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
indicates	indicate	VERB	VBZ	9	O
a	a	DET	DT	5	O
probable	probable	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
sinus	sinus	NOUN	NN	5	B-Disease
bradycardia	bradycardia	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
terbinafine	terbinafine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
ameliorated	ameliorate	VERB	VBD	9	O
first	first	ADV	RB	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
subsequently	subsequently	ADV	RB	9	O
changed	change	VERB	VBN	9	O
to	to	PART	TO	5	O
bisoprolol	bisoprolol	VERB	VB	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
inhibiting	inhibit	VERB	VBG	3	O
the	the	DET	DT	5	O
cytochrome	cytochrome	ADJ	JJ	0	O
P450	P450	PROPN	NNP	1	O
2D6	2d6	NUM	CD	0	O
,	,	PUNCT	,	9	O
terbinafine	terbinafine	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
clearance	clearance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
in	in	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
accumulation	accumulation	NOUN	NN	9	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
resulted	result	VERB	VBN	9	O
in	in	ADP	IN	5	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
sinus	sinus	NOUN	NN	5	B-Disease
bradycardia	bradycardia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Optochiasmatic	optochiasmatic	ADJ	JJ	_	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	PART	TO	5	O
ethambutol	ethambutol	VERB	VB	0	B-Chemical
overtreatment	overtreatment	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Ethambutol	Ethambutol	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
more	more	ADV	RBR	5	O
rarely	rarely	ADV	RB	5	O
,	,	PUNCT	,	9	O
axonal	axonal	ADJ	JJ	3	O
polyneuropathy	polyneuropathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
characterize	characterize	VERB	VBP	9	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
neurophysiological	neurophysiological	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
neuroimaging	neuroimage	VERB	VBG	5	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
72	72	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
visual	visual	ADJ	JJ	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
paresthesias	paresthesia	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
11	11	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
supratherapeutic	supratherapeutic	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
demonstrates	demonstrate	VERB	VBZ	9	O
the	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
vulnerability	vulnerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anterior	anterior	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	O
pathways	pathway	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
nerves	nerve	NOUN	NNS	5	O
to	to	PART	TO	5	O
ethambutol	ethambutol	VERB	VB	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Testosterone	testosterone	NOUN	NN	0	B-Chemical
ameliorates	ameliorate	NOUN	NNS	3	O
streptozotocin	streptozotocin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Adult	adult	ADJ	JJ	9	O
male	male	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
intracerebroventricularly	intracerebroventricularly	ADV	RB	3	O
(	(	PUNCT	-LRB-	9	O
icv	icv	ADJ	JJ	0	O
)	)	PUNCT	-RRB-	9	O
infused	infuse	VERB	VBN	9	O
with	with	ADP	IN	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
750	750	NUM	CD	0	O
ug	ug	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
d	d	PROPN	NNP	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
d	d	NOUN	NN	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Castration	castration	NOUN	NN	3	O
surgery	surgery	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
another	another	DET	DT	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
operation	operation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Testosterone	Testosterone	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
d	d	PUNCT	LS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
sc	sc	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
androgen	androgen	NOUN	NN	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
flutamide	flutamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
d	d	PUNCT	LS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
d	d	PUNCT	LS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
aromatase	aromatase	NOUN	NN	3	O
inhibitor	inhibitor	NOUN	NN	3	O
letrozole	letrozole	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
d	d	PUNCT	LS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
ip	ip	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
d	d	NOUN	NN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
castration	castration	NOUN	NN	3	O
markedly	markedly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
both	both	DET	DT	9	O
STL1	STL1	PROPN	NNP	1	O
(	(	PUNCT	-LRB-	9	O
the	the	DET	DT	5	O
short	short	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
STL2	STL2	PROPN	NNP	1	O
(	(	PUNCT	-LRB-	9	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Testosterone	testosterone	NOUN	NN	0	B-Chemical
replacement	replacement	NOUN	NN	9	O
almost	almost	ADV	RB	9	O
restored	restore	VERB	VBD	3	O
the	the	DET	DT	5	O
STL1	STL1	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
STL2	STL2	PROPN	NNP	1	O
in	in	ADP	IN	5	O
castrated	castrate	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
prolonged	prolong	VERB	VBD	9	O
the	the	DET	DT	5	O
STL1	STL1	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
STL2	STL2	PROPN	NNP	1	O
in	in	ADP	IN	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
flutamide	flutamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
letrozole	letrozole	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
significantly	significantly	ADV	RB	9	O
impaired	impair	VERB	VBD	9	B-Disease
the	the	DET	DT	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
intact	intact	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
replacement	replacement	NOUN	NN	9	O
in	in	ADP	IN	5	O
improving	improve	VERB	VBG	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
castration	castration	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Testosterone	Testosterone	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
ameliorates	ameliorate	VERB	VBZ	3	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
castration	castration	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Behavioral	behavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
neurochemical	neurochemical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
garcinielliptone	garcinielliptone	NOUN	NN	_	B-Chemical
FC	FC	PROPN	NNP	9	I-Chemical
in	in	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Garcinielliptone	Garcinielliptone	PROPN	NNP	_	B-Chemical
FC	FC	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
GFC	GFC	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
isolated	isolate	VERB	VBN	9	O
from	from	ADP	IN	9	O
hexanic	hexanic	ADJ	JJ	0	O
fraction	fraction	NOUN	NN	9	O
seed	seed	NOUN	NN	4	O
extract	extract	NOUN	NN	0	O
of	of	ADP	IN	5	O
species	specie	NOUN	NNS	4	O
Platonia	Platonia	PROPN	NNP	9	O
insignis	insignis	NOUN	NN	4	O
Mart	Mart	PROPN	NNP	4	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
folk	folk	NOUN	NN	5	O
medicine	medicine	NOUN	NN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
skin	skin	NOUN	NN	5	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
humans	human	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
animals	animal	NOUN	NNS	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
seed	seed	NOUN	NN	4	O
decoction	decoction	NOUN	NN	0	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
diarrheas	diarrheas	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
inflammatory	inflammatory	ADJ	JJ	3	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
research	research	NOUN	NN	5	O
on	on	ADP	IN	5	O
GFC	GFC	PROPN	NNP	5	B-Chemical
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
of	of	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
GFC	GFC	PROPN	NNP	5	B-Chemical
effects	effect	NOUN	NNS	9	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
25	25	NUM	CD	9	O
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
or	or	CCONJ	CC	5	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
on	on	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
parameters	parameter	NOUN	NNS	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
their	-PRON-	DET	PRP$	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
amino	amino	ADJ	JJ	1	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
glutamine	glutamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
aspartate	aspartate	NOUN	NN	1	B-Chemical
and	and	CCONJ	CC	5	O
glutathione	glutathione	ADJ	JJ	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
on	on	ADP	IN	5	O
acetylcholinesterase	acetylcholinesterase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
AChE	AChE	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
hippocampus	hippocampus	NOUN	NN	9	O
after	after	ADP	IN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

GFC	GFC	PROPN	NNP	5	B-Chemical
produced	produce	VERB	VBD	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
latency	latency	NOUN	NN	5	O
to	to	ADP	IN	5	O
first	first	ADJ	JJ	9	O
seizure	seizure	VERB	VB	5	B-Disease
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
25mg	25mg	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
12	12	NUM	CD	9	O
+	+	SYM	SYM	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
20	20	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
50mg	50mg	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
95	95	NUM	CD	7	O
+	+	SYM	SYM	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
21	21	NUM	CD	7	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
43	43	NUM	CD	7	O
+	+	SYM	SYM	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
99	99	NUM	CD	7	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
seized	seized	ADJ	JJ	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
content	content	NOUN	NN	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
hippocampus	hippocampus	NOUN	NN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
GFC75	GFC75	PROPN	NNP	_	O
plus	plus	CCONJ	CC	9	O
P400	P400	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
46	46	NUM	CD	7	O
.	.	PUNCT	.	9	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
seized	seized	ADJ	JJ	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
aspartate	aspartate	NOUN	NN	1	B-Chemical
,	,	PUNCT	,	9	O
glutamine	glutamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
levels	level	NOUN	NNS	3	O
detected	detect	VERB	VBD	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
55	55	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
21	21	NUM	CD	7	O
.	.	PUNCT	.	9	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
hippocampus	hippocampus	NOUN	NN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
GFC75	GFC75	PROPN	NNP	_	O
plus	plus	CCONJ	CC	9	O
P400	P400	PROPN	NNP	5	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
seized	seized	ADJ	JJ	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Hippocampus	hippocampus	NOUN	NN	7	O
mice	mouse	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
GFC75	GFC75	PROPN	NNP	_	O
plus	plus	CCONJ	CC	9	O
P400	P400	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
AChE	AChE	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
63	63	NUM	CD	7	O
.	.	PUNCT	.	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
seized	seized	ADJ	JJ	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
GFC	GFC	PROPN	NNP	5	B-Chemical
can	can	VERB	MD	5	O
exert	exert	VERB	VB	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reduce	reduce	VERB	VB	5	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
installation	installation	NOUN	NN	5	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
demonstrated	demonstrate	VERB	VBN	9	O
by	by	ADP	IN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
latency	latency	NOUN	NN	5	O
to	to	ADP	IN	5	O
first	first	ADJ	JJ	9	O
seizure	seizure	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
decrease	decrease	VERB	VB	9	O
in	in	ADP	IN	5	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
GFC	GFC	PROPN	NNP	5	B-Chemical
may	may	VERB	MD	5	O
influence	influence	VERB	VB	5	O
in	in	ADP	IN	5	O
epileptogenesis	epileptogenesis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
promote	promote	VERB	VB	3	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
actions	action	NOUN	NNS	5	O
in	in	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
by	by	ADP	IN	9	O
modulating	modulate	VERB	VBG	9	O
the	the	DET	DT	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
glutamate	glutamate	VERB	VB	0	B-Chemical
contents	content	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
AChE	AChE	PROPN	NNPS	0	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
seized	seized	ADJ	JJ	5	O
mice	mouse	NOUN	NNS	3	O
hippocampus	hippocampus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
compound	compound	NOUN	NN	0	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
neuronal	neuronal	ADJ	JJ	3	O
protection	protection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Standard	standard	ADJ	JJ	9	O
operating	operating	NOUN	NN	5	O
procedures	procedure	NOUN	NNS	5	O
for	for	ADP	IN	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
clinical	clinical	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
interventional	interventional	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
observational	observational	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

INTRODUCTION	INTRODUCTION	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Acute	acute	ADJ	JJ	5	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
AKI	AKI	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
hospitalized	hospitalize	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
66	66	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
Intensive	Intensive	PROPN	NNP	2	O
Care	Care	PROPN	NNP	2	O
Unit	Unit	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
ICU	ICU	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
increases	increase	VERB	VBZ	9	O
mortality	mortality	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hospital	hospital	NOUN	NN	5	O
length	length	NOUN	NN	9	O
of	of	ADP	IN	5	O
stay	stay	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
costs	cost	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
,	,	PUNCT	,	9	O
whether	whether	ADP	IN	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
adherence	adherence	NOUN	NN	5	O
to	to	ADP	IN	5	O
guidelines	guideline	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
standard	standard	ADJ	JJ	5	O
operating	operating	NOUN	NN	5	O
procedures	procedure	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
SOP	SOP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
potentially	potentially	ADV	RB	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
antibiotics	antibiotic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
AKI	AKI	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
clinical	clinical	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
interventional	interventional	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
observational	observational	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
collection	collection	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
170	170	NUM	CD	9	O
days	day	NOUN	NNS	9	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
ICUs	icu	NOUN	NNS	5	O
at	at	ADP	IN	9	O
Charite	Charite	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Universitaetsmedizin	Universitaetsmedizin	PROPN	NNP	2	O
Berlin	Berlin	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
675	675	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
;	;	PUNCT	:	9	O
163	163	NUM	CD	7	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
had	have	VERB	VBD	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
tobramycin	tobramycin	ADJ	JJR	0	B-Chemical
;	;	PUNCT	:	9	O
were	be	VERB	VBD	9	O
>	>	X	XX	0	O
18	18	NUM	CD	7	O
years	year	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
treated	treat	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ICU	ICU	PROPN	NNP	5	O
for	for	ADP	IN	5	O
>	>	X	XX	0	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
adherence	adherence	NOUN	NN	5	O
to	to	ADP	IN	5	O
SOP	SOP	PROPN	NNP	5	O
>	>	X	XX	0	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
were	be	VERB	VBD	9	O
classified	classify	VERB	VBN	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
adherence	adherence	NOUN	NN	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HAG	HAG	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
adherence	adherence	NOUN	NN	5	O
of	of	ADP	IN	5	O
<	<	X	XX	0	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
adherence	adherence	NOUN	NN	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
LAG	LAG	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

AKI	AKI	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
RIFLE	RIFLE	PROPN	NNP	5	O
criteria	criterion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Adherence	adherence	NOUN	NN	5	O
to	to	ADP	IN	5	O
SOPs	sop	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
retrospective	retrospective	ADJ	JJ	5	O
expert	expert	NOUN	NN	5	O
audit	audit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Development	development	NOUN	NN	2	O
of	of	ADP	IN	5	O
AKI	AKI	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
with	with	ADP	IN	5	O
exact	exact	ADJ	JJ	5	O
Chi2	Chi2	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
multivariate	multivariate	ADJ	JJ	5	O
logistic	logistic	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
two	two	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
sided	sided	ADJ	JJ	5	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
LAG	LAG	PROPN	NNP	9	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
75	75	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
46	46	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
88	88	NUM	CD	7	O
HAG	hag	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
54	54	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

AKI	AKI	PROPN	NNP	5	B-Disease
occurred	occur	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
often	often	ADV	RB	5	O
in	in	ADP	IN	5	O
LAG	LAG	PROPN	NNP	9	O
with	with	ADP	IN	5	O
36	36	NUM	CD	9	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
HAG	HAG	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
035	035	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Basic	basic	ADJ	JJ	9	O
characteristics	characteristic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
except	except	ADP	IN	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
soft	soft	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
infections	infection	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
LAG	LAG	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Multivariate	Multivariate	PROPN	NNP	5	O
analysis	analysis	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
an	an	DET	DT	5	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
for	for	ADP	IN	5	O
LAG	LAG	PROPN	NNP	9	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
AKI	AKI	PROPN	NNP	5	B-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
HAG	HAG	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
195	195	NUM	CD	7	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
124	124	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
039	039	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Low	low	ADJ	JJ	9	O
adherence	adherence	NOUN	NN	5	O
to	to	ADP	IN	5	O
SOPs	sop	NOUN	NNS	5	O
for	for	ADP	IN	5	O
potentially	potentially	ADV	RB	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
antibiotics	antibiotic	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
AKI	AKI	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

TRIAL	trial	NOUN	NN	2	O
REGISTRATION	registration	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Current	current	ADJ	JJ	9	O
Controlled	control	VERB	VBN	5	O
Trials	Trials	PROPN	NNPS	5	O
ISRCTN54598675	ISRCTN54598675	PROPN	NNP	_	O
.	.	PUNCT	.	9	O

Registered	register	VERB	VBN	5	O
17	17	NUM	CD	7	O
August	August	PROPN	NNP	2	O
2007	2007	NUM	CD	2	O
.	.	PUNCT	.	9	O

Rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
C	C	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
infected	infect	VERB	VBN	3	I-Disease
patient	patient	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
telaprevir	telaprevir	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
46	46	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
C	C	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
received	receive	VERB	VBD	9	O
triple	triple	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
pegylated	pegylate	VERB	VBN	0	B-Chemical
interferon	interferon	NOUN	NN	3	I-Chemical
and	and	CCONJ	CC	5	O
telaprevir	telaprevir	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
also	also	ADV	RB	9	O
received	receive	VERB	VBD	9	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
after	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
the	the	DET	DT	5	O
antiviral	antiviral	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
because	because	ADP	IN	5	O
he	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
admission	admission	NOUN	NN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
antiviral	antiviral	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
because	because	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NOUN	NN	3	O
peaked	peak	VERB	VBD	9	O
at	at	ADP	IN	9	O
62	62	NUM	CD	7	O
,	,	PUNCT	,	9	O
246	246	NUM	CD	7	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Fourteen	fourteen	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
hospitalization	hospitalization	NOUN	NN	5	O
,	,	PUNCT	,	9	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NUM	CD	3	O
level	level	NOUN	NN	9	O
had	have	VERB	VBD	9	O
returned	return	VERB	VBN	5	O
to	to	ADP	IN	5	O
230	230	NUM	CD	9	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
discharged	discharge	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Telaprevir	Telaprevir	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
the	the	DET	DT	5	O
probable	probable	ADJ	JJ	9	O
causative	causative	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Drug	Drug	PROPN	NNP	5	O
Interaction	Interaction	PROPN	NNP	9	O
Probability	Probability	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
CYP3A4	cyp3a4	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Simvastatin	simvastatin	NOUN	NN	0	B-Chemical
plasma	plasma	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
increased	increase	VERB	VBD	9	O
30	30	NUM	CD	9	O
times	time	NOUN	NNS	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
statin	statin	NOUN	NN	5	B-Chemical
induced	induced	ADJ	JJ	3	O
muscle	muscle	NOUN	NN	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
statin	statin	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
illustrate	illustrate	VERB	VBP	5	O
that	that	DET	DT	5	O
telaprevir	telaprevir	NOUN	NN	5	B-Chemical
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
statins	statin	NOUN	NNS	5	B-Chemical
are	be	VERB	VBP	5	O
susceptible	susceptible	ADJ	JJ	9	O
to	to	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
relevant	relevant	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
bortezomib	bortezomib	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
VTD	VTD	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
consolidation	consolidation	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
after	after	ADP	IN	9	O
autologous	autologous	ADJ	JJ	3	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
for	for	ADP	IN	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
multiple	multiple	ADJ	JJ	5	B-Disease
myeloma	myeloma	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
Japanese	japanese	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Consolidation	consolidation	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	B-Disease
myeloma	myeloma	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
MM	MM	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
widely	widely	ADV	RB	5	O
adopted	adopt	VERB	VBN	5	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
treatment	treatment	NOUN	NN	9	O
response	response	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
autologous	autologous	ADJ	JJ	3	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
retrospectively	retrospectively	ADV	RB	5	O
analyzed	analyze	VERB	VBD	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
regimen	regiman	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bortezomib	bortezomib	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
VTD	VTD	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
consolidation	consolidation	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
24	24	NUM	CD	9	O
Japanese	japanese	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
newly	newly	ADV	RB	9	O
diagnosed	diagnose	VERB	VBN	5	O
MM	MM	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

VTD	VTD	PROPN	NNP	0	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
bortezomib	bortezomib	NOUN	NN	3	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
22	22	NUM	CD	7	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
35	35	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
cycle	cycle	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
oral	oral	ADJ	JJ	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Grade	Grade	PROPN	NNP	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
and	and	CCONJ	CC	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
and	and	CCONJ	CC	5	O
13	13	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
drug	drug	NOUN	NN	5	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
cytopenia	cytopenia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
required	require	VERB	VBN	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
case	case	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
common	common	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
63	63	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
severe	severe	ADJ	JJ	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Very	very	ADV	RB	5	O
good	good	ADJ	JJ	5	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
better	well	ADJ	JJR	5	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
VGPR	VGPR	NOUN	NNS	7	O
)	)	PUNCT	-RRB-	9	O
rates	rate	NOUN	NNS	5	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
consolidation	consolidation	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
were	be	VERB	VBD	9	O
54	54	NUM	CD	7	O
and	and	CCONJ	CC	5	O
79	79	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
probability	probability	NOUN	NN	5	O
of	of	ADP	IN	5	O
improving	improve	VERB	VBG	5	O
from	from	ADP	IN	9	O
<	<	X	XX	0	O
VGPR	VGPR	NOUN	NNS	7	O
before	before	ADP	IN	9	O
consolidation	consolidation	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
to	to	ADP	IN	5	O
>	>	X	XX	0	O
VGPR	VGPR	NOUN	NNS	7	O
after	after	ADP	IN	9	O
consolidation	consolidation	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
041	041	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
VTD	VTD	PROPN	NNP	0	O
regimen	regimen	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
safe	safe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
consolidation	consolidation	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
MM	MM	PROPN	NNP	9	O
in	in	ADP	IN	5	O
Japanese	japanese	ADJ	JJ	9	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Conversion	conversion	NOUN	NN	9	O
to	to	PART	TO	5	O
sirolimus	sirolimus	VERB	VB	0	B-Chemical
ameliorates	ameliorate	NOUN	NNS	3	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
:	:	PUNCT	:	9	O
focus	focus	VERB	VB	5	O
on	on	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
urine	urine	NOUN	NN	9	O
,	,	PUNCT	,	9	O
gene	gene	NOUN	NN	1	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
renal	renal	ADJ	JJ	9	O
expression	expression	NOUN	NN	3	O
biomarkers	biomarker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Protocols	protocol	NOUN	NNS	5	O
of	of	ADP	IN	5	O
conversion	conversion	NOUN	NN	9	O
from	from	ADP	IN	9	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
CsA	CsA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
sirolimus	sirolimus	VERB	VB	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
immunotherapy	immunotherapy	NOUN	NN	5	O
after	after	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
underlying	underlie	VERB	VBG	5	O
these	these	DET	DT	5	O
protocols	protocol	NOUN	NNS	5	O
remain	remain	VERB	VBP	9	O
nuclear	nuclear	ADJ	JJ	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
pathways	pathway	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
putative	putative	ADJ	JJ	1	O
biomarkers	biomarker	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
SRL	srl	NOUN	NN	0	B-Chemical
conversion	conversion	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
animal	animal	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
during	during	ADP	IN	5	O
9	9	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
CsA	CsA	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
conversion	conversion	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CsA	CsA	PROPN	NNP	0	B-Chemical
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Classical	classical	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
emergent	emergent	NOUN	NN	5	O
serum	serum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
urinary	urinary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
kidney	kidney	NOUN	NN	9	O
tissue	tissue	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
gene	gene	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
markers	marker	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
in	in	ADP	IN	5	O
hematoxylin	hematoxylin	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
eosin	eosin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
periodic	periodic	ADJ	JJ	5	O
acid	acid	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
Schiff	Schiff	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Masson	Masson	PROPN	NNP	9	O
'	'	PART	POS	9	O
s	s	VERB	VBZ	9	O
trichrome	trichrome	NOUN	NN	3	O
stains	stain	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

SRL	srl	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
presented	present	VERB	VBD	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
NGAL	NGAL	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
serum	serum	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
urinary	urinary	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
best	good	ADJ	JJS	5	O
markers	marker	NOUN	NNS	3	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Short	short	ADJ	JJ	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
presented	present	VERB	VBD	5	O
slight	slight	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
even	even	ADV	RB	5	O
absent	absent	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
TGF	TGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
b	b	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
NF	nf	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
kb	kb	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
mTOR	mTOR	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
PCNA	PCNA	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
TP53	TP53	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
KIM	KIM	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
CTGF	CTGF	PROPN	NNP	3	O
as	as	ADP	IN	5	O
relevant	relevant	ADJ	JJ	5	O
gene	gene	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Prolonged	prolong	VERB	VBN	9	O
CsA	CsA	PROPN	NNP	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
aggravated	aggravate	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
clear	clear	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
traditional	traditional	ADJ	JJ	5	O
markers	marker	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
with	with	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
serums	serum	NOUN	NNS	9	O
TGF	TGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
b	b	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
TBARs	TBARs	PROPN	NNP	0	O
clearance	clearance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
kidney	kidney	NOUN	NN	9	O
TGF	TGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
b	b	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
mTOR	mTOR	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

Conversion	conversion	NOUN	NN	9	O
to	to	ADP	IN	5	O
SRL	SRL	PROPN	NNP	0	B-Chemical
prevented	prevent	VERB	VBD	9	O
CsA	CsA	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
evolution	evolution	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
absent	absent	ADJ	JJ	9	O
/	/	SYM	SYM	9	O
mild	mild	ADJ	JJ	9	O
grade	grade	NOUN	NN	9	O
lesions	lesion	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
NGAL	NGAL	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
serum	serum	ADJ	JJ	9	O
versus	versus	ADP	IN	9	O
urine	urine	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
feasible	feasible	ADJ	JJ	5	O
biomarker	biomarker	NOUN	NN	9	O
of	of	ADP	IN	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
replacement	replacement	NOUN	NN	9	O
to	to	ADP	IN	5	O
SRL	SRL	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Kinin	Kinin	PROPN	NNP	3	O
B2	B2	PROPN	NNP	9	O
receptor	receptor	NOUN	NN	3	O
deletion	deletion	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
blockage	blockage	NOUN	NN	9	O
ameliorates	ameliorate	NOUN	NNS	3	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Cisplatin	cisplatin	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
adopted	adopt	VERB	VBN	5	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
chemotherapies	chemotherapy	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
can	can	VERB	MD	5	O
induce	induce	VERB	VB	3	O
acute	acute	ADJ	JJ	9	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
due	due	ADJ	JJ	5	O
its	-PRON-	DET	PRP$	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
negatively	negatively	ADV	RB	9	O
affect	affect	VERB	VB	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
augment	augment	NOUN	NN	9	O
serum	serum	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
urea	urea	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
score	score	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
up	up	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
regulate	regulate	ADJ	JJ	3	O
cytokines	cytokine	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
e	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
1b	1b	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
TNF	TNF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
a	a	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
kinin	kinin	NOUN	NN	0	O
B2	b2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
process	process	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
cytokine	cytokine	NOUN	NN	3	O
expression	expression	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
deletion	deletion	NOUN	NN	1	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
status	status	NOUN	NN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kinin	kinin	NOUN	NN	0	O
B2	b2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
in	in	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
kinin	kinin	NOUN	NN	0	O
B2	b2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
knockout	knockout	NOUN	NN	3	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
challenged	challenge	VERB	VBN	3	O
with	with	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
WT	WT	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
B2	b2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
after	after	ADP	IN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

B2	b2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
deficient	deficient	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
WT	WT	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
shown	show	VERB	VBN	9	O
by	by	ADP	IN	9	O
reduced	reduced	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
better	well	ADJ	JJR	5	O
preservation	preservation	NOUN	NN	9	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
down	down	ADP	IN	9	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
cytokines	cytokine	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
less	less	ADV	RBR	5	O
acute	acute	ADJ	JJ	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
kinin	kinin	NOUN	NN	0	O
B2	b2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
effectively	effectively	ADV	RB	5	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
urea	urea	ADJ	JJ	0	B-Chemical
after	after	ADP	IN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
kinin	kinin	NOUN	NN	0	O
B2	b2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
by	by	ADP	IN	9	O
mediating	mediate	VERB	VBG	9	O
the	the	DET	DT	5	O
necrotic	necrotic	ADJ	JJ	3	B-Disease
process	process	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
cytokines	cytokine	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
declined	decline	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
highlight	highlight	VERB	VBP	5	O
the	the	DET	DT	5	O
kinin	kinin	NOUN	NN	0	O
B2	b2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
amelioration	amelioration	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluocinolone	fluocinolone	NOUN	NN	0	B-Chemical
acetonide	acetonide	NOUN	NN	0	I-Chemical
intravitreal	intravitreal	ADJ	JJ	0	O
implant	implant	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
59	59	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
birdshot	birdshot	NOUN	NN	5	B-Disease
retinochoroidopathy	retinochoroidopathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
outcomes	outcome	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
fluocinolone	fluocinolone	NOUN	NN	0	B-Chemical
acetonide	acetonide	NOUN	NN	0	I-Chemical
intravitreal	intravitreal	ADJ	JJ	0	O
implant	implant	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
59	59	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
birdshot	birdshot	NOUN	NN	5	B-Disease
retinochoroidopathy	retinochoroidopathy	ADJ	JJ	5	I-Disease
whose	whose	DET	WP$	9	O
disease	disease	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
refractory	refractory	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
intolerant	intolerant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
immunomodulatory	immunomodulatory	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
retrospective	retrospective	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
series	series	NOUN	NN	5	O
involving	involve	VERB	VBG	5	O
11	11	NUM	CD	7	O
birdshot	birdshot	NOUN	NN	5	B-Disease
retinochoroidopathy	retinochoroidopathy	ADJ	JJ	5	I-Disease
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
eyes	eye	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Eleven	eleven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
eyes	eye	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
underwent	undergo	VERB	VBD	5	O
surgery	surgery	NOUN	NN	5	O
for	for	ADP	IN	5	O
fluocinolone	fluocinolone	NOUN	NN	0	B-Chemical
acetonide	acetonide	NOUN	NN	0	I-Chemical
implant	implant	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
59	59	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
outcomes	outcome	NOUN	NNS	5	O
of	of	ADP	IN	5	O
interest	interest	NOUN	NN	5	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
before	before	ADP	IN	9	O
fluocinolone	fluocinolone	NOUN	NN	0	B-Chemical
acetonide	acetonide	NOUN	NN	0	I-Chemical
implant	implant	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
beyond	beyond	ADP	IN	5	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Disease	Disease	PROPN	NNP	2	O
activity	activity	NOUN	NN	9	O
markers	marker	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ocular	ocular	ADJ	JJ	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
Swedish	swedish	ADJ	JJ	5	O
interactive	interactive	ADJ	JJ	5	O
threshold	threshold	NOUN	NN	5	O
algorithm	algorithm	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
short	short	ADJ	JJ	5	O
wavelength	wavelength	NOUN	NN	0	O
automated	automate	VERB	VBN	5	O
perimetry	perimetry	NOUN	NN	5	O
Humphrey	Humphrey	PROPN	NNP	6	O
visual	visual	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
electroretinographic	electroretinographic	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
optical	optical	ADJ	JJ	5	O
coherence	coherence	NOUN	NN	5	O
tomography	tomography	NOUN	NN	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cataract	cataract	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
raised	raise	VERB	VBN	9	B-Disease
intraocular	intraocular	ADJ	JJ	5	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
eyes	eye	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Intraocular	intraocular	ADJ	JJ	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
54	54	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
beyond	beyond	ADP	IN	5	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
the	the	DET	DT	5	O
implant	implant	NOUN	NN	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Active	active	ADJ	JJ	9	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
36	36	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

More	More	ADJ	JJR	5	O
than	than	ADP	IN	5	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
47	47	NUM	CD	7	O
.	.	PUNCT	.	9	O
61	61	NUM	CD	7	O
-	-	SYM	SYM	7	O
67	67	NUM	CD	7	O
.	.	NOUN	NNS	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
central	central	ADJ	JJ	5	O
retinal	retinal	ADJ	JJ	5	O
thickness	thickness	NOUN	NN	5	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cystoid	cystoid	NOUN	NN	5	B-Disease
macular	macular	ADJ	JJ	5	I-Disease
edema	edema	NOUN	NN	5	I-Disease
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
postimplant	postimplant	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
54	54	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
immunomodulatory	immunomodulatory	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
to	to	ADP	IN	5	O
45	45	NUM	CD	9	O
.	.	PUNCT	.	9	O
45	45	NUM	CD	9	O
,	,	PUNCT	,	9	O
44	44	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
28	28	NUM	CD	7	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
postimplant	postimplant	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
increased	increase	VERB	VBN	9	B-Disease
intraocular	intraocular	ADJ	JJ	5	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
54	54	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
cataract	cataract	NOUN	NN	5	B-Disease
formation	formation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
fluocinolone	fluocinolone	NOUN	NN	0	B-Chemical
acetonide	acetonide	NOUN	NN	0	I-Chemical
implant	implant	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
59	59	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
helps	help	VERB	VBZ	5	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
inflammation	inflammation	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
otherwise	otherwise	ADV	RB	9	O
treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
refractory	refractory	NOUN	NN	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
birdshot	birdshot	NOUN	NN	5	B-Disease
retinochoroidopathy	retinochoroidopathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cataract	cataract	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
requiring	require	VERB	VBG	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Optimal	optimal	ADJ	JJ	5	O
precurarizing	precurarizing	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
rocuronium	rocuronium	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
decrease	decrease	VERB	VB	9	O
fasciculation	fasciculation	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
myalgia	myalgia	ADJ	JJ	5	B-Disease
following	follow	VERB	VBG	9	O
succinylcholine	succinylcholine	ADJ	JJ	5	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Succinylcholine	Succinylcholine	PROPN	NNP	0	B-Chemical
commonly	commonly	ADV	RB	5	O
produces	produce	VERB	VBZ	9	O
frequent	frequent	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculation	fasciculation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
identified	identify	VERB	VBD	9	O
the	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
rocuronium	rocuronium	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
fasciculation	fasciculation	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
rocuronium	rocuronium	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
speed	speed	NOUN	NN	5	O
of	of	ADP	IN	5	O
onset	onset	NOUN	NN	5	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blinded	blinded	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
100	100	NUM	CD	0	O
patients	patient	NOUN	NNS	5	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
into	into	ADP	IN	9	O
five	five	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
each	each	DET	DT	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
06	06	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
rocuronium	rocuronium	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
precurarizing	precurarize	VERB	VBG	9	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Neuromuscular	neuromuscular	ADJ	JJ	2	O
monitoring	monitoring	NOUN	NN	5	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
precurarizing	precurarize	VERB	VBG	9	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
adductor	adductor	NOUN	NN	5	O
pollicis	pollicis	NOUN	NN	5	O
muscle	muscle	NOUN	NN	9	O
using	use	VERB	VBG	9	O
acceleromyography	acceleromyography	NOUN	NN	5	O
with	with	ADP	IN	5	O
train	train	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
of	of	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ulnar	ulnar	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
precurarization	precurarization	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
fasciculations	fasciculation	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
myalgia	myalgia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
at	at	ADP	IN	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
visible	visible	ADJ	JJ	9	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculation	fasciculation	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
with	with	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
precurarizing	precurarize	VERB	VBG	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
rocuronium	rocuronium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Those	those	DET	DT	5	O
of	of	ADP	IN	5	O
myalgia	myalgia	ADJ	JJ	5	B-Disease
tend	tend	VERB	VBP	5	O
to	to	PART	TO	5	O
decrease	decrease	VERB	VB	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
precurarizing	precurarize	VERB	VBG	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
rocuronium	rocuronium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significance	significance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
072	072	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
longer	longer	ADV	RBR	5	O
with	with	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
precurarizing	precurarize	VERB	VBG	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
rocuronium	rocuronium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Precurarization	precurarization	NOUN	NN	_	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
rocuronium	rocuronium	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
considering	consider	VERB	VBG	5	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
fasciculation	fasciculation	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
myalgia	myalgia	ADJ	JJ	5	B-Disease
with	with	ADP	IN	5	O
acceptable	acceptable	ADJ	JJ	5	O
onset	onset	NOUN	NN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
precurarization	precurarization	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Absence	absence	NOUN	NN	9	O
of	of	ADP	IN	5	O
PKC	PKC	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
attenuates	attenuate	VERB	VBZ	3	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
antipsychotic	antipsychotic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
induces	induce	VERB	VBZ	3	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
NDI	NDI	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
decreased	decreased	ADJ	JJ	9	O
capacity	capacity	NOUN	NN	9	O
to	to	PART	TO	5	O
concentrate	concentrate	VERB	VB	9	O
urine	urine	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
likely	likely	ADV	RB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
acutely	acutely	ADV	RB	9	O
disrupting	disrupt	VERB	VBG	9	O
the	the	DET	DT	5	O
cAMP	cAMP	PROPN	NNP	3	B-Chemical
pathway	pathway	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
chronically	chronically	ADV	RB	9	O
reducing	reduce	VERB	VBG	9	O
urea	urea	ADJ	JJ	0	B-Chemical
transporter	transporter	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
UT	UT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
A1	A1	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
water	water	NOUN	NN	0	O
channel	channel	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
AQP2	AQP2	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
inner	inner	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Targeting	target	VERB	VBG	9	O
an	an	DET	DT	5	O
alternative	alternative	NOUN	NN	5	O
signaling	signal	VERB	VBG	3	O
pathway	pathway	NOUN	NN	3	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
PKC	PKC	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
signaling	signaling	NOUN	NN	3	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
of	of	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polyuria	polyuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

PKC	PKC	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
null	null	ADJ	JJ	1	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
PKCa	PKCa	NOUN	NNS	3	O
KO	KO	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
strain	strain	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
wild	wild	ADJ	JJ	1	O
type	type	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
WT	wt	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
controls	control	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
or	or	CCONJ	CC	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

WT	wt	NOUN	NN	3	O
mice	mouse	NOUN	NNS	3	O
had	have	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
urine	urine	NOUN	NN	9	O
output	output	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
lowered	lower	VERB	VBD	9	O
urine	urine	ADJ	JJ	9	O
osmolality	osmolality	NOUN	NN	0	O
after	after	ADP	IN	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
whereas	whereas	ADP	IN	9	O
PKCa	PKCa	NOUN	NNS	3	O
KO	KO	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
urine	urine	NOUN	NN	9	O
output	output	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
concentration	concentration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Western	western	ADJ	JJ	3	O
blot	blot	NOUN	NN	3	O
analysis	analysis	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
AQP2	aqp2	ADJ	JJ	3	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
medullary	medullary	ADJ	JJ	5	O
tissues	tissue	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
lowered	lower	VERB	VBN	9	O
after	after	ADP	IN	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
in	in	ADP	IN	5	O
WT	WT	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
AQP2	AQP2	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
in	in	ADP	IN	5	O
PKCa	PKCa	NOUN	NNS	3	O
KO	KO	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
UT	UT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
A1	A1	PROPN	NNP	9	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
WT	WT	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
had	have	VERB	VBD	9	O
19	19	NUM	CD	7	O
-	-	ADV	RB	7	O
fold	fold	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
urine	urine	NOUN	NN	9	O
output	output	NOUN	NN	5	O
whereas	whereas	DET	WDT	9	O
treated	treat	VERB	VBD	3	O
PKCa	PKCa	NOUN	NNS	3	O
KO	KO	PROPN	NNP	3	O
animals	animal	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	ADV	RB	7	O
fold	fold	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
output	output	NOUN	NN	5	O
.	.	PUNCT	.	9	O

AQP2	AQP2	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
UT	UT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
A1	A1	PROPN	NNP	9	O
expression	expression	NOUN	NN	3	O
was	be	VERB	VBD	9	O
lowered	lower	VERB	VBN	9	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
week	week	NOUN	NN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
WT	WT	PROPN	NNP	3	O
animals	animal	NOUN	NNS	9	O
whereas	whereas	ADP	IN	9	O
in	in	ADP	IN	5	O
treated	treat	VERB	VBN	3	O
PKCa	PKCa	NOUN	NNS	3	O
KO	KO	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
AQP2	AQP2	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
UT	UT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
A1	A1	PROPN	NNP	9	O
expression	expression	NOUN	NN	3	O
was	be	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Urinary	urinary	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
in	in	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
fed	feed	VERB	VBN	9	O
WT	wt	NOUN	NN	3	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
fed	feed	VERB	VBN	9	O
PKCa	PKCa	NOUN	NNS	3	O
KO	KO	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
ablation	ablation	NOUN	NN	9	O
of	of	ADP	IN	5	O
PKCa	PKCa	NOUN	NNS	3	O
preserves	preserve	VERB	VBZ	9	O
AQP2	AQP2	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
UT	UT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
A1	A1	PROPN	NNP	9	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
localization	localization	NOUN	NN	3	O
in	in	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
NDI	NDI	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
prevents	prevent	VERB	VBZ	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
polyuria	polyuria	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Is	be	VERB	VBZ	9	O
Dysguesia	Dysguesia	PROPN	NNP	9	B-Disease
Going	go	VERB	VBG	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
Rare	Rare	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
Common	Common	PROPN	NNP	9	O
Side	Side	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
Amlodipine	Amlodipine	PROPN	NNP	0	B-Chemical
?	?	PUNCT	.	5	O

A	a	DET	DT	9	O
very	very	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
dysguesia	dysguesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
produced	produce	VERB	VBD	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
about	about	ADP	IN	5	O
a	a	DET	DT	5	O
female	female	NOUN	NN	9	O
with	with	ADP	IN	5	O
essential	essential	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
developed	develop	VERB	VBN	5	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
taste	taste	NOUN	NN	5	I-Disease
sensation	sensation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Condition	condition	NOUN	NN	5	O
moderately	moderately	ADV	RB	9	O
improved	improve	VERB	VBD	5	O
on	on	ADP	IN	5	O
stoppage	stoppage	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
25	25	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	DET	DT	5	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
dysguesia	dysguesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
presentation	presentation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
review	review	VERB	VB	5	O
the	the	DET	DT	5	O
relevant	relevant	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
on	on	ADP	IN	5	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
dysguesia	dysguesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
dosage	dosage	NOUN	NN	9	O
increment	increment	NOUN	NN	9	O
in	in	ADP	IN	5	O
clarithromycin	clarithromycin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Clarithromycin	Clarithromycin	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
documented	documented	ADJ	JJ	9	O
cytochrome	cytochrome	ADJ	JJ	0	O
P450	P450	PROPN	NNP	1	O
3A4	3a4	NUM	CD	0	O
(	(	PUNCT	-LRB-	9	O
CYP3A4	CYP3A4	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
inhibitor	inhibitor	NOUN	NN	3	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
an	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
particular	particular	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
of	of	ADP	IN	5	O
interest	interest	NOUN	NN	5	O
as	as	ADP	IN	5	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
only	only	ADV	RB	9	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
clarithromycin	clarithromycin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
raised	raise	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	O
biomarkers	biomarker	NOUN	NNS	9	O
without	without	ADP	IN	9	O
any	any	DET	DT	5	O
obvious	obvious	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
issues	issue	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
phenomenon	phenomenon	NOUN	NN	5	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
linked	link	VERB	VBN	9	O
to	to	ADP	IN	5	O
rhabdomyolysis	rhabdomyolysis	VERB	VB	5	B-Disease
previously	previously	ADV	RB	9	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
date	date	NOUN	NN	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
no	no	DET	DT	9	O
reported	report	VERB	VBN	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
structure	structure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Clinicians	clinician	NOUN	NNS	5	O
need	need	VERB	VBP	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
prescribing	prescribe	VERB	VBG	5	O
concomitant	concomitant	ADJ	JJ	9	O
medications	medication	NOUN	NNS	5	O
that	that	DET	WDT	5	O
increase	increase	VERB	VBP	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
myopathy	myopathy	NOUN	NN	9	B-Disease
or	or	CCONJ	CC	5	O
inhibit	inhibit	VERB	VB	3	O
the	the	DET	DT	5	O
CYP3A4	cyp3a4	NOUN	NN	3	O
enzyme	enzyme	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
case	case	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
troponin	troponin	NOUN	NN	9	O
elevation	elevation	NOUN	NN	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
statin	statin	ADJ	JJ	5	B-Chemical
induced	induced	ADJ	JJ	3	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
warrant	warrant	VERB	VB	9	O
further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Characterization	characterization	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
BCHE	BCHE	PROPN	NNP	7	O
"	"	PUNCT	``	5	O
silent	silent	ADJ	JJ	9	O
"	"	PUNCT	''	5	O
allele	allele	NOUN	NN	1	O
:	:	PUNCT	:	9	O
point	point	NOUN	NN	5	O
mutation	mutation	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
Val204Asp	val204asp	NOUN	NN	_	O
)	)	PUNCT	-RRB-	9	O
causes	cause	VERB	VBZ	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prolonged	prolong	VERB	VBN	9	O
apnea	apnea	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Butyrylcholinesterase	butyrylcholinesterase	ADJ	JJ	7	B-Disease
deficiency	deficiency	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
apnea	apnea	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
relaxants	relaxant	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
mivacurium	mivacurium	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
mutations	mutation	NOUN	NNS	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BCHE	BCHE	PROPN	NNP	7	O
gene	gene	NOUN	NN	1	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
prolonged	prolonged	ADJ	JJ	9	O
neuromuscular	neuromuscular	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
discovery	discovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
BCHE	BCHE	PROPN	NNP	7	O
variant	variant	ADJ	JJ	1	O
(	(	PUNCT	-LRB-	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
695T	695t	NUM	CD	_	O
>	>	X	XX	0	O
A	a	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
Val204Asp	val204asp	NOUN	NN	_	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Inhibition	inhibition	NOUN	NN	3	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
kinetic	kinetic	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
molecular	molecular	ADJ	JJ	9	O
dynamics	dynamic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
understand	understand	VERB	VB	5	O
how	how	ADV	WRB	5	O
this	this	DET	DT	5	O
mutation	mutation	NOUN	NN	1	O
disrupts	disrupt	VERB	VBZ	9	O
the	the	DET	DT	5	O
catalytic	catalytic	ADJ	JJ	1	O
triad	triad	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
determines	determine	VERB	VBZ	5	O
a	a	DET	DT	5	O
"	"	PUNCT	``	5	O
silent	silent	ADJ	JJ	9	O
"	"	PUNCT	''	5	O
phenotype	phenotype	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Low	low	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
patient	patient	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
butyrylcholinesterase	butyrylcholinesterase	ADJ	JJ	0	O
with	with	ADP	IN	5	O
butyrylthiocholine	butyrylthiocholine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
BTC	BTC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
benzoylcholine	benzoylcholine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
dibucaine	dibucaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
fluoride	fluoride	VERB	VB	0	B-Chemical
numbers	number	NOUN	NNS	9	O
fit	fit	VERB	VBP	5	O
with	with	ADP	IN	5	O
heterozygous	heterozygous	ADJ	JJ	1	O
atypical	atypical	ADJ	JJ	5	O
silent	silent	ADJ	JJ	9	O
genotype	genotype	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Electrophoretic	electrophoretic	ADJ	JJ	0	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
BChE	BChE	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
proband	proband	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
his	-PRON-	DET	PRP$	5	O
mother	mother	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
patient	patient	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
reduced	reduce	VERB	VBN	9	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
tetrameric	tetrameric	ADJ	JJ	1	O
enzyme	enzyme	NOUN	NN	0	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
minor	minor	ADJ	JJ	9	O
fast	fast	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
moving	moving	NOUN	NN	5	O
BChE	BChE	PROPN	NNP	0	O
components	component	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
monomer	monomer	NOUN	NN	0	O
,	,	PUNCT	,	9	O
dimer	dimer	NOUN	NN	1	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
monomer	monomer	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
albumin	albumin	NOUN	NN	0	O
conjugate	conjugate	NOUN	NN	0	O
are	be	VERB	VBP	5	O
missing	miss	VERB	VBG	5	O
.	.	PUNCT	.	9	O

Kinetic	Kinetic	PROPN	NNP	0	O
analysis	analysis	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
Val204Asp	Val204Asp	PROPN	NNP	_	O
/	/	SYM	SYM	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
Asp70Gly	Asp70Gly	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
p	p	PROPN	NNP	7	O
.	.	PUNCT	.	9	O
Ala539Thr	Ala539Thr	PROPN	NNP	9	O
BChE	BChE	PROPN	NNP	0	O
displays	display	VERB	VBZ	9	O
a	a	DET	DT	5	O
pure	pure	ADJ	JJ	9	O
Michaelian	michaelian	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
with	with	ADP	IN	5	O
BTC	BTC	PROPN	NNP	9	B-Chemical
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
substrate	substrate	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
catalytic	catalytic	ADJ	JJ	1	O
parameters	parameter	NOUN	NNS	5	O
Km	Km	PROPN	NNP	0	O
=	=	VERB	VBZ	7	O
265	265	NUM	CD	7	O
uM	um	NOUN	NN	0	O
for	for	ADP	IN	5	O
BTC	BTC	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
times	time	NOUN	NNS	5	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
atypical	atypical	ADJ	JJ	5	O
enzyme	enzyme	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
Vmax	Vmax	PROPN	NNP	0	O
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
against	against	ADP	IN	9	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Molecular	molecular	ADJ	JJ	9	O
dynamic	dynamic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MD	MD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
simulations	simulation	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mutation	mutation	NOUN	NN	1	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
Val204Asp	val204asp	NOUN	NN	_	O
is	be	VERB	VBZ	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
hydrogen	hydrogen	NOUN	NN	0	B-Chemical
bonding	bonding	NOUN	NN	5	O
between	between	ADP	IN	5	O
Gln223	gln223	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
Glu441	glu441	NOUN	NN	1	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
Ser198	ser198	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
His438	His438	PROPN	NNP	1	O
to	to	PART	TO	5	O
move	move	VERB	VB	5	O
away	away	ADV	RB	5	O
from	from	ADP	IN	9	O
each	each	DET	DT	5	O
other	other	ADJ	JJ	5	O
with	with	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
catalytic	catalytic	ADJ	JJ	1	O
triad	triad	NOUN	NN	9	O
functionality	functionality	NOUN	NN	9	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
substrate	substrate	NOUN	NN	0	O
.	.	PUNCT	.	9	O

MD	MD	PROPN	NNP	9	O
also	also	ADV	RB	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
enzyme	enzyme	ADJ	JJ	0	O
volume	volume	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
increased	increase	VERB	VBN	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
a	a	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
denaturation	denaturation	ADJ	JJ	0	O
state	state	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
fits	fit	VERB	VBZ	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
reduced	reduce	VERB	VBN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
Ala204Asp	Ala204Asp	PROPN	NNP	_	O
/	/	SYM	SYM	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
Asp70Gly	Asp70Gly	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
p	p	PROPN	NNP	7	O
.	.	PUNCT	.	9	O
Ala539Thr	Ala539Thr	PROPN	NNP	9	O
tetrameric	tetrameric	ADJ	JJ	1	O
enzyme	enzyme	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
detectable	detectable	ADJ	JJ	9	O
fast	fast	ADJ	JJ	5	O
moving	moving	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
bands	band	NOUN	NNS	9	O
on	on	ADP	IN	5	O
electrophoresis	electrophoresis	NOUN	NN	0	O
gels	gel	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Delayed	delay	VERB	VBN	5	O
anemia	anemia	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
injectable	injectable	ADJ	JJ	5	O
artesunate	artesunate	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Democratic	Democratic	PROPN	NNP	4	O
Republic	Republic	PROPN	NNP	2	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Congo	Congo	PROPN	NNP	4	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
manageable	manageable	ADJ	JJ	5	O
issue	issue	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cases	case	NOUN	NNS	9	O
of	of	ADP	IN	5	O
delayed	delay	VERB	VBN	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
injectable	injectable	ADJ	JJ	5	O
artesunate	artesunate	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
World	World	PROPN	NNP	5	O
Health	Health	PROPN	NNP	2	O
Organization	Organization	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
WHO	WHO	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
recommended	recommend	VERB	VBN	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
malaria	malaria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
350	350	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
215	215	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
61	61	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
<	<	X	XX	0	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
135	135	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
38	38	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
>	>	X	XX	0	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
injectable	injectable	ADJ	JJ	5	O
artesunate	artesunate	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
malaria	malaria	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
hospitals	hospital	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
health	health	NOUN	NN	5	O
centers	center	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Democratic	Democratic	PROPN	NNP	4	O
Republic	Republic	PROPN	NNP	2	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Congo	Congo	PROPN	NNP	4	O
.	.	PUNCT	.	9	O

Complete	complete	ADJ	JJ	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
Hb	Hb	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
measurements	measurement	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
available	available	ADJ	JJ	5	O
for	for	ADP	IN	5	O
201	201	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
Hb	Hb	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
between	between	ADP	IN	5	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
23	23	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
Hb	Hb	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
decreased	decrease	VERB	VBD	9	O
below	below	ADP	IN	9	O
5	5	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
during	during	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
one	one	NUM	CD	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
visit	visit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
delayed	delay	VERB	VBN	9	O
anemia	anemia	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
clinically	clinically	ADV	RB	5	O
manageable	manageable	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
resolved	resolve	VERB	VBD	9	O
within	within	ADP	IN	9	O
one	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
signal	signal	NOUN	NN	9	O
transducer	transducer	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
activator	activator	NOUN	NN	3	O
of	of	ADP	IN	5	O
transcription	transcription	NOUN	NN	1	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
apoptotic	apoptotic	ADJ	JJ	3	O
pathways	pathway	NOUN	NNS	9	O
by	by	ADP	IN	9	O
betaine	betaine	NOUN	NN	0	B-Chemical
attenuates	attenuate	VERB	VBZ	3	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
betaine	betaine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
experimentally	experimentally	ADV	RB	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
focusing	focus	VERB	VBG	5	O
on	on	ADP	IN	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
signal	signal	NOUN	NN	9	O
transducer	transducer	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
activator	activator	NOUN	NN	3	O
of	of	ADP	IN	5	O
transcription	transcription	NOUN	NN	1	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
STAT3	STAT3	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
apoptotic	apoptotic	ADJ	JJ	3	O
pathways	pathway	NOUN	NNS	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
underlying	underlie	VERB	VBG	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Sprague	Sprague	PROPN	NNP	9	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
betaine	betaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
200	200	NUM	CD	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
orally	orally	ADV	RB	0	O
for	for	ADP	IN	5	O
40	40	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
myocardial	myocardial	NOUN	NN	9	B-Disease
ischemic	ischemic	ADJ	JJ	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
85	85	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
two	two	NUM	CD	5	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
marker	marker	NOUN	NN	3	O
enzyme	enzyme	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
histopathological	histopathological	ADJ	JJ	9	O
variables	variable	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
protein	protein	NOUN	NN	1	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
betaine	betaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
and	and	CCONJ	CC	5	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
marker	marker	NOUN	NN	3	O
enzyme	enzyme	ADJ	JJ	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prevented	prevent	VERB	VBN	9	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
remodeling	remodeling	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Western	western	ADJ	JJ	3	O
blot	blot	NOUN	NN	3	O
analysis	analysis	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
phosphorylation	phosphorylation	NOUN	NN	3	O
of	of	ADP	IN	5	O
STAT3	STAT3	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
further	further	ADV	RB	9	O
enhanced	enhance	VERB	VBN	3	O
by	by	ADP	IN	9	O
betaine	betaine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
myocardium	myocardium	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
betaine	betaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
and	and	CCONJ	CC	5	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Bcl	Bcl	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
Bax	Bax	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
therefore	therefore	ADV	RB	5	O
causing	cause	VERB	VBG	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
Bcl	Bcl	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
Bax	Bax	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
betaine	betaine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
further	further	ADV	RB	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
histopathological	histopathological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
summary	summary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
betaine	betaine	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
attenuated	attenuate	VERB	VBN	3	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
STAT3	STAT3	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
apoptotic	apoptotic	ADJ	JJ	3	O
pathways	pathway	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Quetiapine	quetiapine	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Quetiapine	quetiapine	NOUN	NN	7	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
dibenzothiazepine	dibenzothiazepine	NOUN	NN	5	O
derivative	derivative	NOUN	NN	0	O
,	,	PUNCT	,	9	O
similar	similar	ADJ	JJ	9	O
to	to	PART	TO	5	O
clozapine	clozapine	VERB	VB	5	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
causing	cause	VERB	VBG	9	O
blood	blood	NOUN	NN	9	B-Disease
dyscrasias	dyscrasia	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
neutropenia	neutropenia	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
some	some	DET	DT	5	O
case	case	NOUN	NN	5	O
reports	report	VERB	VBZ	9	O
about	about	ADP	IN	5	O
this	this	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
possible	possible	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
seldom	seldom	ADV	RB	5	O
discussed	discuss	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
that	that	DET	WDT	5	O
developed	develop	VERB	VBD	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
here	here	ADV	RB	5	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
REPORT	REPORT	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
62	62	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Taiwanese	taiwanese	ADJ	JJ	9	O
widow	widow	NOUN	NN	5	O
with	with	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
at	at	ADP	IN	9	O
age	age	NOUN	NN	5	O
60	60	NUM	CD	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
leucopenia	leucopenia	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
,	,	PUNCT	,	9	O
her	-PRON-	DET	PRP$	5	O
white	white	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cell	cell	NOUN	NN	3	O
count	count	NOUN	NN	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
physicians	physician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
cautious	cautious	ADJ	JJ	5	O
about	about	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
presentation	presentation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
associated	associate	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Hepatic	hepatic	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
concomitant	concomitant	ADJ	JJ	9	O
fever	fever	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
marker	marker	NOUN	NN	3	O
for	for	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
reaction	reaction	NOUN	NN	9	O
to	to	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Lateral	lateral	ADJ	JJ	9	O
antebrachial	antebrachial	ADJ	JJ	5	O
cutaneous	cutaneous	ADJ	JJ	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
steroid	steroid	NOUN	NN	9	B-Chemical
injection	injection	NOUN	NN	9	O
at	at	ADP	IN	9	O
lateral	lateral	ADJ	JJ	5	O
epicondyle	epicondyle	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
OBJECTIVES	objective	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
present	present	VERB	VB	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
lateral	lateral	ADJ	JJ	5	O
antebrachial	antebrachial	ADJ	JJ	5	O
cutaneous	cutaneous	ADJ	JJ	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
LACNP	LACNP	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
that	that	DET	WDT	5	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
injection	injection	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
epicondyle	epicondyle	NOUN	NN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
lateral	lateral	ADJ	JJ	5	B-Disease
epicondylitis	epicondylitis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
40	40	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
.	.	PUNCT	.	9	O

MATERIAL	MATERIAL	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
40	40	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
decreased	decreased	ADJ	JJ	9	O
sensation	sensation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
paresthesia	paresthesia	NOUN	NN	5	B-Disease
over	over	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
right	right	ADJ	JJ	5	O
lateral	lateral	ADJ	JJ	5	O
forearm	forearm	NOUN	NN	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
paresthesia	paresthesia	NOUN	NN	5	B-Disease
had	have	VERB	VBD	9	O
occurred	occur	VERB	VBN	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
injection	injection	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
lateral	lateral	ADJ	JJ	5	O
epicondyle	epicondyle	NOUN	NN	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
before	before	ADV	RB	9	O
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
sensation	sensation	NOUN	NN	5	O
of	of	ADP	IN	5	O
light	light	ADJ	JJ	9	O
touch	touch	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
diminished	diminish	VERB	VBN	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
forearm	forearm	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
wrist	wrist	NOUN	NN	5	O
area	area	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
sensory	sensory	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
potential	potential	ADJ	JJ	9	O
amplitude	amplitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
lateral	lateral	ADJ	JJ	5	O
antebrachial	antebrachial	ADJ	JJ	5	O
cutaneous	cutaneous	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
LACN	LACN	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
uV	uv	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
uV	uv	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
of	of	ADP	IN	5	O
amplitude	amplitude	NOUN	NN	5	O
between	between	ADP	IN	5	O
both	both	DET	DT	9	O
sides	side	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
because	because	ADP	IN	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
a	a	DET	DT	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
right	right	ADJ	JJ	5	O
LACNP	LACNP	PROPN	NNP	_	O
(	(	PUNCT	-LRB-	9	O
mainly	mainly	ADV	RB	9	O
axonal	axonal	ADJ	JJ	3	O
involvement	involvement	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
manifestation	manifestation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
electrodiagnostic	electrodiagnostic	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
symptoms	symptom	NOUN	NNS	5	O
improved	improve	VERB	VBD	5	O
through	through	ADP	IN	9	O
physical	physical	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
persisted	persist	VERB	VBD	9	O
to	to	ADP	IN	5	O
some	some	DET	DT	5	O
degree	degree	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
LACNP	LACNP	PROPN	NNP	_	O
that	that	DET	WDT	5	O
developed	develop	VERB	VBD	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
injection	injection	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
lateral	lateral	ADJ	JJ	5	B-Disease
epicondylitis	epicondylitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
electrodiagnostic	electrodiagnostic	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
a	a	DET	DT	5	O
nerve	nerve	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
LACN	LACN	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
helpful	helpful	ADJ	JJ	6	O
to	to	PART	TO	5	O
diagnose	diagnose	VERB	VB	5	O
right	right	ADJ	JJ	5	O
LACNP	LACNP	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
find	find	VERB	VB	5	O
the	the	DET	DT	5	O
passage	passage	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
LACN	LACN	PROPN	NNP	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
epicondyle	epicondyle	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Curcumin	curcumin	NOUN	NN	0	B-Chemical
prevents	prevent	VERB	VBZ	9	O
maleate	maleate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
relation	relation	NOUN	NN	5	O
to	to	PART	TO	5	O
hemodynamic	hemodynamic	VERB	VB	5	O
alterations	alteration	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	O
complex	complex	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dietary	dietary	ADJ	JJ	5	O
antioxidant	antioxidant	NOUN	NN	0	O
curcumin	curcumin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
Kg	Kg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
maleate	maleate	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Tubular	tubular	ADJ	JJ	9	O
proteinuria	proteinuria	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
maleate	maleate	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Maleate	Maleate	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
included	include	VERB	VBD	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
total	total	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
neutrophil	neutrophil	NOUN	NN	3	O
gelatinase	gelatinase	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
lipocalin	lipocalin	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
NGAL	NGAL	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
acetyl	acetyl	NOUN	NN	0	O
b	b	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
D	d	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glucosaminidase	glucosaminidase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
NAG	NAG	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
molecule	molecule	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
KIM	KIM	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
claudin	claudin	NOUN	NN	3	O
-	-	PUNCT	:	7	O
2	2	NUM	CD	9	O
expression	expression	NOUN	NN	3	O
besides	besides	ADP	IN	9	O
of	of	ADP	IN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
apoptosis	apoptosis	NOUN	NN	3	O
of	of	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
on	on	ADP	IN	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
measuring	measure	VERB	VBG	9	O
the	the	DET	DT	5	O
oxidation	oxidation	NOUN	NN	0	O
of	of	ADP	IN	5	O
lipids	lipid	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
proteins	protein	NOUN	NNS	1	O
and	and	CCONJ	CC	5	O
diminution	diminution	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
Nrf2	Nrf2	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
epithelial	epithelial	ADJ	JJ	3	O
LLC	LLC	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
PK1	PK1	PROPN	NNP	1	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
mitochondria	mitochondria	NOUN	NN	3	O
isolated	isolate	VERB	VBN	9	O
from	from	ADP	IN	9	O
kidneys	kidney	NOUN	NNS	9	O
of	of	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Maleate	maleate	VERB	VB	0	B-Chemical
induced	induced	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
damage	damage	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
(	(	PUNCT	-LRB-	9	O
ROS	ROS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
production	production	NOUN	NN	9	O
in	in	ADP	IN	5	O
LLC	LLC	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
PK1	PK1	PROPN	NNP	1	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
culture	culture	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
maleate	maleate	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
reduced	reduce	VERB	VBD	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
in	in	ADP	IN	5	O
ADP	ADP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
stimulated	stimulate	VERB	VBN	3	O
mitochondria	mitochondria	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
diminished	diminish	VERB	VBD	9	O
respiratory	respiratory	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
index	index	NOUN	NN	5	O
when	when	ADV	WRB	5	O
using	use	VERB	VBG	9	O
malate	malate	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
substrate	substrate	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
complex	complex	ADJ	JJ	9	O
I	-PRON-	PRON	PRP	9	O
and	and	CCONJ	CC	5	O
aconitase	aconitase	NOUN	NN	1	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
diminished	diminish	VERB	VBN	9	O
.	.	PUNCT	.	9	O

All	all	DET	PDT	9	O
the	the	DET	DT	5	O
above	above	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
described	describe	VERB	VBN	9	O
alterations	alteration	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
curcumin	curcumin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
curcumin	curcumin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
attenuate	attenuate	VERB	VB	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
maleate	maleate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
cell	cell	NOUN	NN	3	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
protection	protection	NOUN	NN	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
preservation	preservation	NOUN	NN	9	O
of	of	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	O
complex	complex	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
protection	protection	NOUN	NN	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
ROS	ROS	PROPN	NNP	3	O
production	production	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Anticonvulsant	anticonvulsant	ADJ	JJ	0	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
noncompetitive	noncompetitive	ADJ	JJ	0	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
two	two	NUM	CD	5	O
seizure	seizure	NOUN	NN	5	B-Disease
models	model	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
coadministration	coadministration	NOUN	NN	0	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
major	major	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

First	first	ADV	RB	9	O
,	,	PUNCT	,	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
produced	produce	VERB	VBD	9	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
with	with	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
different	different	ADJ	JJ	9	O
biochemical	biochemical	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
control	control	NOUN	NN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Second	second	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	NUM	CD	7	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
only	only	ADV	RB	9	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
initial	initial	ADJ	JJ	9	O
periods	period	NOUN	NNS	5	O
of	of	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
observation	observation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
demonstration	demonstration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
conclusion	conclusion	NOUN	NN	9	O
derived	derive	VERB	VBN	9	O
from	from	ADP	IN	9	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
experiments	experiment	NOUN	NNS	9	O
that	that	ADP	IN	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	NUM	CD	7	I-Chemical
binding	binding	NOUN	NN	1	O
requires	require	VERB	VBZ	5	O
agonist	agonist	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
opening	opening	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
channel	channel	NOUN	NN	9	O
sites	site	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Third	third	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
relatively	relatively	ADV	RB	5	O
easy	easy	ADJ	JJ	5	O
to	to	PART	TO	5	O
block	block	VERB	VB	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
anticonvulsants	anticonvulsant	NOUN	NNS	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
more	more	ADV	RBR	5	O
difficult	difficult	ADJ	JJ	5	O
to	to	PART	TO	5	O
terminate	terminate	VERB	VB	9	O
ongoing	ongoing	ADJ	JJ	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
block	block	VERB	VB	9	O
the	the	DET	DT	5	O
lethality	lethality	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	NUM	CD	7	I-Chemical
30	30	NUM	CD	9	O
or	or	CCONJ	CC	5	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
gradually	gradually	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
electrical	electrical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
greatly	greatly	ADV	RB	9	O
enhanced	enhance	VERB	VBD	3	O
the	the	DET	DT	5	O
survival	survival	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
plays	play	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
further	further	ADV	RB	9	O
supported	support	VERB	VBN	9	O
by	by	ADP	IN	9	O
results	result	NOUN	NNS	9	O
showing	show	VERB	VBG	9	O
that	that	ADP	IN	5	O
nonconvulsive	nonconvulsive	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
synergistic	synergistic	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
tobramycin	tobramycin	NOUN	NN	0	B-Chemical
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
carbenicillin	carbenicillin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
infections	infection	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cure	cure	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
infections	infection	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
adversely	adversely	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
particular	particular	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
100	100	NUM	CD	0	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
a	a	DET	DT	5	O
poor	poor	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
antibiotics	antibiotic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
overcome	overcome	VERB	VB	5	O
the	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
tobramycin	tobramycin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
by	by	ADP	IN	9	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
carbenicillin	carbenicillin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Tobramycin	Tobramycin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	ADJ	JJ	9	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
carbenicillin	carbenicillin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
gm	gm	NOUN	NN	0	O
every	every	DET	DT	5	O
four	four	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
125	125	NUM	CD	9	O
infectious	infectious	ADJ	JJ	5	O
episodes	episode	NOUN	NNS	5	O
in	in	ADP	IN	5	O
116	116	NUM	CD	7	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
myelosuppressive	myelosuppressive	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
cure	cure	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pneumonia	Pneumonia	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
infection	infection	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
61	61	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
59	59	NUM	CD	7	O
episodes	episode	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
cured	cure	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Gram	gram	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
negative	negative	ADJ	JJ	9	O
bacilli	bacilli	NOUN	NN	9	O
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
causative	causative	ADJ	JJ	9	O
organisms	organism	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
69	69	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
infections	infection	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
cured	cure	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
pathogen	pathogen	NOUN	NN	9	O
was	be	VERB	VBD	9	O
Klebsiella	Klebsiella	PROPN	NNP	4	O
pneumoniae	pneumoniae	ADV	RB	4	B-Disease
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
Escherichia	Escherichia	PROPN	NNP	1	O
coli	coli	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
Pseudomonas	Pseudomonas	PROPN	NNP	4	O
aeruginosa	aeruginosa	NOUN	NN	4	O
,	,	PUNCT	,	9	O
accounted	account	VERB	VBD	5	O
for	for	ADP	IN	5	O
74	74	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
gram	gram	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
negative	negative	ADJ	JJ	9	I-Disease
bacillary	bacillary	ADJ	JJ	5	I-Disease
infections	infection	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Response	response	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
influenced	influence	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
neutrophil	neutrophil	NOUN	NN	3	O
count	count	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
62	62	NUM	CD	7	O
%	%	NOUN	NN	9	O
cure	cure	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
for	for	ADP	IN	5	O
39	39	NUM	CD	7	O
episodes	episode	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
failure	failure	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
neutrophil	neutrophil	NOUN	NN	3	O
count	count	NOUN	NN	9	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
during	during	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
adversely	adversely	ADV	RB	5	O
affected	affected	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Azotemia	Azotemia	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
recognized	recognize	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
episodes	episode	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Major	major	ADJ	JJ	9	O
azotemia	azotemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
serum	serum	ADV	RB	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
or	or	CCONJ	CC	5	O
BUN	BUN	PROPN	NNP	0	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
only	only	ADV	RB	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Azotemia	Azotemia	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
serum	serum	ADV	RB	9	O
tobramycin	tobramycin	ADJ	JJR	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
regimen	regiman	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
both	both	CCONJ	CC	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
acceptable	acceptable	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
for	for	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Incidence	incidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
solid	solid	ADJ	JJ	9	O
tumours	tumour	NOUN	NNS	3	B-Disease
among	among	ADP	IN	5	O
pesticide	pesticide	NOUN	NN	5	O
applicators	applicator	NOUN	NNS	5	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
organophosphate	organophosphate	ADJ	JJ	0	B-Chemical
insecticide	insecticide	ADJ	JJ	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Agricultural	Agricultural	PROPN	NNP	2	O
Health	Health	PROPN	NNP	2	O
Study	Study	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
updated	updated	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Diazinon	Diazinon	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
organophosphate	organophosphate	NOUN	NN	0	B-Chemical
insecticide	insecticide	ADV	RB	5	O
with	with	ADP	IN	5	O
genotoxic	genotoxic	ADJ	JJ	9	O
properties	property	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
lung	lung	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Agricultural	Agricultural	PROPN	NNP	2	O
Health	Health	PROPN	NNP	2	O
Study	Study	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
AHS	AHS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
cohort	cohort	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
few	few	ADJ	JJ	5	O
other	other	ADJ	JJ	5	O
epidemiological	epidemiological	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
examined	examine	VERB	VBN	9	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
cancer	cancer	NOUN	NN	3	B-Disease
risk	risk	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
updated	update	VERB	VBN	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cancer	cancer	NOUN	NN	3	B-Disease
incidence	incidence	NOUN	NN	5	O
information	information	NOUN	NN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
solid	solid	ADJ	JJ	9	O
tumour	tumour	NOUN	NN	3	B-Disease
risk	risk	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
AHS	AHS	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Male	male	ADJ	JJ	7	O
pesticide	pesticide	NOUN	NN	5	O
applicators	applicator	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Iowa	Iowa	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
North	North	PROPN	NNP	4	O
Carolina	Carolina	PROPN	NNP	2	O
reported	report	VERB	VBD	9	O
lifetime	lifetime	NOUN	NN	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
at	at	ADP	IN	9	O
enrolment	enrolment	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1993	1993	NUM	CD	2	O
-	-	SYM	SYM	7	O
1997	1997	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1998	1998	NUM	CD	2	O
-	-	SYM	SYM	7	O
2005	2005	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
cancer	cancer	NOUN	NN	3	B-Disease
incidence	incidence	NOUN	NN	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
through	through	ADP	IN	9	O
2010	2010	NUM	CD	2	O
(	(	PUNCT	-LRB-	9	O
North	North	PROPN	NNP	4	O
Carolina	Carolina	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
2011	2011	NUM	CD	2	O
(	(	PUNCT	-LRB-	9	O
Iowa	Iowa	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
applicators	applicator	NOUN	NNS	5	O
with	with	ADP	IN	5	O
usage	usage	NOUN	NN	9	O
information	information	NOUN	NN	5	O
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
exposure	exposure	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
patterns	pattern	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
used	use	VERB	VBD	5	O
Poisson	Poisson	PROPN	NNP	5	O
regression	regression	NOUN	NN	5	O
to	to	PART	TO	5	O
estimate	estimate	VERB	VB	5	O
adjusted	adjust	VERB	VBN	9	O
rate	rate	NOUN	NN	9	O
ratios	ratio	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
RRs	rr	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
for	for	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
sites	site	NOUN	NNS	9	O
with	with	ADP	IN	5	O
>	>	X	XX	0	O
10	10	NUM	CD	9	O
exposed	expose	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
for	for	ADP	IN	5	O
both	both	DET	DT	9	O
lifetime	lifetime	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
LT	LT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
exposure	exposure	NOUN	NN	9	O
days	day	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
intensity	intensity	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
weighted	weight	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
IW	IW	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
lifetime	lifetime	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
accounting	account	VERB	VBG	5	O
for	for	ADP	IN	5	O
factors	factor	NOUN	NNS	9	O
impacting	impact	VERB	VBG	5	O
exposure	exposure	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
observed	observe	VERB	VBD	9	O
elevated	elevated	ADJ	JJ	9	O
lung	lung	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
risks	risk	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
283	283	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
among	among	ADP	IN	5	O
applicators	applicator	NOUN	NNS	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
greatest	great	ADJ	JJS	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
LT	LT	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
=	=	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
60	60	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
11	11	NUM	CD	7	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
31	31	NUM	CD	7	O
;	;	PUNCT	:	9	O
Ptrend	ptrend	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
IW	IW	PROPN	NNP	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
=	=	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
41	41	NUM	CD	7	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
98	98	NUM	CD	7	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
;	;	PUNCT	:	9	O
Ptrend	ptrend	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Kidney	Kidney	PROPN	NNP	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
94	94	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
risks	risk	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
significantly	significantly	ADV	RB	9	O
elevated	elevated	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
RRLT	RRLT	PROPN	NNP	_	O
days	day	NOUN	NNS	9	O
=	=	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
77	77	NUM	CD	7	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
90	90	NUM	CD	9	O
to	to	PART	TO	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
51	51	NUM	CD	7	O
;	;	PUNCT	:	9	O
Ptrend	ptrend	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
;	;	PUNCT	:	9	O
RRIW	RRIW	PROPN	NNP	_	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
37	37	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
64	64	NUM	CD	7	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
92	92	NUM	CD	7	O
;	;	PUNCT	:	9	O
Ptrend	ptrend	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
50	50	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
were	be	VERB	VBD	9	O
risks	risk	NOUN	NNS	5	O
for	for	ADP	IN	5	O
aggressive	aggressive	ADJ	JJ	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
656	656	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
updated	updated	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
diazinon	diazinon	NOUN	NN	0	B-Chemical
provides	provide	VERB	VBZ	5	O
additional	additional	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
lung	lung	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
risk	risk	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Newly	newly	ADV	RB	9	O
identified	identify	VERB	VBN	9	O
links	link	NOUN	NNS	5	O
to	to	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
associations	association	NOUN	NNS	5	O
with	with	ADP	IN	5	O
aggressive	aggressive	ADJ	JJ	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
require	require	VERB	VBP	5	O
further	further	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Associations	association	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Ozone	Ozone	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
PM2	PM2	PROPN	NNP	1	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
Concentrations	concentration	NOUN	NNS	0	O
With	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	VERB	VBZ	9	I-Disease
Disease	Disease	PROPN	NNP	2	I-Disease
Among	among	ADP	IN	9	O
Participants	participant	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Agricultural	Agricultural	PROPN	NNP	2	O
Health	Health	PROPN	NNP	2	O
Study	Study	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
describes	describe	VERB	VBZ	5	O
associations	association	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ozone	ozone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
fine	fine	ADJ	JJ	5	O
particulate	particulate	NOUN	NN	0	B-Chemical
matter	matter	NOUN	NN	5	I-Chemical
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
observed	observe	VERB	VBN	9	O
among	among	ADP	IN	5	O
farmers	farmer	NOUN	NNS	5	O
in	in	ADP	IN	5	O
North	North	PROPN	NNP	4	O
Carolina	Carolina	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
Iowa	Iowa	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
logistic	logistic	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
associations	association	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
pollutants	pollutant	NOUN	NNS	5	O
with	with	ADP	IN	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
reported	report	VERB	VBN	9	O
,	,	PUNCT	,	9	O
doctor	doctor	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
diagnosed	diagnose	VERB	VBN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Daily	Daily	PROPN	NNP	5	O
predicted	predict	VERB	VBD	9	O
pollutant	pollutant	ADJ	JJ	5	O
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
derive	derive	VERB	VB	5	O
surrogates	surrogate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
link	link	VERB	VB	5	O
them	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
participants	participant	NOUN	NNS	5	O
'	'	PART	POS	9	O
geocoded	geocode	VERB	VBN	5	O
addresses	address	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
observed	observe	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
associations	association	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
ozone	ozone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
=	=	ADP	IN	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
39	39	NUM	CD	7	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
98	98	NUM	CD	7	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
98	98	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
fine	fine	ADJ	JJ	5	O
particulate	particulate	NOUN	NN	0	B-Chemical
matter	matter	NOUN	NN	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
=	=	ADP	IN	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
93	93	NUM	CD	7	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
93	93	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
North	North	PROPN	NNP	4	O
Carolina	Carolina	PROPN	NNP	2	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
Iowa	Iowa	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
plausibility	plausibility	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
ambient	ambient	ADJ	JJ	5	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
pollutants	pollutant	NOUN	NNS	5	O
on	on	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
risk	risk	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
supported	support	VERB	VBN	9	O
by	by	ADP	IN	9	O
experimental	experimental	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
demonstrating	demonstrating	NOUN	NN	9	O
damage	damage	NOUN	NN	9	O
to	to	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
at	at	ADP	IN	9	O
relevant	relevant	ADJ	JJ	5	O
concentrations	concentration	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Additional	additional	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
address	address	VERB	VB	5	O
uncertainties	uncertainty	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
confounding	confound	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
temporal	temporal	ADJ	JJ	5	O
aspects	aspect	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
associations	association	NOUN	NNS	5	O
we	-PRON-	PRON	PRP	5	O
observed	observe	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Low	low	ADJ	JJ	9	O
functional	functional	ADJ	JJ	9	O
programming	programming	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
AT2R	AT2R	PROPN	NNP	3	O
mediates	mediate	VERB	VBZ	3	O
the	the	DET	DT	5	O
developmental	developmental	ADJ	JJ	9	O
origin	origin	NOUN	NN	9	O
of	of	ADP	IN	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
offspring	offspring	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
prenatal	prenatal	ADJ	JJ	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

UNASSIGNED	UNASSIGNED	NOUN	NNS	_	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
previous	previous	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
indicated	indicate	VERB	VBN	9	O
that	that	ADP	IN	5	O
prenatal	prenatal	ADJ	JJ	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PCE	PCE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
could	could	VERB	MD	9	O
induce	induce	VERB	VB	3	O
intrauterine	intrauterine	ADJ	JJ	5	B-Disease
growth	growth	NOUN	NN	3	I-Disease
retardation	retardation	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
IUGR	iugr	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
offspring	offspring	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
research	research	NOUN	NN	5	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
IUGR	iugr	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
whether	whether	ADP	IN	9	O
PCE	PCE	PROPN	NNP	9	O
could	could	VERB	MD	9	O
induce	induce	VERB	VB	3	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
underlying	underlying	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
remain	remain	VERB	VBP	9	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
demonstrate	demonstrate	VERB	VB	9	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
to	to	PART	TO	5	O
glomerulosclerosis	glomerulosclerosis	VERB	VB	3	B-Disease
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
offspring	offspring	NOUN	NN	9	O
by	by	ADP	IN	9	O
PCE	PCE	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
intrauterine	intrauterine	ADJ	JJ	5	O
programming	programming	NOUN	NN	5	O
mechanisms	mechanism	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
IUGR	iugr	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
established	establish	VERB	VBN	9	O
by	by	ADP	IN	9	O
PCE	PCE	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
male	male	ADJ	JJ	9	O
fetuses	fetus	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
adult	adult	NOUN	NN	9	O
offspring	offspring	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
postnatal	postnatal	ADJ	JJ	9	O
week	week	NOUN	NN	9	O
24	24	NUM	CD	9	O
were	be	VERB	VBD	9	O
euthanized	euthanize	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
adult	adult	NOUN	NN	9	O
offspring	offspring	NOUN	NN	9	O
kidneys	kidney	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PCE	PCE	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
exhibited	exhibit	VERB	VBD	9	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
fibrosis	fibrosis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
elevated	elevated	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
protein	protein	NOUN	NN	1	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	II	PROPN	NNP	9	I-Chemical
receptor	receptor	NOUN	NN	3	O
type	type	NOUN	NN	9	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
AT2R	AT2R	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
offspring	offspring	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
PCE	PCE	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	II	PROPN	NNP	9	I-Chemical
receptor	receptor	NOUN	NN	3	O
type	type	NOUN	NN	9	O
1a	1a	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
AT1aR	AT1aR	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
AT2R	AT2R	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
ratio	ratio	NOUN	NN	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
fetal	fetal	ADJ	JJ	9	O
kidneys	kidney	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PCE	PCE	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
displayed	display	VERB	VBD	9	O
an	an	DET	DT	5	O
enlarged	enlarged	ADJ	JJ	9	O
Bowman	Bowman	PROPN	NNP	6	O
'	'	PART	POS	9	O
s	s	PART	POS	9	O
space	space	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
shrunken	shrunken	ADJ	JJ	5	O
glomerular	glomerular	NOUN	NN	5	O
tuft	tuft	NOUN	NN	4	O
,	,	PUNCT	,	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
reduced	reduced	ADJ	JJ	9	O
cortex	cortex	NOUN	NN	5	O
width	width	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
nephrogenic	nephrogenic	ADJ	JJ	5	O
zone	zone	NOUN	NN	9	O
/	/	SYM	SYM	9	O
cortical	cortical	ADJ	JJ	5	O
zone	zone	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Observation	observation	NOUN	NN	5	O
by	by	ADP	IN	9	O
electronic	electronic	ADJ	JJ	5	O
microscope	microscope	NOUN	NN	0	O
revealed	reveal	VERB	VBD	9	O
structural	structural	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
of	of	ADP	IN	5	O
podocytes	podocyte	NOUN	NNS	3	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
reduced	reduced	ADJ	JJ	9	O
expression	expression	NOUN	NN	3	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
podocyte	podocyte	NOUN	NN	3	O
marker	marker	NOUN	NN	3	O
genes	gene	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
nephrin	nephrin	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
podocin	podocin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
detected	detect	VERB	VBN	9	O
by	by	ADP	IN	9	O
q	q	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
PCR	PCR	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
AT2R	AT2R	PROPN	NNP	3	O
gene	gene	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
expressions	expression	NOUN	NNS	9	O
in	in	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	O
kidneys	kidney	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
inhibited	inhibit	VERB	VBN	3	O
by	by	ADP	IN	9	O
PCE	PCE	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
repression	repression	NOUN	NN	1	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
glial	glial	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
neurotrophic	neurotrophic	ADJ	JJ	3	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
GDNF	GDNF	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
tyrosine	tyrosine	NOUN	NN	3	B-Chemical
kinase	kinase	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
c	c	NOUN	NN	9	O
-	-	PUNCT	:	7	O
Ret	Ret	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
signaling	signal	VERB	VBG	3	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
PCE	PCE	PROPN	NNP	9	O
could	could	VERB	MD	9	O
induce	induce	VERB	VB	3	O
dysplasia	dysplasia	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
fetal	fetal	ADJ	JJ	9	I-Disease
kidneys	kidney	NOUN	NNS	9	I-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
offspring	offspring	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
functional	functional	ADJ	JJ	9	O
programming	programming	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
AT2R	AT2R	PROPN	NNP	3	O
might	may	VERB	MD	9	O
mediate	mediate	VERB	VB	3	O
the	the	DET	DT	5	O
developmental	developmental	ADJ	JJ	9	O
origin	origin	NOUN	NN	9	O
of	of	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
Butadiene	Butadiene	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
CML	CML	PROPN	NNP	3	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
:	:	SYM	SYM	9	O
22	22	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
translocation	translocation	NOUN	NN	3	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
reality	reality	NOUN	NN	5	O
check	check	NOUN	NN	5	O
.	.	PUNCT	.	9	O

UNASSIGNED	UNASSIGNED	NOUN	NNS	_	O
:	:	PUNCT	:	9	O
Epidemiological	epidemiological	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
butadiene	butadiene	NOUN	NN	0	I-Chemical
have	have	VERB	VBP	5	O
suggest	suggest	VERB	VBN	9	O
that	that	DET	WDT	5	O
exposures	exposure	NOUN	NNS	5	O
to	to	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
myeloid	myeloid	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
CML	CML	PROPN	NNP	3	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CML	CML	PROPN	NNP	3	B-Disease
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
documented	document	VERB	VBN	9	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
ionizing	ionize	VERB	VBG	3	O
radiation	radiation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
associations	association	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chemical	chemical	NOUN	NN	0	O
exposures	exposure	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
questioned	question	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Ionizing	ionizing	NOUN	NN	3	O
radiation	radiation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
capable	capable	ADJ	JJ	9	O
of	of	ADP	IN	5	O
inducing	induce	VERB	VBG	3	O
the	the	DET	DT	5	O
requisite	requisite	ADJ	JJ	5	O
CML	CML	PROPN	NNP	3	B-Disease
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
:	:	SYM	SYM	9	O
22	22	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
translocation	translocation	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
Philadelphia	Philadelphia	PROPN	NNP	2	B-Disease
chromosome	chromosome	NOUN	NN	1	I-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
appropriate	appropriate	ADJ	JJ	5	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
but	but	CCONJ	CC	9	O
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
far	far	ADV	RB	5	O
,	,	PUNCT	,	9	O
chemicals	chemical	NOUN	NNS	0	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
shown	show	VERB	VBN	9	O
this	this	DET	DT	5	O
capacity	capacity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
proposed	propose	VERB	VBN	5	O
that	that	ADP	IN	5	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
butadiene	butadiene	NOUN	NN	0	I-Chemical
metabolites	metabolite	NOUN	NNS	0	O
be	be	VERB	VB	5	O
so	so	ADV	RB	5	O
tested	test	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
reality	reality	NOUN	NN	5	O
check	check	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
epidemiological	epidemiological	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
conduct	conduct	VERB	VB	5	O
reliable	reliable	ADJ	JJ	5	O
testing	testing	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
regard	regard	NOUN	NN	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
essential	essential	ADJ	JJ	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
for	for	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
be	be	VERB	VB	5	O
available	available	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
used	use	VERB	VBN	5	O
ionizing	ionizing	NOUN	NN	3	O
radiation	radiation	NOUN	NN	9	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
such	such	DET	PDT	5	O
a	a	DET	DT	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
described	describe	VERB	VBN	9	O
here	here	ADV	RB	5	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
does	do	VERB	VBZ	9	O
in	in	ADP	IN	5	O
fact	fact	NOUN	NN	9	O
induce	induce	VERB	VB	3	O
pathogenic	pathogenic	ADJ	JJ	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
:	:	SYM	SYM	9	O
22	22	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
translocations	translocation	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
human	human	ADJ	JJ	3	O
myeloid	myeloid	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
line	line	NOUN	NN	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
does	do	VERB	VBZ	9	O
so	so	ADV	RB	5	O
at	at	ADP	IN	9	O
low	low	ADJ	JJ	9	O
frequencies	frequency	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Conditions	condition	NOUN	NNS	9	O
that	that	DET	WDT	5	O
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
required	require	VERB	VBN	9	O
for	for	ADP	IN	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
butadiene	butadiene	NOUN	NNS	0	I-Chemical
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Cancer	cancer	NOUN	NN	2	B-Disease
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
metolachlor	metolachlor	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Agricultural	Agricultural	PROPN	NNP	2	O
Health	Health	PROPN	NNP	2	O
Study	Study	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
An	an	DET	DT	5	O
update	update	NOUN	NN	5	O
.	.	PUNCT	.	9	O

UNASSIGNED	UNASSIGNED	NOUN	NNS	_	O
:	:	PUNCT	:	9	O
Metolachlor	Metolachlor	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
herbicide	herbicide	NOUN	NN	0	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
classified	classify	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
Group	Group	PROPN	NNP	9	O
C	C	PROPN	NNP	9	O
carcinogen	carcinogen	NOUN	NN	0	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
U	u	NOUN	NN	9	O
.	.	PUNCT	.	9	O
S	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Environmental	Environmental	PROPN	NNP	2	O
Protection	Protection	PROPN	NNP	2	O
Agency	Agency	PROPN	NNP	2	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
liver	liver	NOUN	NN	9	B-Disease
neoplasms	neoplasm	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Epidemiologic	epidemiologic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
health	health	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
metolachlor	metolachlor	NOUN	NN	0	B-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
limited	limit	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Agricultural	Agricultural	PROPN	NNP	2	O
Health	Health	PROPN	NNP	2	O
Study	Study	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
AHS	AHS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
cohort	cohort	NOUN	NN	9	O
study	study	NOUN	NN	9	O
including	include	VERB	VBG	9	O
licensed	license	VERB	VBN	5	O
private	private	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
commercial	commercial	ADJ	JJ	5	O
pesticide	pesticide	NOUN	NN	5	O
applicators	applicator	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Iowa	Iowa	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
North	North	PROPN	NNP	4	O
Carolina	Carolina	PROPN	NNP	2	O
enrolled	enrol	VERB	VBD	5	O
1993	1993	NUM	CD	2	O
-	-	SYM	SYM	7	O
1997	1997	NUM	CD	2	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
evaluated	evaluate	VERB	VBD	9	O
cancer	cancer	NOUN	NN	3	B-Disease
incidence	incidence	NOUN	NN	5	O
through	through	ADP	IN	9	O
2010	2010	NUM	CD	2	O
/	/	SYM	SYM	9	O
2011	2011	NUM	CD	2	O
(	(	PUNCT	-LRB-	9	O
NC	NC	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
IA	IA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
49	49	NUM	CD	7	O
,	,	PUNCT	,	9	O
616	616	NUM	CD	7	O
applicators	applicator	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
53	53	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
reported	report	VERB	VBD	9	O
ever	ever	ADV	RB	5	O
using	use	VERB	VBG	9	O
metolachlor	metolachlor	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
Poisson	Poisson	PROPN	NNP	5	O
regression	regression	NOUN	NN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
relations	relation	NOUN	NNS	5	O
between	between	ADP	IN	5	O
two	two	NUM	CD	5	O
metrics	metric	NOUN	NNS	5	O
of	of	ADP	IN	5	O
metolachlor	metolachlor	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
lifetime	lifetime	NOUN	NN	5	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
intensity	intensity	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
weighted	weight	VERB	VBN	5	O
lifetime	lifetime	NOUN	NN	5	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
cancer	cancer	NOUN	NN	3	B-Disease
incidence	incidence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
saw	see	VERB	VBD	5	O
no	no	DET	DT	9	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
metolachlor	metolachlor	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
cancers	cancer	NOUN	NNS	9	B-Disease
combined	combine	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
701	701	NUM	CD	7	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
lag	lag	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
most	most	ADJ	JJS	9	O
site	site	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
cancers	cancer	NOUN	NNS	9	B-Disease
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
liver	liver	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
analyses	analysis	NOUN	NNS	9	O
restricted	restrict	VERB	VBN	9	O
to	to	ADP	IN	5	O
exposed	expose	VERB	VBN	9	O
workers	worker	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
elevations	elevation	NOUN	NNS	9	O
observed	observe	VERB	VBD	9	O
at	at	ADP	IN	9	O
higher	high	ADJ	JJR	9	O
categories	category	NOUN	NNS	5	O
of	of	ADP	IN	5	O
use	use	NOUN	NN	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
trends	trend	NOUN	NNS	5	O
for	for	ADP	IN	5	O
both	both	DET	DT	9	O
lifetime	lifetime	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intensity	intensity	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
weighted	weight	VERB	VBN	5	O
lifetime	lifetime	NOUN	NN	5	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
metolachor	metolachor	NOUN	NN	_	B-Chemical
use	use	NOUN	NN	5	O
were	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
unexposed	unexposed	ADJ	JJ	9	O
reference	reference	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
similar	similar	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
for	for	ADP	IN	5	O
follicular	follicular	ADJ	JJ	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
lymphoma	lymphoma	NOUN	NN	9	B-Disease
subtypes	subtype	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
earlier	early	ADJ	JJR	9	O
suggestion	suggestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
lung	lung	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
risk	risk	NOUN	NN	5	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
metolachlor	metolachlor	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
confirmed	confirm	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
update	update	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
suggestion	suggestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
metolachlor	metolachlor	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
among	among	ADP	IN	5	O
pesticide	pesticide	NOUN	NN	5	O
applicators	applicator	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
finding	finding	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
echoes	echo	NOUN	NNS	5	O
observation	observation	NOUN	NN	9	O
of	of	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
liver	liver	NOUN	NN	9	B-Disease
neoplasms	neoplasm	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
animal	animal	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
findings	finding	NOUN	NNS	9	O
for	for	ADP	IN	5	O
both	both	DET	DT	9	O
liver	liver	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
follicular	follicular	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
lymphoma	lymphoma	NOUN	NN	9	B-Disease
warrant	warrant	NOUN	NN	9	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
to	to	PART	TO	5	O
better	better	ADV	RBR	5	O
differentiate	differentiate	VERB	VB	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
metolachlor	metolachlor	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
from	from	ADP	IN	9	O
other	other	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Mechanisms	Mechanisms	PROPN	NNP	9	O
Underlying	Underlying	PROPN	NNP	5	O
Latent	Latent	PROPN	NNP	5	O
Disease	Disease	PROPN	NNP	2	O
Risk	Risk	PROPN	NNP	5	O
Associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
Early	early	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
Life	Life	PROPN	NNP	2	O
Arsenic	Arsenic	PROPN	NNP	0	B-Chemical
Exposure	exposure	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Current	Current	PROPN	NNP	9	O
Research	Research	PROPN	NNP	2	O
Trends	Trends	PROPN	NNPS	5	O
and	and	CCONJ	CC	5	O
Scientific	Scientific	PROPN	NNP	0	O
Gaps	Gaps	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Millions	million	NOUN	NNS	5	O
of	of	ADP	IN	5	O
individuals	individual	NOUN	NNS	5	O
worldwide	worldwide	ADV	RB	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
those	those	DET	DT	5	O
living	live	VERB	VBG	5	O
in	in	ADP	IN	5	O
rural	rural	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
developing	develop	VERB	VBG	5	O
areas	area	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
harmful	harmful	ADJ	JJ	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
inorganic	inorganic	ADJ	JJ	0	B-Chemical
arsenic	arsenic	ADJ	JJ	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
iAs	ia	NOUN	NNS	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
drinking	drinking	NOUN	NN	5	O
water	water	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Inorganic	inorganic	ADJ	JJ	0	B-Chemical
As	as	ADP	IN	9	I-Chemical
exposure	exposure	NOUN	NN	9	O
during	during	ADP	IN	5	O
key	key	ADJ	JJ	9	O
developmental	developmental	ADJ	JJ	9	O
periods	period	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
including	include	VERB	VBG	9	O
those	those	DET	DT	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
evident	evident	ADJ	JJ	9	O
in	in	ADP	IN	5	O
adulthood	adulthood	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
considerable	considerable	ADJ	JJ	5	O
interest	interest	NOUN	NN	5	O
in	in	ADP	IN	5	O
identifying	identify	VERB	VBG	5	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
that	that	DET	WDT	5	O
relate	relate	VERB	VBP	5	O
early	early	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
iAs	ia	NOUN	NNS	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
latent	latent	NOUN	NN	5	O
diseases	disease	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
relationship	relationship	NOUN	NN	5	O
to	to	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
work	work	NOUN	NN	5	O
summarizes	summarize	VERB	VBZ	5	O
research	research	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
that	that	DET	WDT	5	O
underlie	underlie	VERB	VBP	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
development	development	NOUN	NN	9	O
in	in	ADP	IN	5	O
adulthood	adulthood	NOUN	NN	5	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
early	early	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
iAs	ia	NOUN	NNS	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Epigenetic	epigenetic	ADJ	JJ	5	O
reprogramming	reprogramming	NOUN	NN	3	O
that	that	DET	WDT	5	O
imparts	impart	VERB	VBZ	9	O
functional	functional	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
stem	stem	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
immunomodulation	immunomodulation	NOUN	NN	3	O
are	be	VERB	VBP	5	O
plausible	plausible	ADJ	JJ	5	O
underlying	underlying	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
early	early	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
iAs	ia	NOUN	NNS	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
elicits	elicit	VERB	VBZ	9	O
latent	latent	NOUN	NN	5	O
carcinogenic	carcinogenic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Evidence	evidence	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
mounting	mount	VERB	VBG	9	O
that	that	ADP	IN	5	O
relates	relate	VERB	VBZ	5	O
early	early	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
iAs	ia	NOUN	NNS	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cancer	cancer	NOUN	NN	3	B-Disease
development	development	NOUN	NN	9	O
later	later	ADV	RB	9	O
in	in	ADP	IN	5	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Future	future	ADJ	JJ	5	O
research	research	NOUN	NN	5	O
should	should	VERB	MD	5	O
include	include	VERB	VB	5	O
animal	animal	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
that	that	DET	WDT	5	O
address	address	VERB	VBP	5	O
mechanistic	mechanistic	ADJ	JJ	9	O
hypotheses	hypothesis	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
populations	population	NOUN	NNS	9	O
that	that	DET	WDT	5	O
integrate	integrate	VERB	VBP	5	O
early	early	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
molecular	molecular	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
latent	latent	NOUN	NN	5	O
disease	disease	NOUN	NN	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Nifedipine	nifedipine	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBD	3	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
autonomic	autonomic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
80	80	NUM	CD	9	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
male	male	NOUN	NN	9	O
with	with	ADP	IN	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
autonomic	autonomic	ADJ	JJ	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
with	with	ADP	IN	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
flutter	flutter	ADV	RB	5	I-Disease
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
70	70	NUM	CD	9	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
which	which	DET	WDT	5	O
slowed	slow	VERB	VBD	9	O
down	down	PART	RP	9	O
to	to	ADP	IN	5	O
30	30	NUM	CD	9	O
-	-	SYM	SYM	7	O
40	40	NUM	CD	9	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
when	when	ADV	WRB	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
divided	divided	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
which	which	DET	WDT	5	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
paced	pace	VERB	VBN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
70	70	NUM	CD	9	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
inconsistent	inconsistent	ADJ	JJ	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
established	establish	VERB	VBN	9	O
finding	finding	NOUN	NN	9	O
that	that	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
induces	induce	VERB	VBZ	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
normally	normally	ADV	RB	9	O
innervated	innervate	VERB	VBN	5	O
hearts	heart	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
hearts	heart	NOUN	NNS	3	O
deprived	deprive	VERB	VBN	9	O
of	of	ADP	IN	5	O
compensatory	compensatory	ADJ	JJ	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
drive	drive	NOUN	NN	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
intoxication	intoxication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
the	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
intraperitoneal	intraperitoneal	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
death	death	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
70	70	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
82	82	NUM	CD	7	O
%	%	NOUN	NN	9	O
death	death	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Haloperidol	Haloperidol	PROPN	NNP	7	B-Chemical
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
lower	lower	VERB	VB	9	O
the	the	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
at	at	ADP	IN	9	O
most	most	ADJ	JJS	9	O
doses	dose	NOUN	NNS	0	O
tested	test	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Haloperidol	Haloperidol	PROPN	NNP	7	B-Chemical
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
highest	high	ADJ	JJS	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
lowering	lowering	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reach	reach	VERB	VB	5	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
at	at	ADP	IN	9	O
any	any	DET	DT	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
blocker	blocker	NOUN	NN	0	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
against	against	ADP	IN	9	O
death	death	NOUN	NN	9	O
from	from	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
without	without	ADP	IN	9	O
reducing	reduce	VERB	VBG	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
demonstrated	demonstrate	VERB	VBD	9	O
an	an	DET	DT	5	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
without	without	ADP	IN	9	O
significantly	significantly	ADV	RB	9	O
reducing	reduce	VERB	VBG	9	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Autoradiographic	autoradiographic	ADJ	JJ	0	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
binding	bind	VERB	VBG	1	O
sites	site	NOUN	NNS	9	O
in	in	ADP	IN	5	O
nuclei	nucleus	NOUN	NNS	3	O
of	of	ADP	IN	5	O
diethylstilbesterol	diethylstilbesterol	NOUN	NN	0	B-Chemical
induced	induced	ADJ	JJ	3	O
hamster	hamster	NOUN	NN	3	O
renal	renal	ADJ	JJ	9	B-Disease
carcinomas	carcinoma	NOUN	NNS	3	I-Disease
.	.	PUNCT	.	9	O

Estrogen	Estrogen	PROPN	NNP	9	B-Chemical
binding	bind	VERB	VBG	1	O
sites	site	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
by	by	ADP	IN	9	O
autoradiography	autoradiography	NOUN	NN	0	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
transplantable	transplantable	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
primary	primary	ADJ	JJ	9	O
diethylstilbesterol	diethylstilbesterol	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBD	3	O
renal	renal	ADJ	JJ	9	B-Disease
carcinomas	carcinoma	NOUN	NNS	3	I-Disease
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
hamsters	hamster	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Radiolabelling	radiolabelling	NOUN	NN	0	O
,	,	PUNCT	,	9	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
3H	3h	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
17	17	NUM	CD	7	O
beta	beta	NOUN	NN	9	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
only	only	ADV	RB	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
nuclei	nucleus	NOUN	NNS	3	O
of	of	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
cells	cell	NOUN	NNS	3	O
;	;	PUNCT	,	9	O
stereologic	stereologic	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	:	7	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
times	time	NOUN	NNS	5	O
higher	high	ADJ	JJR	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
reduced	reduce	VERB	VBN	9	O
silver	silver	NOUN	NN	0	B-Chemical
grains	grain	NOUN	NNS	0	O
over	over	ADP	IN	5	O
nuclei	nucleus	NOUN	NNS	3	O
than	than	ADP	IN	5	O
cytoplasm	cytoplasm	NOUN	NN	3	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
rapid	rapid	ADJ	JJ	5	O
tubular	tubular	ADJ	JJ	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
which	which	DET	WDT	5	O
peaked	peak	VERB	VBD	9	O
in	in	ADP	IN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
bind	bind	VERB	VB	1	O
the	the	DET	DT	5	O
ligand	ligand	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
published	publish	VERB	VBN	9	O
report	report	NOUN	NN	5	O
documenting	document	VERB	VBG	5	O
the	the	DET	DT	5	O
preferential	preferential	ADJ	JJ	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
binding	bind	VERB	VBG	1	O
of	of	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
to	to	ADP	IN	5	O
nuclei	nucleus	NOUN	NNS	3	O
of	of	ADP	IN	5	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
induced	induce	VERB	VBD	3	O
hamster	hamster	NOUN	NN	3	O
renal	renal	ADJ	JJ	9	B-Disease
carcinomas	carcinoma	NOUN	NNS	3	I-Disease
.	.	PUNCT	.	9	O

Bradycardia	Bradycardia	NOUN	NNS	7	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
biperiden	biperiden	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
38	38	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
postzosteric	postzosteric	ADJ	JJ	_	B-Disease
trigeminal	trigeminal	ADJ	JJ	5	B-Disease
neuralgia	neuralgia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
intravenous	intravenous	ADJ	JJ	0	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
biperiden	biperiden	NOUN	NN	5	B-Chemical
lactate	lactate	NOUN	NN	0	I-Chemical
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
lasting	last	VERB	VBG	5	O
paradoxical	paradoxical	ADJ	JJ	5	O
reaction	reaction	NOUN	NN	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
considerable	considerable	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
dysarthria	dysarthria	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dysphagia	dysphagia	VERB	VB	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
back	back	ADV	RB	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
within	within	ADP	IN	9	O
12	12	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
upon	upon	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
orciprenaline	orciprenaline	NOUN	NN	0	B-Chemical
under	under	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Bradycardia	Bradycardia	PROPN	NNP	7	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
biperiden	biperiden	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
speed	speed	NOUN	NN	5	O
of	of	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
dual	dual	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
on	on	ADP	IN	5	O
muscarine	muscarine	NOUN	NN	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Deliberate	deliberate	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
isoflurane	isoflurane	VERB	VB	0	B-Chemical
for	for	ADP	IN	5	O
middle	middle	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
ear	ear	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
feasibility	feasibility	NOUN	NN	5	O
of	of	ADP	IN	5	O
using	use	VERB	VBG	9	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
blocking	block	VERB	VBG	3	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
agent	agent	NOUN	NN	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
inhalation	inhalation	NOUN	NN	5	O
anaesthetics	anaesthetic	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
23	23	NUM	CD	7	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
middle	middle	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
ear	ear	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
from	from	ADP	IN	9	O
86	86	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
mean	mean	VERB	VB	5	O
)	)	PUNCT	-RRB-	9	O
mmHg	mmhg	NOUN	NN	7	O
to	to	PART	TO	5	O
52	52	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
mmHg	mmhg	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
kPa	kpa	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
98	98	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
min	min	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
H	H	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
from	from	ADP	IN	9	O
79	79	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
53	53	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
mmHg	mmhg	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
kPa	kpa	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
129	129	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
min	min	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
E	E	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
from	from	ADP	IN	9	O
80	80	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
to	to	ADP	IN	5	O
49	49	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
mmHg	mmhg	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
kPa	kpa	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
135	135	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
I	i	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
H	H	PROPN	NNP	9	B-Chemical
concentration	concentration	NOUN	NN	0	O
during	during	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
inspiratory	inspiratory	ADJ	JJ	5	O
gas	gas	NOUN	NN	0	O
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
vol	vol	NOUN	NN	0	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
E	e	NOUN	NN	9	B-Chemical
concentration	concentration	NOUN	NN	0	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
vol	vol	NOUN	NN	0	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mean	mean	NOUN	NN	5	O
I	-PRON-	PRON	PRP	9	B-Chemical
concentration	concentration	NOUN	NN	0	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
vol	vol	NOUN	NN	0	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
d	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tubocurarine	tubocurarine	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
lowering	lower	VERB	VBG	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
52	52	NUM	CD	7	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
59	59	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
stable	stable	ADJ	JJ	9	O
without	without	ADP	IN	9	O
tachy	tachy	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
or	or	CCONJ	CC	5	I-Disease
bradycardia	bradycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
operating	operate	VERB	VBG	5	O
conditions	condition	NOUN	NNS	9	O
regarding	regard	VERB	VBG	5	O
bleeding	bleed	VERB	VBG	5	B-Disease
were	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
manner	manner	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
rose	rise	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
groups	group	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
values	value	NOUN	NNS	5	O
before	before	ADP	IN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
returned	return	VERB	VBD	5	O
postoperatively	postoperatively	ADV	RB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
except	except	ADP	IN	9	O
the	the	DET	DT	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
rebound	rebound	NOUN	NN	5	O
phenomenon	phenomenon	NOUN	NN	5	O
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
induces	induce	NOUN	NNS	3	O
easily	easily	ADV	RB	5	O
adjustable	adjustable	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	O
compensatory	compensatory	ADJ	JJ	5	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
rebound	rebound	VERB	VB	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Convulsion	convulsion	NOUN	NN	7	B-Disease
following	follow	VERB	VBG	9	O
intravenous	intravenous	ADJ	JJ	0	O
fluorescein	fluorescein	NOUN	NN	0	B-Chemical
angiography	angiography	ADV	RB	5	O
.	.	PUNCT	.	9	O

Tonic	tonic	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
clonic	clonic	NOUN	NN	5	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
followed	follow	VERB	VBD	9	O
intravenous	intravenous	ADJ	JJ	0	O
fluorescein	fluorescein	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
for	for	ADP	IN	5	O
fundus	fundus	NOUN	NN	5	O
angiography	angiography	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
47	47	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
precautions	precaution	NOUN	NNS	5	O
this	this	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
reaction	reaction	NOUN	NN	9	O
recurred	recur	VERB	VBD	5	O
on	on	ADP	IN	5	O
re	re	NOUN	NN	5	O
-	-	NOUN	NN	7	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
fluorescein	fluorescein	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Pharmacology	pharmacology	NOUN	NN	2	O
of	of	ADP	IN	5	O
ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
prodrug	prodrug	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
disodium	disodium	NOUN	NN	0	B-Chemical
phosphate	phosphate	NOUN	NN	0	I-Chemical
ester	ester	NOUN	NN	0	I-Chemical
of	of	ADP	IN	5	O
3	3	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxymethyl	hydroxymethyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diphenylhydantoin	diphenylhydantoin	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
prodrug	prodrug	NOUN	NN	0	O
of	of	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
advantageous	advantageous	ADJ	JJ	5	O
physicochemical	physicochemical	ADJ	JJ	0	O
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	PROPN	NNP	7	I-Chemical
is	be	VERB	VBZ	5	O
rapidly	rapidly	ADV	RB	9	O
converted	convert	VERB	VBN	9	O
enzymatically	enzymatically	ADV	RB	0	O
to	to	PART	TO	5	O
phenytoin	phenytoin	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	NUM	CD	7	I-Chemical
and	and	CCONJ	CC	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
have	have	VERB	VBP	5	O
equivalent	equivalent	ADJ	JJ	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
against	against	ADP	IN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
maximal	maximal	ADJ	JJ	9	O
electroshock	electroshock	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MES	MES	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
following	follow	VERB	VBG	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
oral	oral	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ED50	ED50	PROPN	NNP	0	O
doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
16	16	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
for	for	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	NUM	CD	7	I-Chemical
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
for	for	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	NUM	CD	7	I-Chemical
and	and	CCONJ	CC	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
have	have	VERB	VBP	5	O
similar	similar	ADJ	JJ	9	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
against	against	ADP	IN	9	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	NUM	CD	7	I-Chemical
or	or	CCONJ	CC	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
necessary	necessary	ADJ	JJ	5	O
to	to	PART	TO	5	O
convert	convert	VERB	VB	9	O
the	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
sinus	sinus	NOUN	NN	5	O
rhythm	rhythm	NOUN	NN	5	O
were	be	VERB	VBD	9	O
24	24	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Only	only	ADJ	JJ	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
displayed	display	VERB	VBD	9	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
against	against	ADP	IN	9	O
strophanthidin	strophanthidin	VERB	VBN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
guinea	guinea	NOUN	NN	9	O
pig	pig	NOUN	NN	9	O
right	right	ADV	RB	5	O
atria	atria	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
anesthetized	anesthetized	ADJ	JJ	0	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
31	31	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
infused	infuse	VERB	VBN	9	O
over	over	ADP	IN	5	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
equimolar	equimolar	ADJ	JJ	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
21	21	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	PROPN	NNP	7	I-Chemical
and	and	CCONJ	CC	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
treatments	treatment	NOUN	NNS	9	O
produced	produce	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
marked	marked	ADJ	JJ	9	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
diastolic	diastolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
contractile	contractile	NOUN	NN	9	O
force	force	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
LVdP	LVdP	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
dt	dt	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
maximum	maximum	ADJ	JJ	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	NUM	CD	7	I-Chemical
and	and	CCONJ	CC	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
were	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
rabbits	rabbit	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dogs	dog	NOUN	NNS	5	O
by	by	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
m	m	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
routes	route	NOUN	NNS	5	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
systemic	systemic	ADJ	JJ	9	O
toxic	toxic	ADJ	JJ	0	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
agents	agent	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
occurred	occur	VERB	VBD	9	O
at	at	ADP	IN	9	O
approximately	approximately	ADV	RB	9	O
equivalent	equivalent	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Importantly	importantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
local	local	ADJ	JJ	5	O
irritation	irritation	NOUN	NN	5	O
of	of	ADP	IN	5	O
ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9653	9653	PROPN	NNP	7	I-Chemical
was	be	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
following	follow	VERB	VBG	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
m	m	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Tachyphylaxis	Tachyphylaxis	PROPN	NNP	5	O
to	to	PART	TO	5	O
systemic	systemic	VERB	VB	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
to	to	PART	TO	5	O
airway	airway	VERB	VB	5	O
responses	response	NOUN	NNS	5	O
during	during	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
inhaled	inhale	VERB	VBN	5	O
salbutamol	salbutamol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
asthmatics	asthmatic	NOUN	NNS	9	B-Disease
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
inhaled	inhale	VERB	VBN	5	O
salbutamol	salbutamol	ADJ	JJ	0	B-Chemical
produce	produce	VERB	VBP	9	O
substantial	substantial	ADJ	JJ	9	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
airway	airway	NOUN	NN	5	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
asthma	asthma	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
systemic	systemic	ADJ	JJ	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
tachyphylaxis	tachyphylaxis	NOUN	NN	5	O
occurs	occur	VERB	VBZ	9	O
during	during	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
inhaled	inhale	VERB	VBN	5	O
salbutamol	salbutamol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Twelve	twelve	NUM	CD	9	O
asthmatic	asthmatic	ADJ	JJ	9	B-Disease
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
FEV1	FEV1	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
81	81	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
predicted	predict	VERB	VBN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
requiring	require	VERB	VBG	5	O
only	only	ADV	RB	9	O
occasional	occasional	ADJ	JJ	5	O
inhaled	inhale	VERB	VBN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
agonists	agonist	NOUN	NNS	3	O
as	as	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
sole	sole	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
a	a	DET	DT	5	O
14	14	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
inhaled	inhale	VERB	VBN	5	O
salbutamol	salbutamol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
HDS	HDS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
daily	daily	ADV	RB	5	O
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
inhaled	inhale	VERB	VBN	5	O
salbutamol	salbutamol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
LDS	LDS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
800	800	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
daily	daily	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PI	PI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
metered	metered	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
inhaler	inhaler	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomized	ADJ	JJ	5	O
crossover	crossover	NOUN	NN	5	O
design	design	NOUN	NN	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
14	14	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
run	run	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
in	in	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
washout	washout	NOUN	NN	0	O
periods	period	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
inhaled	inhale	VERB	VBN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
agonists	agonist	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
withheld	withhold	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
ipratropium	ipratropium	NOUN	NN	5	B-Chemical
bromide	bromide	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
substituted	substitute	VERB	VBN	0	O
for	for	ADP	IN	5	O
rescue	rescue	NOUN	NN	3	O
purposes	purpose	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
14	14	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
curve	curve	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
DRC	DRC	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
airway	airway	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
FEV1	FEV1	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
FEF25	FEF25	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
75	75	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
chronotropic	chronotropic	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
HR	HR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
tremor	tremor	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
metabolic	metabolic	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
K	K	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
Glu	Glu	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
at	at	ADP	IN	9	O
each	each	DET	DT	5	O
step	step	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
100	100	NUM	CD	0	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
baseline	baseline	ADJ	JJ	5	O
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
FEV1	FEV1	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
FEF25	FEF25	PROPN	NNP	7	O
-	-	SYM	SYM	7	O
75	75	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
HDS	HDS	PROPN	NNP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
displace	displace	VERB	VB	9	O
the	the	DET	DT	5	O
DRC	DRC	PROPN	NNP	2	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	NOUN	NN	5	O
.	.	PUNCT	.	9	O

DRC	drc	VERB	VB	2	O
for	for	ADP	IN	5	O
HR	hr	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	VERB	VBZ	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Glu	Glu	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
attenuated	attenuate	VERB	VBN	3	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
HDS	HDS	PROPN	NNP	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
PI	PI	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
HDS	HDS	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
LDS	LDS	PROPN	NNP	9	O
for	for	ADP	IN	5	O
HR	HR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Glu	Glu	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
responses	response	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
subjective	subjective	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
after	after	ADP	IN	9	O
HDS	HDS	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
tremor	tremor	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
palpitations	palpitation	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Phenytoin	phenytoin	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBD	3	O
fatal	fatal	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
61	61	NUM	CD	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
female	female	NOUN	NN	9	O
developed	develop	VERB	VBN	5	O
fatal	fatal	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
typical	typical	ADJ	JJ	9	O
multisystem	multisystem	NOUN	NN	5	O
clinical	clinical	ADJ	JJ	5	O
pattern	pattern	NOUN	NN	9	O
precedes	precede	VERB	VBZ	9	O
the	the	DET	DT	5	O
manifestations	manifestation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hematologic	hematologic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
biochemical	biochemical	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
pathologic	pathologic	NOUN	NN	5	O
features	feature	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
a	a	DET	DT	5	O
mixed	mixed	ADJ	JJ	9	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
drug	drug	NOUN	NN	5	B-Disease
hypersensitivity	hypersensitivity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
receiving	receiving	NOUN	NN	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
who	who	PRON	WP	5	O
presents	present	VERB	VBZ	5	O
a	a	DET	DT	5	O
viral	viral	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
illness	illness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
early	early	ADJ	JJ	9	O
recognition	recognition	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
are	be	VERB	VBP	5	O
mandatory	mandatory	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
lethal	lethal	ADJ	JJ	9	O
pertussis	pertussis	NOUN	NN	9	B-Chemical
vaccine	vaccine	NOUN	NN	5	I-Chemical
reaction	reaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
histamine	histamine	NOUN	NN	0	B-Chemical
H1	H1	PROPN	NNP	9	O
antagonists	antagonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
mortality	mortality	NOUN	NN	5	O
after	after	ADP	IN	9	O
pertussis	pertussis	NOUN	NN	9	B-Disease
immunization	immunization	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mouse	mouse	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Without	without	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
73	73	NUM	CD	7	O
of	of	ADP	IN	5	O
92	92	NUM	CD	7	O
animals	animal	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
died	die	VERB	VBD	9	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
bovine	bovine	ADJ	JJ	9	O
serum	serum	ADJ	JJ	9	O
albumin	albumin	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
BSA	BSA	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
7	7	NUM	CD	9	O
of	of	ADP	IN	5	O
pertussis	pertussis	NOUN	NN	9	B-Disease
immunization	immunization	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
cyproheptadine	cyproheptadine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
mianserin	mianserin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
chlorpheniramine	chlorpheniramine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
5	5	NUM	CD	9	O
of	of	ADP	IN	5	O
105	105	NUM	CD	9	O
animals	animal	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
died	die	VERB	VBD	9	O
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
BSA	BSA	PROPN	NNP	0	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Blockade	Blockade	PROPN	NNP	3	O
of	of	ADP	IN	5	O
histamine	histamine	NOUN	NN	0	B-Chemical
H1	H1	PROPN	NNP	9	O
receptors	receptor	NOUN	NNS	3	O
may	may	VERB	MD	5	O
reduce	reduce	VERB	VB	5	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
pertussis	pertussis	NOUN	NN	9	B-Disease
immunization	immunization	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Support	support	NOUN	NN	5	O
for	for	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
hypertension	hypertension	NOUN	NN	5	B-Disease
hypothesis	hypothesis	NOUN	NN	9	O
:	:	PUNCT	:	9	O
18	18	NUM	CD	7	O
hour	hour	NOUN	NN	0	O
pressor	pressor	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
after	after	ADP	IN	9	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
crossover	crossover	NOUN	NN	5	O
study	study	NOUN	NN	9	O
6	6	NUM	CD	9	O
h	h	NOUN	NN	0	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
;	;	PUNCT	:	9	O
1	1	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
458	458	NUM	CD	7	O
pmol	pmol	ADJ	JJ	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
;	;	PUNCT	:	9	O
1	1	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
911	911	NUM	CD	7	O
pmol	pmol	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
dextrose	dextrose	NOUN	NN	0	B-Chemical
solution	solution	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
ten	ten	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
in	in	ADP	IN	5	O
random	random	ADJ	JJ	5	O
order	order	NOUN	NN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
apart	apart	ADV	RB	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
arterial	arterial	ADJ	JJ	5	O
ambulatory	ambulatory	NOUN	NN	5	O
monitoring	monitor	VERB	VBG	5	O
the	the	DET	DT	5	O
haemodynamic	haemodynamic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
for	for	ADP	IN	5	O
18	18	NUM	CD	7	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
infusions	infusion	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Adrenaline	Adrenaline	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
delayed	delay	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
protracted	protract	VERB	VBN	5	O
pressor	pressor	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Over	over	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
postinfusion	postinfusion	NOUN	NN	0	O
period	period	NOUN	NN	5	O
systolic	systolic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
were	be	VERB	VBD	9	O
6	6	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
SEM	SEM	PROPN	NNP	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
after	after	ADP	IN	9	O
dextrose	dextrose	VERB	VBP	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
ANOVA	ANOVA	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
"	"	PUNCT	``	5	O
stress	stress	NOUN	NN	9	O
"	"	PUNCT	''	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
230	230	NUM	CD	9	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
h	h	NOUN	NN	0	O
cause	cause	NOUN	NN	5	O
a	a	DET	DT	5	O
delayed	delay	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
protracted	protract	VERB	VBN	5	O
pressor	pressor	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
strong	strong	ADJ	JJ	9	O
support	support	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
hypertension	hypertension	NOUN	NN	5	B-Disease
hypothesis	hypothesis	NOUN	NN	9	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
alkylxanthines	alkylxanthine	NOUN	NNS	9	B-Chemical
on	on	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Adenosine	adenosine	NOUN	NN	0	B-Chemical
antagonists	antagonist	NOUN	NNS	3	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
benefit	benefit	NOUN	NN	5	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
ischaemic	ischaemic	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ARF	ARF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
alkylxanthines	alkylxanthine	NOUN	NNS	9	B-Chemical
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
potencies	potency	NOUN	NNS	0	O
as	as	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
antagonists	antagonist	VERB	VBZ	3	O
8	8	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phenyltheophylline	phenyltheophylline	NOUN	NN	_	I-Chemical
,	,	PUNCT	,	9	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
enprofylline	enprofylline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
developing	develop	VERB	VBG	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
4	4	NUM	CD	9	O
daily	daily	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
biochemical	biochemical	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
plasma	plasma	NOUN	NN	9	O
urea	urea	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
functional	functional	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
urine	urine	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
inulin	inulin	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
[	[	PUNCT	-LRB-	9	O
14C	14c	NUM	CD	0	O
]	]	PUNCT	-RRB-	9	O
p	p	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminohippuric	aminohippuric	ADJ	JJ	9	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
clearances	clearance	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
morphological	morphological	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
indices	index	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
various	various	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
treatments	treatment	NOUN	NNS	9	O
produced	produce	VERB	VBD	9	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
all	all	DET	DT	5	O
,	,	PUNCT	,	9	O
measurements	measurement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
any	any	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
largely	largely	ADV	RB	9	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
exerted	exert	VERB	VBN	9	O
by	by	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
vehicle	vehicle	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
polyethylene	polyethylene	NOUN	NN	0	B-Chemical
glycol	glycol	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
NaOH	NaOH	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
consistent	consistent	ADJ	JJ	9	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
noted	note	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
alkylxanthines	alkylxanthine	NOUN	NNS	9	B-Chemical
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
plays	play	VERB	VBZ	9	O
little	little	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
if	if	ADP	IN	5	O
any	any	DET	DT	5	O
,	,	PUNCT	,	9	O
pathophysiological	pathophysiological	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ARF	ARF	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
ocular	ocular	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
possibly	possibly	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
isotretinoin	isotretinoin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
261	261	NUM	CD	7	O
adverse	adverse	ADJ	JJ	5	O
ocular	ocular	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
237	237	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
isotretinoin	isotretinoin	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
cystic	cystic	ADJ	JJ	5	O
acne	acne	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Blepharoconjunctivitis	Blepharoconjunctivitis	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
subjective	subjective	ADJ	JJ	5	O
complaints	complaint	NOUN	NNS	5	O
of	of	ADP	IN	5	O
dry	dry	ADJ	JJ	0	B-Disease
eyes	eye	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
blurred	blur	VERB	VBD	5	B-Disease
vision	vision	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
contact	contact	NOUN	NN	5	O
lens	lens	NOUN	NN	5	O
intolerance	intolerance	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
photodermatitis	photodermatitis	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
reversible	reversible	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

More	more	ADV	RBR	5	O
serious	serious	ADJ	JJ	5	O
ocular	ocular	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
include	include	VERB	VBP	5	O
papilledema	papilledema	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
pseudotumor	pseudotumor	NOUN	NN	5	B-Disease
cerebri	cerebri	VERB	VBD	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
white	white	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
gray	gray	ADJ	JJ	9	O
subepithelial	subepithelial	ADJ	JJ	5	O
corneal	corneal	ADJ	JJ	5	B-Disease
opacities	opacity	NOUN	NNS	5	I-Disease
;	;	PUNCT	:	9	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
are	be	VERB	VBP	5	O
reversible	reversible	ADJ	JJ	9	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Reported	report	VERB	VBN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	O
dark	dark	ADJ	JJ	9	O
adaptation	adaptation	NOUN	NN	5	O
are	be	VERB	VBP	5	O
under	under	ADP	IN	9	O
investigation	investigation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Isotretinoin	Isotretinoin	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
contraindicated	contraindicate	VERB	VBN	5	O
in	in	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
many	many	ADJ	JJ	5	O
reported	report	VERB	VBN	9	O
congenital	congenital	ADJ	JJ	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
after	after	ADP	IN	9	O
maternal	maternal	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
including	include	VERB	VBG	9	O
microphthalmos	microphthalmos	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
orbital	orbital	ADJ	JJ	5	O
hypertelorism	hypertelorism	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
optic	optic	ADJ	JJ	5	B-Disease
nerve	nerve	NOUN	NN	5	I-Disease
hypoplasia	hypoplasia	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Procaterol	procaterol	NOUN	NN	7	B-Chemical
and	and	CCONJ	CC	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
bronchial	bronchial	ADJ	JJ	9	B-Disease
asthma	asthma	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
over	over	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Procaterol	Procaterol	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
stimulant	stimulant	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
over	over	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
bronchial	bronchial	ADJ	JJ	9	B-Disease
asthma	asthma	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Oral	Oral	PROPN	NNP	9	O
procaterol	procaterol	NOUN	NN	0	B-Chemical
50	50	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
procaterol	procaterol	NOUN	NN	0	B-Chemical
100	100	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
t	t	NOUN	NN	5	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
randomly	randomly	ADV	RB	5	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
periods	period	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
best	good	ADJ	JJS	5	O
clinical	clinical	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
with	with	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
asthmatic	asthmatic	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	O
tremorgenic	tremorgenic	ADJ	JJ	0	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
procaterol	procaterol	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Procaterol	procaterol	NOUN	NN	7	B-Chemical
appeared	appear	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
tested	test	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
twice	twice	ADV	RB	9	O
daily	daily	ADJ	JJ	5	O
regimen	regimen	NOUN	NN	5	O
would	would	VERB	MD	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
suitable	suitable	ADJ	JJ	5	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Subacute	subacute	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
B	B	PROPN	NNP	9	O
24	24	NUM	CD	9	O
/	/	SYM	SYM	9	O
76	76	NUM	CD	7	O
on	on	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rat	rat	NOUN	NN	3	O
heart	heart	NOUN	NN	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
correlation	correlation	NOUN	NN	9	O
with	with	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
blocker	blocker	NOUN	NN	0	O
,	,	PUNCT	,	9	O
B	B	PROPN	NNP	9	O
24	24	NUM	CD	9	O
/	/	SYM	SYM	9	O
76	76	NUM	CD	7	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	:	7	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
dichlorophenoxy	dichlorophenoxy	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
3	3	NUM	CD	9	O
[	[	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
dimethoxyphenyl	dimethoxyphenyl	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
ethanolamino	ethanolamino	NOUN	NN	_	O
]	]	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
prop	prop	NOUN	NN	5	O
an	an	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
ol	ol	NOUN	NN	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
beta	beta	NOUN	NN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
blocking	blocking	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
stimulating	stimulate	VERB	VBG	9	O
properties	property	NOUN	NNS	9	O
with	with	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
using	use	VERB	VBG	9	O
an	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
heart	heart	NOUN	NN	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
neither	neither	CCONJ	CC	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
nor	nor	CCONJ	CC	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
attempt	attempt	NOUN	NN	5	O
to	to	PART	TO	5	O
suppress	suppress	VERB	VB	3	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
influenced	influence	VERB	VBD	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
different	different	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
reproducible	reproducible	ADJ	JJ	5	O
extent	extent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
possible	possible	ADJ	JJ	5	O
to	to	PART	TO	5	O
suppress	suppress	VERB	VB	3	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
ornithine	ornithine	ADJ	JJ	0	B-Chemical
decarboxylase	decarboxylase	NOUN	NN	1	O
activity	activity	NOUN	NN	9	O
with	with	ADP	IN	5	O
both	both	CCONJ	CC	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
in	in	ADP	IN	5	O
hypertrophied	hypertrophy	VERB	VBN	9	B-Disease
hearts	heart	NOUN	NNS	3	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
mass	mass	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Neither	neither	DET	DT	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
nor	nor	CCONJ	CC	9	O
B	B	PROPN	NNP	9	O
24	24	NUM	CD	9	O
/	/	SYM	SYM	9	O
76	76	NUM	CD	7	O
could	could	VERB	MD	9	O
stop	stop	VERB	VB	9	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
characteristic	characteristic	ADJ	JJ	9	O
myosin	myosin	NOUN	NN	3	O
isoenzyme	isoenzyme	NOUN	NN	9	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hypertrophied	hypertrophied	ADJ	JJ	9	B-Disease
rat	rat	NOUN	NN	3	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
investigations	investigation	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
provide	provide	VERB	VB	5	O
any	any	DET	DT	5	O
evidence	evidence	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
blockers	blocker	NOUN	NNS	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
B	B	PROPN	NNP	9	O
24	24	NUM	CD	9	O
/	/	SYM	SYM	9	O
76	76	NUM	CD	7	O
have	have	VERB	VBP	5	O
the	the	DET	DT	5	O
potency	potency	NOUN	NN	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
from	from	ADP	IN	9	O
producing	produce	VERB	VBG	9	O
heart	heart	NOUN	NN	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
behavioral	behavioral	ADJ	JJ	5	O
ratings	rating	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
somatic	somatic	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methoxy	methoxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxyphenethyleneglycol	hydroxyphenethyleneglycol	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
MHPG	MHPG	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
17	17	NUM	CD	7	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
21	21	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
meeting	meet	VERB	VBG	5	O
DSM	DSM	PROPN	NNP	4	O
-	-	PUNCT	HYPH	7	O
III	III	PROPN	NNP	9	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
agoraphobia	agoraphobia	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
or	or	CCONJ	CC	5	O
panic	panic	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Caffeine	caffeine	NOUN	NN	0	B-Chemical
produced	produce	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
subject	subject	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
rated	rate	VERB	VBN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
nervousness	nervousness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
fear	fear	NOUN	NN	5	O
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
palpitations	palpitation	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
restlessness	restlessness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
tremors	tremor	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Seventy	seventy	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
reported	report	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
experienced	experience	VERB	VBN	5	O
during	during	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Caffeine	caffeine	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
alter	alter	VERB	VB	9	O
plasma	plasma	NOUN	NN	9	O
MHPG	MHPG	PROPN	NNP	0	B-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
either	either	CCONJ	CC	9	O
the	the	DET	DT	5	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Caffeine	caffeine	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBN	9	O
plasma	plasma	NOUN	NN	9	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
levels	level	NOUN	NNS	3	O
equally	equally	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
healthy	healthy	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
adenosine	adenosine	ADJ	JJ	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
some	some	DET	DT	5	O
panic	panic	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
abnormalities	abnormality	NOUN	NNS	9	B-Disease
in	in	ADP	IN	5	I-Disease
neuronal	neuronal	ADJ	JJ	3	I-Disease
systems	system	NOUN	NNS	5	I-Disease
involving	involve	VERB	VBG	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
may	may	VERB	MD	5	O
benefit	benefit	VERB	VB	5	O
by	by	ADP	IN	9	O
avoiding	avoid	VERB	VBG	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
foods	food	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
beverages	beverage	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Comparison	Comparison	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxitropium	oxitropium	NOUN	NN	0	B-Chemical
bromide	bromide	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
slow	slow	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
nocturnal	nocturnal	ADJ	JJ	5	O
asthma	asthma	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
inhaled	inhale	VERB	VBN	5	O
antimuscarinic	antimuscarinic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
oxitropium	oxitropium	NOUN	NN	0	B-Chemical
bromide	bromide	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
slow	slow	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
preparation	preparation	NOUN	NN	9	O
upon	upon	ADP	IN	9	O
nocturnal	nocturnal	ADJ	JJ	5	O
asthma	asthma	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
:	:	PUNCT	:	9	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
oxitropium	oxitropium	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
600	600	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
at	at	ADP	IN	9	O
400	400	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
t	t	NOUN	NN	5	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O

(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
whereas	whereas	ADP	IN	9	O
11	11	NUM	CD	7	O
received	receive	VERB	VBD	9	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O

Morning	morning	NOUN	NN	5	O
dipping	dipping	NOUN	NN	5	O
,	,	PUNCT	,	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
peak	peak	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
overnight	overnight	ADV	RB	0	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
periods	period	NOUN	NNS	5	O
when	when	ADV	WRB	5	O
either	either	DET	DT	9	O
active	active	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
no	no	DET	DT	9	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
noticed	notice	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
noticed	notice	VERB	VBN	9	O
between	between	ADP	IN	5	O
results	result	NOUN	NNS	9	O
obtained	obtain	VERB	VBN	9	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
active	active	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxitropium	oxitropium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
subject	subject	NOUN	NN	5	O
reported	report	VERB	VBD	9	O
side	side	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
oxitropium	oxitropium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
three	three	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
reporting	report	VERB	VBG	5	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
tremors	tremor	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Oxitropium	oxitropium	NOUN	NN	0	B-Chemical
proves	prove	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
valuable	valuable	ADJ	JJ	5	O
alternative	alternative	NOUN	NN	5	O
to	to	ADP	IN	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
nocturnal	nocturnal	ADJ	JJ	5	O
asthma	asthma	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
equally	equally	ADV	RB	9	O
potent	potent	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
safer	safe	ADJ	JJR	5	O
and	and	CCONJ	CC	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
require	require	VERB	VB	5	O
the	the	DET	DT	5	O
titration	titration	NOUN	NN	0	O
of	of	ADP	IN	5	O
dosage	dosage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Penicillin	Penicillin	PROPN	NNP	0	B-Chemical
anaphylaxis	anaphylaxis	ADJ	JJ	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
anaphylaxis	anaphylaxis	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
terminology	terminology	NOUN	NN	5	O
,	,	PUNCT	,	9	O
occurrence	occurrence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
clinical	clinical	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
pathogenesis	pathogenesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
prevention	prevention	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
anaphylaxis	anaphylaxis	NOUN	NN	9	B-Disease
are	be	VERB	VBP	5	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Emergency	emergency	NOUN	NN	2	O
physicians	physician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
anaphylaxis	anaphylaxis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
its	-PRON-	DET	PRP$	9	O
occurrence	occurrence	NOUN	NN	5	O
by	by	ADP	IN	9	O
prescribing	prescribe	VERB	VBG	5	O
the	the	DET	DT	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
judiciously	judiciously	ADV	RB	5	O
and	and	CCONJ	CC	5	O
knowledgeably	knowledgeably	ADV	RB	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
offer	offer	VERB	VB	5	O
optimal	optimal	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
once	once	ADP	IN	5	O
this	this	DET	DT	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
reaction	reaction	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
begun	begin	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Reversible	reversible	ADJ	JJ	0	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dementia	dementia	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reversible	reversible	ADJ	JJ	0	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dementia	dementia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
21	21	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
insidious	insidious	ADJ	JJ	5	O
progressive	progressive	ADJ	JJ	5	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
global	global	ADJ	JJ	5	O
cognitive	cognitive	ADJ	JJ	5	O
abilities	ability	NOUN	NNS	5	O
documented	document	VERB	VBN	9	O
by	by	ADP	IN	9	O
serial	serial	ADJ	JJ	9	O
neuropsychological	neuropsychological	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Repeat	repeat	VERB	VB	9	O
neuropsychological	neuropsychological	ADJ	JJ	5	O
testing	testing	NOUN	NN	5	O
7	7	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
dramatic	dramatic	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
IQ	iq	NOUN	NN	5	O
,	,	PUNCT	,	9	O
memory	memory	NOUN	NN	5	O
,	,	PUNCT	,	9	O
naming	naming	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
tasks	task	NOUN	NNS	5	O
commensurate	commensurate	VERB	VBP	5	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
in	in	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
intellectual	intellectual	ADJ	JJ	5	O
capacity	capacity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
pathophysiological	pathophysiological	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
operative	operative	ADJ	JJ	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
include	include	VERB	VBP	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CNS	CNS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
toxic	toxic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
;	;	PUNCT	:	9	O
a	a	DET	DT	5	O
paradoxical	paradoxical	ADJ	JJ	5	O
epileptogenic	epileptogenic	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
indirect	indirect	ADJ	JJ	5	O
CNS	CNS	PROPN	NNP	9	O
toxic	toxic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
mediated	mediate	VERB	VBN	3	O
through	through	ADP	IN	9	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperammonemia	hyperammonemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
by	by	ADP	IN	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
and	and	CCONJ	CC	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
training	training	NOUN	NN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
five	five	NUM	CD	9	O
experiments	experiment	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
modulating	modulating	NOUN	NN	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
retention	retention	NOUN	NN	9	B-Disease
deficit	deficit	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
paradigm	paradigm	NOUN	NN	5	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Scopolamine	Scopolamine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
methyl	methyl	NOUN	NN	0	B-Chemical
scopolamine	scopolamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
induced	induce	VERB	VBD	3	O
an	an	DET	DT	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
latency	latency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
parameters	parameter	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Naloxone	Naloxone	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
injected	inject	VERB	VBD	3	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
training	training	NOUN	NN	5	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
retention	retention	NOUN	NN	9	B-Disease
deficit	deficit	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
peak	peak	NOUN	NN	9	O
of	of	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
antagonized	antagonize	VERB	VBN	3	O
with	with	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
demonstrating	demonstrate	VERB	VBG	9	O
the	the	DET	DT	5	O
opioid	opioid	ADJ	JJ	5	O
specificity	specificity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
naloxone	naloxone	ADJ	JJ	0	B-Chemical
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
training	training	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
split	split	NOUN	NN	5	O
dose	dose	NOUN	NN	9	O
also	also	ADV	RB	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Control	control	NOUN	NN	9	O
experiments	experiment	NOUN	NNS	9	O
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
neither	neither	CCONJ	CC	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
sensitivity	sensitivity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
training	training	ADJ	JJ	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
nor	nor	CCONJ	CC	9	O
an	an	DET	DT	5	O
induced	induced	ADJ	JJ	3	O
aversive	aversive	ADJ	JJ	5	O
state	state	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
training	training	NOUN	NN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
retention	retention	NOUN	NN	9	B-Disease
deficit	deficit	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
extend	extend	VERB	VBP	9	O
previous	previous	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
implicating	implicate	VERB	VBG	9	O
a	a	DET	DT	5	O
cholinergic	cholinergic	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
opioid	opioid	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
in	in	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
processes	process	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
possible	possible	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
involving	involve	VERB	VBG	5	O
the	the	DET	DT	5	O
septo	septo	ADJ	JJ	2	O
-	-	PUNCT	HYPH	7	O
hippocampal	hippocampal	ADJ	JJ	3	O
cholinergic	cholinergic	NOUN	NN	3	O
pathway	pathway	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Electron	Electron	PROPN	NNP	0	O
microscopic	microscopic	ADJ	JJ	9	O
investigations	investigation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
lesions	lesion	NOUN	NNS	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
urinary	urinary	ADJ	JJ	9	I-Disease
bladder	bladder	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
prevention	prevention	NOUN	NN	5	O
by	by	ADP	IN	9	O
mesna	mesna	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Fully	fully	ADV	RB	9	O
developed	develop	VERB	VBN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
nearly	nearly	ADV	RB	9	O
complete	complete	ADJ	JJ	9	O
detachment	detachment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
urothelium	urothelium	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
submucosal	submucosal	NOUN	NN	5	O
edema	edema	NOUN	NN	5	B-Disease
owing	owe	VERB	VBG	5	O
to	to	ADP	IN	5	O
damage	damage	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
microvascular	microvascular	ADJ	JJ	5	O
bed	bed	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
focal	focal	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
necroses	necrose	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
attack	attack	NOUN	NN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
metabolites	metabolite	NOUN	NNS	0	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
fragmentation	fragmentation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
luminal	luminal	ADJ	JJ	3	B-Chemical
membrane	membrane	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
damages	damage	VERB	VBZ	9	O
the	the	DET	DT	5	O
cellular	cellular	ADJ	JJ	3	O
barrier	barrier	NOUN	NN	5	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
hypertonic	hypertonic	ADJ	JJ	0	O
urine	urine	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Subsequent	subsequent	ADJ	JJ	9	O
breaks	break	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
cell	cell	NOUN	NN	3	O
membranes	membrane	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
superficial	superficial	ADJ	JJ	5	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
membranes	membrane	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
intermediate	intermediate	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
basal	basal	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
intercellular	intercellular	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
intracellular	intracellular	ADJ	JJ	3	O
edema	edema	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
disintegration	disintegration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
desmosomes	desmosome	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
hemidesmosomes	hemidesmosome	VERB	VBZ	3	O
lead	lead	VERB	VBP	5	O
to	to	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
degeneration	degeneration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
detachment	detachment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
epithelial	epithelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
with	with	ADP	IN	5	O
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
splitting	splitting	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
morphological	morphological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
become	become	VERB	VBP	5	O
more	more	ADV	RBR	5	O
pronounced	pronounced	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
later	later	ADJ	JJ	9	O
stages	stage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
experiment	experiment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
diameter	diameter	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
location	location	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
damage	damage	NOUN	NN	9	O
indicate	indicate	VERB	VBP	9	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
damage	damage	NOUN	NN	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
mediator	mediator	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
permeability	permeability	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
morphological	morphological	ADJ	JJ	9	O
correlate	correlate	NOUN	NN	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
gaps	gap	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
interendothelial	interendothelial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
connections	connection	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
venules	venule	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
effectively	effectively	ADV	RB	5	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
mesna	mesna	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
sign	sign	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
involvement	involvement	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
specific	specific	ADJ	JJ	9	O
granules	granule	NOUN	NNS	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
presumed	presume	VERB	VBN	9	O
lysosomal	lysosomal	ADJ	JJ	3	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
superficial	superficial	ADJ	JJ	5	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Increase	increase	VERB	VB	9	O
in	in	ADP	IN	5	O
intragastric	intragastric	ADJ	JJ	0	O
pressure	pressure	NOUN	NN	5	O
during	during	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculations	fasciculation	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
inhibition	inhibition	NOUN	NN	3	O
by	by	ADP	IN	9	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
intragastric	intragastric	ADJ	JJ	0	O
pressure	pressure	NOUN	NN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	,	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
32	32	NUM	CD	7	O
children	child	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
yr	yr	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
either	either	CCONJ	CC	9	O
physiological	physiological	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
alfentanil	alfentanil	VERB	VBP	0	B-Chemical
50	50	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O

Anaesthesia	Anaesthesia	PROPN	NNP	2	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
with	with	ADP	IN	5	O
thiopentone	thiopentone	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculations	fasciculation	NOUN	NNS	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
intragastric	intragastric	ADJ	JJ	0	O
pressure	pressure	NOUN	NN	5	O
during	during	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculations	fasciculation	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
16	16	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
SEM	SEM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
cm	cm	VERB	VBZ	9	O
H2O	H2O	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
SEM	SEM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
cm	cm	VERB	VBZ	9	O
H2O	H2O	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
intragastric	intragastric	ADJ	JJ	0	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
directly	directly	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculations	fasciculation	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
regression	regression	NOUN	NN	5	O
line	line	NOUN	NN	9	O
:	:	PUNCT	:	9	O
y	y	PUNCT	LS	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
78x	78x	NOUN	NNS	9	O
with	with	ADP	IN	5	O
r	r	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
78	78	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
intragastric	intragastric	ADJ	JJ	0	O
pressure	pressure	NOUN	NN	5	O
increases	increase	VERB	VBZ	9	O
significantly	significantly	ADV	RB	9	O
during	during	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculations	fasciculation	NOUN	NNS	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Alfentanil	Alfentanil	PROPN	NNP	0	B-Chemical
50	50	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	:	7	O
1	1	NUM	CD	9	O
effectively	effectively	ADV	RB	5	O
inhibits	inhibit	VERB	VBZ	3	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculations	fasciculation	NOUN	NNS	5	I-Disease
;	;	PUNCT	:	9	O
moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
intragastric	intragastric	ADJ	JJ	0	O
pressure	pressure	NOUN	NN	5	O
remains	remain	VERB	VBZ	9	O
at	at	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
control	control	NOUN	NN	9	O
value	value	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
insulin	insulin	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
normalizes	normalize	VERB	VBZ	9	O
the	the	DET	DT	5	O
resistance	resistance	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
cardiotoxic	cardiotoxic	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
diabetic	diabetic	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
morphometric	morphometric	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
insulin	insulin	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
earlier	earlier	ADV	RBR	9	O
reported	report	VERB	VBN	9	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
diabetes	diabete	NOUN	NNS	5	B-Disease
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
cardiotoxic	cardiotoxic	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ISO	ISO	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
to	to	PART	TO	5	O
135	135	NUM	CD	7	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
crystalline	crystalline	ADJ	JJ	0	O
insulin	insulin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
ISO	ISO	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
subcutaneously	subcutaneously	ADV	RB	3	O
and	and	CCONJ	CC	5	O
when	when	ADV	WRB	5	O
ISO	ISO	PROPN	NNP	0	B-Chemical
induced	induced	ADJ	JJ	3	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
myocardium	myocardium	NOUN	NN	9	O
was	be	VERB	VBD	9	O
morphometrically	morphometrically	ADV	RB	5	O
analyzed	analyze	VERB	VBN	9	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RBR	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
highly	highly	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
83	83	NUM	CD	7	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
006	006	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
slope	slope	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
insulin	insulin	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
appeared	appear	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	O
content	content	NOUN	NN	9	O
of	of	ADP	IN	5	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
8	8	NUM	CD	9	O
day	day	NOUN	NN	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
content	content	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
while	while	ADP	IN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
enhanced	enhance	VERB	VBN	3	O
sympathetic	sympathetic	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
consequent	consequent	NOUN	NN	9	O
down	down	ADP	IN	9	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
could	could	VERB	MD	9	O
,	,	PUNCT	,	9	O
therefore	therefore	ADV	RB	5	O
,	,	PUNCT	,	9	O
explain	explain	VERB	VB	9	O
this	this	DET	DT	5	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
resistance	resistance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
reversion	reversion	NOUN	NN	9	O
after	after	ADP	IN	9	O
insulin	insulin	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
excludes	exclude	VERB	VBZ	9	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
itself	-PRON-	PRON	PRP	9	O
causes	cause	VERB	VBZ	9	O
the	the	DET	DT	5	O
ISO	ISO	PROPN	NNP	0	B-Chemical
resistance	resistance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
points	point	NOUN	NNS	5	O
towards	towards	ADP	IN	5	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
insulin	insulin	NOUN	NN	3	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
sensitivity	sensitivity	NOUN	NN	9	O
in	in	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
phenomenon	phenomenon	NOUN	NN	5	O
described	describe	VERB	VBD	9	O
might	may	VERB	MD	9	O
elucidate	elucidate	VERB	VB	9	O
pathogenetic	pathogenetic	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
behind	behind	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
myocardial	myocardial	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
degeneration	degeneration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
possibly	possibly	ADV	RB	9	O
have	have	VERB	VB	5	O
relevance	relevance	NOUN	NN	9	O
for	for	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
in	in	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Differential	differential	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
steroidal	steroidal	ADJ	JJ	0	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
on	on	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
cholinergic	cholinergic	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
induces	induce	NOUN	NNS	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
widespread	widespread	ADJ	JJ	5	O
damage	damage	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
forebrain	forebrain	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
steroidal	steroidal	ADJ	JJ	0	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
salicylate	salicylate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
phenylbutazone	phenylbutazone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
ibuprofen	ibuprofen	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
mefenamic	mefenamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
salicylate	salicylate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
ED50	ED50	PROPN	NNP	0	O
103	103	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
-	-	SYM	SYM	7	O
174	174	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
phenylbutazone	phenylbutazone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
59	59	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
-	-	SYM	SYM	7	O
70	70	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
converted	convert	VERB	VBD	9	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
convulsant	convulsant	ADJ	JJ	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
convulsant	convulsant	NOUN	NN	0	O
one	one	NUM	CD	5	O
.	.	PUNCT	.	9	O

Indomethacin	indomethacin	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
ibuprofen	ibuprofen	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
modulate	modulate	VERB	VB	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Mefenamic	mefenamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
26	26	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
prevented	prevent	VERB	VBN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
protected	protect	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
from	from	ADP	IN	9	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
brain	brain	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
380	380	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
steroidal	steroidal	ADJ	JJ	0	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
differentially	differentially	ADV	RB	9	O
modulate	modulate	VERB	VBP	9	O
the	the	DET	DT	5	O
threshold	threshold	NOUN	NN	5	O
for	for	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
neurologic	neurologic	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
malignant	malignant	ADJ	JJ	3	B-Disease
glioma	glioma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Etoposide	Etoposide	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
VP	VP	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
16	16	NUM	CD	9	I-Chemical
-	-	SYM	SYM	7	I-Chemical
213	213	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
many	many	ADJ	JJ	5	O
solid	solid	ADJ	JJ	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
and	and	CCONJ	CC	5	O
hematologic	hematologic	ADJ	JJ	5	B-Disease
malignancies	malignancy	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
autologous	autologous	ADJ	JJ	3	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
activity	activity	NOUN	NN	9	O
against	against	ADP	IN	9	O
several	several	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
cancers	cancer	NOUN	NNS	9	B-Disease
including	include	VERB	VBG	9	O
malignant	malignant	ADJ	JJ	3	B-Disease
glioma	glioma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
we	-PRON-	PRON	PRP	5	O
treated	treat	VERB	VBD	3	O
for	for	ADP	IN	5	O
recurrent	recurrent	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
resistant	resistant	ADJ	JJ	9	O
glioma	glioma	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
sudden	sudden	ADJ	JJ	5	O
severe	severe	ADJ	JJ	5	O
neurologic	neurologic	ADJ	JJ	5	B-Disease
deterioration	deterioration	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
median	median	NOUN	NN	9	O
of	of	ADP	IN	5	O
9	9	NUM	CD	7	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
included	include	VERB	VBN	5	O
confusion	confusion	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
papilledema	papilledema	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
somnolence	somnolence	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
exacerbation	exacerbation	NOUN	NN	5	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sharp	sharp	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
abnormalities	abnormality	NOUN	NNS	9	O
resolved	resolve	VERB	VBD	9	O
rapidly	rapidly	ADV	RB	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
intravenous	intravenous	ADJ	JJ	0	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
computerized	computerized	ADJ	JJ	5	O
tomographic	tomographic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CT	CT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
brain	brain	NOUN	NN	5	O
scans	scan	NOUN	NNS	5	O
demonstrated	demonstrate	VERB	VBD	9	O
stability	stability	NOUN	NN	9	O
in	in	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
size	size	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
peritumor	peritumor	NOUN	NN	3	O
edema	edema	NOUN	NN	5	B-Disease
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
pretransplant	pretransplant	ADJ	JJ	5	O
scans	scan	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
represent	represent	VERB	VB	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
new	new	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
malignant	malignant	ADJ	JJ	3	B-Disease
glioma	glioma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Progressive	progressive	ADJ	JJ	5	O
bile	bile	NOUN	NN	0	B-Disease
duct	duct	NOUN	NN	5	I-Disease
injury	injury	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
thiabendazole	thiabendazole	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
27	27	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
yr	yr	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
2	2	NUM	CD	9	O
wk	wk	ADV	RB	9	O
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
thiabendazole	thiabendazole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Cholestasis	cholestasis	NOUN	NN	7	B-Disease
persisted	persist	VERB	VBD	9	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
yr	yr	NOUN	NN	7	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
which	which	DET	WDT	5	O
time	time	NOUN	NN	5	O
a	a	DET	DT	5	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
specimens	specimen	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
hepatectomy	hepatectomy	NOUN	NN	5	O
specimen	speciman	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
remarkable	remarkable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
almost	almost	ADV	RB	9	O
complete	complete	ADJ	JJ	9	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
interlobular	interlobular	ADJ	JJ	5	O
bile	bile	NOUN	NN	0	O
ducts	duct	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Prominent	prominent	ADJ	JJ	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	O
regeneration	regeneration	NOUN	NN	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
present	present	ADJ	JJ	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
lobular	lobular	ADJ	JJ	5	O
architecture	architecture	NOUN	NN	5	O
was	be	VERB	VBD	9	O
preserved	preserve	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
represents	represent	VERB	VBZ	9	O
an	an	DET	DT	5	O
example	example	NOUN	NN	5	O
of	of	ADP	IN	5	O
"	"	PUNCT	``	5	O
idiosyncratic	idiosyncratic	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
liver	liver	NOUN	NN	9	I-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
target	target	NOUN	NN	9	O
of	of	ADP	IN	5	O
injury	injury	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
bile	bile	ADJ	JJ	0	O
duct	duct	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
autoimmune	autoimmune	ADJ	JJ	3	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bile	bile	ADJ	JJ	0	B-Disease
duct	duct	NOUN	NN	5	I-Disease
destruction	destruction	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Differential	differential	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydropyridine	dihydropyridine	NOUN	NN	0	I-Chemical
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	I-Chemical
blockers	blocker	NOUN	NNS	9	I-Chemical
:	:	PUNCT	:	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
implications	implication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Increasing	increase	VERB	VBG	9	O
recognition	recognition	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
stimulated	stimulate	VERB	VBN	3	O
research	research	NOUN	NN	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	I-Chemical
blocking	block	VERB	VBG	3	I-Chemical
agents	agent	NOUN	NNS	5	I-Chemical
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
favorable	favorable	ADJ	JJ	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
profiles	profile	NOUN	NNS	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
make	make	VERB	VBP	5	O
them	-PRON-	PRON	PRP	5	O
attractive	attractive	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
modalities	modality	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
applications	application	NOUN	NNS	5	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	I-Chemical
blockers	blocker	NOUN	NNS	9	I-Chemical
parallel	parallel	VERB	VBP	5	O
their	-PRON-	DET	PRP$	5	O
tissue	tissue	NOUN	NN	9	O
selectivity	selectivity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
roughly	roughly	ADV	RB	5	O
equipotent	equipotent	ADJ	JJ	0	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
actions	action	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
vascular	vascular	ADJ	JJ	5	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dihydropyridine	dihydropyridine	NOUN	NN	0	B-Chemical
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	I-Chemical
blockers	blocker	NOUN	NNS	9	I-Chemical
are	be	VERB	VBP	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
potent	potent	ADJ	JJ	3	O
peripheral	peripheral	ADJ	JJ	9	O
vasodilator	vasodilator	NOUN	NN	0	O
agents	agent	NOUN	NNS	5	O
that	that	DET	WDT	5	O
exert	exert	VERB	VBP	9	O
minimal	minimal	ADJ	JJ	9	O
electrophysiologic	electrophysiologic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
nodal	nodal	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
conduction	conduction	NOUN	NN	5	O
tissue	tissue	NOUN	NN	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
dihydropyridine	dihydropyridine	NOUN	NN	0	B-Chemical
available	available	ADJ	JJ	5	O
for	for	ADP	IN	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
controls	control	NOUN	NNS	9	O
angina	angina	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
minimal	minimal	ADJ	JJ	9	O
depression	depression	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Additional	additional	ADJ	JJ	9	O
members	member	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	I-Chemical
blockers	blocker	NOUN	NNS	9	I-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
studied	study	VERB	VBN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
indications	indication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
which	which	DET	WDT	5	O
they	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
offer	offer	VERB	VB	5	O
advantages	advantage	NOUN	NNS	5	O
over	over	ADP	IN	5	O
current	current	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Once	once	ADV	RB	5	O
or	or	CCONJ	CC	5	O
twice	twice	ADV	RB	9	O
daily	daily	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
possible	possible	ADJ	JJ	5	O
with	with	ADP	IN	5	O
nitrendipine	nitrendipine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
nisoldipine	nisoldipine	NOUN	NN	0	B-Chemical
offers	offer	VERB	VBZ	5	O
a	a	DET	DT	5	O
convenient	convenient	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
schedule	schedule	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
encourages	encourage	VERB	VBZ	5	O
patient	patient	ADJ	JJ	5	O
compliance	compliance	NOUN	NN	5	O
in	in	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
coronary	coronary	ADJ	JJ	5	O
vasodilating	vasodilating	NOUN	NN	5	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nisoldipine	nisoldipine	NOUN	NN	0	B-Chemical
have	have	VERB	VBP	5	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
for	for	ADP	IN	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
angina	angina	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Selectivity	selectivity	NOUN	NN	0	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
cerebrovascular	cerebrovascular	ADJ	JJ	5	O
bed	bed	NOUN	NN	5	O
makes	make	VERB	VBZ	5	O
nimodipine	nimodipine	NOUN	NN	0	B-Chemical
potentially	potentially	ADV	RB	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
subarachnoid	subarachnoid	NOUN	NN	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
migraine	migraine	ADJ	JJ	5	B-Disease
headache	headache	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
dementia	dementia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
stroke	stroke	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
general	general	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dihydropyridine	dihydropyridine	NOUN	NN	0	B-Chemical
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	I-Chemical
blockers	blocker	NOUN	NNS	9	I-Chemical
are	be	VERB	VBP	5	O
usually	usually	ADV	RB	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
headache	headache	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
facial	facial	ADJ	JJ	5	O
flushing	flushing	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
palpitations	palpitation	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
edema	edema	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
anorexia	anorexia	INTJ	UH	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dizziness	dizziness	NOUN	NN	5	B-Disease
being	be	VERB	VBG	5	O
the	the	DET	DT	5	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
aminonucleoside	aminonucleoside	ADJ	JJ	0	B-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
protamine	protamine	NOUN	NN	0	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
focal	focal	ADJ	JJ	5	B-Disease
segmental	segmental	ADJ	JJ	5	I-Disease
glomerular	glomerular	ADJ	JJ	5	I-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
FSGS	FSGS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminonucleoside	aminonucleoside	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
AMNS	AMNS	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
protamine	protamine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PS	PS	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
uninephrectomized	uninephrectomize	VERB	VBD	3	O
three	three	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
before	before	ADV	RB	9	O
,	,	PUNCT	,	9	O
received	receive	VERB	VBD	9	O
daily	daily	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
AMNS	AMNS	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
body	body	NOUN	NN	5	O
wt	wt	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
intravenous	intravenous	ADJ	JJ	0	O
PS	PS	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
separated	separate	VERB	VBN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
body	body	NOUN	NN	5	O
wt	wt	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
four	four	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
injections	injection	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
repeated	repeat	VERB	VBN	5	O
another	another	DET	DT	9	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
at	at	ADP	IN	9	O
10	10	NUM	CD	9	O
day	day	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
sacrificed	sacrifice	VERB	VBN	3	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
24	24	NUM	CD	9	O
,	,	PUNCT	,	9	O
52	52	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
80	80	NUM	CD	9	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
finally	finally	ADV	RB	9	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
course	course	NOUN	NN	5	O
curve	curve	NOUN	NN	9	O
of	of	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
dropped	drop	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
showed	show	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
,	,	PUNCT	,	9	O
AMNS	AMNS	PROPN	NNP	9	B-Chemical
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
PS	PS	PROPN	NNP	9	B-Chemical
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
saline	saline	NOUN	NN	0	O
injected	inject	VERB	VBN	3	O
.	.	PUNCT	.	9	O

Their	-PRON-	DET	PRP$	5	O
glomeruli	glomerulus	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
FSGS	FSGS	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
particles	particle	NOUN	NNS	0	O
of	of	ADP	IN	5	O
perfused	perfuse	VERB	VBN	0	O
ruthenium	ruthenium	NOUN	NN	0	B-Chemical
red	red	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
lamina	lamina	NOUN	NN	9	O
rara	rara	NOUN	NN	2	O
externa	externa	NOUN	NN	4	O
and	and	CCONJ	CC	5	O
marked	mark	VERB	VBD	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
epithelial	epithelial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
cytoplasm	cytoplasm	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
PS	PS	PROPN	NNP	9	B-Chemical
enhances	enhance	VERB	VBZ	3	O
the	the	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
AMNS	AMNS	PROPN	NNP	9	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
glomerulus	glomerulus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
readily	readily	ADV	RB	9	O
produces	produce	VERB	VBZ	9	O
progressive	progressive	ADJ	JJ	5	O
FSGS	FSGS	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Theophylline	theophylline	NOUN	NN	0	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
pregnant	pregnant	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
altered	alter	VERB	VBN	9	O
in	in	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
20	20	NUM	CD	9	O
days	day	NOUN	NNS	9	O
pregnant	pregnant	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
nonpregnant	nonpregnant	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
strain	strain	NOUN	NN	1	O
received	receive	VERB	VBD	9	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
aminophylline	aminophylline	NOUN	NN	0	B-Chemical
until	until	ADP	IN	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
maximal	maximal	NOUN	NN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
which	which	DET	WDT	5	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
28	28	NUM	CD	7	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Theophylline	theophylline	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
at	at	ADP	IN	9	O
this	this	DET	DT	5	O
endpoint	endpoint	NOUN	NN	5	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
total	total	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
CSF	csf	NOUN	NN	9	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
serum	serum	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
free	free	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
slightly	slightly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
in	in	ADP	IN	5	O
pregnant	pregnant	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Theophylline	theophylline	NOUN	NN	0	B-Chemical
serum	serum	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
binding	bind	VERB	VBG	1	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
equilibrium	equilibrium	NOUN	NN	9	O
dialysis	dialysis	NOUN	NN	5	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
pregnant	pregnant	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Fetal	fetal	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
at	at	ADP	IN	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mother	mother	NOUN	NN	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
maternal	maternal	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
CSF	csf	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
correlated	correlate	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
former	former	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
pregnancy	pregnancy	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
negligible	negligible	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Hyperkalemia	Hyperkalemia	PROPN	NNP	7	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
indomethacin	indomethacin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
naproxen	naproxen	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
fludrocortisone	fludrocortisone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
mefenamic	mefenamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
inappropriate	inappropriate	ADJ	JJ	5	O
hypoaldosteronism	hypoaldosteronism	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
both	both	CCONJ	CC	9	O
indomethacin	indomethacin	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
naproxen	naproxen	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
major	major	ADJ	JJ	9	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
that	that	ADP	IN	5	O
preexisting	preexist	VERB	VBG	9	O
renal	renal	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
predisposed	predispose	VERB	VBD	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
to	to	PART	TO	5	O
type	type	VERB	VB	9	B-Disease
IV	iv	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
acidosis	acidosis	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
synthetase	synthetase	NOUN	NN	1	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
unable	unable	ADJ	JJ	9	O
to	to	PART	TO	5	O
discontinue	discontinue	VERB	VB	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
fludrocortisone	fludrocortisone	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
added	add	VERB	VBN	0	O
,	,	PUNCT	,	9	O
correcting	correct	VERB	VBG	5	O
the	the	DET	DT	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
allowing	allow	VERB	VBG	5	O
indomethacin	indomethacin	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
continued	continue	VERB	VBN	9	O
safely	safely	ADV	RB	5	O
.	.	PUNCT	.	9	O

Hypotension	hypotension	NOUN	NN	7	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
colorectal	colorectal	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
while	while	ADP	IN	9	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
CDDP	CDDP	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
left	leave	VERB	VBN	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
required	require	VERB	VBD	9	O
therapy	therapy	NOUN	NN	5	O
discontinuation	discontinuation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
enzymes	enzyme	NOUN	NNS	1	O
remained	remain	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
despite	despite	ADP	IN	9	O
transient	transient	ADJ	JJ	9	O
electrocardiographic	electrocardiographic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EKG	EKG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
changes	change	VERB	VBZ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
presentation	presentation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
echocardiographic	echocardiographic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
scintigraphic	scintigraphic	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
new	new	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
influenced	influence	VERB	VBN	5	O
by	by	ADP	IN	9	O
CDDP	CDDP	PROPN	NNP	3	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
pathophysiologic	pathophysiologic	NOUN	NN	5	O
mechanisms	mechanism	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Fatal	fatal	ADJ	JJ	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
carbamazepine	carbamazepine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
woman	woman	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
concerns	concern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
bone	bone	NOUN	NN	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
only	only	ADV	RB	9	O
the	the	DET	DT	5	O
fourth	fourth	ADJ	JJ	9	O
documented	document	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
published	publish	VERB	VBN	9	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
physicians	physician	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
exceedingly	exceedingly	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
potentially	potentially	ADV	RB	5	O
fatal	fatal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
better	better	ADV	RBR	5	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
clinical	clinical	ADJ	JJ	5	O
than	than	ADP	IN	5	O
by	by	ADP	IN	9	O
laboratory	laboratory	NOUN	NN	9	O
monitoring	monitoring	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Participation	participation	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
bulbospinal	bulbospinal	ADJ	JJ	5	O
serotonergic	serotonergic	NOUN	NN	5	O
pathway	pathway	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
brain	brain	NOUN	NN	5	O
in	in	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
microliter	microliter	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
into	into	ADP	IN	9	O
a	a	DET	DT	5	O
region	region	NOUN	NN	9	O
adjacent	adjacent	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
ventrolateral	ventrolateral	ADJ	JJ	5	O
surface	surface	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
medulla	medulla	NOUN	NN	9	O
oblongata	oblongata	NOUN	NN	5	O
on	on	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
urethane	urethane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
anesthetized	anesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Intramedullary	intramedullary	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
saline	saline	VERB	VB	0	O
vehicle	vehicle	NOUN	NN	3	O
,	,	PUNCT	,	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
antagonized	antagonize	VERB	VBN	3	O
by	by	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
spinal	spinal	ADJ	JJ	5	O
transection	transection	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
bilateral	bilateral	ADJ	JJ	5	O
vagotomy	vagotomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
antagonized	antagonize	VERB	VBN	3	O
by	by	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
bilateral	bilateral	ADJ	JJ	5	O
vagotomy	vagotomy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
spinal	spinal	ADJ	JJ	5	O
transection	transection	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
selective	selective	ADJ	JJ	9	O
destruction	destruction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
nerves	nerve	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
bilateral	bilateral	ADJ	JJ	5	O
spinal	spinal	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxytryptamine	dihydroxytryptamine	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
vasodepressor	vasodepressor	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
bradycardiac	bradycardiac	ADJ	JJ	5	B-Disease
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
microinjected	microinjecte	VERB	VBN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
area	area	NOUN	NN	5	O
near	near	ADP	IN	9	O
the	the	DET	DT	5	O
ventrolateral	ventrolateral	ADJ	JJ	5	O
surface	surface	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
medulla	medulla	NOUN	NN	9	O
oblongata	oblongata	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
bulbospinal	bulbospinal	ADJ	JJ	5	O
serotonergic	serotonergic	NOUN	NN	5	O
pathway	pathway	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
brought	bring	VERB	VBN	5	O
about	about	PART	RP	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
efferent	efferent	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
induced	induce	VERB	VBN	3	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
vagal	vagal	ADJ	JJ	5	O
efferent	efferent	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Hypertension	hypertension	NOUN	NN	7	B-Disease
in	in	ADP	IN	5	O
neuroblastoma	neuroblastoma	NOUN	NN	3	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
imipramine	imipramine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Hypertension	hypertension	NOUN	NN	7	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
known	know	VERB	VBN	9	O
finding	finding	NOUN	NN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
neuroblastoma	neuroblastoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
Imipramine	Imipramine	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
190	190	NUM	CD	9	O
/	/	SYM	SYM	9	O
160	160	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
with	with	ADP	IN	5	O
neuroblastoma	neuroblastoma	NOUN	NN	3	B-Disease
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
Imipramine	Imipramine	PROPN	NNP	0	B-Chemical
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
a	a	DET	DT	5	O
behavior	behavior	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
later	later	ADV	RB	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
tumor	tumor	NOUN	NN	3	B-Disease
was	be	VERB	VBD	9	O
recurring	recur	VERB	VBG	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
episode	episode	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
elevation	elevation	NOUN	NN	9	O
at	at	ADP	IN	9	O
initial	initial	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
none	none	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Imipramine	Imipramine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
when	when	ADV	WRB	5	O
she	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
florid	florid	ADJ	JJ	5	O
relapse	relapse	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
believe	believe	VERB	VBP	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
underlying	underlying	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
alone	alone	ADV	RB	9	O
caused	cause	VERB	VBD	9	O
her	-PRON-	DET	PRP$	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
believed	believe	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
increased	increase	VERB	VBN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
vasoactive	vasoactive	ADJ	JJ	5	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
interference	interference	NOUN	NN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
physiologic	physiologic	NOUN	NN	9	O
inactivation	inactivation	NOUN	NN	9	O
by	by	ADP	IN	9	O
Imipramine	Imipramine	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
this	this	DET	DT	5	O
experience	experience	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
urge	urge	VERB	VBP	5	O
extreme	extreme	ADJ	JJ	5	O
caution	caution	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressants	antidepressant	NOUN	NNS	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
active	active	ADJ	JJ	9	O
neuroblastoma	neuroblastoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Rechallenge	rechallenge	NOUN	NN	3	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
oral	oral	ADJ	JJ	9	B-Disease
candidiasis	candidiasi	NOUN	NNS	5	I-Disease
or	or	CCONJ	CC	5	O
hoarseness	hoarseness	VERB	VB	5	B-Disease
with	with	ADP	IN	5	O
beclomethasone	beclomethasone	ADJ	JJ	0	B-Chemical
dipropionate	dipropionate	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
158	158	NUM	CD	7	O
asthmatic	asthmatic	ADJ	JJ	9	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
placed	place	VERB	VBN	5	O
on	on	ADP	IN	5	O
inhaled	inhale	VERB	VBN	5	O
beclomethasone	beclomethasone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
either	either	CCONJ	CC	9	O
hoarseness	hoarseness	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
oral	oral	ADJ	JJ	9	O
thrush	thrush	NOUN	NN	4	B-Disease
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
their	-PRON-	DET	PRP$	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
subsided	subside	VERB	VBN	5	O
,	,	PUNCT	,	9	O
seven	seven	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
15	15	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
rechallenged	rechallenge	VERB	VBN	3	O
with	with	ADP	IN	5	O
inhaled	inhale	VERB	VBN	5	O
beclomethasone	beclomethasone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
included	include	VERB	VBD	5	O
five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
hoarseness	hoarseness	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
three	three	NUM	CD	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
Candidiasis	Candidiasis	PROPN	NNP	7	B-Disease
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
both	both	DET	DT	9	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
thrush	thrush	NOUN	NN	4	B-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
recur	recur	VERB	VB	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hoarseness	hoarseness	NOUN	NN	5	B-Disease
had	have	VERB	VBD	9	O
recurrence	recurrence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
restarted	restart	VERB	VBN	5	O
on	on	ADP	IN	5	O
inhaled	inhale	VERB	VBN	5	O
beclomethasone	beclomethasone	NOUN	NN	0	B-Chemical
when	when	ADV	WRB	5	O
clinically	clinically	ADV	RB	5	O
indicated	indicate	VERB	VBD	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
recurrence	recurrence	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
develop	develop	VERB	VBP	5	O
hoarseness	hoarseness	NOUN	NN	5	B-Disease
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
re	re	VERB	VBN	5	O
-	-	VERB	VBN	7	O
challenged	challenge	VERB	VBN	3	O
.	.	PUNCT	.	9	O

Concomitant	concomitant	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
prednisone	prednisone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
topical	topical	ADJ	JJ	0	O
beclomethasone	beclomethasone	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
hoarseness	hoarseness	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
candidiasis	candidiasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
dosing	dose	VERB	VBG	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
undergo	undergo	VERB	VBP	9	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
are	be	VERB	VBP	5	O
generally	generally	ADV	RB	5	O
immunosuppressed	immunosuppresse	VERB	VBN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CYA	CYA	PROPN	NNP	4	B-Chemical
)	)	PUNCT	-RRB-	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
usually	usually	ADV	RB	5	O
calculated	calculate	VERB	VBN	5	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NUM	CD	9	O
weight	weight	NOUN	NN	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
these	these	DET	DT	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
,	,	PUNCT	,	9	O
serious	serious	ADJ	JJ	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
definitive	definitive	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
such	such	ADJ	JJ	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agent	agent	NOUN	NN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
generally	generally	ADV	RB	5	O
correlates	correlate	VERB	VBZ	9	O
with	with	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
per	per	ADP	IN	9	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
retrospectively	retrospectively	ADV	RB	5	O
calculated	calculate	VERB	VBD	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
transplanted	transplant	VERB	VBN	3	O
at	at	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
institution	institution	NOUN	NN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
per	per	ADP	IN	9	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Eighty	eighty	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
for	for	ADP	IN	5	O
four	four	NUM	CD	9	O
days	day	NOUN	NNS	9	O
as	as	ADP	IN	5	O
preparation	preparation	NOUN	NN	9	O
for	for	ADP	IN	5	O
marrow	marrow	NOUN	NN	3	O
grafting	grafting	NOUN	NN	5	O
underwent	undergo	VERB	VBD	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
84	84	NUM	CD	7	O
transplants	transplant	NOUN	NNS	9	O
for	for	ADP	IN	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
Wiskott	Wiskott	PROPN	NNP	1	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Aldrich	Aldrich	PROPN	NNP	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	B-Disease
combined	combined	ADJ	JJ	9	I-Disease
immunodeficiency	immunodeficiency	NOUN	NN	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Fourteen	fourteen	NUM	CD	9	O
of	of	ADP	IN	5	O
84	84	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
signs	sign	NOUN	NNS	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
within	within	ADP	IN	9	O
ten	ten	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
receiving	receive	VERB	VBG	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
with	with	ADP	IN	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
per	per	ADP	IN	9	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
was	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
dose	dose	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Group	Group	PROPN	NNP	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
CYA	CYA	PROPN	NNP	4	B-Chemical
less	less	ADV	RBR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
55	55	NUM	CD	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
;	;	PUNCT	:	9	O
Group	Group	PROPN	NNP	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
CYA	CYA	PROPN	NNP	4	B-Chemical
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
55	55	NUM	CD	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
thought	think	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
32	32	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
13	13	NUM	CD	7	O
/	/	SYM	SYM	9	O
52	52	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
025	025	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Congestive	congestive	ADJ	JJ	7	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
caused	cause	VERB	VBD	9	O
or	or	CCONJ	CC	5	O
contributed	contribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
0	0	NUM	CD	7	O
/	/	SYM	SYM	9	O
32	32	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
1	1	NUM	CD	9	O
v	v	ADP	IN	0	O
6	6	NUM	CD	9	O
/	/	SYM	SYM	9	O
52	52	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
engraftment	engraftment	NOUN	NN	3	O
of	of	ADP	IN	5	O
evaluable	evaluable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
correlates	correlate	VERB	VBZ	9	O
with	with	ADP	IN	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
dosage	dosage	NOUN	NN	9	O
as	as	ADP	IN	5	O
calculated	calculate	VERB	VBN	5	O
by	by	ADP	IN	9	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
immunodeficiencies	immunodeficiency	NOUN	NNS	5	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
effectively	effectively	ADV	RB	5	O
prepared	prepare	VERB	VBN	0	O
for	for	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
grafting	grafting	NOUN	NN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
CYA	CYA	PROPN	NNP	4	B-Chemical
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
55	55	NUM	CD	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
for	for	ADP	IN	5	O
four	four	NUM	CD	9	O
days	day	NOUN	NNS	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
than	than	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
whose	whose	DET	WP$	9	O
CYA	CYA	PROPN	NNP	4	B-Chemical
dosage	dosage	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
calculated	calculate	VERB	VBN	5	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
weight	weight	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
reaffirms	reaffirm	VERB	VBZ	5	O
the	the	DET	DT	5	O
principle	principle	NOUN	NN	5	O
that	that	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
correlates	correlate	VERB	VBZ	9	O
with	with	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
per	per	ADP	IN	9	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
epidemiology	epidemiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
fully	fully	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Experimental	experimental	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
human	human	ADJ	JJ	3	O
volunteers	volunteer	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
aminoglycosides	aminoglycoside	NOUN	NNS	9	B-Chemical
cause	cause	VERB	VBP	5	O
proximal	proximal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
rarely	rarely	ADV	RB	5	O
,	,	PUNCT	,	9	O
if	if	ADP	IN	5	O
ever	ever	ADV	RB	5	O
,	,	PUNCT	,	9	O
cause	cause	VERB	VB	5	O
glomerular	glomerular	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	I-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aminoglycosides	aminoglycoside	NOUN	NNS	9	B-Chemical
in	in	ADP	IN	5	O
seriously	seriously	ADV	RB	5	O
ill	ill	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
ranges	range	NOUN	NNS	5	O
from	from	ADP	IN	9	O
8	8	NUM	CD	9	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
attributable	attributable	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
advanced	advanced	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
initial	initial	ADJ	JJ	9	O
estimated	estimate	VERB	VBN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
,	,	PUNCT	,	9	O
female	female	ADJ	JJ	9	O
gender	gender	NOUN	NN	5	O
all	all	DET	DT	5	O
increase	increase	VERB	VBP	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
shock	shock	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
an	an	DET	DT	5	O
additive	additive	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Predictive	predictive	ADJ	JJ	5	O
models	model	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
developed	develop	VERB	VBN	5	O
from	from	ADP	IN	9	O
these	these	DET	DT	5	O
analyses	analysis	NOUN	NNS	9	O
that	that	DET	WDT	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
for	for	ADP	IN	5	O
identifying	identify	VERB	VBG	5	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
models	model	NOUN	NNS	5	O
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
insights	insight	NOUN	NNS	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Central	central	ADJ	JJ	4	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
narcotic	narcotic	ADJ	JJ	5	O
analgesics	analgesic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Part	part	NOUN	NN	9	O
IV	IV	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Noradrenergic	noradrenergic	ADP	IN	5	O
influences	influence	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
analgesics	analgesic	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
naphazoline	naphazoline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
xylometazoline	xylometazoline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
analgesia	analgesia	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
codeine	codeine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pentazocine	pentazocine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
cataleptic	cataleptic	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
codine	codine	NOUN	NN	_	B-Chemical
and	and	CCONJ	CC	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
biochemical	biochemical	NOUN	NN	9	O
assays	assay	NOUN	NNS	3	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
analgesics	analgesic	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
turnover	turnover	NOUN	NN	9	O
of	of	ADP	IN	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
NA	NA	PROPN	NNP	7	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
that	that	ADP	IN	5	O
three	three	NUM	CD	9	O
drugs	drug	NOUN	NNS	5	O
stimulating	stimulate	VERB	VBG	9	O
central	central	ADJ	JJ	5	O
NA	NA	PROPN	NNP	7	B-Chemical
receptors	receptor	NOUN	NNS	3	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
analgesic	analgesic	ADJ	JJ	5	O
ED50	ED50	PROPN	NNP	0	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
antinociceptive	antinociceptive	ADJ	JJ	0	O
agents	agent	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
they	-PRON-	PRON	PRP	5	O
enhanced	enhance	VERB	VBD	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Codeine	codeine	NOUN	NN	0	B-Chemical
catalepsy	catalepsy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
by	by	ADP	IN	9	O
naphazoline	naphazoline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
xylometazoline	xylometazoline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
NA	NA	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
changed	change	VERB	VBN	9	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
codeine	codeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
45	45	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
slightly	slightly	ADV	RB	9	O
enhanced	enhance	VERB	VBD	3	O
it	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

Pentazocine	pentazocine	NOUN	NN	7	B-Chemical
dose	dose	NOUN	NN	9	O
-	-	PUNCT	:	7	O
dependently	dependently	ADV	RB	3	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
NA	NA	PROPN	NNP	7	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
NA	NA	PROPN	NNP	7	B-Chemical
turnover	turnover	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
altered	alter	VERB	VBN	9	O
by	by	ADP	IN	9	O
analgesics	analgesic	NOUN	NNS	5	O
except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
following	follow	VERB	VBG	9	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
NA	NA	PROPN	NNP	7	B-Chemical
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
was	be	VERB	VBD	9	O
diminished	diminish	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
light	light	NOUN	NN	9	O
of	of	ADP	IN	5	O
various	various	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
uniform	uniform	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
NA	NA	PROPN	NNP	7	B-Chemical
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
less	less	ADV	RBR	5	O
important	important	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
monoamines	monoamine	NOUN	NNS	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
behavioural	behavioural	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
potent	potent	ADJ	JJ	3	O
analgesics	analgesic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Flurothyl	flurothyl	ADV	RB	9	B-Chemical
seizure	seizure	VERB	VB	5	B-Disease
thresholds	threshold	NOUN	NNS	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
neonatally	neonatally	ADV	RB	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
monosodium	monosodium	NOUN	NN	0	B-Chemical
glutamate	glutamate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MSG	MSG	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
in	in	ADP	IN	5	O
flurothyl	flurothyl	ADJ	JJ	0	B-Chemical
seizure	seizure	NOUN	NN	5	B-Disease
testing	testing	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Monosodium	Monosodium	PROPN	NNP	0	B-Chemical
glutamate	glutamate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MSG	MSG	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
to	to	ADP	IN	5	O
neonatal	neonatal	ADJ	JJ	9	O
rodents	rodent	NOUN	NNS	9	O
produces	produce	VERB	VBZ	9	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
numerous	numerous	ADJ	JJ	9	O
biochemical	biochemical	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	O
deficits	deficit	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
neonatal	neonatal	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
MSG	MSG	PROPN	NNP	9	B-Chemical
produced	produce	VERB	VBD	9	O
permanent	permanent	ADJ	JJ	5	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
susceptibility	susceptibility	NOUN	NN	9	O
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
previous	previous	ADJ	JJ	9	O
investigations	investigation	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
inconclusive	inconclusive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
flurothyl	flurothyl	ADJ	JJ	0	B-Chemical
ether	ether	ADJ	JJ	0	B-Chemical
seizure	seizure	NOUN	NN	5	B-Disease
screening	screening	NOUN	NN	5	O
technique	technique	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
seizure	seizure	VERB	VB	5	B-Disease
susceptibility	susceptibility	NOUN	NN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
neonatal	neonatal	ADJ	JJ	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
MSG	MSG	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
g	g	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

MSG	MSG	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
whole	whole	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
alter	alter	VERB	VB	9	O
seizure	seizure	NOUN	NN	5	B-Disease
threshold	threshold	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
challenge	challenge	NOUN	NN	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
ineffective	ineffective	ADJ	JJ	9	O
in	in	ADP	IN	5	O
altering	alter	VERB	VBG	9	O
the	the	DET	DT	5	O
seizure	seizure	NOUN	NN	5	B-Disease
thresholds	threshold	NOUN	NNS	5	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
MSG	MSG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Flurothyl	flurothyl	ADV	RB	9	B-Chemical
ether	ether	INTJ	UH	0	B-Chemical
produced	produce	VERB	VBD	9	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
flurothyl	flurothyl	ADJ	JJ	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
to	to	PART	TO	5	O
seizure	seizure	VERB	VB	5	B-Disease
induction	induction	NOUN	NN	3	O
was	be	VERB	VBD	9	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Flurothyl	flurothyl	ADV	RB	9	B-Chemical
seizure	seizure	VERB	VB	5	B-Disease
testing	testing	NOUN	NN	5	O
proved	prove	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
reliable	reliable	ADJ	JJ	5	O
technique	technique	NOUN	NN	5	O
with	with	ADP	IN	5	O
which	which	DET	WDT	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
seizure	seizure	VERB	VB	5	B-Disease
susceptibility	susceptibility	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
after	after	ADP	IN	9	O
microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
vinyl	vinyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
GABA	GABA	PROPN	NNP	0	I-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
substantia	substantia	ADJ	JJ	9	O
nigra	nigra	NOUN	NN	4	O
.	.	PUNCT	.	9	O

Pilocarpine	Pilocarpine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
reproduces	reproduce	VERB	VBZ	5	O
the	the	DET	DT	5	O
neuropathological	neuropathological	ADJ	JJ	5	O
sequelae	sequelae	NOUN	NN	5	O
of	of	ADP	IN	5	O
temporal	temporal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
provides	provide	VERB	VBZ	5	O
a	a	DET	DT	5	O
relevant	relevant	ADJ	JJ	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
studying	study	VERB	VBG	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
buildup	buildup	NOUN	NN	5	O
of	of	ADP	IN	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
pathways	pathway	VERB	VBZ	9	O
operative	operative	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
generalization	generalization	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
propagation	propagation	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
forebrain	forebrain	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
manipulating	manipulate	VERB	VBG	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
synaptic	synaptic	ADJ	JJ	5	O
inhibition	inhibition	NOUN	NN	3	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
substantia	substantia	ADJ	JJ	9	O
nigra	nigra	NOUN	NN	4	O
on	on	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
animals	animal	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
microinjections	microinjection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
150	150	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
synthesizing	synthesize	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
,	,	PUNCT	,	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glutamic	glutamic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
decarboxylase	decarboxylase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
substantia	substantia	ADJ	JJ	9	O
nigra	nigra	NOUN	NN	4	O
pars	par	NOUN	NNS	4	O
reticulata	reticulata	VERB	VBP	4	O
(	(	PUNCT	-LRB-	9	O
SNR	SNR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
bilaterally	bilaterally	ADV	RB	5	O
,	,	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
convulsant	convulsant	ADJ	JJ	0	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
and	and	CCONJ	CC	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
limbic	limbic	NOUN	NN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Electroencephalographic	electroencephalographic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
profound	profound	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
threshold	threshold	NOUN	NN	5	O
for	for	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Morphological	morphological	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
frontal	frontal	ADJ	JJ	5	O
forebrain	forebrain	NOUN	NN	3	O
sections	section	NOUN	NNS	9	O
with	with	ADP	IN	5	O
light	light	ADJ	JJ	9	O
microscopy	microscopy	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
damage	damage	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
formation	formation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
thalamus	thalamus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
amygdala	amygdala	NOUN	NN	5	O
,	,	PUNCT	,	9	O
olfactory	olfactory	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
substantia	substantia	ADJ	JJ	9	O
nigra	nigra	NOUN	NN	4	O
and	and	CCONJ	CC	5	O
neocortex	neocortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
typically	typically	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
exceeding	exceed	VERB	VBG	9	O
350	350	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Bilateral	bilateral	ADJ	JJ	5	O
intrastriatal	intrastriatal	ADJ	JJ	3	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
augment	augment	NOUN	NN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Application	application	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
irreversible	irreversible	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
transaminase	transaminase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
vinyl	vinyl	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
GABA	GABA	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
D	D	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
amino	amino	ADJ	JJ	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hex	hex	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
enoic	enoic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
SNR	SNR	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
bilaterally	bilaterally	ADV	RB	5	O
,	,	PUNCT	,	9	O
suppressed	suppress	VERB	VBD	3	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
electrographic	electrographic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
380	380	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
protect	protect	VERB	VB	9	O
animals	animal	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Microinjections	microinjection	NOUN	NNS	3	O
of	of	ADP	IN	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
vinyl	vinyl	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
GABA	GABA	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
dorsal	dorsal	ADJ	JJ	5	O
striatum	striatum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
bilaterally	bilaterally	ADV	RB	5	O
,	,	PUNCT	,	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
380	380	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
threshold	threshold	NOUN	NN	5	O
for	for	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
synaptic	synaptic	ADJ	JJ	5	O
inhibition	inhibition	NOUN	NN	3	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
substantia	substantia	ADJ	JJ	9	O
nigra	nigra	NOUN	NN	4	O
.	.	PUNCT	.	9	O

Human	human	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
canine	canine	VERB	VB	9	O
ventricular	ventricular	ADJ	JJ	5	O
vasoactive	vasoactive	ADJ	JJ	5	O
intestinal	intestinal	ADJ	JJ	9	O
polypeptide	polypeptide	NOUN	NN	1	O
:	:	PUNCT	:	9	O
decrease	decrease	NOUN	NN	9	O
with	with	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Vasoactive	vasoactive	ADJ	JJ	7	O
intestinal	intestinal	ADJ	JJ	9	O
polypeptide	polypeptide	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
VIP	VIP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
systemic	systemic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
coronary	coronary	ADJ	JJ	5	O
vasodilator	vasodilator	NOUN	NN	0	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
positive	positive	ADJ	JJ	9	O
inotropic	inotropic	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
VIP	VIP	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
assayed	assay	VERB	VBN	3	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
canine	canine	NOUN	NN	9	O
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
cobalt	cobalt	NOUN	NN	0	B-Chemical
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
eight	eight	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
by	by	ADP	IN	9	O
radioimmunoassay	radioimmunoassay	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
35	35	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
protein	protein	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
protein	protein	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
six	six	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
VIP	VIP	PROPN	NNP	9	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
31	31	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
11	11	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
protein	protein	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
VIP	vip	NOUN	NN	9	O
content	content	NOUN	NN	9	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
of	of	ADP	IN	5	O
resected	resect	VERB	VBN	5	O
failing	fail	VERB	VBG	5	O
hearts	heart	NOUN	NNS	3	O
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
heart	heart	NOUN	NN	5	O
transplant	transplant	NOUN	NN	9	O
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
papillary	papillary	ADJ	JJ	5	O
muscles	muscle	NOUN	NNS	5	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
five	five	NUM	CD	9	O
with	with	ADP	IN	5	O
rheumatic	rheumatic	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
nine	nine	NUM	CD	9	O
with	with	ADP	IN	5	O
myxomatous	myxomatous	ADJ	JJ	5	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	O
receiving	receive	VERB	VBG	9	O
mitral	mitral	ADJ	JJ	5	O
valve	valve	NOUN	NN	5	O
prostheses	prosthesis	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
lowest	low	ADJ	JJS	9	O
myocardial	myocardial	ADJ	JJ	9	O
VIP	vip	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hearts	heart	NOUN	NNS	3	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
transplant	transplant	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
three	three	NUM	CD	9	O
receiving	receive	VERB	VBG	9	O
mitral	mitral	ADJ	JJ	5	O
prostheses	prosthesis	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
protein	protein	NOUN	NN	1	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
transplantation	transplantation	NOUN	NN	9	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
of	of	ADP	IN	5	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
VIP	VIP	PROPN	NNP	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
protein	protein	NOUN	NN	1	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hearts	heart	NOUN	NNS	3	O
without	without	ADP	IN	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
average	average	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
62	62	NUM	CD	7	O
%	%	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
VIP	vip	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
hearts	heart	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
hearts	heart	NOUN	NNS	3	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
transplant	transplant	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
subjects	subject	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
a	a	DET	DT	5	O
weak	weak	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
57	57	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
tissue	tissue	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
VIP	vip	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
invasive	invasive	ADJ	JJ	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
body	body	NOUN	NN	5	O
surface	surface	VERB	VBP	9	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
mapping	mapping	NOUN	NN	5	O
after	after	ADP	IN	9	O
dipyridamole	dipyridamole	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Electrocardiographic	electrocardiographic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
after	after	ADP	IN	9	O
dipyridamole	dipyridamole	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
568	568	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
4	4	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
41	41	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
after	after	ADP	IN	9	O
submaximal	submaximal	ADJ	JJ	5	O
treadmill	treadmill	NOUN	NN	5	O
exercise	exercise	NOUN	NN	5	O
by	by	ADP	IN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
mapping	mapping	NOUN	NN	5	O
technique	technique	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
19	19	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
non	non	PROPN	NNP	9	O
-	-	ADJ	JJ	7	O
MI	MI	PROPN	NNP	9	B-Disease
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
with	with	ADP	IN	5	O
anterior	anterior	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ANT	ANT	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
MI	MI	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
eight	eight	NUM	CD	9	O
with	with	ADP	IN	5	O
inferior	inferior	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
INF	INF	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
MI	MI	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Eighty	eighty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
seven	seven	NUM	CD	9	O
unipolar	unipolar	ADJ	JJ	5	O
electrocardiograms	electrocardiogram	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
ECGs	ecg	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
distributed	distribute	VERB	VBN	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
thoracic	thoracic	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
were	be	VERB	VBD	9	O
simultaneously	simultaneously	ADV	RB	5	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
dipyridamole	dipyridamole	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
ST	st	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
depression	depression	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
mV	mv	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
84	84	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
MI	MI	PROPN	NNP	9	B-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
29	29	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ANT	ANT	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
MI	MI	PROPN	NNP	9	I-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
63	63	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
INF	INF	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
MI	MI	PROPN	NNP	9	I-Disease
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
61	61	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Exercise	exercise	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ST	ST	PROPN	NNP	9	O
depression	depression	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
84	84	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
MI	MI	PROPN	NNP	9	B-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ANT	ANT	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
MI	MI	PROPN	NNP	9	I-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
38	38	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
INF	INF	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
MI	MI	PROPN	NNP	9	I-Disease
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
61	61	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	NOUN	NN	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
individual	individual	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
obvious	obvious	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
distribution	distribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
ST	ST	PROPN	NNP	9	O
depression	depression	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
pressure	pressure	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
product	product	NOUN	NN	9	O
after	after	ADP	IN	9	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
treadmill	treadmill	NOUN	NN	5	O
exercise	exercise	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
inhomogenous	inhomogenous	ADJ	JJ	5	O
distribution	distribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
dipyridamole	dipyridamole	ADJ	JJ	0	B-Chemical
ECG	ECG	PROPN	NNP	5	O
test	test	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
as	as	ADV	RB	5	O
useful	useful	ADJ	JJ	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
exercise	exercise	NOUN	NN	5	O
ECG	ECG	PROPN	NNP	5	O
test	test	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Bradycardia	Bradycardia	NOUN	NNS	7	B-Disease
after	after	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
intravenous	intravenous	ADJ	JJ	0	O
methylprednisolone	methylprednisolone	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
5	5	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
intravenous	intravenous	ADJ	JJ	0	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
MP	MP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
g	g	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
or	or	CCONJ	CC	5	O
3	3	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
pulse	pulse	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
most	most	ADV	RBS	9	O
pronounced	pronounce	VERB	VBN	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
the	the	DET	DT	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
complaints	complaint	NOUN	NNS	5	O
of	of	ADP	IN	5	O
substernal	substernal	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reversal	reversal	NOUN	NN	9	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O

Electrocardiographic	Electrocardiographic	PROPN	NNP	5	O
registrations	registration	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
sinus	sinus	NOUN	NN	5	B-Disease
bradycardia	bradycardia	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
electrolytes	electrolyte	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Careful	careful	ADJ	JJ	5	O
observation	observation	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
MP	MP	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
MP	mp	NOUN	NN	9	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
contraindicated	contraindicate	VERB	VBN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
known	known	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
downbeat	downbeat	ADJ	JJ	5	B-Disease
nystagmus	nystagmus	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
oscillopsia	oscillopsia	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Downbeat	Downbeat	VERB	VBN	5	B-Disease
nystagmus	nystagmus	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
often	often	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
structural	structural	ADJ	JJ	9	O
lesions	lesion	NOUN	NNS	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
craniocervical	craniocervical	ADJ	JJ	5	O
junction	junction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
has	have	VERB	VBZ	9	O
occasionally	occasionally	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
metabolic	metabolic	ADJ	JJ	9	O
imbalance	imbalance	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	O
intoxication	intoxication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recorded	record	VERB	VBD	5	O
the	the	DET	DT	5	O
eye	eye	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
reversible	reversible	ADJ	JJ	9	O
downbeat	downbeat	ADJ	JJ	5	B-Disease
nystagmus	nystagmus	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
nystagmus	nystagmus	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
resolved	resolve	VERB	VBN	9	O
after	after	ADP	IN	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Neuroradiologic	neuroradiologic	ADJ	JJ	9	O
investigations	investigation	NOUN	NNS	9	O
including	include	VERB	VBG	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	image	VERB	VBG	5	O
scans	scan	NOUN	NNS	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
intracranial	intracranial	ADJ	JJ	5	O
abnormality	abnormality	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
downbeat	downbeat	ADJ	JJ	5	B-Disease
nystagmus	nystagmus	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
taking	take	VERB	VBG	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
medications	medication	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
consideration	consideration	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
before	before	ADP	IN	9	O
further	further	ADJ	JJ	9	O
investigation	investigation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
undertaken	undertake	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Improvement	improvement	NOUN	NN	5	O
by	by	ADP	IN	9	O
denopamine	denopamine	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
TA	TA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
064	064	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dog	dog	NOUN	NN	5	O
heart	heart	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
lung	lung	NOUN	NN	9	O
preparation	preparation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
denopamine	denopamine	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
orally	orally	ADV	RB	0	O
active	active	ADJ	JJ	9	O
beta	beta	NOUN	NN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
improving	improve	VERB	VBG	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
dog	dog	NOUN	NN	5	O
heart	heart	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
lung	lung	NOUN	NN	9	O
preparations	preparation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
functions	function	NOUN	NNS	9	O
depressed	depress	VERB	VBN	5	O
by	by	ADP	IN	9	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
118	118	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
28	28	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
mean	mean	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
such	such	ADJ	JJ	5	O
that	that	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
maximum	maximum	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
rise	rise	NOUN	NN	9	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
LV	LV	PROPN	NNP	9	O
dP	dP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dt	dt	NOUN	NN	9	O
max	max	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
about	about	ADV	RB	5	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
respective	respective	ADJ	JJ	9	O
controls	control	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
improved	improve	VERB	VBN	5	O
by	by	ADP	IN	9	O
denopamine	denopamine	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
300	300	NUM	CD	0	O
micrograms	micrograms	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
100	100	NUM	CD	0	O
micrograms	micrograms	NOUN	NN	0	O
denopamine	denopamine	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
almost	almost	ADV	RB	9	O
complete	complete	ADJ	JJ	9	O
restoration	restoration	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
performance	performance	NOUN	NN	5	O
was	be	VERB	VBD	9	O
attained	attain	VERB	VBN	9	O
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
slight	slight	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
these	these	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
denopamine	denopamine	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
warrant	warrant	VERB	VBP	9	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
of	of	ADP	IN	5	O
denopamine	denopamine	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Clonazepam	Clonazepam	PROPN	NNP	0	B-Chemical
monotherapy	monotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
childhood	childhood	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sixty	sixty	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
range	range	NOUN	NN	9	O
one	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
to	to	ADP	IN	5	O
14	14	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
infantile	infantile	ADJ	JJ	5	B-Disease
spasms	spasm	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
clonazepam	clonazepam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Disappearance	Disappearance	PROPN	NNP	9	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
normalization	normalization	NOUN	NN	5	O
of	of	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	O
EEG	EEG	PROPN	NNP	5	O
with	with	ADP	IN	5	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
recognized	recognize	VERB	VBN	9	O
in	in	ADP	IN	5	O
77	77	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Seizures	Seizures	PROPN	NNP	5	B-Disease
disappeared	disappear	VERB	VBD	9	O
in	in	ADP	IN	5	O
71	71	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
generalized	generalized	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
89	89	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
partial	partial	ADJ	JJ	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	O
EEG	EEG	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
noticed	notice	VERB	VBN	9	O
in	in	ADP	IN	5	O
76	76	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
diffuse	diffuse	NOUN	NN	5	O
paroxysms	paroxysm	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
67	67	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
focal	focal	ADJ	JJ	5	O
paroxysms	paroxysm	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
excellent	excellent	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
dosages	dosage	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
086	086	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
021	021	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
in	in	ADP	IN	5	O
infants	infant	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
057	057	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
022	022	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
in	in	ADP	IN	5	O
schoolchildren	schoolchildren	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
drowsiness	drowsiness	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
ataxia	ataxia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Postmarketing	postmarkete	VERB	VBG	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
hydrochlorothiazide	hydrochlorothiazide	NOUN	NN	0	B-Chemical
antihypertensive	antihypertensive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
postmarketing	postmarketing	ADJ	JJ	5	O
surveillance	surveillance	NOUN	NN	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
fixed	fix	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
ratio	ratio	NOUN	NN	9	O
combination	combination	NOUN	NN	9	O
containing	contain	VERB	VBG	0	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
maleate	maleate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NNS	0	O
of	of	ADP	IN	5	O
hydrochlorothiazide	hydrochlorothiazide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
administered	administer	VERB	VBD	9	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
one	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
to	to	ADP	IN	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
037	037	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
by	by	ADP	IN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
455	455	NUM	CD	7	O
participating	participate	VERB	VBG	5	O
physicians	physician	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
decreased	decrease	VERB	VBD	9	O
25	25	NUM	CD	9	O
mmHg	mmhg	SYM	SYM	7	O
and	and	CCONJ	CC	5	O
mean	mean	VERB	VB	5	O
diastolic	diastolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
declined	decline	VERB	VBD	9	O
15	15	NUM	CD	9	O
mmHg	mmHg	NOUN	NNS	7	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
of	of	ADP	IN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
hydrochlorothiazide	hydrochlorothiazide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
comparisons	comparison	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Age	age	NOUN	NN	7	O
,	,	PUNCT	,	9	O
race	race	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sex	sex	NOUN	NN	5	O
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
no	no	DET	DT	9	O
influence	influence	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
more	more	ADJ	JJR	5	O
severe	severe	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
453	453	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
658	658	NUM	CD	7	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
being	be	VERB	VBG	5	O
fatigue	fatigue	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
dizziness	dizziness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
weakness	weakness	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
590	590	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Salicylate	salicylate	ADJ	JJ	0	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Gunn	Gunn	PROPN	NNP	6	O
rat	rat	NOUN	NN	3	O
:	:	PUNCT	:	9	O
potential	potential	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
prostaglandins	prostaglandin	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
prostaglandins	prostaglandin	NOUN	NNS	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
analgesic	analgesic	ADJ	JJ	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Gunn	Gunn	PROPN	NNP	6	O
strain	strain	NOUN	NN	1	O
of	of	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
homozygous	homozygous	ADJ	JJ	1	O
Gunn	Gunn	PROPN	NNP	6	O
rats	rat	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
unconjugated	unconjugate	VERB	VBN	3	O
hyperbilirubinemia	hyperbilirubinemia	NOUN	NN	5	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
glucuronyl	glucuronyl	ADJ	JJ	1	B-Chemical
transferase	transferase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
marked	mark	VERB	VBN	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
deposition	deposition	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
papilla	papilla	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
highly	highly	ADV	RB	9	O
susceptible	susceptible	ADJ	JJ	9	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
papillary	papillary	ADJ	JJ	5	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
analgesic	analgesic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
homozygous	homozygous	ADJ	JJ	1	O
(	(	PUNCT	-LRB-	9	O
jj	jj	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
phenotypically	phenotypically	ADV	RB	9	O
normal	normal	ADJ	JJ	9	O
heterozygous	heterozygous	ADJ	JJ	1	O
(	(	PUNCT	-LRB-	9	O
jJ	jj	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
:	:	PUNCT	:	9	O
jj	jj	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
jJ	jj	NOUN	NN	7	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
either	either	CCONJ	CC	9	O
with	with	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
every	every	DET	DT	5	O
other	other	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
sham	sham	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
one	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
slices	slice	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
outer	outer	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
inner	inner	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
from	from	ADP	IN	9	O
one	one	NUM	CD	5	O
kidney	kidney	NOUN	NN	9	O
were	be	VERB	VBD	9	O
incubated	incubate	VERB	VBN	0	O
in	in	ADP	IN	5	O
buffer	buffer	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
radioimmunoassay	radioimmunoassay	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
kidney	kidney	NOUN	NN	9	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
histologically	histologically	ADV	RB	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
marked	marked	ADJ	JJ	9	O
corticomedullary	corticomedullary	ADJ	JJ	3	O
gradient	gradient	NOUN	NN	9	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

PGE2	PGE2	PROPN	NNP	3	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
outer	outer	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
cortex	cortex	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
inner	inner	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
jj	jj	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
38	38	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
prot	prot	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
jJ	jj	NOUN	NN	7	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Aspirin	aspirin	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
reduced	reduce	VERB	VBD	9	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
regions	region	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
outer	outer	ADJ	JJ	9	O
medullary	medullary	ADJ	JJ	5	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
remained	remain	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
jj	jj	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
18	18	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
jJ	jj	NOUN	NN	7	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

PGF2	PGF2	PROPN	NNP	0	B-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
outer	outer	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
of	of	ADP	IN	5	O
jj	jj	NOUN	NN	3	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
aspirin	aspirin	ADJ	JJ	9	B-Chemical
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
were	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
aspirin	aspirin	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
jj	jj	NOUN	NN	3	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
jJ	jj	NOUN	NN	7	O
rats	rat	NOUN	NNS	9	O
as	as	ADP	IN	5	O
evidenced	evidence	VERB	VBN	9	O
by	by	ADP	IN	9	O
:	:	PUNCT	:	9	O
increased	increase	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
hematuria	hematuria	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
increase	increase	VERB	VB	9	O
in	in	ADP	IN	5	O
outer	outer	ADJ	JJ	9	O
medullary	medullary	ADJ	JJ	5	O
histopathologic	histopathologic	ADJ	JJ	9	O
lesions	lesion	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
either	either	CCONJ	CC	9	O
sham	sham	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
jj	jj	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
aspirin	aspirin	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
jJ	jj	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
enhanced	enhance	VERB	VBN	3	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
contributes	contribute	NOUN	NNS	9	O
to	to	ADP	IN	5	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
morphological	morphological	ADJ	JJ	9	O
integrity	integrity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
pathological	pathological	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
medullary	medullary	ADJ	JJ	5	I-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
deterioration	deterioration	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Prophylactic	prophylactic	ADJ	JJ	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
seen	see	VERB	VBN	9	O
within	within	ADP	IN	9	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
entered	enter	VERB	VBD	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
randomized	randomize	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
vs	vs	ADP	IN	7	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
1	1	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
sustained	sustain	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
204	204	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lidocaine	Lidocaine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
intramuscularly	intramuscularly	ADV	RB	0	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
intravenously	intravenously	ADV	RB	0	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
sustained	sustain	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
warning	warning	NOUN	NN	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
between	between	ADP	IN	5	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
45	45	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
10	10	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
a	a	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
infarction	infarction	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
lidocaine	lidocaine	ADJ	JJR	0	B-Chemical
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocking	block	VERB	VBG	3	O
agents	agent	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
no	no	ADV	RB	9	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
that	that	DET	DT	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
not	not	ADV	RB	5	O
on	on	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
blocking	block	VERB	VBG	3	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
study	study	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
nine	nine	NUM	CD	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
from	from	ADP	IN	9	O
asystole	asystole	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
had	have	VERB	VBD	9	O
had	have	VERB	VBN	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
cannot	cannot	VERB	VBP	5	O
advocate	advocate	VERB	VBP	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
prophylactically	prophylactically	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
hours	hour	NOUN	NNS	9	O
of	of	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
cholinergic	cholinergic	ADJ	JJ	3	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Experiments	experiment	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
tested	test	VERB	VBD	9	O
previous	previous	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
that	that	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
cholinergic	cholinergic	NOUN	NN	3	O
systems	system	NOUN	NNS	5	O
promotes	promote	NOUN	NNS	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
cholinergic	cholinergic	NOUN	NN	3	O
mechanisms	mechanism	NOUN	NNS	9	O
need	need	VERB	VBP	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
intact	intact	ADJ	JJ	9	O
for	for	ADP	IN	5	O
full	full	ADJ	JJ	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Large	large	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cholinomimetic	cholinomimetic	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
could	could	VERB	MD	9	O
induce	induce	VERB	VB	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
when	when	ADV	WRB	5	O
peripheral	peripheral	ADJ	JJ	9	O
cholinergic	cholinergic	NOUN	NN	3	O
receptors	receptor	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
blocked	block	VERB	VBN	3	O
.	.	PUNCT	.	9	O

Low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
pronounced	pronounced	ADJ	JJ	9	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
blocker	blocker	NOUN	NN	0	O
,	,	PUNCT	,	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
muscarinic	muscarinic	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
blocker	blocker	NOUN	NN	0	O
,	,	PUNCT	,	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
disrupted	disrupt	VERB	VBD	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Intracranial	intracranial	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
synthesis	synthesis	NOUN	NN	9	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
hemicholinium	hemicholinium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
usually	usually	ADV	RB	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
neuroleptics	neuroleptic	NOUN	NNS	5	B-Chemical
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
actually	actually	ADV	RB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
intrinsic	intrinsic	ADJ	JJ	9	O
central	central	ADJ	JJ	5	O
cholinergic	cholinergic	NOUN	NN	3	O
systems	system	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Alternatively	alternatively	ADV	RB	9	O
,	,	PUNCT	,	9	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
cholinergic	cholinergic	NOUN	NN	3	O
systems	system	NOUN	NNS	5	O
could	could	VERB	MD	9	O
promote	promote	VERB	VB	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
systems	system	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cardiovascular	cardiovascular	ADJ	JJ	2	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
to	to	PART	TO	5	O
sodium	sodium	VERB	VB	0	B-Chemical
pentobarbital	pentobarbital	NOUN	NN	0	I-Chemical
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
barium	barium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
ingestion	ingestion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Barium	barium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
supplemented	supplement	VERB	VBN	0	O
Long	Long	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Evans	Evans	PROPN	NNP	6	O
hooded	hood	VERB	VBN	4	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
persistent	persistent	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
evident	evident	ADJ	JJ	9	O
after	after	ADP	IN	9	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
of	of	ADP	IN	5	O
barium	barium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
mineral	mineral	NOUN	NN	0	O
fortified	fortify	VERB	VBD	5	O
water	water	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
myocardial	myocardial	ADJ	JJ	9	O
excitability	excitability	NOUN	NN	5	O
,	,	PUNCT	,	9	O
contractility	contractility	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
metabolic	metabolic	ADJ	JJ	9	O
characteristics	characteristic	NOUN	NNS	5	O
at	at	ADP	IN	9	O
16	16	NUM	CD	9	O
months	month	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
other	other	ADJ	JJ	5	O
significant	significant	ADJ	JJ	9	O
barium	barium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
disturbances	disturbance	NOUN	NNS	5	B-Disease
within	within	ADP	IN	9	I-Disease
the	the	DET	DT	5	I-Disease
cardiovascular	cardiovascular	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
distinctive	distinctive	ADJ	JJ	9	O
aspect	aspect	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
barium	barium	NOUN	NN	0	B-Chemical
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
demonstrated	demonstrated	ADJ	JJ	9	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
to	to	PART	TO	5	O
sodium	sodium	VERB	VB	0	B-Chemical
pentobarbital	pentobarbital	ADJ	JJ	0	I-Chemical
.	.	PUNCT	.	9	O

Under	under	ADP	IN	9	O
barbiturate	barbiturate	NOUN	NN	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
virtually	virtually	ADV	RB	9	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	O
contractile	contractile	NOUN	NN	9	O
indices	index	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
depressed	depress	VERB	VBN	5	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
barium	barium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
corresponding	correspond	VERB	VBG	9	O
control	control	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
fed	feed	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
xylazine	xylazine	NOUN	NN	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
pentobarbital	pentobarbital	ADJ	JJ	0	I-Chemical
in	in	ADP	IN	5	O
barium	barium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
linked	link	VERB	VBN	9	O
specifically	specifically	ADV	RB	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
anesthetic	anesthetic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
representative	representative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
generalized	generalized	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	O
pathophysiologic	pathophysiologic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
metabolic	metabolic	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
barium	barium	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
manifest	manifest	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
irrespective	irrespective	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
employed	employed	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
contractile	contractile	ADJ	JJ	9	O
element	element	NOUN	NN	9	O
shortening	shorten	VERB	VBG	9	O
velocity	velocity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
fibers	fiber	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
slower	slow	ADJ	JJR	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
barium	barium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
irrespective	irrespective	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
significant	significant	ADJ	JJ	9	O
disturbances	disturbance	NOUN	NNS	5	O
in	in	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
energy	energy	NOUN	NN	5	O
metabolism	metabolism	NOUN	NN	9	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
barium	barium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
reduced	reduced	ADJ	JJ	9	O
contractile	contractile	NOUN	NN	9	O
element	element	NOUN	NN	9	O
shortening	shorten	VERB	VBG	9	O
velocity	velocity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
excitability	excitability	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
conduction	conduction	NOUN	NN	5	O
system	system	NOUN	NN	5	O
was	be	VERB	VBD	9	O
depressed	depress	VERB	VBN	5	O
preferentially	preferentially	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
atrioventricular	atrioventricular	ADJ	JJ	5	O
nodal	nodal	ADJ	JJ	5	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
hearts	heart	NOUN	NNS	3	O
from	from	ADP	IN	9	O
barium	barium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
altered	altered	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
contractility	contractility	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
excitability	excitability	NOUN	NN	5	O
characteristics	characteristic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	O
metabolic	metabolic	NOUN	NN	9	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
to	to	PART	TO	5	O
sodium	sodium	VERB	VB	0	B-Chemical
pentobarbital	pentobarbital	ADJ	JJ	0	I-Chemical
suggest	suggest	VERB	VBP	9	O
the	the	DET	DT	5	O
existence	existence	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
heretofore	heretofore	ADV	RB	5	O
undescribed	undescribed	ADJ	JJ	4	O
cardiomyopathic	cardiomyopathic	ADJ	JJ	3	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
barium	barium	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
represent	represent	VERB	VBP	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
indication	indication	NOUN	NN	5	O
that	that	ADP	IN	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
long	long	ADJ	JJ	5	O
barium	barium	NOUN	NN	0	B-Chemical
ingestion	ingestion	NOUN	NN	9	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
significant	significant	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
mammalian	mammalian	ADJ	JJ	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Propranolol	propranolol	ADJ	JJ	0	B-Chemical
antagonism	antagonism	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenylpropanolamine	phenylpropanolamine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Phenylpropanolamine	Phenylpropanolamine	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
PPA	PPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
overdose	overdose	NOUN	NN	0	B-Disease
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
severe	severe	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
either	either	CCONJ	CC	9	O
by	by	ADP	IN	9	O
mouth	mouth	NOUN	NN	5	O
for	for	ADP	IN	5	O
48	48	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
before	before	ADP	IN	9	O
PPA	PPA	PROPN	NNP	9	B-Chemical
or	or	CCONJ	CC	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
after	after	ADP	IN	9	O
PPA	PPA	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

PPA	PPA	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
31	31	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
14	14	NUM	CD	7	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
systolic	systolic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
diastolic	diastolic	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
antagonized	antagonize	VERB	VBD	3	O
this	this	DET	DT	5	O
increase	increase	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
systolic	systolic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
diastolic	diastolic	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
PPA	PPA	PROPN	NNP	9	B-Chemical
also	also	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Left	leave	VERB	VBN	9	O
ventricular	ventricular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
stroke	stroke	NOUN	NN	5	B-Disease
volume	volume	NOUN	NN	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
62	62	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
to	to	PART	TO	5	O
80	80	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
22	22	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
64	64	NUM	CD	7	O
%	%	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
L	l	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
reversed	reverse	VERB	VBD	9	O
these	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
PPA	PPA	PROPN	NNP	9	B-Chemical
28	28	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
1710	1710	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
200	200	NUM	CD	0	O
to	to	ADP	IN	5	O
2190	2190	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
700	700	NUM	CD	9	O
dyne	dyne	ADJ	JJ	0	O
X	x	NOUN	NN	9	O
sec	sec	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
cm5	cm5	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
further	further	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
to	to	ADP	IN	5	O
2660	2660	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1200	1200	NUM	CD	0	O
dyne	dyne	ADJ	JJ	0	O
X	x	NOUN	NN	9	O
sec	sec	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
cm5	cm5	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
increases	increase	VERB	VBZ	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
by	by	ADP	IN	9	O
increasing	increase	VERB	VBG	9	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
antagonizes	antagonize	VERB	VBZ	3	O
this	this	DET	DT	5	O
increase	increase	NOUN	NN	9	O
by	by	ADP	IN	9	O
reversing	reverse	VERB	VBG	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
on	on	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
.	.	PUNCT	.	9	O

That	that	DET	DT	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
antagonizes	antagonize	VERB	VBZ	3	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
in	in	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
enhances	enhance	VERB	VBZ	3	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
probably	probably	ADV	RB	9	O
because	because	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
has	have	VERB	VBZ	9	O
less	less	ADJ	JJR	5	O
beta	beta	ADJ	JJ	9	O
2	2	NUM	CD	9	O
activity	activity	NOUN	NN	9	O
than	than	ADP	IN	5	O
does	do	VERB	VBZ	9	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Mesangial	mesangial	ADJ	JJ	3	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
aminonucleoside	aminonucleoside	ADJ	JJ	0	B-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
mesangial	mesangial	ADJ	JJ	3	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
male	male	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
repeated	repeat	VERB	VBN	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
injections	injection	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
five	five	NUM	CD	9	O
controls	control	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
saline	saline	NOUN	NN	0	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
the	the	DET	DT	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
severely	severely	ADV	RB	9	O
proteinuric	proteinuric	ADJ	JJ	9	B-Disease
(	(	PUNCT	-LRB-	9	O
190	190	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
24	24	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
colloidal	colloidal	ADJ	JJ	0	O
carbon	carbon	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CC	cc	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
intravenously	intravenously	ADV	RB	0	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
5	5	NUM	CD	9	O
months	month	NOUN	NNS	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glomeruli	glomeruli	NOUN	NN	9	O
of	of	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
rats	rat	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
glomeruli	glomerulus	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
controls	control	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Glomeruli	Glomeruli	PROPN	NNP	3	O
of	of	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
rats	rat	NOUN	NNS	9	O
contained	contain	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADJ	JJR	5	O
CC	cc	NOUN	NN	9	O
than	than	ADP	IN	5	O
glomeruli	glomerulus	NOUN	NNS	9	O
of	of	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Glomeruli	Glomeruli	PROPN	NNP	3	O
with	with	ADP	IN	5	O
sclerosis	sclerosis	NOUN	NN	5	B-Disease
contained	contain	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADJ	JJR	5	O
CC	cc	NOUN	NN	9	O
than	than	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
sclerotic	sclerotic	ADJ	JJ	5	O
glomeruli	glomerulus	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
kidneys	kidney	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CC	CC	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
preferentially	preferentially	ADV	RB	9	O
localized	localize	VERB	VBN	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
sclerotic	sclerotic	ADJ	JJ	5	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
affected	affect	VERB	VBN	9	O
glomeruli	glomeruli	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
mesangial	mesangial	ADJ	JJ	3	O
CC	cc	NOUN	NN	9	O
clearance	clearance	NOUN	NN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
mesangium	mesangium	NOUN	NN	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
during	during	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
preferential	preferential	ADJ	JJ	9	O
CC	cc	NOUN	NN	9	O
localization	localization	NOUN	NN	3	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
lesions	lesion	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
CC	cc	NOUN	NN	9	O
uptake	uptake	NOUN	NN	0	O
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
in	in	ADP	IN	5	O
apparent	apparent	ADJ	JJ	9	O
vulnerable	vulnerable	ADJ	JJ	5	O
areas	area	NOUN	NNS	5	O
where	where	ADV	WRB	5	O
sclerosis	sclerosis	NOUN	NN	5	B-Disease
will	will	VERB	MD	5	O
develop	develop	VERB	VB	5	O
subsequently	subsequently	ADV	RB	9	O
.	.	PUNCT	.	9	O

Cluster	cluster	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
random	random	ADJ	JJ	5	O
distribution	distribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
lesions	lesion	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
glomeruli	glomeruli	NOUN	NN	9	O
in	in	ADP	IN	5	O
concordance	concordance	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
random	random	ADJ	JJ	5	O
localization	localization	NOUN	NN	3	O
of	of	ADP	IN	5	O
mesangial	mesangial	ADJ	JJ	3	O
areas	area	NOUN	NNS	5	O
with	with	ADP	IN	5	O
dysfunction	dysfunction	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
remnant	remnant	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	O
model	model	NOUN	NN	5	O
in	in	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
"	"	PUNCT	``	5	O
mesangial	mesangial	ADJ	JJ	3	O
overloading	overloading	NOUN	NN	5	O
.	.	PUNCT	.	9	O
"	"	PUNCT	''	5	O

Relationship	relationship	NOUN	NN	9	O
between	between	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
nicotinic	nicotinic	ADJ	JJ	0	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
controversy	controversy	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
existed	exist	VERB	VBN	9	O
for	for	ADP	IN	5	O
several	several	ADJ	JJ	9	O
years	year	NOUN	NNS	5	O
concerning	concern	VERB	VBG	5	O
the	the	DET	DT	5	O
physiological	physiological	ADJ	JJ	9	O
relevance	relevance	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nicotinic	nicotinic	ADJ	JJ	0	O
receptor	receptor	NOUN	NN	3	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
bungarotoxin	bungarotoxin	NOUN	NN	0	O
binding	binding	NOUN	NN	1	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
mice	mouse	NOUN	NNS	3	O
derived	derive	VERB	VBN	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
classical	classical	ADJ	JJ	9	O
F2	F2	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
backcross	backcross	ADJ	JJ	9	O
genetic	genetic	ADJ	JJ	5	O
design	design	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
bungarotoxin	bungarotoxin	NOUN	NN	0	O
nicotinic	nicotinic	ADJ	JJ	0	O
receptor	receptor	NOUN	NN	3	O
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Mice	mouse	NOUN	NNS	3	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
convulsant	convulsant	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
bungarotoxin	bungarotoxin	NOUN	NN	0	O
binding	bind	VERB	VBG	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
than	than	ADP	IN	5	O
seizure	seizure	VERB	VB	5	B-Disease
insensitive	insensitive	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
binding	bind	VERB	VBG	1	O
sites	site	NOUN	NNS	9	O
from	from	ADP	IN	9	O
seizure	seizure	NOUN	NN	5	B-Disease
sensitive	sensitive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
resistant	resistant	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
equally	equally	ADV	RB	9	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
dithiothreitol	dithiothreitol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
trypsin	trypsin	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
heat	heat	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
it	-PRON-	PRON	PRP	5	O
appears	appear	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
sensitive	sensitive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
insensitive	insensitive	ADJ	JJ	9	O
animals	animal	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
nicotinic	nicotinic	ADJ	JJ	0	O
receptor	receptor	NOUN	NN	3	O
concentration	concentration	NOUN	NN	0	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
with	with	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
bungarotoxin	bungarotoxin	NOUN	NN	0	O
binding	binding	NOUN	NN	1	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
p	p	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminophenol	aminophenol	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
bis	bis	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	:	7	I-Chemical
nitrophenyl	nitrophenyl	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
phosphate	phosphate	VERB	VBP	0	I-Chemical
on	on	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
p	p	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminophenol	aminophenol	NOUN	NN	0	I-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
metabolism	metabolism	NOUN	NN	9	O
in	in	ADP	IN	5	O
Fischer	Fischer	PROPN	NNP	6	O
344	344	NUM	CD	7	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Acetaminophen	Acetaminophen	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
APAP	APAP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
produces	produce	VERB	VBZ	9	O
proximal	proximal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
Fischer	Fischer	PROPN	NNP	6	O
344	344	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
F344	f344	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminophenol	aminophenol	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAP	PAP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
known	know	VERB	VBN	9	O
potent	potent	ADJ	JJ	3	O
nephrotoxicant	nephrotoxicant	NOUN	NN	0	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
metabolite	metabolite	NOUN	NN	0	O
of	of	ADP	IN	5	O
APAP	APAP	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
F344	f344	NOUN	NN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
PAP	PAP	PROPN	NNP	9	B-Chemical
formation	formation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
requisite	requisite	ADJ	JJ	5	O
step	step	NOUN	NN	9	O
in	in	ADP	IN	5	O
APAP	APAP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
bis	bis	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	:	7	I-Chemical
nitrophenyl	nitrophenyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
phosphate	phosphate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BNPP	BNPP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
acylamidase	acylamidase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
APAP	APAP	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
PAP	PAP	PROPN	NNP	9	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
metabolism	metabolism	NOUN	NN	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

BNPP	BNPP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
mM	mM	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
reduced	reduce	VERB	VBD	9	O
APAP	APAP	PROPN	NNP	0	B-Chemical
deacetylation	deacetylation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
covalent	covalent	NOUN	NN	0	O
binding	binding	NOUN	NN	1	O
in	in	ADP	IN	5	O
F344	f344	NOUN	NN	3	O
renal	renal	ADJ	JJ	9	O
cortical	cortical	ADJ	JJ	5	O
homogenates	homogenate	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
with	with	ADP	IN	5	O
BNPP	BNPP	PROPN	NNP	0	B-Chemical
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
APAP	APAP	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
PAP	PAP	PROPN	NNP	9	B-Chemical
administration	administration	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
marked	marked	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
APAP	APAP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
900	900	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
PAP	PAP	PROPN	NNP	9	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
result	result	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
altered	alter	VERB	VBN	9	O
disposition	disposition	NOUN	NN	5	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
APAP	APAP	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
acetylated	acetylate	VERB	VBD	0	O
metabolites	metabolite	NOUN	NNS	0	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
cortical	cortical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
hepatic	hepatic	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Rather	rather	ADV	RB	5	O
,	,	PUNCT	,	9	O
BNPP	BNPP	PROPN	NNP	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
fraction	fraction	NOUN	NN	9	O
of	of	ADP	IN	5	O
APAP	APAP	PROPN	NNP	0	B-Chemical
excreted	excrete	VERB	VBN	0	O
as	as	ADP	IN	5	O
PAP	PAP	PROPN	NNP	9	B-Chemical
by	by	ADP	IN	9	O
64	64	NUM	CD	7	O
and	and	CCONJ	CC	5	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
after	after	ADP	IN	9	O
APAP	APAP	PROPN	NNP	0	B-Chemical
doses	dose	VERB	VBZ	0	O
of	of	ADP	IN	5	O
750	750	NUM	CD	0	O
and	and	CCONJ	CC	5	O
900	900	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

BNPP	BNPP	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
alter	alter	VERB	VB	9	O
the	the	DET	DT	5	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
APAP	APAP	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
deacetylated	deacetylated	ADJ	JJ	0	O
metabolites	metabolite	NOUN	NNS	0	O
nor	nor	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
BNPP	BNPP	PROPN	NNP	0	B-Chemical
alter	alter	NOUN	NN	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
PAP	PAP	PROPN	NNP	9	B-Chemical
or	or	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
metabolites	metabolite	NOUN	NNS	0	O
after	after	ADP	IN	9	O
PAP	PAP	PROPN	NNP	9	B-Chemical
doses	dose	VERB	VBZ	0	O
of	of	ADP	IN	5	O
150	150	NUM	CD	0	O
and	and	CCONJ	CC	5	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
BNPP	BNPP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
APAP	APAP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
APAP	APAP	PROPN	NNP	0	B-Chemical
deacetylation	deacetylation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
PAP	PAP	PROPN	NNP	9	B-Chemical
formation	formation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
accounts	account	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
APAP	APAP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
newborn	newborn	ADJ	JJ	9	O
infants	infant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
neonates	neonate	NOUN	NNS	9	O
suffered	suffer	VERB	VBD	5	O
from	from	ADP	IN	9	O
generalized	generalized	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
morphine	morphine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
for	for	ADP	IN	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
analgesia	analgesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
received	receive	VERB	VBD	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
32	32	NUM	CD	7	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
hr	hr	INTJ	UH	0	O
and	and	CCONJ	CC	5	O
40	40	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
hr	hr	INTJ	UH	0	O
larger	large	ADJ	JJR	5	O
than	than	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
neonates	neonate	NOUN	NNS	9	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
24	24	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
hr	hr	INTJ	UH	0	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
neonates	neonate	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
excessive	excessive	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
and	and	CCONJ	CC	5	O
90	90	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
known	know	VERB	VBN	9	O
reasons	reason	NOUN	NNS	5	O
for	for	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
ruled	rule	VERB	VBN	9	O
out	out	PART	RP	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
stopped	stop	VERB	VBD	9	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reoccur	reoccur	VERB	VB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
subsequent	subsequent	ADJ	JJ	9	O
8	8	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
morphine	morphine	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
exceed	exceed	VERB	VB	5	O
20	20	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
in	in	ADP	IN	5	O
neonates	neonate	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Indomethacin	indomethacin	ADV	RB	0	B-Chemical
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
volume	volume	NOUN	NN	9	O
depleted	deplete	VERB	VBD	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
indomethacin	indomethacin	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
IDM	IDM	PROPN	NNP	1	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
volume	volume	NOUN	NN	9	O
depleted	deplete	VERB	VBD	3	O
rats	rat	NOUN	NNS	9	O
plasma	plasma	NOUN	NN	9	O
renin	renin	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PRA	PRA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
fell	fall	VERB	VBD	5	O
significantly	significantly	ADV	RB	9	O
within	within	ADP	IN	9	O
four	four	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
repleted	replete	VERB	VBD	3	O
animals	animal	NOUN	NNS	9	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BP	BP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
although	although	ADP	IN	9	O
plasma	plasma	NOUN	NN	9	O
renin	renin	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
indomethacin	indomethacin	VERB	VBN	0	B-Chemical
by	by	ADP	IN	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
may	may	VERB	MD	5	O
diminish	diminish	VERB	VB	9	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
maintaining	maintain	VERB	VBG	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
stimulated	stimulate	VERB	VBN	3	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
volume	volume	NOUN	NN	9	O
depletion	depletion	NOUN	NN	3	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
one	one	NUM	CD	5	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
substituted	substitute	VERB	VBN	0	O
piperazine	piperazine	NOUN	NN	0	B-Chemical
derivative	derivative	NOUN	NN	0	O
of	of	ADP	IN	5	O
trans	trans	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
amino	amino	NOUN	NN	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxy	hydroxy	NUM	CD	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrahydroanaphthalene	tetrahydroanaphthalene	NOUN	NN	_	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
compound	compound	NOUN	NN	0	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
trans	trans	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxy	hydroxy	NUM	CD	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrahydro	tetrahydro	NUM	CD	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
naphthyl	naphthyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
oxo	oxo	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phenyl	phenyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylpropyl	methylpropyl	NOUN	NNS	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
piperazine	piperazine	NOUN	NN	0	I-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
referred	refer	VERB	VBD	5	O
to	to	ADP	IN	5	O
as	as	ADP	IN	5	O
P11	P11	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
studied	study	VERB	VBN	9	O
on	on	ADP	IN	5	O
anaesthesized	anaesthesized	ADJ	JJ	0	O
cats	cat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
Wistar	wistar	ADJ	JJ	9	O
albino	albino	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
on	on	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
anaesthesized	anaesthesized	ADJ	JJ	0	O
rabbits	rabbit	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
used	use	VERB	VBN	5	O
-	-	PUNCT	:	7	O
-	-	PUNCT	HYPH	7	O
with	with	ADP	IN	5	O
BaCl2	BaCl2	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
chloroform	chloroform	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
strophantine	strophantine	ADJ	JJ	_	B-Chemical
G	g	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
compound	compound	NOUN	NN	0	O
P11	P11	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
introduced	introduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADV	RB	0	O
intravenously	intravenously	ADV	RB	0	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADV	RB	0	O
orally	orally	ADV	RB	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
compound	compound	NOUN	NN	0	O
manifests	manifest	NOUN	NNS	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
used	use	VERB	VBD	5	O
,	,	PUNCT	,	9	O
causing	cause	VERB	VBG	9	O
greatest	great	ADJ	JJS	9	O
inhibition	inhibition	NOUN	NN	3	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
chloroform	chloroform	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
in	in	ADP	IN	5	O
90	90	NUM	CD	9	O
per	per	NOUN	NN	9	O
cent	cent	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
BaCl2	BaCl2	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
in	in	ADP	IN	5	O
84	84	NUM	CD	7	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
obtained	obtain	VERB	VBN	9	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoblocking	adrenoblocke	VERB	VBG	_	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
membrane	membrane	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
stabilizing	stabilize	VERB	VBG	9	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
compound	compound	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Recurrent	recurrent	ADJ	JJ	5	O
subarachnoid	subarachnoid	NOUN	NN	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
aminocaproic	aminocaproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
artery	artery	NOUN	NN	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Epsilon	epsilon	NOUN	NN	9	B-Chemical
aminocaproic	aminocaproic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
EACA	EACA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
rebleeding	rebleede	VERB	VBG	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
subarachnoid	subarachnoid	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SAH	SAH	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
this	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
does	do	VERB	VBZ	9	O
decrease	decrease	VERB	VB	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
rebleeding	rebleeding	NOUN	NN	5	O
,	,	PUNCT	,	9	O
several	several	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
EACA	EACA	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
complications	complication	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
included	include	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
deterioration	deterioration	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intracranial	intracranial	ADJ	JJ	5	B-Disease
vascular	vascular	ADJ	JJ	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
SAH	SAH	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
arteriolar	arteriolar	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
capillary	capillary	ADJ	JJ	0	O
fibrin	fibrin	NOUN	NN	0	O
thrombi	thrombi	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
fibrinolytic	fibrinolytic	ADJ	JJ	5	O
syndromes	syndrome	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
EACA	EACA	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
phenomena	phenomenon	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
intravascular	intravascular	ADJ	JJ	5	O
fibrin	fibrin	NOUN	NN	0	O
thrombi	thrombi	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
often	often	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
fibrinolytic	fibrinolytic	ADJ	JJ	5	O
disorders	disorder	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
EACA	EACA	PROPN	NNP	0	B-Chemical
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
fibrin	fibrin	ADJ	JJ	0	O
thrombi	thrombi	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
disseminated	disseminate	VERB	VBN	5	B-Disease
intravascular	intravascular	ADJ	JJ	5	I-Disease
coagulation	coagulation	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
"	"	PUNCT	``	5	O
consumption	consumption	NOUN	NN	5	B-Disease
coagulopathies	coagulopathie	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O
"	"	PUNCT	''	5	O
This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
subtotal	subtotal	ADJ	JJ	5	O
infarction	infarction	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
a	a	DET	DT	5	I-Disease
normal	normal	ADJ	JJ	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
artery	artery	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
occlusion	occlusion	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
EACA	EACA	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
SAH	SAH	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
histopathological	histopathological	ADJ	JJ	9	O
documentation	documentation	NOUN	NN	5	O
of	of	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
SAH	SAH	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
corresponding	corresponding	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
marked	marked	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
abrupt	abrupt	ADJ	JJ	5	O
neurological	neurological	ADJ	JJ	5	O
deterioration	deterioration	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
Pseudomonas	Pseudomonas	PROPN	NNP	4	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
monkeys	monkey	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rhesus	rhesus	ADJ	JJ	9	O
monkeys	monkey	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
intravenous	intravenous	ADJ	JJ	0	O
challenge	challenge	NOUN	NN	9	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
Pseudomonas	Pseudomonas	PROPN	NNP	4	O
aeruginosa	aeruginosa	NOUN	NN	4	O
organisms	organism	NOUN	NNS	9	O
caused	cause	VERB	VBD	9	O
acute	acute	ADJ	JJ	9	O
illness	illness	NOUN	NN	5	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
'	'	PART	POS	9	O
duration	duration	NOUN	NN	5	O
with	with	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
in	in	ADP	IN	5	O
13	13	NUM	CD	7	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
monkeys	monkey	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
blood	blood	NOUN	NN	9	O
cultures	culture	NOUN	NNS	3	O
became	become	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
3	3	NUM	CD	9	O
to	to	PART	TO	5	O
17	17	NUM	CD	7	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
challenge	challenge	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Leukocytosis	leukocytosis	NOUN	NN	7	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
monkeys	monkey	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
or	or	CCONJ	CC	5	O
intratracheal	intratracheal	ADJ	JJ	3	O
inoculation	inoculation	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
leukopenia	leukopenia	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
4	4	NUM	CD	9	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
inoculation	inoculation	NOUN	NN	9	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
pyocin	pyocin	NOUN	NN	1	O
type	type	NOUN	NN	9	O
6	6	NUM	CD	9	O
Pseudomonas	Pseudomonas	PROPN	NNP	4	O
organisms	organism	NOUN	NNS	9	O
in	in	ADP	IN	5	O
monkeys	monkey	NOUN	NNS	5	O
given	give	VERB	VBN	5	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
previously	previously	ADV	RB	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
infection	infection	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
of	of	ADP	IN	5	O
14	14	NUM	CD	7	O
monkeys	monkey	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
receiving	receive	VERB	VBG	9	O
Pseudomonas	Pseudomonas	PROPN	NNP	4	O
alone	alone	ADV	RB	9	O
died	die	VERB	VBD	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
an	an	DET	DT	5	O
antimetabolite	antimetabolite	ADV	RB	0	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
leukopenia	leukopenia	NOUN	NN	9	B-Disease
predisposes	predispose	NOUN	NNS	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
Pseudomonas	Pseudomonas	PROPN	NNP	4	O
sepsis	sepsis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
such	such	ADJ	JJ	5	O
monkeys	monkey	NOUN	NNS	5	O
may	may	VERB	MD	5	O
serve	serve	VERB	VB	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
biological	biological	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
comparative	comparative	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
antimicrobial	antimicrobial	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Modification	modification	NOUN	NN	9	O
by	by	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
induced	induced	ADJ	JJ	3	O
hypoglycaemia	hypoglycaemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hypoglycaemia	hypoglycaemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockade	blockade	NOUN	NN	3	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
fourteen	fourteen	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
men	man	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
received	receive	VERB	VBD	9	O
insulin	insulin	NOUN	NN	3	O
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
eight	eight	NUM	CD	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
original	original	ADJ	JJ	5	O
insulin	insulin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
only	only	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
insulin	insulin	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
insulin	insulin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
group	group	NOUN	NN	9	O
the	the	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypoglycaemia	hypoglycaemia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
diastolic	diastolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
insulin	insulin	NOUN	NN	3	O
group	group	NOUN	NN	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
subjects	subject	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
diastolic	diastolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Typical	Typical	PROPN	NNP	9	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
T	T	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
T	T	PROPN	NNP	3	O
changes	change	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
insulin	insulin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
group	group	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
insulin	insulin	NOUN	NN	3	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Hypertension	hypertension	NOUN	NN	7	B-Disease
in	in	ADP	IN	5	O
diabetics	diabetic	NOUN	NNS	5	B-Disease
prone	prone	ADJ	JJ	5	O
to	to	ADP	IN	5	O
hypoglycaemia	hypoglycaemia	ADJ	JJ	5	B-Disease
attacks	attack	NOUN	NNS	5	O
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
because	because	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
a	a	DET	DT	5	O
sharp	sharp	ADJ	JJ	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
such	such	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
maternal	maternal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
fetal	fetal	ADJ	JJ	9	O
outcome	outcome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Propranolol	Propranolol	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
blocking	block	VERB	VBG	3	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
found	find	VERB	VBN	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
position	position	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
practice	practice	NOUN	NN	5	O
of	of	ADP	IN	5	O
medicine	medicine	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Its	-PRON-	DET	PRP$	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
question	question	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
detrimental	detrimental	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
fetus	fetus	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
neonate	neonate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
pregnancies	pregnancy	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
where	where	ADV	WRB	5	O
chronic	chronic	ADJ	JJ	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
serial	serial	ADJ	JJ	9	O
pregnancies	pregnancy	NOUN	NNS	5	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
examined	examine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Maternal	maternal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
fetal	fetal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
neonatal	neonatal	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
examined	examine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
attempt	attempt	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
made	make	VERB	VBN	5	O
to	to	PART	TO	5	O
differentiate	differentiate	VERB	VB	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
complications	complication	NOUN	NNS	5	O
from	from	ADP	IN	9	O
maternal	maternal	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBD	9	O
hypoglycemia	hypoglycemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hyperbilirubinemia	hyperbilirubinemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
polycythemia	polycythemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
neonatal	neonatal	ADJ	JJ	9	B-Disease
apnea	apnea	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
invariable	invariable	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
statistically	statistically	ADV	RB	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Growth	growth	NOUN	NN	9	B-Disease
retardation	retardation	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
significant	significant	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
series	series	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Central	central	ADJ	JJ	4	O
excitatory	excitatory	ADJ	JJ	5	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
flurazepam	flurazepam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Toxic	toxic	ADJ	JJ	0	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
flurazepam	flurazepam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
FZP	FZP	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
cats	cat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
mice	mouse	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
caused	cause	VERB	VBD	9	O
an	an	DET	DT	5	O
apparent	apparent	ADJ	JJ	9	O
central	central	ADJ	JJ	5	O
excitation	excitation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
most	most	ADV	RBS	9	O
clearly	clearly	ADV	RB	9	O
seen	see	VERB	VBN	9	O
as	as	ADP	IN	5	O
clonic	clonic	ADJ	JJ	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
superimposed	superimpose	VERB	VBN	5	O
on	on	ADP	IN	5	O
general	general	ADJ	JJ	5	O
depression	depression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
lethal	lethal	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
death	death	NOUN	NN	9	O
was	be	VERB	VBD	9	O
always	always	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Comparing	compare	VERB	VBG	9	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
central	central	ADJ	JJ	5	O
depression	depression	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
excitation	excitation	NOUN	NN	0	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
least	least	ADV	RBS	9	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
that	that	DET	WDT	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
first	first	ADV	RB	9	O
cause	cause	VERB	VB	5	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
consciousness	consciousness	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
cats	cat	NOUN	NNS	9	O
most	most	ADV	RBS	9	O
clearly	clearly	ADV	RB	9	O
showed	show	VERB	VBD	9	O
marked	mark	VERB	VBN	9	O
central	central	ADJ	JJ	5	O
excitatory	excitatory	ADJ	JJ	5	O
actions	action	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
FZP	FZP	PROPN	NNP	5	B-Chemical
toxocity	toxocity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
cats	cat	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
excessive	excessive	ADJ	JJ	5	O
salivation	salivation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
extreme	extreme	ADJ	JJ	5	O
apprehensive	apprehensive	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
retching	retching	NOUN	NN	5	O
,	,	PUNCT	,	9	O
muscle	muscle	NOUN	NN	9	B-Disease
tremors	tremor	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
FZP	FZP	PROPN	NNP	5	B-Chemical
and	and	CCONJ	CC	5	O
pentylenetetrazol	pentylenetetrazol	NOUN	NNS	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PTZ	PTZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
by	by	ADP	IN	9	O
pretreating	pretreate	VERB	VBG	3	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
FZP	FZP	PROPN	NNP	5	B-Chemical
before	before	ADP	IN	9	O
PTZ	ptz	NOUN	NN	0	B-Chemical
challenge	challenge	NOUN	NN	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
a	a	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
FZP	FZP	PROPN	NNP	5	B-Chemical
first	first	ADV	RB	9	O
protected	protect	VERB	VBD	9	O
against	against	ADP	IN	9	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
again	again	ADV	RB	9	O
emerged	emerge	VERB	VBD	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
FZP	FZP	PROPN	NNP	5	B-Chemical
were	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
that	that	DET	WDT	5	O
would	would	VERB	MD	5	O
alone	alone	ADV	RB	9	O
cause	cause	VERB	VB	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
relevant	relevant	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
FZP	FZP	PROPN	NNP	5	B-Chemical
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
situations	situation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
increased	increase	VERB	VBN	9	O
neural	neural	ADJ	JJ	5	O
excitability	excitability	NOUN	NN	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
sedative	sedative	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
hypnotic	hypnotic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
orthostatic	orthostatic	ADJ	JJ	5	I-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
orthostatic	orthostatic	ADJ	JJ	5	I-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
physiologic	physiologic	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
autonomic	autonomic	ADJ	JJ	5	O
dysfunction	dysfunction	NOUN	NN	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
all	all	DET	DT	5	O
exhibited	exhibit	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
plasma	plasma	NOUN	NN	9	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
and	and	CCONJ	CC	5	O
plasma	plasma	NOUN	NN	9	O
renin	renin	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
recumbent	recumbent	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
upright	upright	ADJ	JJ	5	O
positions	position	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
marked	mark	VERB	VBN	9	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
infused	infuse	VERB	VBN	9	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
propanolol	propanolol	NOUN	NN	0	B-Chemical
administered	administer	VERB	VBD	9	O
intravenously	intravenously	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
produced	produce	VERB	VBN	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
supine	supine	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
upright	upright	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
4	4	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
individuals	individual	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rises	rise	NOUN	NNS	9	O
ranging	range	VERB	VBG	9	O
from	from	ADP	IN	9	O
11	11	NUM	CD	7	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
22	22	NUM	CD	7	O
/	/	SYM	SYM	9	O
11	11	NUM	CD	7	O
mmHg	mmHg	NOUN	NNS	7	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
-	-	SYM	SYM	7	O
160	160	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
also	also	ADV	RB	9	O
elevated	elevate	VERB	VBD	9	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
pressures	pressure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
individuals	individual	NOUN	NNS	5	O
with	with	ADP	IN	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
order	order	NOUN	NN	5	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
-	-	SYM	SYM	7	O
35	35	NUM	CD	9	O
/	/	SYM	SYM	9	O
15	15	NUM	CD	9	O
-	-	SYM	SYM	7	O
25	25	NUM	CD	9	O
mmg	mmg	NOUN	NN	7	O
being	be	VERB	VBG	5	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
marked	marked	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
had	have	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
withdrawn	withdraw	VERB	VBN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
otherwise	otherwise	ADV	RB	9	O
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
important	important	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
continued	continue	VERB	VBN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
individuals	individual	NOUN	NNS	5	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
months	month	NOUN	NNS	5	O
with	with	ADP	IN	5	O
persistence	persistence	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
there	there	ADV	EX	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
some	some	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
with	with	ADP	IN	5	O
time	time	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hemodynamic	hemodynamic	ADJ	JJ	5	O
measurements	measurement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
demonstrated	demonstrate	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
total	total	ADJ	JJ	9	O
peripheral	peripheral	ADJ	JJ	9	O
resistance	resistance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
essentially	essentially	ADV	RB	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
studies	study	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
selected	select	VERB	VBN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
orthostatic	orthostatic	ADJ	JJ	5	I-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
intravenous	intravenous	ADJ	JJ	0	O
anesthesia	anesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

III	iii	NUM	CD	9	O
.	.	PUNCT	.	9	O

Some	some	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
required	require	VERB	VBN	9	O
to	to	PART	TO	5	O
maintain	maintain	VERB	VB	5	O
sleep	sleep	NOUN	NN	5	O
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
surgery	surgery	NOUN	NN	5	O
under	under	ADP	IN	9	O
regional	regional	ADJ	JJ	5	O
local	local	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Premedication	premedication	NOUN	NN	5	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sleep	sleep	NOUN	NN	5	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
maintained	maintain	VERB	VBN	9	O
by	by	ADP	IN	9	O
intermittent	intermittent	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
whenever	whenever	ADV	WRB	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
would	would	VERB	MD	5	O
open	open	VERB	VB	5	O
his	-PRON-	DET	PRP$	5	O
eyes	eye	NOUN	NNS	5	O
on	on	ADP	IN	5	O
request	request	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
mean	mean	ADJ	JJ	5	O
overall	overall	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
microgram	microgram	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O
was	be	VERB	VBD	9	O
required	require	VERB	VBN	9	O
to	to	PART	TO	5	O
maintain	maintain	VERB	VB	5	O
sleep	sleep	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
great	great	ADJ	JJ	5	O
individual	individual	ADJ	JJ	5	O
variation	variation	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
older	old	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
requiring	require	VERB	VBG	5	O
less	less	ADJ	JJR	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
after	after	ADP	IN	9	O
18	18	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
pain	pain	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
myoclonia	myoclonia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
caused	cause	VERB	VBD	9	O
the	the	DET	DT	5	O
technique	technique	NOUN	NN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
abandoned	abandon	VERB	VBN	5	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
considered	consider	VERB	VBN	5	O
unlikely	unlikely	ADJ	JJ	9	O
that	that	ADP	IN	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
will	will	VERB	MD	5	O
prove	prove	VERB	VB	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
hypnotic	hypnotic	NOUN	NN	5	O
of	of	ADP	IN	5	O
choice	choice	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
totally	totally	ADV	RB	9	O
intravenous	intravenous	ADJ	JJ	0	O
anesthetic	anesthetic	ADJ	JJ	5	O
technique	technique	NOUN	NN	5	O
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
myoclonia	myoclonia	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
prolonged	prolonged	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
several	several	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
uncontrollable	uncontrollable	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
movements	movement	NOUN	NNS	5	O
persisted	persist	VERB	VBD	9	O
for	for	ADP	IN	5	O
many	many	ADJ	JJ	5	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
complete	complete	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
consciousness	consciousness	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptors	adrenoceptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
single	single	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
atenolol	atenolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
cardioselective	cardioselective	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
nonselective	nonselective	ADJ	JJ	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
on	on	ADP	IN	5	O
both	both	DET	DT	9	O
exercise	exercise	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
experiments	experiment	NOUN	NNS	9	O
involving	involve	VERB	VBG	5	O
nine	nine	NUM	CD	9	O
normal	normal	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Maximal	maximal	ADJ	JJ	9	O
exercise	exercise	NOUN	NN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
from	from	ADP	IN	9	O
187	187	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
SEM	SEM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
to	to	ADP	IN	5	O
146	146	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
bpm	bpm	NOUN	NN	5	O
after	after	ADP	IN	9	O
atenolol	atenolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
138	138	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
bpm	bpm	NOUN	NN	5	O
after	after	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
tachycardia	tachycardia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
IV	IV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
sensitivity	sensitivity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
intravenous	intravenous	ADJ	JJ	0	O
dose	dose	NOUN	NN	9	O
that	that	DET	WDT	5	O
increased	increase	VERB	VBD	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
by	by	ADP	IN	9	O
25	25	NUM	CD	9	O
bpm	bpm	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CD25	CD25	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
after	after	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
to	to	ADP	IN	5	O
38	38	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
after	after	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
after	after	ADP	IN	9	O
atenolol	atenolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
was	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
the	the	DET	DT	5	O
CD25	CD25	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
after	after	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
atenolol	atenolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
after	after	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
micrograms	micrograms	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
remained	remain	VERB	VBD	9	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
atenolol	atenolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
change	change	NOUN	NN	9	O
with	with	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
sensitivity	sensitivity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
apparent	apparent	ADJ	JJ	9	O
Ka	Ka	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
by	by	ADP	IN	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ng	ng	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
exercise	exercise	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
results	result	NOUN	NNS	9	O
largely	largely	ADV	RB	9	O
from	from	ADP	IN	9	O
beta	beta	ADJ	JJ	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
activation	activation	NOUN	NN	3	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
both	both	CCONJ	CC	9	O
cardioselective	cardioselective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
nonselective	nonselective	ADJ	JJ	0	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
activates	activate	VERB	VBZ	3	O
both	both	CCONJ	CC	9	O
beta	beta	NOUN	NN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
receptors	receptor	NOUN	NNS	3	O
so	so	ADP	IN	5	O
that	that	ADP	IN	5	O
after	after	ADP	IN	9	O
cardioselective	cardioselective	ADJ	JJ	5	O
blockade	blockade	NOUN	NN	3	O
there	there	ADV	EX	5	O
remains	remain	VERB	VBZ	9	O
a	a	DET	DT	5	O
beta	beta	ADJ	JJ	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
component	component	NOUN	NN	9	O
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
blocked	block	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
nonselective	nonselective	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
there	there	ADV	EX	5	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
beta	beta	ADJ	JJ	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
heart	heart	NOUN	NN	5	O
,	,	PUNCT	,	9	O
their	-PRON-	DET	PRP$	5	O
physiologic	physiologic	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
pathologic	pathologic	NOUN	NN	5	O
roles	role	NOUN	NNS	9	O
remain	remain	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
defined	define	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Hormones	hormone	NOUN	NNS	2	O
and	and	CCONJ	CC	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
reports	report	VERB	VBZ	9	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
menopausal	menopausal	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
hormonal	hormonal	ADJ	JJ	9	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
29	29	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
surgical	surgical	ADJ	JJ	5	O
menopause	menopause	NOUN	NN	5	O
;	;	PUNCT	:	9	O
their	-PRON-	DET	PRP$	5	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
was	be	VERB	VBD	9	O
45	45	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
hypothesized	hypothesize	VERB	VBN	9	O
that	that	ADP	IN	5	O
progestins	progestin	NOUN	NNS	5	B-Chemical
could	could	VERB	MD	9	O
equilibrate	equilibrate	VERB	VB	0	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
estrogenic	estrogenic	ADJ	JJ	0	O
stimulation	stimulation	NOUN	NN	3	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
mammary	mammary	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
endometrial	endometrial	ADJ	JJ	9	O
target	target	NOUN	NN	9	O
tissues	tissue	NOUN	NNS	9	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
hormonal	hormonal	ADJ	JJ	9	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
schedule	schedule	NOUN	NN	5	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
conjugated	conjugate	VERB	VBN	0	B-Chemical
estrogens	estrogen	NOUN	NNS	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
Premarin	Premarin	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
21	21	NUM	CD	7	O
days	day	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
Medroxyprogesterone	Medroxyprogesterone	PROPN	NNP	0	B-Chemical
acetate	acetate	VERB	VBP	0	I-Chemical
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
month	month	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
period	period	NOUN	NN	5	O
was	be	VERB	VBD	9	O
18	18	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
attention	attention	NOUN	NN	5	O
was	be	VERB	VBD	9	O
paid	pay	VERB	VBN	5	O
to	to	ADP	IN	5	O
breast	breast	NOUN	NN	3	O
modifications	modification	NOUN	NNS	9	O
as	as	ADP	IN	5	O
evidenced	evidence	VERB	VBN	9	O
by	by	ADP	IN	9	O
symptomatology	symptomatology	NOUN	NN	5	O
,	,	PUNCT	,	9	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
plate	plate	VERB	VB	0	O
thermography	thermography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Mastodynia	Mastodynia	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
by	by	ADP	IN	9	O
21	21	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
light	light	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
breast	breast	NOUN	NN	3	O
firmness	firmness	NOUN	NN	5	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
moderate	moderate	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
breast	breast	NOUN	NN	3	O
nodularity	nodularity	NOUN	NN	5	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Themography	Themography	PROPN	NNP	_	O
confirmed	confirm	VERB	VBD	9	O
the	the	DET	DT	5	O
existence	existence	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
excessive	excessive	ADJ	JJ	5	O
breast	breast	NOUN	NN	3	O
stimulation	stimulation	NOUN	NN	3	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
mastodynia	mastodynia	X	FW	5	B-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
7	7	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
mastodynia	mastodynia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Normalization	normalization	NOUN	NN	5	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
by	by	ADP	IN	9	O
halving	halve	VERB	VBG	5	O
the	the	DET	DT	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
hormonal	hormonal	ADJ	JJ	9	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
safely	safely	ADV	RB	5	O
prescribed	prescribe	VERB	VBN	5	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
criteria	criterion	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
satisfied	satisfied	ADJ	JJ	5	O
:	:	PUNCT	:	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
preliminary	preliminary	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
metabolic	metabolic	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cytologic	cytologic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
mammographic	mammographic	ADJ	JJ	5	O
perspective	perspective	NOUN	NN	5	O
;	;	PUNCT	:	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
cyclic	cyclic	ADJ	JJ	0	O
treatment	treatment	NOUN	NN	9	O
schedule	schedule	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
progestative	progestative	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
periodic	periodic	ADJ	JJ	5	O
complete	complete	ADJ	JJ	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
accurate	accurate	ADJ	JJ	5	O
thermographic	thermographic	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
breast	breast	NOUN	NN	3	O
target	target	NOUN	NN	9	O
tissues	tissue	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Early	early	ADJ	JJ	9	O
infections	infection	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
on	on	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Eighty	eighty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
renal	renal	NOUN	NN	9	O
,	,	PUNCT	,	9	O
seventeen	seventeen	NUM	CD	9	O
heart	heart	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
twenty	twenty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
for	for	ADP	IN	5	O
infection	infection	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Seventeen	seventeen	NUM	CD	9	O
renal	renal	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
Aza	Aza	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
prednisone	prednisone	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
immunosuppression	immunosuppression	NOUN	NN	5	O
with	with	ADP	IN	5	O
21	21	NUM	CD	7	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
prednisone	prednisone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
others	other	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
prednisone	prednisone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
randomized	randomized	ADJ	JJ	5	O
Aza	Aza	PROPN	NNP	3	B-Chemical
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
overall	overall	ADJ	JJ	5	O
infections	infection	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
nonviral	nonviral	ADJ	JJ	9	O
infections	infection	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Heart	heart	NOUN	NN	2	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
infections	infection	NOUN	NNS	5	B-Disease
than	than	ADP	IN	5	O
cyclosporine	cyclosporine	ADJ	JJ	0	B-Chemical
renal	renal	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
fewer	few	ADJ	JJR	5	O
infections	infection	NOUN	NNS	5	B-Disease
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
Aza	Aza	PROPN	NNP	3	B-Chemical
renal	renal	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
infectious	infectious	ADJ	JJ	5	O
deaths	death	NOUN	NNS	5	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
Aza	Aza	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
infection	infection	NOUN	NN	9	B-Disease
played	play	VERB	VBD	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
cardiac	cardiac	ADJ	JJ	5	O
transplant	transplant	NOUN	NN	9	O
deaths	death	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
8	8	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
9	9	NUM	CD	7	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
deaths	death	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
fewest	few	ADJ	JJS	5	O
bacteremias	bacteremias	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
infection	infection	NOUN	NN	9	B-Disease
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
preponderance	preponderance	NOUN	NN	9	O
of	of	ADP	IN	5	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
intrathoracic	intrathoracic	VERB	VBP	5	O
infections	infection	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
urinary	urinary	ADJ	JJ	9	B-Disease
tract	tract	NOUN	NN	9	I-Disease
infections	infection	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pulmonary	pulmonary	ADJ	JJ	9	O
infections	infection	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
Aza	Aza	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Aza	aza	ADJ	JJ	3	B-Chemical
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
staphylococcal	staphylococcal	ADJ	JJ	9	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
than	than	ADP	IN	5	O
all	all	DET	DT	5	O
other	other	ADJ	JJ	5	O
transplant	transplant	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
systemic	systemic	ADJ	JJ	9	O
fungal	fungal	ADJ	JJ	4	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
occurred	occur	VERB	VBD	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cytomegalovirus	Cytomegalovirus	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
CMV	CMV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
shedding	shedding	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
serological	serological	ADJ	JJ	9	O
rises	rise	NOUN	NNS	9	O
in	in	ADP	IN	5	O
antibody	antibody	NOUN	NN	3	O
titer	titer	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
78	78	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclosporine	cyclosporine	ADJ	JJ	0	B-Chemical
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
76	76	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
Aza	Aza	PROPN	NNP	3	B-Chemical
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
cyclosporine	cyclosporine	ADJ	JJ	0	B-Chemical
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
had	have	VERB	VBD	9	O
symptoms	symptom	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
CMV	CMV	PROPN	NNP	9	B-Disease
infection	infection	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Serological	serological	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
Epstein	Epstein	PROPN	NNP	6	B-Disease
Barr	Barr	PROPN	NNP	6	I-Disease
Virus	Virus	PROPN	NNP	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
65	65	NUM	CD	7	O
cyclosporine	cyclosporine	ADJ	JJ	0	B-Chemical
patients	patient	NOUN	NNS	5	O
studied	study	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
had	have	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
lymphoma	lymphoma	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Structure	structure	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
relationships	relationship	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antagonism	antagonism	NOUN	NN	9	O
of	of	ADP	IN	5	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
by	by	ADP	IN	9	O
cholecystokinin	cholecystokinin	ADJ	JJ	3	B-Chemical
,	,	PUNCT	,	9	O
fragments	fragment	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
analogues	analogue	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cholecystokinin	cholecystokinin	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Intraperitoneal	intraperitoneal	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
cholecystokinin	cholecystokinin	ADJ	JJ	3	B-Chemical
octapeptide	octapeptide	ADJ	JJ	0	I-Chemical
sulphate	sulphate	NOUN	NN	0	O
ester	ester	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
nonsulphated	nonsulphate	VERB	VBN	9	O
cholecystokinin	cholecystokinin	ADJ	JJ	3	B-Chemical
octapeptide	octapeptide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
NS	ns	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
enhanced	enhance	VERB	VBD	3	O
the	the	DET	DT	5	O
latency	latency	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Experiments	experiment	NOUN	NNS	9	O
with	with	ADP	IN	5	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
C	c	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
terminal	terminal	NOUN	NN	9	O
fragments	fragment	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
C	c	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
terminal	terminal	NOUN	NN	9	O
tetrapeptide	tetrapeptide	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
CCK	CCK	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
active	active	ADJ	JJ	9	O
centre	centre	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
CCK	CCK	PROPN	NNP	3	O
octapeptide	octapeptide	NOUN	NN	0	O
molecule	molecule	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
analogues	analogue	NOUN	NNS	0	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
NS	ns	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
dose	dose	NOUN	NN	9	O
range	range	NOUN	NN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
caerulein	caerulein	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
range	range	NOUN	NN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
bell	bell	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
shaped	shape	VERB	VBN	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
curves	curve	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
greatest	great	ADJ	JJS	9	O
maximum	maximum	ADJ	JJ	5	O
inhibition	inhibition	NOUN	NN	3	O
for	for	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
NS	ns	NOUN	NN	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
peptide	peptide	NOUN	NN	9	O
CCK	CCK	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
had	have	VERB	VBD	9	O
weak	weak	ADJ	JJ	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
octapeptides	octapeptide	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
larger	large	ADJ	JJR	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
reference	reference	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
totally	totally	ADV	RB	9	O
prevented	prevent	VERB	VBN	9	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
peptides	peptide	NOUN	NNS	9	O
tested	test	VERB	VBN	9	O
was	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Experiments	experiment	NOUN	NNS	9	O
with	with	ADP	IN	5	O
analogues	analogue	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
derivatives	derivative	NOUN	NNS	0	O
of	of	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
alanyl	alanyl	NOUN	NN	1	O
derivatives	derivative	NOUN	NNS	0	O
of	of	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
were	be	VERB	VBD	9	O
enhanced	enhance	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
equipotent	equipotent	NOUN	NN	0	O
with	with	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
CCK	CCK	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
analogues	analogue	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
Ser	Ser	PROPN	NNP	1	O
(	(	PUNCT	-LRB-	9	O
SO3H	SO3H	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
Ac	Ac	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
CCK	CCK	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
Thr	Thr	PROPN	NNP	1	O
(	(	PUNCT	-LRB-	9	O
SO3H	SO3H	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
Ac	Ac	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
CCK	CCK	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
Hyp	Hyp	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
SO3H	SO3H	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
Ac	Ac	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
CCK	CCK	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
SE	SE	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
slightly	slightly	ADV	RB	9	O
more	more	ADV	RBR	5	O
active	active	ADJ	JJ	9	O
than	than	ADP	IN	5	O
CCK	CCK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8	8	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Vasopressin	Vasopressin	PROPN	NNP	0	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
contributor	contributor	NOUN	NN	9	O
to	to	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
vasopressin	vasopressin	NOUN	NN	9	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
agent	agent	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
process	process	NOUN	NN	5	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Vasopressin	Vasopressin	PROPN	NNP	0	B-Chemical
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
DOCA	doca	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
salt	salt	NOUN	NN	0	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
the	the	DET	DT	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
substantial	substantial	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
diabetes	diabetes	NOUN	NN	5	B-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
DOCA	doca	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
salt	salt	NOUN	NN	0	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
DDAVP	DDAVP	PROPN	NNP	0	B-Chemical
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
antidiuretic	antidiuretic	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
minimal	minimal	ADJ	JJ	9	O
vasopressor	vasopressor	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
observed	observe	VERB	VBN	9	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
AVP	AVP	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
vasopressin	vasopressin	NOUN	NN	9	B-Chemical
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
important	important	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
the	the	DET	DT	5	O
enhanced	enhance	VERB	VBN	3	O
pressor	pressor	NOUN	NN	5	O
responsiveness	responsiveness	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hormone	hormone	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Increased	increased	ADJ	JJ	9	O
secretion	secretion	NOUN	NN	3	O
of	of	ADP	IN	5	O
vasopressin	vasopressin	NOUN	NN	9	B-Chemical
from	from	ADP	IN	9	O
neurohypophysis	neurohypophysis	NOUN	NN	9	O
also	also	ADV	RB	9	O
promotes	promote	VERB	VBZ	3	O
the	the	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hormone	hormone	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
pathogenetic	pathogenetic	ADJ	JJ	5	O
factor	factor	NOUN	NN	9	O
in	in	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
unproportional	unproportional	ADJ	JJ	5	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
vasopressin	vasopressin	NOUN	NN	9	B-Chemical
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
plasma	plasma	VERB	VB	9	O
osmolality	osmolality	NOUN	NN	0	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
adjusting	adjust	VERB	VBG	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	II	PROPN	NNP	9	O
forming	forming	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
receptor	receptor	NOUN	NN	3	O
binding	bind	VERB	VBG	1	O
capacity	capacity	NOUN	NN	9	O
for	for	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
balance	balance	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
vasopressin	vasopressin	NOUN	NN	9	B-Chemical
remains	remain	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	O
essential	essential	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Toxic	Toxic	PROPN	NNP	0	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
alcoholic	alcoholic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
reversible	reversible	ADJ	JJ	9	O
toxic	toxic	ADJ	JJ	0	B-Disease
liver	liver	NOUN	NN	9	I-Disease
damage	damage	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
alcoholic	alcoholic	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
causative	causative	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
was	be	VERB	VBD	9	O
proven	prove	VERB	VBN	5	O
by	by	ADP	IN	9	O
challenge	challenge	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Atrial	atrial	ADJ	JJ	7	B-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
involving	involve	VERB	VBG	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
of	of	ADP	IN	5	O
F	F	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
344	344	NUM	CD	7	O
rats	rat	NOUN	NNS	9	O
ingesting	ingest	VERB	VBG	5	O
quinacrine	quinacrine	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Quinacrine	quinacrine	ADJ	JJ	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
toxic	toxic	ADJ	JJ	0	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
of	of	ADP	IN	5	O
F	F	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
344	344	NUM	CD	7	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBD	3	O
with	with	ADP	IN	5	O
500	500	NUM	CD	0	O
ppm	ppm	NOUN	NN	0	O
quinacrine	quinacrine	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
diet	diet	NOUN	NN	9	O
all	all	DET	DT	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
dilatation	dilatation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
focal	focal	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
died	die	VERB	VBD	9	O
from	from	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
congestion	congestion	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lungs	lung	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
liver	liver	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
organs	organ	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Seventy	seventy	NUM	CD	5	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
250	250	NUM	CD	0	O
ppm	ppm	NOUN	NN	0	O
quinacrine	quinacrine	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
ppm	ppm	NOUN	NN	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitrite	nitrite	NOUN	NN	0	I-Chemical
simultaneously	simultaneously	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
diet	diet	NOUN	NN	9	O
had	have	VERB	VBD	9	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
atria	atria	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
untreated	untreated	ADJ	JJ	3	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
laboratory	laboratory	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Sodium	sodium	NOUN	NN	0	B-Chemical
nitrite	nitrite	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
quinacrine	quinacrine	ADJ	JJ	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
no	no	DET	DT	9	O
additional	additional	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Alternating	alternate	VERB	VBG	5	B-Disease
sinus	sinus	NOUN	NN	5	I-Disease
rhythm	rhythm	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
intermittent	intermittent	ADJ	JJ	5	O
sinoatrial	sinoatrial	ADJ	JJ	5	B-Disease
block	block	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Alternating	alternate	VERB	VBG	5	B-Disease
sinus	sinus	NOUN	NN	5	I-Disease
rhythm	rhythm	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
intermittent	intermittent	ADJ	JJ	5	O
sinoatrial	sinoatrial	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	I-Disease
S	S	PROPN	NNP	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
A	A	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
block	block	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
57	57	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
,	,	PUNCT	,	9	O
under	under	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
angina	angina	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
daily	daily	ADV	RB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
alternation	alternation	NOUN	NN	5	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
short	short	ADJ	JJ	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
occasional	occasional	ADJ	JJ	5	O
pauses	pause	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
pauses	pause	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
always	always	ADV	RB	5	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
short	short	ADJ	JJ	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
usually	usually	ADV	RB	5	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
two	two	NUM	CD	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
92	92	NUM	CD	7	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
95	95	NUM	CD	7	O
s	s	NOUN	NNS	9	O
representing	represent	VERB	VBG	9	O
the	the	DET	DT	5	O
basic	basic	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
cycle	cycle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
these	these	DET	DT	5	O
basic	basic	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
cycles	cycle	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
alternating	alternate	VERB	VBG	5	B-Disease
rhythm	rhythm	NOUN	NN	5	I-Disease
started	start	VERB	VBD	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
longer	long	ADJ	JJR	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
interval	interval	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
ranged	range	VERB	VBD	9	O
between	between	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
12	12	NUM	CD	9	O
s	s	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
short	short	ADJ	JJ	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
between	between	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
80	80	NUM	CD	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
84	84	NUM	CD	7	O
s	s	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pauses	pause	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
equal	equal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
almost	almost	ADV	RB	9	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
one	one	NUM	CD	5	O
short	short	ADJ	JJ	5	O
plus	plus	CCONJ	CC	9	O
one	one	NUM	CD	5	O
long	long	ADJ	JJ	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
interval	interval	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
to	to	PART	TO	5	O
twice	twice	ADV	RB	9	O
the	the	DET	DT	5	O
basic	basic	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
cycle	cycle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
one	one	NUM	CD	5	O
recording	record	VERB	VBG	5	O
a	a	DET	DT	5	O
short	short	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
regular	regular	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
rhythm	rhythm	NOUN	NN	5	O
with	with	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
1	1	NUM	CD	9	O
S	S	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
A	A	PROPN	NNP	9	I-Disease
block	block	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
short	short	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
sinus	sinus	NOUN	NN	5	O
rhythm	rhythm	NOUN	NN	5	O
was	be	VERB	VBD	9	O
interrupted	interrupt	VERB	VBN	5	O
by	by	ADP	IN	9	O
sudden	sudden	ADJ	JJ	5	O
prolongation	prolongation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
interval	interval	NOUN	NN	5	O
starting	start	VERB	VBG	9	O
the	the	DET	DT	5	O
alternative	alternative	ADJ	JJ	5	O
rhythm	rhythm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
small	small	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
shape	shape	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
P	p	NOUN	NN	9	O
waves	wave	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
R	r	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
A	a	NOUN	NN	9	O
conduction	conduction	NOUN	NN	5	O
through	through	ADP	IN	9	O
two	two	NUM	CD	5	O
pathways	pathway	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
with	with	ADP	IN	5	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
1	1	NUM	CD	9	O
block	block	NOUN	NN	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
having	have	VERB	VBG	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
12	12	NUM	CD	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
14	14	NUM	CD	7	O
s	s	PART	POS	9	O
longer	long	ADJ	JJR	5	O
conduction	conduction	NOUN	NN	5	O
time	time	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
occasional	occasional	ADJ	JJ	5	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
1	1	NUM	CD	9	O
block	block	NOUN	NN	9	O
was	be	VERB	VBD	9	O
proposed	propose	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
explanation	explanation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
alternating	alternate	VERB	VBG	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
interval	interval	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
seen	see	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Atropine	atropine	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
given	give	VERB	VBN	5	O
intravenously	intravenously	ADV	RB	0	O
resulted	result	VERB	VBN	9	O
in	in	ADP	IN	5	O
shortening	shortening	NOUN	NN	9	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
P	p	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
without	without	ADP	IN	9	O
changing	change	VERB	VBG	5	O
the	the	DET	DT	5	O
rhythm	rhythm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
abnormal	abnormal	ADJ	JJ	9	O
rhythm	rhythm	NOUN	NN	5	O
disappeared	disappear	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
restarted	restart	VERB	VBN	5	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
1	1	NUM	CD	9	O
S	S	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
A	A	PROPN	NNP	9	I-Disease
block	block	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
accepted	accept	VERB	VBN	5	O
as	as	ADP	IN	5	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
being	be	VERB	VBG	5	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
conduction	conduction	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Antitumor	Antitumor	PROPN	NNP	0	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
IgM	IgM	PROPN	NNP	3	O
solid	solid	ADJ	JJ	9	O
immunocytoma	immunocytoma	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
bearing	bear	VERB	VBG	3	O
LOU	LOU	PROPN	NNP	2	O
/	/	SYM	SYM	9	O
M	M	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
WSL	WSL	PROPN	NNP	0	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Antitumor	Antitumor	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
LOU	LOU	PROPN	NNP	2	O
/	/	SYM	SYM	9	O
M	M	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
WSL	WSL	PROPN	NNP	0	O
inbred	inbreed	VERB	VBD	9	O
rats	rat	NOUN	NNS	9	O
each	each	DET	DT	5	O
bearing	bear	VERB	VBG	3	O
a	a	DET	DT	5	O
transplantable	transplantable	ADJ	JJ	3	O
solid	solid	ADJ	JJ	9	O
IgM	IgM	PROPN	NNP	3	O
immunocytoma	immunocytoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
(	(	PUNCT	-LRB-	9	O
diameter	diameter	NOUN	NN	9	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
iv	iv	NUM	CD	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
5	5	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
1	1	NUM	CD	9	O
weekly	weekly	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
dose	dose	NOUN	NN	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
015	015	NUM	CD	7	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
wt	wt	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Tumor	tumor	NOUN	NN	9	B-Disease
regression	regression	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Complete	complete	ADJ	JJ	9	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
with	with	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Histologic	histologic	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
scored	score	VERB	VBN	5	O
as	as	ADP	IN	5	O
grade	grade	NOUN	NN	9	O
III	III	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Light	light	ADJ	JJ	9	O
microscopic	microscopic	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
above	above	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
albuminuria	albuminuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
very	very	ADV	RB	5	O
low	low	ADJ	JJ	9	O
serum	serum	ADJ	JJ	9	O
albumin	albumin	NOUN	NN	0	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
albumin	albumin	NOUN	NN	0	O
level	level	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
liter	liter	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Ascites	ascite	NOUN	NNS	9	B-Disease
and	and	CCONJ	CC	5	O
hydrothorax	hydrothorax	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
simultaneously	simultaneously	ADV	RB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
experiments	experiment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
tumor	tumor	ADJ	JJ	3	B-Disease
-	-	PUNCT	HYPH	7	O
bearing	bear	VERB	VBG	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
no	no	DET	DT	9	O
major	major	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
antitumor	antitumor	CCONJ	CC	3	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
simultaneously	simultaneously	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
LOU	LOU	PROPN	NNP	2	O
/	/	SYM	SYM	9	O
M	M	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
WSL	WSL	PROPN	NNP	0	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Albuminuria	Albuminuria	PROPN	NNP	7	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
extremely	extremely	ADV	RB	5	O
low	low	ADJ	JJ	9	O
serum	serum	ADJ	JJ	9	O
albumin	albumin	NOUN	NN	0	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
so	so	ADV	RB	5	O
ascites	ascite	NOUN	NNS	3	B-Disease
and	and	CCONJ	CC	5	O
hydrothorax	hydrothorax	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
necessarily	necessarily	ADV	RB	5	O
a	a	DET	DT	5	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Intraoperative	intraoperative	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
eye	eye	NOUN	NN	5	O
drops	drop	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
69	69	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
yr	yr	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
concurrently	concurrently	ADV	RB	9	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
nitrate	nitrate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
maleate	maleate	ADJ	JJ	0	I-Chemical
eye	eye	NOUN	NN	5	O
drops	drop	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
became	become	VERB	VBD	9	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
during	during	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
subsequently	subsequently	ADV	RB	9	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	NOUN	NN	0	O
collection	collection	NOUN	NN	5	O
of	of	ADP	IN	5	O
urine	urine	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Timolol	Timolol	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
sample	sample	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
removed	remove	VERB	VBN	9	O
during	during	ADP	IN	5	O
surgery	surgery	NOUN	NN	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
ng	ng	ADP	IN	0	O
ml	ml	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
partial	partial	ADJ	JJ	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
blockade	blockade	NOUN	NN	3	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
postulated	postulate	VERB	VBN	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
action	action	NOUN	NN	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
enhanced	enhance	VERB	VBN	3	O
during	during	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
anaesthesia	anaesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
resultant	resultant	ADJ	JJ	9	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Pilocarpine	Pilocarpine	PROPN	NNP	0	B-Chemical
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
had	have	VERB	VBN	9	O
a	a	DET	DT	5	O
contributory	contributory	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Succinylcholine	succinylcholine	ADJ	JJ	0	B-Chemical
apnoea	apnoea	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
attempted	attempt	VERB	VBN	5	O
reversal	reversal	NOUN	NN	9	O
with	with	ADP	IN	5	O
anticholinesterases	anticholinesterase	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Anticholinesterases	anticholinesterase	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
attempt	attempt	NOUN	NN	5	O
to	to	PART	TO	5	O
antagonize	antagonize	VERB	VB	3	O
prolonged	prolong	VERB	VBN	9	O
neuromuscular	neuromuscular	ADJ	JJ	5	B-Disease
blockade	blockade	NOUN	NN	3	I-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
later	later	ADV	RB	9	O
found	find	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
homozygous	homozygous	ADJ	JJ	1	O
for	for	ADP	IN	5	O
atypical	atypical	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
cholinesterase	cholinesterase	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Edrophonium	Edrophonium	PROPN	NNP	5	B-Chemical
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
74	74	NUM	CD	7	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
train	train	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
of	of	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
stimulation	stimulation	NOUN	NN	3	O
was	be	VERB	VBD	9	O
characteristic	characteristic	ADJ	JJ	9	O
of	of	ADP	IN	5	O
phase	phase	NOUN	NN	5	O
II	ii	NUM	CD	9	O
block	block	NOUN	NN	9	O
,	,	PUNCT	,	9	O
produced	produce	VERB	VBD	9	O
partial	partial	ADJ	JJ	9	O
antagonism	antagonism	NOUN	NN	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
sustained	sustain	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Repeated	repeat	VERB	VBN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
edrophonium	edrophonium	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
70	70	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
neostigmine	neostigmine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
antagonize	antagonize	VERB	VB	3	O
or	or	CCONJ	CC	5	O
augment	augment	VERB	VB	9	O
the	the	DET	DT	5	O
block	block	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Spontaneous	spontaneous	ADJ	JJ	9	O
respiration	respiration	NOUN	NN	9	O
recommenced	recommence	VERB	VBD	5	O
200	200	NUM	CD	0	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
anticholinesterases	anticholinesterase	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
only	only	ADV	RB	9	O
partially	partially	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
restoring	restore	VERB	VBG	9	O
neuromuscular	neuromuscular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
apnoea	apnoea	ADV	RB	5	B-Disease
despite	despite	ADP	IN	9	O
muscle	muscle	NOUN	NN	9	O
twitch	twitch	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
typical	typical	ADJ	JJ	9	O
of	of	ADP	IN	5	O
phase	phase	NOUN	NN	5	O
II	ii	NUM	CD	9	O
block	block	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
omega	omega	NOUN	NN	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
I	i	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
131	131	NUM	CD	7	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
heptadecanoic	heptadecanoic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
myocardial	myocardial	ADJ	JJ	9	O
scintigraphy	scintigraphy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
echocardiography	echocardiography	NOUN	NN	5	O
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
serial	serial	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
dynamic	dynamic	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	O
scintigraphy	scintigraphy	NOUN	NN	5	O
with	with	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
omega	omega	NOUN	NN	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
I	i	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
131	131	NUM	CD	7	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
heptadecanoic	heptadecanoic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
I	I	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
131	131	NUM	CD	7	I-Chemical
HA	HA	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
global	global	ADJ	JJ	5	O
left	left	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
ventricular	ventricular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
determined	determine	VERB	VBN	9	O
echocardiographically	echocardiographically	ADV	RB	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
nine	nine	NUM	CD	9	O
mongrel	mongrel	NOUN	NN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
extractable	extractable	ADJ	JJ	0	O
myocardial	myocardial	ADJ	JJ	9	O
lipid	lipid	NOUN	NN	0	O
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
postmortem	postmortem	NOUN	NN	9	O
between	between	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
control	control	NOUN	NN	9	O
dogs	dog	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
progressive	progressive	ADJ	JJ	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
global	global	ADJ	JJ	5	O
LV	LV	PROPN	NNP	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	O
t1	t1	NOUN	NN	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
I	I	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
131	131	NUM	CD	7	I-Chemical
HA	HA	PROPN	NNP	9	I-Chemical
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
only	only	ADV	RB	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
alteration	alteration	NOUN	NN	9	O
in	in	ADP	IN	5	O
total	total	ADJ	JJ	9	O
extractable	extractable	ADJ	JJ	0	O
myocardial	myocardial	ADJ	JJ	9	O
lipids	lipid	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
control	control	NOUN	NN	9	O
dogs	dog	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
alteration	alteration	NOUN	NN	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
dynamic	dynamic	ADJ	JJ	5	O
imaging	imaging	NOUN	NN	5	O
with	with	ADP	IN	5	O
I	I	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
131	131	NUM	CD	7	I-Chemical
HA	ha	NOUN	NN	9	I-Chemical
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
initiating	initiate	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
in	in	ADP	IN	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Hemodynamics	hemodynamic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
myocardial	myocardial	ADJ	JJ	9	O
metabolism	metabolism	NOUN	NN	9	O
under	under	ADP	IN	9	O
deliberate	deliberate	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Coronary	coronary	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
work	work	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
metabolism	metabolism	NOUN	NN	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
under	under	ADP	IN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
SNP	SNP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
trimetaphan	trimetaphan	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
TMP	TMP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
deliberate	deliberate	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
mean	mean	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
decrease	decrease	NOUN	NN	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Regarding	regard	VERB	VBG	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
,	,	PUNCT	,	9	O
aortic	aortic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
coronary	coronary	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
metabolic	metabolic	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
pH	pH	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
pO2	po2	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pCO2	pco2	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
we	-PRON-	PRON	PRP	5	O
could	could	VERB	MD	9	O
confirm	confirm	VERB	VB	9	O
that	that	DET	DT	5	O
nitroprusside	nitroprusside	NOUN	NN	0	B-Chemical
hypotension	hypotension	NOUN	NN	5	B-Disease
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
safely	safely	ADV	RB	5	O
used	use	VERB	VBN	5	O
to	to	ADP	IN	5	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
mean	mean	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
decrease	decrease	NOUN	NN	9	O
from	from	ADP	IN	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
trimetaphan	trimetaphan	ADP	IN	9	B-Chemical
hypotension	hypotension	NOUN	NN	5	B-Disease
to	to	ADP	IN	5	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
mean	mean	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
decrease	decrease	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
work	work	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
during	during	ADP	IN	5	O
SNP	SNP	PROPN	NNP	9	B-Chemical
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Myocardial	Myocardial	PROPN	NNP	9	O
O2	O2	PROPN	NNP	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
O2	o2	INTJ	UH	0	B-Chemical
availability	availability	NOUN	NN	5	O
were	be	VERB	VBD	9	O
directly	directly	ADV	RB	9	O
dependent	dependent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
coronary	coronary	ADJ	JJ	5	O
perfusion	perfusion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Careful	careful	ADJ	JJ	5	O
invasive	invasive	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
gases	gas	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ECG	ECG	PROPN	NNP	5	O
ST	ST	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
T	T	PROPN	NNP	3	O
segment	segment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
mandatory	mandatory	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
noradrenergic	noradrenergic	ADP	IN	5	O
involvement	involvement	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	O
stimulant	stimulant	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Male	male	ADJ	JJ	7	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
neurotoxin	neurotoxin	NOUN	NN	0	O
DSP4	DSP4	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
amphetamine	amphetamine	NOUN	NN	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
or	or	CCONJ	CC	5	O
40	40	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	PUNCT	,	9	O
kg	kg	ADV	RB	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
amphetamine	amphetamine	NOUN	NN	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
DSP4	DSP4	PROPN	NNP	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
rearings	rearing	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
stereotypies	stereotypie	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
DSP4	DSP4	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	ADJ	JJ	5	B-Chemical
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
DSP4	DSP4	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
uptake	uptake	ADJ	JJ	0	O
blocking	blocking	NOUN	NN	3	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
prevents	prevent	VERB	VBZ	9	O
the	the	DET	DT	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
DSP4	DSP4	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
noradrenergic	noradrenergic	ADJ	JJ	5	O
neurones	neurone	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	O
stimulant	stimulant	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Accelerated	accelerated	ADJ	JJ	9	B-Disease
junctional	junctional	ADJ	JJ	9	I-Disease
rhythms	rhythm	NOUN	NNS	5	I-Disease
during	during	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
atrioventricular	atrioventricular	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
AV	av	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
dissociation	dissociation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
accelerated	accelerate	VERB	VBD	9	B-Disease
junctional	junctional	ADJ	JJ	9	I-Disease
rhythms	rhythm	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
59	59	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
oral	oral	ADJ	JJ	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Accelerated	accelerated	ADJ	JJ	9	B-Disease
junctional	junctional	ADJ	JJ	9	I-Disease
rhythms	rhythm	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
AV	av	NOUN	NN	9	O
dissociation	dissociation	NOUN	NN	9	O
were	be	VERB	VBD	9	O
frequent	frequent	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
supraventricular	supraventricular	ADJ	JJ	5	B-Disease
tachyarrhythmias	tachyarrhythmia	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
AV	AV	PROPN	NNP	9	O
nodal	nodal	ADJ	JJ	5	O
reentry	reentry	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
to	to	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
junctional	junctional	ADJ	JJ	9	O
pacemakers	pacemaker	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
various	various	ADJ	JJ	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
syndromes	syndrome	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
neither	neither	CCONJ	CC	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
junctional	junctional	ADJ	JJ	9	O
rhythms	rhythm	NOUN	NNS	5	O
nor	nor	CCONJ	CC	9	O
suppressed	suppress	VERB	VBD	3	O
their	-PRON-	DET	PRP$	5	O
role	role	NOUN	NN	9	O
as	as	ADP	IN	5	O
escape	escape	NOUN	NN	5	O
rhythms	rhythm	NOUN	NNS	5	O
under	under	ADP	IN	9	O
physiologically	physiologically	ADV	RB	9	O
appropriate	appropriate	ADJ	JJ	5	O
circumstances	circumstance	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Interstrain	interstrain	NOUN	NN	9	O
variation	variation	NOUN	NN	5	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
toxic	toxic	ADJ	JJ	0	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
among	among	ADP	IN	5	O
inbred	inbreed	VERB	VBN	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
toxic	toxic	ADJ	JJ	0	O
dosage	dosage	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
males	male	NOUN	NNS	9	O
from	from	ADP	IN	9	O
seven	seven	NUM	CD	9	O
inbred	inbreed	VERB	VBN	9	O
mouse	mouse	NOUN	NN	3	O
strains	strain	NOUN	NNS	1	O
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
/	/	SYM	SYM	9	O
J	J	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
cJ	cJ	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
CBA	CBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
J	J	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
C3H	C3H	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
HeJ	HeJ	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6J	6J	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2J	2j	NOUN	NN	3	O
,	,	PUNCT	,	9	O
SWR	SWR	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
J	J	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6J	6J	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
chosen	choose	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
"	"	PUNCT	``	5	O
prototypic	prototypic	ADJ	JJ	9	O
"	"	PUNCT	''	5	O
mouse	mouse	NOUN	NN	3	O
strain	strain	NOUN	NN	1	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
behavioral	behavioral	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
broad	broad	ADJ	JJ	5	O
range	range	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
phenotypic	phenotypic	ADJ	JJ	9	O
characteristics	characteristic	NOUN	NNS	5	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
righting	right	VERB	VBG	5	O
ability	ability	NOUN	NN	9	O
,	,	PUNCT	,	9	O
clonic	clonic	ADJ	JJ	5	B-Disease
seizure	seizure	NOUN	NN	5	I-Disease
induction	induction	NOUN	NN	3	O
,	,	PUNCT	,	9	O
stress	stress	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
lethality	lethality	NOUN	NN	3	O
,	,	PUNCT	,	9	O
death	death	NOUN	NN	9	O
without	without	ADP	IN	9	O
external	external	ADJ	JJ	5	O
stress	stress	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	,	7	O
were	be	VERB	VBD	9	O
scored	score	VERB	VBN	5	O
at	at	ADP	IN	9	O
various	various	ADJ	JJ	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
naive	naive	ADJ	JJ	3	O
animals	animal	NOUN	NNS	9	O
under	under	ADP	IN	9	O
empirically	empirically	ADV	RB	5	O
optimized	optimize	VERB	VBN	9	O
,	,	PUNCT	,	9	O
rigidly	rigidly	ADV	RB	5	O
constant	constant	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Mice	Mice	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
for	for	ADP	IN	5	O
each	each	DET	DT	5	O
point	point	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
single	single	ADJ	JJ	9	O
IP	IP	PROPN	NNP	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
fixed	fix	VERB	VBN	9	O
volume	volume	NOUN	NN	9	O
/	/	SYM	SYM	9	O
g	g	NOUN	NN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
of	of	ADP	IN	5	O
physiological	physiological	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
carrier	carrier	NOUN	NN	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
ranging	range	VERB	VBG	9	O
from	from	ADP	IN	9	O
125	125	NUM	CD	9	O
-	-	SYM	SYM	7	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
righting	right	VERB	VBG	5	O
ability	ability	NOUN	NN	9	O
was	be	VERB	VBD	9	O
scored	score	VERB	VBN	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
post	post	NOUN	NN	9	O
dosing	dosing	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
intervals	interval	NOUN	NNS	5	O
thereafter	thereafter	ADV	RB	9	O
for	for	ADP	IN	5	O
20	20	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
animals	animal	NOUN	NNS	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
clonic	clonic	NOUN	NN	5	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
scored	score	VERB	VBN	5	O
as	as	ADP	IN	5	O
to	to	ADP	IN	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
onset	onset	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
for	for	ADP	IN	5	O
20	20	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
these	these	DET	DT	5	O
proceeded	proceed	VERB	VBD	9	O
to	to	PART	TO	5	O
tonic	tonic	VERB	VB	5	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
death	death	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
20	20	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
surviving	survive	VERB	VBG	9	O
for	for	ADP	IN	5	O
20	20	NUM	CD	9	O
min	min	NOUN	NN	0	O
were	be	VERB	VBD	9	O
immediately	immediately	ADV	RB	9	O
stressed	stress	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
swim	swim	ADJ	JJ	5	O
test	test	NOUN	NN	5	O
in	in	ADP	IN	5	O
25	25	NUM	CD	9	O
degrees	degree	NOUN	NNS	5	O
C	c	NOUN	NN	9	O
water	water	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
producing	produce	VERB	VBG	9	O
tonic	tonic	NOUN	NN	5	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
scored	score	VERB	VBN	5	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
other	other	ADJ	JJ	5	O
animals	animal	NOUN	NNS	9	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
15	15	NUM	CD	9	O
or	or	CCONJ	CC	5	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
any	any	DET	DT	5	O
single	single	ADJ	JJ	9	O
behavioral	behavioral	ADJ	JJ	5	O
criterion	criterion	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
criteria	criterion	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
marked	mark	VERB	VBD	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
strains	strain	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
testing	testing	NOUN	NN	5	O
of	of	ADP	IN	5	O
alkylxanthines	alkylxanthine	NOUN	NNS	9	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
mouse	mouse	NOUN	NN	3	O
strain	strain	NOUN	NN	1	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
misleading	misleading	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
suggest	suggest	VERB	VB	9	O
that	that	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
responses	response	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
class	class	NOUN	NN	9	O
of	of	ADP	IN	5	O
compounds	compound	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
genetically	genetically	ADV	RB	9	O
influenced	influence	VERB	VBN	5	O
in	in	ADP	IN	5	O
mammals	mammal	NOUN	NNS	4	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
cis	cis	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
platinum	platinum	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
,	,	PUNCT	,	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
hexamethylmelamine	hexamethylmelamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
2	2	NUM	CD	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
38	38	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
cisplatinum	cisplatinum	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CPDD	CPDD	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
,	,	PUNCT	,	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
hexamethylmelamine	hexamethylmelamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
HMM	HMM	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADV	RB	0	O
daily	daily	ADV	RB	5	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Each	each	DET	DT	5	O
course	course	NOUN	NN	5	O
was	be	VERB	VBD	9	O
repeated	repeat	VERB	VBN	5	O
monthly	monthly	ADV	RB	5	O
.	.	PUNCT	.	9	O

2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
stage	stage	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
stage	stage	NOUN	NN	9	O
III	iii	NUM	CD	9	O
and	and	CCONJ	CC	5	O
22	22	NUM	CD	7	O
stage	stage	NOUN	NN	9	O
IV	iv	NOUN	NN	9	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

14	14	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
38	38	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
with	with	ADP	IN	5	O
radiation	radiation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
with	with	ADP	IN	5	O
both	both	DET	DT	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
radiation	radiation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
17	17	NUM	CD	7	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
any	any	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
before	before	ADP	IN	9	O
CPDD	cpdd	ADJ	JJ	5	B-Chemical
combination	combination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

31	31	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
38	38	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
81	81	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
demonstrated	demonstrate	VERB	VBD	9	O
objective	objective	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
lasting	last	VERB	VBG	5	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
partial	partial	ADJ	JJ	9	O
in	in	ADP	IN	5	O
19	19	NUM	CD	7	O
and	and	CCONJ	CC	5	O
complete	complete	ADJ	JJ	9	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hematologic	hematologic	ADJ	JJ	7	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
moderate	moderate	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
reversible	reversible	ADJ	JJ	9	O
anemia	anemia	NOUN	NN	9	B-Disease
developing	develop	VERB	VBG	5	O
in	in	ADP	IN	5	O
71	71	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Gastrointestinal	gastrointestinal	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
from	from	ADP	IN	9	O
CPDD	CPDD	PROPN	NNP	5	B-Chemical
were	be	VERB	VBD	9	O
universal	universal	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

HMM	hmm	INTJ	UH	5	B-Chemical
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
necessitated	necessitate	VERB	VBD	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
reversible	reversible	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
deaths	death	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Nontraumatic	nontraumatic	ADJ	JJ	5	O
dissecting	dissect	VERB	VBG	5	B-Disease
aneurysm	aneurysm	NOUN	NNS	5	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
basilar	basilar	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
nontraumatic	nontraumatic	ADJ	JJ	5	O
dissecting	dissect	VERB	VBG	5	B-Disease
aneurysm	aneurysm	NOUN	NNS	5	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
basilar	basilar	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
smoke	smoke	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
young	young	ADJ	JJ	5	O
female	female	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
locked	lock	VERB	VBN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
in	in	PART	RP	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
method	method	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
tremor	tremor	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
tocolytic	tocolytic	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
mimetics	mimetic	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
method	method	NOUN	NN	5	O
permitting	permit	VERB	VBG	5	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
finger	finger	NOUN	NN	5	O
tremor	tremor	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
displacement	displacement	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
curve	curve	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
test	test	NOUN	NN	5	O
system	system	NOUN	NN	5	O
with	with	ADP	IN	5	O
simple	simple	ADJ	JJ	5	O
amplitude	amplitude	NOUN	NN	5	O
calibration	calibration	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
coordinates	coordinate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
inversion	inversion	NOUN	NN	5	O
points	point	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
displacement	displacement	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
curves	curve	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
transferred	transfer	VERB	VBN	9	O
through	through	ADP	IN	9	O
graphical	graphical	ADJ	JJ	5	O
input	input	NOUN	NN	5	O
equipment	equipment	NOUN	NN	5	O
to	to	ADP	IN	5	O
punched	punch	VERB	VBN	5	O
tape	tape	NOUN	NN	5	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
computer	computer	NOUN	NN	5	O
program	program	NOUN	NN	5	O
,	,	PUNCT	,	9	O
periods	period	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
amplitudes	amplitude	NOUN	NNS	5	O
of	of	ADP	IN	5	O
tremor	tremor	NOUN	NN	5	B-Disease
oscillations	oscillation	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
classified	classify	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
event	event	NOUN	NN	5	O
frequency	frequency	NOUN	NN	5	O
for	for	ADP	IN	5	O
each	each	DET	DT	5	O
class	class	NOUN	NN	9	O
of	of	ADP	IN	5	O
periods	period	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
amplitudes	amplitude	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
fenoterol	fenoterol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydrobromide	hydrobromide	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
ritodrin	ritodrin	NOUN	NN	_	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCl	HCl	NOUN	NNS	0	I-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
by	by	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
crossover	crossover	NOUN	NN	5	O
study	study	NOUN	NN	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
by	by	ADP	IN	9	O
this	this	DET	DT	5	O
method	method	NOUN	NN	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
both	both	DET	DT	9	O
substances	substance	NOUN	NNS	0	O
raised	raise	VERB	VBD	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
tremor	tremor	NOUN	NN	5	B-Disease
amplitude	amplitude	NOUN	NN	5	O
to	to	ADP	IN	5	O
about	about	ADV	RB	5	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
within	within	ADP	IN	9	O
each	each	DET	DT	5	O
class	class	NOUN	NN	9	O
of	of	ADP	IN	5	O
amplitudes	amplitude	NOUN	NNS	5	O
shortened	shorten	VERB	VBN	9	O
by	by	ADP	IN	9	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
20	20	NUM	CD	9	O
ms	m	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
periods	period	NOUN	NNS	5	O
calculated	calculate	VERB	VBN	5	O
from	from	ADP	IN	9	O
all	all	DET	DT	5	O
oscillations	oscillation	NOUN	NNS	5	O
together	together	ADV	RB	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
fenoterol	fenoterol	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydrobromide	hydrobromide	NOUN	NN	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
tremor	tremor	NOUN	NN	5	B-Disease
amplitudes	amplitude	NOUN	NNS	5	O
decreased	decrease	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
faster	faster	ADV	RBR	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
following	follow	VERB	VBG	9	O
ritodrin	ritodrin	NOUN	NN	_	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCl	HCl	NOUN	NNS	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
liver	liver	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
damage	damage	NOUN	NN	9	O
,	,	PUNCT	,	9	O
proven	prove	VERB	VBN	5	O
by	by	ADP	IN	9	O
rechallenge	rechallenge	NOUN	NN	3	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
presents	present	VERB	VBZ	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
histologic	histologic	ADJ	JJ	9	O
picture	picture	NOUN	NN	5	O
resembling	resemble	VERB	VBG	9	O
chronic	chronic	ADJ	JJ	5	B-Disease
active	active	ADJ	JJ	9	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
remission	remission	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
bepridil	bepridil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Bepridil	Bepridil	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
active	active	ADJ	JJ	9	O
compound	compound	NOUN	NN	0	O
for	for	ADP	IN	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
anginal	anginal	ADJ	JJ	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
induced	induce	VERB	VBD	3	O
persistent	persistent	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
specific	specific	ADJ	JJ	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
tachycardial	tachycardial	ADJ	JJ	9	B-Disease
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vitro	vitro	NOUN	NN	3	O
perfusion	perfusion	NOUN	NN	5	O
of	of	ADP	IN	5	O
bepridil	bepridil	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
support	support	NOUN	NN	5	O
medium	medium	NOUN	NN	0	O
for	for	ADP	IN	5	O
isolated	isolated	ADJ	JJ	9	O
sino	sino	ADJ	JJ	2	O
-	-	PUNCT	HYPH	7	O
atrial	atrial	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
from	from	ADP	IN	9	O
rabbit	rabbit	NOUN	NN	3	O
heart	heart	NOUN	NN	5	O
,	,	PUNCT	,	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
action	action	NOUN	NN	5	O
potential	potential	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
AP	AP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
spike	spike	ADJ	JJ	5	O
frequency	frequency	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
recorded	record	VERB	VBN	5	O
by	by	ADP	IN	9	O
KCl	KCl	NOUN	NNS	0	B-Chemical
microelectrodes	microelectrode	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
starting	start	VERB	VBG	9	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
X	x	NOUN	NN	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
M	m	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
up	up	PART	RP	5	O
to	to	ADP	IN	5	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
X	x	NOUN	NN	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
M	m	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whereupon	whereupon	NOUN	NN	9	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
sinus	sinus	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
set	set	VERB	VBN	5	O
in	in	PART	RP	5	O
.	.	PUNCT	.	9	O

Bepridil	Bepridil	NOUN	NNS	0	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
X	x	NOUN	NN	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
M	M	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
AP	AP	PROPN	NNP	9	O
amplitude	amplitude	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
falling	fall	VERB	VBG	5	O
from	from	ADP	IN	9	O
71	71	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
mV	mv	NOUN	NN	0	O
to	to	ADP	IN	5	O
47	47	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
mV	mV	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
maximum	maximum	ADJ	JJ	5	O
systolic	systolic	ADJ	JJ	5	O
depolarization	depolarization	NOUN	NN	9	O
velocity	velocity	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
phase	phase	PROPN	NNP	5	O
0	0	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
which	which	DET	WDT	5	O
fell	fall	VERB	VBD	5	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
85	85	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
V	v	NOUN	NN	9	O
/	/	SYM	SYM	9	O
s	s	NOUN	NN	9	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
84	84	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
28	28	NUM	CD	7	O
V	v	NOUN	NN	9	O
/	/	SYM	SYM	9	O
s	s	NOUN	NN	9	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
maximum	maximum	ADJ	JJ	5	O
diastolic	diastolic	ADJ	JJ	5	O
depolarization	depolarization	NOUN	NN	9	O
velocity	velocity	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
phase	phase	NOUN	NN	5	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
which	which	DET	WDT	5	O
fell	fall	VERB	VBD	5	O
from	from	ADP	IN	9	O
38	38	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
mV	mv	NOUN	NN	0	O
/	/	PUNCT	,	9	O
s	s	NOUN	NN	9	O
to	to	ADP	IN	5	O
24	24	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
mV	mv	NOUN	NN	0	O
/	/	SYM	SYM	9	O
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vivo	vivo	NOUN	NNS	3	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
bepridil	bepridil	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
into	into	ADP	IN	9	O
6	6	NUM	CD	9	O
anaesthetized	anaesthetized	ADJ	JJ	0	O
dogs	dog	NOUN	NNS	5	O
which	which	DET	WDT	5	O
had	have	VERB	VBD	9	O
undergone	undergo	VERB	VBN	5	O
ablation	ablation	NOUN	NN	9	O
of	of	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
extrinsic	extrinsic	NOUN	NN	5	O
cardiac	cardiac	ADJ	JJ	5	O
afferent	afferent	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
supply	supply	NOUN	NN	5	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
bilateral	bilateral	ADJ	JJ	5	O
medullo	medullo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenalectomy	adrenalectomy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
which	which	DET	WDT	5	O
fell	fall	VERB	VBD	5	O
from	from	ADP	IN	9	O
98	98	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
beats	beat	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
to	to	ADP	IN	5	O
76	76	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
beats	beat	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
sustained	sustain	VERB	VBN	5	O
for	for	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
45	45	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
bepridil	bepridil	NOUN	NN	0	B-Chemical
reduces	reduce	VERB	VBZ	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
by	by	ADP	IN	9	O
acting	act	VERB	VBG	9	O
directly	directly	ADV	RB	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
sinus	sinus	NOUN	NN	5	O
node	node	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
results	result	VERB	VBZ	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
flattening	flattening	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
phase	phase	NOUN	NN	5	O
0	0	NUM	CD	7	O
and	and	CCONJ	CC	5	O
phase	phase	NOUN	NN	5	O
4	4	NUM	CD	9	O
slope	slope	NOUN	NN	5	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
longer	long	ADJ	JJR	5	O
AP	AP	PROPN	NNP	9	O
duration	duration	NOUN	NN	5	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
constants	constant	NOUN	NNS	0	O
of	of	ADP	IN	5	O
slow	slow	ADJ	JJ	5	O
inward	inward	ADJ	JJ	5	O
ionic	ionic	ADJ	JJ	0	O
currents	current	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
already	already	ADV	RB	5	O
demonstrated	demonstrate	VERB	VBN	9	O
elsewhere	elsewhere	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
time	time	NOUN	NN	5	O
constant	constant	ADJ	JJ	9	O
for	for	ADP	IN	5	O
deactivation	deactivation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
outward	outward	ADJ	JJ	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
current	current	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
Ip	Ip	PROPN	NNP	6	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Hepatitis	Hepatitis	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
acidosis	acidosis	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
anesthesia	anesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
methoxyflurane	methoxyflurane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
69	69	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
operated	operate	VERB	VBN	5	O
for	for	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
cholecystitis	cholecystitis	NOUN	NN	5	I-Disease
under	under	ADP	IN	9	O
methoxyflurane	methoxyflurane	ADJ	JJ	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
postoperatively	postoperatively	ADV	RB	5	O
a	a	DET	DT	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
acidosis	acidosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Massive	massive	ADJ	JJ	5	O
bleeding	bleeding	NOUN	NN	5	B-Disease
appeared	appear	VERB	VBD	9	O
during	during	ADP	IN	5	O
surgery	surgery	NOUN	NN	5	O
which	which	DET	WDT	5	O
lasted	last	VERB	VBD	5	O
for	for	ADP	IN	5	O
six	six	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Postoperative	postoperative	ADJ	JJ	5	O
evolution	evolution	NOUN	NN	5	O
under	under	ADP	IN	9	O
supportive	supportive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
favourable	favourable	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Complete	complete	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
was	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
repeated	repeat	VERB	VBN	5	O
controls	control	NOUN	NNS	9	O
performed	perform	VERB	VBN	9	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pituitary	pituitary	ADJ	JJ	2	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
luteinizing	luteinize	VERB	VBG	0	O
hormone	hormone	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
releasing	release	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
during	during	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
infusion	infusion	NOUN	NN	0	O
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
prolactin	prolactin	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
luteinizing	luteinize	VERB	VBG	0	O
hormone	hormone	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
LH	LH	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
male	male	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
the	the	DET	DT	5	O
infusions	infusion	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pituitary	pituitary	ADJ	JJ	3	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
LH	lh	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
releasing	release	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
LH	LH	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
RH	RH	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
.	.	PUNCT	.	9	O

Control	control	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
NaCl	NaCl	PROPN	NNP	0	B-Chemical
solution	solution	NOUN	NN	0	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
infusions	infusion	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
significant	significant	ADJ	JJ	9	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
abolished	abolish	VERB	VBN	3	O
pituitary	pituitary	ADJ	JJ	3	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
LH	LH	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
RH	RH	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
responses	response	NOUN	NNS	5	O
of	of	ADP	IN	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Antirifampicin	Antirifampicin	PROPN	NNP	_	O
antibodies	antibody	NOUN	NNS	3	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
rifampicin	rifampicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
with	with	ADP	IN	5	O
thrombopenia	thrombopenia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
reintroduction	reintroduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
rifampicin	rifampicin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
taken	take	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	DT	5	O
but	but	ADP	IN	9	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
antirifampicin	antirifampicin	NOUN	NN	_	O
antibodies	antibody	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Antibodies	antibody	NOUN	NNS	3	O
suggested	suggest	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
IgM	IgM	PROPN	NNP	3	O
class	class	NOUN	NN	9	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hematological	hematological	ADJ	JJ	9	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
specific	specific	ADJ	JJ	9	O
acute	acute	ADJ	JJ	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
biopsied	biopsie	VERB	VBN	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
indistinguishable	indistinguishable	ADJ	JJ	9	O
from	from	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	O
origin	origin	NOUN	NN	9	O
,	,	PUNCT	,	9	O
raised	raise	VERB	VBD	9	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
vascular	vascular	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
triggering	trigger	VERB	VBG	9	O
immunoallergic	immunoallergic	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Cardiovascular	cardiovascular	ADJ	JJ	2	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
triphosphate	triphosphate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	ADV	RB	0	I-Chemical
on	on	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
denervated	denervate	VERB	VBN	3	O
hearts	heart	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Adenosine	adenosine	NOUN	NN	0	B-Chemical
triphosphate	triphosphate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
SNP	SNP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
and	and	CCONJ	CC	5	O
control	control	VERB	VB	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

SNP	SNP	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
authorized	authorize	VERB	VBN	5	O
for	for	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
USA	USA	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
UK	UK	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
ATP	ATP	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
clinically	clinically	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
other	other	ADJ	JJ	5	O
countries	country	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
Japan	Japan	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
how	how	ADV	WRB	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
drugs	drug	NOUN	NNS	5	O
act	act	VERB	VBP	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
systems	system	NOUN	NNS	5	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
whose	whose	DET	WP$	9	O
hearts	heart	NOUN	NNS	3	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
denervated	denervate	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
devised	devise	VERB	VBN	5	O
.	.	PUNCT	.	9	O

ATP	ATP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
SNP	SNP	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
by	by	ADP	IN	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Before	before	ADV	RB	9	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
measured	measure	VERB	VBD	9	O
major	major	ADJ	JJ	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hypotension	hypotension	NOUN	NN	7	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
significant	significant	ADJ	JJ	9	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
central	central	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	NOUN	NN	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
peripheral	peripheral	ADJ	JJ	9	O
resistance	resistance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
rate	rate	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
product	product	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
body	body	NOUN	NN	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
all	all	DET	PDT	5	O
these	these	DET	DT	5	O
variables	variable	NOUN	NNS	5	O
returned	return	VERB	VBD	5	O
normal	normal	ADJ	JJ	9	O
within	within	ADP	IN	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
output	output	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
SNP	SNP	PROPN	NNP	9	B-Chemical
similar	similar	ADJ	JJ	9	O
decreases	decrease	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
central	central	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	NOUN	NN	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
peripheral	peripheral	ADJ	JJ	9	O
resistance	resistance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
rate	rate	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
product	product	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
content	content	NOUN	NN	9	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
mixed	mixed	ADJ	JJ	9	O
venous	venous	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Recoveries	recovery	NOUN	NNS	0	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
shown	show	VERB	VBN	9	O
within	within	ADP	IN	9	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
SNP	SNP	PROPN	NNP	9	B-Chemical
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
SNP	SNP	PROPN	NNP	9	B-Chemical
should	should	VERB	MD	5	O
act	act	VERB	VB	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
pacemaker	pacemaker	NOUN	NN	5	O
tissue	tissue	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Comparative	comparative	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Endografine	Endografine	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
diatrizoate	diatrizoate	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Vasurix	Vasurix	PROPN	NNP	_	B-Chemical
polyvidone	polyvidone	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
acetrizoate	acetrizoate	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Dimer	Dimer	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
X	X	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
iocarmate	iocarmate	ADJ	JJ	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Hexabrix	Hexabrix	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ioxaglate	ioxaglate	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
hysterosalpingography	hysterosalpingography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hysterosalpingography	hysterosalpingography	NOUN	NN	5	O
with	with	ADP	IN	5	O
Dimer	Dimer	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
X	X	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
Hexabrix	Hexabrix	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
Vasurix	Vasurix	PROPN	NNP	_	B-Chemical
polyvidone	polyvidone	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
Endografine	Endografine	PROPN	NNP	_	B-Chemical
in	in	ADP	IN	5	O
142	142	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
receiving	receive	VERB	VBG	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
four	four	NUM	CD	9	O
tested	test	VERB	VBN	9	O
media	medium	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
from	from	ADP	IN	9	O
replies	reply	NOUN	NNS	5	O
to	to	ADP	IN	5	O
postal	postal	ADJ	JJ	5	O
questionnaires	questionnaire	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Dimer	Dimer	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
X	X	PROPN	NNP	9	I-Chemical
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
dizziness	dizziness	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Endografine	Endografine	PROPN	NNP	_	B-Chemical
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
differences	difference	NOUN	NNS	9	O
occur	occur	VERB	VBP	5	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
age	age	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
under	under	ADP	IN	9	O
30	30	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hexabrix	Hexabrix	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
Vasurix	Vasurix	PROPN	NNP	_	B-Chemical
polyvidone	polyvidone	NOUN	NN	0	I-Chemical
are	be	VERB	VBP	5	O
considered	consider	VERB	VBN	5	O
the	the	DET	DT	5	O
best	good	ADJ	JJS	5	O
contrast	contrast	NOUN	NN	9	B-Chemical
media	medium	NOUN	NNS	9	I-Chemical
for	for	ADP	IN	5	O
hysterosalpingography	hysterosalpingography	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
perhaps	perhaps	ADV	RB	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
low	low	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
Hexabrix	Hexabrix	PROPN	NNP	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
preferred	prefer	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
suxamethonium	suxamethonium	ADJ	JJ	5	B-Chemical
pains	pain	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
Nigerian	nigerian	ADJ	JJ	5	O
surgical	surgical	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Contrary	contrary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
earlier	early	ADJ	JJR	9	O
report	report	NOUN	NN	5	O
by	by	ADP	IN	9	O
Coxon	Coxon	PROPN	NNP	6	O
,	,	PUNCT	,	9	O
scoline	scoline	NOUN	NN	0	B-Chemical
pain	pain	NOUN	NN	5	B-Disease
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
African	african	ADJ	JJ	5	O
negroes	negro	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Its	-PRON-	DET	PRP$	5	O
incidence	incidence	NOUN	NN	5	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
involving	involve	VERB	VBG	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
Nigerian	nigerian	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
out	out	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
in	in	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

About	about	ADV	RB	9	O
62	62	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
out	out	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
scoline	scoline	NOUN	NN	0	B-Chemical
pain	pain	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
about	about	ADV	RB	5	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
in	in	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
abolition	abolition	NOUN	NN	5	O
of	of	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
fasciculations	fasciculation	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
by	by	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
075mg	075mg	PROPN	NNP	_	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
Fazadinium	Fazadinium	PROPN	NNP	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
influence	influence	VERB	VB	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
scoline	scoline	NOUN	NN	0	B-Chemical
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Neither	neither	CCONJ	CC	9	O
the	the	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
agent	agent	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Althesin	Althesin	PROPN	NNP	5	B-Chemical
or	or	CCONJ	CC	5	O
Thiopentone	Thiopentone	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
nor	nor	CCONJ	CC	9	O
the	the	DET	DT	5	O
salt	salt	NOUN	NN	0	O
preparation	preparation	NOUN	NN	9	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
used	use	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
chloride	chloride	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
bromide	bromide	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
affected	affect	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
scoline	scoline	NOUN	NN	0	B-Chemical
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Invasive	invasive	ADJ	JJ	9	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
pelvis	pelvi	NOUN	NNS	5	I-Disease
following	follow	VERB	VBG	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
nonmalignant	nonmalignant	ADJ	JJ	3	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
47	47	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
right	right	ADJ	JJ	5	O
hydroureteronephrosis	hydroureteronephrosis	NOUN	NN	5	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
ureterovesical	ureterovesical	ADJ	JJ	5	O
junction	junction	NOUN	NN	9	O
obstruction	obstruction	NOUN	NN	5	O
had	have	VERB	VBD	9	O
gross	gross	ADJ	JJ	5	O
hematuria	hematuria	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
five	five	NUM	CD	9	O
years	year	NOUN	NNS	5	O
wtih	wtih	NOUN	NN	3	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
right	right	ADJ	JJ	5	O
nephroureterectomy	nephroureterectomy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
required	require	VERB	VBN	9	O
for	for	ADP	IN	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
bleeding	bleed	VERB	VBG	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pathology	pathology	NOUN	NN	5	O
specimen	speciman	NOUN	NNS	9	O
contained	contain	VERB	VBD	9	O
clinically	clinically	ADV	RB	5	O
occult	occult	VERB	VBP	5	O
invasive	invasive	ADJ	JJ	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
pelvis	pelvi	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
cytologic	cytologic	ADJ	JJ	5	O
abnormalities	abnormality	NOUN	NNS	9	O
indistinguishable	indistinguishable	ADJ	JJ	9	O
from	from	ADP	IN	9	O
high	high	ADJ	JJ	9	O
grade	grade	NOUN	NN	9	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
known	know	VERB	VBN	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
less	less	ADV	RBR	5	O
widely	widely	ADV	RB	5	O
appreciated	appreciate	VERB	VBN	5	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
also	also	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
urinary	urinary	ADJ	JJ	9	I-Disease
tract	tract	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
carcinomas	carcinoma	NOUN	NNS	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
urinary	urinary	ADJ	JJ	9	I-Disease
bladder	bladder	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
prostate	prostate	NOUN	NN	3	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
pelvis	pelvi	NOUN	NNS	5	I-Disease
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
urinary	urinary	ADJ	JJ	9	B-Disease
tract	tract	NOUN	NN	9	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
nonmalignant	nonmalignant	ADJ	JJ	3	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
association	association	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
with	with	ADP	IN	5	O
preexisting	preexist	VERB	VBG	9	O
hydroureteronephrosis	hydroureteronephrosis	NOUN	NN	5	B-Disease
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
stasis	stasis	NOUN	NN	5	O
prolonged	prolong	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
intensified	intensify	VERB	VBN	5	O
exposure	exposure	NOUN	NN	9	O
of	of	ADP	IN	5	O
upper	upper	ADJ	JJ	9	O
urinary	urinary	ADJ	JJ	9	O
tract	tract	NOUN	NN	9	O
epithelium	epithelium	NOUN	NN	3	O
to	to	PART	TO	5	O
cyclophosphamide	cyclophosphamide	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
candidates	candidate	NOUN	NNS	9	O
for	for	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
routinely	routinely	ADV	RB	9	O
evaluated	evaluate	VERB	VBN	9	O
for	for	ADP	IN	5	O
obstructive	obstructive	ADJ	JJ	5	B-Disease
uropathy	uropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Medial	medial	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
spasm	spasm	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
norepinephrine	norepinephrine	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
media	medium	NOUN	NNS	9	O
of	of	ADP	IN	5	O
small	small	ADJ	JJ	9	O
arteries	artery	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
in	in	ADP	IN	5	O
diameter	diameter	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
previously	previously	ADV	RB	9	O
was	be	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
contain	contain	VERB	VB	9	O
intracellular	intracellular	ADJ	JJ	3	O
vacuoles	vacuole	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
identified	identify	VERB	VBN	9	O
ultrastructurally	ultrastructurally	ADV	RB	3	O
as	as	ADP	IN	5	O
herniations	herniation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
one	one	NUM	CD	5	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
cell	cell	NOUN	NN	3	O
into	into	ADP	IN	9	O
another	another	DET	DT	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
intense	intense	ADJ	JJ	9	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
would	would	VERB	MD	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
such	such	ADJ	JJ	5	O
vacuoles	vacuole	NOUN	NNS	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
tested	test	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
media	medium	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
saphenous	saphenous	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
distal	distal	ADJ	JJ	9	O
branch	branch	NOUN	NN	5	O
,	,	PUNCT	,	9	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
norepinephrine	norepinephrine	NOUN	NN	9	I-Chemical
produced	produce	VERB	VBD	9	O
many	many	ADJ	JJ	5	O
cell	cell	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
hernias	hernia	NOUN	NNS	5	B-Disease
within	within	ADP	IN	9	O
15	15	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
1	1	NUM	CD	9	O
day	day	NOUN	NN	9	O
their	-PRON-	DET	PRP$	5	O
number	number	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
to	to	ADP	IN	5	O
about	about	ADV	RB	5	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
10	10	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
original	original	ADJ	JJ	5	O
number	number	NOUN	NN	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
the	the	DET	DT	5	O
vessel	vessel	NOUN	NN	5	O
was	be	VERB	VBD	9	O
almost	almost	ADV	RB	9	O
restored	restore	VERB	VBN	3	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Triple	triple	ADJ	JJ	9	O
stimulation	stimulation	NOUN	NN	3	O
over	over	ADP	IN	5	O
1	1	NUM	CD	9	O
day	day	NOUN	NN	9	O
induced	induce	VERB	VBD	3	O
more	more	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
media	medium	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
susceptible	susceptible	ADJ	JJ	9	O
to	to	ADP	IN	5	O
damage	damage	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
specific	specific	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
in	in	ADP	IN	5	O
relation	relation	NOUN	NN	5	O
to	to	ADP	IN	5	O
medial	medial	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
other	other	ADJ	JJ	5	O
instances	instance	NOUN	NNS	5	O
of	of	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
spasm	spasm	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Endothelial	endothelial	ADJ	JJ	3	O
changes	change	NOUN	NNS	9	O
that	that	DET	WDT	5	O
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
were	be	VERB	VBD	9	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
paper	paper	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Bilateral	bilateral	ADJ	JJ	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
choriocapillaris	choriocapillaris	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
corticosteroid	corticosteroid	ADJ	JJ	5	B-Chemical
suspensions	suspension	NOUN	NNS	0	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
I	-PRON-	PRON	PRP	9	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
documented	document	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
choriocapillaris	choriocapillaris	NOUN	NN	5	I-Disease
occlusions	occlusion	NOUN	NNS	5	I-Disease
with	with	ADP	IN	5	O
blindness	blindness	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
head	head	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
neck	neck	VERB	VB	5	O
soft	soft	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
tissue	tissue	NOUN	NN	9	O
injection	injection	NOUN	NN	9	O
with	with	ADP	IN	5	O
methylprednisolone	methylprednisolone	ADJ	JJ	0	B-Chemical
acetate	acetate	ADJ	JJ	0	I-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
had	have	VERB	VBD	9	O
only	only	ADV	RB	9	O
a	a	DET	DT	5	O
unilateral	unilateral	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
observations	observation	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
hazy	hazy	ADJ	JJ	5	O
sensorium	sensorium	NOUN	NN	5	O
,	,	PUNCT	,	9	O
superior	superior	ADJ	JJ	5	O
gaze	gaze	ADJ	JJ	5	O
palsy	palsy	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
pupillary	pupillary	ADJ	JJ	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
conjunctival	conjunctival	NOUN	NN	5	O
hemorrhages	hemorrhage	NOUN	NNS	5	B-Disease
with	with	ADP	IN	5	O
edema	edema	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
changes	change	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
marked	mark	VERB	VBN	9	O
visual	visual	ADJ	JJ	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
constricted	constrict	VERB	VBD	5	O
visual	visual	ADJ	JJ	5	O
fields	field	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
optic	optic	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
pallor	pallor	NOUN	NN	5	O
,	,	PUNCT	,	9	O
vascular	vascular	ADJ	JJ	5	O
attenuation	attenuation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
chorioretinal	chorioretinal	ADJ	JJ	5	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
reviewed	review	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
causes	cause	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Abnormalities	abnormality	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pupil	pupil	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
visual	visual	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
evoked	evoked	ADJ	JJ	5	O
potential	potential	NOUN	NN	9	O
in	in	ADP	IN	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
amblyopia	amblyopia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
blindness	blindness	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
transient	transient	ADJ	JJ	9	O
tonic	tonic	NOUN	NN	5	B-Disease
pupillary	pupillary	ADJ	JJ	5	I-Disease
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
denervation	denervation	NOUN	NN	5	O
supersensitivity	supersensitivity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
abnormal	abnormal	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
potentials	potential	NOUN	NNS	5	O
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
54	54	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
for	for	ADP	IN	5	O
leg	leg	NOUN	NN	5	B-Disease
cramps	cramp	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
later	later	ADV	RB	9	O
recovered	recover	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
transient	transient	ADJ	JJ	9	O
tonic	tonic	NOUN	NN	5	B-Disease
pupillary	pupillary	ADJ	JJ	5	I-Disease
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
denervation	denervation	NOUN	NN	5	O
supersensitivity	supersensitivity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
abnormal	abnormal	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
potentials	potential	NOUN	NNS	5	O
in	in	ADP	IN	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Suxamethonium	suxamethonium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
jaw	jaw	NOUN	NN	5	B-Disease
stiffness	stiffness	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
atypical	atypical	ADJ	JJ	5	O
cholinesterase	cholinesterase	NOUN	NN	0	O
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
11	11	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
boy	boy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
nitrous	nitrous	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
pancuronium	pancuronium	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
for	for	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
jaw	jaw	NOUN	NN	5	B-Disease
stiffness	stiffness	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
which	which	DET	WDT	5	O
lasted	last	VERB	VBD	5	O
for	for	ADP	IN	5	O
two	two	NUM	CD	5	O
minutes	minute	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
were	be	VERB	VBD	9	O
terminated	terminate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
of	of	ADP	IN	5	O
apnoea	apnoea	NOUN	NN	5	B-Disease
ensued	ensue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
he	-PRON-	PRON	PRP	5	O
suffered	suffer	VERB	VBD	5	O
generalized	generalize	VERB	VBN	5	O
severe	severe	ADJ	JJ	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
lasting	last	VERB	VBG	5	O
for	for	ADP	IN	5	O
one	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
atypical	atypical	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
cholinesterase	cholinesterase	NOUN	NN	0	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
dibucaine	dibucaine	ADJ	JJ	0	B-Chemical
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
homozygocity	homozygocity	NOUN	NN	1	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
verified	verify	VERB	VBN	9	O
by	by	ADP	IN	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
family	family	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	B-Disease
jaw	jaw	NOUN	NN	5	I-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
after	after	ADP	IN	9	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
atypical	atypical	ADJ	JJ	5	O
cholinesterase	cholinesterase	NOUN	NN	0	O
despite	despite	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
pancuronium	pancuronium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Indomethacin	indomethacin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
gouty	gouty	NOUN	NN	5	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
severe	severe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
developed	develop	VERB	VBN	5	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
gouty	gouty	NOUN	NN	5	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
indomethacin	indomethacin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
an	an	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	ADJ	JJ	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
consequent	consequent	ADJ	JJ	9	O
hyporeninemic	hyporeninemic	ADJ	JJ	9	B-Disease
hypoaidosteronism	hypoaidosteronism	NOUN	NN	_	I-Disease
.	.	PUNCT	.	9	O

Careful	careful	ADJ	JJ	5	O
attention	attention	NOUN	NN	5	O
to	to	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
balance	balance	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
preexisting	preexist	VERB	VBG	9	O
renal	renal	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
will	will	VERB	MD	5	O
help	help	VERB	VB	5	O
prevent	prevent	VERB	VB	5	O
this	this	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
serious	serious	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Etomidate	etomidate	VERB	VB	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
foreshortened	foreshortened	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
clinical	clinical	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
outpatient	outpatient	NOUN	NN	5	O
cystoscopy	cystoscopy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
embarked	embark	VERB	VBN	5	O
upon	upon	ADP	IN	9	O
.	.	PUNCT	.	9	O

Unpremedicated	unpremedicated	ADJ	JJ	_	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
microgram	microgram	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	ADP	IN	0	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Anaesthesia	Anaesthesia	PROPN	NNP	2	O
was	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
with	with	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
interviewed	interview	VERB	VBN	5	O
personally	personally	ADV	RB	5	O
later	later	ADV	RB	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
questionnaire	questionnaire	NOUN	NN	5	O
three	three	NUM	CD	9	O
to	to	PART	TO	5	O
four	four	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
trial	trial	NOUN	NN	5	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
after	after	ADP	IN	9	O
20	20	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
unacceptable	unacceptable	ADJ	JJ	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Venous	venous	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
68	68	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
had	have	VERB	VBD	9	O
redness	redness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pain	pain	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
swelling	swell	VERB	VBG	5	B-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
site	site	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
cases	case	NOUN	NNS	5	O
lasting	last	VERB	VBG	5	O
up	up	PART	RP	5	O
to	to	PART	TO	5	O
three	three	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Skeletal	skeletal	ADJ	JJ	9	O
movements	movement	NOUN	NNS	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
experienced	experience	VERB	VBD	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
upset	upset	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
sufficiently	sufficiently	ADV	RB	5	O
severe	severe	ADJ	JJ	5	O
to	to	PART	TO	5	O
necessitate	necessitate	VERB	VB	5	O
abandoning	abandon	VERB	VBG	5	O
the	the	DET	DT	5	O
technique	technique	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Nausea	nausea	NOUN	NN	7	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
had	have	VERB	VBD	9	O
disturbing	disturb	VERB	VBG	5	O
emergence	emergence	NOUN	NN	9	O
psychoses	psychosis	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
are	be	VERB	VBP	5	O
improved	improve	VERB	VBN	5	O
by	by	ADP	IN	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	B-Disease
disability	disability	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
seven	seven	NUM	CD	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
responsive	responsive	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
challenge	challenge	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
mixed	mixed	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
twice	twice	ADV	RB	9	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
11	11	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
47	47	NUM	CD	7	O
%	%	NOUN	NN	9	O
improvement	improvement	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
without	without	ADP	IN	9	O
modification	modification	NOUN	NN	9	O
of	of	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
motor	motor	NOUN	NN	5	B-Disease
disability	disability	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
predominantly	predominantly	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
limbs	limb	NOUN	NNS	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
dystonic	dystonic	ADJ	JJ	5	B-Disease
dyskinesias	dyskinesia	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
onset	onset	NOUN	NN	5	O
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
of	of	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
limbs	limb	NOUN	NNS	5	O
during	during	ADP	IN	5	O
choreic	choreic	ADJ	JJ	5	B-Disease
mid	mid	ADJ	JJ	9	I-Disease
-	-	ADJ	JJ	7	I-Disease
dose	dose	ADJ	JJ	9	I-Disease
dyskinesias	dyskinesia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
brain	brain	NOUN	NN	5	O
serotoninergic	serotoninergic	ADJ	JJ	5	O
transmission	transmission	NOUN	NN	5	O
with	with	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
reduce	reduce	VERB	VB	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
agonist	agonist	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
without	without	ADP	IN	9	O
aggravating	aggravate	VERB	VBG	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
motor	motor	NOUN	NN	5	B-Disease
disability	disability	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
large	large	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
trimethoprim	trimethoprim	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sulfamethoxazole	sulfamethoxazole	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
trimethoprim	trimethoprim	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cephalexin	cephalexin	VERB	VB	0	B-Chemical
for	for	ADP	IN	5	O
uncommon	uncommon	ADJ	JJ	5	O
serious	serious	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
45	45	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
232	232	NUM	CD	7	O
,	,	PUNCT	,	9	O
390	390	NUM	CD	9	O
people	people	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
prescribed	prescribe	VERB	VBN	5	O
trimethoprim	trimethoprim	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sulfamethoxazole	sulfamethoxazole	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
TMP	TMP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
SMZ	SMZ	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
266	266	NUM	CD	7	O
,	,	PUNCT	,	9	O
951	951	NUM	CD	7	O
prescribed	prescribe	VERB	VBD	5	O
trimethoprim	trimethoprim	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
196	196	NUM	CD	7	O
,	,	PUNCT	,	9	O
397	397	NUM	CD	7	O
prescribed	prescribe	VERB	VBD	5	O
cephalexin	cephalexin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
estimate	estimate	VERB	VB	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	I-Disease
blood	blood	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	I-Disease
skin	skin	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
referral	referral	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
hospitalization	hospitalization	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
information	information	NOUN	NN	5	O
recorded	record	VERB	VBN	5	O
on	on	ADP	IN	5	O
office	office	NOUN	NN	5	O
computers	computer	NOUN	NNS	5	O
by	by	ADP	IN	9	O
selected	select	VERB	VBN	9	O
general	general	ADJ	JJ	5	O
practitioners	practitioner	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
Kingdom	Kingdom	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
clinically	clinically	ADV	RB	5	O
important	important	ADJ	JJ	9	O
idiopathic	idiopathic	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
for	for	ADP	IN	5	O
persons	person	NOUN	NNS	5	O
prescribed	prescribe	VERB	VBN	5	O
TMP	TMP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
SMZ	SMZ	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
prescribed	prescribe	VERB	VBN	5	O
trimethoprim	trimethoprim	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
those	those	DET	DT	5	O
prescribed	prescribe	VERB	VBN	5	O
cephalexin	cephalexin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
somewhat	somewhat	ADV	RB	5	O
lower	low	ADJ	JJR	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
blood	blood	NOUN	NN	9	O
disorders	disorder	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
was	be	VERB	VBD	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
TMP	TMP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
SMZ	SMZ	PROPN	NNP	0	I-Chemical
;	;	PUNCT	:	9	O
of	of	ADP	IN	5	O
seven	seven	NUM	CD	9	O
with	with	ADP	IN	5	O
erythema	erythema	NOUN	NN	5	B-Disease
multiforme	multiforme	NOUN	NNS	9	I-Disease
and	and	CCONJ	CC	5	O
Stevens	Stevens	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Johnson	Johnson	PROPN	NNP	6	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
four	four	NUM	CD	9	O
were	be	VERB	VBD	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
TMP	TMP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
SMZ	SMZ	PROPN	NNP	0	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	B-Disease
epidermal	epidermal	ADJ	JJ	3	I-Disease
necrolysis	necrolysis	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
took	take	VERB	VBD	5	O
cephalexin	cephalexin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
parenchymal	parenchymal	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
,	,	PUNCT	,	9	O
none	none	NOUN	NN	9	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
study	study	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
diseases	disease	NOUN	NNS	5	O
studied	study	VERB	VBN	9	O
is	be	VERB	VBZ	5	O
small	small	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
compares	compare	VERB	VBZ	5	O
reasonably	reasonably	ADV	RB	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
many	many	ADJ	JJ	5	O
other	other	ADJ	JJ	5	O
antibiotics	antibiotic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

STUDY	study	NOUN	NN	2	O
OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
setting	setting	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MI	MI	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
retrospective	retrospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
multicenter	multicenter	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

SETTING	set	VERB	VBG	2	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
university	university	NOUN	NN	5	O
,	,	PUNCT	,	9	O
university	university	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
affiliated	affiliate	VERB	VBN	2	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
community	community	NOUN	NN	5	O
hospitals	hospital	NOUN	NNS	5	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
117	117	NUM	CD	7	O
cumulative	cumulative	ADJ	JJ	5	O
hospital	hospital	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

PARTICIPANTS	participant	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
MI	MI	PROPN	NNP	9	B-Disease
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Of	of	ADP	IN	9	O
29	29	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
setting	setting	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
MI	MI	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
patient	patient	NOUN	NN	5	O
died	die	VERB	VBD	9	O
;	;	PUNCT	:	9	O
exhibited	exhibit	VERB	VBN	9	O
bradydysrhythmias	bradydysrhythmias	NOUN	NN	_	B-Disease
,	,	PUNCT	,	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
;	;	PUNCT	:	9	O
or	or	CCONJ	CC	5	O
experienced	experience	VERB	VBD	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
11	11	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Despite	despite	ADP	IN	5	O
theoretical	theoretical	ADJ	JJ	5	O
concerns	concern	NOUN	NNS	5	O
that	that	DET	WDT	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
enhance	enhance	VERB	VB	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
MI	MI	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	I-Disease
central	central	ADJ	JJ	5	I-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Experimental	experimental	ADJ	JJ	9	O
progressive	progressive	ADJ	JJ	5	O
muscular	muscular	ADJ	JJ	5	B-Disease
dystrophy	dystrophy	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
anabolizing	anabolize	VERB	VBG	_	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
are	be	VERB	VBP	5	O
still	still	ADV	RB	5	O
a	a	DET	DT	5	O
long	long	ADJ	JJ	5	O
way	way	NOUN	NN	5	O
from	from	ADP	IN	9	O
discovering	discover	VERB	VBG	5	O
an	an	DET	DT	5	O
unequivocal	unequivocal	ADJ	JJ	9	O
pathogenetic	pathogenetic	ADJ	JJ	5	O
interpretation	interpretation	NOUN	NN	5	O
of	of	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
muscular	muscular	ADJ	JJ	5	B-Disease
dystrophy	dystrophy	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Noteworthy	noteworthy	ADJ	JJ	9	O
efforts	effort	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
made	make	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
;	;	PUNCT	:	9	O
a	a	DET	DT	5	O
recessive	recessive	ADJ	JJ	9	O
autosomic	autosomic	ADJ	JJ	5	O
form	form	NOUN	NN	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mouse	mouse	NOUN	NN	3	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
bear	bear	VERB	VB	9	O
the	the	DET	DT	5	O
closest	close	ADJ	JJS	9	O
resemblance	resemblance	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
form	form	NOUN	NN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
genetic	genetic	ADJ	JJ	5	O
point	point	NOUN	NN	5	O
of	of	ADP	IN	5	O
view	view	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Myopathy	Myopathy	PROPN	NNP	7	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
myopathy	myopathy	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
certain	certain	ADJ	JJ	5	O
viruses	virus	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
much	much	ADJ	JJ	5	O
in	in	ADP	IN	5	O
common	common	ADJ	JJ	5	O
anatomically	anatomically	ADV	RB	5	O
and	and	CCONJ	CC	5	O
pathologically	pathologically	ADV	RB	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
form	form	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
induced	induce	VERB	VBD	3	O
myodystrophy	myodystrophy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
by	by	ADP	IN	9	O
giving	give	VERB	VBG	5	O
it	-PRON-	PRON	PRP	5	O
a	a	DET	DT	5	O
diet	diet	NOUN	NN	9	O
lacking	lack	VERB	VBG	1	O
in	in	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
degenerative	degenerative	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
brought	bring	VERB	VBN	5	O
about	about	PART	RP	5	O
by	by	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
deficiency	deficiency	NOUN	NN	9	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
muscles	muscle	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
illustrated	illustrate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
thus	thus	ADV	RB	9	O
confirmed	confirm	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
histological	histological	ADJ	JJ	9	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
myopathic	myopathic	ADJ	JJ	5	B-Disease
rat	rat	NOUN	NN	3	O
muscle	muscle	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
experimentally	experimentally	ADV	RB	9	O
are	be	VERB	VBP	5	O
extraordinarily	extraordinarily	ADV	RB	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
myopathy	myopathy	NOUN	NN	9	B-Disease
as	as	ADP	IN	5	O
confirmed	confirm	VERB	VBN	9	O
during	during	ADP	IN	5	O
biopsies	biopsy	NOUN	NNS	9	O
performed	perform	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
Orthopaedic	Orthopaedic	PROPN	NNP	2	O
Traumatological	Traumatological	PROPN	NNP	9	O
Centre	Centre	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Florence	Florence	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
encouraging	encouraging	ADJ	JJ	5	O
results	result	NOUN	NNS	9	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
authoratative	authoratative	ADJ	JJ	_	O
departments	department	NOUN	NNS	5	O
in	in	ADP	IN	5	O
myopathic	myopathic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
anabolizing	anabolize	VERB	VBG	_	O
steroids	steroid	NOUN	NNS	9	B-Chemical
have	have	VERB	VBP	5	O
encouraged	encourage	VERB	VBN	5	O
the	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
one	one	NUM	CD	5	O
anabolizing	anabolize	VERB	VBG	_	O
agent	agent	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Dianabol	Dianabol	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
CIBA	CIBA	PROPN	NNP	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
rendered	render	VERB	VBN	9	O
myopathic	myopathic	ADJ	JJ	5	B-Disease
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
diet	diet	NOUN	NN	9	O
deficient	deficient	ADJ	JJ	3	O
in	in	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
way	way	NOUN	NN	5	O
they	-PRON-	PRON	PRP	5	O
obtained	obtain	VERB	VBD	9	O
appreciable	appreciable	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
increased	increase	VERB	VBN	9	O
from	from	ADP	IN	9	O
50	50	NUM	CD	0	O
to	to	PART	TO	5	O
70	70	NUM	CD	9	O
g	g	NOUN	NN	0	O
after	after	ADP	IN	9	O
forty	forty	NUM	CD	5	O
days	day	NOUN	NNS	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
anabolizing	anabolize	VERB	VBG	_	O
agent	agent	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
they	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
histological	histological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
"	"	PUNCT	``	5	O
regenerative	regenerative	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
muscle	muscle	NOUN	NN	9	O
tissue	tissue	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
however	however	ADV	RB	9	O
maintained	maintain	VERB	VBD	9	O
its	-PRON-	DET	PRP$	9	O
myopathic	myopathic	ADJ	JJ	5	B-Disease
characteristics	characteristic	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
anabolizing	anabolize	VERB	VBG	_	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
conclude	conclude	VERB	VBP	9	O
by	by	ADP	IN	9	O
affirming	affirm	VERB	VBG	5	O
the	the	DET	DT	5	O
undoubted	undoubted	ADJ	JJ	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anabolizing	anabolize	VERB	VBG	_	O
steroids	steroid	NOUN	NNS	9	B-Chemical
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
myopathic	myopathic	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
they	-PRON-	PRON	PRP	5	O
have	have	VERB	VBP	5	O
reservations	reservation	NOUN	NNS	5	O
as	as	ADP	IN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
transfer	transfer	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
field	field	NOUN	NN	5	O
,	,	PUNCT	,	9	O
where	where	ADV	WRB	5	O
high	high	ADJ	JJ	9	O
dosage	dosage	NOUN	NN	9	O
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
continuously	continuously	ADV	RB	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
on	on	ADP	IN	5	O
virility	virility	NOUN	NN	5	O
;	;	PUNCT	:	9	O
because	because	ADP	IN	5	O
the	the	DET	DT	5	O
tissue	tissue	NOUN	NN	9	O
injury	injury	NOUN	NN	9	O
too	too	ADV	RB	5	O
often	often	ADV	RB	5	O
occurs	occur	VERB	VBZ	9	O
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
irreversible	irreversible	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
vis	vis	X	FW	0	O
-	-	PUNCT	HYPH	7	O
a	a	X	FW	5	O
-	-	PUNCT	HYPH	7	O
vis	vis	X	FW	0	O
the	the	DET	DT	5	O
"	"	PUNCT	``	5	O
regeneration	regeneration	NOUN	NN	9	O
"	"	PUNCT	''	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
muscle	muscle	NOUN	NN	9	O
tissue	tissue	NOUN	NN	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
finally	finally	ADV	RB	9	O
because	because	ADP	IN	5	O
the	the	DET	DT	5	O
dystrophic	dystrophic	ADJ	JJ	3	O
injurious	injurious	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
certainly	certainly	ADV	RB	5	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
but	but	CCONJ	CC	9	O
something	something	NOUN	NN	5	O
as	as	ADP	IN	5	O
yet	yet	ADV	RB	9	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Paclitaxel	paclitaxel	ADJ	JJ	0	B-Chemical
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
infusion	infusion	NOUN	NN	0	O
given	give	VERB	VBN	5	O
alone	alone	ADV	RB	9	O
and	and	CCONJ	CC	5	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
preliminary	preliminary	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
escalation	escalation	NOUN	NN	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Paclitaxel	Paclitaxel	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Taxol	Taxol	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
Bristol	Bristol	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Myers	Myers	PROPN	NNP	6	O
Squibb	Squibb	PROPN	NNP	2	O
Company	Company	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Princeton	Princeton	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
NJ	NJ	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
infusion	infusion	NOUN	NN	0	O
was	be	VERB	VBD	9	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
I	I	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
directed	direct	VERB	VBN	9	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
non	non	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
small	small	ADJ	JJ	9	I-Disease
cell	cell	NOUN	NN	3	I-Disease
lung	lung	NOUN	NN	9	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Carboplatin	Carboplatin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
fixed	fix	VERB	VBN	9	O
target	target	NOUN	NN	9	O
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
curve	curve	NOUN	NN	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
Calvert	Calvert	PROPN	NNP	6	O
formula	formula	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
escalated	escalate	VERB	VBN	5	O
in	in	ADP	IN	5	O
patient	patient	ADJ	JJ	5	O
cohorts	cohort	NOUN	NNS	9	O
from	from	ADP	IN	9	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
dose	dose	NOUN	NN	9	O
level	level	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
175	175	NUM	CD	7	O
,	,	PUNCT	,	9	O
200	200	NUM	CD	0	O
,	,	PUNCT	,	9	O
225	225	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
225	225	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
expanded	expand	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
since	since	ADP	IN	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
level	level	NOUN	NN	9	O
achieved	achieve	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
required	require	VERB	VBD	9	O
modification	modification	NOUN	NN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
nonhematologic	nonhematologic	ADJ	JJ	5	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
arthralgia	arthralgia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
sensory	sensory	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Therapeutic	therapeutic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
at	at	ADP	IN	9	O
all	all	DET	DT	5	O
dose	dose	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
objective	objective	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
in	in	ADP	IN	5	O
17	17	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
two	two	NUM	CD	5	O
complete	complete	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
partial	partial	ADJ	JJ	9	O
regressions	regression	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
41	41	NUM	CD	7	O
previously	previously	ADV	RB	9	O
untreated	untreated	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Toxicities	toxicity	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
I	-PRON-	PRON	PRP	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
at	at	ADP	IN	9	O
identical	identical	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Carboplatin	Carboplatin	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
add	add	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hematologic	hematologic	ADJ	JJ	5	B-Disease
toxicities	toxicity	NOUN	NNS	5	I-Disease
observed	observe	VERB	VBD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
combination	combination	NOUN	NN	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
dosed	dose	VERB	VBN	0	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
well	well	ADV	RB	9	O
compensated	compensated	ADJ	JJ	5	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Misoprostol	Misoprostol	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
acutely	acutely	ADV	RB	9	O
counteract	counteract	VERB	VB	9	O
the	the	DET	DT	5	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
well	well	ADV	RB	9	O
compensated	compensated	ADJ	JJ	5	O
cirrhotic	cirrhotic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Parameters	parameter	NOUN	NNS	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
tubular	tubular	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
water	water	NOUN	NN	0	O
handling	handling	NOUN	NN	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
clearance	clearance	NOUN	NN	9	O
techniques	technique	NOUN	NNS	5	O
in	in	ADP	IN	5	O
26	26	NUM	CD	7	O
well	well	ADV	RB	9	O
compensated	compensated	ADJ	JJ	5	O
cirrhotic	cirrhotic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
an	an	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
indomethacin	indomethacin	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
various	various	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
200	200	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
micrograms	micrograms	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
totally	totally	ADV	RB	9	O
abolish	abolish	VERB	VB	9	O
the	the	DET	DT	5	O
deleterious	deleterious	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
indomethacin	indomethacin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
800	800	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
micrograms	micrograms	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
worsening	worsening	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
retention	retention	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
maximal	maximal	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hour	hour	NOUN	NN	0	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
medications	medication	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
slowly	slowly	ADV	RB	5	O
returned	return	VERB	VBD	5	O
toward	toward	ADP	IN	5	O
base	base	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
thereafter	thereafter	ADV	RB	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
protective	protective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
until	until	ADP	IN	5	O
this	this	DET	DT	5	O
apparent	apparent	ADJ	JJ	9	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
of	of	ADP	IN	5	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
indomethacin	indomethacin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
confirmed	confirm	VERB	VBN	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
frequent	frequent	ADJ	JJ	5	O
dosing	dosing	NOUN	NN	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
prudent	prudent	ADJ	JJ	5	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
angio	angio	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
oedema	oedema	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
converting	convert	VERB	VBG	9	I-Chemical
enzyme	enzyme	ADJ	JJ	0	I-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
to	to	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
well	well	ADV	RB	9	O
recognized	recognize	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
urticaria	urticaria	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
angio	angio	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
oedema	oedema	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Angiotensin	angiotensin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
converting	convert	VERB	VBG	9	I-Chemical
enzyme	enzyme	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
ACE	ACE	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
,	,	PUNCT	,	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
introduced	introduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
Europe	Europe	PROPN	NNP	4	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
middle	middle	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
eighties	eighty	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
increased	increase	VERB	VBN	9	O
progressively	progressively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Soon	soon	ADV	RB	6	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
introduction	introduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
ACE	ACE	PROPN	NNP	9	B-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	O
bouts	bout	NOUN	NNS	5	O
of	of	ADP	IN	5	O
angio	angio	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
oedema	oedema	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
wish	wish	VERB	VBP	6	O
to	to	PART	TO	5	O
draw	draw	VERB	VB	5	O
attention	attention	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
to	to	ADP	IN	5	O
ACE	ACE	PROPN	NNP	9	B-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
after	after	ADP	IN	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
existing	existing	ADJ	JJ	5	O
angio	angio	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
oedema	oedema	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Myoclonus	myoclonus	NOUN	NN	7	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
lorazepam	lorazepam	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
very	very	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
birth	birth	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
weight	weight	NOUN	NN	9	O
infants	infant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Lorazepam	Lorazepam	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
being	be	VERB	VBG	5	O
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
frequency	frequency	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
sedative	sedative	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
newborn	newborn	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
young	young	ADJ	JJ	5	O
infant	infant	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Concern	concern	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
raised	raise	VERB	VBN	9	O
with	with	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
lorazepam	lorazepam	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
age	age	NOUN	NN	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
very	very	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
birth	birth	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
weight	weight	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
VLBW	vlbw	NOUN	NN	5	O
;	;	PUNCT	:	9	O
<	<	X	XX	0	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
500	500	NUM	CD	0	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
infants	infant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
young	young	ADJ	JJ	5	O
infants	infant	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
birth	birth	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
<	<	X	XX	0	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
500	500	NUM	CD	0	O
g	g	NOUN	NN	0	O
,	,	PUNCT	,	9	O
experienced	experience	VERB	VBD	5	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lorazepam	lorazepam	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
vehicle	vehicle	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
population	population	NOUN	NN	5	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Injectable	injectable	ADJ	JJ	0	O
lorazepam	lorazepam	NOUN	NN	5	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
caution	caution	NOUN	NN	5	O
in	in	ADP	IN	5	O
VLBW	VLBW	PROPN	NNP	5	O
infants	infant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Transvenous	transvenous	ADJ	JJ	5	O
right	right	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
pacing	pacing	NOUN	NN	5	O
during	during	ADP	IN	5	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
resuscitation	resuscitation	NOUN	NN	5	O
of	of	ADP	IN	5	O
pediatric	pediatric	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
resuscitation	resuscitation	NOUN	NN	5	O
efforts	effort	NOUN	NNS	5	O
on	on	ADP	IN	5	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
presented	present	VERB	VBD	5	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
circulatory	circulatory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
from	from	ADP	IN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
acute	acute	ADJ	JJ	9	O
viral	viral	ADJ	JJ	9	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
one	one	PRON	PRP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
eosinophilic	eosinophilic	NOUN	NN	5	B-Disease
myocarditis	myocarditis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
one	one	PRON	PRP	5	O
had	have	VERB	VBD	9	O
cardiac	cardiac	ADJ	JJ	5	O
hemosiderosis	hemosiderosis	NOUN	NN	5	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
cardiogenic	cardiogenic	ADJ	JJ	5	B-Disease
shock	shock	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
continuously	continuously	ADV	RB	5	O
monitored	monitor	VERB	VBN	9	O
with	with	ADP	IN	5	O
central	central	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
arterial	arterial	ADJ	JJ	5	O
catheters	catheter	NOUN	NNS	5	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
routine	routine	ADJ	JJ	5	O
noninvasive	noninvasive	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
introducer	introducer	NOUN	NN	5	O
sheath	sheath	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
pacemaker	pacemaker	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sterile	sterile	ADJ	JJ	0	O
pacing	pacing	NOUN	NN	5	O
wires	wire	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
readily	readily	ADV	RB	9	O
available	available	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
should	should	VERB	MD	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
arise	arise	VERB	VB	5	O
to	to	PART	TO	5	O
terminate	terminate	VERB	VB	9	O
resistant	resistant	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
dysrhythmias	dysrhythmia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
cardiocirculatory	cardiocirculatory	ADJ	JJ	5	O
arrest	arrest	NOUN	NN	3	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
extreme	extreme	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
dysrhythmias	dysrhythmia	NOUN	NNS	5	B-Disease
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
48	48	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
admission	admission	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
pediatric	pediatric	ADJ	JJ	5	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PICU	PICU	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Right	right	ADJ	JJ	9	O
ventricular	ventricular	ADJ	JJ	5	O
pacemaker	pacemaker	NOUN	NN	5	O
wires	wire	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
inserted	insert	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
during	during	ADP	IN	5	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
resuscitation	resuscitation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CPR	CPR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
pacing	pacing	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
temporary	temporary	ADJ	JJ	5	O
captured	capture	VERB	VBN	5	O
rhythm	rhythm	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
restoration	restoration	NOUN	NN	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
event	event	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
death	death	NOUN	NN	9	O
,	,	PUNCT	,	9	O
within	within	ADP	IN	9	O
10	10	NUM	CD	9	O
to	to	PART	TO	5	O
60	60	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
pacing	pacing	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
used	use	VERB	VBN	5	O
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
he	-PRON-	PRON	PRP	5	O
converted	convert	VERB	VBD	9	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
sinus	sinus	NOUN	NN	5	O
rhythm	rhythm	NOUN	NN	5	O
by	by	ADP	IN	9	O
electrical	electrical	ADJ	JJ	5	O
defibrillation	defibrillation	NOUN	NN	5	O
within	within	ADP	IN	9	O
three	three	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
of	of	ADP	IN	5	O
initiating	initiate	VERB	VBG	9	O
CPR	CPR	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
pacing	pacing	NOUN	NN	5	O
during	during	ADP	IN	5	O
resuscitative	resuscitative	ADJ	JJ	5	O
efforts	effort	NOUN	NNS	5	O
in	in	ADP	IN	5	O
pediatric	pediatric	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
value	value	NOUN	NN	9	O
in	in	ADP	IN	5	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
itself	-PRON-	PRON	PRP	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
if	if	ADP	IN	5	O
temporary	temporary	ADJ	JJ	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
stability	stability	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
achieved	achieve	VERB	VBN	5	O
by	by	ADP	IN	9	O
this	this	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
provide	provide	VERB	VB	5	O
additional	additional	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
institute	institute	VERB	VB	5	O
other	other	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
modalities	modality	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Efficacy	efficacy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
granisetron	granisetron	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptamine	hydroxytryptamine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
antiemetic	antiemetic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
different	different	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
granisetron	granisetron	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Kytril	Kytril	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
SmithKline	SmithKline	PROPN	NNP	2	O
Beecham	Beecham	PROPN	NNP	6	O
Pharmaceuticals	Pharmaceuticals	PROPN	NNPS	2	O
,	,	PUNCT	,	9	O
Philadelphia	Philadelphia	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
PA	PA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
intravenous	intravenous	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
IV	IV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
dose	dose	NOUN	NN	9	O
for	for	ADP	IN	5	O
prophylaxis	prophylaxis	NOUN	NN	5	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
eighty	eighty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
naive	naive	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
81	81	NUM	CD	7	O
to	to	PART	TO	5	O
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
granisetron	granisetron	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
40	40	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBN	9	O
before	before	ADP	IN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
on	on	ADP	IN	5	O
an	an	DET	DT	5	O
inpatient	inpatient	NOUN	NN	5	O
basis	basis	NOUN	NN	5	O
for	for	ADP	IN	5	O
18	18	NUM	CD	7	O
to	to	PART	TO	5	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
vital	vital	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
retching	retch	VERB	VBG	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
appetite	appetite	NOUN	NN	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
analyses	analysis	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
experiences	experience	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
parameter	paramet	ADJ	JJR	5	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
After	after	ADP	IN	9	O
granisetron	granisetron	NOUN	NN	0	B-Chemical
doses	dose	VERB	VBZ	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
40	40	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
two	two	NUM	CD	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
retching	retch	VERB	VBG	5	O
episodes	episode	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
antiemetic	antiemetic	ADJ	JJ	5	O
rescue	rescue	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
in	in	ADP	IN	5	O
23	23	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
57	57	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
58	58	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
no	no	DET	DT	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
retching	retch	VERB	VBG	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
antiemetic	antiemetic	ADJ	JJ	5	O
rescue	rescue	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
41	41	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
47	47	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
longer	long	ADJ	JJR	5	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
first	first	ADJ	JJ	9	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
nausea	nausea	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
0015	0015	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
fewer	few	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
additional	additional	ADJ	JJ	9	O
antiemetic	antiemetic	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
dosing	dose	VERB	VBG	9	O
groups	group	NOUN	NNS	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
dosing	dose	VERB	VBG	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
granisetron	granisetron	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
,	,	PUNCT	,	9	O
appetite	appetite	ADJ	JJ	5	O
return	return	NOUN	NN	5	O
increased	increase	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
040	040	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Headache	Headache	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
frequently	frequently	ADV	RB	5	O
reported	report	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
single	single	ADJ	JJ	9	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
40	40	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
granisetron	granisetron	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
controlling	control	VERB	VBG	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
57	57	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
81	81	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
totally	totally	ADV	RB	9	O
prevented	prevent	VERB	VBN	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
47	47	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
40	40	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Granisetron	Granisetron	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
at	at	ADP	IN	9	O
all	all	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
atrioventricular	atrioventricular	ADJ	JJ	5	B-Disease
(	(	PUNCT	-LRB-	9	I-Disease
AV	av	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
block	block	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARIES	summary	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
54	54	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
hyperaldosteronism	hyperaldosteronism	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
480	480	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
spironolactone	spironolactone	ADJ	JJ	0	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
minimal	minimal	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
bid	bid	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
complete	complete	ADJ	JJ	9	O
AV	av	NOUN	NN	9	B-Disease
block	block	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
resolved	resolve	VERB	VBD	9	O
upon	upon	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
medications	medication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
65	65	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
extended	extend	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
240	240	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
bid	bid	NOUN	NN	5	O
she	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
complete	complete	ADJ	JJ	9	O
AV	av	NOUN	NN	9	B-Disease
block	block	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
resolved	resolve	VERB	VBD	9	O
after	after	ADV	RB	9	O
all	all	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
An	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
two	two	NUM	CD	5	O
such	such	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
discuss	discuss	VERB	VB	5	O
the	the	DET	DT	5	O
various	various	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
that	that	DET	WDT	5	O
might	may	VERB	MD	9	O
cause	cause	VERB	VB	5	O
such	such	DET	PDT	5	O
an	an	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
acquainted	acquaint	VERB	VBN	5	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
possibly	possibly	ADV	RB	9	O
fatal	fatal	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
two	two	NUM	CD	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Caution	caution	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
in	in	ADP	IN	5	O
combining	combine	VERB	VBG	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
sinus	sinus	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
AV	av	NOUN	NN	9	O
node	node	NOUN	NN	5	O
dysfunction	dysfunction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
two	two	NUM	CD	5	O
drugs	drug	NOUN	NNS	5	O
may	may	VERB	MD	5	O
act	act	VERB	VB	9	O
synergistically	synergistically	ADV	RB	9	O
on	on	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
AV	av	NOUN	NN	9	O
node	node	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
circulation	circulation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pharmacological	pharmacological	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
dihydrothienopyridine	dihydrothienopyridine	NOUN	NN	_	B-Chemical
calcium	calcium	NOUN	NN	0	I-Chemical
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
312	312	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
d	d	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

5th	5th	ADJ	JJ	9	O
communication	communication	NOUN	NN	5	O
:	:	PUNCT	:	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
312	312	PROPN	NNP	7	I-Chemical
,	,	PUNCT	,	9	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
312	312	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
d	d	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
312	312	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
l	l	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
antagonists	antagonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
showed	show	VERB	VBD	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
audiogenic	audiogenic	ADJ	JJ	3	B-Disease
tonic	tonic	NOUN	NN	5	I-Disease
convulsions	convulsion	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
ED50	ED50	PROPN	NNP	0	O
values	value	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
flunarizine	flunarizine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
34	34	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
(	(	PUNCT	-LRB-	9	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
44	44	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
moderate	moderate	ADJ	JJ	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
312	312	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
d	d	NOUN	NN	9	I-Chemical
in	in	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
clonic	clonic	NOUN	NN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pentylenetetrazole	pentylenetetrazole	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
85	85	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
bemegride	bemegride	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
,	,	PUNCT	,	9	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
electroshock	electroshock	NOUN	NN	5	O
in	in	ADP	IN	5	O
Slc	Slc	PROPN	NNP	3	O
:	:	PUNCT	:	9	O
ddY	ddY	NOUN	NNS	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
312	312	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
d	d	PROPN	NNP	9	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Transmural	transmural	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
sumatriptan	sumatriptan	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
sumatriptan	sumatriptan	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
tightness	tightness	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
chest	chest	NOUN	NN	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
unknown	unknown	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
47	47	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
sumatriptan	sumatriptan	ADJ	JJ	0	B-Chemical
6	6	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
subcutaneously	subcutaneously	ADV	RB	3	O
for	for	ADP	IN	5	O
cluster	cluster	NOUN	NN	9	B-Disease
headache	headache	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
underlying	underlie	VERB	VBG	5	O
ischaemic	ischaemic	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
Prinzmetal	Prinzmetal	PROPN	NNP	6	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
angina	angina	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
recovered	recover	VERB	VBD	9	O
without	without	ADP	IN	9	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Flumazenil	Flumazenil	PROPN	NNP	0	B-Chemical
induces	induce	VERB	VBZ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
mixed	mixed	ADJ	JJ	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
intoxications	intoxication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

STUDY	study	NOUN	NN	2	O
HYPOTHESIS	HYPOTHESIS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
benzodiazepine	benzodiazepine	ADJ	JJ	5	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
unmask	unmask	VERB	VB	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
mixed	mixed	ADJ	JJ	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
benzodiazepine	benzodiazepine	NOUN	NN	5	B-Chemical
intoxication	intoxication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Male	Male	PROPN	NNP	7	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
IP	ip	NOUN	NN	9	O
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
challenged	challenge	VERB	VBN	3	O
with	with	ADP	IN	5	O
vehicle	vehicle	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
or	or	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
IP	IP	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Animal	animal	NOUN	NN	2	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
and	and	CCONJ	CC	5	O
incidence	incidence	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
death	death	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
and	and	CCONJ	CC	5	O
incidence	incidence	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cortical	cortical	ADJ	JJ	5	O
EEG	EEG	PROPN	NNP	5	O
tracings	tracing	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

INTERVENTIONS	intervention	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
after	after	ADP	IN	9	O
they	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
group	group	NOUN	NN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
vehicle	vehicle	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
developing	develop	VERB	VBG	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Group	group	NOUN	NN	9	O
2	2	NUM	CD	9	O
received	receive	VERB	VBD	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
followed	follow	VERB	VBD	9	O
by	by	ADP	IN	9	O
vehicle	vehicle	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
became	become	VERB	VBD	9	O
somnolent	somnolent	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
none	none	NOUN	NN	9	O
died	die	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Group	group	NOUN	NN	9	O
3	3	NUM	CD	9	O
received	receive	VERB	VBD	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
became	become	VERB	VBD	9	O
somnolent	somnolent	ADJ	JJ	5	O
after	after	ADP	IN	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
active	active	ADJ	JJ	9	O
after	after	ADP	IN	9	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
group	group	NOUN	NN	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
simultaneously	simultaneously	ADV	RB	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
no	no	DET	DT	9	O
overt	overt	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
EEG	EEG	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
detectable	detectable	ADJ	JJ	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Group	group	NOUN	NN	9	O
5	5	NUM	CD	9	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
later	later	ADV	RB	9	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
group	group	NOUN	NN	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

Group	Group	PROPN	NNP	9	O
6	6	NUM	CD	9	O
received	receive	VERB	VBD	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
also	also	ADV	RB	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
,	,	PUNCT	,	9	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
group	group	NOUN	NN	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Flumazenil	Flumazenil	PROPN	NNP	0	B-Chemical
can	can	VERB	MD	5	O
unmask	unmask	VERB	VB	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
combined	combined	ADJ	JJ	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
intoxications	intoxication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Mechanisms	mechanism	NOUN	NNS	9	O
for	for	ADP	IN	5	O
protective	protective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
free	free	ADJ	JJ	9	O
radical	radical	ADJ	JJ	0	O
scavengers	scavenger	NOUN	NNS	0	O
on	on	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
free	free	ADJ	JJ	9	O
radical	radical	ADJ	JJ	0	O
scavengers	scavenger	NOUN	NNS	0	O
on	on	ADP	IN	5	O
gentamicin	gentamicin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
GM	GM	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Administration	Administration	PROPN	NNP	2	O
of	of	ADP	IN	5	O
GM	GM	PROPN	NNP	9	B-Chemical
at	at	ADP	IN	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
sc	sc	NOUN	NN	9	O
for	for	ADP	IN	5	O
13	13	NUM	CD	7	O
days	day	NOUN	NNS	9	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
RBF	RBF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
inulin	inulin	ADJ	JJ	0	O
clearance	clearance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CIn	CIn	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
marked	mark	VERB	VBN	9	O
tubular	tubular	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
guanosine	guanosine	NOUN	NN	0	B-Chemical
3	3	NUM	CD	9	I-Chemical
'	'	PUNCT	''	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
'	'	PUNCT	``	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
cyclic	cyclic	NOUN	NN	0	I-Chemical
monophosphate	monophosphate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
cGMP	cGMP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
excretion	excretion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
cortical	cortical	ADJ	JJ	5	O
renin	renin	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
endothelin	endothelin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
contents	content	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
GM	GM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Superoxide	superoxide	ADJ	JJ	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
SOD	SOD	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
dimethylthiourea	dimethylthiourea	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DMTU	DMTU	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
significantly	significantly	ADV	RB	9	O
lessened	lessen	VERB	VBD	5	O
the	the	DET	DT	5	O
GM	GM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
decrement	decrement	NOUN	NN	5	O
in	in	ADP	IN	5	O
CIn	CIn	NOUN	NNS	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
SOD	sod	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
RBF	RBF	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
cGMP	cGMP	PROPN	NNP	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
renin	renin	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
endothelin	endothelin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
content	content	NOUN	NN	9	O
.	.	PUNCT	.	9	O

SOD	SOD	PROPN	NNP	0	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
attenuate	attenuate	VERB	VB	9	O
the	the	DET	DT	5	O
tubular	tubular	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
DMTU	DMTU	PROPN	NNP	0	B-Chemical
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
tubular	tubular	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
renal	renal	ADJ	JJ	9	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
vasoactive	vasoactive	ADJ	JJ	5	O
substances	substance	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Neither	neither	CCONJ	CC	9	O
SOD	SOD	PROPN	NNP	0	O
nor	nor	CCONJ	CC	9	O
DMTU	DMTU	PROPN	NNP	0	B-Chemical
affected	affect	VERB	VBD	9	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
cortical	cortical	NOUN	NN	5	O
GM	GM	PROPN	NNP	9	B-Chemical
content	content	NOUN	NN	9	O
in	in	ADP	IN	5	O
GM	GM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
both	both	CCONJ	CC	9	O
SOD	SOD	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
DMTU	DMTU	PROPN	NNP	0	B-Chemical
have	have	VERB	VBP	5	O
protective	protective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
GM	GM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
differ	differ	VERB	VBP	9	O
for	for	ADP	IN	5	O
SOD	SOD	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
DMTU	DMTU	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
anions	anion	NOUN	NNS	0	O
play	play	VERB	VBP	9	O
a	a	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
GM	GM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cephalothin	cephalothin	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
immune	immune	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
Coombs	Coombs	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
cephalothin	cephalothin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
cephalothin	cephalothin	ADJ	JJ	0	B-Chemical
IgG	igg	NOUN	NN	3	O
antibody	antibody	NOUN	NN	3	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
serum	serum	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
eluates	eluate	NOUN	NNS	0	O
from	from	ADP	IN	9	O
her	-PRON-	DET	PRP$	5	O
erythrocytes	erythrocyte	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
nonimmunologic	nonimmunologic	ADJ	JJ	5	O
binding	binding	NOUN	NN	1	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
patient	patient	ADJ	JJ	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
serum	serum	ADJ	JJ	9	O
proteins	protein	NOUN	NNS	1	O
to	to	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
own	own	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
cephalothin	cephalothin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
coated	coat	VERB	VBN	0	O
normal	normal	ADJ	JJ	9	O
red	red	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Skin	skin	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
lymphocyte	lymphocyte	X	FW	3	O
stimulation	stimulation	NOUN	NN	3	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
sensitized	sensitize	VERB	VBN	3	O
to	to	PART	TO	5	O
cephalothin	cephalothin	VERB	VB	0	B-Chemical
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
to	to	PART	TO	5	O
ampicillin	ampicillin	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

Careful	careful	ADJ	JJ	5	O
investigation	investigation	NOUN	NN	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemias	anemias	NOUN	NN	5	I-Disease
reveals	reveal	VERB	VBZ	9	O
the	the	DET	DT	5	O
complexity	complexity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
immune	immune	ADJ	JJ	3	O
mechanisms	mechanism	NOUN	NNS	9	O
involved	involve	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
DNA	dna	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
during	during	ADP	IN	5	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
to	to	PART	TO	5	O
synthesize	synthesize	VERB	VB	9	O
DNA	dna	NOUN	NN	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
experimentally	experimentally	ADV	RB	9	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
delivered	deliver	VERB	VBN	5	O
by	by	ADP	IN	9	O
osmotic	osmotic	ADJ	JJ	0	O
minipump	minipump	NOUN	NN	0	O
implantation	implantation	NOUN	NN	5	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
C3Heb	C3Heb	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
FeJ	FeJ	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
46	46	NUM	CD	7	O
%	%	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
area	area	NOUN	NN	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
DNA	dna	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
autoradiographic	autoradiographic	ADJ	JJ	0	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
isolated	isolated	ADJ	JJ	9	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
hypertrophic	hypertrophic	ADJ	JJ	3	B-Disease
hearts	heart	NOUN	NNS	3	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
survey	survey	NOUN	NN	5	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
independent	independent	ADJ	JJ	9	O
inbred	inbreed	VERB	VBN	9	O
strains	strain	NOUN	NNS	1	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
nuclear	nuclear	ADJ	JJ	3	O
number	number	NOUN	NN	9	O
ranged	range	VERB	VBN	9	O
from	from	ADP	IN	9	O
3	3	NUM	CD	9	O
to	to	ADP	IN	5	O
13	13	NUM	CD	7	O
%	%	NOUN	NN	9	O
mononucleate	mononucleate	NOUN	NN	3	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
terminal	terminal	ADJ	JJ	9	O
differentiation	differentiation	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
influenced	influence	VERB	VBN	5	O
directly	directly	ADV	RB	9	O
or	or	CCONJ	CC	5	O
indirectly	indirectly	ADV	RB	9	O
by	by	ADP	IN	9	O
genetic	genetic	ADJ	JJ	5	O
background	background	NOUN	NN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
capacity	capacity	NOUN	NN	9	O
for	for	ADP	IN	5	O
reactive	reactive	ADJ	JJ	9	O
DNA	dna	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
subject	subject	ADJ	JJ	5	O
to	to	ADP	IN	5	O
genetic	genetic	ADJ	JJ	5	O
regulation	regulation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
strains	strain	NOUN	NNS	1	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
comprising	comprise	VERB	VBG	9	O
the	the	DET	DT	5	O
extremes	extreme	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nuclear	nuclear	ADJ	JJ	3	O
number	number	NOUN	NN	9	O
survey	survey	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
mouse	mouse	NOUN	NN	3	O
atrial	atrial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
ventricular	ventricular	ADJ	JJ	5	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
synthesize	synthesize	VERB	VB	9	O
DNA	dna	NOUN	NN	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Central	central	ADJ	JJ	4	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
AVP	AVP	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
ANP	ANP	PROPN	NNP	9	O
in	in	ADP	IN	5	O
normotensive	normotensive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
arginine	arginine	NOUN	NN	0	B-Chemical
vasopressin	vasopressin	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
AVP	AVP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	O
natriuretic	natriuretic	ADJ	JJ	9	O
peptide	peptide	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ANP	ANP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MAP	MAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HR	hr	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
normotensive	normotensive	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
WKY	WKY	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
(	(	PUNCT	-LRB-	9	O
SHR	SHR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
experiments	experiment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
30	30	NUM	CD	9	O
WKY	WKY	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
SHR	SHR	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
chronically	chronically	ADV	RB	9	O
instrumented	instrument	VERB	VBD	5	O
with	with	ADP	IN	5	O
guide	guide	NOUN	NN	5	O
tubes	tube	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
ventricle	ventricle	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
LV	LV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
arterial	arterial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
venous	venous	ADJ	JJ	5	O
catheters	catheter	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

MAP	MAP	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
HR	hr	NOUN	NN	9	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
vehicle	vehicle	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
ng	ng	NOUN	NNS	0	O
of	of	ADP	IN	5	O
AVP	AVP	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
25	25	NUM	CD	9	O
,	,	PUNCT	,	9	O
125	125	NUM	CD	9	O
and	and	CCONJ	CC	5	O
500	500	NUM	CD	0	O
ng	ng	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ANP	ANP	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
component	component	NOUN	NN	9	O
of	of	ADP	IN	5	O
baroreflex	baroreflex	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CCB	CCB	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
expressed	express	VERB	VBD	3	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
slope	slope	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
regression	regression	NOUN	NN	5	O
line	line	NOUN	NN	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
from	from	ADP	IN	9	O
relationships	relationship	NOUN	NNS	5	O
between	between	ADP	IN	5	O
systolic	systolic	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SAP	SAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
HR	hr	NOUN	NN	9	O
period	period	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
HRp	HRp	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Phe	Phe	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
SN	SN	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CCB	CCB	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
vehicle	vehicle	NOUN	NN	3	O
,	,	PUNCT	,	9	O
AVP	AVP	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
ANP	ANP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
peptides	peptide	NOUN	NNS	9	O
together	together	ADV	RB	9	O
.	.	PUNCT	.	9	O

Increases	increase	NOUN	NNS	9	O
of	of	ADP	IN	5	O
MAP	MAP	PROPN	NNP	9	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
LV	LV	PROPN	NNP	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
ng	ng	NOUN	NNS	0	O
of	of	ADP	IN	5	O
AVP	AVP	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
WKY	WKY	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
ng	ng	NOUN	NNS	0	O
in	in	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

ANP	ANP	PROPN	NNP	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
cause	cause	VERB	VB	5	O
significant	significant	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
MAP	MAP	PROPN	NNP	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
strains	strain	NOUN	NNS	1	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
vehicle	vehicle	NOUN	NN	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
abolished	abolish	VERB	VBD	3	O
AVP	AVP	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
MAP	MAP	PROPN	NNP	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
WKY	WKY	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
SHR	SHR	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

CCB	CCB	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
WKY	WKY	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
SHR	SHR	PROPN	NNP	9	O
after	after	ADP	IN	9	O
LV	LV	PROPN	NNP	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
AVP	AVP	PROPN	NNP	9	B-Chemical
during	during	ADP	IN	5	O
SN	SN	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
SHR	SHR	PROPN	NNP	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
WKY	WKY	PROPN	NNP	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ANP	ANP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
AVP	AVP	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
ANP	ANP	PROPN	NNP	9	O
+	+	SYM	SYM	9	O
AVP	AVP	PROPN	NNP	9	B-Chemical
decreased	decrease	VERB	VBD	9	O
CCB	CCB	PROPN	NNP	9	O
during	during	ADP	IN	5	O
Phe	Phe	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
MAP	MAP	PROPN	NNP	9	O
elevation	elevation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
centrally	centrally	ADV	RB	5	O
applied	apply	VERB	VBD	5	O
AVP	AVP	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
ANP	ANP	PROPN	NNP	9	O
exert	exert	ADJ	JJ	9	O
differential	differential	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
baroreflex	baroreflex	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
WKY	WKY	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
SHR	SHR	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
suggest	suggest	VERB	VB	9	O
interaction	interaction	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
peptides	peptide	NOUN	NNS	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
regulation	regulation	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cutaneous	cutaneous	ADJ	JJ	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
anticoagulant	anticoagulant	NOUN	NN	9	O
causing	cause	VERB	VBG	9	O
an	an	DET	DT	5	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
intercerebral	intercerebral	ADJ	JJ	9	O
hematoma	hematoma	NOUN	NN	5	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
coagulopathy	coagulopathy	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
39	39	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
had	have	VERB	VBD	9	O
spread	spread	VERB	VBN	5	O
a	a	DET	DT	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
rat	rat	NOUN	NN	3	O
poison	poison	NOUN	NN	9	O
around	around	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
house	house	NOUN	NN	5	O
weekly	weekly	ADV	RB	5	O
using	use	VERB	VBG	9	O
her	-PRON-	DET	PRP$	5	O
bare	bare	ADJ	JJ	5	O
hands	hand	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
washing	washing	ADJ	JJ	0	O
post	post	NOUN	NN	9	O
application	application	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Percutaneous	percutaneous	ADJ	JJ	5	O
absorption	absorption	NOUN	NN	0	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
causing	cause	VERB	VBG	9	O
coagulopathy	coagulopathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
reported	report	VERB	VBD	9	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	NOUN	NN	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
if	if	ADP	IN	5	O
protective	protective	ADJ	JJ	9	O
measures	measure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
gloves	glove	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
piroxicam	piroxicam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
she	-PRON-	PRON	PRP	5	O
took	take	VERB	VBD	5	O
occasionally	occasionally	ADV	RB	5	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
exacerbated	exacerbate	VERB	VBN	9	O
the	the	DET	DT	5	O
coagulopathy	coagulopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Pediatric	pediatric	ADJ	JJ	2	O
heart	heart	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
without	without	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
maintenance	maintenance	NOUN	NN	9	O
steroids	steroid	NOUN	NNS	9	B-Chemical
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
1986	1986	NUM	CD	2	O
to	to	ADP	IN	5	O
February	February	PROPN	NNP	2	O
1993	1993	NUM	CD	2	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
children	child	NOUN	NNS	5	O
aged	age	VERB	VBN	9	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
to	to	ADP	IN	5	O
18	18	NUM	CD	7	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
average	average	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
underwent	underwent	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Indications	indication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
transplantation	transplantation	NOUN	NN	9	O
were	be	VERB	VBD	9	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
52	52	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
congenital	congenital	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
repair	repair	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
71	71	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
29	29	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
hypertrophic	hypertrophic	ADJ	JJ	3	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
valvular	valvular	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
managed	manage	VERB	VBN	5	O
with	with	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
prophylaxis	prophylaxis	NOUN	NN	5	O
with	with	ADP	IN	5	O
antilymphocyte	antilymphocyte	NOUN	NN	3	O
globulin	globulin	NOUN	NN	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Steroids	steroid	NOUN	NNS	0	B-Chemical
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
39	39	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
for	for	ADP	IN	5	O
refractory	refractory	ADJ	JJ	9	O
rejection	rejection	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
weaning	weaning	NOUN	NN	5	O
was	be	VERB	VBD	9	O
always	always	ADV	RB	5	O
attempted	attempt	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
generally	generally	ADV	RB	5	O
successful	successful	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
64	64	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
maintenance	maintenance	NOUN	NN	9	O
steroids	steroid	NOUN	NNS	9	B-Chemical
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
perioperative	perioperative	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
died	die	VERB	VBD	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
no	no	DET	DT	9	O
deaths	death	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
rejection	rejection	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
infection	infection	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Average	average	ADJ	JJ	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
was	be	VERB	VBD	9	O
36	36	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
19	19	NUM	CD	7	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VBP	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
65	65	NUM	CD	7	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Cumulative	cumulative	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
88	88	NUM	CD	7	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
7	7	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
rejection	rejection	NOUN	NN	5	O
was	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
noninvasively	noninvasively	ADV	RB	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
postoperative	postoperative	ADJ	JJ	5	O
month	month	NOUN	NN	5	O
,	,	PUNCT	,	9	O
89	89	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
rejection	rejection	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Freedom	freedom	NOUN	NN	5	O
from	from	ADP	IN	9	O
serious	serious	ADJ	JJ	5	O
infections	infection	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
83	83	NUM	CD	7	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
65	65	NUM	CD	7	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cytomegalovirus	Cytomegalovirus	PROPN	NNP	2	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
successfully	successfully	ADV	RB	5	O
with	with	ADP	IN	5	O
ganciclovir	ganciclovir	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
growth	growth	NOUN	NN	3	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
transplantation	transplantation	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
control	control	NOUN	NN	9	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
undergone	undergo	VERB	VBN	5	O
annual	annual	ADJ	JJ	5	O
catheterizations	catheterization	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
sign	sign	NOUN	NN	5	O
of	of	ADP	IN	5	O
graft	graft	NOUN	NN	5	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Seizures	Seizures	PROPN	NNP	5	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
28	28	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
disabled	disabled	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
lymphoproliferative	lymphoproliferative	ADJ	JJ	3	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Delirium	delirium	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
high	high	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressant	antidepressant	ADJ	JJ	5	O
concentrations	concentration	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
well	well	ADV	RB	9	O
established	establish	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
exist	exist	VERB	VBP	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
SSRIs	SSRIs	PROPN	NNPS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
some	some	DET	DT	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
citalopram	citalopram	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
600	600	NUM	CD	0	O
nmol	nmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
somnolence	somnolence	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
movement	movement	NOUN	NN	5	B-Disease
difficulties	difficulty	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Widespread	widespread	ADJ	JJ	9	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
delirium	delirium	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
linked	link	VERB	VBN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
SSRIs	ssri	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
report	report	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hyperkinetic	hyperkinetic	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	B-Disease
connected	connect	VERB	VBN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
serum	serum	ADJ	JJ	9	O
total	total	ADJ	JJ	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
desmethylfluoxetine	desmethylfluoxetine	NOUN	NN	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
concentration	concentration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Pulmonary	pulmonary	ADJ	JJ	9	B-Disease
edema	edema	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
shock	shock	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
aracytine	aracytine	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
C	c	NOUN	NN	9	I-Chemical
for	for	ADP	IN	5	O
lymphoma	lymphoma	NOUN	NN	9	B-Disease
;	;	PUNCT	,	9	O
possible	possible	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
TNF	TNF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
PAF	PAF	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
23	23	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
Ara	Ara	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
C	C	PROPN	NNP	9	I-Chemical
for	for	ADP	IN	5	O
lymphomas	lymphoma	NOUN	NNS	3	B-Disease
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
institution	institution	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
strikingly	strikingly	ADV	RB	9	O
similar	similar	ADJ	JJ	9	O
syndrome	syndrome	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
perfusion	perfusion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
fever	fever	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
diarrhea	diarrhea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
shock	shock	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
metabolic	metabolic	NOUN	NN	9	B-Disease
acidosis	acidosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
leukocytosis	leukocytosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Thorough	Thorough	PROPN	NNP	5	O
bacteriological	bacteriological	ADJ	JJ	5	O
screening	screening	NOUN	NN	5	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
provide	provide	VERB	VB	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
infection	infection	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Sequential	sequential	ADJ	JJ	5	O
biological	biological	ADJ	JJ	5	O
assays	assay	NOUN	NNS	3	O
of	of	ADP	IN	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
2	2	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
TNF	TNF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
PAF	PAF	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
during	during	ADP	IN	5	O
Ara	Ara	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
C	C	PROPN	NNP	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
to	to	ADP	IN	5	O
ten	ten	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
the	the	DET	DT	5	O
four	four	NUM	CD	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

TNF	TNF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
PAF	PAF	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	NOUN	NN	9	O
of	of	ADP	IN	5	O
respectively	respectively	ADV	RB	9	O
two	two	NUM	CD	5	O
and	and	CCONJ	CC	5	O
four	four	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
six	six	NUM	CD	9	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
TNF	TNF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
PAF	PAF	PROPN	NNP	9	O
are	be	VERB	VBP	5	O
thought	think	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
septic	septic	ADJ	JJ	5	O
shock	shock	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
adult	adult	NOUN	NN	9	B-Disease
respiratory	respiratory	ADJ	JJ	5	I-Disease
distress	distress	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
hypothesize	hypothesize	VERB	VBP	9	O
that	that	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
Ara	Ara	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
C	C	PROPN	NNP	9	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
cytokine	cytokine	NOUN	NN	3	O
release	release	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
clentiazem	clentiazem	NOUN	NN	_	B-Chemical
against	against	ADP	IN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
clentiazem	clentiazem	NOUN	NN	_	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
benzothiazepine	benzothiazepine	NOUN	NN	0	I-Chemical
calcium	calcium	NOUN	NN	0	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
chronic	chronic	NOUN	NN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
16	16	NUM	CD	9	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
died	die	VERB	VBD	9	O
within	within	ADP	IN	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
ventricles	ventricle	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	O
atrial	atrial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
papillary	papillary	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
contractile	contractile	NOUN	NN	9	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
enhanced	enhance	VERB	VBN	3	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Left	leave	VERB	VBN	9	O
ventricular	ventricular	ADJ	JJ	5	O
alpha	alpha	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
densities	density	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
clentiazem	clentiazem	ADJ	JJ	_	B-Chemical
prevented	prevent	VERB	VBN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
death	death	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Left	leave	VERB	VBN	9	O
atrial	atrial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
papillary	papillary	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
contractile	contractile	NOUN	NN	9	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
in	in	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
clentiazem	clentiazem	NOUN	NN	_	B-Chemical
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
clentiazem	clentiazem	X	FW	_	B-Chemical
restored	restore	VERB	VBN	3	O
left	left	ADJ	JJ	5	O
atrial	atrial	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
enhanced	enhance	VERB	VBD	3	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
papillary	papillary	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
clentiazem	clentiazem	NOUN	NN	_	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
down	down	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
adrenoceptors	adrenoceptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Interestingly	interestingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
clentiazem	clentiazem	ADJ	JJ	_	B-Chemical
,	,	PUNCT	,	9	O
infused	infuse	VERB	VBD	9	O
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	O
adrenergic	adrenergic	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
densities	density	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
ventricle	ventricle	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Clentiazem	Clentiazem	PROPN	NNP	_	B-Chemical
also	also	ADV	RB	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
enhanced	enhance	VERB	VBN	3	O
responses	response	NOUN	NNS	5	O
to	to	PART	TO	5	O
calcium	calcium	VERB	VB	0	B-Chemical
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
clentiazem	clentiazem	NOUN	NN	_	B-Chemical
partially	partially	ADV	RB	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
maximal	maximal	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
calcium	calcium	VERB	VB	0	B-Chemical
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
clentiazem	clentiazem	ADJ	JJ	_	B-Chemical
attenuated	attenuate	VERB	VBN	3	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
through	through	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
adrenergic	adrenergic	NOUN	NN	9	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Kaliuretic	kaliuretic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	ADJ	JJ	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hypokalemia	Hypokalemia	PROPN	NNP	7	B-Disease
,	,	PUNCT	,	9	O
sometimes	sometimes	ADV	RB	5	O
severe	severe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
normokalemic	normokalemic	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
by	by	ADP	IN	9	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
,	,	PUNCT	,	9	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

L	L	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Dopa	Dopa	PROPN	NNP	0	I-Chemical
intake	intake	NOUN	NN	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sometimes	sometimes	ADV	RB	5	O
also	also	ADV	RB	9	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hypokalemic	hypokalemic	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
normokalemic	normokalemic	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
prohibited	prohibit	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
dopa	dopa	ADJ	JJ	0	O
decarbodylase	decarbodylase	NOUN	NN	_	O
inhibitor	inhibitor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
known	know	VERB	VBN	9	O
why	why	ADV	WRB	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
individuals	individual	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
others	other	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
our	-PRON-	DET	PRP$	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
a	a	DET	DT	5	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
production	production	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
induced	induce	VERB	VBD	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
probably	probably	ADV	RB	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
nitroglycerin	nitroglycerin	ADJ	JJ	5	B-Chemical
and	and	CCONJ	CC	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
blocking	block	VERB	VBG	3	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
monitored	monitor	VERB	VBN	9	O
by	by	ADP	IN	9	O
ECG	ECG	PROPN	NNP	5	O
in	in	ADP	IN	5	O
freely	freely	ADV	RB	5	O
moving	move	VERB	VBG	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
new	new	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
to	to	PART	TO	5	O
test	test	VERB	VB	5	O
potential	potential	ADJ	JJ	9	O
protectors	protector	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
laboratory	laboratory	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
histology	histology	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
most	most	ADV	RBS	9	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
doxorubicin	doxorubicin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
monitoring	monitor	VERB	VBG	5	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
large	large	ADJ	JJ	5	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
ECG	ECG	PROPN	NNP	5	O
values	value	NOUN	NNS	5	O
in	in	ADP	IN	5	O
freely	freely	ADV	RB	5	O
moving	move	VERB	VBG	5	O
mice	mouse	NOUN	NNS	3	O
by	by	ADP	IN	9	O
telemetry	telemetry	NOUN	NN	5	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
ECG	ECG	PROPN	NNP	5	O
of	of	ADP	IN	5	O
freely	freely	ADV	RB	5	O
moving	move	VERB	VBG	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
c	c	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
ICRF	ICRF	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
187	187	NUM	CD	7	I-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ST	ST	PROPN	NNP	9	O
interval	interval	NOUN	NN	5	O
significantly	significantly	ADV	RB	9	O
widened	widen	VERB	VBD	5	O
from	from	ADP	IN	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	ADP	IN	5	O
56	56	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
ms	ms	NOUN	NN	5	O
in	in	ADP	IN	5	O
week	week	NOUN	NN	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
weekly	weekly	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
given	give	VERB	VBN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
plus	plus	CCONJ	CC	9	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
observation	observation	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ECG	ECG	PROPN	NNP	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
sacrifice	sacrifice	NOUN	NN	9	O
the	the	DET	DT	5	O
hearts	heart	NOUN	NNS	3	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
enlarged	enlarge	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
atria	atrium	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
hypertrophic	hypertrophic	ADJ	JJ	3	B-Disease
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
this	this	DET	DT	5	O
schedule	schedule	NOUN	NN	5	O
exerted	exert	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
than	than	ADP	IN	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
protective	protective	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
protection	protection	NOUN	NN	9	O
of	of	ADP	IN	5	O
ICRF	ICRF	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
187	187	PROPN	NNP	7	I-Chemical
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
schedule	schedule	NOUN	NN	5	O
with	with	ADP	IN	5	O
lower	low	ADJ	JJR	9	O
general	general	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
weekly	weekly	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
given	give	VERB	VBN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
plus	plus	CCONJ	CC	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
observation	observation	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
this	this	DET	DT	5	O
schedule	schedule	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
'	'	PART	POS	9	O
hearts	heart	NOUN	NNS	3	O
appeared	appear	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
after	after	ADP	IN	9	O
sacrifice	sacrifice	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ICRF	ICRF	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
187	187	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	ADV	RB	0	O
given	give	VERB	VBN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	NOUN	NN	9	O
1	1	NUM	CD	9	O
h	h	NOUN	NN	0	O
before	before	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
provided	provide	VERB	VBD	9	O
almost	almost	ADV	RB	9	O
full	full	ADJ	JJ	5	O
protection	protection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
histology	histology	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
new	new	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
very	very	ADV	RB	5	O
sensitive	sensitive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
enables	enable	VERB	VBZ	5	O
monitoring	monitoring	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
time	time	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
result	result	VERB	VBP	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
that	that	DET	WDT	5	O
allows	allow	VERB	VBZ	5	O
the	the	DET	DT	5	O
testing	testing	NOUN	NN	5	O
of	of	ADP	IN	5	O
protectors	protector	NOUN	NNS	5	O
against	against	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
as	as	ADP	IN	5	O
demonstrated	demonstrate	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
protection	protection	NOUN	NN	9	O
provided	provide	VERB	VBN	9	O
by	by	ADP	IN	9	O
ICRF	ICRF	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
187	187	NUM	CD	7	I-Chemical
.	.	PUNCT	.	9	O

Epinephrine	epinephrine	ADJ	JJ	0	B-Chemical
dysrhythmogenicity	dysrhythmogenicity	NOUN	NN	_	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
enhanced	enhance	VERB	VBN	3	O
by	by	ADP	IN	9	O
subtoxic	subtoxic	ADJ	JJ	3	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
both	both	DET	DT	9	O
precipitate	precipitate	VERB	VB	0	O
dysrhythmias	dysrhythmia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
circulating	circulate	VERB	VBG	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
during	during	ADP	IN	5	O
regional	regional	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
could	could	VERB	MD	9	O
potentiate	potentiate	VERB	VB	3	O
dysrhythmogenic	dysrhythmogenic	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
therefore	therefore	ADV	RB	5	O
examined	examine	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
alters	alter	NOUN	NNS	9	O
the	the	DET	DT	5	O
dysrhythmogenicity	dysrhythmogenicity	NOUN	NN	_	O
of	of	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
healthy	healthy	ADJ	JJ	5	O
dogs	dog	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
conscious	conscious	ADJ	JJ	5	O
dogs	dog	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Seventeen	seventeen	NUM	CD	9	O
animals	animal	NOUN	NNS	9	O
responded	respond	VERB	VBD	9	O
with	with	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
VT	VT	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
within	within	ADP	IN	9	O
3	3	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
3	3	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
responders	responder	NOUN	NNS	5	O
randomly	randomly	ADV	RB	5	O
received	receive	VERB	VBD	9	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
saline	saline	VERB	VB	0	O
over	over	ADP	IN	5	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
caused	cause	VERB	VBD	9	O
fewer	few	ADJ	JJR	5	O
prodysrhythmic	prodysrhythmic	ADJ	JJ	_	O
effects	effect	NOUN	NNS	9	O
than	than	ADP	IN	5	O
without	without	ADP	IN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

VT	VT	PROPN	NNP	9	B-Disease
appeared	appear	VERB	VBD	9	O
in	in	ADP	IN	5	O
fewer	few	ADJ	JJR	5	O
dogs	dog	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
later	later	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
sinoatrial	sinoatrial	ADJ	JJ	5	O
beats	beat	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
less	less	ADJ	JJR	5	O
ectopies	ectopie	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Epinephrine	Epinephrine	PROPN	NNP	0	B-Chemical
shortened	shorten	VERB	VBD	9	O
QT	QT	PROPN	NNP	5	O
less	less	ADV	RBR	5	O
after	after	ADP	IN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
experimental	experimental	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
six	six	NUM	CD	9	O
additional	additional	ADJ	JJ	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
anesthetized	anesthetized	ADJ	JJ	0	O
dogs	dog	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
4	4	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
until	until	ADP	IN	5	O
VT	VT	PROPN	NNP	9	B-Disease
appeared	appear	VERB	VBD	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
45	45	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
over	over	ADP	IN	5	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
again	again	ADV	RB	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
4	4	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
these	these	DET	DT	5	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
prodysrhythmic	prodysrhythmic	ADJ	JJ	_	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
mitigated	mitigate	VERB	VBN	9	O
by	by	ADP	IN	9	O
preceding	precede	VERB	VBG	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
antagonizes	antagonize	NOUN	NNS	3	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
dysrhythmogenicity	dysrhythmogenicity	NOUN	NN	_	O
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
dogs	dog	NOUN	NNS	5	O
susceptible	susceptible	ADJ	JJ	9	O
to	to	ADP	IN	5	O
VT	VT	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
postinfarct	postinfarct	NOUN	NN	5	O
dysrhythmias	dysrhythmia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
that	that	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
subtoxic	subtoxic	ADJ	JJ	3	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
enhances	enhance	VERB	VBZ	3	O
the	the	DET	DT	5	O
dysrhythmogenicity	dysrhythmogenicity	NOUN	NN	_	O
of	of	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Milk	milk	NOUN	NN	7	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
25	25	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
OH	OH	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
2D	2d	NOUN	NN	5	I-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
hypoparathyroidism	hypoparathyroidism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Milk	milk	NOUN	NN	7	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
first	first	ADV	RB	9	O
described	describe	VERB	VBN	9	O
70	70	NUM	CD	9	O
years	year	NOUN	NNS	5	O
ago	ago	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
context	context	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
peptic	peptic	ADJ	JJ	5	B-Disease
ulcer	ulcer	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
large	large	ADJ	JJ	5	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
alkali	alkali	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
with	with	ADP	IN	5	O
current	current	ADJ	JJ	5	O
ulcer	ulcer	NOUN	NN	5	B-Disease
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
H	h	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
omeprazole	omeprazole	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sucralfate	sucralfate	ADJ	JJ	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
milk	milk	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
decreased	decrease	VERB	VBN	9	O
significantly	significantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
classic	classic	ADJ	JJ	5	O
triad	triad	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
alkalosis	alkalosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
remains	remain	VERB	VBZ	9	O
the	the	DET	DT	5	O
hallmark	hallmark	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Milk	milk	NOUN	NN	7	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
can	can	VERB	MD	5	O
present	present	VERB	VB	9	O
serious	serious	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
occasionally	occasionally	ADV	RB	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
illness	illness	NOUN	NN	5	O
unless	unless	ADP	IN	9	O
diagnosed	diagnose	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
treated	treat	VERB	VBN	3	O
appropriately	appropriately	ADV	RB	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
article	article	NOUN	NN	6	O
presents	present	VERB	VBZ	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
hypoparathyroidism	hypoparathyroidism	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
carbonate	carbonate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
calcitriol	calcitriol	NOUN	NNS	3	B-Chemical
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
admissions	admission	NOUN	NNS	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
for	for	ADP	IN	5	O
milk	milk	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
successfully	successfully	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
pamidronate	pamidronate	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
first	first	ADJ	JJ	9	O
admission	admission	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
hydrocortisone	hydrocortisone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
illustrates	illustrate	VERB	VBZ	5	O
intravenous	intravenous	ADJ	JJ	0	O
pamidronate	pamidronate	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
valuable	valuable	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
tool	tool	NOUN	NN	5	O
when	when	ADV	WRB	5	O
milk	milk	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
presents	present	NOUN	NNS	5	O
as	as	ADP	IN	5	O
hypercalcemic	hypercalcemic	ADJ	JJ	5	B-Disease
emergency	emergency	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Famotidine	Famotidine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
delirium	delirium	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Famotidine	Famotidine	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
histamine	histamine	ADJ	JJ	0	O
H2	h2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
inpatient	inpatient	NOUN	NN	5	O
settings	setting	NOUN	NNS	5	O
for	for	ADP	IN	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
stress	stress	NOUN	NN	9	O
ulcers	ulcer	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
showing	show	VERB	VBG	9	O
increasing	increase	VERB	VBG	9	O
popularity	popularity	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
low	low	ADJ	JJ	9	O
cost	cost	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
currently	currently	ADV	RB	5	O
available	available	ADJ	JJ	5	O
H2	h2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
the	the	DET	DT	5	O
propensity	propensity	NOUN	NN	5	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
delirium	delirium	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
two	two	NUM	CD	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
famotidine	famotidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
report	report	VERB	VBP	5	O
on	on	ADP	IN	5	O
six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
famotidine	famotidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
delirium	delirium	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
hospitalized	hospitalize	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
cleared	clear	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
upon	upon	ADP	IN	9	O
removal	removal	NOUN	NN	9	O
of	of	ADP	IN	5	O
famotidine	famotidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
of	of	ADP	IN	5	O
famotidine	famotidine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
reviewed	review	VERB	VBN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
metabolism	metabolism	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
seen	see	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
implications	implication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
using	use	VERB	VBG	9	O
famotidine	famotidine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
persons	person	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
during	during	ADP	IN	5	O
amitriptyline	amitriptyline	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
are	be	VERB	VBP	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
serotonin	serotonin	NOUN	NN	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
spectrum	spectrum	NOUN	NN	9	O
disorders	disorder	NOUN	NNS	5	O
?	?	PUNCT	.	5	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
amitriptyline	amitriptyline	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
remission	remission	NOUN	NN	5	O
of	of	ADP	IN	5	O
unipolar	unipolar	ADJ	JJ	5	B-Disease
depression	depression	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
diagnosed	diagnose	VERB	VBN	5	O
as	as	ADP	IN	5	O
having	have	VERB	VBG	5	O
either	either	CCONJ	CC	9	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
NMS	NMS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
serotonin	serotonin	NOUN	NN	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SS	ss	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
determinant	determinant	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
/	/	SYM	SYM	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
imbalance	imbalance	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
NMS	nms	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADP	IN	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
that	that	DET	WDT	5	O
develops	develop	VERB	VBZ	5	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
antidepressants	antidepressant	NOUN	NNS	5	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
NMS	NMS	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
SS	SS	PROPN	NNP	9	B-Disease
are	be	VERB	VBP	5	O
spectrum	spectrum	ADJ	JJ	9	O
disorders	disorder	NOUN	NNS	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
drugs	drug	NOUN	NNS	5	O
with	with	ADP	IN	5	O
both	both	CCONJ	CC	9	O
antidopaminergic	antidopaminergic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
serotonergic	serotonergic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Genetic	genetic	ADJ	JJ	9	O
separation	separation	NOUN	NN	5	O
of	of	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
growth	growth	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
phenotypes	phenotype	NOUN	NNS	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tumor	tumor	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Fischer	Fischer	PROPN	NNP	6	O
344	344	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
F344	f344	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
rat	rat	NOUN	NN	3	O
induces	induce	NOUN	NNS	3	O
growth	growth	NOUN	NN	3	O
of	of	ADP	IN	5	O
large	large	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
pituitary	pituitary	ADJ	JJ	3	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
diethylstilbestrol	diethylstilbestrol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DES	DES	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
caused	cause	VERB	VBD	9	O
female	female	ADJ	JJ	9	O
F344	f344	NOUN	NN	3	O
rat	rat	NOUN	NN	3	O
pituitaries	pituitary	NOUN	NNS	3	O
to	to	PART	TO	5	O
grow	grow	VERB	VB	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
average	average	NOUN	NN	5	O
of	of	ADP	IN	5	O
109	109	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
for	for	ADP	IN	5	O
untreated	untreated	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
become	become	VERB	VB	5	O
highly	highly	ADV	RB	9	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
DES	DES	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
produced	produce	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
for	for	ADP	IN	5	O
treated	treated	ADJ	JJ	3	O
females	female	NOUN	NNS	9	O
versus	versus	ADP	IN	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
for	for	ADP	IN	5	O
untreated	untreated	ADJ	JJ	3	O
females	female	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
morphological	morphological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
Brown	Brown	PROPN	NNP	6	O
Norway	Norway	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
BN	BN	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
rat	rat	NOUN	NN	3	O
pituitaries	pituitary	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
F1	f1	ADJ	JJ	9	O
hybrid	hybrid	NOUN	NN	9	O
of	of	ADP	IN	5	O
F344	F344	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
BN	BN	PROPN	NNP	9	O
exhibited	exhibit	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
pituitary	pituitary	ADJ	JJ	3	O
growth	growth	NOUN	NN	3	O
after	after	ADP	IN	9	O
10	10	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
DES	DES	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
mass	mass	NOUN	NN	9	O
of	of	ADP	IN	5	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
for	for	ADP	IN	5	O
untreated	untreated	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Surprisingly	surprisingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
F1	F1	PROPN	NNP	9	O
hybrid	hybrid	NOUN	NN	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
hemoglobin	hemoglobin	NOUN	NN	0	O
content	content	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
outward	outward	ADJ	JJ	5	O
appearance	appearance	NOUN	NN	9	O
identical	identical	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
BN	BN	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
growth	growth	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
morphological	morphological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
genes	gene	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
DES	DES	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
pituitary	pituitary	ADJ	JJ	3	O
growth	growth	NOUN	NN	3	O
exhibited	exhibit	VERB	VBD	9	O
quantitative	quantitative	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
additive	additive	ADJ	JJ	9	O
inheritance	inheritance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
phenotype	phenotype	NOUN	NN	3	O
exhibited	exhibit	VERB	VBD	9	O
recessive	recessive	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
epistatic	epistatic	ADJ	JJ	5	O
inheritance	inheritance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
5	5	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
160	160	NUM	CD	9	O
F2	F2	PROPN	NNP	9	O
pituitaries	pituitary	NOUN	NNS	3	O
exhibited	exhibit	VERB	VBD	9	O
the	the	DET	DT	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
phenotype	phenotype	NOUN	NN	3	O
;	;	PUNCT	:	9	O
36	36	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
160	160	NUM	CD	9	O
F2	F2	PROPN	NNP	9	O
pituitaries	pituitary	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
F344	f344	NOUN	NN	3	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
mass	mass	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
31	31	NUM	CD	7	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
phenotype	phenotype	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
merely	merely	ADV	RB	5	O
a	a	DET	DT	5	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
extensive	extensive	ADJ	JJ	5	O
growth	growth	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
F2	f2	NOUN	NN	9	O
pituitaries	pituitary	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
all	all	ADV	RB	5	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
massive	massive	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
genes	gene	NOUN	NNS	1	O
regulate	regulate	VERB	VBP	3	O
both	both	DET	DT	9	O
phenotypes	phenotype	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
neuronal	neuronal	ADJ	JJ	3	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
synthase	synthase	NOUN	NN	1	O
in	in	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
afferent	afferent	NOUN	NN	5	O
pathways	pathway	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
chronic	chronic	ADJ	JJ	5	O
bladder	bladder	NOUN	NN	9	B-Disease
irritation	irritation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Immunocytochemical	immunocytochemical	ADJ	JJ	3	O
techniques	technique	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
neuronal	neuronal	ADJ	JJ	3	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
NOS	NOS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
pathways	pathway	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
acute	acute	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
irritation	irritation	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
urinary	urinary	ADJ	JJ	9	I-Disease
tract	tract	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Chemical	chemical	NOUN	NN	0	O
cystitis	cystitis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CYP	CYP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
metabolized	metabolize	VERB	VBN	0	O
to	to	PART	TO	5	O
acrolein	acrolein	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
irritant	irritant	NOUN	NN	0	O
eliminated	eliminate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urine	urine	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
2	2	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
perfusion	perfusion	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
acute	acute	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
increased	increase	VERB	VBD	9	O
Fos	Fos	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
immunoreactivity	immunoreactivity	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
IR	IR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dorsal	dorsal	ADJ	JJ	5	O
commissure	commissure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
dorsal	dorsal	ADJ	JJ	5	O
horn	horn	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
autonomic	autonomic	ADJ	JJ	5	O
regions	region	NOUN	NNS	9	O
of	of	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
segments	segment	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
L1	L1	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
L2	L2	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
L6	L6	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
S1	S1	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
which	which	DET	WDT	5	O
receive	receive	VERB	VBP	5	O
afferent	afferent	ADJ	JJ	5	O
inputs	input	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
,	,	PUNCT	,	9	O
urethra	urethra	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
ureter	ureter	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Fos	Fos	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
IR	IR	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
changed	change	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
receiving	receive	VERB	VBG	9	O
chronic	chronic	ADJ	JJ	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
every	every	DET	DT	5	O
3rd	3rd	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBD	3	O
acutely	acutely	ADV	RB	9	O
with	with	ADP	IN	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
small	small	ADJ	JJ	9	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
NOS	NOS	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
IR	IR	PROPN	NNP	9	O
cells	cell	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
cell	cell	NOUN	NN	3	O
profiles	profile	NOUN	NNS	9	O
/	/	SYM	SYM	9	O
sections	section	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
L6	l6	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
S1	s1	VERB	VB	9	O
dorsal	dorsal	ADJ	JJ	5	O
root	root	NOUN	NN	5	O
ganglia	ganglion	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
DRG	DRG	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Chronic	Chronic	PROPN	NNP	9	O
CYP	CYP	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBN	9	O
bladder	bladder	NOUN	NN	9	O
weight	weight	NOUN	NN	9	O
by	by	ADP	IN	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
11	11	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
fold	fold	VERB	VB	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
NOS	NOS	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
immunoreactive	immunoreactive	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
IR	IR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
afferent	afferent	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
L6	l6	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
S1	s1	VERB	VB	9	O
DRG	DRG	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
small	small	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	:	7	O
fold	fold	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
also	also	ADV	RB	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
L1	L1	PROPN	NNP	9	O
DRG	DRG	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
L2	L2	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
L5	L5	PROPN	NNP	9	O
DRG	DRG	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

Bladder	bladder	NOUN	NN	9	O
afferent	afferent	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
L6	l6	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
S1	S1	PROPN	NNP	9	O
DRG	DRG	PROPN	NNP	3	O
labeled	label	VERB	VBN	3	O
by	by	ADP	IN	9	O
Fluorogold	Fluorogold	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
microliters	microliter	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
injected	inject	VERB	VBD	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
wall	wall	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
exhibit	exhibit	VERB	VB	9	O
NOS	NOS	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
IR	IR	PROPN	NNP	9	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
following	follow	VERB	VBG	9	O
chronic	chronic	ADJ	JJ	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
afferent	afferent	NOUN	NN	5	O
neurons	neuron	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
NOS	NOS	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
IR	IR	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
L6	L6	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
S1	S1	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
neuronal	neuronal	ADJ	JJ	3	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
visceral	visceral	ADJ	JJ	9	O
sensory	sensory	ADJ	JJ	5	O
pathways	pathway	NOUN	NNS	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
upregulated	upregulate	VERB	VBN	3	O
by	by	ADP	IN	9	O
chemical	chemical	NOUN	NN	0	O
irritation	irritation	NOUN	NN	5	O
of	of	ADP	IN	5	O
afferent	afferent	ADJ	JJ	5	O
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
tract	tract	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
that	that	ADP	IN	5	O
pathological	pathological	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
tract	tract	NOUN	NN	9	O
can	can	VERB	MD	5	O
initiate	initiate	VERB	VB	9	O
chemical	chemical	NOUN	NN	0	O
signals	signal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
alter	alter	VERB	VBP	9	O
the	the	DET	DT	5	O
chemical	chemical	ADJ	JJ	0	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
visceral	visceral	ADJ	JJ	9	O
afferent	afferent	NOUN	NN	5	O
neurons	neuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
CD	CD	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
832	832	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
partial	partial	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CD	CD	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
832	832	NUM	CD	7	I-Chemical
on	on	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ISO	ISO	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
partial	partial	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
circumflex	circumflex	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
findings	finding	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
for	for	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
min	min	NOUN	NN	0	O
periods	period	NOUN	NNS	5	O
of	of	ADP	IN	5	O
intracoronary	intracoronary	ADJ	JJ	5	O
ISO	ISO	PROPN	NNP	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBN	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
maximal	maximal	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
rise	rise	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
percentage	percentage	NOUN	NN	9	O
segmental	segmental	NOUN	NN	5	O
shortening	shortening	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ST	st	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
epicardial	epicardial	ADJ	JJ	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
ISO	ISO	PROPN	NNP	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
with	with	ADP	IN	5	O
stenosis	stenosis	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
,	,	PUNCT	,	9	O
equihypotensive	equihypotensive	ADJ	JJ	_	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
CD	CD	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
832	832	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
infused	infuse	VERB	VBN	9	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
third	third	ADJ	JJ	9	O
ISO	ISO	PROPN	NNP	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
CD	CD	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
832	832	NUM	CD	7	I-Chemical
and	and	CCONJ	CC	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
ISO	ISO	PROPN	NNP	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
CD	CD	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
832	832	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
percentage	percentage	NOUN	NN	9	O
segmental	segmental	NOUN	NN	5	O
shortening	shorten	VERB	VBG	9	O
from	from	ADP	IN	9	O
32	32	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
115	115	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
value	value	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
ST	st	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
elevation	elevation	NOUN	NN	9	O
from	from	ADP	IN	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mV	mv	NOUN	NN	0	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mV	mV	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
ISO	ISO	PROPN	NNP	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
with	with	ADP	IN	5	O
stenosis	stenosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Diltiazem	Diltiazem	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
also	also	ADV	RB	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
percentage	percentage	NOUN	NN	9	O
segmental	segmental	NOUN	NN	5	O
shortening	shorten	VERB	VBG	9	O
from	from	ADP	IN	9	O
34	34	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
63	63	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
value	value	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
ST	st	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
elevation	elevation	NOUN	NN	9	O
from	from	ADP	IN	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mV	mv	NOUN	NN	0	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mV	mV	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
ISO	ISO	PROPN	NNP	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
with	with	ADP	IN	5	O
stenosis	stenosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
CD	CD	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
832	832	PROPN	NNP	7	I-Chemical
improves	improve	VERB	VBZ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
during	during	ADP	IN	5	O
ISO	ISO	PROPN	NNP	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
with	with	ADP	IN	5	O
stenosis	stenosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
chronotropic	chronotropic	ADJ	JJ	5	O
property	property	NOUN	NN	5	O
of	of	ADP	IN	5	O
CD	CD	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
832	832	PROPN	NNP	7	I-Chemical
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CD	CD	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
832	832	NUM	CD	7	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
recombinant	recombinant	ADJ	JJ	3	O
human	human	ADJ	JJ	3	O
insulin	insulin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
on	on	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recently	recently	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
recombinant	recombinant	ADJ	JJ	3	O
hGH	hgh	NUM	CD	1	O
exacerbates	exacerbate	NOUN	NNS	9	O
renal	renal	ADJ	JJ	9	O
functional	functional	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
structural	structural	ADJ	JJ	9	O
injury	injury	NOUN	NN	9	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
examined	examine	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
recombinant	recombinant	ADJ	JJ	3	O
human	human	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
rh	rh	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
safer	safe	ADJ	JJR	5	O
alternative	alternative	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
growth	growth	NOUN	NN	3	B-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
glomerulopathy	glomerulopathy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
seven	seven	NUM	CD	9	O
serial	serial	ADJ	JJ	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
over	over	ADP	IN	5	O
12	12	NUM	CD	9	O
wk	wk	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Experimental	experimental	ADJ	JJ	9	O
animals	animal	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
rhIGF	rhIGF	PROPN	NNP	9	O
-	-	PUNCT	:	7	O
I	I	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
400	400	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
vehicle	vehicle	NOUN	NN	3	O
.	.	PUNCT	.	9	O

rhIGF	rhigf	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
improved	improve	VERB	VBD	5	O
weight	weight	NOUN	NN	9	O
gain	gain	NOUN	NN	5	O
by	by	ADP	IN	9	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
altering	alter	VERB	VBG	9	O
hematocrit	hematocrit	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Urinary	urinary	NOUN	NN	9	O
protein	protein	NOUN	NN	1	O
excretion	excretion	NOUN	NN	0	O
was	be	VERB	VBD	9	O
unaltered	unaltered	ADJ	JJ	9	O
by	by	ADP	IN	9	O
rhIGF	rhigf	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
12	12	NUM	CD	9	O
wk	wk	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
inulin	inulin	ADJ	JJ	0	O
clearance	clearance	NOUN	NN	9	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
rhIGF	rhigf	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
I	i	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
48	48	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
versus	versus	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
24	24	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
06	06	NUM	CD	7	O
mL	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
of	of	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
in	in	ADP	IN	5	O
untreated	untreated	ADJ	JJ	3	O
PAN	PAN	PROPN	NNP	0	B-Chemical
nephropathy	nephropathy	ADJ	JJ	9	B-Disease
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
GFR	GFR	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
enhanced	enhance	VERB	VBN	3	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
segmental	segmental	ADJ	JJ	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
tubulointerstitial	tubulointerstitial	ADJ	JJ	3	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
cortical	cortical	ADJ	JJ	5	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
content	content	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
rhIGF	rhigf	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
increased	increase	VERB	VBD	9	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
I	I	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
GH	GH	PROPN	NNP	9	O
receptor	receptor	NOUN	NN	3	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
altering	alter	VERB	VBG	9	O
the	the	DET	DT	5	O
steady	steady	ADJ	JJ	5	O
state	state	NOUN	NN	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
receptor	receptor	VERB	VBP	3	O
mRNA	mRNA	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
intact	intact	ADJ	JJ	9	O
kidneys	kidney	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
rhIGF	rhigf	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
alter	alter	VERB	VB	9	O
weight	weight	NOUN	NN	9	O
gain	gain	NOUN	NN	5	O
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
GFR	GFR	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
glomerular	glomerular	NOUN	NN	5	O
planar	planar	NOUN	NN	5	O
area	area	NOUN	NN	5	O
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	O
cortical	cortical	ADJ	JJ	5	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
content	content	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
glomerular	glomerular	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
tubulointerstitial	tubulointerstitial	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
untreated	untreated	ADJ	JJ	3	O
animals	animal	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

rhIGF	rhigf	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
treatment	treatment	NOUN	NN	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
steady	steady	ADJ	JJ	5	O
state	state	NOUN	NN	5	O
renal	renal	ADJ	JJ	9	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
mRNA	mRNA	NOUN	NNS	3	O
level	level	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
modify	modify	VERB	VB	9	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
I	I	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
GH	GH	PROPN	NNP	9	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
:	:	PUNCT	:	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
rhIGF	rhigf	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
improves	improve	VERB	VBZ	5	O
growth	growth	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
GFR	GFR	PROPN	NNP	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
unlike	unlike	ADP	IN	9	O
rhGH	rhGH	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
rhIGF	rhigf	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
worsen	worsen	VERB	VB	5	O
renal	renal	ADJ	JJ	9	O
functional	functional	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
structural	structural	ADJ	JJ	9	O
injury	injury	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
disease	disease	NOUN	NN	5	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Nefiracetam	nefiracetam	NOUN	NN	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
DM	DM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9384	9384	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
reverses	reverse	VERB	VBZ	3	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
response	response	NOUN	NN	9	O
:	:	PUNCT	:	9	O
delayed	delay	VERB	VBN	9	O
emergence	emergence	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
memory	memory	NOUN	NN	5	O
retention	retention	NOUN	NN	9	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Nefiracetam	nefiracetam	NOUN	NN	_	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
pyrrolidone	pyrrolidone	NOUN	NN	0	B-Chemical
derivative	derivative	NOUN	NN	0	O
which	which	DET	WDT	5	O
attenuates	attenuate	VERB	VBZ	3	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
learning	learning	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
post	post	ADJ	JJ	9	I-Disease
-	-	ADJ	JJ	7	I-Disease
training	training	ADJ	JJ	5	I-Disease
consolidation	consolidation	NOUN	NN	5	I-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
that	that	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
inhibits	inhibit	VERB	VBZ	3	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
retention	retention	NOUN	NN	9	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
during	during	ADP	IN	5	O
training	training	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
defined	define	VERB	VBN	5	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
12h	12h	PROPN	NNPS	0	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
training	training	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
nefiracetam	nefiracetam	NOUN	NN	9	B-Chemical
to	to	PART	TO	5	O
attenuate	attenuate	VERB	VB	9	O
amnesia	amnesia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
agonism	agonism	NOUN	NN	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
step	step	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
down	down	PART	RP	9	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
paradigm	paradigm	NOUN	NN	5	O
was	be	VERB	VBD	9	O
employed	employ	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
nefiracetam	nefiracetam	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
alone	alone	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
during	during	ADP	IN	5	O
training	training	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
12h	12h	PROPN	NNPS	0	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
training	training	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
consolidation	consolidation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Co	co	NOUN	NN	0	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
nefiracetam	nefiracetam	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
during	during	ADP	IN	5	O
training	training	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
10h	10h	NOUN	NNS	0	O
thereafter	thereafter	ADV	RB	9	O
produced	produce	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
amnesic	amnesic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
nefiracetam	nefiracetam	NOUN	NN	9	B-Chemical
during	during	ADP	IN	5	O
training	training	NOUN	NN	5	O
completely	completely	ADV	RB	9	O
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
10h	10h	NOUN	NNS	0	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
training	training	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
converse	converse	NOUN	NN	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
true	true	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
as	as	ADP	IN	5	O
nefiracetam	nefiracetam	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
millimolar	millimolar	ADJ	JJ	0	O
concentrations	concentration	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
displace	displace	VERB	VB	9	O
either	either	CCONJ	CC	9	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
SCH	SCH	PROPN	NNP	9	B-Chemical
23390	23390	NUM	CD	0	I-Chemical
or	or	CCONJ	CC	5	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
spiperone	spiperone	VERB	VBN	0	B-Chemical
binding	bind	VERB	VBG	1	O
from	from	ADP	IN	9	O
D1	d1	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
D2	d2	NOUN	NN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptor	receptor	NOUN	NN	3	O
subtypes	subtype	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
nefiracetam	nefiracetam	NOUN	NN	9	B-Chemical
augments	augment	NOUN	NNS	3	O
molecular	molecular	ADJ	JJ	9	O
processes	process	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
stages	stage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
events	event	NOUN	NNS	5	O
which	which	DET	WDT	5	O
ultimately	ultimately	ADV	RB	5	O
lead	lead	VERB	VBP	5	O
to	to	ADP	IN	5	O
consolidation	consolidation	NOUN	NN	5	O
of	of	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Phenytoin	phenytoin	NOUN	NN	0	B-Chemical
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
as	as	ADP	IN	5	O
probable	probable	ADJ	JJ	9	O
idiosyncratic	idiosyncratic	ADJ	JJ	5	O
reaction	reaction	NOUN	NN	9	O
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DPH	DPH	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
with	with	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
EEG	EEG	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
mental	mental	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
adequate	adequate	ADJ	JJ	5	O
oral	oral	ADJ	JJ	9	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
DPH	DPH	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
very	very	ADV	RB	5	O
low	low	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
microgramg	microgramg	NOUN	NNS	_	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
was	be	VERB	VBD	9	O
probably	probably	ADV	RB	9	O
an	an	DET	DT	5	O
idiosyncratic	idiosyncratic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
not	not	ADV	RB	5	O
toxic	toxic	ADJ	JJ	0	O
or	or	CCONJ	CC	5	O
allergic	allergic	ADJ	JJ	9	O
reaction	reaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
fact	fact	NOUN	NN	9	O
the	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
free	free	ADJ	JJ	9	O
DPH	DPH	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
presented	present	VERB	VBD	5	O
a	a	DET	DT	5	O
retarded	retarded	ADJ	JJ	9	O
morbilliform	morbilliform	NOUN	NN	5	O
rash	rash	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
DPH	DPH	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
protidogram	protidogram	NOUN	NN	_	O
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
intradermic	intradermic	ADJ	JJ	0	O
DPH	DPH	PROPN	NNP	0	B-Chemical
injection	injection	NOUN	NN	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
local	local	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
starting	start	VERB	VBG	9	O
DPH	DPH	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
an	an	DET	DT	5	O
unexpected	unexpected	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
EEG	EEG	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
mental	mental	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
occurring	occur	VERB	VBG	9	O
simultaneously	simultaneously	ADV	RB	5	O
,	,	PUNCT	,	9	O
should	should	VERB	MD	5	O
alert	alert	VERB	VB	5	O
the	the	DET	DT	5	O
physician	physician	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
eliminating	eliminate	VERB	VBG	5	O
DPH	DPH	PROPN	NNP	0	B-Chemical
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
regimen	regimen	NOUN	NN	5	O
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
if	if	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
low	low	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Prevention	prevention	NOUN	NN	2	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
climacteric	climacteric	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
oestrogen	oestrogen	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
regimens	regimen	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
74	74	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
among	among	ADP	IN	5	O
850	850	NUM	CD	9	O
climacteric	climacteric	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
oestrogen	oestrogen	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cystic	cystic	ADJ	JJ	2	O
hyperplasia	hyperplasia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
unopposed	unopposed	ADJ	JJ	5	O
oestrogen	oestrogen	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
without	without	ADP	IN	9	O
progestagen	progestagen	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
21	21	NUM	CD	7	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
norethisterone	norethisterone	NUM	CD	0	B-Chemical
daily	daily	ADV	RB	5	O
caused	cause	VERB	VBD	9	O
reversion	reversion	NOUN	NN	9	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
57	57	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cystic	cystic	ADJ	JJ	5	O
hyperplasia	hyperplasia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
8	8	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
atypical	atypical	ADJ	JJ	5	O
hyperplasia	hyperplasia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

4	4	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
referred	refer	VERB	VBD	5	O
from	from	ADP	IN	9	O
elsewhere	elsewhere	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBD	9	O
the	the	DET	DT	5	O
problems	problem	NOUN	NNS	5	O
of	of	ADP	IN	5	O
inappropriate	inappropriate	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
unsupervised	unsupervised	ADJ	JJ	5	O
unopposed	unopposed	ADJ	JJ	5	O
oestrogen	oestrogen	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
difficulty	difficulty	NOUN	NN	5	O
in	in	ADP	IN	5	O
distinguishing	distinguish	VERB	VBG	5	O
severe	severe	ADJ	JJ	5	O
hyperplasia	hyperplasia	NOUN	NN	9	B-Disease
from	from	ADP	IN	9	O
malignancy	malignancy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Cyclical	cyclical	ADJ	JJ	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
oestrogen	oestrogen	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
13	13	NUM	CD	7	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
progestagen	progestagen	NOUN	NN	0	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
seem	seem	VERB	VB	5	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
exercise	exercise	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
exercise	exercise	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ninety	ninety	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
exercise	exercise	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
E	E	PROPN	NNP	9	O
-	-	PROPN	NNP	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
exercise	exercise	NOUN	NN	5	O
control	control	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
EC	EC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
groups	group	NOUN	NNS	9	O
exercised	exercise	VERB	VBD	5	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
thirty	thirty	NUM	CD	5	O
days	day	NOUN	NNS	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
treadmill	treadmill	NOUN	NN	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
mph	mph	NOUN	NN	5	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
grade	grade	NOUN	NN	9	O
while	while	ADP	IN	9	O
animals	animal	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sedentary	sedentary	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
I	I	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
group	group	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
sedentary	sedentary	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
sedentary	sedentary	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SC	SC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
group	group	NOUN	NN	9	O
which	which	DET	WDT	5	O
remained	remain	VERB	VBD	9	O
sedentary	sedentary	ADJ	JJ	5	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
final	final	ADJ	JJ	9	O
exercise	exercise	NOUN	NN	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
I	I	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
E	e	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
animals	animal	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
I	I	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
exhibited	exhibit	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
Pp	pp	VERB	VB	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
greater	great	ADJ	JJR	5	O
mortality	mortality	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
E	e	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Serum	Serum	PROPN	NNP	9	O
CPK	CPK	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
for	for	ADP	IN	5	O
E	e	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
animals	animal	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
for	for	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
I	I	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
EC	EC	PROPN	NNP	9	O
groups	group	NOUN	NNS	9	O
twenty	twenty	NUM	CD	5	O
hours	hour	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBD	3	O
groups	group	NOUN	NNS	9	O
for	for	ADP	IN	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
induced	induce	VERB	VBN	3	O
lesions	lesion	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
to	to	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
ratios	ratio	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
exercise	exercise	NOUN	NN	5	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
large	large	ADJ	JJ	5	O
dosages	dosage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
but	but	CCONJ	CC	9	O
had	have	VERB	VBD	9	O
little	little	ADJ	JJ	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
infarction	infarction	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Human	human	ADJ	JJ	9	O
corticotropin	corticotropin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
releasing	release	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
thyrotropin	thyrotropin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
releasing	release	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
modulate	modulate	VERB	VB	9	O
the	the	DET	DT	5	O
hypercapnic	hypercapnic	ADJ	JJ	5	B-Disease
ventilatory	ventilatory	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Human	human	ADJ	JJ	9	O
corticotropin	corticotropin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
releasing	release	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
hCRH	hCRH	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
thyrotropin	thyrotropin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
releasing	release	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
TRH	TRH	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
stimulate	stimulate	VERB	VB	3	O
ventilation	ventilation	NOUN	NN	5	O
after	after	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
clarify	clarify	VERB	VB	9	O
if	if	ADP	IN	5	O
both	both	DET	DT	9	O
peptides	peptide	NOUN	NNS	9	O
act	act	VERB	VBP	9	O
by	by	ADP	IN	9	O
altering	alter	VERB	VBG	9	O
central	central	ADJ	JJ	5	O
chemosensitivity	chemosensitivity	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
subsequent	subsequent	ADJ	JJ	9	O
CO2	CO2	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
rebreathing	rebreathe	VERB	VBG	5	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
young	young	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
test	test	NOUN	NN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
NaCl	NaCl	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
;	;	PUNCT	:	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
test	test	NOUN	NN	5	O
200	200	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
of	of	ADP	IN	5	O
hCRH	hCRH	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
400	400	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
of	of	ADP	IN	5	O
TRH	TRH	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
Nine	nine	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
NaCl	NaCl	PROPN	NNP	0	B-Chemical
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
during	during	ADP	IN	5	O
both	both	DET	DT	9	O
rebreathing	rebreathing	NOUN	NN	5	O
manoeuvres	manoeuvre	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
CO2	CO2	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
curves	curve	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
subject	subject	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
hCRH	hCRH	PROPN	NNP	3	O
group	group	NOUN	NN	9	O
a	a	DET	DT	5	O
marked	mark	VERB	VBN	9	O
parallel	parallel	ADJ	JJ	5	O
shift	shift	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
CO2	CO2	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
curve	curve	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
after	after	ADP	IN	9	O
hCRH	hCRH	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
following	follow	VERB	VBG	9	O
TRH	TRH	PROPN	NNP	3	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
striking	striking	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

hCRH	hCRH	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
TRH	TRH	PROPN	NNP	3	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
CO2	CO2	PROPN	NNP	0	B-Chemical
threshold	threshold	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
CO2	CO2	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
curves	curve	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
nearly	nearly	ADV	RB	9	O
identical	identical	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
an	an	DET	DT	5	O
additive	additive	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
releasing	release	VERB	VBG	9	O
hormones	hormone	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
hypercapnic	hypercapnic	ADJ	JJ	5	B-Disease
ventilatory	ventilatory	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
presumably	presumably	ADV	RB	9	O
independent	independent	ADJ	JJ	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
chemosensitivity	chemosensitivity	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Lamivudine	Lamivudine	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
suppressing	suppress	VERB	VBG	3	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	O
DNA	dna	NOUN	NN	9	O
in	in	ADP	IN	5	O
Chinese	chinese	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
surface	surface	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
carriers	carrier	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Lamivudine	Lamivudine	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
2	2	NUM	CD	9	B-Chemical
'	'	PUNCT	''	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
'	'	PART	POS	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dideoxy	dideoxy	NOUN	NN	9	I-Chemical
cytosine	cytosine	NOUN	NN	1	I-Chemical
analogue	analogue	NOUN	NN	0	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
potent	potent	ADJ	JJ	3	O
inhibitory	inhibitory	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	O
replication	replication	NOUN	NN	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
its	-PRON-	DET	PRP$	9	O
effectiveness	effectiveness	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
in	in	ADP	IN	5	O
Chinese	chinese	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
surface	surface	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
carriers	carrier	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
Chinese	chinese	ADJ	JJ	9	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
carriers	carrier	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
lamivudine	lamivudine	VERB	VB	5	B-Chemical
orally	orally	ADV	RB	0	O
in	in	ADP	IN	5	O
dosages	dosage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
for	for	ADP	IN	5	O
each	each	DET	DT	5	O
dosage	dosage	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
closely	closely	ADV	RB	9	O
monitored	monitor	VERB	VBN	9	O
clinically	clinically	ADV	RB	5	O
,	,	PUNCT	,	9	O
biochemically	biochemically	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
serologically	serologically	ADV	RB	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
36	36	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
HBV	HBV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
DNA	DNA	PROPN	NNP	9	O
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
>	>	X	XX	0	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
slightly	slightly	ADV	RB	9	O
less	less	ADV	RBR	5	O
effective	effective	ADJ	JJ	5	O
than	than	ADP	IN	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
011	011	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
still	still	ADV	RB	5	O
induced	induce	VERB	VBD	3	O
94	94	NUM	CD	7	O
%	%	NOUN	NN	9	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
DNA	DNA	PROPN	NNP	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
fourth	fourth	ADJ	JJ	9	O
week	week	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

HBV	HBV	PROPN	NNP	9	O
DNA	DNA	PROPN	NNP	9	O
values	value	NOUN	NNS	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
pretreatment	pretreatment	ADJ	JJ	0	O
levels	level	NOUN	NNS	3	O
within	within	ADP	IN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
e	e	PROPN	NNP	9	O
antigen	antigen	NOUN	NN	3	O
status	status	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
aminotransferase	aminotransferase	NOUN	NN	7	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
safe	safe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
DNA	DNA	PROPN	NNP	9	O
in	in	ADP	IN	5	O
Chinese	Chinese	PROPN	NNP	9	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
carriers	carrier	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
suppression	suppression	NOUN	NN	9	O
was	be	VERB	VBD	9	O
>	>	X	XX	0	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
reversible	reversible	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
with	with	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
DNA	DNA	PROPN	NNP	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
achieved	achieve	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Population	population	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
various	various	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Four	four	NUM	CD	9	O
studies	study	NOUN	NNS	9	O
published	publish	VERB	VBN	9	O
since	since	ADP	IN	9	O
December	December	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
1995	1995	NUM	CD	2	O
,	,	PUNCT	,	9	O
reported	report	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
VTE	VTE	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
used	use	VERB	VBD	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
OCs	oc	NOUN	NNS	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
containing	contain	VERB	VBG	0	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
progestagens	progestagen	VERB	VBZ	0	B-Chemical
gestodene	gestodene	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
desogestrel	desogestrel	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
OCs	oc	NOUN	NNS	5	B-Chemical
containing	contain	VERB	VBG	0	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
progestagens	progestagen	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
confounding	confounding	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
bias	bias	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
design	design	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
affected	affect	VERB	VBN	9	O
the	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
re	re	VERB	VB	5	O
-	-	VERB	VB	7	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
OC	OC	PROPN	NNP	9	B-Chemical
use	use	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
different	different	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
design	design	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
analysis	analysis	NOUN	NN	9	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bias	bias	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
confounding	confounding	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
earlier	early	ADJ	JJR	9	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
computer	computer	NOUN	NN	5	O
records	record	NOUN	NNS	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
from	from	ADP	IN	9	O
143	143	NUM	CD	7	O
general	general	ADJ	JJ	5	O
practices	practice	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
UK	UK	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
of	of	ADP	IN	5	O
about	about	ADP	IN	5	O
540	540	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
born	bear	VERB	VBN	5	O
between	between	ADP	IN	5	O
1941	1941	NUM	CD	4	O
and	and	CCONJ	CC	5	O
1981	1981	NUM	CD	2	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
recorded	record	VERB	VBN	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
deep	deep	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
vein	vein	NOUN	NN	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
venous	venous	ADJ	JJ	5	B-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
not	not	ADV	RB	5	O
otherwise	otherwise	ADV	RB	9	O
specified	specify	VERB	VBN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
embolus	embolus	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
anticoagulant	anticoagulant	NOUN	NN	9	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
as	as	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
did	do	VERB	VBD	9	O
a	a	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
to	to	PART	TO	5	O
estimate	estimate	VERB	VB	5	O
and	and	CCONJ	CC	5	O
compare	compare	VERB	VB	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
OC	OC	PROPN	NNP	9	B-Chemical
preparations	preparation	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
nested	nested	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
calculate	calculate	VERB	VB	5	O
the	the	DET	DT	5	O
odds	odd	NOUN	NNS	5	O
ratios	ratio	NOUN	NNS	9	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
different	different	ADJ	JJ	9	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
OC	OC	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
adjustment	adjustment	NOUN	NN	5	O
for	for	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
confounding	confound	VERB	VBG	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
matched	match	VERB	VBD	9	O
cases	case	NOUN	NNS	5	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
by	by	ADP	IN	9	O
exact	exact	ADJ	JJ	5	O
year	year	NOUN	NN	5	O
of	of	ADP	IN	5	O
birth	birth	NOUN	NN	5	O
,	,	PUNCT	,	9	O
practice	practice	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
current	current	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
OCs	oc	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
a	a	DET	DT	5	O
multiple	multiple	ADJ	JJ	5	O
logistic	logistic	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
model	model	NOUN	NN	5	O
that	that	DET	WDT	5	O
included	include	VERB	VBD	5	O
body	body	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
mass	mass	NOUN	NN	9	O
index	index	NOUN	NN	5	O
,	,	PUNCT	,	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
cycles	cycle	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
OC	OC	PROPN	NNP	9	B-Chemical
prescribed	prescribe	VERB	VBN	5	O
within	within	ADP	IN	9	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
event	event	NOUN	NN	5	O
,	,	PUNCT	,	9	O
previous	previous	ADJ	JJ	9	O
pregnancy	pregnancy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
concurrent	concurrent	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

FINDINGS	finding	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
85	85	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
met	meet	VERB	VBD	5	O
the	the	DET	DT	5	O
inclusion	inclusion	NOUN	NN	5	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
were	be	VERB	VBD	9	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
progestagen	progestagen	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
only	only	ADJ	JJ	9	O
OCs	oc	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
83	83	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
OCs	oc	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
43	43	NUM	CD	7	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
as	as	ADP	IN	5	O
deep	deep	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
vein	vein	NOUN	NN	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
35	35	NUM	CD	9	O
as	as	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
as	as	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
not	not	ADV	RB	5	O
otherwise	otherwise	ADV	RB	9	O
specified	specify	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
crude	crude	ADJ	JJ	0	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
per	per	ADP	IN	9	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
woman	woman	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
years	year	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
10	10	NUM	CD	9	O
in	in	ADP	IN	5	O
current	current	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
OC	OC	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
10	10	NUM	CD	9	O
in	in	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
OCs	oc	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
96	96	NUM	CD	9	O
in	in	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
preparations	preparation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
adjustment	adjustment	NOUN	NN	5	O
for	for	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
OCs	oc	NOUN	NNS	5	B-Chemical
was	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
68	68	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Logistic	logistic	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
between	between	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
OCs	oc	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
progestagens	progestagen	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
desogestrel	desogestrel	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
20	20	NUM	CD	9	O
g	g	NOUN	NN	0	O
ethinyloestradiol	ethinyloestradiol	NOUN	NNS	0	B-Chemical
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
gestodene	gestodene	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
desogestrel	desogestrel	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
30	30	NUM	CD	9	O
g	g	NOUN	NN	0	O
ethinyloestradiol	ethinyloestradiol	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
all	all	DET	DT	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
OCs	oc	NOUN	NNS	5	B-Chemical
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
reference	reference	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
odds	odd	NOUN	NNS	5	O
ratios	ratio	NOUN	NNS	9	O
for	for	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
were	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
49	49	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
21	21	NUM	CD	7	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
desogestrel	desogestrel	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
20	20	NUM	CD	9	O
g	g	NOUN	NN	0	O
ethinyloestradiol	ethinyloestradiol	NOUN	NNS	0	B-Chemical
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
18	18	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
66	66	NUM	CD	7	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
progestagens	progestagen	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

INTERPRETATION	interpretation	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
OCs	oc	NOUN	NNS	5	B-Chemical
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
products	product	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
the	the	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
residual	residual	ADJ	JJ	9	O
confounding	confound	VERB	VBG	5	O
by	by	ADP	IN	9	O
age	age	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
products	product	NOUN	NNS	9	O
containing	contain	VERB	VBG	0	O
20	20	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
ethinyloestradiol	ethinyloestradiol	NOUN	NNS	0	B-Chemical
and	and	CCONJ	CC	5	O
desogestrel	desogestrel	NOUN	NN	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
30	30	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
product	product	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
biologically	biologically	ADV	RB	9	O
implausible	implausible	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
preferential	preferential	ADJ	JJ	9	O
prescribing	prescribing	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
confounding	confound	VERB	VBG	5	O
.	.	PUNCT	.	9	O

MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	NUM	CD	7	I-Chemical
augments	augment	NOUN	NNS	3	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
electrographic	electrographic	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
but	but	CCONJ	CC	9	O
protects	protect	VERB	VBZ	3	O
against	against	ADP	IN	9	O
brain	brain	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

1	1	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizure	seizure	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Intraperitoneal	intraperitoneal	ADJ	JJ	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBN	3	O
tonic	tonic	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
clonic	clonic	NOUN	NN	5	I-Disease
seizure	seizure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Scopolamine	Scopolamine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
prevented	prevent	VERB	VBN	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
behavioral	behavioral	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
but	but	CCONJ	CC	9	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
.	.	PUNCT	.	9	O

2	2	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
electrical	electrical	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
measured	measure	VERB	VBN	9	O
with	with	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
EEG	EEG	PROPN	NNP	5	O
appeared	appear	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Scopolamine	scopolamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
blocked	block	VERB	VBD	3	O
the	the	DET	DT	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
electrographic	electrographic	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	NUM	CD	7	I-Chemical
treatment	treatment	NOUN	NN	9	O
augmented	augment	VERB	VBD	9	O
the	the	DET	DT	5	O
electrographic	electrographic	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Brain	brain	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
examining	examine	VERB	VBG	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
microscopically	microscopically	ADV	RB	9	O
.	.	PUNCT	.	9	O

Pilocarpine	Pilocarpine	PROPN	NNP	0	B-Chemical
produced	produce	VERB	VBD	9	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
death	death	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
showed	show	VERB	VBD	9	O
pyknotic	pyknotic	ADJ	JJ	3	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pentobarbital	Pentobarbital	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
protected	protect	VERB	VBD	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
though	though	ADP	IN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
pyramidal	pyramidal	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
hippocampus	hippocampus	NOUN	NN	9	O
appeared	appear	VERB	VBD	9	O
darker	dark	ADJ	JJR	4	O
than	than	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	DT	5	O
treatments	treatment	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

4	4	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
initiated	initiate	VERB	VBN	9	O
by	by	ADP	IN	9	O
cholinergic	cholinergic	NOUN	NN	3	O
overstimulation	overstimulation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
propagated	propagate	VERB	VBN	9	O
by	by	ADP	IN	9	O
glutamatergic	glutamatergic	ADJ	JJ	3	O
transmission	transmission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
brain	brain	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
through	through	ADP	IN	9	O
an	an	DET	DT	5	O
excitatory	excitatory	ADJ	JJ	5	O
NMDA	nmda	ADJ	JJ	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
mechanism	mechanism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Paclitaxel	paclitaxel	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
folinic	folinic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
:	:	PUNCT	:	9	O
BRE	BRE	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
26	26	NUM	CD	7	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

5	5	PUNCT	LS	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
Fluorouracil	fluorouracil	ADJ	JJ	0	I-Chemical
plus	plus	CCONJ	CC	9	O
folinic	folinic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Taxol	Taxol	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
Bristol	Bristol	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Myers	Myers	PROPN	NNP	6	O
Squibb	Squibb	PROPN	NNP	2	O
Company	Company	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Princeton	Princeton	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
NJ	NJ	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
effective	effective	ADJ	JJ	5	O
salvage	salvage	NOUN	NN	5	O
therapies	therapy	NOUN	NNS	5	O
for	for	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
have	have	VERB	VBP	5	O
additive	additive	ADJ	JJ	9	O
cytotoxicity	cytotoxicity	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
MCF	MCF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
7	7	NUM	CD	9	O
cell	cell	NOUN	NN	3	O
lines	line	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
175	175	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
over	over	ADP	IN	5	O
3	3	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
followed	follow	VERB	VBD	9	O
by	by	ADP	IN	9	O
folinic	folinic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
over	over	ADP	IN	5	O
1	1	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
before	before	ADP	IN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
350	350	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
every	every	DET	DT	5	O
28	28	NUM	CD	7	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
TFL	TFL	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Analysis	analysis	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
on	on	ADP	IN	5	O
37	37	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
minimum	minimum	NOUN	NN	5	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
192	192	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
of	of	ADP	IN	5	O
TFL	tfl	NOUN	NN	5	O
:	:	PUNCT	:	9	O
nine	nine	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
requiring	require	VERB	VBG	5	O
hospitalization	hospitalization	NOUN	NN	5	O
;	;	PUNCT	:	9	O
seven	seven	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
cycles	cycle	NOUN	NNS	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
required	require	VERB	VBD	9	O
granulocyte	granulocyte	NOUN	NN	3	B-Chemical
colony	colony	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
stimulating	stimulate	VERB	VBG	9	I-Chemical
factor	factor	NOUN	NN	9	I-Chemical
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
no	no	DET	DT	9	O
patient	patient	NOUN	NN	5	O
required	require	VERB	VBN	9	O
platelet	platelet	NOUN	NN	9	O
transfusions	transfusion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Grade	Grade	PROPN	NNP	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
4	4	NUM	CD	9	O
nonhematologic	nonhematologic	ADJ	JJ	5	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
uncommon	uncommon	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
the	the	DET	DT	5	O
34	34	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
evaluable	evaluable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
three	three	NUM	CD	9	O
complete	complete	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
partial	partial	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
53	53	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
62	62	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
19	19	NUM	CD	7	O
evaluable	evaluable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
58	58	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
responded	respond	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
nine	nine	NUM	CD	9	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Plasma	plasma	NOUN	NN	0	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
in	in	ADP	IN	5	O
19	19	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

TFL	TFL	PROPN	NNP	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
active	active	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
regimen	regiman	NOUN	NNS	5	O
in	in	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Efficacy	efficacy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
proarrhythmia	proarrhythmia	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
for	for	ADP	IN	5	O
sustained	sustained	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachyarrhythmias	tachyarrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
prospectively	prospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
efficacy	efficacy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
presumable	presumable	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
for	for	ADP	IN	5	O
sustained	sustained	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachyarrhythmias	tachyarrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Eighty	eighty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
54	54	NUM	CD	7	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
with	with	ADP	IN	5	O
dilated	dilate	VERB	VBN	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
inducible	inducible	ADJ	JJ	3	O
sustained	sustain	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
received	receive	VERB	VBD	9	O
oral	oral	ADJ	JJ	9	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachyarrhythmia	tachyarrhythmia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
loading	loading	NOUN	NN	9	O
with	with	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
,	,	PUNCT	,	9	O
continuous	continuous	ADJ	JJ	5	O
electrocardiographic	electrocardiographic	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
ECG	ECG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
monitoring	monitoring	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Those	those	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
prevented	prevent	VERB	VBN	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
discharged	discharge	VERB	VBN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
followed	follow	VERB	VBD	9	O
up	up	PART	RP	5	O
on	on	ADP	IN	5	O
an	an	DET	DT	5	O
outpatient	outpatient	NOUN	NN	5	O
basis	basis	NOUN	NN	5	O
for	for	ADP	IN	5	O
21	21	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
18	18	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachyarrhythmia	tachyarrhythmia	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
in	in	ADP	IN	5	O
35	35	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachyarrhythmia	tachyarrhythmia	NOUN	NN	5	I-Disease
remained	remain	VERB	VBD	9	O
inducible	inducible	ADJ	JJ	3	O
in	in	ADP	IN	5	O
40	40	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
49	49	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
tolerate	tolerate	VERB	VB	5	O
even	even	ADV	RB	5	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
from	from	ADP	IN	9	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
.	.	PUNCT	.	9	O

Neither	neither	CCONJ	CC	9	O
ECG	ECG	PROPN	NNP	5	O
[	[	PUNCT	-LRB-	9	O
sinus	sinus	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
cycle	cycle	NOUN	NN	9	O
length	length	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SCL	SCL	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
QT	QT	PROPN	NNP	5	O
or	or	CCONJ	CC	5	O
QTc	qtc	ADJ	JJ	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
U	u	NOUN	NN	9	O
wave	wave	NOUN	NN	5	O
]	]	PUNCT	-RRB-	9	O
nor	nor	CCONJ	CC	9	O
clinical	clinical	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
identified	identify	VERB	VBD	9	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
46	46	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
328	328	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
53	53	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0017	0017	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
U	u	NOUN	NN	9	O
wave	wave	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
049	049	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
female	female	ADJ	JJ	9	O
gender	gender	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
015	015	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
significant	significant	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
corrected	correct	VERB	VBN	5	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
SCL	SCL	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
QTc	qtc	ADJ	JJ	5	O
interval	interval	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
,	,	PUNCT	,	9	O
seven	seven	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
nonfatal	nonfatal	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
recurrence	recurrence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
suddenly	suddenly	ADV	RB	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
female	female	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
stable	stable	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
had	have	VERB	VBD	9	O
recurrent	recurrent	ADJ	JJ	5	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
successful	successful	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
.	.	PUNCT	.	9	O

Torsades	torsade	NOUN	NNS	2	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
occurred	occur	VERB	VBD	9	O
early	early	ADV	RB	9	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
even	even	ADV	RB	5	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
.	.	PUNCT	.	9	O

Pronounced	pronounced	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
surface	surface	NOUN	NN	9	O
ECG	ECG	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
cycle	cycle	NOUN	NN	9	O
length	length	NOUN	NN	9	O
,	,	PUNCT	,	9	O
QT	QT	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
QTc	QTc	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
relation	relation	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
might	may	VERB	MD	9	O
identify	identify	VERB	VB	9	O
a	a	DET	DT	5	O
subgroup	subgroup	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
ECG	ECG	PROPN	NNP	5	O
parameters	parameter	NOUN	NNS	5	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
identify	identify	VERB	VB	9	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Recurrence	recurrence	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachyarrhythmias	tachyarrhythmia	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
high	high	ADJ	JJ	9	O
despite	despite	ADP	IN	9	O
complete	complete	ADJ	JJ	9	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
programmed	program	VERB	VBN	5	O
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
programmed	program	VERB	VBN	5	O
electrical	electrical	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
sotalol	sotalol	NOUN	NN	5	I-Chemical
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
limited	limited	ADJ	JJ	5	O
prognostic	prognostic	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
neurons	neuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
tuberoinfundibular	tuberoinfundibular	ADJ	JJ	3	O
dopaminergic	dopaminergic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
TIDA	TIDA	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
system	system	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
inhibit	inhibit	VERB	VB	3	O
prolactin	prolactin	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
PRL	PRL	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
secretion	secretion	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
young	young	ADJ	JJ	5	O
animals	animal	NOUN	NNS	9	O
this	this	DET	DT	5	O
system	system	NOUN	NN	5	O
responds	respond	VERB	VBZ	9	O
to	to	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
elevations	elevation	NOUN	NNS	9	O
in	in	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
PRL	PRL	PROPN	NNP	3	O
by	by	ADP	IN	9	O
increasing	increase	VERB	VBG	9	O
its	-PRON-	DET	PRP$	9	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
responsiveness	responsiveness	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
lost	lose	VERB	VBN	9	O
in	in	ADP	IN	5	O
aging	age	VERB	VBG	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
chronically	chronically	ADV	RB	9	O
high	high	ADJ	JJ	9	O
serum	serum	ADJ	JJ	9	O
PRL	PRL	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
for	for	ADP	IN	5	O
extended	extended	ADJ	JJ	5	O
periods	period	NOUN	NNS	5	O
of	of	ADP	IN	5	O
time	time	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
examine	examine	VERB	VB	9	O
its	-PRON-	DET	PRP$	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
systems	system	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hyperprolactinemia	Hyperprolactinemia	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Palkovits	Palkovits	PROPN	NNPS	6	O
'	'	PART	POS	9	O
microdissection	microdissection	NOUN	NN	5	O
technique	technique	NOUN	NN	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
performance	performance	NOUN	NN	5	O
liquid	liquid	NOUN	NN	0	O
chromatography	chromatography	NOUN	NN	0	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
neurotransmitter	neurotransmitter	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
several	several	ADJ	JJ	9	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
DA	DA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
eminence	eminence	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ME	ME	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBD	9	O
by	by	ADP	IN	9	O
84	84	NUM	CD	7	O
%	%	NOUN	NN	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nine	nine	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ME	ME	PROPN	NNP	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
DA	DA	PROPN	NNP	9	B-Chemical
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
lost	lose	VERB	VBN	9	O
if	if	ADP	IN	5	O
a	a	DET	DT	5	O
9	9	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
long	long	ADJ	JJ	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
month	month	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
long	long	ADV	RB	5	O
extremely	extremely	ADV	RB	5	O
high	high	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
PRL	PRL	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
implantation	implantation	NOUN	NN	5	O
of	of	ADP	IN	5	O
MMQ	MMQ	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
capsule	capsule	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
NE	NE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	SYM	SYM	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
metabolites	metabolite	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
arcuate	arcuate	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
AN	AN	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
medial	medial	ADJ	JJ	5	O
preoptic	preoptic	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MPA	MPA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
caudate	caudate	NOUN	NN	5	O
putamen	putaman	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
CP	CP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
substantia	substantia	NOUN	NN	9	O
nigra	nigra	NOUN	NN	4	O
(	(	PUNCT	-LRB-	9	O
SN	SN	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
zona	zona	NOUN	NN	9	O
incerta	incerta	NOUN	NNS	4	O
(	(	PUNCT	-LRB-	9	O
ZI	ZI	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxyindoleacetic	hydroxyindoleacetic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HIAA	HIAA	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
AN	AN	PROPN	NNP	9	O
after	after	ADP	IN	9	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
AN	AN	PROPN	NNP	9	O
after	after	ADP	IN	9	O
9	9	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
specifically	specifically	ADV	RB	9	O
affects	affect	VERB	VBZ	9	O
TIDA	tida	NOUN	NN	3	O
neurons	neuron	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
these	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
vary	vary	VERB	VBP	5	O
,	,	PUNCT	,	9	O
depending	depend	VERB	VBG	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
hypothalamic	hypothalamic	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
function	function	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
PRL	PRL	PROPN	NNP	3	O
secretion	secretion	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
disseminated	disseminate	VERB	VBD	5	O
necrotizing	necrotizing	NOUN	NN	5	O
leukoencephalopathy	leukoencephalopathy	ADJ	JJ	5	B-Disease
with	with	ADP	IN	5	O
characteristic	characteristic	ADJ	JJ	9	O
contrast	contrast	NOUN	NN	9	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
unique	unique	ADJ	JJ	9	O
contrast	contrast	NOUN	NN	9	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
on	on	ADP	IN	5	O
T1	T1	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
weighted	weight	VERB	VBN	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
images	image	NOUN	NNS	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
disseminated	disseminate	VERB	VBN	5	O
necrotizing	necrotizing	NOUN	NN	5	O
leukoencephalopathy	leukoencephalopathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
developed	develop	VERB	VBD	5	O
from	from	ADP	IN	9	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
enhancement	enhancement	NOUN	NN	9	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
pronounced	pronounced	ADJ	JJ	9	O
near	near	ADP	IN	9	O
the	the	DET	DT	5	O
base	base	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
than	than	ADP	IN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
vertex	vertex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Necropsy	Necropsy	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
myelination	myelination	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
causing	cause	VERB	VBG	9	O
such	such	DET	PDT	5	O
a	a	DET	DT	5	O
leukoencephalopathy	leukoencephalopathy	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Thrombotic	thrombotic	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
promyelocytic	promyelocytic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
during	during	ADP	IN	5	O
all	all	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
trans	trans	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
retinoic	retinoic	ADJ	JJ	3	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
occlusion	occlusion	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
vessels	vessel	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
promyelocytic	promyelocytic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
APL	APL	PROPN	NNP	3	B-Disease
)	)	PUNCT	-RRB-	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
all	all	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
trans	trans	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
retinoic	retinoic	ADJ	JJ	3	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
recently	recently	ADV	RB	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
APL	APL	PROPN	NNP	3	B-Disease
patient	patient	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
alone	alone	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
further	further	ADV	RB	9	O
supports	support	VERB	VBZ	9	O
the	the	DET	DT	5	O
concern	concern	NOUN	NN	5	O
about	about	ADP	IN	5	O
thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
APL	APL	PROPN	NNP	3	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
43	43	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
,	,	PUNCT	,	9	O
presented	present	VERB	VBD	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
APL	APL	PROPN	NNP	3	B-Disease
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
protocol	protocol	NOUN	NN	9	O
with	with	ADP	IN	5	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
reversible	reversible	ADJ	JJ	9	O
after	after	ADP	IN	9	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
of	of	ADP	IN	5	O
APL	APL	PROPN	NNP	3	B-Disease
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
therapy	therapy	NOUN	NN	5	O
discontinued	discontinue	VERB	VBD	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
valid	valid	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
choice	choice	NOUN	NN	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
APL	APL	PROPN	NNP	3	B-Disease
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
procoagulant	procoagulant	ADJ	JJ	9	O
tendency	tendency	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
completely	completely	ADV	RB	9	O
corrected	correct	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Thrombotic	thrombotic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
avoided	avoid	VERB	VBN	5	O
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
heparin	heparin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Pupillary	pupillary	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
stimulant	stimulant	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mania	mania	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
subject	subject	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
study	study	NOUN	NN	9	O
evaluating	evaluate	VERB	VBG	5	O
the	the	DET	DT	5	O
anticraving	anticrave	VERB	VBG	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
stimulant	stimulant	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
diethylpropion	diethylpropion	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DEP	DEP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
became	become	VERB	VBD	9	O
manic	manic	ADJ	JJ	5	B-Disease
during	during	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
second	second	ADJ	JJ	9	O
week	week	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pupillometric	pupillometric	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
while	while	ADP	IN	9	O
on	on	ADP	IN	5	O
DEP	DEP	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
power	power	NOUN	NN	5	O
of	of	ADP	IN	5	O
pupillary	pupillary	ADJ	JJ	5	B-Disease
oscillation	oscillation	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
dramatically	dramatically	ADV	RB	9	O
different	different	ADJ	JJ	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
eight	eight	NUM	CD	9	O
other	other	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
become	become	VERB	VB	5	O
manic	manic	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
large	large	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
total	total	ADJ	JJ	9	O
power	power	NOUN	NN	5	O
of	of	ADP	IN	5	O
pupillary	pupillary	ADJ	JJ	5	B-Disease
oscillation	oscillation	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
became	become	VERB	VBD	9	O
fully	fully	ADV	RB	9	O
manic	manic	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
power	power	NOUN	NN	5	O
of	of	ADP	IN	5	O
pupillary	pupillary	ADJ	JJ	5	B-Disease
oscillation	oscillation	NOUN	NN	5	I-Disease
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
utility	utility	NOUN	NN	5	O
in	in	ADP	IN	5	O
identifying	identify	VERB	VBG	5	O
persons	person	NOUN	NNS	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
manic	manic	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
psychomotor	psychomotor	NOUN	NN	5	O
stimulants	stimulant	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
sympathomimetic	sympathomimetic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fetal	fetal	ADJ	JJ	9	O
risks	risk	NOUN	NNS	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
mothers	mother	NOUN	NNS	5	O
with	with	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
valve	valve	NOUN	NN	5	O
prosthesis	prosthesis	NOUN	NN	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
a	a	DET	DT	5	O
caesarean	caesarean	ADJ	JJ	5	O
section	section	NOUN	NN	5	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
one	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
after	after	ADP	IN	9	O
replacement	replacement	NOUN	NN	9	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
with	with	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
baby	baby	NOUN	NN	5	O
died	die	VERB	VBD	9	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
mother	mother	NOUN	NN	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
male	male	ADJ	JJ	9	O
infant	infant	NOUN	NN	5	O
by	by	ADP	IN	9	O
caesarean	caesarean	ADJ	JJ	5	O
section	section	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
baby	baby	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
embryopathy	embryopathy	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
nasal	nasal	NOUN	NN	5	B-Disease
hypoplasia	hypoplasia	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
stippled	stippled	ADJ	JJ	9	B-Disease
epiphyses	epiphysis	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
chondrodysplasia	chondrodysplasia	NOUN	NN	1	B-Disease
punctata	punctata	NOUN	NN	4	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Nasal	Nasal	PROPN	NNP	5	B-Disease
hypoplasia	hypoplasia	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
stippled	stippled	ADJ	JJ	9	B-Disease
epiphyses	epiphysis	NOUN	NNS	5	I-Disease
has	have	VERB	VBZ	9	O
now	now	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
infants	infant	NOUN	NNS	5	O
born	bear	VERB	VBN	5	O
to	to	ADP	IN	5	O
mothers	mother	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
trimester	trimester	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
causal	causal	ADJ	JJ	5	O
association	association	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
probable	probable	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
view	view	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
risks	risk	NOUN	NNS	5	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
mother	mother	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
fetus	fetus	NOUN	NN	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
prosthetic	prosthetic	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
valves	valve	VERB	VBZ	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
that	that	ADP	IN	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
abortion	abortion	NOUN	NN	5	O
be	be	VERB	VB	5	O
advised	advise	VERB	VBN	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
alternative	alternative	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
mucosal	mucosal	NOUN	NN	9	O
potential	potential	NOUN	NN	9	O
:	:	PUNCT	:	9	O
separating	separate	VERB	VBG	9	O
central	central	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
NSAIDs	nsaid	NOUN	NNS	5	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
wanted	want	VERB	VBD	5	O
to	to	PART	TO	5	O
test	test	VERB	VB	5	O
whether	whether	ADP	IN	9	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
a	a	DET	DT	5	O
central	central	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
signal	signal	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
chemo	chemo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
somatosensory	somatosensory	ADJ	JJ	5	O
evoked	evoked	ADJ	JJ	5	O
potential	potential	NOUN	NN	9	O
,	,	PUNCT	,	9	O
CSSEP	CSSEP	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
concomitantly	concomitantly	ADV	RB	9	O
recorded	record	VERB	VBN	5	O
peripheral	peripheral	ADJ	JJ	9	O
signal	signal	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
negative	negative	ADJ	JJ	9	O
mucosal	mucosal	NOUN	NN	9	O
potential	potential	NOUN	NN	9	O
,	,	PUNCT	,	9	O
NMP	NMP	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
allows	allow	VERB	VBZ	5	O
for	for	ADP	IN	5	O
separation	separation	NOUN	NN	5	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
NSAIDs	nsaid	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
this	this	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
,	,	PUNCT	,	9	O
experimental	experimental	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
created	create	VERB	VBN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
NSAIDs	nsaid	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
been	be	VERB	VBN	9	O
observed	observe	VERB	VBN	9	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
phasic	phasic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tonic	tonic	NOUN	NN	5	O
pain	pain	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
either	either	DET	DT	9	O
central	central	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
According	accord	VERB	VBG	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomised	randomise	VERB	VBN	5	O
,	,	PUNCT	,	9	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
threefold	threefold	ADJ	JJ	9	O
cross	cross	NOUN	NN	5	O
-	-	ADJ	JJ	7	O
over	over	ADJ	JJ	5	O
design	design	NOUN	NN	5	O
,	,	PUNCT	,	9	O
18	18	NUM	CD	7	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
males	male	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
females	female	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
26	26	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
either	either	DET	DT	9	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
ibuprofen	ibuprofen	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
ibuprofen	ibuprofen	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Phasic	phasic	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
by	by	ADP	IN	9	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
short	short	ADJ	JJ	5	O
pulses	pulse	NOUN	NNS	5	O
of	of	ADP	IN	5	O
CO2	CO2	PROPN	NNP	0	B-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
nasal	nasal	NOUN	NN	5	O
mucosa	mucosa	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
stimulus	stimulus	NOUN	NN	5	O
duration	duration	NOUN	NN	5	O
500	500	NUM	CD	0	O
ms	ms	NOUN	NN	5	O
,	,	PUNCT	,	9	O
interval	interval	NOUN	NN	5	O
approximately	approximately	ADV	RB	9	O
60	60	NUM	CD	9	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
tonic	tonic	NOUN	NN	5	O
pain	pain	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
nasal	nasal	NOUN	NN	5	O
cavity	cavity	NOUN	NN	5	O
by	by	ADP	IN	9	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
dry	dry	ADJ	JJ	0	O
air	air	NOUN	NN	5	O
of	of	ADP	IN	5	O
controlled	control	VERB	VBN	5	O
temperature	temperature	NOUN	NN	0	O
,	,	PUNCT	,	9	O
humidity	humidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
flow	flow	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
degrees	degree	NOUN	NNS	5	O
C	c	NOUN	NN	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
relative	relative	ADJ	JJ	9	O
humidity	humidity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
145	145	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O
s	s	PUNCT	LS	9	O
-	-	PUNCT	:	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
CSSEPs	cssep	NOUN	NNS	_	O
as	as	ADP	IN	5	O
central	central	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
NMPs	nmp	NOUN	NNS	5	O
as	as	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	O
correlates	correlate	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
CO2	CO2	PROPN	NNP	0	B-Chemical
stimuli	stimulus	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
rated	rate	VERB	VBD	5	O
the	the	DET	DT	5	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
phasic	phasic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tonic	tonic	NOUN	NN	5	O
pain	pain	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	O
analogue	analogue	NOUN	NN	0	O
scales	scale	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
As	as	ADP	IN	9	O
described	describe	VERB	VBN	9	O
earlier	earlier	ADV	RBR	9	O
,	,	PUNCT	,	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ibuprofen	ibuprofen	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
tonic	tonic	NOUN	NN	5	O
pain	pain	NOUN	NN	5	B-Disease
but	but	CCONJ	CC	9	O
-	-	PUNCT	HYPH	7	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	,	7	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
correlates	correlate	NOUN	NNS	9	O
of	of	ADP	IN	5	O
phasic	phasic	NOUN	NN	5	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
ibuprofen	ibuprofen	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
stimuli	stimulus	NOUN	NNS	5	O
under	under	ADP	IN	9	O
these	these	DET	DT	5	O
special	special	ADJ	JJ	5	O
experimental	experimental	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
behaviour	behaviour	NOUN	NN	5	O
of	of	ADP	IN	5	O
CSSEP	CSSEP	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
NMP	NMP	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
process	process	NOUN	NN	5	O
underlying	underlie	VERB	VBG	5	O
this	this	DET	DT	5	O
phenomenon	phenomenon	NOUN	NN	5	O
was	be	VERB	VBD	9	O
localised	localise	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
periphery	periphery	NOUN	NN	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
simultaneous	simultaneous	ADJ	JJ	5	O
recording	recording	NOUN	NN	5	O
of	of	ADP	IN	5	O
interrelated	interrelated	ADJ	JJ	5	O
peripheral	peripheral	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
central	central	ADJ	JJ	5	O
electrophysiologic	electrophysiologic	ADJ	JJ	5	O
correlates	correlate	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nociception	nociception	NOUN	NN	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
possible	possible	ADJ	JJ	5	O
to	to	PART	TO	5	O
separate	separate	VERB	VB	9	O
central	central	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
NSAID	NSAID	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
advantage	advantage	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
obtaining	obtain	VERB	VBG	5	O
peripheral	peripheral	ADJ	JJ	9	O
pain	pain	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
activity	activity	NOUN	NN	9	O
directly	directly	ADV	RB	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
invasive	invasive	ADJ	JJ	5	O
technique	technique	NOUN	NN	5	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Glucarates	glucarate	NOUN	NNS	_	I-Chemical
on	on	ADP	IN	5	O
basic	basic	ADJ	JJ	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Dehydrated	dehydrate	VERB	VBN	0	B-Disease
rats	rat	NOUN	NNS	9	O
regularly	regularly	ADV	RB	5	O
develop	develop	VERB	VBP	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
single	single	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
aminoglycoside	aminoglycoside	ADJ	JJ	9	B-Chemical
antibiotics	antibiotic	NOUN	NNS	5	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
dextran	dextran	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
of	of	ADP	IN	5	O
antibiotics	antibiotic	NOUN	NNS	5	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
di	di	NOUN	NN	2	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
O	o	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acetyl	acetyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glucaro	glucaro	VERB	VBN	_	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	SYM	SYM	7	I-Chemical
6	6	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dilactone	dilactone	NOUN	NN	0	I-Chemical
protected	protect	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
against	against	ADP	IN	9	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
kanamycin	kanamycin	NOUN	NN	1	B-Chemical
-	-	PUNCT	HYPH	7	O
dextran	dextran	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
prevalent	prevalent	ADJ	JJ	9	O
among	among	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glucarates	glucarate	NOUN	NNS	_	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
to	to	ADP	IN	5	O
other	other	ADJ	JJ	5	O
saccharic	saccharic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
hexauronic	hexauronic	ADJ	JJ	_	B-Chemical
acids	acid	NOUN	NNS	0	I-Chemical
and	and	CCONJ	CC	5	O
hexaaldonic	hexaaldonic	ADJ	JJ	_	B-Chemical
acids	acid	NOUN	NNS	0	I-Chemical
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
lesser	less	ADJ	JJR	9	O
degree	degree	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
hexaaldose	hexaaldose	NOUN	NN	_	O
,	,	PUNCT	,	9	O
sugar	sugar	NOUN	NN	0	B-Chemical
alcohols	alcohol	NOUN	NNS	0	I-Chemical
,	,	PUNCT	,	9	O
substances	substance	NOUN	NNS	0	O
inthe	inthe	VERB	VBP	9	O
TCA	TCA	PROPN	NNP	0	B-Chemical
cycle	cycle	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
acidic	acidic	ADJ	JJ	0	O
compounds	compound	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
Glucarates	glucarate	NOUN	NNS	_	I-Chemical
were	be	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
against	against	ADP	IN	9	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
peptide	peptide	NOUN	NN	9	O
antibiotics	antibiotic	NOUN	NNS	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
various	various	ADJ	JJ	9	O
aminoglycoside	aminoglycoside	ADJ	JJ	9	B-Chemical
antibitocis	antibitocis	NOUN	NN	_	O
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Glucarates	Glucarates	PROPN	NNPS	_	I-Chemical
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
a	a	DET	DT	5	O
D	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glucarate	glucarate	NOUN	NN	0	I-Chemical
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
fixed	fix	VERB	VBN	9	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
approximately	approximately	ADV	RB	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
protection	protection	NOUN	NN	9	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
against	against	ADP	IN	9	O
renal	renal	ADJ	JJ	9	B-Disease
damages	damage	NOUN	NNS	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
different	different	ADJ	JJ	9	O
basic	basic	ADJ	JJ	5	O
antibiotics	antibiotic	NOUN	NNS	5	O
despite	despite	ADP	IN	9	O
large	large	ADJ	JJ	5	O
disparities	disparity	NOUN	NNS	5	O
in	in	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
different	different	ADJ	JJ	9	O
antibiotics	antibiotic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
Glucarates	Glucarates	PROPN	NNP	_	I-Chemical
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
to	to	PART	TO	5	O
cure	cure	VERB	VB	5	O
it	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
excreted	excrete	VERB	VBD	0	O
acidic	acidic	ADJ	JJ	0	O
urine	urine	NOUN	NN	9	O
when	when	ADV	WRB	5	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
spared	spare	VERB	VBN	5	O
from	from	ADP	IN	9	O
renal	renal	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
by	by	ADP	IN	9	O
monosaccharides	monosaccharide	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glucarates	glucarate	NOUN	NNS	_	I-Chemical
against	against	ADP	IN	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
basic	basic	ADJ	JJ	5	O
antibiotics	antibiotic	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
severe	severe	ADJ	JJ	5	O
depression	depression	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
peri	peri	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
operative	operative	NOUN	NN	5	O
ondansetron	ondansetron	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
41	41	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
nausea	nausea	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
vomiting	vomiting	NOUN	NN	5	I-Disease
presented	present	VERB	VBN	5	O
for	for	ADP	IN	5	O
abdominal	abdominal	ADJ	JJ	5	O
hysterectomy	hysterectomy	NOUN	NN	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
anaesthetic	anaesthetic	NOUN	NN	5	O
where	where	ADV	WRB	5	O
ondansetron	ondansetron	NOUN	NN	0	B-Chemical
prophylaxis	prophylaxis	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	O
major	major	ADJ	JJ	9	B-Disease
depression	depression	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
almost	almost	ADV	RB	9	O
immediately	immediately	ADV	RB	9	O
thereafter	thereafter	ADV	RB	9	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
related	related	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Nine	nine	NUM	CD	9	O
years	year	NOUN	NNS	5	O
before	before	ADP	IN	9	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
experienced	experience	VERB	VBN	5	O
a	a	DET	DT	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
limited	limit	VERB	VBN	5	O
puerperal	puerperal	ADJ	JJ	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
episode	episode	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Anaesthesia	Anaesthesia	PROPN	NNP	2	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
avoidance	avoidance	NOUN	NN	5	O
of	of	ADP	IN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
antagonists	antagonist	NOUN	NNS	3	O
provided	provide	VERB	VBD	9	O
a	a	DET	DT	5	O
nausea	nausea	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
postoperative	postoperative	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
without	without	ADP	IN	9	O
exacerbation	exacerbation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
depression	depression	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Hypertensive	hypertensive	ADJ	JJ	7	B-Disease
response	response	NOUN	NN	9	O
during	during	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
stress	stress	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
129	129	NUM	CD	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
stress	stress	NOUN	NN	9	O
echocardiographic	echocardiographic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BP	BP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
220	220	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
110	110	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
30	30	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
response	response	NOUN	NN	9	O
more	more	ADV	RBR	5	O
often	often	ADV	RB	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
resting	rest	VERB	VBG	5	O
systolic	systolic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
before	before	ADP	IN	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Continuously	continuously	ADV	RB	5	O
nebulized	nebulize	VERB	VBN	0	O
albuterol	albuterol	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
exacerbations	exacerbation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
asthma	asthma	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
retrospective	retrospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
analysis	analysis	NOUN	NN	9	O
comparing	compare	VERB	VBG	9	O
patients	patient	NOUN	NNS	5	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
exacerbations	exacerbation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
asthma	asthma	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
continuously	continuously	ADV	RB	5	O
nebulized	nebulize	VERB	VBN	0	O
albuterol	albuterol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
CNA	CNA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
intermittent	intermittent	ADJ	JJ	5	O
albuterol	albuterol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
INA	INA	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
treatments	treatment	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
matched	match	VERB	VBD	9	O
pairs	pair	NOUN	NNS	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
asthma	asthma	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
compared	compare	VERB	VBN	9	O
.	.	PUNCT	.	9	O

CNA	CNA	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
mean	mean	NOUN	NN	5	O
of	of	ADP	IN	5	O
11	11	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysrhythmias	dysrhythmia	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Symptomatic	symptomatic	ADJ	JJ	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
occur	occur	VERB	VB	5	O
.	.	PUNCT	.	9	O

CNA	CNA	PROPN	NNP	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
heart	heart	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
reflect	reflect	VERB	VB	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
illness	illness	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
intubation	intubation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
CNA	CNA	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
INA	INA	PROPN	NNP	0	O
demonstrated	demonstrate	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
profiles	profile	NOUN	NNS	9	O
with	with	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	ADP	IN	5	O
safety	safety	NOUN	NN	5	O
,	,	PUNCT	,	9	O
morbidity	morbidity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Paraplegia	paraplegia	NOUN	NN	7	B-Disease
following	follow	VERB	VBG	9	O
intrathecal	intrathecal	ADJ	JJ	3	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
:	:	PUNCT	:	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
paraplegia	paraplegia	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
instillation	instillation	NOUN	NN	0	O
of	of	ADP	IN	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
discribed	discribe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ten	ten	NOUN	NN	9	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
complication	complication	NOUN	NN	5	O
are	be	VERB	VBP	5	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
factors	factor	NOUN	NNS	9	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
predispose	predispose	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
:	:	PUNCT	:	9	O
abnormal	abnormal	ADJ	JJ	9	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
dynamics	dynamic	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	B-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
epidural	epidural	ADJ	JJ	5	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
leakage	leakage	NOUN	NN	9	O
;	;	PUNCT	:	9	O
elevated	elevated	ADJ	JJ	9	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	ADJ	JJ	5	O
methothexate	methothexate	ADJ	JJ	_	B-Chemical
concentration	concentration	NOUN	NN	0	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	ADJ	JJ	5	O
dynamics	dynamic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
inappropriately	inappropriately	ADV	RB	5	O
high	high	ADJ	JJ	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
doses	dose	NOUN	NNS	0	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
calculations	calculation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
children	child	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
adults	adult	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
preservatives	preservative	NOUN	NNS	0	O
in	in	ADP	IN	5	O
commercially	commercially	ADV	RB	0	O
available	available	ADJ	JJ	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
preparations	preparation	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
diluents	diluent	NOUN	NNS	0	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
diluents	diluent	NOUN	NNS	0	O
of	of	ADP	IN	5	O
unphysiologic	unphysiologic	ADJ	JJ	5	O
pH	pH	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
ionic	ionic	ADJ	JJ	0	O
content	content	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
osmolarity	osmolarity	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
contaminants	contaminant	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
local	local	ADJ	JJ	5	O
folate	folate	ADJ	JJ	9	B-Disease
deficiency	deficiency	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cranial	cranial	ADJ	JJ	5	O
irradiation	irradiation	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
employing	employ	VERB	VBG	9	O
lower	low	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	B-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
children	child	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
adults	adult	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
epidural	epidural	ADJ	JJ	5	O
leakage	leakage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
preservative	preservative	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
Elliott	Elliott	PROPN	NNP	6	O
'	'	PART	POS	9	O
s	s	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
Solution	Solution	PROPN	NNP	0	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
not	not	ADV	RB	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Periodic	periodic	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
of	of	ADP	IN	5	O
cerebruspinal	cerebruspinal	ADJ	JJ	_	O
fluid	fluid	ADJ	JJ	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
levels	level	NOUN	NNS	3	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
predictive	predictive	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Hyperosmolar	hyperosmolar	ADJ	JJ	0	B-Disease
nonketotic	nonketotic	ADJ	JJ	5	I-Disease
coma	coma	NOUN	NN	5	I-Disease
precipitated	precipitate	VERB	VBN	0	O
by	by	ADP	IN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
45	45	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
manic	manic	ADJ	JJ	5	B-Disease
depression	depression	NOUN	NN	5	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
with	with	ADP	IN	5	O
hyperosmolar	hyperosmolar	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	I-Disease
nonketotic	nonketotic	ADJ	JJ	5	I-Disease
coma	coma	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
gave	give	VERB	VBD	9	O
a	a	DET	DT	5	O
five	five	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
polyuria	polyuria	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
polydipsia	polydipsia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
which	which	DET	WDT	5	O
time	time	NOUN	NN	5	O
urinalysis	urinalysis	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
negative	negative	ADJ	JJ	9	O
for	for	ADP	IN	5	O
glucose	glucose	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
recovery	recovery	NOUN	NN	9	O
from	from	ADP	IN	9	O
hyperglycaemia	hyperglycaemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
remained	remain	VERB	VBD	9	O
polyuric	polyuric	ADJ	JJ	5	B-Disease
despite	despite	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
;	;	PUNCT	:	9	O
water	water	NOUN	NN	0	O
deprivation	deprivation	NOUN	NN	9	O
testing	testing	NOUN	NN	5	O
indicated	indicate	VERB	VBD	9	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
hypothesize	hypothesize	VERB	VBP	9	O
that	that	ADP	IN	5	O
when	when	ADV	WRB	5	O
this	this	DET	DT	5	O
man	man	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
type	type	NOUN	NN	9	B-Disease
2	2	NUM	CD	9	I-Disease
diabetes	diabete	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
chronic	chronic	VERB	VB	5	O
polyuria	polyuria	NOUN	NNS	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
precipitate	precipitate	VERB	VB	0	O
hyperosmolar	hyperosmolar	ADJ	JJ	5	O
dehydration	dehydration	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
intracoronary	intracoronary	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
systolic	systolic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
large	large	ADJ	JJ	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
causes	cause	VERB	VBZ	9	O
a	a	DET	DT	5	O
profound	profound	ADJ	JJ	9	O
deterioration	deterioration	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
left	left	ADJ	JJ	5	I-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
LV	LV	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
systolic	systolic	ADJ	JJ	5	I-Disease
function	function	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
LV	LV	PROPN	NNP	9	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
intracoronary	intracoronary	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
concentration	concentration	NOUN	NN	0	O
on	on	ADP	IN	5	O
LV	LV	PROPN	NNP	9	O
systolic	systolic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
aged	age	VERB	VBD	9	O
39	39	NUM	CD	7	O
to	to	PART	TO	5	O
72	72	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
referred	refer	VERB	VBD	5	O
for	for	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
catheterization	catheterization	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
measured	measure	VERB	VBD	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
systemic	systemic	ADJ	JJ	9	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
LV	LV	PROPN	NNP	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
first	first	ADJ	JJ	9	O
derivative	derivative	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
dP	dP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dt	dt	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
LV	LV	PROPN	NNP	9	O
volumes	volume	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
final	final	ADJ	JJ	9	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
3	3	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
intracoronary	intracoronary	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
variable	variable	NOUN	NN	5	O
changed	change	VERB	VBN	9	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
concentration	concentration	NOUN	NN	0	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
coronary	coronary	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
was	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
mg	mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
magnitude	magnitude	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
concentration	concentration	NOUN	NN	0	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
abusers	abuser	NOUN	NNS	5	O
dying	die	VERB	VBG	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
intoxication	intoxication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
induced	induce	VERB	VBD	3	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
LV	LV	PROPN	NNP	9	O
dP	dP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dt	dt	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
positive	positive	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
negative	negative	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
LV	LV	PROPN	NNP	9	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
caused	cause	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
systolic	systolic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
mean	mean	VERB	VB	5	O
arterial	arterial	ADJ	JJ	5	O
pressures	pressure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
LV	LV	PROPN	NNP	9	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
LV	LV	PROPN	NNP	9	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
systolic	systolic	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
LV	LV	PROPN	NNP	9	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
humans	human	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
intracoronary	intracoronary	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
sufficient	sufficient	ADJ	JJ	9	O
in	in	ADP	IN	5	O
amount	amount	NOUN	NN	9	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
concentration	concentration	NOUN	NN	0	O
in	in	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
blood	blood	NOUN	NN	9	O
causes	cause	VERB	VBZ	9	O
a	a	DET	DT	5	O
deterioration	deterioration	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
LV	LV	PROPN	NNP	9	I-Disease
systolic	systolic	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
diastolic	diastolic	ADJ	JJ	5	I-Disease
performance	performance	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Ascending	ascend	VERB	VBG	5	O
dose	dose	NOUN	NN	9	O
tolerance	tolerance	NOUN	NN	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
intramuscular	intramuscular	ADJ	JJ	9	O
carbetocin	carbetocin	NOUN	NN	5	B-Chemical
administered	administer	VERB	VBN	9	O
after	after	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
vaginal	vaginal	ADJ	JJ	9	O
birth	birth	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
tolerated	tolerate	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
MTD	MTD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
carbetocin	carbetocin	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
synthetic	synthetic	ADJ	JJ	0	O
analogue	analogue	NOUN	NN	0	O
of	of	ADP	IN	5	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
vaginal	vaginal	ADJ	JJ	9	O
delivery	delivery	NOUN	NN	5	O
at	at	ADP	IN	9	O
term	term	NOUN	NN	5	O
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Carbetocin	Carbetocin	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
intramuscular	intramuscular	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
birth	birth	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
infant	infant	NOUN	NN	5	O
in	in	ADP	IN	5	O
45	45	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
singleton	singleton	NOUN	NN	5	O
pregnancies	pregnancy	NOUN	NNS	5	O
who	who	PRON	WP	5	O
delivered	deliver	VERB	VBD	5	O
vaginally	vaginally	ADV	RB	5	O
at	at	ADP	IN	9	O
term	term	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dosage	dosage	NOUN	NN	0	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
,	,	PUNCT	,	9	O
75	75	NUM	CD	9	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
125	125	NUM	CD	9	O
,	,	PUNCT	,	9	O
150	150	NUM	CD	0	O
,	,	PUNCT	,	9	O
175	175	NUM	CD	7	O
or	or	CCONJ	CC	5	O
200	200	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
carbetocin	carbetocin	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
blocks	block	NOUN	NNS	9	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
continual	continual	ADJ	JJ	5	O
reassessment	reassessment	NOUN	NN	5	O
method	method	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CRM	CRM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
dosage	dosage	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
except	except	ADP	IN	9	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
100	100	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
200	200	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
18	18	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Recorded	record	VERB	VBN	5	O
were	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
hyper	hyper	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
or	or	CCONJ	CC	5	I-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
three	three	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
retained	retain	VERB	VBD	9	B-Disease
placenta	placenta	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
four	four	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
seven	seven	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
blood	blood	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
1000	1000	NUM	CD	9	O
ml	ml	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
four	four	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
manual	manual	ADJ	JJ	5	O
placenta	placenta	NOUN	NN	9	O
removal	removal	NOUN	NN	9	O
,	,	PUNCT	,	9	O
five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
additional	additional	ADJ	JJ	9	O
oxytocics	oxytocic	NOUN	NNS	5	O
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
transfusion	transfusion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Maximum	maximum	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
greatest	great	ADJ	JJS	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	O
dose	dose	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
lowest	low	ADJ	JJS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
70	70	NUM	CD	9	O
-	-	SYM	SYM	7	O
125	125	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
range	range	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
blood	blood	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
1000	1000	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
200	200	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
of	of	ADP	IN	5	O
additional	additional	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxytocics	oxytocic	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
/	/	SYM	SYM	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
transfusion	transfusion	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
retained	retain	VERB	VBN	9	O
placentae	placentae	NOUN	NN	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
MTD	MTD	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
at	at	ADP	IN	9	O
200	200	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
carbetocin	carbetocin	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

Heparin	Heparin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
paradoxical	paradoxical	ADJ	JJ	5	O
thromboembolism	thromboembolism	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
several	several	ADJ	JJ	9	O
new	new	ADJ	JJ	5	O
anticoagulant	anticoagulant	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
in	in	ADP	IN	5	O
development	development	NOUN	NN	9	O
,	,	PUNCT	,	9	O
heparin	heparin	NOUN	NN	0	B-Chemical
remains	remain	VERB	VBZ	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
of	of	ADP	IN	5	O
choice	choice	NOUN	NN	5	O
for	for	ADP	IN	5	O
most	most	ADJ	JJS	9	O
anticoagulation	anticoagulation	NOUN	NN	5	O
needs	need	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
meritorious	meritorious	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
do	do	VERB	VBP	5	O
exist	exist	VERB	VB	9	O
.	.	PUNCT	.	9	O

Important	important	ADJ	JJ	5	O
untoward	untoward	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
including	include	VERB	VBG	9	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
eosinophilia	eosinophilia	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
skin	skin	NOUN	NN	5	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
allergic	allergic	ADJ	JJ	9	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
other	other	ADJ	JJ	5	O
than	than	ADP	IN	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
alopecia	alopecia	NOUN	NN	5	B-Disease
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
discussed	discuss	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
article	article	NOUN	NN	6	O
.	.	PUNCT	.	9	O

Nonopaque	nonopaque	NOUN	NN	_	O
crystal	crystal	NOUN	NN	0	O
deposition	deposition	NOUN	NN	9	O
causing	cause	VERB	VBG	9	O
ureteric	ureteric	ADJ	JJ	5	B-Disease
obstruction	obstruction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
undergoing	undergo	VERB	VBG	9	O
indinavir	indinavir	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
unique	unique	ADJ	JJ	9	O
CT	CT	PROPN	NNP	9	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ureteric	ureteric	ADJ	JJ	5	B-Disease
calculi	calculi	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
HIV	HIV	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
indinavir	indinavir	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
HIV	HIV	PROPN	NNP	5	O
protease	protease	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
urolithiasis	urolithiasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Ureteric	ureteric	ADJ	JJ	5	B-Disease
obstruction	obstruction	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
precipitated	precipitated	ADJ	JJ	0	O
indinavir	indinavir	ADJ	JJ	0	B-Chemical
crystals	crystal	NOUN	NNS	0	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
difficult	difficult	ADJ	JJ	5	O
to	to	PART	TO	5	O
diagnose	diagnose	VERB	VB	5	O
with	with	ADP	IN	5	O
unenhanced	unenhanced	ADJ	JJ	5	O
CT	CT	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
calculi	calculi	NOUN	NN	5	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
opaque	opaque	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
secondary	secondary	ADJ	JJ	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
obstruction	obstruction	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
absent	absent	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
minimal	minimal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
sought	seek	VERB	VBN	9	O
carefully	carefully	ADV	RB	5	O
.	.	PUNCT	.	9	O

Images	image	NOUN	NNS	9	O
may	may	VERB	MD	5	O
need	need	VERB	VB	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
obtained	obtain	VERB	VBN	9	O
using	use	VERB	VBG	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	NFP	9	O
contrast	contrast	NOUN	NN	9	O
material	material	NOUN	NN	5	O
to	to	PART	TO	5	O
enable	enable	VERB	VB	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
ureteric	ureteric	ADJ	JJ	5	B-Disease
stones	stone	NOUN	NNS	5	I-Disease
or	or	CCONJ	CC	5	I-Disease
obstruction	obstruction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
infection	infection	NOUN	NN	9	I-Disease
who	who	PRON	WP	5	O
receive	receive	VERB	VBP	5	O
indinavir	indinavir	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ischemic	ischemic	ADJ	JJ	9	B-Disease
colitis	colitis	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
sumatriptan	sumatriptan	ADJ	JJ	0	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sumatriptan	Sumatriptan	PROPN	NNP	0	B-Chemical
succinate	succinate	ADJ	JJ	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptamine	hydroxytryptamine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
antimigraine	antimigraine	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
act	act	VERB	VB	9	O
by	by	ADP	IN	9	O
selectively	selectively	ADV	RB	3	O
constricting	constrict	VERB	VBG	5	O
intracranial	intracranial	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
vasopressor	vasopressor	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
distinct	distinct	ADJ	JJ	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
cranial	cranial	ADJ	JJ	5	O
circulation	circulation	NOUN	NN	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
demonstrated	demonstrate	VERB	VBN	9	O
to	to	PART	TO	5	O
occur	occur	VERB	VB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
systemic	systemic	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
pulmonary	pulmonary	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
coronary	coronary	ADJ	JJ	5	O
circulations	circulation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cases	case	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
published	publish	VERB	VBN	9	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
vasospasm	vasospasm	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
occurring	occur	VERB	VBG	9	O
after	after	ADP	IN	9	O
sumatriptan	sumatriptan	ADJ	JJ	0	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
serious	serious	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
colitis	colitis	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
sumatriptan	sumatriptan	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Pallidotomy	pallidotomy	VERB	VB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
gamma	gamma	NOUN	NN	9	O
knife	knife	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
experience	experience	NOUN	NN	5	O
.	.	PUNCT	.	9	O

51	51	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
medically	medically	ADV	RB	5	O
refractory	refractory	ADJ	JJ	9	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
underwent	undergo	VERB	VBD	5	O
stereotactic	stereotactic	ADJ	JJ	5	O
posteromedial	posteromedial	ADJ	JJ	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
between	between	ADP	IN	5	O
August	August	PROPN	NNP	2	O
1993	1993	NUM	CD	2	O
and	and	CCONJ	CC	5	O
February	February	PROPN	NNP	2	O
1997	1997	NUM	CD	2	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
bradykinesia	bradykinesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
rigidity	rigidity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
29	29	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
pallidotomies	pallidotomie	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
Leksell	Leksell	PROPN	NNP	5	O
Gamma	Gamma	PROPN	NNP	9	O
Knife	Knife	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
22	22	NUM	CD	7	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
radiofrequency	radiofrequency	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
RF	RF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
method	method	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
blinded	blind	VERB	VBN	5	O
ratings	rating	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Unified	Unified	PROPN	NNP	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
Disease	Disease	PROPN	NNP	2	I-Disease
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
UPDRS	UPDRS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
scores	score	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
pre	pre	ADJ	JJ	9	O
-	-	VERB	VB	7	O
and	and	CCONJ	CC	5	O
postoperatively	postoperatively	ADV	RB	5	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
time	time	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VBP	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
48	48	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
except	except	ADP	IN	9	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
followed	follow	VERB	VBN	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

85	85	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
relieved	relieve	VERB	VBN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
pallidotomies	pallidotomie	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
Gamma	Gamma	PROPN	NNP	9	O
Knife	Knife	PROPN	NNP	5	O
or	or	CCONJ	CC	5	O
radiofrequency	radiofrequency	NOUN	NN	5	O
methods	method	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

About	about	ADV	RB	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
3	3	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
Gamma	Gamma	PROPN	NNP	9	O
Knife	Knife	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
radiofrequency	radiofrequency	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
bradykinesia	bradykinesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
when	when	ADV	WRB	5	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
neither	neither	CCONJ	CC	9	O
the	the	DET	DT	5	O
Gamma	Gamma	PROPN	NNP	9	O
Knife	Knife	PROPN	NNP	5	O
nor	nor	CCONJ	CC	9	O
the	the	DET	DT	5	O
radiofrequency	radiofrequency	NOUN	NN	5	O
group	group	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
UPDRS	UPDRS	PROPN	NNP	5	O
scores	score	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Gamma	Gamma	PROPN	NNP	9	O
Knife	Knife	PROPN	NNP	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
homonymous	homonymous	ADJ	JJ	5	B-Disease
hemianopsia	hemianopsia	NOUN	NN	5	I-Disease
9	9	NUM	CD	7	O
months	month	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
radiofrequency	radiofrequency	NOUN	NN	5	O
group	group	NOUN	NN	9	O
became	become	VERB	VBD	9	O
transiently	transiently	ADV	RB	3	O
confused	confuse	VERB	VBN	4	O
postoperatively	postoperatively	ADV	RB	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Gamma	Gamma	PROPN	NNP	9	O
Knife	Knife	PROPN	NNP	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
as	as	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
as	as	ADP	IN	5	O
radiofrequency	radiofrequency	NOUN	NN	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
in	in	ADP	IN	5	O
controlling	control	VERB	VBG	9	O
certain	certain	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
practical	practical	ADJ	JJ	5	O
technique	technique	NOUN	NN	5	O
available	available	ADJ	JJ	5	O
in	in	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
take	take	VERB	VBP	5	O
anticoagulants	anticoagulant	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
bleeding	bleed	VERB	VBG	5	B-Disease
diatheses	diathese	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
serious	serious	ADJ	JJ	5	O
systemic	systemic	ADJ	JJ	9	O
medical	medical	ADJ	JJ	5	O
illnesses	illness	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
viable	viable	ADJ	JJ	9	O
option	option	NOUN	NN	5	O
for	for	ADP	IN	5	O
other	other	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
.	.	PUNCT	.	9	O

Centrally	centrally	ADV	RB	5	O
mediated	mediate	VERB	VBN	3	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
intracisternal	intracisternal	ADJ	JJ	0	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
intracisternal	intracisternal	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
c	c	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
intravenous	intravenous	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
guanethidine	guanethidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
hexamethonium	hexamethonium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
phentolamine	phentolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
conversely	conversely	ADV	RB	9	O
,	,	PUNCT	,	9	O
potentiated	potentiate	VERB	VBN	3	O
by	by	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
desmethylimipramine	desmethylimipramine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
selectively	selectively	ADV	RB	3	O
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
enlargement	enlargement	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
pulse	pulse	NOUN	NN	5	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	X	XX	9	O
.	.	PUNCT	.	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	X	XX	9	O
.	.	PUNCT	.	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
almost	almost	ADV	RB	9	O
completely	completely	ADV	RB	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
hexamethonium	hexamethonium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
500	500	NUM	CD	0	O
mug	mug	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
chlorpromazine	chlorpromazine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mug	mug	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
significantly	significantly	ADV	RB	9	O
potentiated	potentiate	VERB	VBN	3	O
by	by	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
desmethylimipramine	desmethylimipramine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	X	XX	9	O
.	.	PUNCT	.	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
after	after	ADP	IN	9	O
sectioning	section	VERB	VBG	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bilateral	bilateral	ADJ	JJ	5	O
cervical	cervical	ADJ	JJ	5	O
vagal	vagal	ADJ	JJ	5	O
nerves	nerve	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
disappeared	disappear	VERB	VBD	9	O
after	after	ADP	IN	9	O
sectioning	section	VERB	VBG	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
C7	C7	PROPN	NNP	8	O
-	-	PUNCT	HYPH	7	O
C8	C8	PROPN	NNP	8	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
the	the	DET	DT	5	O
above	above	ADJ	JJ	9	O
result	result	NOUN	NN	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	X	XX	9	O
.	.	PUNCT	.	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
ortral	ortral	ADJ	JJ	_	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
adrenergic	adrenergic	NOUN	NN	9	O
mechanisms	mechanism	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
trunk	trunk	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Neuroleptic	neuroleptic	ADJ	JJ	2	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
female	female	NOUN	NN	9	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
probably	probably	ADV	RB	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
defects	defect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
supratentorial	supratentorial	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
including	include	VERB	VBG	9	O
the	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
ganglia	ganglion	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
multicystic	multicystic	ADJ	JJ	5	B-Disease
encephalomalacia	encephalomalacia	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
perinatal	perinatal	ADJ	JJ	5	O
hypoxic	hypoxic	ADJ	JJ	3	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
ischemic	ischemic	ADJ	JJ	9	I-Disease
encephalopathy	encephalopathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
predisposing	predispose	VERB	VBG	5	O
factor	factor	NOUN	NN	9	O
causing	cause	VERB	VBG	9	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
blockade	blockade	NOUN	NN	3	O
mechanism	mechanism	NOUN	NN	9	O
generally	generally	ADV	RB	5	O
is	be	VERB	VBZ	5	O
accepted	accept	VERB	VBN	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
agonist	agonist	NOUN	NN	3	O
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
uptake	uptake	NOUN	NN	0	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
therefore	therefore	ADV	RB	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
systems	system	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brainstem	brainstem	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
mainly	mainly	ADV	RB	9	O
the	the	DET	DT	5	O
midbrain	midbrain	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
were	be	VERB	VBD	9	O
unlikely	unlikely	ADJ	JJ	9	O
to	to	PART	TO	5	O
participate	participate	VERB	VB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
relative	relative	ADJ	JJ	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
ergic	ergic	ADJ	JJ	0	O
deficiency	deficiency	NOUN	NN	9	O
might	may	VERB	MD	9	O
occur	occur	VERB	VB	5	O
because	because	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
mimetic	mimetic	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
strikingly	strikingly	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
reported	report	VERB	VBN	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
probably	probably	ADV	RB	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

Differential	differential	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
17alpha	17alpha	NUM	CD	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ethinylestradiol	ethinylestradiol	NOUN	NNS	0	I-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
neutral	neutral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
acidic	acidic	ADJ	JJ	0	O
pathways	pathway	NOUN	NNS	9	O
of	of	ADP	IN	5	O
bile	bile	ADJ	JJ	0	B-Chemical
salt	salt	NOUN	NN	0	I-Chemical
synthesis	synthesis	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
17alpha	17alpha	NUM	CD	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ethinylestradiol	ethinylestradiol	NOUN	NNS	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
EE	EE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
neutral	neutral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
acidic	acidic	ADJ	JJ	0	O
biosynthetic	biosynthetic	ADJ	JJ	9	O
pathways	pathway	NOUN	NNS	9	O
of	of	ADP	IN	5	O
bile	bile	ADJ	JJ	0	B-Chemical
salt	salt	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BS	BS	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
synthesis	synthesis	NOUN	NN	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
intact	intact	ADJ	JJ	9	O
enterohepatic	enterohepatic	ADJ	JJ	5	O
circulation	circulation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
bile	bile	NOUN	NN	0	O
diversion	diversion	NOUN	NN	5	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
BS	bs	NOUN	NN	9	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
this	this	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
,	,	PUNCT	,	9	O
bile	bile	ADJ	JJ	0	B-Chemical
salt	salt	NOUN	NN	0	I-Chemical
pool	pool	NOUN	NN	9	O
composition	composition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
synthesis	synthesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
individual	individual	ADJ	JJ	5	O
BS	BS	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
hepatic	hepatic	ADJ	JJ	9	O
activities	activity	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
expression	expression	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
7alpha	7alpha	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hydroxylase	hydroxylase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
CYP7A	cyp7a	NOUN	NN	1	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sterol	sterol	VERB	VB	0	B-Chemical
27	27	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
hydroxylase	hydroxylase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
CYP27	CYP27	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
enzymes	enzyme	NOUN	NNS	1	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
BS	BS	PROPN	NNP	9	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
EE	EE	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
vehicle	vehicle	NOUN	NN	3	O
.	.	PUNCT	.	9	O

BS	bs	NOUN	NN	9	B-Chemical
pool	pool	NOUN	NN	9	O
size	size	NOUN	NN	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
by	by	ADP	IN	9	O
27	27	NUM	CD	7	O
%	%	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
total	total	ADJ	JJ	9	O
BS	BS	PROPN	NNP	9	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
EE	EE	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
intact	intact	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Synthesis	synthesis	NOUN	NN	0	O
of	of	ADP	IN	5	O
cholate	cholate	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
68	68	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
EE	ee	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
chenodeoxycholate	chenodeoxycholate	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
recently	recently	ADV	RB	9	O
identified	identify	VERB	VBN	9	O
Delta22	delta22	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
isomer	isomer	NOUN	NN	0	O
of	of	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
muricholate	muricholate	NOUN	NN	_	O
contributed	contribute	VERB	VBD	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
pool	pool	NOUN	NN	9	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
EE	ee	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
could	could	VERB	MD	9	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
bile	bile	NOUN	NN	0	O
after	after	ADP	IN	9	O
exhaustion	exhaustion	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pool	pool	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
clear	clear	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
BS	BS	PROPN	NNP	9	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
bile	bile	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
diverted	divert	VERB	VBN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
EE	EE	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
yet	yet	CCONJ	CC	9	O
biliary	biliary	ADJ	JJ	5	O
BS	BS	PROPN	NNP	9	B-Chemical
composition	composition	NOUN	NN	9	O
was	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
minimally	minimally	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
CYP7A	cyp7a	NOUN	NN	1	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
by	by	ADP	IN	9	O
EE	EE	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
intact	intact	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
bile	bile	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
diverted	divert	VERB	VBN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
CYP27	CYP27	PROPN	NNP	1	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Hepatic	hepatic	ADJ	JJ	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
CYP7A	cyp7a	NOUN	NN	1	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
EE	EE	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
bile	bile	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
diverted	divert	VERB	VBN	5	O
rats	rat	NOUN	NNS	9	O
only	only	ADV	RB	9	O
;	;	PUNCT	:	9	O
CYP27	CYP27	PROPN	NNP	1	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
EE	EE	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
sterol	sterol	NOUN	NN	0	B-Chemical
12alpha	12alpha	NUM	CD	_	O
-	-	PUNCT	HYPH	7	O
hydroxylase	hydroxylase	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
lithocholate	lithocholate	VERB	VB	0	O
6beta	6beta	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
hydroxylase	hydroxylase	NOUN	NN	1	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
bile	bile	NOUN	NN	0	O
diversion	diversion	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
suppressed	suppress	VERB	VBN	3	O
by	by	ADP	IN	9	O
EE	EE	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
17alpha	17alpha	NUM	CD	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ethinylestradiol	ethinylestradiol	NOUN	NNS	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
EE	EE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
intrahepatic	intrahepatic	ADJ	JJ	9	B-Disease
cholestasis	cholestasis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
neutral	neutral	ADJ	JJ	5	O
pathway	pathway	NOUN	NN	3	O
of	of	ADP	IN	5	O
bile	bile	ADJ	JJ	0	B-Chemical
salt	salt	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BS	BS	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
synthesis	synthesis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Simultaneous	simultaneous	ADJ	JJ	9	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
enzymes	enzyme	NOUN	NNS	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BS	BS	PROPN	NNP	9	B-Chemical
biosynthetic	biosynthetic	ADJ	JJ	9	O
pathways	pathway	NOUN	NNS	9	O
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
overall	overall	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
EE	EE	PROPN	NNP	9	B-Chemical
on	on	ADP	IN	5	O
BS	BS	PROPN	NNP	9	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Glibenclamide	glibenclamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
helodermin	helodermin	NOUN	NN	9	B-Chemical
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
helodermin	helodermin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
basic	basic	ADJ	JJ	5	O
35	35	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
amino	amino	NOUN	NN	1	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
peptide	peptide	NOUN	NN	9	O
isolated	isolate	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
venom	venom	NOUN	NN	4	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
lizard	lizard	ADJ	JJ	4	O
salivary	salivary	ADJ	JJ	9	O
gland	gland	NOUN	NN	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
,	,	PUNCT	,	9	O
focusing	focus	VERB	VBG	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
ATP	ATP	PROPN	NNP	0	B-Chemical
sensitive	sensitive	ADJ	JJ	9	O
K	K	PROPN	NNP	9	B-Chemical
+	+	CCONJ	CC	9	O
(	(	PUNCT	-LRB-	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
channels	channel	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
responses	response	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
vasoactive	vasoactive	ADJ	JJ	5	O
intestinal	intestinal	ADJ	JJ	9	O
polypeptide	polypeptide	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
VIP	VIP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Helodermin	helodermin	NOUN	NN	9	B-Chemical
produced	produce	VERB	VBD	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
with	with	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
similar	similar	ADJ	JJ	9	O
potency	potency	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
to	to	ADP	IN	5	O
VIP	VIP	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Hypotension	hypotension	NOUN	NN	7	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
both	both	DET	DT	9	O
peptides	peptide	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBN	3	O
by	by	ADP	IN	9	O
glibenclamide	glibenclamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
abolished	abolish	VERB	VBD	3	O
a	a	DET	DT	5	O
levcromakalim	levcromakalim	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
produced	produce	VERB	VBN	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Oxyhemoglobin	Oxyhemoglobin	PROPN	NNP	0	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
helodermin	helodermin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
shortened	shorten	VERB	VBD	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ACh	ACh	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
produced	produce	VERB	VBN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
helodermin	helodermin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
produced	produce	VERB	VBN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
partly	partly	ADV	RB	9	O
attributable	attributable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
glibenclamide	glibenclamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
K	K	PROPN	NNP	9	B-Chemical
+	+	SYM	SYM	9	O
channels	channel	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
channels	channel	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
presumably	presumably	ADV	RB	9	O
exist	exist	VERB	VBP	9	O
on	on	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

EDRF	EDRF	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
endothelium	endothelium	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
relaxing	relaxing	ADJ	JJ	5	O
factor	factor	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
seem	seem	VERB	VB	5	O
to	to	PART	TO	5	O
play	play	VERB	VB	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
peptide	peptide	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
produced	produce	VERB	VBN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
of	of	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
sustained	sustain	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
tablets	tablet	NOUN	NNS	0	O
for	for	ADP	IN	5	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
psoriasis	psoriasis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Thirteen	thirteen	NUM	CD	9	O
psoriatic	psoriatic	ADJ	JJ	3	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
A	a	DET	DT	9	I-Chemical
therapy	therapy	NOUN	NN	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
25	25	NUM	CD	9	O
months	month	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
,	,	PUNCT	,	9	O
sustained	sustained	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
exhibited	exhibit	VERB	VBN	9	O
a	a	DET	DT	5	O
subclinical	subclinical	ADJ	JJ	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
state	state	NOUN	NN	5	O
before	before	ADP	IN	9	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
A	a	DET	DT	9	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
systolic	systolic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressures	pressure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
significantly	significantly	ADV	RB	9	O
after	after	ADP	IN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
range	range	NOUN	NN	9	O
thereafter	thereafter	ADV	RB	9	O
for	for	ADP	IN	5	O
25	25	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
during	during	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
included	include	VERB	VBD	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	B-Chemical
urea	urea	ADJ	JJ	0	I-Chemical
nitrogen	nitrogen	NOUN	NN	0	I-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
9	9	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
gingival	gingival	NOUN	NN	5	B-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
sustained	sustain	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
useful	useful	ADJ	JJ	5	O
for	for	ADP	IN	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
psoriatic	psoriatic	ADJ	JJ	3	B-Disease
patients	patient	NOUN	NNS	5	O
under	under	ADP	IN	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
monitored	monitor	VERB	VBN	9	O
for	for	ADP	IN	5	O
gingival	gingival	NOUN	NN	5	B-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

